<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="0" size="12" family="Times" color="#000000"/>
	<fontspec id="1" size="12" family="Times" color="#000000"/>
	<fontspec id="2" size="20" family="Times" color="#000000"/>
	<fontspec id="3" size="16" family="Times" color="#000000"/>
	<fontspec id="4" size="14" family="Times" color="#000000"/>
	<fontspec id="5" size="14" family="Times" color="#000000"/>
	<fontspec id="6" size="14" family="Times" color="#000000"/>
	<fontspec id="7" size="10" family="Times" color="#000000"/>
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-1_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="439" width="44" height="19" font="1">Page 1 </text>
<text top="124" left="436" width="51" height="29" font="2"><b>2018 </b></text>
<text top="151" left="119" width="686" height="29" font="2"><b>AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA </b></text>
<text top="179" left="218" width="487" height="29" font="2"><b>Guideline on the Management of Blood Cholesterol </b></text>
<text top="234" left="122" width="678" height="23" font="3"><b>A Report of the American College of Cardiology/American Heart Association Task Force on </b></text>
<text top="256" left="359" width="204" height="23" font="3"><b>Clinical Practice Guidelines </b></text>
<text top="312" left="346" width="231" height="21" font="4"><b>WRITING COMMITTEE MEMBERS </b></text>
<text top="332" left="323" width="277" height="21" font="5">Scott M. Grundy, MD, PhD, FAHA, <i>Chair</i>* </text>
<text top="354" left="317" width="288" height="21" font="5">Neil J. Stone, MD, FACC, FAHA, <i>Vice Chair</i>* </text>
<text top="374" left="123" width="256" height="21" font="5">Alison L. Bailey, MD, FACC, FAACVPR† </text>
<text top="374" left="467" width="195" height="21" font="5">Daniel W. Jones, MD, FAHA§ </text>
<text top="394" left="123" width="122" height="21" font="5">Craig Beam, CRE* </text>
<text top="394" left="467" width="299" height="21" font="5">Donald Lloyd-Jones, MD, SCM, FACC, FAHA* </text>
<text top="414" left="123" width="290" height="21" font="5">Kim K. Birtcher, MS, PharmD, AACC, FNLA‡ </text>
<text top="414" left="467" width="226" height="21" font="5">Nuria Lopez-Pajares, MD, MPH§§ </text>
<text top="434" left="123" width="310" height="21" font="5">Roger S. Blumenthal, MD, FACC, FAHA, FNLA§ </text>
<text top="434" left="467" width="247" height="21" font="5">Chiadi E. Ndumele, MD, PhD, FAHA* </text>
<text top="454" left="123" width="311" height="21" font="5">Lynne T. Braun, PhD, CNP, FAHA, FPCNA, FNLA</text>
<text top="454" left="434" width="280" height="22" font="5">║  Carl E. Orringer, MD, FACC, FNLA║║ </text>
<text top="475" left="123" width="200" height="21" font="5">Sarah de Ferranti, MD, MPH* </text>
<text top="475" left="467" width="204" height="21" font="5">Carmen A. Peralta, MD, MAS* </text>
<text top="495" left="123" width="251" height="21" font="5">Joseph Faiella-Tommasino, PhD, PA-C</text>
<text top="496" left="375" width="9" height="19" font="1">¶</text>
<text top="495" left="383" width="4" height="21" font="5"> </text>
<text top="495" left="467" width="259" height="21" font="5">Joseph J. Saseen, PharmD, FNLA, FAHA</text>
<text top="496" left="726" width="18" height="19" font="1">¶¶</text>
<text top="495" left="744" width="4" height="21" font="5"> </text>
<text top="515" left="123" width="211" height="21" font="5">Daniel E. Forman, MD, FAHA** </text>
<text top="515" left="467" width="260" height="21" font="5">Sidney C. Smith, Jr, MD, MACC, FAHA* </text>
<text top="535" left="123" width="165" height="21" font="5">Ronald Goldberg, MD†† </text>
<text top="535" left="467" width="317" height="21" font="5">Laurence Sperling, MD, FACC, FAHA, FASPC*** </text>
<text top="556" left="123" width="300" height="21" font="5">Paul A. Heidenreich, MD, MS, FACC, FAHA‡‡ </text>
<text top="556" left="467" width="261" height="21" font="5">Salim S. Virani, MD, PhD, FACC, FAHA* </text>
<text top="577" left="123" width="230" height="21" font="5">Mark A. Hlatky, MD, FACC, FAHA* </text>
<text top="577" left="467" width="277" height="21" font="5">Joseph Yeboah, MD, MS, FACC, FAHA††† </text>
<text top="581" left="123" width="4" height="21" font="5"> </text>
<text top="626" left="345" width="231" height="21" font="4"><b>ACC/AHA TASK FORCE MEMBERS </b></text>
<text top="646" left="325" width="271" height="21" font="5">Glenn N. Levine, MD, FACC, FAHA, <i>Chair</i> </text>
<text top="666" left="300" width="322" height="21" font="5">Patrick T. O’Gara, MD, MACC, FAHA, <i>Chair-Elect </i></text>
<text top="686" left="243" width="436" height="21" font="5">Jonathan L. Halperin, MD, FACC, FAHA,<i> Immediate Past Chair</i>‡‡‡ </text>
<text top="707" left="133" width="282" height="21" font="5">Sana M. Al-Khatib, MD, MHS, FACC, FAHA </text>
<text top="707" left="467" width="210" height="21" font="5">Samuel Gidding, MD, FAHA‡‡‡ </text>
<text top="727" left="133" width="238" height="21" font="5">Joshua A. Beckman, MD, MS, FAHA </text>
<text top="727" left="467" width="310" height="21" font="5">Zachary D. Goldberger, MD, MSc, FACC, FAHA </text>
<text top="747" left="133" width="239" height="21" font="5">Kim K. Birtcher, PharmD, MS, AACC </text>
<text top="747" left="467" width="222" height="21" font="5">Mark A. Hlatky, MD, FACC, FAHA </text>
<text top="767" left="133" width="288" height="21" font="5">Biykem Bozkurt, MD, PhD, FACC, FAHA‡‡‡ </text>
<text top="767" left="467" width="224" height="21" font="5">John Ikonomidis, MD, PhD, FAHA </text>
<text top="787" left="133" width="256" height="21" font="5">Ralph G. Brindis, MD, MPH, MACC‡‡‡ </text>
<text top="787" left="467" width="212" height="21" font="5">José A. Joglar, MD, FACC, FAHA </text>
<text top="807" left="133" width="206" height="21" font="5">Joaquin E. Cigarroa, MD, FACC </text>
<text top="807" left="467" width="198" height="21" font="5">Laura Mauri, MD, MSc, FAHA </text>
<text top="827" left="133" width="210" height="21" font="5">Lesley H. Curtis, PhD, FAHA‡‡‡ </text>
<text top="827" left="467" width="226" height="21" font="5">Mariann R. Piano, RN, PhD, FAHA </text>
<text top="847" left="133" width="251" height="21" font="5">Anita Deswal, MD, MPH, FACC, FAHA </text>
<text top="847" left="467" width="245" height="21" font="5">Susan J. Pressler, PhD, RN, FAHA‡‡‡ </text>
<text top="868" left="133" width="220" height="21" font="5">Lee A. Fleisher, MD, FACC, FAHA </text>
<text top="868" left="467" width="233" height="21" font="5">Barbara Riegel, PhD, RN, FAHA‡‡‡ </text>
<text top="888" left="133" width="189" height="21" font="5">Federico Gentile, MD, FACC </text>
<text top="888" left="467" width="247" height="21" font="5">Duminda N. Wijeysundera, MD, PhD </text>
<text top="945" left="108" width="702" height="19" font="1">*ACC/AHA Representative. †AACVPR Representative. ‡ACC/AHA Task Force on Clinical Practice Guidelines Liaison.</text>
<text top="963" left="108" width="221" height="19" font="1">§Prevention Subcommittee Liaison. </text>
<text top="963" left="329" width="481" height="20" font="1">║PCNA Representative. ¶AAPA Representative. **AGS Representative. ††ADA</text>
<text top="981" left="108" width="399" height="19" font="1">Representative. ‡‡PM Representative. §§ACPM Representative. </text>
<text top="981" left="507" width="303" height="20" font="1">║║NLA Representative. ¶¶APhA Representative.</text>
<text top="1000" left="108" width="702" height="19" font="1">***ASPC Representative. †††ABC Representative.  ‡‡‡Former Task Force member; current member during the</text>
<text top="1018" left="108" width="85" height="19" font="1">writing effort.</text>
<text top="1055" left="108" width="709" height="19" font="1">This document was approved by the American College of Cardiology Clinical Policy Approval Committee, the </text>
<text top="1073" left="108" width="705" height="19" font="1">American Heart Association Science Advisory and Coordinating Committee, American Association of Cardiovascular </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="2" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="8" size="12" family="Times" color="#0000ff"/>
	<fontspec id="9" size="12" family="Times" color="#000000"/>
	<fontspec id="10" size="12" family="Times" color="#000000"/>
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-2_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="439" width="44" height="19" font="1">Page 2 </text>
<text top="124" left="108" width="709" height="19" font="1">and Pulmonary Rehabilitation, American Academy  of Physician Assistants, Association of Black Cardiologists, </text>
<text top="142" left="108" width="707" height="19" font="1">American College of Preventive Medicine, American Diabetes Association, American Geriatrics Society, American </text>
<text top="161" left="108" width="705" height="19" font="1">Pharmacists Association, American Society for Preventive Cardiology, National Lipid Association,  and Preventive </text>
<text top="179" left="108" width="709" height="19" font="1">Cardiovascular Nurses Association in October 2018, and the American Heart Association Executive Committee in  </text>
<text top="197" left="108" width="91" height="19" font="1">October 2018. </text>
<text top="216" left="108" width="3" height="19" font="1"> </text>
<text top="234" left="108" width="342" height="19" font="1">Supplemental materials are available with this article at </text>
<text top="252" left="108" width="448" height="19" font="8"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625</a></text>
<text top="252" left="556" width="7" height="19" font="1"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">.</a> </text>
<text top="271" left="108" width="3" height="19" font="1"> </text>
<text top="289" left="108" width="705" height="19" font="1">The American Heart Association requests that this document be cited as follows: Grundy SM, Stone NJ, Bailey AL, </text>
<text top="307" left="108" width="709" height="19" font="1">Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S,  Faiella-Tommasino J, Forman DE, Goldberg R, </text>
<text top="326" left="108" width="705" height="19" font="1">Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen </text>
<text top="344" left="108" width="152" height="19" font="1">JJ, Smith SC </text>
<text top="344" left="300" width="301" height="19" font="1">Jr, Sperling L, Virani SS, </text>
<text top="344" left="640" width="213" height="19" font="1">Yeboah J. 2018 </text>
<text top="362" left="108" width="705" height="19" font="1">AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA  guideline  on the management  of  blood </text>
<text top="381" left="108" width="708" height="19" font="1">cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical </text>
<text top="399" left="108" width="599" height="19" font="1">Practice Guidelines. <i>Circulation.</i> 2018;:–. DOI: 10.1161/CIR.0000000000000625. </text>
<text top="417" left="108" width="3" height="19" font="1"> </text>
<text top="435" left="108" width="531" height="19" font="1">This article has been copublished in the <i>Journal of the American College of Cardiology</i>.  </text>
<text top="454" left="108" width="3" height="19" font="1"> </text>
<text top="472" left="108" width="565" height="19" font="1">Copies: This document is available on the websites of the American College of Cardiology<a href="http://www.acc.org/"> (</a></text>
<text top="472" left="673" width="80" height="19" font="8"><a href="http://www.acc.org/">www.acc.org</a></text>
<text top="472" left="753" width="60" height="19" font="1"><a href="http://www.acc.org/">) </a>and the </text>
<text top="490" left="108" width="208" height="19" font="1">American Heart Association<a href="https://professional.heart.org/"> (</a></text>
<text top="490" left="316" width="135" height="19" font="8"><a href="https://professional.heart.org/">professional.heart.org</a></text>
<text top="490" left="451" width="373" height="19" font="1"><a href="https://professional.heart.org/">  </a>A copy of the document is also available at </text>
<text top="509" left="108" width="257" height="19" font="8"><a href="https://professional.heart.org/statements">https://professional.heart.org/statements</a></text>
<text top="509" left="365" width="454" height="19" font="1"><a href="https://professional.heart.org/statements">  </a>by selecting the “Guidelines &amp; Statements” button. To purchase </text>
<text top="527" left="108" width="508" height="19" font="1">additional reprints, call 843-216-2533 or e-mail kelle.ramsay@wolterskluwer.com.. </text>
<text top="545" left="108" width="3" height="19" font="1"> </text>
<text top="564" left="108" width="707" height="19" font="1">The expert peer review of AHA-commissioned documents (eg, scientific statements, clinical practice guidelines, </text>
<text top="582" left="108" width="708" height="19" font="1">systematic reviews) is conducted by the AHA Office of Science Operations. For more on AHA statements and </text>
<text top="600" left="108" width="192" height="19" font="1">guidelines development, visit<a href="https://professional.heart.org/statements"> </a></text>
<text top="600" left="300" width="257" height="19" font="8"><a href="https://professional.heart.org/statements">https://professional.heart.org/statements</a></text>
<text top="600" left="557" width="260" height="19" font="1"><a href="https://professional.heart.org/statements">.</a> Select the “Guidelines &amp; Statements” </text>
<text top="618" left="108" width="527" height="19" font="1">drop-down menu near the top of the webpage, then click “Publication Development.” </text>
<text top="637" left="108" width="3" height="19" font="1"> </text>
<text top="655" left="108" width="706" height="19" font="1">Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not </text>
<text top="673" left="108" width="705" height="19" font="1">permitted without the express permission of the American Heart Association. Instructions for obtaining permission </text>
<text top="692" left="108" width="90" height="19" font="1">are located at<a href="https://www.heart.org/permissions"> </a></text>
<text top="692" left="198" width="218" height="19" font="8"><a href="https://www.heart.org/permissions">https://www.heart.org/permissions</a></text>
<text top="692" left="416" width="398" height="19" font="1"><a href="https://www.heart.org/permissions">.</a> A link to the “Copyright Permissions Request Form” appears in </text>
<text top="710" left="108" width="141" height="19" font="1">the second paragra<a href="https://www.heart.org/en/about-us/statements-and-policies/copyright-request-form">ph (</a></text>
<text top="710" left="249" width="523" height="19" font="8"><a href="https://www.heart.org/en/about-us/statements-and-policies/copyright-request-form">https://www.heart.org/en/about-us/statements-and-policies/copyright-request-form</a></text>
<text top="710" left="772" width="12" height="19" font="1"><a href="https://www.heart.org/en/about-us/statements-and-policies/copyright-request-form">)</a>. </text>
<text top="728" left="108" width="3" height="19" font="1"> </text>
<text top="747" left="108" width="458" height="19" font="0"><b>(<i>Circulation</i></b><b>. 2018;000:e000–e000. DOI: 10.1161/CIR.0000000000000625) </b></text>
<text top="765" left="108" width="3" height="19" font="1"> </text>
<text top="783" left="108" width="617" height="19" font="1">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="802" left="108" width="3" height="19" font="1"> </text>
<text top="819" left="108" width="409" height="20" font="9"><i>Circulation </i>is available at https://www.ahajournals.org/journal/circ</text>
<text top="818" left="517" width="4" height="21" font="5"> </text>
<text top="838" left="108" width="4" height="21" font="5"> </text>
<text top="870" left="108" width="4" height="21" font="5"> </text>
<text top="870" left="324" width="4" height="21" font="5"> </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="3" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-3_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="439" width="44" height="19" font="1">Page 3 </text>
<text top="124" left="393" width="136" height="23" font="3"><b>Table of Contents </b></text>
<text top="146" left="108" width="655" height="21" font="4"><a href="CIR.0000000000000625.html#5"><b>Top 10 Take-Home Messages to Reduce Risk of Atherosclerotic Cardiovascular Disease Through </b></a></text>
<text top="166" left="108" width="706" height="21" font="4"><a href="CIR.0000000000000625.html#5"><b>Cholesterol Management ............................................................................................................................ 5 </b></a></text>
<text top="186" left="108" width="706" height="21" font="4"><a href="CIR.0000000000000625.html#7"><b>Preamble ....................................................................................................................................................... 7 </b></a></text>
<text top="206" left="108" width="706" height="21" font="4"><a href="CIR.0000000000000625.html#8"><b>1. Introduction .............................................................................................................................................. 8 </b></a></text>
<text top="226" left="125" width="689" height="21" font="5"><a href="CIR.0000000000000625.html#8">1.1. Methodology and Evidence Review ................................................................................................... 8 </a></text>
<text top="246" left="125" width="689" height="21" font="5"><a href="CIR.0000000000000625.html#9">1.2. Organization of the Writing Committee ............................................................................................ 9 </a></text>
<text top="267" left="125" width="689" height="21" font="5"><a href="CIR.0000000000000625.html#9">1.3. Document Review and Approval ....................................................................................................... 9 </a></text>
<text top="287" left="125" width="689" height="21" font="5"><a href="CIR.0000000000000625.html#9">1.4. Scope of the Guideline ....................................................................................................................... 9 </a></text>
<text top="307" left="125" width="689" height="21" font="5"><a href="CIR.0000000000000625.html#10">1.5. Class of Recommendation and Level of Evidence ............................................................................ 10 </a></text>
<text top="327" left="125" width="689" height="21" font="5"><a href="CIR.0000000000000625.html#12">1.6. Abbreviations ................................................................................................................................... 12 </a></text>
<text top="347" left="108" width="706" height="21" font="4"><a href="CIR.0000000000000625.html#13"><b>2. High Blood Cholesterol and ASCVD ....................................................................................................... 13 </b></a></text>
<text top="367" left="125" width="689" height="21" font="5"><a href="CIR.0000000000000625.html#13">2.1. Serum Cholesterol, Lipoproteins, and ASCVD .................................................................................. 13 </a></text>
<text top="388" left="162" width="652" height="21" font="5"><a href="CIR.0000000000000625.html#13">2.1.1. Cholesterol, Lipoproteins, and Apolipoprotein B ................................................................ 13 </a></text>
<text top="408" left="162" width="652" height="21" font="5"><a href="CIR.0000000000000625.html#13">2.1.2. Cholesterol, LDL-C, and ASCVD ............................................................................................ 13 </a></text>
<text top="428" left="162" width="652" height="21" font="5"><a href="CIR.0000000000000625.html#13">2.1.3. LDL-C and Other Risk Factors ............................................................................................... 13 </a></text>
<text top="448" left="125" width="689" height="21" font="5"><a href="CIR.0000000000000625.html#14">2.2. Measurements of LDL-C and Non–HDL-C ........................................................................................ 14 </a></text>
<text top="468" left="125" width="689" height="21" font="5"><a href="CIR.0000000000000625.html#15">2.3. Measurements of Apolipoprotein B and Lipoprotein (a) ................................................................. 15 </a></text>
<text top="488" left="125" width="689" height="21" font="5"><a href="CIR.0000000000000625.html#15">2.4. Monitoring Response of LDL-C to Statin Therapy ............................................................................ 15 </a></text>
<text top="508" left="108" width="706" height="21" font="4"><a href="CIR.0000000000000625.html#16"><b>3. Therapeutic Modalities .......................................................................................................................... 16 </b></a></text>
<text top="528" left="125" width="689" height="21" font="5"><a href="CIR.0000000000000625.html#16">3.1. Lifestyle Therapies ........................................................................................................................... 16 </a></text>
<text top="549" left="162" width="652" height="21" font="5"><a href="CIR.0000000000000625.html#16">3.1.1. Diet Composition, Weight Control, and Physical Activity .................................................... 16 </a></text>
<text top="569" left="162" width="652" height="21" font="5"><a href="CIR.0000000000000625.html#16">3.1.2. Lifestyle Therapies and Metabolic Syndrome ...................................................................... 16 </a></text>
<text top="589" left="125" width="689" height="21" font="5"><a href="CIR.0000000000000625.html#16">3.2. Lipid-Lowering Drugs ....................................................................................................................... 16 </a></text>
<text top="609" left="162" width="652" height="21" font="5"><a href="CIR.0000000000000625.html#16">3.2.1. Statin Therapy ...................................................................................................................... 16 </a></text>
<text top="629" left="162" width="652" height="21" font="5"><a href="CIR.0000000000000625.html#17">3.2.2. Nonstatin Therapies ............................................................................................................. 17 </a></text>
<text top="649" left="162" width="652" height="21" font="5"><a href="CIR.0000000000000625.html#18">3.2.3. Nonstatin Add-on Drugs to Statin Therapy .......................................................................... 18 </a></text>
<text top="669" left="108" width="706" height="21" font="4"><a href="CIR.0000000000000625.html#18"><b>4. Patient Management Groups ................................................................................................................ 18 </b></a></text>
<text top="690" left="125" width="689" height="21" font="5"><a href="CIR.0000000000000625.html#18">4.1. Secondary ASCVD Prevention .......................................................................................................... 18 </a></text>
<text top="710" left="125" width="689" height="21" font="5"><a href="CIR.0000000000000625.html#25">4.2. Severe Hypercholesterolemia (LDL-C ≥190 mg/dL [≥4.9 mmol/L]) ................................................. 25 </a></text>
<text top="730" left="125" width="689" height="21" font="5"><a href="CIR.0000000000000625.html#27">4.3. Diabetes Mellitus in Adults .............................................................................................................. 27 </a></text>
<text top="750" left="125" width="689" height="21" font="5"><a href="CIR.0000000000000625.html#30">4.4. Primary Prevention .......................................................................................................................... 30 </a></text>
<text top="770" left="162" width="652" height="21" font="5"><a href="CIR.0000000000000625.html#32">4.4.1. Evaluation and Risk Assessment .......................................................................................... 32 </a></text>
<text top="790" left="162" width="651" height="21" font="5"><a href="CIR.0000000000000625.html#35">4.4.2. Primary Prevention Adults 40 to 75 Years of Age With LDL-C Levels 70 to 189 mg/dL (1.7 to </a></text>
<text top="811" left="162" width="652" height="21" font="5"><a href="CIR.0000000000000625.html#35">4.8 mmol/L) .................................................................................................................................... 35 </a></text>
<text top="831" left="162" width="652" height="21" font="5"><a href="CIR.0000000000000625.html#41">4.4.3. Monitoring in Response to LDL-C–Lowering Therapy ......................................................... 41 </a></text>
<text top="851" left="162" width="652" height="21" font="5"><a href="CIR.0000000000000625.html#42">4.4.4. Primary Prevention in Other Age Groups ............................................................................ 42 </a></text>
<text top="871" left="125" width="689" height="21" font="5"><a href="CIR.0000000000000625.html#48">4.5. Other Populations at Risk ................................................................................................................ 48 </a></text>
<text top="891" left="162" width="652" height="21" font="5"><a href="CIR.0000000000000625.html#48">4.5.1. Ethnicity ............................................................................................................................... 48 </a></text>
<text top="911" left="162" width="652" height="21" font="5"><a href="CIR.0000000000000625.html#52">4.5.2. Hypertriglyceridemia ........................................................................................................... 52 </a></text>
<text top="931" left="108" width="706" height="21" font="4"><a href="CIR.0000000000000625.html#58"><b>5. Statin Safety and Statin-Associated Side Effects ................................................................................... 58 </b></a></text>
<text top="951" left="108" width="706" height="21" font="4"><a href="CIR.0000000000000625.html#63"><b>6. Implementation ...................................................................................................................................... 63 </b></a></text>
<text top="972" left="108" width="706" height="21" font="4"><a href="CIR.0000000000000625.html#65"><b>7. Cost and Value Considerations .............................................................................................................. 65 </b></a></text>
<text top="992" left="125" width="689" height="21" font="5"><a href="CIR.0000000000000625.html#65">7.1. Economic Value Considerations: PCSK9 Inhibitors .......................................................................... 65 </a></text>
<text top="1012" left="108" width="706" height="21" font="4"><a href="CIR.0000000000000625.html#68"><b>8. Limitations and Knowledge Gaps .......................................................................................................... 68 </b></a></text>
<text top="1032" left="125" width="689" height="21" font="5"><a href="CIR.0000000000000625.html#68">8.1. Randomized Controlled Trials .......................................................................................................... 68 </a></text>
<text top="1052" left="125" width="689" height="21" font="5"><a href="CIR.0000000000000625.html#68">8.2. Risk Assessment ............................................................................................................................... 68 </a></text>
<text top="1072" left="162" width="652" height="21" font="5"><a href="CIR.0000000000000625.html#68">8.2.1. Continuing Refinement of PCE ............................................................................................. 68 </a></text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="4" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-4_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="439" width="44" height="19" font="1">Page 4 </text>
<text top="124" left="162" width="652" height="21" font="5"><a href="CIR.0000000000000625.html#69">8.2.2. Improvement in Lifetime Risk Estimate ............................................................................... 69 </a></text>
<text top="144" left="162" width="652" height="21" font="5"><a href="CIR.0000000000000625.html#69">8.2.3. Refinement of Clinician–Patient Risk Discussion ................................................................. 69 </a></text>
<text top="164" left="162" width="652" height="21" font="5"><a href="CIR.0000000000000625.html#69">8.2.4. Monitoring and Adjustment of Treatment .......................................................................... 69 </a></text>
<text top="184" left="162" width="652" height="21" font="5"><a href="CIR.0000000000000625.html#69">8.2.5. Prognostic Significance of CAC ............................................................................................. 69 </a></text>
<text top="204" left="108" width="583" height="21" font="4"><a href="CIR.0000000000000625.html#71"><b>Appendix 1. Author Relationships With Industry and Other Entities (Relevant)—2018 </b></a></text>
<text top="224" left="108" width="621" height="21" font="4"><a href="CIR.0000000000000625.html#71"><b>AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the </b></a></text>
<text top="245" left="108" width="706" height="21" font="4"><a href="CIR.0000000000000625.html#71"><b>Management of Blood Cholesterol* (August 2018) .................................................................................. 71 </b></a></text>
<text top="265" left="108" width="645" height="21" font="4"><a href="CIR.0000000000000625.html#74"><b>Appendix 2. Reviewer Relationships With Industry and Other Entities (Comprehensive)—2018 </b></a></text>
<text top="285" left="108" width="621" height="21" font="4"><a href="CIR.0000000000000625.html#74"><b>AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the </b></a></text>
<text top="305" left="108" width="706" height="21" font="4"><a href="CIR.0000000000000625.html#74"><b>Management of Blood Cholesterol (August 2018) .................................................................................... 74 </b></a></text>
<text top="325" left="108" width="706" height="21" font="4"><a href="CIR.0000000000000625.html#85"><b>References .................................................................................................................................................. 85 </b></a></text>
<text top="345" left="108" width="4" height="21" font="5"> </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="5" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="11" size="21" family="Times" color="#000000"/>
	<fontspec id="12" size="14" family="Times" color="#ff0000"/>
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-5_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="439" width="44" height="19" font="1">Page 5 </text>
<text top="124" left="108" width="631" height="31" font="11"><b>Top 10 Take-Home Messages to Reduce Risk of Atherosclerotic </b></text>
<text top="157" left="108" width="581" height="31" font="11"><b>Cardiovascular Disease Through Cholesterol Management </b></text>
<text top="200" left="108" width="709" height="21" font="5">1.  <b>In all individuals, emphasize a  heart-healthy lifestyle across the life  course</b>. A healthy lifestyle </text>
<text top="220" left="135" width="678" height="21" font="5">reduces atherosclerotic cardiovascular disease (ASCVD) risk at all ages. In younger individuals, healthy </text>
<text top="241" left="135" width="681" height="21" font="5">lifestyle can reduce development of risk factors and is the foundation of ASCVD risk reduction. In </text>
<text top="261" left="135" width="679" height="21" font="5">young adults 20 to 39 years of age, an assessment of lifetime risk facilitates the clinician–patient risk </text>
<text top="281" left="135" width="679" height="21" font="5">discussion (see No. 6) and emphasizes intensive lifestyle efforts. In all age groups, lifestyle therapy is </text>
<text top="301" left="135" width="342" height="21" font="5">the primary intervention for metabolic syndrome.  </text>
<text top="321" left="108" width="702" height="21" font="5">2.  <b>In patients with clinical ASCVD, reduce low-density lipoprotein cholesterol (LDL-C)  with high-</b></text>
<text top="341" left="135" width="679" height="21" font="4"><b>intensity statin therapy or maximally tolerated statin therapy. </b>The more LDL-C is reduced on statin </text>
<text top="361" left="135" width="675" height="21" font="5">therapy, the greater will be subsequent risk reduction.  Use a maximally tolerated statin to lower LDL-</text>
<text top="381" left="135" width="122" height="21" font="5">C levels by ≥50%.  </text>
<text top="402" left="108" width="707" height="21" font="5">3.  <b>In very high-risk ASCVD, use a LDL-C threshold of 70 mg/dL (1.8 mmol/L)</b> <b>to consider addition of </b></text>
<text top="422" left="135" width="680" height="21" font="4"><b>nonstatins to statin therapy.</b> Very high-risk includes a history of multiple major ASCVD events or 1 </text>
<text top="442" left="135" width="678" height="21" font="5">major ASCVD event and multiple high-risk conditions. In very high-risk ASCVD patients, it is reasonable </text>
<text top="462" left="135" width="679" height="21" font="5">to add ezetimibe to maximally tolerated statin therapy when the LDL-C level remains ≥70 mg/dL (≥1.8 </text>
<text top="482" left="135" width="679" height="21" font="5">mmol/L).  In  patients at very high  risk whose LDL-C  level  remains  ≥70 mg/dL  (≥1.8 mmol/L)  on </text>
<text top="502" left="135" width="680" height="21" font="5">maximally tolerated statin and ezetimibe therapy, adding a PCSK9 inhibitor is reasonable, although </text>
<text top="523" left="135" width="643" height="21" font="5">the long-term safety (&gt;3 years) is uncertain and cost effectiveness is low at mid-2018 list prices. </text>
<text top="543" left="108" width="706" height="21" font="5">4.  <b>In patients with severe primary hypercholesterolemia (LDL-C  level  ≥190 mg/dL  [≥4.9  mmol/L]), </b></text>
<text top="563" left="135" width="675" height="21" font="4"><b>without calculating 10-year ASCVD risk, begin high-intensity statin therapy without calculating 10-</b></text>
<text top="583" left="135" width="678" height="21" font="4"><b>year ASCVD risk. </b>If the LDL-C level remains ≥100 mg/dL (≥2.6 mmol/L), adding ezetimibe is reasonable. </text>
<text top="603" left="135" width="680" height="21" font="5">If the LDL-C level on statin plus ezetimibe remains ≥100 mg/dL (≥2.6 mmol/L) and the patient has </text>
<text top="623" left="135" width="679" height="21" font="5">multiple factors that increase subsequent risk of ASCVD events, a PCSK9 inhibitor may be considered, </text>
<text top="643" left="135" width="679" height="21" font="5">although the long-term safety (&gt;3 years) is uncertain and economic value is low at mid-2018 list prices. </text>
<text top="663" left="108" width="707" height="21" font="5">5.  <b>In patients 40 to 75 years of age with diabetes mellitus and LDL-C ≥70 mg/dL (≥1.8 mmol/L), start </b></text>
<text top="683" left="135" width="679" height="21" font="4"><b>moderate-intensity statin therapy without calculating 10-year ASCVD risk.</b> In patients with diabetes </text>
<text top="704" left="135" width="680" height="21" font="5">mellitus at higher risk, especially those with multiple risk factors or those 50 to 75 years of age, it is </text>
<text top="724" left="135" width="512" height="21" font="5">reasonable to use a high-intensity statin to reduce the LDL-C level by ≥50%.  </text>
<text top="744" left="108" width="706" height="21" font="5">6.  <b>In adults 40 to 75 years of age evaluated for primary ASCVD prevention, have a clinician–patient </b></text>
<text top="764" left="135" width="680" height="21" font="4"><b>risk discussion before starting statin therapy. </b>Risk discussion should include a review of major risk </text>
<text top="784" left="135" width="679" height="21" font="5">factors (e.g., cigarette smoking, elevated blood pressure, LDL-C, hemoglobin A1C [if indicated], and </text>
<text top="804" left="135" width="679" height="21" font="5">calculated 10-year risk of ASCVD); the presence of risk-enhancing factors (see No. 8); the potential </text>
<text top="824" left="135" width="678" height="21" font="5">benefits of lifestyle and statin therapies; the potential for adverse effects and drug–drug interactions; </text>
<text top="845" left="135" width="675" height="21" font="5">consideration of costs of statin therapy; and patient preferences  and values  in shared  decision-</text>
<text top="865" left="135" width="60" height="21" font="5">making.  </text>
<text top="885" left="108" width="706" height="21" font="5">7.  <b>In adults 40 to 75 years of age without diabetes mellitus and with LDL-C levels ≥70 mg/dL (≥1.8 </b></text>
<text top="905" left="135" width="681" height="21" font="4"><b>mmol/L), at a 10-year ASCVD risk of </b>≥<b>7.5%, start a moderate-intensity statin if a discussion of </b></text>
<text top="925" left="135" width="680" height="21" font="4"><b>treatment options favors statin therapy. </b>Risk-enhancing factors favor statin therapy (see No. 8). If </text>
<text top="945" left="135" width="679" height="21" font="5">risk status is uncertain, consider using coronary artery calcium (CAC) to improve specificity (see No. </text>
<text top="965" left="135" width="18" height="21" font="5">9).</text>
<text top="965" left="152" width="4" height="21" font="12"><b> </b></text>
<text top="965" left="156" width="658" height="21" font="5">If statins are indicated, reduce LDL-C levels by ≥30%, and if 10-year risk is ≥20%, reduce LDL-C levels </text>
<text top="986" left="135" width="68" height="21" font="5">by ≥50%.  </text>
<text top="1006" left="108" width="706" height="21" font="5">8.  <b>In  adults 40  to  75 years  of age  without  diabetes mellitus  and 10-year risk of 7.5%  to  19.9% </b></text>
<text top="1026" left="135" width="675" height="21" font="4"><b>(intermediate risk), risk-enhancing  factors  favor  initiation of statin therapy (see No.  7).</b>  Risk-</text>
<text top="1046" left="135" width="679" height="21" font="5">enhancing factors include family history of premature ASCVD; persistently elevated LDL-C levels ≥160 </text>
<text top="1066" left="135" width="683" height="21" font="5">mg/dL  (≥4.1  mmol/L);  metabolic syndrome;  chronic kidney disease;  history of preeclampsia or </text>
<text top="1087" left="135" width="680" height="21" font="5">premature menopause (age &lt;40 years); chronic inflammatory disorders (e.g., rheumatoid arthritis, </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="6" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-6_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="439" width="44" height="19" font="1">Page 6 </text>
<text top="124" left="135" width="683" height="21" font="5">psoriasis,  or chronic HIV);  high-risk  ethnic groups  (e.g.,  South Asian);  persistent elevations of </text>
<text top="144" left="135" width="680" height="21" font="5">triglycerides ≥175 mg/dL (≥1.97 mmol/L); and, if measured in selected individuals, apolipoprotein B </text>
<text top="164" left="135" width="679" height="21" font="5">≥130 mg/dL,  high-sensitivity C-reactive protein ≥2.0 mg/L, ankle-brachial index &lt;0.9 and lipoprotein </text>
<text top="184" left="135" width="678" height="21" font="5">(a) ≥50 mg/dL or 125 nmol/L, especially at higher values of lipoprotein (a). Risk-enhancing factors may </text>
<text top="204" left="135" width="493" height="21" font="5">favor statin therapy in patients at 10-year risk of 5-7.5% (borderline risk). </text>
<text top="224" left="108" width="705" height="21" font="5">9.  <b>In adults 40 to 75 years of age without diabetes mellitus and with LDL-C levels ≥70 mg/dL- 189 mg/dL </b></text>
<text top="245" left="135" width="679" height="21" font="4"><b>(≥1.8-4.9 mmol/L), at a 10-year ASCVD risk of ≥7.5% to 19.9%, if a decision about statin therapy is </b></text>
<text top="265" left="135" width="679" height="21" font="4"><b>uncertain, consider measuring CAC.</b> If CAC is zero, treatment with statin therapy may be withheld or </text>
<text top="285" left="135" width="681" height="21" font="5">delayed, except in cigarette smokers, those with diabetes mellitus, and those with a strong family </text>
<text top="305" left="135" width="679" height="21" font="5">history of premature ASCVD. A CAC score of 1 to 99 favors statin therapy, especially in those ≥55 years </text>
<text top="325" left="135" width="679" height="21" font="5">of age. For any patient, if the CAC score is ≥100 Agatston units or ≥75th percentile, statin therapy is </text>
<text top="345" left="135" width="594" height="21" font="5">indicated unless otherwise deferred by the outcome of clinician–patient risk discussion.  </text>
<text top="366" left="108" width="707" height="21" font="5">10. <b>Assess adherence and percentage response to LDL-C–lowering medications and lifestyle changes </b></text>
<text top="386" left="135" width="679" height="21" font="4"><b>with repeat lipid measurement 4 to 12 weeks after statin initiation or dose adjustment, repeated </b></text>
<text top="406" left="135" width="681" height="21" font="4"><b>every 3  to 12 months as needed. </b>Define<b>  </b>responses to lifestyle and statin therapy by percentage </text>
<text top="426" left="135" width="680" height="21" font="5">reductions in LDL-C levels compared with baseline. In ASCVD patients at very high-risk, triggers for </text>
<text top="446" left="135" width="679" height="21" font="5">adding nonstatin drug therapy are defined by threshold LDL-C levels ≥70 mg/dL (≥1.8 mmol/L) on </text>
<text top="466" left="135" width="238" height="21" font="5">maximal statin therapy (see No. 3). </text>
<text top="495" left="108" width="4" height="21" font="5"> </text>
<text top="530" left="108" width="4" height="21" font="5"> </text>
<text top="524" left="324" width="5" height="29" font="2"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="7" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="13" size="14" family="Times" color="#0000ff"/>
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-7_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="439" width="44" height="19" font="1">Page 7 </text>
<text top="124" left="108" width="101" height="31" font="11"><b>Preamble </b></text>
<text top="167" left="108" width="709" height="21" font="5">Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have </text>
<text top="187" left="108" width="712" height="21" font="5">translated scientific evidence into clinical practice guidelines with recommendations to improve </text>
<text top="207" left="108" width="706" height="21" font="5">cardiovascular health. These guidelines, which are based on systematic methods to evaluate and classify </text>
<text top="227" left="108" width="706" height="21" font="5">evidence, provide a foundation for the delivery of quality cardiovascular care. The ACC and AHA sponsor </text>
<text top="247" left="108" width="706" height="21" font="5">the development and publication of clinical practice guidelines without commercial support, and </text>
<text top="267" left="108" width="432" height="21" font="5">members volunteer their time to the writing and review efforts. </text>
<text top="287" left="162" width="654" height="21" font="5">Clinical practice  guidelines provide recommendations applicable to patients with or at risk of </text>
<text top="307" left="108" width="706" height="21" font="5">developing cardiovascular disease (CVD). The focus is on medical practice in the United States, but these </text>
<text top="328" left="108" width="708" height="21" font="5">guidelines are relevant to patients throughout the world. Although guidelines may be used to inform </text>
<text top="348" left="108" width="707" height="21" font="5">regulatory or payer decisions, the intent is to improve quality of care and align with patients’ interests. </text>
<text top="368" left="108" width="711" height="21" font="5">Guidelines are intended to define practices meeting the needs of patients in most, but not all, </text>
<text top="388" left="108" width="383" height="21" font="5">circumstances, and should not replace clinical judgment. </text>
<text top="408" left="162" width="652" height="21" font="5">Recommendations for guideline-directed management and therapy, which encompasses clinical </text>
<text top="428" left="108" width="707" height="21" font="5">evaluation, diagnostic testing, and both pharmacological and procedural treatments, are effective only </text>
<text top="449" left="108" width="706" height="21" font="5">when followed by both practitioners and patients. Adherence to recommendations can be enhanced by </text>
<text top="469" left="108" width="713" height="21" font="5">shared decision-making between clinicians and patients, with patient engagement in selecting </text>
<text top="489" left="108" width="706" height="21" font="5">interventions on the basis of individual values, preferences, and associated conditions and comorbidities. </text>
<text top="509" left="162" width="651" height="21" font="5">The ACC/AHA Task Force on Clinical Practice Guidelines strives to ensure that the guideline writing </text>
<text top="529" left="108" width="706" height="21" font="5">committee both contains requisite expertise and is representative of the broader medical community by </text>
<text top="549" left="108" width="707" height="21" font="5">selecting experts from a broad array of backgrounds, representing different geographic regions, sexes, </text>
<text top="569" left="108" width="711" height="21" font="5">races,  ethnicities, intellectual perspectives/biases, and scopes of clinical practice, and by inviting </text>
<text top="589" left="108" width="706" height="21" font="5">organizations and professional societies with related interests and expertise to participate as partners or </text>
<text top="610" left="108" width="709" height="21" font="5">collaborators.  The ACC and AHA have rigorous policies and methods to ensure that documents are </text>
<text top="630" left="108" width="707" height="21" font="5">developed without bias or improper influence. The complete policy on relationships with industry and </text>
<text top="650" left="108" width="290" height="21" font="5">other entities (RWI) can be found at<a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy"> </a></text>
<text top="650" left="397" width="413" height="21" font="13"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">http://www.acc.org/guidelines/about-guidelines-and-clinical-</a></text>
<text top="670" left="108" width="307" height="21" font="13"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">documents/relationships-with-industry-policy</a></text>
<text top="670" left="415" width="8" height="21" font="5"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">.</a> </text>
<text top="690" left="162" width="652" height="21" font="5">Beginning in 2017, numerous modifications to the guidelines have been and continue to be </text>
<text top="710" left="108" width="708" height="21" font="5">implemented  to make guidelines shorter and enhance “user friendliness.”  Guidelines are written and </text>
<text top="730" left="108" width="713" height="21" font="5">presented in a modular knowledge chunk format,  in  which  each chunk  includes a table of </text>
<text top="751" left="108" width="708" height="21" font="5">recommendations, a brief synopsis, recommendation-specific supportive text and,  when appropriate, </text>
<text top="771" left="108" width="706" height="21" font="5">flow diagrams or additional tables. Hyperlinked references are provided for each modular knowledge </text>
<text top="791" left="108" width="706" height="21" font="5">chunk to facilitate quick access and review. More structured guidelines—including word limits (“targets”) </text>
<text top="811" left="108" width="706" height="21" font="5">and a web guideline supplement for useful but noncritical tables and figures—are 2 such changes. This </text>
<text top="831" left="108" width="726" height="21" font="5">Preamble  is  an abbreviated version, with  the detailed version available at: </text>
<text top="851" left="108" width="493" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625</a></text>
<text top="851" left="602" width="8" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">.</a> </text>
<text top="871" left="108" width="4" height="21" font="5"> </text>
<text top="891" left="108" width="230" height="21" font="6"><i>Glenn N. Levine, MD, FACC, FAHA  </i></text>
<text top="911" left="108" width="386" height="21" font="6"><i>Chair, ACC/AHA Task Force on Clinical Practice Guidelines </i></text>
<text top="932" left="108" width="4" height="21" font="5"> </text>
<text top="932" left="324" width="4" height="21" font="5"> </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="8" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-8_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="439" width="44" height="19" font="1">Page 8 </text>
<text top="124" left="108" width="154" height="31" font="11"><b>1. Introduction </b></text>
<text top="166" left="108" width="373" height="29" font="2"><b>1.1. Methodology and Evidence Review </b></text>
<text top="207" left="108" width="707" height="21" font="5">The recommendations listed in the present guideline are, whenever possible, evidence based. An initial </text>
<text top="227" left="108" width="708" height="21" font="5">extensive evidence review, which included literature derived from research involving human subjects, </text>
<text top="247" left="108" width="706" height="21" font="5">published in English, and indexed in MEDLINE (through PubMed), EMBASE, the Cochrane Library, the </text>
<text top="268" left="108" width="709" height="21" font="5">Agency for Healthcare Research and Quality, and other selected databases relevant to the present </text>
<text top="288" left="108" width="706" height="21" font="5">guideline, was conducted from May 1980 to July 2017. Key search words included but were not limited to </text>
<text top="308" left="108" width="711" height="21" font="5">the following:  <i>hyperlipidemia,  cholesterol, LDL-C, HDL-C,  ezetimibe, bile acid sequestrants, PCSK9 </i></text>
<text top="327" left="108" width="705" height="21" font="6"><i>inhibitors, lifestyle, diet, exercise, medications, child, adolescent, screening, primary prevention, secondary </i></text>
<text top="347" left="108" width="702" height="21" font="6"><i>prevention, cardiovascular disease, coronary artery calcium, familial hypercholesterolemia. ASCVD risk-</i></text>
<text top="367" left="108" width="708" height="21" font="6"><i>enhancing factors, statin therapy, diabetes mellitus, women, adherence, Hispanic/Latino, South Asian, </i></text>
<text top="388" left="108" width="706" height="22" font="6"><i>African American.</i> Additional relevant studies published through August 2018 during the guideline writing </text>
<text top="409" left="108" width="710" height="21" font="5">process, were also considered by the writing committee and added to the evidence tables when </text>
<text top="429" left="108" width="720" height="21" font="5">appropriate. The final evidence tables are  included in the Online Data Supplement </text>
<text top="449" left="108" width="5" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">(</a></text>
<text top="449" left="113" width="494" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625</a></text>
<text top="449" left="607" width="208" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">) </a>and summarize the evidence </text>
<text top="469" left="108" width="706" height="21" font="5">used by the writing committee to formulate recommendations. References selected and published in the </text>
<text top="489" left="108" width="397" height="21" font="5">present document are representative and not all-inclusive. </text>
<text top="509" left="162" width="652" height="21" font="5">As noted in the detailed version of the Preamble, an independent evidence review committee </text>
<text top="529" left="108" width="710" height="21" font="5">was commissioned to perform a formal systematic review of critical clinical questions related to </text>
<text top="550" left="108" width="707" height="21" font="5">cholesterol (Table 1), the results of which were considered by the writing committee for incorporation </text>
<text top="570" left="108" width="707" height="21" font="5">into the present guideline. Concurrent with this process, writing committee members evaluated study </text>
<text top="590" left="108" width="706" height="21" font="5">data relevant to the rest of the guideline. The findings of the evidence review committee and the writing </text>
<text top="610" left="108" width="712" height="21" font="5">committee members were formally presented and discussed, and then recommendations were </text>
<text top="630" left="108" width="706" height="21" font="5">developed. The systematic review  for the 2018 Cholesterol  Clinical Practice Guidelines  (S1.1<a href="CIR.0000000000000625.html#85">-1)</a>  is </text>
<text top="650" left="108" width="657" height="21" font="5">published in conjunction with the present guideline and includes its respective data supplements. </text>
<text top="670" left="162" width="648" height="21" font="5">Numerical values for triglycerides, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-</text>
<text top="690" left="108" width="706" height="21" font="5">C), high-density lipoprotein cholesterol (HDL-C), and non–HDL-C are given in both mg/dL and mmol/L. To </text>
<text top="711" left="108" width="707" height="21" font="5">convert to mmol/L, the values in mg/dL for TC, LDL-C, HDL-C, and non–HDL-C were divided by 38.6 and </text>
<text top="731" left="108" width="170" height="21" font="5">for triglycerides, by 88.6. </text>
<text top="751" left="162" width="648" height="21" font="5">On May 10, 2018  a writing committee member discussed their participation in an industry-</text>
<text top="771" left="108" width="708" height="21" font="5">supported,  multicenter study, which they had thought was not relevant to this prevention guideline. </text>
<text top="791" left="108" width="709" height="21" font="5">However, when this was reviewed using specific ACC/AHA criteria it was considered to represent a </text>
<text top="811" left="108" width="705" height="21" font="5">relevant relationship with industry. Given the current policy that a prevention guideline writing committee </text>
<text top="831" left="108" width="707" height="21" font="5">member must be free of any relevant relationships with industry, this member was removed from the </text>
<text top="852" left="108" width="706" height="21" font="5">committee. The 2 sections authored by the writing committee member were removed and replaced by </text>
<text top="872" left="108" width="708" height="21" font="5">new material written by the guideline chairs, and the  revised sections  reviewed  and approved  by all </text>
<text top="892" left="108" width="705" height="21" font="5">remaining writing committee members. The writing committee member did not participate in any further </text>
<text top="912" left="108" width="483" height="21" font="5">guideline discussions or review of the manuscript or recommendations. </text>
<text top="932" left="108" width="4" height="21" font="5"> </text>
<text top="952" left="108" width="4" height="21" font="4"><b> </b></text>
<text top="952" left="324" width="4" height="21" font="4"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="9" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="14" size="16" family="Times" color="#000000"/>
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-9_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="439" width="44" height="19" font="1">Page 9 </text>
<text top="124" left="108" width="161" height="21" font="4"><b>Table 1. ERC Questions</b> </text>
<text top="147" left="108" width="4" height="21" font="5"> </text>
<text top="191" left="116" width="66" height="21" font="4"><b>Question </b></text>
<text top="171" left="727" width="54" height="21" font="4"><b>Section </b></text>
<text top="191" left="724" width="60" height="21" font="4"><b>Number </b></text>
<text top="212" left="116" width="563" height="21" font="5">In adults ≥20 years of age with clinical atherosclerotic disease (e.g., CHD, peripheral </text>
<text top="232" left="116" width="221" height="21" font="5">artery disease, or CVD) or at high</text>
<text top="234" left="338" width="5" height="19" font="1">-</text>
<text top="232" left="342" width="333" height="21" font="5">risk of ASCVD, what are the magnitude of benefit </text>
<text top="252" left="116" width="547" height="21" font="5">(absolute reduction; NNT) in individual endpoints and composite ischemic events </text>
<text top="272" left="116" width="475" height="21" font="5">(e.g., fatal cardiovascular event, nonfatal MI, nonfatal stroke, unstable </text>
<text top="293" left="116" width="566" height="21" font="5">angina/revascularization) and magnitude of harm (absolute increase; NNH) in terms </text>
<text top="313" left="116" width="569" height="21" font="5">of adverse events (e.g., cancer, rhabdomyolysis, diabetes mellitus) derived from LDL-</text>
<text top="333" left="116" width="535" height="21" font="5">C lowering in large RCTs (&gt;1,000 participants and originally designed to last &gt;12 </text>
<text top="353" left="116" width="537" height="21" font="5">months) with statin therapy plus a second lipid-modifying agent compared with </text>
<text top="373" left="116" width="90" height="21" font="5">statin alone? </text>
<text top="212" left="742" width="25" height="21" font="4"><b>4.1 </b></text>
<text top="394" left="108" width="706" height="19" font="1">Clinical atherosclerotic cardiovascular disease (ASCVD) includes acute coronary syndrome (ACS), those with history </text>
<text top="413" left="108" width="708" height="19" font="1">of myocardial infarction (MI), stable or unstable angina or  coronary or  other arterial revascularization, stroke, </text>
<text top="431" left="108" width="706" height="19" font="1">transient ischemic attack (TIA), or peripheral artery disease (PAD) including aortic aneurysm, all of atherosclerotic </text>
<text top="449" left="108" width="42" height="19" font="1">origin. </text>
<text top="467" left="108" width="706" height="19" font="1">ASCVD indicates atherosclerotic cardiovascular disease; CHD, coronary heart disease; CVD, cardiovascular disease; </text>
<text top="486" left="108" width="709" height="19" font="1">ERC, Evidence Review Committee; LDL-C,  low-density lipoprotein  cholesterol; MI, myocardial infarction; NNH, </text>
<text top="504" left="108" width="572" height="19" font="1">number needed to harm; NNT number needed to treat; and RCT, randomized controlled trial. </text>
<text top="522" left="108" width="4" height="23" font="14"> </text>
<text top="544" left="108" width="410" height="29" font="2"><b>1.2. Organization of the Writing Committee </b></text>
<text top="585" left="108" width="706" height="21" font="5">The writing committee consisted of medical experts including cardiologists, internists, interventionalists, </text>
<text top="605" left="108" width="707" height="21" font="5">a nurse practitioner, pharmacists, a physician assistant, a pediatrician, a nephrologist, and a lay/patient </text>
<text top="625" left="108" width="706" height="21" font="5">representative. The writing committee included representatives from the American Heart Association </text>
<text top="645" left="108" width="708" height="21" font="5">(AHA),  American College of Cardiology (ACC), American Association of Cardiovascular and Pulmonary </text>
<text top="665" left="108" width="707" height="21" font="5">Rehabilitation (AACVPR), American Association Academy of Physician Assistants (AAPA), Association of </text>
<text top="685" left="108" width="712" height="21" font="5">Black Cardiologists (ABC),  American College of Preventive Medicine (ACPM),  American Diabetes </text>
<text top="706" left="108" width="706" height="21" font="5">Association (ADA),  American Geriatrics Society (AGS),  American Pharmacists Association (APhA), </text>
<text top="726" left="108" width="706" height="21" font="5">American Society for Preventive Cardiology (ASPC),  National  Lipid Association (NLA),  and  Preventive </text>
<text top="746" left="108" width="707" height="21" font="5">Cardiovascular Nurses Association (PCNA). Appendix 1 of the present document lists writing committee </text>
<text top="766" left="108" width="707" height="21" font="5">members’ relevant relationships with industry and other entities. For the purposes of full transparency, </text>
<text top="786" left="108" width="706" height="21" font="5">the writing committee members’ comprehensive disclosure information is available online </text>
<text top="806" left="108" width="5" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">(</a></text>
<text top="806" left="113" width="494" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625</a></text>
<text top="806" left="607" width="13" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">).</a> </text>
<text top="835" left="108" width="346" height="29" font="2"><b>1.3. Document Review and Approval </b></text>
<text top="876" left="108" width="705" height="21" font="5">This document was reviewed by 21 official reviewers each nominated by the ACC, AHA, AAPA, ABC, ACPM, </text>
<text top="896" left="108" width="709" height="21" font="5">ADA, AGS, APhA, ASPC, NLA,  and PCNA,  as well as  27  individual content reviewers. Reviewers’ RWI </text>
<text top="916" left="108" width="689" height="21" font="5">information was distributed to the writing committee and is published in this document (Appendix 2).  </text>
<text top="936" left="162" width="652" height="21" font="5">This document was approved for publication by the governing bodies of the AHA, the ACC, AAPA, </text>
<text top="957" left="108" width="352" height="21" font="5">ABC, ACPM, ADA, AGS, APhA, ASPC, NLA, and PCNA. </text>
<text top="986" left="108" width="261" height="29" font="2"><b>1.4. Scope of the Guideline  </b></text>
<text top="1026" left="108" width="706" height="21" font="5">The purpose of the present guideline is to address the practical management of patients with high blood </text>
<text top="1046" left="108" width="709" height="21" font="5">cholesterol and related disorders. The  writing committee reviewed previously  published guidelines, </text>
<text top="1067" left="108" width="287" height="21" font="5">evidence reviews, and related statements<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">. </a></text>
<text top="1067" left="395" width="218" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Table S1 in the Web Supplement</a></text>
<text top="1067" left="613" width="201" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625"> </a>contains a list of publications </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="10" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-10_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="51" height="19" font="1">Page 10 </text>
<text top="124" left="108" width="708" height="21" font="5">and  statements deemed pertinent.  The primary sources of evidence are randomized controlled trials </text>
<text top="144" left="108" width="706" height="21" font="5">(RCTs). Most RCTs in this area have been performed with statins as the only cholesterol-lowering drug </text>
<text top="164" left="108" width="706" height="21" font="5">(S1.4<a href="CIR.0000000000000625.html#85">-1–S1.4-3)</a>. Since the 2013 ACC/AHA cholesterol guideline  (S1.4<a href="CIR.0000000000000625.html#85">-4)</a>, newer cholesterol-lowering </text>
<text top="184" left="108" width="706" height="21" font="5">agents (nonstatin drugs) have been introduced and subjected to RCTs. They include ezetimibe and PCSK9 </text>
<text top="204" left="108" width="706" height="21" font="5">inhibitors, and their use is limited mainly to secondary prevention in patients at very high-risk of new </text>
<text top="224" left="108" width="706" height="21" font="5">atherosclerotic cardiovascular disease (ASCVD) events. Most other patients with ASCVD are treated with </text>
<text top="245" left="108" width="717" height="21" font="5">statins alone. In primary prevention, statins are recommended for patients with severe </text>
<text top="265" left="108" width="705" height="21" font="5">hypercholesterolemia and in adults 40 to 75 years of age either with diabetes mellitus or at higher ASCVD </text>
<text top="285" left="108" width="706" height="21" font="5">risk.  Throughout these  guidelines  similar to the 2013 guidelines,  consistent  attention is given to  a </text>
<text top="305" left="108" width="706" height="21" font="5">clinician–patient risk discussion for making shared decisions. Besides major risk factors of the pooled </text>
<text top="325" left="108" width="706" height="21" font="5">cohort equations (PCE), the clinician–patient risk discussion can include other risk-enhancing factors, and </text>
<text top="345" left="108" width="702" height="21" font="5">when risk status is uncertain, a coronary artery calcium (CAC) score is an option to facilitate decision-</text>
<text top="366" left="108" width="708" height="21" font="5">making in adults ≥40 years  of age.  In children, adolescents,  and young adults, identifying those with </text>
<text top="386" left="108" width="708" height="21" font="5">familial hypercholesterolemia (FH) is a priority. However, most attention is given to reducing lifetime </text>
<text top="406" left="108" width="265" height="21" font="5">ASCVD risk through lifestyle therapies.  </text>
<text top="435" left="108" width="494" height="29" font="2"><b>1.5. Class of Recommendation and Level of Evidence </b></text>
<text top="476" left="108" width="707" height="21" font="5">Recommendations are designated with both a class of recommendation (COR) and a level of evidence </text>
<text top="496" left="108" width="710" height="21" font="5">(LOE). The class of recommendation indicates the strength of recommendation, encompassing the </text>
<text top="516" left="108" width="706" height="21" font="5">estimated magnitude and certainty of benefit in proportion to risk. The level of evidence rates the quality </text>
<text top="536" left="108" width="707" height="21" font="5">of scientific evidence supporting the intervention on the basis of the type, quantity, and consistency of </text>
<text top="556" left="108" width="403" height="21" font="5">data from clinical trials and other sources (Table 2) (S1.5-1). </text>
<text top="588" left="108" width="4" height="21" font="5"> </text>
<text top="620" left="108" width="4" height="21" font="4"><b> </b></text>
<text top="620" left="324" width="4" height="21" font="4"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="11" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="15" size="20" family="Times" color="#000000"/>
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-11_1.jpg"/>
<image top="173" left="108" width="702" height="721" src="blood-cholesterol-management/CIR.0000000000000625-11_2.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="51" height="19" font="1">Page 11 </text>
<text top="124" left="108" width="702" height="21" font="4"><b>Table 2. Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, </b></text>
<text top="144" left="108" width="509" height="21" font="4"><b>Treatments, or Diagnostic Testing in Patient Care* (Updated August 2015)</b> </text>
<text top="878" left="810" width="4" height="21" font="5"> </text>
<text top="906" left="108" width="4" height="21" font="5"> </text>
<text top="938" left="108" width="5" height="29" font="15"> </text>
<text top="938" left="324" width="5" height="29" font="2"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="12" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-12_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="51" height="19" font="1">Page 12 </text>
<text top="124" left="108" width="176" height="29" font="2"><b>1.6. Abbreviations </b></text>
<text top="167" left="116" width="97" height="21" font="4"><b>Abbreviation  </b></text>
<text top="167" left="258" width="118" height="21" font="4"><b>Meaning/Phrase </b></text>
<text top="191" left="116" width="26" height="21" font="5">ABI </text>
<text top="191" left="258" width="139" height="21" font="5">ankle-brachial index </text>
<text top="216" left="116" width="30" height="21" font="5">ACS </text>
<text top="216" left="258" width="175" height="21" font="5">acute coronary syndrome </text>
<text top="240" left="116" width="35" height="21" font="5">AIDS </text>
<text top="240" left="258" width="261" height="21" font="5">acquired immunodeficiency syndrome </text>
<text top="264" left="116" width="38" height="21" font="5">apoB </text>
<text top="264" left="258" width="116" height="21" font="5">apolipoprotein B </text>
<text top="289" left="116" width="31" height="21" font="5">ARR </text>
<text top="289" left="258" width="158" height="21" font="5">absolute risk reduction </text>
<text top="313" left="116" width="49" height="21" font="5">ASCVD </text>
<text top="313" left="258" width="259" height="21" font="5">atherosclerotic cardiovascular disease </text>
<text top="338" left="116" width="31" height="21" font="5">CAC </text>
<text top="338" left="258" width="163" height="21" font="5">coronary artery calcium </text>
<text top="362" left="116" width="33" height="21" font="5">CHD </text>
<text top="362" left="258" width="157" height="21" font="5">coronary heart disease </text>
<text top="386" left="116" width="21" height="21" font="5">CK </text>
<text top="386" left="258" width="105" height="21" font="5">creatine kinase </text>
<text top="411" left="116" width="31" height="21" font="5">CKD </text>
<text top="411" left="258" width="155" height="21" font="5">chronic kidney disease </text>
<text top="435" left="116" width="32" height="21" font="5">COR </text>
<text top="435" left="258" width="178" height="21" font="5">Class of Recommendation </text>
<text top="459" left="116" width="29" height="21" font="5">CTT </text>
<text top="459" left="258" width="210" height="21" font="5">Cholesterol Treatment Trialists </text>
<text top="484" left="116" width="32" height="21" font="5">CVD </text>
<text top="484" left="258" width="154" height="21" font="5">cardiovascular disease </text>
<text top="508" left="116" width="39" height="21" font="5">eGFR </text>
<text top="508" left="258" width="242" height="21" font="5">estimated glomerular filtration rate </text>
<text top="532" left="116" width="22" height="21" font="5">FH </text>
<text top="532" left="258" width="203" height="21" font="5">familial hypercholesterolemia </text>
<text top="557" left="116" width="35" height="21" font="5">HDL  </text>
<text top="557" left="258" width="164" height="21" font="5">high-density lipoprotein </text>
<text top="584" left="116" width="22" height="21" font="5">HF </text>
<text top="584" left="258" width="87" height="21" font="5">heart failure </text>
<text top="610" left="116" width="28" height="21" font="5">HIV </text>
<text top="610" left="258" width="214" height="21" font="5">human immunodeficiency virus </text>
<text top="635" left="116" width="42" height="21" font="5">LDL-C </text>
<text top="635" left="258" width="238" height="21" font="5">low-density lipoprotein cholesterol </text>
<text top="659" left="116" width="30" height="21" font="5">LOE </text>
<text top="659" left="258" width="120" height="21" font="5">Level of Evidence </text>
<text top="683" left="116" width="37" height="21" font="5">Lp(a) </text>
<text top="683" left="258" width="100" height="21" font="5">lipoprotein (a) </text>
<text top="708" left="116" width="22" height="21" font="5">MI </text>
<text top="708" left="258" width="146" height="21" font="5">myocardial infarction </text>
<text top="732" left="116" width="29" height="21" font="5">PCE </text>
<text top="732" left="258" width="169" height="21" font="5">pooled cohort equations </text>
<text top="757" left="116" width="39" height="21" font="5">QALY </text>
<text top="757" left="258" width="172" height="21" font="5">quality-adjusted life-year </text>
<text top="781" left="116" width="22" height="21" font="5">RA </text>
<text top="781" left="258" width="140" height="21" font="5">rheumatoid arthritis </text>
<text top="805" left="116" width="29" height="21" font="5">RCT </text>
<text top="805" left="258" width="193" height="21" font="5">randomized controlled trials </text>
<text top="830" left="116" width="31" height="21" font="5">RRR </text>
<text top="830" left="258" width="150" height="21" font="5">relative risk reduction </text>
<text top="854" left="116" width="31" height="21" font="5">RWI </text>
<text top="854" left="258" width="306" height="21" font="5">relationships with industry and other entities </text>
<text top="878" left="116" width="43" height="21" font="5">SAMS </text>
<text top="878" left="258" width="242" height="21" font="5">statin-associated muscle symptoms </text>
<text top="903" left="116" width="20" height="21" font="5">SR </text>
<text top="903" left="258" width="124" height="21" font="5">systematic review </text>
<text top="928" left="116" width="21" height="21" font="5">TC </text>
<text top="928" left="258" width="114" height="21" font="5">total cholesterol </text>
<text top="953" left="116" width="37" height="21" font="5">VLDL </text>
<text top="953" left="258" width="192" height="21" font="5">very low-density lipoprotein </text>
<text top="979" left="116" width="51" height="21" font="5">VLDL-C </text>
<text top="979" left="258" width="271" height="21" font="5">very low-density lipoprotein cholesterol </text>
<text top="1009" left="108" width="5" height="16" font="14"> </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="13" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="16" size="19" family="Times" color="#000000"/>
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-13_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 13</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="374" height="31" font="11"><b>2. High Blood Cholesterol and ASCVD </b></text>
<text top="166" left="108" width="460" height="29" font="2"><b>2.1. Serum Cholesterol, Lipoproteins, and ASCVD </b></text>
<text top="207" left="108" width="470" height="27" font="16"><i><b>2.1.1. Cholesterol, Lipoproteins, and Apolipoprotein B </b></i></text>
<text top="246" left="108" width="708" height="21" font="5">Serum cholesterol and its lipoprotein carriers (LDL, very low-density lipoprotein [VLDL],  and HDL) are </text>
<text top="266" left="108" width="706" height="21" font="5">known to be related to ASCVD. LDL-C is the dominant form of atherogenic cholesterol. VLDL is the chief </text>
<text top="286" left="108" width="710" height="21" font="5">carrier of triglycerides, and VLDL cholesterol (VLDL-C)  is also atherogenic. HDL-C is seemingly not </text>
<text top="306" left="108" width="714" height="21" font="5">atherogenic.  Chylomicrons  transport dietary fat; chylomicron atherogenicity is uncertain. The </text>
<text top="326" left="108" width="707" height="21" font="5">combination of LDL-C and VLDL-C is called non–HDL-C and is more atherogenic than either lipoprotein </text>
<text top="346" left="108" width="706" height="21" font="5">alone. The main protein embedded in LDL and VLDL is apolipoprotein B (apoB), and like non–HDL-C, apoB </text>
<text top="366" left="108" width="393" height="21" font="5">is a stronger indicator of atherogenicity than LDL-C alone.  </text>
<text top="396" left="108" width="322" height="27" font="16"><i><b>2.1.2. Cholesterol, LDL-C, and ASCVD </b></i></text>
<text top="434" left="108" width="709" height="21" font="5">Evidence that serum cholesterol contributes to ASCVD comes from several sources: animal studies, </text>
<text top="454" left="108" width="702" height="21" font="5">genetic forms of hypercholesterolemia, epidemiological studies, and RCTs. U.S. population studies (S2.1.2-</text>
<text top="474" left="108" width="709" height="21" font="5"><a href="CIR.0000000000000625.html#85">1,</a>  S2.1.2<a href="CIR.0000000000000625.html#85">-2)</a>  suggest that optimal total cholesterol  levels are about 150 mg/dL  (3.8 mmol/L), which </text>
<text top="495" left="108" width="709" height="21" font="5">corresponds to an LDL-C  level  of about 100 mg/dL  (2.6 mmol/L). Adult populations with cholesterol </text>
<text top="515" left="108" width="705" height="21" font="5">concentrations in this range manifest low rates of ASCVD (S2.1.2<a href="CIR.0000000000000625.html#85">-3)</a>. RCTs of cholesterol-lowering drugs in </text>
<text top="535" left="108" width="707" height="21" font="5">high-risk patients confirm that LDL-C lowering produces marked reductions in ASCVD. This confirms the </text>
<text top="555" left="108" width="710" height="21" font="5">general principle that “lower is better” for LDL-C  (S2.1.2<a href="CIR.0000000000000625.html#86">-4–S2.1-6)</a>.  The present guideline looks to </text>
<text top="575" left="108" width="708" height="21" font="5">evidence from new RCTs to aid in the translation of RCT data to the individual patient to provide net </text>
<text top="595" left="108" width="124" height="21" font="5">benefit (S2.1.2<a href="CIR.0000000000000625.html#86">-7)</a>. </text>
<text top="625" left="108" width="308" height="27" font="16"><i><b>2.1.3. LDL-C and Other Risk Factors </b></i></text>
<text top="663" left="108" width="706" height="21" font="5">Although LDL-C is a primary cause of atherosclerosis, other risk factors contribute, as well. The <i>major risk </i></text>
<text top="682" left="108" width="710" height="22" font="6"><i>factors</i>  include cigarette smoking, hypertension, dysglycemia, and other lipoprotein abnormalities. </text>
<text top="703" left="108" width="707" height="21" font="5">Because atherosclerosis progresses with advancing age, a person’s age also counts as a risk factor. By </text>
<text top="723" left="108" width="705" height="21" font="5">combining all major risk factors into a prediction equation, an individual’s probability of developing ASCVD </text>
<text top="743" left="108" width="706" height="21" font="5">can be estimated. The Framingham Heart Study (S2.1.3<a href="CIR.0000000000000625.html#86">-1)</a>  took the lead in creating risk-prediction </text>
<text top="764" left="108" width="705" height="21" font="5">equations. These were improved in the 2013 ACC/AHA cholesterol guidelines (S2.1.3<a href="CIR.0000000000000625.html#86">-2)</a> by compiling data </text>
<text top="784" left="108" width="706" height="21" font="5">from 5 community-based cohorts that were broadly representative of the U.S. population. These so-called </text>
<text top="804" left="108" width="706" height="21" font="5">population cohort equations have been validated in a large community-based U.S. population (S2.1.3<a href="CIR.0000000000000625.html#86">-3)</a>. </text>
<text top="824" left="108" width="705" height="21" font="5">Initially, data from the Women’s Health Initiative, a contemporary multiethnic cohort of postmenopausal </text>
<text top="844" left="108" width="707" height="21" font="5">women, appeared to indicate that these pooled cohort equations overestimated ASCVD risk. However, </text>
<text top="864" left="108" width="708" height="21" font="5">when event surveillance was improved by data from Centers for Medicare &amp;  Medicaid Services, the </text>
<text top="884" left="108" width="453" height="21" font="5">authors found that the equations discriminated risk well (S2.1.3<a href="CIR.0000000000000625.html#86">-4)</a>. </text>
<text top="904" left="162" width="648" height="21" font="5">Several other factors associate with ASCVD, and in the present document these are called <i>risk-</i></text>
<text top="924" left="108" width="706" height="22" font="6"><i>enhancing factors. </i>Projections of future risk derived from major risk factors and risk-enhancing factors </text>
<text top="945" left="108" width="403" height="21" font="5">can be used to adjust the intensity of LDL-lowering therapy. </text>
<text top="974" left="108" width="4" height="21" font="5"> </text>
<text top="994" left="108" width="4" height="21" font="5"> </text>
<text top="1023" left="108" width="4" height="21" font="5"> </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="14" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="17" size="13" family="Times" color="#000000"/>
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-14_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 14</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="420" height="29" font="2"><b>2.2. Measurements of LDL-C and Non–HDL-C </b></text>
<text top="165" left="244" width="434" height="21" font="4"><b>Recommendations for Measurements of LDL-C and Non–HDL-C </b></text>
<text top="188" left="132" width="474" height="21" font="5">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625"> </a></text>
<text top="188" left="606" width="176" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Online Data Supplement 1</a></text>
<text top="188" left="782" width="8" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">.</a><b> </b></text>
<text top="214" left="127" width="33" height="21" font="4"><b>COR </b></text>
<text top="214" left="195" width="30" height="21" font="4"><b>LOE </b></text>
<text top="214" left="461" width="132" height="21" font="4"><b>Recommendations </b></text>
<text top="272" left="139" width="8" height="21" font="4"><b>I </b></text>
<text top="272" left="191" width="38" height="21" font="4"><b>B-NR</b> </text>
<text top="241" left="250" width="556" height="21" font="4"><b>1.  In adults who are 20 years of age or older and not on lipid-lowering therapy, </b></text>
<text top="261" left="276" width="534" height="21" font="4"><b>measurement of either a fasting or a  nonfasting plasma lipid profile is </b></text>
<text top="282" left="276" width="526" height="21" font="4"><b>effective in estimating ASCVD risk and documenting baseline LDL-C (S2.2<a href="CIR.0000000000000625.html#86">-1–</a></b></text>
<text top="302" left="276" width="56" height="21" font="4"><a href="CIR.0000000000000625.html#86"><b>S2.2-6)</b></a><b>. </b></text>
<text top="353" left="139" width="8" height="21" font="4"><b>I </b></text>
<text top="353" left="191" width="38" height="21" font="4"><b>B-NR </b></text>
<text top="323" left="250" width="556" height="21" font="4"><b>2.  In adults who are 20 years of age or older and in whom an initial nonfasting </b></text>
<text top="343" left="276" width="530" height="21" font="4"><b>lipid profile reveals a triglycerides level of 400 mg/dL (≥4.5 mmol/L) or higher, </b></text>
<text top="363" left="276" width="530" height="21" font="4"><b>a repeat lipid profile in the fasting state should be performed for assessment </b></text>
<text top="383" left="276" width="436" height="21" font="4"><b>of fasting triglyceride levels and baseline LDL-C (S2.2<a href="CIR.0000000000000625.html#86">-1–S2.2-4)</a></b><b>. </b></text>
<text top="424" left="133" width="21" height="21" font="4"><b>IIa</b> </text>
<text top="424" left="193" width="35" height="21" font="4"><b>C-LD </b></text>
<text top="404" left="250" width="555" height="21" font="4"><b>3.  For patients with an  LDL-C  level less than  70 mg/dL  (&lt;1.8 mmol/L), </b></text>
<text top="424" left="276" width="530" height="21" font="4"><b>measurement of direct LDL-C or modified  LDL-C  estimate  is reasonable to </b></text>
<text top="444" left="276" width="435" height="21" font="4"><b>improve accuracy over the Friedewald formula (S2.2<a href="CIR.0000000000000625.html#87">-7–S2.2-9)</a></b><b>. </b></text>
<text top="505" left="133" width="21" height="21" font="4"><b>IIa </b></text>
<text top="505" left="193" width="35" height="21" font="4"><b>C-LD </b></text>
<text top="465" left="250" width="556" height="21" font="4"><b>4.  In adults who are 20 years of age or older and without a personal history of </b></text>
<text top="485" left="277" width="537" height="21" font="4"><b>ASCVD but with a family history of premature ASCVD  or genetic </b></text>
<text top="505" left="277" width="529" height="21" font="4"><b>hyperlipidemia, measurement of a fasting plasma lipid profile is reasonable </b></text>
<text top="526" left="277" width="207" height="21" font="4"><b>as part of an initial evaluation</b></text>
<text top="525" left="484" width="4" height="21" font="17"> </text>
<text top="526" left="488" width="317" height="21" font="4"><b>to aid in the understanding and identification </b></text>
<text top="546" left="277" width="178" height="21" font="4"><b>of familial lipid disorders. </b></text>
<text top="567" left="108" width="4" height="21" font="5"> </text>
<text top="596" left="108" width="63" height="21" font="4"><b>Synopsis </b></text>
<text top="635" left="108" width="706" height="21" font="5">The standard calculation method for LDL-C is the Friedewald formula: LDL-C = (TC) – (triglycerides /5) – </text>
<text top="655" left="108" width="706" height="21" font="5">(HDL-C).  When triglyceride levels are not elevated, this equation is sufficiently accurate. In </text>
<text top="675" left="108" width="706" height="21" font="5">hypertriglyceridemia, however, Friedewald-calculated LDL-C can be erroneous. After normal food intake, </text>
<text top="696" left="108" width="707" height="21" font="5">LDL-C differs minimally with time (S2.2<a href="CIR.0000000000000625.html#87">-10)</a>. Fasting and nonfasting TC and HDL-C levels appear to have </text>
<text top="716" left="108" width="710" height="21" font="5">fairly similar prognostic value and associations with CVD outcomes (S2.2<a href="CIR.0000000000000625.html#86">-1–S2.2-6,</a>  S2.2<a href="CIR.0000000000000625.html#87">-11)</a>. Thus, </text>
<text top="736" left="108" width="705" height="21" font="5">nonfasting samples can be used for risk assessment in primary prevention and for assessment of baseline </text>
<text top="756" left="108" width="707" height="21" font="5">LDL-C levels before the initiation of a statin in primary and secondary prevention. If more precision is </text>
<text top="776" left="108" width="706" height="21" font="5">necessary, fasting lipids can be measured, but a nonfasting sample is reasonable for most situations. The </text>
<text top="796" left="108" width="706" height="21" font="5">unreliability of the Friedewald-calculated LDL-C levels appears to be greatest at lower levels of LDL-C, </text>
<text top="816" left="108" width="702" height="21" font="5">particularly &lt;70 mg/dL (&lt;1.8 mmol/L) (S2.2-7). Martin et al. have validated an approach to estimating LDL-</text>
<text top="836" left="108" width="706" height="21" font="5">C levels from a standard lipid panel when LDL-C levels is &lt;70 mg/dL (&lt;1.8 mmol/L) and triglycerides levels </text>
<text top="857" left="108" width="322" height="21" font="5">are &gt;150 mg/dL (&gt;1.7 mmol/L) (S2.2<a href="CIR.0000000000000625.html#87">-7–S2.2-9)</a>.  </text>
<text top="886" left="108" width="295" height="21" font="4"><b>Recommendation-Specific Supportive Text </b></text>
<text top="925" left="108" width="706" height="21" font="5">1.  If an individual has ingested an extremely high-fat meal in the preceding 8 hours, it may be prudent </text>
<text top="945" left="135" width="680" height="21" font="5">to assess lipids on another day after counseling the patient to avoid such meals. Documentation of </text>
<text top="965" left="135" width="680" height="21" font="5">the baseline LDL-C level will be useful in assessing the patient’s response to the initiation of statin </text>
<text top="985" left="135" width="679" height="21" font="5">therapy, if that is undertaken (S2.2<a href="CIR.0000000000000625.html#86">-1–S2.2-6)</a>. Similarly, given relatively modest differences in LDL-C </text>
<text top="1006" left="135" width="679" height="21" font="5">levels associated with the postprandial state, use of a nonfasting sample is effective to document </text>
<text top="1026" left="135" width="675" height="21" font="5">baseline lipid levels before initiation of statin therapy in individuals with clinical ASCVD (S2.2<a href="CIR.0000000000000625.html#86">-1–S2.2-</a></text>
<text top="1046" left="135" width="678" height="21" font="5"><a href="CIR.0000000000000625.html#86">6)</a>. In adults with a family history of premature ASCVD or genetic hyperlipidemia, a fasting lipid profile </text>
<text top="1066" left="135" width="235" height="21" font="5">is reasonable for initial evaluation. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="15" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-15_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 15</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="705" height="21" font="5">2.  Given relatively modest differences in LDL-C levels between fasting and non-fasting samples, the latter </text>
<text top="144" left="135" width="675" height="21" font="5">is generally adequate to document baseline lipid levels prior to initiation of statin therapy (S2.2<a href="CIR.0000000000000625.html#86">-1–</a></text>
<text top="164" left="135" width="55" height="21" font="5"><a href="CIR.0000000000000625.html#86">S2.2-6)</a>. </text>
<text top="184" left="108" width="707" height="21" font="5">3.  The unreliability of the Friedewald-calculated LDL-C levels rises at lower levels of LDL-C, particularly </text>
<text top="204" left="135" width="679" height="21" font="5">&lt;70 mg/dL (&lt;1.8 mmol/L). If accurate measurements of LDL-C levels<b> </b>are needed at very low LDL-C, </text>
<text top="225" left="135" width="683" height="21" font="5">calculation adjustments can be used  (S2.2<a href="CIR.0000000000000625.html#87">-7–S2.2-9)</a>.  Measurement of apoB  may be useful in </text>
<text top="245" left="135" width="601" height="21" font="5">determining whether hypertriglyceridemia is an atherogenic condition (S2.2<a href="CIR.0000000000000625.html#87">-12,</a> S2.2<a href="CIR.0000000000000625.html#87">-13)</a>. </text>
<text top="265" left="108" width="706" height="21" font="5">4.  In adults with a family history of premature ASCVD or genetic hyperlipidemia, a fasting lipid profile is </text>
<text top="285" left="135" width="683" height="21" font="5">reasonable for initial evaluation to aid in the understanding and identification of familial lipid </text>
<text top="305" left="135" width="192" height="21" font="5">disorders (S2.2<a href="CIR.0000000000000625.html#87">-12,</a> S2.2<a href="CIR.0000000000000625.html#87">-13)</a>. </text>
<text top="325" left="108" width="4" height="21" font="5"> </text>
<text top="354" left="108" width="559" height="29" font="2"><b>2.3. Measurements of Apolipoprotein B and Lipoprotein (a) </b></text>
<text top="395" left="108" width="706" height="21" font="5">Two lipoprotein entities related to LDL-C are apoB and lipoprotein (a) [Lp(a)]. Because apoB is the major </text>
<text top="415" left="108" width="705" height="21" font="5">apolipoprotein embedded in LDL and VLDL, several investigators identify strength of association between </text>
<text top="435" left="108" width="706" height="21" font="5">apoB and ASCVD (S2.3<a href="CIR.0000000000000625.html#87">-1)</a>. Others report a high correlation between apoB and non–HDL-C (S2.3<a href="CIR.0000000000000625.html#87">-2)</a>. Under </text>
<text top="455" left="108" width="706" height="21" font="5">certain circumstances, particularly in patients with hypertriglyceridemia, the measurement of apoB may </text>
<text top="476" left="108" width="706" height="21" font="5">have advantages (S2.3<a href="CIR.0000000000000625.html#87">-3)</a>. Nevertheless, apoB measurement carries extra expense, and its measurement </text>
<text top="496" left="108" width="708" height="21" font="5">in some laboratories may not be reliable (S2.3<a href="CIR.0000000000000625.html#87">-4)</a>. A relative indication for its measurement would be </text>
<text top="516" left="108" width="706" height="21" font="5">triglyceride ≥200 mg/dL. A level &gt;130 mg/dL corresponds to an LDL-C level<b> </b>≥160 mg/dL and constitutes a </text>
<text top="536" left="108" width="706" height="21" font="5">risk-enhancing factor.  A persistent elevation of apoB  can be considered a risk-enhancing factor. </text>
<text top="556" left="108" width="706" height="21" font="5">Separately, Lp(a) is a modified form of LDL that appears to possess atherogenic potential (S2.3<a href="CIR.0000000000000625.html#87">-5)</a>. Relative </text>
<text top="576" left="108" width="706" height="21" font="5">indications for its measurement are family history of premature ASCVD or personal history of ASCVD not </text>
<text top="596" left="108" width="706" height="21" font="5">explained by major risk factors. Lp(a) increases ASCVD risk especially at higher levels. Thus, if a decision is </text>
<text top="616" left="108" width="706" height="21" font="5">made to measure Lp(a), an Lp(a) ≥50 mg/dL or ≥125 nmol/L, Lp(a) may be considered a risk-enhancing </text>
<text top="637" left="108" width="707" height="21" font="5">factor (S2.3<a href="CIR.0000000000000625.html#87">-6)</a>. Current evidence shows that it should be considered in women only in the presence of </text>
<text top="657" left="108" width="705" height="21" font="5">hypercholesterolemia and with the understanding that the improvement in risk prediction in adult women </text>
<text top="677" left="108" width="706" height="21" font="5">in a large clinical trial was minimal (S2.3<a href="CIR.0000000000000625.html#87">-7)</a>. In the present document, an elevation of Lp(a) is considered </text>
<text top="697" left="108" width="707" height="21" font="5">to be a risk-enhancing factor (S2.3<a href="CIR.0000000000000625.html#87">-6)</a>. This is especially in those with higher Lp(a) values and, if used in </text>
<text top="717" left="108" width="426" height="21" font="5">women, only in the presence of hypercholesterolemia (S2.3<a href="CIR.0000000000000625.html#87">-7)</a>. </text>
<text top="746" left="108" width="493" height="29" font="2"><b>2.4. Monitoring Response of LDL-C to Statin Therapy </b></text>
<text top="787" left="108" width="706" height="21" font="5">In large RCTs of cholesterol-lowering therapy, LDL-C lowering has been consistently shown to reduce the </text>
<text top="807" left="108" width="706" height="21" font="5">risk of ASCVD. One large meta-analysis (S2.4-1) of statin clinical trials showed a progressive reduction in </text>
<text top="827" left="108" width="702" height="21" font="5">risk of major ASCVD events with lower on-treatment LDL-C levels. In another larger meta-analysis (S2.4-</text>
<text top="847" left="108" width="706" height="21" font="5">2)  of 14 statin trials, it was  observed that a 38.7-mg/dL (1-mmol/L)  reduction of LDL-C  levels  is </text>
<text top="868" left="108" width="706" height="21" font="5">accompanied by a 21% reduction in ASCVD risk. In clinical practice, however, absolute responses in LDL-C </text>
<text top="888" left="108" width="707" height="21" font="5">to statin therapy depend on baseline LDL-C concentrations. A given dose of statins produces a similar </text>
<text top="908" left="108" width="705" height="21" font="5">percentage reduction in LDL-C levels across a broad range of baseline LDL-C levels. For this reason, a more </text>
<text top="928" left="108" width="708" height="21" font="5">reliable indicator of statin efficacy is percentage reduction.  In the present document, the percentage </text>
<text top="948" left="108" width="706" height="21" font="5">reduction is used in follow-up monitoring of patients to estimate the efficacy of statin therapy. As a rough </text>
<text top="968" left="108" width="706" height="21" font="5">guide, a lowering of LDL-C  levels<b>  </b>of 1% gives an approximate 1% reduction in the risk of  ASCVD— </text>
<text top="988" left="108" width="672" height="21" font="5">somewhat more at higher baseline LDL-C levels and somewhat less at lower baseline levels (S2.4-1). </text>
<text top="1018" left="108" width="4" height="21" font="5"> </text>
<text top="1047" left="108" width="4" height="21" font="5"> </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="16" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-16_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 16</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="260" height="31" font="11"><b>3. Therapeutic Modalities </b></text>
<text top="166" left="108" width="219" height="29" font="2"><b>3.1. Lifestyle Therapies </b></text>
<text top="207" left="108" width="540" height="27" font="16"><i><b>3.1.1. Diet Composition, Weight Control, and Physical Activity </b></i></text>
<text top="246" left="108" width="706" height="21" font="5">For many years, the AHA and ACC have recommended essentials of a healthy diet for the general public </text>
<text top="266" left="108" width="708" height="21" font="5">and for patients at risk for ASCVD. The current document supports evidence-based recommendations </text>
<text top="286" left="108" width="707" height="21" font="5">provided in the 2013 AHA/ACC guidelines on lifestyle management (S3.1.1<a href="CIR.0000000000000625.html#88">-1,</a> S3.1.1<a href="CIR.0000000000000625.html#88">-2)</a>. Patients should </text>
<text top="306" left="108" width="707" height="21" font="5">consume a dietary pattern that emphasizes intake of vegetables, fruits, whole grains, legumes, healthy </text>
<text top="326" left="108" width="707" height="21" font="5">protein sources (low-fat dairy products, low-fat poultry (without the skin), fish/seafood, and nuts), and </text>
<text top="346" left="108" width="706" height="21" font="5">nontropical vegetable oils; and limits intake of sweets, sugar-sweetened beverages, and red meats.  This </text>
<text top="366" left="108" width="709" height="21" font="5">dietary pattern should be adjusted to appropriate calorie  requirements, personal and cultural food </text>
<text top="387" left="108" width="705" height="21" font="5">preferences, and nutritional therapy for other medical conditions including diabetes. Caloric intake should </text>
<text top="407" left="108" width="707" height="21" font="5">be adjusted to avoid weight gain, or in overweight/obese patients, to promote weight loss. In general, </text>
<text top="427" left="108" width="706" height="21" font="5">adults should be advised to engage in aerobic physical activity 3-4 sessions per week, lasting on average </text>
<text top="447" left="108" width="581" height="21" font="5">40 minutes per session and involving moderate-to vigorous-intensity physical activity.  </text>
<text top="476" left="108" width="443" height="27" font="16"><i><b>3.1.2. Lifestyle Therapies and Metabolic Syndrome </b></i></text>
<text top="515" left="108" width="706" height="21" font="5">Lifestyle therapies are particularly indicated for the metabolic syndrome, which is a cluster of risk factors </text>
<text top="535" left="108" width="706" height="21" font="5">associated with an increased risk of ASCVD, diabetes mellitus, and all-cause death (S3.1.2<a href="CIR.0000000000000625.html#88">-1,</a> S3.1.2<a href="CIR.0000000000000625.html#88">-2)</a>. </text>
<text top="555" left="108" width="708" height="21" font="5">Metabolic syndrome is a risk-enhancing factor  for ASCVD.  The  most widely used clinical definition of </text>
<text top="575" left="108" width="708" height="21" font="5">metabolic syndrome is that  proposed by an international consortium of cardiovascular and diabetes </text>
<text top="595" left="108" width="707" height="21" font="5">organizations (S3.1.2<a href="CIR.0000000000000625.html#88">-3)</a>. The diagnosis is made by the presence of any 3 of the following 5 risk factors: </text>
<text top="615" left="108" width="706" height="21" font="5">elevated waist circumference, elevated serum triglycerides, reduced HDL-C, elevated blood pressure, and </text>
<text top="635" left="108" width="168" height="21" font="5">elevated fasting glucos<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">e (</a></text>
<text top="635" left="276" width="215" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Table S2 in the Web Supplement</a></text>
<text top="635" left="491" width="322" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">).</a> Metabolic syndrome is closely linked to excess </text>
<text top="656" left="108" width="705" height="21" font="5">weight and particularly to abdominal obesity (S3.1.2<a href="CIR.0000000000000625.html#88">-4)</a>. Therefore, the prevalence of metabolic syndrome </text>
<text top="676" left="108" width="705" height="21" font="5">has risen sharply among both adults and children as levels of overweight and obesity have risen. Metabolic </text>
<text top="696" left="108" width="705" height="21" font="5">syndrome is now found in approximately one-third of the adults in the United States (S3.1.2<a href="CIR.0000000000000625.html#88">-5)</a> and is likely </text>
<text top="716" left="108" width="710" height="21" font="5">underrecognized  because of  insufficient rates of screening. The prevalence of metabolic syndrome </text>
<text top="736" left="108" width="627" height="21" font="5">increases with age and very commonly occurs in patients with type 2 diabetes mellitus. See<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625"> </a></text>
<text top="736" left="736" width="79" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Table S2 in </a></text>
<text top="756" left="108" width="143" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">the Web Supplement</a></text>
<text top="756" left="251" width="8" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">.</a> </text>
<text top="785" left="108" width="247" height="29" font="2"><b>3.2. Lipid-Lowering Drugs  </b></text>
<text top="826" left="108" width="709" height="21" font="5">Among  lipid-lowering  drugs,  statins are the cornerstone of therapy,  in addition to healthy lifestyle </text>
<text top="846" left="108" width="706" height="21" font="5">interventions. Other LDL-lowering drugs include ezetimibe, bile acid sequestrants, and PCSK9 inhibitors. </text>
<text top="866" left="108" width="706" height="21" font="5">Triglyceride-lowering drugs are fibrates and niacin; they have a mild LDL-lowering action, but RCTs do not </text>
<text top="887" left="108" width="707" height="21" font="5">support their use as add-on drugs to statin therapy (S3.2<a href="CIR.0000000000000625.html#88">-1)</a>. Characteristics of LDL-lowering drugs are </text>
<text top="907" left="108" width="102" height="21" font="5">summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625"> </a></text>
<text top="907" left="210" width="219" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Table S3 in the Web Supplement</a></text>
<text top="907" left="429" width="8" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">.</a> </text>
<text top="936" left="108" width="186" height="27" font="16"><i><b>3.2.1. Statin Therapy </b></i></text>
<text top="974" left="108" width="702" height="21" font="5">The intensity of statin therapy is divided into 3 categories: high-intensity, moderate-intensity, and low-</text>
<text top="994" left="108" width="702" height="21" font="5">intensity  (S3.2.1<a href="CIR.0000000000000625.html#89">-1)</a>.  High-intensity statin therapy typically lowers LDL-C  levels  by  ≥50%,  moderate-</text>
<text top="1015" left="108" width="706" height="21" font="5">intensity statin therapy by 30% to 49%, and low-intensity statin therapy by &lt;30% (Table 3). Of course, the </text>
<text top="1035" left="108" width="706" height="21" font="5">magnitude of LDL-C lowering will vary in clinical practice (S3.2.1-2). Certain Asian populations may have a </text>
<text top="1055" left="108" width="705" height="21" font="5">greater response to certain statins (S3.2.1-18). Pharmacokinetic profiles among statins are heterogeneous </text>
<text top="1075" left="108" width="5" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">(</a></text>
<text top="1075" left="113" width="235" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Table  S4  in the Web Supplement</a></text>
<text top="1075" left="348" width="463" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">).</a>  Statin safety has been extensively evaluated (S3.2.1-19).  Statin-</text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="17" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="18" size="12" family="Times" color="#262626"/>
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-17_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 17</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="705" height="21" font="5">associated side effects are discussed in Section 5. Common medications that may potentially interact with </text>
<text top="144" left="108" width="132" height="21" font="5">statins are listed in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625"> </a></text>
<text top="144" left="239" width="221" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Table S5 in the Web Supplement</a></text>
<text top="144" left="460" width="354" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">.</a> More information on statin drug–drug interactions </text>
<text top="164" left="108" width="316" height="21" font="5">can be obtained from the ACC LDL-C Manager <a href="http://tools.acc.org/ldl">(</a></text>
<text top="164" left="424" width="154" height="21" font="13"><a href="http://tools.acc.org/ldl">http://tools.acc.org/ldl</a></text>
<text top="164" left="578" width="93" height="21" font="5"><a href="http://tools.acc.org/ldl">)</a> (S3.2.1-20).  </text>
<text top="184" left="108" width="4" height="21" font="5"> </text>
<text top="213" left="108" width="422" height="21" font="4"><b>Table 3. High-, Moderate-, and Low-Intensity Statin Therapy*</b> </text>
<text top="234" left="108" width="4" height="21" font="5"> </text>
<text top="258" left="116" width="3" height="19" font="0"><b> </b></text>
<text top="258" left="202" width="93" height="19" font="0"><b>High Intensity  </b></text>
<text top="258" left="385" width="127" height="19" font="0"><b>Moderate Intensity  </b></text>
<text top="258" left="575" width="90" height="19" font="0"><b>Low Intensity  </b></text>
<text top="279" left="116" width="38" height="19" font="0"><b>LDL-C </b></text>
<text top="300" left="116" width="69" height="19" font="0"><b>lowering†  </b></text>
<text top="280" left="202" width="37" height="19" font="1">≥50% </text>
<text top="280" left="385" width="63" height="19" font="1">30%–49% </text>
<text top="280" left="575" width="37" height="19" font="1">&lt;30% </text>
<text top="322" left="116" width="46" height="19" font="0"><b>Statins </b></text>
<text top="322" left="202" width="158" height="19" font="0"><b>Atorvastatin (40 mg‡) 80 </b></text>
<text top="344" left="202" width="23" height="19" font="0"><b>mg </b></text>
<text top="365" left="202" width="148" height="19" font="0"><b>Rosuvastatin 20 mg (<i>40 </i></b></text>
<text top="386" left="202" width="23" height="19" font="10"><i><b>mg</b></i> </text>
<text top="322" left="385" width="173" height="19" font="0"><b>Atorvastatin 10 mg </b>(20 mg)<b> </b></text>
<text top="344" left="385" width="168" height="19" font="0"><b>Rosuvastatin </b>(5 mg)<b> 10 mg </b></text>
<text top="365" left="385" width="148" height="19" font="0"><b>Simvastatin 20–40 mg§ </b></text>
<text top="323" left="575" width="115" height="19" font="1">Simvastatin 10 mg </text>
<text top="393" left="116" width="3" height="19" font="0"><b> </b></text>
<text top="407" left="202" width="14" height="19" font="0"><b>… </b></text>
<text top="407" left="385" width="166" height="19" font="0"><b>Pravastatin 40 mg </b>(80 mg)<b> </b></text>
<text top="428" left="385" width="159" height="19" font="0"><b>Lovastatin 40 mg </b>(80 mg)<b> </b></text>
<text top="450" left="385" width="128" height="19" font="1">Fluvastatin XL 80 mg </text>
<text top="471" left="385" width="139" height="19" font="0"><b>Fluvastatin 40 mg BID </b></text>
<text top="492" left="385" width="124" height="19" font="1">Pitavastatin 1–4 mg<b> </b></text>
<text top="407" left="575" width="138" height="19" font="0"><b>Pravastatin 10–20 mg </b></text>
<text top="428" left="575" width="109" height="19" font="0"><b>Lovastatin 20 mg </b></text>
<text top="450" left="575" width="134" height="19" font="1">Fluvastatin 20–40 mg </text>
<text top="514" left="108" width="705" height="19" font="1">*Percent reductions are estimates from data across large populations. Individual responses to statin therapy varied </text>
<text top="532" left="108" width="447" height="19" font="1">in the RCTs and should be expected to vary in clinical practice (S3.2.1<a href="CIR.0000000000000625.html#89">-2)</a>.  </text>
<text top="550" left="108" width="482" height="19" font="1">†LDL-C lowering that should occur with the dosage listed below each intensity. </text>
<text top="568" left="108" width="708" height="19" font="1">‡Evidence from 1 RCT only: down titration if unable to tolerate atorvastatin 80 mg in the IDEAL (Incremental </text>
<text top="587" left="108" width="379" height="19" font="1">Decrease through Aggressive Lipid Lowering) study (S3.2.1-3). </text>
<text top="605" left="108" width="707" height="19" font="1">§Although simvastatin 80 mg was evaluated in RCTs, initiation of simvastatin 80 mg or titration to 80 mg is not </text>
<text top="623" left="108" width="589" height="19" font="1">recommended by the FDA because of the increased risk of myopathy, including rhabdomyolysis. </text>
<text top="642" left="108" width="705" height="19" font="1">Percent LDL-C reductions with the primary statin medications used in clinical practice (atorvastatin, rosuvastatin, </text>
<text top="660" left="108" width="705" height="19" font="1">simvastatin) were estimated using the median reduction in LDL-C from the VOYAGER database (S3.2.1<a href="CIR.0000000000000625.html#89">-2)</a>. Reductions </text>
<text top="678" left="108" width="706" height="19" font="1">in LDL-C for other statin medications (fluvastatin, lovastatin, pitavastatin, pravastatin) were identified according to </text>
<text top="697" left="108" width="712" height="19" font="1">FDA-approved product labeling in adults with hyperlipidemia, primary hypercholesterolemia,  and mixed </text>
<text top="715" left="108" width="146" height="19" font="1">dyslipidemia (S3.2.1<a href="CIR.0000000000000625.html#89">-4)</a>. </text>
<text top="733" left="108" width="706" height="19" font="0"><b>Boldface type</b> indicates specific statins and doses that were evaluated in RCTs (S3.2.1-3, S3.2.1<a href="CIR.0000000000000625.html#89">-5–S3.2.1-16</a>), and </text>
<text top="752" left="108" width="707" height="19" font="1">the  Cholesterol Treatment Trialists’  2010 meta-analysis  (S3.2.1-17).  All  these RCTs demonstrated a reduction in </text>
<text top="770" left="108" width="182" height="19" font="1">major cardiovascular events.  </text>
<text top="788" left="108" width="706" height="19" font="1">BID indicates twice daily; FDA, U.S. Food and Drug Administration; LDL-C, low-density lipoprotein cholesterol; RCT, </text>
<text top="806" left="108" width="241" height="19" font="1">randomized controlled trial; VOYAGER, </text>
<text top="806" left="349" width="465" height="19" font="18">an indiVidual patient data meta-analysis Of statin therapY in At risk Groups: </text>
<text top="825" left="108" width="319" height="19" font="18">Effects of Rosuvastatin, atorvastatin and simvastatin</text>
<text top="825" left="427" width="167" height="19" font="1">; and XL, extended release. </text>
<text top="848" left="108" width="5" height="16" font="14"> </text>
<text top="884" left="108" width="234" height="27" font="16"><i><b>3.2.2. Nonstatin Therapies </b></i></text>
<text top="923" left="108" width="706" height="21" font="5">Ezetimibe is the most commonly used nonstatin agent. It lowers LDL-C levels by 13% to 20% and has a low </text>
<text top="943" left="108" width="706" height="21" font="5">incidence of side effects (S3.2.2<a href="CIR.0000000000000625.html#90">-1,</a> S3.2.2<a href="CIR.0000000000000625.html#90">-2)</a>. Bile acid sequestrants reduce LDL-C levels by 15% to 30% </text>
<text top="963" left="108" width="707" height="21" font="5">depending on the dose. Bile acid sequestrants are not absorbed and do not cause systemic side effects, </text>
<text top="983" left="108" width="710" height="21" font="5">but  they  are associated with gastrointestinal complaints (e.g., constipation) and can cause severe </text>
<text top="1003" left="108" width="709" height="21" font="5">hypertriglyceridemia when fasting triglycerides are ≥300  mg/dL  (≥3.4 mmol/L).  PCSK9 inhibitors are </text>
<text top="1023" left="108" width="706" height="21" font="5">powerful LDL-lowering drugs. They generally are well tolerated, but long-term safety remains to be proven </text>
<text top="1043" left="108" width="708" height="21" font="5">(S3.2.2<a href="CIR.0000000000000625.html#90">-4–S3.2.2-6)</a>. Two categories of triglyceride-lowering drugs, niacin and fibrates, may also mildly </text>
<text top="1064" left="108" width="706" height="21" font="5">lower LDL-C levels in patients with normal triglycerides. They may be useful in some patients with severe </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="18" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="19" size="14" family="Times" color="#000000"/>
	<fontspec id="20" size="8" family="Times" color="#000000"/>
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-18_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 18</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="647" height="21" font="5">hypertriglyceridemia, but in the present document they are not listed as LDL-lowering drugs. Se<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">e </a></text>
<text top="124" left="754" width="59" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Table S4 </a></text>
<text top="144" left="108" width="159" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">in the Web Supplement</a></text>
<text top="144" left="267" width="8" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">.</a> </text>
<text top="173" left="108" width="424" height="27" font="16"><i><b>3.2.3. Nonstatin Add-on Drugs to Statin Therapy </b></i></text>
<text top="212" left="108" width="706" height="21" font="5">Under certain circumstances, nonstatin  medications  (ezetimibe, bile acid sequestrants, and  PCSK9 </text>
<text top="232" left="108" width="707" height="21" font="5">inhibitors) may be useful in combination with statin therapy. The addition of a bile acid sequestrant or </text>
<text top="252" left="108" width="706" height="21" font="5">ezetimibe to a statin regimen increases the magnitude of LDL-C lowering by approximately 15% to 30% </text>
<text top="272" left="108" width="707" height="21" font="5">and 13% to 20%, respectively (S3.2.3<a href="CIR.0000000000000625.html#90">-1,</a> S3.2.3<a href="CIR.0000000000000625.html#90">-2)</a>. The addition of a PCSK9 inhibitor to a statin regimen </text>
<text top="292" left="108" width="571" height="21" font="5">has been shown to further reduce LDL-C levels by 43% to 64% (S3.2.3<a href="CIR.0000000000000625.html#90">-3,</a> S3.2.3<a href="CIR.0000000000000625.html#90">-4)</a>. S<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">ee </a></text>
<text top="292" left="679" width="135" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Table S5 in the Web </a></text>
<text top="312" left="108" width="81" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Supplement</a></text>
<text top="312" left="189" width="8" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">.</a> </text>
<text top="342" left="108" width="4" height="21" font="5"> </text>
<text top="374" left="108" width="318" height="31" font="11"><b>4. Patient Management Groups </b></text>
<text top="416" left="108" width="324" height="29" font="2"><b>4.1. Secondary ASCVD Prevention  </b></text>
<text top="458" left="234" width="453" height="21" font="4"><b>Recommendations for Statin Therapy Use in Patients With ASCVD </b></text>
<text top="481" left="120" width="474" height="21" font="5">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625"> </a></text>
<text top="481" left="594" width="207" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Online Data Supplements 6, 7, </a></text>
<text top="504" left="328" width="8" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">8</a></text>
<text top="504" left="336" width="75" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625"> </a>and in the<a href="https://www.ahajournals.org/doi/10.1161/CIR.0000000000000626"> </a></text>
<text top="504" left="411" width="174" height="21" font="13"><a href="https://www.ahajournals.org/doi/10.1161/CIR.0000000000000626">Systematic Review Report</a></text>
<text top="504" left="586" width="8" height="21" font="5"><a href="https://www.ahajournals.org/doi/10.1161/CIR.0000000000000626">.</a> </text>
<text top="528" left="131" width="33" height="21" font="4"><b>COR </b></text>
<text top="528" left="209" width="30" height="21" font="4"><b>LOE </b></text>
<text top="528" left="471" width="132" height="21" font="4"><b>Recommendations </b></text>
<text top="566" left="143" width="8" height="21" font="4"><b>I </b></text>
<text top="566" left="217" width="14" height="21" font="4"><b>A </b></text>
<text top="552" left="269" width="532" height="21" font="4"><b>1.  In patients who are 75 years of age or younger with clinical ASCVD,* high-</b></text>
<text top="572" left="297" width="510" height="21" font="4"><b>intensity statin therapy should be initiated or continued with the aim of </b></text>
<text top="592" left="297" width="468" height="21" font="4"><b>achieving a 50% or greater reduction in LDL-C levels (S4.1<a href="CIR.0000000000000625.html#90">-1–S4.1-5)</a></b><b>. </b></text>
<text top="647" left="143" width="8" height="21" font="4"><b>I </b></text>
<text top="647" left="217" width="14" height="21" font="4"><b>A </b></text>
<text top="613" left="269" width="538" height="21" font="4"><b>2.  In patients with clinical ASCVD in whom high-intensity statin therapy is </b></text>
<text top="633" left="297" width="518" height="21" font="4"><b>contraindicated or who experience statin-associated side effects, </b></text>
<text top="653" left="297" width="510" height="21" font="4"><b>moderate-intensity statin therapy should be initiated or continued with </b></text>
<text top="673" left="297" width="505" height="21" font="4"><b>the aim of achieving a 30% to 49% reduction in LDL-C levels (S4.1<a href="CIR.0000000000000625.html#91">-3, </a></b><b>S4.1-</b></text>
<text top="693" left="297" width="81" height="21" font="4"><a href="CIR.0000000000000625.html#91"><b>6–S4.1-13)</b></a><b>. </b></text>
<text top="738" left="143" width="8" height="21" font="4"><b>I </b></text>
<text top="738" left="204" width="38" height="21" font="4"><b>B-NR </b></text>
<text top="714" left="269" width="537" height="21" font="4"><b>3.  In patients with clinical ASCVD who are  judged to be very high risk and </b></text>
<text top="735" left="297" width="508" height="21" font="19"><i><b>considered for PCSK9 inhibitor therapy,</b></i><b>  maximally tolerated LDL-C </b></text>
<text top="755" left="297" width="510" height="21" font="4"><b>lowering therapy should include maximally tolerated statin therapy and </b></text>
<text top="775" left="297" width="203" height="21" font="4"><b>ezetimibe  (S4.1<a href="CIR.0000000000000625.html#91">-14, </a></b><b>S4.1<a href="CIR.0000000000000625.html#91">-15)</a></b><b>. </b></text>
<text top="840" left="137" width="21" height="21" font="4"><b>IIa </b></text>
<text top="840" left="211" width="10" height="21" font="4"><b>A</b></text>
<text top="840" left="221" width="11" height="13" font="20"><b>SR</b></text>
<text top="840" left="232" width="4" height="21" font="4"><b> </b></text>
<text top="796" left="269" width="538" height="21" font="4"><b>4.  In patients with clinical ASCVD who are judged to be very high risk and </b></text>
<text top="816" left="297" width="509" height="21" font="4"><b>who are on maximally tolerated LDL-C  lowering  therapy  with  LDL-C  70 </b></text>
<text top="836" left="297" width="508" height="21" font="4"><b>mg/dL (≥1.8 mmol/L) or higher or a non–HDL-C level of 100 mg/dL (≥2.6 </b></text>
<text top="856" left="297" width="509" height="21" font="4"><b>mmol/L) or higher, it is reasonable to add a PCSK9 inhibitor following a </b></text>
<text top="876" left="297" width="505" height="21" font="4"><b>clinician–patient discussion about the net benefit, safety, and cost</b> <b>(S4.1-</b></text>
<text top="896" left="297" width="89" height="21" font="4"><b>15–S4.1-19). </b></text>
<text top="942" left="135" width="24" height="21" font="4"><b> IIa </b></text>
<text top="942" left="210" width="27" height="21" font="4"><b>B-R </b></text>
<text top="917" left="269" width="539" height="21" font="4"><b>5.  In patients with clinical ASCVD who are on maximally tolerated statin </b></text>
<text top="937" left="297" width="509" height="21" font="4"><b>therapy and are judged to be at very high risk and have an LDL-C level of </b></text>
<text top="958" left="297" width="512" height="21" font="4"><b>70 mg/dL (≥1.8  mmol/L)  or higher, it is reasonable to add ezetimibe </b></text>
<text top="978" left="297" width="185" height="21" font="4"><b>therapy (S4.1-14, S4.1-15). </b></text>
<text top="999" left="165" width="43" height="21" font="4"><b>Value </b></text>
<text top="1022" left="147" width="80" height="21" font="4"><b>Statement: </b></text>
<text top="1045" left="149" width="75" height="21" font="4"><b>Low Value </b></text>
<text top="1068" left="145" width="83" height="21" font="4"><b>(LOE: B-NR) </b></text>
<text top="999" left="269" width="536" height="21" font="4"><b>6.  At mid-2018 list prices, PCSK9 inhibitors have a low cost value (&gt;$150,000 </b></text>
<text top="1019" left="297" width="510" height="21" font="4"><b>per QALY) compared to good cost value (&lt;$50,000 per QALY) (Section 7 </b></text>
<text top="1039" left="297" width="508" height="21" font="4"><b>provides a full discussion of the dynamic interaction of different prices and </b></text>
<text top="1059" left="297" width="237" height="21" font="4"><b>clinical benefit) (S4.1-20–S4.1-22). </b></text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="19" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-19_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 19</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="159" left="137" width="21" height="21" font="4"><b>IIa </b></text>
<text top="159" left="210" width="27" height="21" font="4"><b>B-R </b></text>
<text top="125" left="269" width="536" height="21" font="4"><b>7.  In patients older than 75 years of age with clinical ASCVD, it is reasonable </b></text>
<text top="145" left="297" width="510" height="21" font="4"><b>to initiate moderate- or high-intensity statin therapy after evaluation of </b></text>
<text top="165" left="297" width="509" height="21" font="4"><b>the potential for ASCVD risk  reduction, adverse effects, and  drug–drug </b></text>
<text top="185" left="297" width="505" height="21" font="4"><b>interactions, as well as patient frailty and patient preferences (S4.1<a href="CIR.0000000000000625.html#92">-23–</a></b></text>
<text top="205" left="297" width="64" height="21" font="4"><a href="CIR.0000000000000625.html#92"><b>S4.1-31)</b></a><b>.</b> </text>
<text top="260" left="137" width="21" height="21" font="4"><b>IIa </b></text>
<text top="260" left="206" width="35" height="21" font="4"><b>C-LD </b></text>
<text top="226" left="269" width="536" height="21" font="4"><b>8.  In patients older than 75 years of age who are tolerating high-intensity </b></text>
<text top="246" left="297" width="510" height="21" font="4"><b>statin therapy, it is reasonable to continue high-intensity statin therapy </b></text>
<text top="266" left="297" width="508" height="21" font="4"><b>after evaluation of the potential for ASCVD risk reduction, adverse effects, </b></text>
<text top="286" left="297" width="516" height="21" font="4"><b>and  drug-drug interactions, as well as patient frailty and patient </b></text>
<text top="306" left="297" width="440" height="21" font="4"><b>preferences (S4.1<a href="CIR.0000000000000625.html#91">-3, </a></b><b>S4.1<a href="CIR.0000000000000625.html#91">-10, </a></b><b>S4.1<a href="CIR.0000000000000625.html#92">-23</a></b><b>, S4.1<a href="CIR.0000000000000625.html#92">-26</a></b><b>, S4.1<a href="CIR.0000000000000625.html#92">-31–S4.1-36</a></b><b>). </b></text>
<text top="342" left="136" width="21" height="21" font="4"><b>IIb </b></text>
<text top="342" left="210" width="27" height="21" font="4"><b>B-R </b></text>
<text top="327" left="269" width="539" height="21" font="4"><b>9.  In patients with clinical ASCVD who are receiving maximally tolerated </b></text>
<text top="348" left="297" width="509" height="21" font="4"><b>statin therapy and whose LDL-C level remains 70 mg/dL (≥1.8 mmol/L) or </b></text>
<text top="368" left="297" width="388" height="21" font="4"><b>higher, it may be reasonable to add ezetimibe (S4.1<a href="CIR.0000000000000625.html#91">-15)</a></b><b>. </b></text>
<text top="423" left="136" width="21" height="21" font="4"><b>IIb </b></text>
<text top="423" left="210" width="27" height="21" font="4"><b>B-R </b></text>
<text top="389" left="269" width="543" height="21" font="4"><b>10. In patients with heart failure  (HF)  with reduced ejection fraction </b></text>
<text top="409" left="297" width="515" height="21" font="4"><b>attributable  to ischemic heart disease who have a reasonable life </b></text>
<text top="429" left="297" width="508" height="21" font="4"><b>expectancy (3 to 5 years) and are not already on a statin because of ASCVD, </b></text>
<text top="449" left="297" width="510" height="21" font="4"><b>clinicians may consider initiation of moderate-intensity statin therapy to </b></text>
<text top="469" left="297" width="343" height="21" font="4"><b>reduce the occurrence of ASCVD events (S4.1<a href="CIR.0000000000000625.html#92">-37</a></b><b>). </b></text>
<text top="490" left="108" width="705" height="19" font="1">*Clinical atherosclerotic cardiovascular disease (ASCVD) includes acute coronary syndrome (ACS), those with history </text>
<text top="509" left="108" width="708" height="19" font="1">of myocardial infarction (MI), stable or unstable angina or  coronary or  other arterial revascularization, stroke, </text>
<text top="527" left="108" width="706" height="19" font="1">transient ischemic attack (TIA), or peripheral artery disease (PAD) including aortic aneurysm, all of atherosclerotic </text>
<text top="545" left="108" width="42" height="19" font="1">origin. </text>
<text top="564" left="108" width="3" height="19" font="1"> </text>
<text top="582" left="108" width="3" height="19" font="1"> </text>
<text top="600" left="108" width="67" height="21" font="4"><b>Synopsis  </b></text>
<text top="639" left="108" width="706" height="21" font="5">Clinical ASCVD encompasses ACS, those with history of MI, stable or unstable angina or coronary or other </text>
<text top="659" left="108" width="706" height="21" font="5">arterial revascularization, stroke, TIA or PAD including aortic aneurysm, all of atherosclerotic origin. The </text>
<text top="680" left="108" width="706" height="21" font="5">writing group used primarily the Cholesterol Treatment Trialists’ (CTT) meta-analysis (S4.1<a href="CIR.0000000000000625.html#91">-3,</a> S4.1<a href="CIR.0000000000000625.html#91">-4)</a> of </text>
<text top="700" left="108" width="706" height="21" font="5">statin RCTs plus 4 other RCTs (S4.1<a href="CIR.0000000000000625.html#90">-1,</a> S4.1<a href="CIR.0000000000000625.html#90">-2,</a> S4.1<a href="CIR.0000000000000625.html#92">-38</a>, S4.1<a href="CIR.0000000000000625.html#93">-39</a>). Additional RCTs have used nonstatin drugs </text>
<text top="720" left="108" width="706" height="21" font="5">as add-ons to statin therapy and are included here. As a primary recommendation, high-intensity statin </text>
<text top="740" left="108" width="706" height="21" font="5">therapy is indicated for clinical ASCVD, but if this cannot be used, moderate-intensity statin therapy can </text>
<text top="760" left="108" width="706" height="21" font="5">be initiated (Figure 1). The first goal is to achieve a ≥50% reduction in LDL-C<b> </b>levels, but if LDL-C levels<b> </b></text>
<text top="780" left="108" width="709" height="21" font="5">remains  ≥70 mg/dL  (≥1.8  mmol/L)  on maximally tolerated statin therapy, adding ezetimibe may be </text>
<text top="800" left="108" width="707" height="21" font="5">reasonable. In patients &gt;75 years of age with ASCVD, potential benefits versus adverse effects of statin </text>
<text top="820" left="108" width="707" height="21" font="5">therapy should be considered before initiation of statin therapy. Finally, in very high-risk patients with </text>
<text top="841" left="108" width="711" height="21" font="5">multiple  high-risk clinical factors, ezetimibe can be added to maximally tolerated statin therapy. </text>
<text top="861" left="108" width="707" height="21" font="5">Furthermore, if LDL-C levels remain ≥70 mg/dL (≥1.8 mmol/L), adding a PCSK9 inhibitor is reasonable if </text>
<text top="881" left="108" width="706" height="21" font="5">the cost/benefit ratio is favorable. In patients with HF due to ischemic heart disease, moderate-intensity </text>
<text top="901" left="108" width="183" height="21" font="5">statins may be considered. </text>
<text top="933" left="108" width="295" height="21" font="4"><b>Recommendation-Specific Supportive Text </b></text>
<text top="972" left="108" width="708" height="21" font="5"> 1.  CTT meta-analysis  (S4.1<a href="CIR.0000000000000625.html#91">-3,</a> S4.1<a href="CIR.0000000000000625.html#91">-4)</a>  showed that LDL-C lowering with statins reduces major ASCVD </text>
<text top="993" left="135" width="680" height="21" font="5">events. Patients with stroke (S4.1<a href="CIR.0000000000000625.html#90">-1)</a> or peripheral artery disease (S4.1<a href="CIR.0000000000000625.html#91">-5)</a> also derive these benefits. </text>
<text top="1013" left="135" width="679" height="21" font="5">In a meta-analysis of 5 RCTs (S4.1<a href="CIR.0000000000000625.html#91">-3)</a>, high-intensity statins compared with moderate-intensity statin </text>
<text top="1033" left="135" width="679" height="21" font="5">therapy, significantly reduced major vascular events by 15% with no significant reduction in coronary </text>
<text top="1053" left="135" width="679" height="21" font="5">deaths. Large absolute LDL-C reduction was associated with a larger proportional reduction in major </text>
<text top="1073" left="135" width="681" height="21" font="5">vascular events (S4.1<a href="CIR.0000000000000625.html#91">-4)</a>. High-intensity statin therapy generally reduces LDL-C levels by ≥50%. This </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="20" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-20_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 20</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="135" width="680" height="21" font="5">percentage can be used to judge clinical efficacy. Absolute benefit from statin therapy depends on </text>
<text top="144" left="135" width="675" height="21" font="5">baseline LDL-C levels; the greatest absolute benefit accrues to patients with the highest baseline LDL-</text>
<text top="164" left="135" width="681" height="21" font="5">C levels. Percentage  reduction of LDL-C  levels  is  the most efficient means  to estimate expected </text>
<text top="184" left="135" width="679" height="21" font="5">efficacy. An alternative to evaluating adequacy of therapy is to examine LDL-C on maximum-intensity </text>
<text top="204" left="135" width="679" height="21" font="5">statins. In a patient with ASCVD, if LDL-C level is ≥70 mg/dL (≥1.8 mmol/L), adding ezetimibe may be </text>
<text top="225" left="135" width="254" height="21" font="5">reasonable (see Recommendation 3). </text>
<text top="245" left="108" width="708" height="21" font="5">2.  Moderate-intensity  statin therapy also reduces major vascular events and coronary heart disease </text>
<text top="265" left="135" width="679" height="21" font="5">(CHD) deaths in patients with ASCVD (S4.1<a href="CIR.0000000000000625.html#91">-6,</a> S4.1<a href="CIR.0000000000000625.html#91">-7,</a> S4.1<a href="CIR.0000000000000625.html#91">-9–S4.1-13,</a> S4.1<a href="CIR.0000000000000625.html#93">-40)</a>. In RCTs, most of which </text>
<text top="285" left="135" width="678" height="21" font="5">included moderate-intensity statin therapy, there was a significant reduction in major vascular events </text>
<text top="305" left="135" width="679" height="21" font="5">even among those &gt;75 years of age. Therefore, an upper age cutoff for moderate-intensity statin </text>
<text top="325" left="135" width="342" height="21" font="5">therapy was not identified in patients with ASCVD. </text>
<text top="345" left="108" width="706" height="21" font="5">3.  Patients with clinical ASCVD who are judged to be very high risk include those with a history of multiple </text>
<text top="366" left="135" width="681" height="21" font="5">major ASCVD events or 1 major ASCVD event and multiple high-risk conditions (Table 4). In these </text>
<text top="386" left="135" width="679" height="21" font="5">patients, additional net benefit from further LDL-C lowering when LDL-C is ≥70 mg/dL (≥1.8 mmol/L) </text>
<text top="406" left="135" width="681" height="21" font="5">or  non–HDL-C  ≥100 mg/dL (≥2.6 mmol/L) by ezetimibe and 2  PCSK9 inhibitors (evolocumab and </text>
<text top="426" left="135" width="681" height="21" font="5">alirocumab) has been demonstrated by 3 RCTs (S4.1-15, S4.1-17, S4.1-18). This guideline makes a </text>
<text top="446" left="135" width="679" height="21" font="5">strong recommendation (COR I) for clinicians to add ezetimibe to maximally tolerated statin therapy </text>
<text top="466" left="135" width="679" height="21" font="5">as a first step in lowering LDL-C further. Although no RCT specifically tested the strategy of ezetimibe </text>
<text top="486" left="135" width="680" height="21" font="5">first and then a PCSK9 inhibitor, ezetimibe was allowed at entry along with statin therapy in both </text>
<text top="507" left="135" width="679" height="21" font="5">PCSK9 inhibitor trials (FOURIER, ODYSSEY OUTCOMES). Even so, only very small numbers (3% and 5% </text>
<text top="527" left="135" width="679" height="21" font="5">respectively) were on ezetimibe during these trials. The strategy of ezetimibe before PCSK9 inhibitor </text>
<text top="547" left="135" width="680" height="21" font="5">is recommended because ezetimibe is widely available as a generic drug and has proven safety and </text>
<text top="567" left="135" width="680" height="21" font="5">tolerability (S4.1-15). This approach is supported by 2 simulation studies from large populations of </text>
<text top="587" left="135" width="680" height="21" font="5">very high-risk patients; these reports showed that addition of ezetimibe to statin therapy will lower </text>
<text top="607" left="135" width="680" height="21" font="5">LDL-C to &lt;70 mg/dL (1.8 mmol/L) in the majority of patients, leaving a minority eligible for a PCSK9 </text>
<text top="627" left="135" width="678" height="21" font="5">inhibitor (S4.1-41, S4.1-42). These 2 well-designed simulation studies favor the strategy of addition of </text>
<text top="648" left="135" width="430" height="21" font="5">ezetimibe before PCSK9 inhibitor and warrants an LOE of B-NR.  </text>
<text top="668" left="108" width="706" height="21" font="5">4.  The FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with </text>
<text top="688" left="135" width="680" height="21" font="5">Elevated Risk) evaluated the PCSK9 inhibitor evolocumab among patients with ASCVD who met at </text>
<text top="708" left="135" width="679" height="21" font="5">least 1 major or 2 minor criteria (S4.1-17). Recruitment was limited to patients who had LDL-C &gt;70 </text>
<text top="728" left="135" width="679" height="21" font="5">mg/dL (≥1.8 mmol/L) (or non–HDL-C &gt;100 mg/dL (≥2.6 mmol/L)) on maximal statin + ezetimibe. At a </text>
<text top="748" left="135" width="679" height="21" font="5">median follow-up of 2.2 years, evolocumab significantly reduced composite ASCVD (15% RRR; 1.5% </text>
<text top="768" left="135" width="679" height="21" font="5">AAR) without neurocognitive side effects (S4.1<a href="CIR.0000000000000625.html#91">-16</a>, S4.1-17), The ODYSSEY OUTCOMES trial (ODYSSEY </text>
<text top="789" left="135" width="684" height="21" font="5">Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During </text>
<text top="809" left="135" width="680" height="21" font="5">Treatment With Alirocumab), tested alirocumab in patients on maximal statin + ezetimibe with ACS </text>
<text top="829" left="135" width="679" height="21" font="5">over a median of 2.8 years, observed a 15% RRR (1.6% ARR) in composite ASCVD events (S4.1<a href="CIR.0000000000000625.html#91">-18</a>). </text>
<text top="849" left="135" width="679" height="21" font="5">Together, FOURIER and ODYSSEY OUTCOMES justify a COR of IIa for PCSK9 inhibitors (acknowledging </text>
<text top="869" left="135" width="680" height="21" font="5">efficacy, but at the same time recognizing that there is limited experience with long-term tolerance </text>
<text top="889" left="135" width="685" height="21" font="5">of expensive monoclonal antibodies that is also inconvenient because it requires repetitive </text>
<text top="909" left="135" width="680" height="21" font="5">administration via the parenteral route). Because of the statistically significant results in two large </text>
<text top="930" left="135" width="680" height="21" font="5">RCTS showing reductions in ASCVD events in patients who had very high risk and LDL-C ≥70 mg/dL </text>
<text top="950" left="135" width="680" height="21" font="5">(≥1.8 mmol/L) while on maximally tolerated LDL-C lowering therapy this recommendation warrants </text>
<text top="970" left="135" width="681" height="21" font="5">an LOE of A. There are 2 alternative pathways to initiation of PCSK9 inhibitors: (a) in patients on </text>
<text top="990" left="135" width="681" height="21" font="5">maximally tolerated statin + ezetimibe; and (b) in those on maximally tolerated statin alone. The </text>
<text top="1010" left="135" width="681" height="21" font="5">strategy of (a) statin + ezetimibe before PCSK9 inhibitor, was graded COR  I for reasons given in </text>
<text top="1030" left="135" width="680" height="21" font="5">Recommendation 3. Second, strategy (b), excluding ezetimibe, would expose more patients to the </text>
<text top="1050" left="135" width="679" height="21" font="5">inconvenience of antibody therapy and reduce overall cost effectiveness. If patients develop 2 </text>
<text top="1071" left="135" width="680" height="21" font="5">consecutive LDL-C levels &lt;25 mg/dL while on a PCSK9 inhibitor, clinical judgment should be used to </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="21" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-21_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 21</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="135" width="680" height="21" font="5">determine whether de-intensification of lipid lowering regimen is warranted as long-term safety of </text>
<text top="144" left="135" width="295" height="21" font="5">such low levels of LDL-C remains unknown.  </text>
<text top="164" left="108" width="706" height="21" font="5">5.  In IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) (S4.1<a href="CIR.0000000000000625.html#91">-15)</a>, </text>
<text top="184" left="135" width="679" height="21" font="5">addition of ezetimibe to moderate-intensity statin therapy among patients with ACS and LDL-C levels<b> </b></text>
<text top="204" left="135" width="679" height="21" font="5">≥50 mg/dL (≥1.3 mmol/L) resulted in a significant ASCVD risk reduction (7% relative risk reduction </text>
<text top="225" left="135" width="679" height="21" font="5">[RRR]; 2% absolute risk reduction [ARR]) at a median follow-up of 6 years. The TIMI (Thrombolysis in </text>
<text top="245" left="135" width="683" height="21" font="5">Myocardial Infarction) Risk Score for Secondary Prevention (TRS 2ºP) is an integer-based risk </text>
<text top="265" left="135" width="679" height="21" font="5">stratification tool for patients with ASCVD. TRS 2ºP includes 9 readily available clinical high-risk </text>
<text top="285" left="135" width="679" height="21" font="5">features and was initially developed in a population of patients with MI within 2 weeks to 1 year of </text>
<text top="305" left="135" width="675" height="21" font="5">randomization to a thrombin receptor agonist (S4.1<a href="CIR.0000000000000625.html#93">-43</a>) and further validated in IMPROVE-IT (S4.1-</text>
<text top="325" left="135" width="679" height="21" font="5"><a href="CIR.0000000000000625.html#91">14)</a>. A higher number of these high-risk features was associated with a higher risk of recurrent ASCVD </text>
<text top="345" left="135" width="681" height="21" font="5">events. In post-ACS patients with ≥3 high-risk features, addition of ezetimibe was associated with </text>
<text top="366" left="135" width="679" height="21" font="5">substantial risk reduction (19% RRR; 6.3% ARR; number needed to treat, 16); those with 2 high-risk </text>
<text top="386" left="135" width="679" height="21" font="5">features had some benefit, whereas those with 0 or 1 additional features had no benefit (S4.1<a href="CIR.0000000000000625.html#91">-14)</a>. </text>
<text top="406" left="135" width="683" height="21" font="5">Therefore, it is reasonable to initiate ezetimibe in patients with ASCVD who are on maximally </text>
<text top="426" left="135" width="679" height="21" font="5">tolerated statin therapy and judged to be at very high risk. For the present guideline, a definition of </text>
<text top="446" left="135" width="682" height="21" font="5">very high  risk  is amalgamated from TRS 2ºP and the recruitment criteria of 2 trials with PCSK9 </text>
<text top="466" left="135" width="134" height="21" font="5">inhibitors (Table 4). </text>
<text top="486" left="108" width="708" height="21" font="5">6.   The cost-effectiveness of using PCSK9 inhibitors for the secondary prevention of ASCVD has been </text>
<text top="507" left="135" width="679" height="21" font="5">evaluated in 7 published simulation models, as detailed in Section 7 (and Online Data Supplements 44 </text>
<text top="527" left="135" width="681" height="21" font="5">and 45). The reported incremental cost-effectiveness ratios range from $141,700 to $450,000 per </text>
<text top="547" left="135" width="680" height="21" font="5">added (QALY), with all but 1 model reporting “low value” (&gt;$150,000 per QALY added). All models </text>
<text top="567" left="135" width="678" height="21" font="5">agree that the value provided by PCSK9 inhibitors would be significantly improved by price reductions </text>
<text top="587" left="135" width="500" height="21" font="5">of 70% to 85% from the mid-2018 U.S. list price of roughly $14,000 a year. </text>
<text top="607" left="108" width="706" height="21" font="5">7.  When high-intensity stain therapy was compared with moderate-intensity statin therapy in patients </text>
<text top="627" left="135" width="679" height="21" font="5">&gt;75 years of age with ASCVD (S4.1<a href="CIR.0000000000000625.html#91">-3)</a>, there was no heterogeneity of effect among age groups &gt;75, </text>
<text top="648" left="135" width="678" height="21" font="5">&gt;65 to ≤75, and ≤65 years. However, analyses of RCTs that compared statin therapy (mostly moderate </text>
<text top="668" left="135" width="679" height="21" font="5">intensity) with placebo among patients &gt;75 years of age with ASCVD showed statistically significant </text>
<text top="688" left="135" width="680" height="21" font="5">reduction in major vascular events (S4.1<a href="CIR.0000000000000625.html#91">-3)</a>. Because older adults may have a higher risk of adverse </text>
<text top="708" left="135" width="681" height="21" font="5">events (e.g., liver function test abnormalities), lower statin adherence, and higher discontinuation </text>
<text top="728" left="135" width="686" height="21" font="5">rates with high-intensity therapy (S4.1-44), a moderate-intensity statin may be preferable. </text>
<text top="748" left="135" width="679" height="21" font="5">Nevertheless, the decision to initiate moderate- or high-intensity statin therapy in patients &gt;75 years </text>
<text top="768" left="135" width="675" height="21" font="5">of age with ASCVD should be based on expected benefit versus competing comorbidities (S4.1<a href="CIR.0000000000000625.html#92">-23–</a></text>
<text top="789" left="135" width="63" height="21" font="5"><a href="CIR.0000000000000625.html#92">S4.1-31</a>). </text>
<text top="809" left="108" width="708" height="21" font="5">8.  This recommendation is based on the observation that the age reported in clinical trials of statin </text>
<text top="829" left="135" width="678" height="21" font="5">therapy in patients with ASCVD represents the patient’s age at study entry. Therefore, it is reasonable </text>
<text top="849" left="135" width="679" height="21" font="5">to consider continuation of high-intensity therapy in patients &gt;75 years of age with ASCVD if they are </text>
<text top="869" left="135" width="680" height="21" font="5">tolerating the statin and have a low risk of competing morbidities (S4.1<a href="CIR.0000000000000625.html#92">-23</a>, S4.1<a href="CIR.0000000000000625.html#92">-26</a>, S4.1<a href="CIR.0000000000000625.html#92">-31</a>). RCTs </text>
<text top="889" left="135" width="675" height="21" font="5">(S4.1-32, S4.1<a href="CIR.0000000000000625.html#92">-33</a>, S4.1<a href="CIR.0000000000000625.html#92">-35</a>, S4.1<a href="CIR.0000000000000625.html#92">-36</a>) have not shown an adverse effect of statin therapy on cognition. </text>
<text top="909" left="108" width="702" height="21" font="5">9.  Although moderate-intensity  statin  therapy reduces ASCVD events, it is less effective than high-</text>
<text top="930" left="135" width="678" height="21" font="5">intensity therapy (S4.1<a href="CIR.0000000000000625.html#91">-3)</a>. This difference presumably is due to differences in LDL-C–lowering potency. </text>
<text top="950" left="135" width="679" height="21" font="5">Hence, if ezetimibe were to be added to a moderate-intensity therapy to compensate for  the </text>
<text top="970" left="135" width="680" height="21" font="5">difference in LDL-C–lowering ability between moderate- and high-intensity statins, the combination </text>
<text top="990" left="135" width="679" height="21" font="5">of moderate-intensity statin and ezetimibe could potentially produce a level of ASCVD risk reduction </text>
<text top="1010" left="135" width="679" height="21" font="5">similar to that produced by high-intensity therapy alone. This hypothesis is supported by the finding </text>
<text top="1030" left="135" width="679" height="21" font="5">that ezetimibe enhanced risk reduction when combined with moderate-intensity therapy in patients </text>
<text top="1050" left="135" width="680" height="21" font="5">after ACS (S4.1<a href="CIR.0000000000000625.html#91">-15)</a>. Thus, it may be reasonable to add ezetimibe to moderate-intensity therapy in </text>
<text top="1071" left="135" width="679" height="21" font="5">patients with ASCVD for whom high-intensity therapy is indicated but cannot be used, provided their </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="22" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-22_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 22</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="135" width="680" height="21" font="5">LDL-C level remains ≥70 mg/dL (≥1.8 mmol/L) on moderate-intensity therapy. The same reasoning </text>
<text top="144" left="135" width="680" height="21" font="5">holds for any patient whose LDL-C level remains ≥70 mg/dL (≥1.8 mmol/L) on maximally tolerated </text>
<text top="164" left="135" width="101" height="21" font="5">statin therapy  </text>
<text top="184" left="108" width="706" height="21" font="5">10.  The CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure) trial (S4.1<a href="CIR.0000000000000625.html#92">-38</a>) (patients </text>
<text top="204" left="135" width="680" height="21" font="5">with ischemic HF and left ventricular ejection fraction &lt;40%) and GISSI HF trial (Effects of n-3 PUFA </text>
<text top="225" left="135" width="679" height="21" font="5">and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic CHF) (S4.1<a href="CIR.0000000000000625.html#93">-45</a>) (patients with </text>
<text top="245" left="135" width="679" height="21" font="5">ischemic and nonischemic HF, 9.8% with left ventricular ejection fraction &gt;40%) evaluated the efficacy </text>
<text top="265" left="135" width="679" height="21" font="5">and safety of initiation of 10 mg of rosuvastatin daily compared with placebo. Neither trial met its </text>
<text top="285" left="135" width="683" height="21" font="5">primary outcome. Rosuvastatin reduced the risk of total hospitalizations, hospitalizations for a </text>
<text top="305" left="135" width="683" height="21" font="5">cardiovascular cause, and hospitalizations for worsening HF in CORONA. A subsequent analysis </text>
<text top="325" left="135" width="675" height="21" font="5">accounting for repeat HF hospitalizations showed significant reduction in HF hospitalizations (S4.1-</text>
<text top="345" left="135" width="679" height="21" font="5"><a href="CIR.0000000000000625.html#93">46</a>). Post  hoc analyses from CORONA showed that patients randomized to rosuvastatin with less </text>
<text top="366" left="135" width="679" height="21" font="5">advanced HF with reduced ejection fraction (lowest tertile of NT-proBNP) had a significant reduction </text>
<text top="386" left="135" width="679" height="21" font="5">in the primary outcome, but no benefit was seen among patients with more advanced HF (S4.1<a href="CIR.0000000000000625.html#93">-47</a>). </text>
<text top="406" left="135" width="679" height="21" font="5">The CORONA and GISSI studies were notable for high overall and cardiovascular mortality rates, with </text>
<text top="426" left="135" width="679" height="21" font="5">MI occurring in a small minority. A subsequent patient-level analysis (S4.1<a href="CIR.0000000000000625.html#92">-37</a>) that pooled data from </text>
<text top="446" left="135" width="678" height="21" font="5">both these trials and accounted for competing causes of death showed a significant 19% reduction in </text>
<text top="466" left="135" width="602" height="21" font="5">the risk of MI with rosuvastatin in patients with ischemic HF, although the ARR was small. </text>
<text top="486" left="108" width="4" height="21" font="5"> </text>
<text top="486" left="324" width="4" height="21" font="5"> </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="23" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-23_1.jpg"/>
<image top="163" left="108" width="702" height="514" src="blood-cholesterol-management/CIR.0000000000000625-23_2.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 23</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="434" height="21" font="4"><b>Figure 1. Secondary Prevention in Patients With Clinical ASCVD </b></text>
<text top="661" left="810" width="4" height="23" font="3"><b> </b></text>
<text top="690" left="108" width="359" height="19" font="1">Colors correspond to Class of Recommendation in Table 2. </text>
<text top="708" left="108" width="708" height="19" font="1">Clinical ASCVD consists of ACS, those with history of MI, stable or unstable angina or  coronary  other arterial </text>
<text top="726" left="108" width="710" height="19" font="1">revascularization, stroke, transient ischemic attack (TIA), or peripheral artery disease (PAD) including aortic </text>
<text top="744" left="108" width="234" height="19" font="1">aneurysm, all of atherosclerotic origin </text>
<text top="763" left="108" width="705" height="19" font="1">Very high-risk includes a history of multiple major ASCVD events or 1 major ASCVD event and multiple high-risk </text>
<text top="781" left="108" width="128" height="19" font="1">conditions (Table 4).<b> </b></text>
<text top="799" left="108" width="705" height="19" font="1">ACS indicates acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; LDL-C, low-density </text>
<text top="818" left="108" width="706" height="19" font="1">lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; MI, myocardial infarction; and PCSK9-I, PCSK9 </text>
<text top="836" left="108" width="59" height="19" font="1">inhibitor. </text>
<text top="859" left="108" width="5" height="16" font="14"> </text>
<text top="884" left="108" width="4" height="21" font="5"> </text>
<text top="884" left="324" width="4" height="21" font="5"> </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="24" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="21" size="7" family="Times" color="#000000"/>
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-24_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 24</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="335" height="21" font="4"><b>Table 4. Very High-Risk* of Future ASCVD Events</b> </text>
<text top="144" left="108" width="4" height="21" font="5"> </text>
<text top="165" left="116" width="132" height="19" font="0"><b>Major ASCVD Events </b></text>
<text top="187" left="116" width="218" height="19" font="1">Recent ACS (within the past 12 mo) </text>
<text top="209" left="116" width="345" height="19" font="1">History of MI (other than recent ACS event listed above) </text>
<text top="231" left="116" width="161" height="19" font="1">History of ischemic stroke </text>
<text top="253" left="116" width="681" height="19" font="1">Symptomatic peripheral arterial disease (history of claudication with ABI &lt;0.85, or previous revascularization or </text>
<text top="274" left="116" width="137" height="19" font="1">amputation (S4.1<a href="CIR.0000000000000625.html#93">-39)</a>) </text>
<text top="295" left="116" width="132" height="19" font="0"><b>High-Risk Conditions </b></text>
<text top="317" left="116" width="63" height="19" font="1">Age ≥65 y </text>
<text top="339" left="116" width="272" height="19" font="1">Heterozygous familial hypercholesterolemia </text>
<text top="361" left="116" width="656" height="19" font="1">History of prior coronary artery bypass surgery or percutaneous coronary intervention outside of the major </text>
<text top="382" left="116" width="98" height="19" font="1">ASCVD event(s) </text>
<text top="404" left="116" width="109" height="19" font="1">Diabetes mellitus </text>
<text top="425" left="116" width="86" height="19" font="1">Hypertension </text>
<text top="447" left="116" width="202" height="19" font="1">CKD (eGFR 15-59 mL/min/1.73 m</text>
<text top="447" left="318" width="5" height="12" font="21">2</text>
<text top="447" left="323" width="119" height="19" font="1">) (S4.1<a href="CIR.0000000000000625.html#91">-15,</a> S4.1<a href="CIR.0000000000000625.html#91">-17)</a> </text>
<text top="469" left="116" width="104" height="19" font="1">Current smoking </text>
<text top="492" left="116" width="283" height="19" font="1">Persistently elevated LDL-C (LDL-C ≥100 mg/dL</text>
<text top="491" left="400" width="9" height="21" font="5"> [</text>
<text top="492" left="409" width="379" height="19" font="1">≥2.6 mmol/L]) despite maximally tolerated statin therapy and </text>
<text top="514" left="116" width="63" height="19" font="1">ezetimibe </text>
<text top="536" left="116" width="151" height="19" font="1">History of congestive HF </text>
<text top="558" left="108" width="705" height="19" font="1">*Very high risk includes a history of multiple major ASCVD events or 1 major ASCVD event and multiple high-risk </text>
<text top="576" left="108" width="71" height="19" font="1">conditions. </text>
<text top="594" left="108" width="706" height="19" font="1">ABI indicates ankle-brachial index; ACS, acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; </text>
<text top="613" left="108" width="705" height="19" font="1">CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HF, heart failure; LDL, low-density </text>
<text top="631" left="108" width="333" height="19" font="1">lipoprotein cholesterol; and MI, myocardial infarction. </text>
<text top="649" left="108" width="3" height="19" font="1"> </text>
<text top="676" left="108" width="4" height="21" font="5"> </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="25" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-25_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 25</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="645" height="29" font="2"><b>4.2. Severe Hypercholesterolemia (LDL-C ≥190 mg/dL [≥4.9 mmol/L]) </b></text>
<text top="165" left="132" width="658" height="21" font="4"><b>Recommendations for Primary Severe Hypercholesterolemia (LDL-C ≥190 mg/dL [≥4.9 mmol/L]) </b></text>
<text top="185" left="131" width="474" height="21" font="5">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625"> </a></text>
<text top="185" left="605" width="186" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Online Data Supplements 9 </a></text>
<text top="208" left="434" width="46" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">and 10</a></text>
<text top="208" left="480" width="8" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">.</a> </text>
<text top="232" left="134" width="33" height="21" font="4"><b>COR </b></text>
<text top="232" left="214" width="30" height="21" font="4"><b>LOE </b></text>
<text top="232" left="473" width="132" height="21" font="4"><b>Recommendations </b></text>
<text top="273" left="147" width="8" height="21" font="4"><b>I </b></text>
<text top="273" left="215" width="27" height="21" font="4"><b>B-R </b></text>
<text top="253" left="273" width="532" height="21" font="4"><b>1.  In patients</b> <b>20 to 75 years of age with an LDL-C level of 190 mg/dL (≥4.9 </b></text>
<text top="273" left="297" width="508" height="21" font="4"><b>mmol/L) or higher, maximally tolerated statin therapy is recommended </b></text>
<text top="294" left="297" width="111" height="21" font="4"><b>(S4.2<a href="CIR.0000000000000625.html#93">-1–S4.2-7)</a></b><b>. </b></text>
<text top="355" left="140" width="21" height="21" font="4"><b>IIa </b></text>
<text top="355" left="215" width="27" height="21" font="4"><b>B-R </b></text>
<text top="314" left="273" width="532" height="21" font="4"><b>2.  In patients 20 to 75 years of age with an LDL-C level of 190 mg/dL (≥4.9 </b></text>
<text top="335" left="297" width="509" height="21" font="4"><b>mmol/L) or higher who achieve less than a 50% reduction in LDL-C while </b></text>
<text top="355" left="297" width="508" height="21" font="4"><b>receiving maximally tolerated statin therapy and/or have an LDL-C level of </b></text>
<text top="375" left="297" width="505" height="21" font="4"><b>100 mg/dL (≥2.6 mmol/L) or higher, ezetimibe therapy is reasonable (S4.2-</b></text>
<text top="395" left="297" width="84" height="21" font="4"><a href="CIR.0000000000000625.html#94"><b>8–S4.2-10)</b></a><b>.</b> <b> </b></text>
<text top="456" left="140" width="21" height="21" font="4"><b>IIb </b></text>
<text top="456" left="215" width="27" height="21" font="4"><b>B-R </b></text>
<text top="416" left="273" width="532" height="21" font="4"><b>3.  In patients 20 to 75 years of age with a baseline LDL-C level ≥190 mg/dL </b></text>
<text top="436" left="297" width="509" height="21" font="4"><b>(≥4.9 mmol/L), who achieve less than a 50% reduction in LDL-C levels and </b></text>
<text top="456" left="297" width="515" height="21" font="4"><b>have fasting triglycerides ≤300 mg/dL (≤3.4 mmol/L). while taking </b></text>
<text top="476" left="297" width="510" height="21" font="4"><b>maximally tolerated statin and ezetimibe therapy, the addition of a bile </b></text>
<text top="496" left="297" width="378" height="21" font="4"><b>acid sequestrant may be considered (S4.2<a href="CIR.0000000000000625.html#94">-11, </a></b><b>S4.2<a href="CIR.0000000000000625.html#94">-12)</a></b><b>. </b></text>
<text top="548" left="140" width="21" height="21" font="4"><b>IIb </b></text>
<text top="548" left="215" width="27" height="21" font="4"><b>B-R </b></text>
<text top="517" left="273" width="532" height="21" font="4"><b>4.  In patients 30 to 75 years of age with heterozygous FH and with an LDL-C </b></text>
<text top="537" left="297" width="508" height="21" font="4"><b>level of  100 mg/dL (≥2.6  mmol/L)  or higher while taking maximally </b></text>
<text top="558" left="297" width="510" height="21" font="4"><b>tolerated statin and ezetimibe therapy, the addition of a PCSK9 inhibitor </b></text>
<text top="578" left="297" width="312" height="21" font="4"><b>may be considered (S4.2<a href="CIR.0000000000000625.html#94">-9, </a></b><b>S4.2<a href="CIR.0000000000000625.html#94">-13–S4.2-15)</a></b><b>. </b></text>
<text top="639" left="140" width="21" height="21" font="4"><b>IIb </b></text>
<text top="639" left="211" width="35" height="21" font="4"><b>C-LD </b></text>
<text top="599" left="273" width="532" height="21" font="4"><b>5.  In patients 40 to 75 years of age with a baseline LDL-C level of 220 mg/dL </b></text>
<text top="619" left="297" width="510" height="21" font="4"><b>(≥5.7 mmol/L) or higher and who achieve an on-treatment LDL-C level of </b></text>
<text top="639" left="297" width="509" height="21" font="4"><b>130 mg/dL (≥3.4 mmol/L) or higher while receiving maximally tolerated </b></text>
<text top="659" left="297" width="511" height="21" font="4"><b>statin and ezetimibe therapy, the addition of a PCSK9 inhibitor may be </b></text>
<text top="679" left="297" width="207" height="21" font="4"><b>considered (S4.2<a href="CIR.0000000000000625.html#94">-13–S4.2-17)</a></b><b>. </b></text>
<text top="700" left="167" width="43" height="21" font="4"><b>Value </b></text>
<text top="720" left="148" width="80" height="21" font="4"><b>Statement: </b></text>
<text top="740" left="153" width="71" height="21" font="4"><b>Uncertain </b></text>
<text top="760" left="167" width="43" height="21" font="4"><b>Value </b></text>
<text top="781" left="164" width="49" height="21" font="4"><b>(B-NR) </b></text>
<text top="700" left="273" width="538" height="21" font="4"><b>6.  Among patients with FH without evidence of clinical ASCVD taking </b></text>
<text top="720" left="297" width="515" height="21" font="4"><b>maximally tolerated statin and ezetimibe therapy, PCSK9 inhibitors </b></text>
<text top="740" left="297" width="357" height="21" font="4"><b>provide uncertain value at mid-2018 U.S. list prices. </b></text>
<text top="811" left="108" width="4" height="21" font="5"> </text>
<text top="840" left="108" width="63" height="21" font="4"><b>Synopsis </b></text>
<text top="879" left="108" width="706" height="21" font="5">Patients with severe hypercholesterolemia have a high lifetime risk, and decisions about statins in these </text>
<text top="899" left="108" width="706" height="21" font="5">patients do not require ASCVD risk scoring. These patients derive net ASCVD risk reduction benefit from </text>
<text top="919" left="108" width="705" height="21" font="5">interventions that increase expression of LDL receptors. The strongest data have been derived from statin </text>
<text top="939" left="108" width="710" height="21" font="5">RCTs, which have demonstrated greater risk reduction with statins than with  placebo and greater </text>
<text top="960" left="108" width="706" height="21" font="5">reduction from higher-intensity statin therapy  than with moderate-intensity statin  therapy.  Ezetimibe </text>
<text top="980" left="108" width="706" height="21" font="5">plus a moderate-intensity statin is associated with greater LDL-C reduction than is statin monotherapy in </text>
<text top="1000" left="108" width="706" height="21" font="5">patients with heterozygous FH, and the combination reduces ASCVD risk more than moderate-intensity </text>
<text top="1020" left="108" width="712" height="21" font="5">statin monotherapy in patients who have had a recent ACS. In selected patients with severe </text>
<text top="1040" left="108" width="708" height="21" font="5">hypercholesterolemia  whose  LDL-C  is  inadequately controlled with drug therapy, LDL apheresis is an </text>
<text top="1060" left="108" width="360" height="21" font="5">option. Referral to a lipid specialist may be indicated. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="26" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-26_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 26</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="299" height="21" font="4"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="163" left="108" width="707" height="21" font="5">1.  Patients with primary severe hypercholesterolemia (LDL-C levels<b> </b>≥190 mg/dL [≥4.9 mmol/L]) have a </text>
<text top="183" left="135" width="679" height="21" font="5">high-risk of ASCVD (S4.2<a href="CIR.0000000000000625.html#93">-2,</a> S4.2<a href="CIR.0000000000000625.html#93">-4,</a> S4.2<a href="CIR.0000000000000625.html#94">-18)</a> and premature and recurrent coronary events (S4.2<a href="CIR.0000000000000625.html#93">-3)</a>. </text>
<text top="203" left="135" width="678" height="21" font="5">Although there have been no randomized, placebo-controlled trials of statin therapy done exclusively </text>
<text top="223" left="135" width="681" height="21" font="5">in subjects with LDL-C  levels ≥190 mg/dL  (≥4.9 mmol/L),  a placebo-controlled primary prevention </text>
<text top="244" left="135" width="679" height="21" font="5">study performed in men with a mean baseline LDL-C  level  of  192±17 mg/dL (4.9±0.4  mmol/L) </text>
<text top="264" left="135" width="680" height="21" font="5">demonstrated a reduced incidence of MI and cardiovascular death in those receiving pravastatin 40 </text>
<text top="284" left="135" width="675" height="21" font="5">mg daily (S4.2<a href="CIR.0000000000000625.html#93">-5)</a>. These findings were extended in a post hoc analysis of 2,560 exclusively primary-</text>
<text top="304" left="135" width="680" height="21" font="5">prevention subjects in that RCT and in a 20-year observational post-trial long-term follow-up study </text>
<text top="324" left="135" width="680" height="21" font="5">(S4.2<a href="CIR.0000000000000625.html#94">-19)</a>. In addition, retrospective cohort studies have demonstrated that statin therapy reduces </text>
<text top="344" left="135" width="680" height="21" font="5">risk of incident MI (S4.2<a href="CIR.0000000000000625.html#93">-6)</a> and of CHD and all-cause death (S4.2<a href="CIR.0000000000000625.html#93">-1)</a> in patients with phenotypic or </text>
<text top="365" left="135" width="680" height="21" font="5">genetically confirmed FH. Because moderate- or high-intensity statins have been shown to reduce </text>
<text top="385" left="135" width="682" height="21" font="5">ASCVD risk in both primary-  and  secondary-prevention trials and because  high-intensity statins </text>
<text top="405" left="135" width="679" height="21" font="5">provide greater ASCVD risk reduction than moderate-intensity statins or placebo (S4.2<a href="CIR.0000000000000625.html#94">-7)</a>, maximally </text>
<text top="425" left="135" width="693" height="21" font="5">tolerated statin therapy should be administered to patients with primary severe </text>
<text top="445" left="135" width="155" height="21" font="5">hypercholesterolemia. </text>
<text top="465" left="108" width="709" height="21" font="5">2.  A large placebo-controlled RCT examined the effect of simvastatin 80 mg  daily, with or without </text>
<text top="485" left="135" width="678" height="21" font="5">ezetimibe 10 mg daily, on carotid intima-media thickness and plasma lipoproteins over 2 years. Mean </text>
<text top="505" left="135" width="679" height="21" font="5">LDL-C reduction was greater in the combined-therapy group, but there was no difference in carotid </text>
<text top="526" left="135" width="680" height="21" font="5">intima-media thickness between the 2 groups. The study was not powered to examine the risk of </text>
<text top="546" left="135" width="678" height="21" font="5">ASCVD events (S4.2<a href="CIR.0000000000000625.html#94">-10)</a>. However, a very large placebo-controlled RCT examining ASCVD outcomes in </text>
<text top="566" left="135" width="679" height="21" font="5">post-ACS patients, performed over a period of 7 years, showed that the addition of ezetimibe 10 mg </text>
<text top="586" left="135" width="679" height="21" font="5">to simvastatin 40 mg daily resulted in greater ASCVD risk reduction than that produced by statin </text>
<text top="606" left="135" width="682" height="21" font="5">monotherapy  (S4.2<a href="CIR.0000000000000625.html#94">-8)</a>.  Secondary-prevention patients with certain ASCVD risk indicators exhibit </text>
<text top="626" left="135" width="679" height="21" font="5">greater ASCVD risk reduction from ezetimibe therapy than do patients without these characteristics </text>
<text top="646" left="135" width="682" height="21" font="5">(S4.2<a href="CIR.0000000000000625.html#94">-20)</a>.  Patients with severe hypercholesterolemia who are adherent to statins, achieve &lt;50% </text>
<text top="667" left="135" width="679" height="21" font="5">reduction in LDL-C levels<b> </b>with maximally tolerated statin therapy, and have an LDL-C level ≥100 mg/dL </text>
<text top="687" left="135" width="681" height="21" font="5">(≥2.6 mmol/L) are likely to derive additional ASCVD risk reduction from ezetimibe add-on therapy </text>
<text top="707" left="135" width="296" height="21" font="5">through additional LDL-C lowering (S4.2<a href="CIR.0000000000000625.html#94">-9)</a>.  </text>
<text top="727" left="108" width="705" height="21" font="5">3.  When administered to patients with severe hypercholesterolemia who are taking maximally tolerated </text>
<text top="747" left="135" width="679" height="21" font="5">statins with or without ezetimibe, bile acid sequestrants have demonstrated LDL-C-lowering efficacy </text>
<text top="767" left="135" width="680" height="21" font="5">(S4.2-11, S4.2-12). However, the clinical utility of bile acid sequestrants is limited by the absence of </text>
<text top="788" left="135" width="679" height="21" font="5">ASCVD outcomes data when used in combination with statins, as well as by the issues of twice-daily </text>
<text top="808" left="135" width="680" height="21" font="5">dosing, high pill burden, the absence of well-tolerated generic formulations, drug interactions, and </text>
<text top="828" left="135" width="692" height="21" font="5">the potential for triglyceride elevation. Nonetheless, in patients with very severe </text>
<text top="848" left="135" width="681" height="21" font="5">hypercholesterolemia, adding sequestrants to otherwise maximal cholesterol-lowering therapy in </text>
<text top="868" left="135" width="476" height="21" font="5">patients who are not eligible for a PCSK9 inhibitor may be considered.  </text>
<text top="888" left="108" width="702" height="21" font="5">4.  PCSK9 inhibitors are promising drugs for treatment of FH (S4.2-9, S4.2-13–S4.2-15). Two placebo-</text>
<text top="908" left="135" width="679" height="21" font="5">controlled RCTs of the efficacy and safety of PCSK9 inhibitors in patients with heterozygous FH who </text>
<text top="928" left="135" width="679" height="21" font="5">were ≥18 years of age and taking stable, maximally tolerated statin therapy demonstrated favorable </text>
<text top="949" left="135" width="680" height="21" font="5">safety profiles and an additional ≥50% reduction in LDL-C (S4.2<a href="CIR.0000000000000625.html#94">-10,</a> S4.2<a href="CIR.0000000000000625.html#94">-15)</a>. There are no currently </text>
<text top="969" left="135" width="678" height="21" font="5">available outcomes trials of PCSK9 inhibitors in patients with ASCVD heterozygous FH. In patients with </text>
<text top="989" left="135" width="681" height="21" font="5">LDL-C levels<b> </b>≥190 mg/dL (≥4.9 mmol/L), advancing age is associated with progressively increasing </text>
<text top="1009" left="135" width="679" height="21" font="5">ASCVD risk (S4.2<a href="CIR.0000000000000625.html#93">-4)</a>, and age-related risk would likely apply to those with heterozygous FH because of </text>
<text top="1029" left="135" width="680" height="21" font="5">their higher lifetime exposure to increased LDL-C concentration (S4.2<a href="CIR.0000000000000625.html#94">-18)</a>. A long-term prospective </text>
<text top="1049" left="135" width="679" height="21" font="5">cohort registry study of 2,404  patients with heterozygous FH  (molecularly  defined)  taking </text>
<text top="1069" left="135" width="680" height="21" font="5">contemporary statin with or without ezetimibe treatment regimens identified age &gt;30 years, male </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="27" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-27_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 27</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="135" width="679" height="21" font="5">sex, history of ASCVD, high blood pressure, increased waist circumference, active smoking, Lp(a) ≥50 </text>
<text top="144" left="135" width="679" height="21" font="5">mg/dL, and LDL-C levels<b> </b>≥100 mg/dL (≥2.6 mmol/L) as independent predictors of incident ASCVD over </text>
<text top="164" left="135" width="679" height="21" font="5">a 5.5-year follow-up period (S4.2<a href="CIR.0000000000000625.html#94">-14)</a>. Because other medical interventions that lower LDL-C levels<b> </b>via </text>
<text top="184" left="135" width="681" height="21" font="5">increased expression of LDL receptors reduce ASCVD risk (S4.2<a href="CIR.0000000000000625.html#94">-9)</a>,  the use of PCSK9 inhibitors in </text>
<text top="204" left="135" width="679" height="21" font="5">selected maximally treated patients with heterozygous FH with persistently elevated LDL-C levels may </text>
<text top="225" left="135" width="678" height="21" font="5">be considered after a clinician–patient discussion of the net benefits versus the cost of such therapy. </text>
<text top="245" left="108" width="705" height="21" font="5">5.  Regardless of whether a patient with LDL-C levels<b> </b>≥190 mg/dL (≥4.9 mmol/L) is found to have a genetic </text>
<text top="265" left="135" width="678" height="21" font="5">mutation associated with FH, those with very high LDL-C values are most likely to achieve the greatest </text>
<text top="285" left="135" width="680" height="21" font="5">benefit from evidence-based LDL-C–lowering therapy. Consequently, patients who have a baseline </text>
<text top="305" left="135" width="679" height="21" font="5">LDL-C level ≥220 mg/dL (≥5.7 mmol/L) and an on-treatment LDL-C level ≥130 mg/dL (≥3.4 mmol/L) </text>
<text top="325" left="135" width="680" height="21" font="5">despite maximally tolerated statin and ezetimibe therapy may be considered for treatment with a </text>
<text top="345" left="135" width="679" height="21" font="5">PCSK9 inhibitor after a clinician–patient discussion of the net benefits versus the costs of such therapy. </text>
<text top="366" left="108" width="706" height="21" font="5">6.  The cost-effectiveness of PCSK9 inhibitors for primary prevention among patients with LDL-C levels </text>
<text top="386" left="135" width="683" height="21" font="5">&gt;190 mg/dL  (≥4.9 mmol/L), or with FH, has not been evaluated extensively, and their clinical </text>
<text top="406" left="135" width="679" height="21" font="5">effectiveness in reducing ASCVD events in these patients has also not been established. The 2 </text>
<text top="426" left="135" width="679" height="21" font="5">published cost-effectiveness models for primary prevention (see Online Data Supplements 44 and 45 </text>
<text top="446" left="135" width="679" height="21" font="5">and Section 7.) report very different results, with one suggesting an incremental cost-effectiveness </text>
<text top="466" left="135" width="679" height="21" font="5">ratio of $503,000 per QALY added, and the other reporting $75,000 per QALY added. Because of the </text>
<text top="486" left="135" width="678" height="21" font="5">lack of consistent evidence, the use of PCSK9 inhibitors has uncertain value for the primary prevention </text>
<text top="507" left="135" width="377" height="21" font="5">of ASCVD in patients with severe hypercholesterolemia. </text>
<text top="527" left="108" width="4" height="21" font="5"> </text>
<text top="556" left="108" width="297" height="29" font="2"><b>4.3. Diabetes Mellitus in Adults </b></text>
<text top="597" left="272" width="377" height="21" font="4"><b>Recommendations for Patients With Diabetes Mellitus </b></text>
<text top="617" left="126" width="474" height="21" font="5">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625"> </a></text>
<text top="617" left="600" width="195" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Online Data Supplements 11 </a></text>
<text top="640" left="434" width="46" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">and 12</a></text>
<text top="640" left="480" width="8" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">.</a> </text>
<text top="673" left="127" width="33" height="21" font="4"><b>COR </b></text>
<text top="673" left="196" width="30" height="21" font="4"><b>LOE </b></text>
<text top="673" left="462" width="132" height="21" font="4"><b>Recommendations </b></text>
<text top="720" left="140" width="8" height="21" font="4"><b>I </b></text>
<text top="720" left="204" width="14" height="21" font="4"><b>A </b></text>
<text top="706" left="251" width="554" height="21" font="4"><b>1.  In adults 40 to 75 years of age with diabetes mellitus, regardless of estimated </b></text>
<text top="726" left="278" width="524" height="21" font="4"><b>10-year ASCVD risk, moderate-intensity statin therapy is indicated (S4.3<a href="CIR.0000000000000625.html#94">-1–</a></b></text>
<text top="746" left="278" width="59" height="21" font="4"><a href="CIR.0000000000000625.html#94"><b>S4.3-9)</b></a><b>.  </b></text>
<text top="792" left="133" width="21" height="21" font="4"><b>IIa </b></text>
<text top="792" left="192" width="38" height="21" font="4"><b>B-NR </b></text>
<text top="767" left="251" width="554" height="21" font="4"><b>2.  In adults 40 to 75 years of age with diabetes mellitus and an LDL-C level of 70 </b></text>
<text top="787" left="278" width="528" height="21" font="4"><b>to 189 mg/dL</b> <b>(1.7 to 4.8 mmol/L), it is reasonable to assess the 10-year risk </b></text>
<text top="808" left="278" width="528" height="21" font="4"><b>of a first ASCVD event by using the race and sex-specific PCE to help stratify </b></text>
<text top="828" left="278" width="206" height="21" font="4"><b>ASCVD risk (S4.3<a href="CIR.0000000000000625.html#95">-10, </a></b><b>S4.3<a href="CIR.0000000000000625.html#95">-11)</a></b><b>. </b></text>
<text top="867" left="133" width="21" height="21" font="4"><b>IIa </b></text>
<text top="867" left="197" width="27" height="21" font="4"><b>B-R </b></text>
<text top="849" left="251" width="555" height="21" font="4"><b>3.  In adults with diabetes mellitus who have multiple ASCVD risk factors, it is </b></text>
<text top="869" left="278" width="528" height="21" font="4"><b>reasonable to prescribe high-intensity statin therapy with the aim to reduce </b></text>
<text top="889" left="278" width="324" height="21" font="4"><b>LDL-C levels by 50% or more (S4.3<a href="CIR.0000000000000625.html#95">-12, </a></b><b>S4.3<a href="CIR.0000000000000625.html#95">-13)</a></b><b>. </b></text>
<text top="938" left="133" width="21" height="21" font="4"><b>IIa </b></text>
<text top="938" left="192" width="38" height="21" font="4"><b>B-NR </b></text>
<text top="919" left="251" width="557" height="21" font="4"><b>4.  In adults  older than 75 years of age with diabetes mellitus and who are </b></text>
<text top="939" left="278" width="527" height="21" font="4"><b>already on statin therapy, it is reasonable to continue statin therapy (S4.3<a href="CIR.0000000000000625.html#95">-5, </a></b></text>
<text top="959" left="278" width="114" height="21" font="4"><b>S4.3<a href="CIR.0000000000000625.html#95">-8, </a></b><b>S4.3<a href="CIR.0000000000000625.html#95">-13)</a></b><b>. </b></text>
<text top="1008" left="133" width="21" height="21" font="4"><b>IIb </b></text>
<text top="1008" left="194" width="35" height="21" font="4"><b>C-LD </b></text>
<text top="989" left="251" width="555" height="21" font="4"><b>5.  In adults with diabetes mellitus and 10-year ASCVD risk of 20% or higher, it </b></text>
<text top="1009" left="278" width="527" height="21" font="4"><b>may be reasonable to add ezetimibe to maximally tolerated statin therapy to </b></text>
<text top="1029" left="278" width="375" height="21" font="4"><b>reduce LDL-C levels by 50% or more (S4.3<a href="CIR.0000000000000625.html#95">-14, </a></b><b>S4.3<a href="CIR.0000000000000625.html#95">-15)</a></b><b>. </b></text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="28" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-28_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 28</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="143" left="133" width="21" height="21" font="4"><b>IIb </b></text>
<text top="143" left="194" width="35" height="21" font="4"><b>C-LD </b></text>
<text top="125" left="251" width="554" height="21" font="4"><b>6.  In adults older than 75 years with diabetes mellitus, it may be reasonable to </b></text>
<text top="145" left="278" width="534" height="21" font="4"><b>initiate statin therapy after a clinician–patient discussion of potential </b></text>
<text top="165" left="278" width="294" height="21" font="4"><b>benefits and risks (S4.3<a href="CIR.0000000000000625.html#95">-5, </a></b><b>S4.3<a href="CIR.0000000000000625.html#95">-8, </a></b><b>S4.3<a href="CIR.0000000000000625.html#95">-13)</a></b><b>. </b></text>
<text top="243" left="133" width="21" height="21" font="4"><b>IIb </b></text>
<text top="243" left="194" width="35" height="21" font="4"><b>C-LD </b></text>
<text top="195" left="251" width="554" height="21" font="4"><b>7.  In adults 20 to 39 years of age with diabetes mellitus that is either of long </b></text>
<text top="215" left="278" width="527" height="21" font="4"><b>duration (≥10 years of type 2 diabetes mellitus, ≥20 years of type 1 diabetes </b></text>
<text top="235" left="278" width="527" height="21" font="4"><b>mellitus), albuminuria (≥30 mcg of  albumin/mg creatinine), estimated </b></text>
<text top="255" left="278" width="424" height="21" font="4"><b>glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m</b></text>
<text top="255" left="702" width="5" height="13" font="20"><b>2</b></text>
<text top="255" left="708" width="99" height="21" font="4"><b>, retinopathy, </b></text>
<text top="275" left="278" width="531" height="21" font="4"><b>neuropathy,  or  ankle-brachial index (ABI;  &lt;0.9),  it  may be reasonable to </b></text>
<text top="296" left="278" width="432" height="21" font="4"><b>initiate statin therapy (S4.3<a href="CIR.0000000000000625.html#95">-5, </a></b><b>S4.3<a href="CIR.0000000000000625.html#95">-6, </a></b><b>S4.3<a href="CIR.0000000000000625.html#95">-8, </a></b><b>S4.3<a href="CIR.0000000000000625.html#95">-16–S4.3-25)</a></b><b>. </b></text>
<text top="325" left="108" width="4" height="21" font="5"> </text>
<text top="354" left="108" width="67" height="21" font="4"><b>Synopsis  </b></text>
<text top="394" left="108" width="706" height="21" font="5">Although most adults 40 to 75 years of age with diabetes mellitus are at intermediate or high-risk of their </text>
<text top="414" left="108" width="706" height="21" font="5">first ASCVD event (S4.3<a href="CIR.0000000000000625.html#95">-5,</a> S4.3<a href="CIR.0000000000000625.html#95">-6,</a> S4.3<a href="CIR.0000000000000625.html#95">-8,</a> S4.3<a href="CIR.0000000000000625.html#95">-9)</a>, evaluation of ASCVD risk will help refine risk estimates </text>
<text top="434" left="108" width="702" height="21" font="5">and therapeutic decision-making.  Because  primary-prevention trials demonstrate  that moderate-</text>
<text top="454" left="108" width="706" height="21" font="5">intensity statin therapy in large cohorts with diabetes mellitus provides significant benefit (S4.3<a href="CIR.0000000000000625.html#94">-1–S4.3-4,</a> </text>
<text top="474" left="108" width="709" height="21" font="5">S4.3<a href="CIR.0000000000000625.html#95">-7)</a>, this treatment is indicated in such  individuals. However, given the increased morbidity and </text>
<text top="494" left="108" width="706" height="21" font="5">mortality associated with a first event in diabetes mellitus and the residual risk among the statin-treated </text>
<text top="515" left="108" width="709" height="21" font="5">groups in these trials, together with the evidence of  benefit from high-intensity  statin treatment in </text>
<text top="535" left="108" width="706" height="21" font="5">primary prevention among men &gt;50 years of age and women &gt;60 years of age (S4.3<a href="CIR.0000000000000625.html#95">-13)</a>, high-intensity </text>
<text top="555" left="108" width="706" height="21" font="5">statin therapy to maximize risk reduction is preferred for patients with diabetes mellitus as they age or if </text>
<text top="575" left="108" width="702" height="21" font="5">they have risk modifiers. Adults 20 to 39 years of age are mostly at low 10-year risk, although moderate-</text>
<text top="595" left="108" width="706" height="21" font="5">intensity statin therapy in those with long-standing  diabetes mellitus  or  a  concomitant  higher-risk </text>
<text top="615" left="108" width="706" height="21" font="5">condition may be reasonable (Table 5) (S4.3<a href="CIR.0000000000000625.html#95">-17,</a> S4.3<a href="CIR.0000000000000625.html#96">-20,</a> S4.3<a href="CIR.0000000000000625.html#96">-21)</a>. Adults &gt;75 years of age with diabetes </text>
<text top="635" left="108" width="707" height="21" font="5">mellitus are at high-risk (S4.3<a href="CIR.0000000000000625.html#95">-5,</a> S4.3<a href="CIR.0000000000000625.html#95">-8)</a> and clinical trial evidence (S4.3<a href="CIR.0000000000000625.html#96">-26)</a> suggests they are likely to </text>
<text top="656" left="108" width="709" height="21" font="5">benefit from continuing or initiating statin therapy,  although this may be compromised by reduced </text>
<text top="676" left="108" width="271" height="21" font="5">longevity and increased adverse events. </text>
<text top="705" left="108" width="295" height="21" font="4"><b>Recommendation-Specific Supportive Text </b></text>
<text top="744" left="108" width="706" height="21" font="5">1.  Most adults 40 to 75 years of age with diabetes mellitus are at intermediate or high-risk (PCE ≥7.5% </text>
<text top="764" left="135" width="675" height="21" font="5">10-year  risk) of  ASCVD events (S4.3<a href="CIR.0000000000000625.html#95">-5,</a> S4.3<a href="CIR.0000000000000625.html#95">-6,</a>  S4.3<a href="CIR.0000000000000625.html#95">-8,</a>  S4.3<a href="CIR.0000000000000625.html#95">-9)</a>. Three of 4 double-blinded  primary-</text>
<text top="784" left="135" width="679" height="21" font="5">prevention RCTs of moderate statin therapy in large cohorts with diabetes mellitus in this age range </text>
<text top="804" left="135" width="681" height="21" font="5">showed significant reductions in ASCVD events (S4.3<a href="CIR.0000000000000625.html#94">-1,</a>  S4.3<a href="CIR.0000000000000625.html#95">-2,</a> S4.3<a href="CIR.0000000000000625.html#95">-4,</a>  S4.3<a href="CIR.0000000000000625.html#95">-7)</a>. A meta-analysis of </text>
<text top="825" left="135" width="680" height="21" font="5">these trials found that moderate-intensity statin therapy is associated with a risk reduction of 25% </text>
<text top="845" left="135" width="682" height="21" font="5">(S4.3<a href="CIR.0000000000000625.html#95">-3)</a>,  resulting in a risk level similar to that of people without diabetes mellitus  and with no </text>
<text top="865" left="135" width="679" height="21" font="5">apparent difference in benefit between type 1 and type 2 diabetes mellitus. Therefore, on the basis </text>
<text top="885" left="135" width="679" height="21" font="5">of a high level of evidence, moderate-intensity statin therapy is indicated in patients 40 to 75 years of </text>
<text top="905" left="135" width="344" height="21" font="5">age with diabetes mellitus for primary prevention.  </text>
<text top="925" left="108" width="706" height="21" font="5">2.  Although it is well recognized that the frequency of a first ASCVD event in adults with diabetes mellitus </text>
<text top="946" left="135" width="679" height="21" font="5">is significantly increased compared with those without diabetes mellitus, there is a wide spectrum of </text>
<text top="966" left="135" width="679" height="21" font="5">risk among individuals with diabetes mellitus  (S4.3<a href="CIR.0000000000000625.html#95">-5,</a>  S4.3<a href="CIR.0000000000000625.html#95">-6,</a>  S4.3<a href="CIR.0000000000000625.html#95">-8,</a>  S4.3<a href="CIR.0000000000000625.html#95">-9)</a>  that varies with age, </text>
<text top="986" left="135" width="679" height="21" font="5">duration of diabetes mellitus, and the presence of traditional risk factors and risk modifiers common </text>
<text top="1006" left="135" width="679" height="21" font="5">to the general population, as well as those specific to the population with diabetes mellitus (Table 5). </text>
<text top="1026" left="135" width="680" height="21" font="5">Because the decision to upgrade statin treatment from moderate to high intensity is influenced by </text>
<text top="1046" left="135" width="679" height="21" font="5">the level of ASCVD risk, the PCE risk estimator in adults 40 to 75 years of age with diabetes mellitus </text>
<text top="1066" left="135" width="680" height="21" font="5">has utility in refining treatment decisions in these patients (S4.3<a href="CIR.0000000000000625.html#95">-10,</a> S4.3<a href="CIR.0000000000000625.html#95">-11)</a>. The ASCVD risk score, </text>
<text top="1087" left="135" width="679" height="21" font="5">however,  does not determine  whether  statin intensity should be increased.  Rather,  it  begins  an </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="29" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-29_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 29</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="135" width="681" height="21" font="5">evaluation that includes clinician judgment of the individual’s global risk, the potential for benefit </text>
<text top="144" left="135" width="679" height="21" font="5">from a high-intensity statin versus the potential for adverse effects or drug-drug interactions and </text>
<text top="164" left="135" width="425" height="21" font="5">evaluation should also include patient preferences and values.  </text>
<text top="184" left="108" width="706" height="21" font="5">3.  The occurrence of a first ASCVD event in patients 40 to 75 years of age with diabetes mellitus is </text>
<text top="204" left="135" width="679" height="21" font="5">associated with increased morbidity and mortality compared with those without diabetes mellitus, </text>
<text top="225" left="135" width="679" height="21" font="5">which places a particularly high premium on primary prevention in those with diabetes mellitus in </text>
<text top="245" left="135" width="683" height="21" font="5">that age range. Although trials using moderate-intensity statin therapy demonstrate significant </text>
<text top="265" left="135" width="680" height="21" font="5">benefit in such individuals, the residual risk in the statin treatment groups in these trials remained </text>
<text top="285" left="135" width="679" height="21" font="5">high (e.g.,  8.5% had major cardiovascular events  in  3.8 years) (S4.3<a href="CIR.0000000000000625.html#95">-3)</a>.  Strong  general evidence </text>
<text top="305" left="135" width="679" height="21" font="5">indicates that the benefit from statin therapy is related to both global risk and intensity of treatment </text>
<text top="325" left="135" width="680" height="21" font="5">(S4.3<a href="CIR.0000000000000625.html#95">-12)</a>, and no RCTs of high-intensity statin therapy have been carried out in cohorts of patients </text>
<text top="345" left="135" width="678" height="21" font="5">exclusively with diabetes mellitus. On the basis of these considerations and the fact that patients with </text>
<text top="366" left="135" width="679" height="21" font="5">diabetes mellitus have a higher trajectory of lifetime risk than do those without diabetes mellitus, </text>
<text top="386" left="135" width="678" height="21" font="5">high-intensity statin therapy is preferred in patients with diabetes mellitus as they age or develop risk </text>
<text top="406" left="135" width="138" height="21" font="5">modifiers (Table 5).  </text>
<text top="426" left="108" width="702" height="21" font="5">4.  ASCVD risk increases incrementally with age in diabetes mellitus (S4.3<a href="CIR.0000000000000625.html#95">-5,</a> S4.3<a href="CIR.0000000000000625.html#95">-6,</a> S4.3<a href="CIR.0000000000000625.html#95">-8)</a>. In one long-</text>
<text top="446" left="135" width="679" height="21" font="5">term cohort study of type 2 diabetes mellitus without ASCVD, incident rates of MI averaged 25.6 per </text>
<text top="466" left="135" width="679" height="21" font="5">1000 person-years (S4.3<a href="CIR.0000000000000625.html#95">-5)</a> in those &gt;75 years of age, while another in a type 1 diabetes mellitus </text>
<text top="486" left="135" width="679" height="21" font="5">cohort found the 10-year fatal CVD risk in those &gt;75 years of age was 70% in men and 40% in women </text>
<text top="507" left="135" width="679" height="21" font="5">(S4.3<a href="CIR.0000000000000625.html#95">-8)</a>. Although no controlled statin trials in people &gt;75 years of age are available, a meta-analysis </text>
<text top="527" left="135" width="681" height="21" font="5">of the JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating </text>
<text top="547" left="135" width="683" height="21" font="5">Rosuvastatin)  and HOPE-3  (Heart Outcomes Prevention Evaluation) trials demonstrated similar </text>
<text top="567" left="135" width="679" height="21" font="5">benefits in ASCVD reduction among those &gt;70 of age versus &lt;70 years of age (S4.3<a href="CIR.0000000000000625.html#96">-26)</a>. Although that </text>
<text top="587" left="135" width="679" height="21" font="5">study included few patients with diabetes mellitus, it does support the continuation of moderate- or </text>
<text top="607" left="135" width="679" height="21" font="5">high-intensity statin therapy for primary prevention in those &gt;75 years of age with diabetes mellitus, </text>
<text top="627" left="135" width="679" height="21" font="5">who comprise 21% of the population in this age category. The clinician should note that the benefit </text>
<text top="648" left="135" width="679" height="21" font="5">may be offset by limited life span or increased susceptibility to adverse events in patients in this age </text>
<text top="668" left="135" width="51" height="21" font="5">group.  </text>
<text top="688" left="108" width="707" height="21" font="5">5.  According to a CTT analysis (S4.3<a href="CIR.0000000000000625.html#95">-12)</a>, the higher the 10-year ASCVD risk, the greater is the benefit </text>
<text top="708" left="135" width="679" height="21" font="5">from increased LDL-C reduction. This is supported by the meta-analyses comparing high-intensity </text>
<text top="728" left="135" width="679" height="21" font="5">versus -low-intensity statin therapy (S4.3<a href="CIR.0000000000000625.html#95">-12)</a> and those comparing the benefit of statins and nonstatin </text>
<text top="748" left="135" width="684" height="21" font="5">therapeutic agents (i.e.,  ezetimibe, bile sequestrants, PCSK9 antagonists) that upregulate LDL </text>
<text top="768" left="135" width="679" height="21" font="5">receptors (S4.3<a href="CIR.0000000000000625.html#96">-27)</a>. Therefore, a risk discussion may be held on the benefits of achieving ≥50% LDL-C </text>
<text top="789" left="135" width="679" height="21" font="5">lowering in adults with diabetes mellitus who have ≥20% ASCVD risk. Addition of ezetimibe 10 mg/d </text>
<text top="809" left="135" width="680" height="21" font="5">to moderate-intensity statin therapy can achieve the same percent LDL-C lowering as that achieved </text>
<text top="829" left="135" width="675" height="21" font="5">with high-intensity statin therapy (S4.3<a href="CIR.0000000000000625.html#95">-14)</a>. In this RCT, 27% of patients had diabetes mellitus (S4.3-</text>
<text top="849" left="135" width="679" height="21" font="5"><a href="CIR.0000000000000625.html#96">28)</a>. Thus, ezetimibe added to a moderate-intensity statin can be considered if a high-intensity statin </text>
<text top="869" left="135" width="461" height="21" font="5">cannot be tolerated or does not lower LDL-C, as expected, by ≥50%.  </text>
<text top="889" left="108" width="706" height="21" font="5">6.  Although the risk of ASCVD is high in adults &gt;75 years of age with diabetes mellitus (S4.3<a href="CIR.0000000000000625.html#95">-5,</a> S4.3<a href="CIR.0000000000000625.html#95">-6,</a> </text>
<text top="909" left="135" width="681" height="21" font="5">S4.3<a href="CIR.0000000000000625.html#95">-8)</a> who are not receiving statin therapy, particularly those with additional risk factors or risk </text>
<text top="930" left="135" width="679" height="21" font="5">modifiers, the benefit of initiating statin therapy in these individuals may be limited by their reduced </text>
<text top="950" left="135" width="680" height="21" font="5">life span or increased susceptibility to adverse effects of treatment. Among this group will also be </text>
<text top="970" left="135" width="679" height="21" font="5">individuals with recent or newly diagnosed diabetes mellitus for whom the impact of diabetes mellitus </text>
<text top="990" left="135" width="678" height="21" font="5">on ASCVD risk is not well known. It may therefore be reasonable to have a clinician–patient discussion </text>
<text top="1010" left="135" width="664" height="21" font="5">in which the potential benefits and risks of initiating statin therapy in this age group are reviewed.  </text>
<text top="1030" left="108" width="706" height="21" font="5">7.  There is limited information on ASCVD rates among individuals 20 to 39 years of age with diabetes </text>
<text top="1050" left="135" width="681" height="21" font="5">mellitus and no information on whether statin therapy is beneficial in these individuals. Available </text>
<text top="1071" left="135" width="679" height="21" font="5">evidence indicates that although rates of ASCVD are low in those &lt;30 years of age, they increase with </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="30" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="22" size="8" family="Times" color="#000000"/>
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-30_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 30</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="135" width="680" height="21" font="5">time (S4.3<a href="CIR.0000000000000625.html#95">-6,</a> S4.3<a href="CIR.0000000000000625.html#95">-17,</a> S4.3<a href="CIR.0000000000000625.html#96">-20,</a> S4.3<a href="CIR.0000000000000625.html#96">-23)</a> and may reach intermediate-risk levels by 30 to 39 years of </text>
<text top="144" left="135" width="681" height="21" font="5">age, especially in individuals with long-standing type 2 diabetes mellitus (S4.3<a href="CIR.0000000000000625.html#95">-17)</a>, who may have </text>
<text top="164" left="135" width="680" height="21" font="5">more advanced subclinical coronary atherosclerosis than do nondiabetic subjects (S4.3<a href="CIR.0000000000000625.html#96">-21)</a>, and in </text>
<text top="184" left="135" width="683" height="21" font="5">those with type 1 diabetes mellitus  of &gt;20 years’  duration  (S4.3<a href="CIR.0000000000000625.html#96">-23)</a>. ASCVD rates will also be </text>
<text top="204" left="135" width="679" height="21" font="5">influenced by hypertension and diabetic microvascular complications that may be prevalent in these </text>
<text top="225" left="135" width="682" height="21" font="5">age groups (S4.3<a href="CIR.0000000000000625.html#95">-18,</a>  S4.3<a href="CIR.0000000000000625.html#96">-23)</a>. Thus, it may be reasonable to have a discussion about initiating </text>
<text top="245" left="135" width="679" height="21" font="5">moderate-intensity statin therapy with patients who have had type 2 diabetes mellitus for at least 10 </text>
<text top="265" left="135" width="678" height="21" font="5">years or type 1 diabetes mellitus for at least 20 years and with patients with 1 or more major CVD risk </text>
<text top="285" left="135" width="679" height="21" font="5">factors or complications, such as diabetic retinopathy (S4.3<a href="CIR.0000000000000625.html#96">-19)</a>, neuropathy (S4.3<a href="CIR.0000000000000625.html#95">-16)</a>, nephropathy </text>
<text top="305" left="135" width="181" height="21" font="5">(eGFR &lt;60 mL/min/1.73 m</text>
<text top="305" left="316" width="5" height="13" font="22">2</text>
<text top="305" left="321" width="493" height="21" font="5"> or albuminuria ≥30 mcg albumin/mg creatinine) (S4.3<a href="CIR.0000000000000625.html#96">-25)</a>, or an ABI of </text>
<text top="325" left="135" width="225" height="21" font="5">&lt;0.9 (S4.3<a href="CIR.0000000000000625.html#96">-22,</a> S4.3<a href="CIR.0000000000000625.html#96">-24)</a> (Table 5).  </text>
<text top="345" left="108" width="4" height="21" font="5"> </text>
<text top="366" left="108" width="4" height="21" font="5"> </text>
<text top="386" left="108" width="667" height="21" font="4"><b>Table 5. Diabetes-Specific Risk Enhancers That Are Independent of Other Risk Factors in Diabetes </b></text>
<text top="406" left="108" width="60" height="21" font="4"><b>Mellitus</b> </text>
<text top="439" left="116" width="96" height="19" font="0"><b>Risk Enhancers </b></text>
<text top="458" left="116" width="513" height="20" font="1">•  Long duration (≥10 years for type 2 diabetes mellitus (S.4.3-20) or ≥20 years for </text>
<text top="477" left="143" width="204" height="19" font="1">type 1 diabetes mellitus (S4.3<a href="CIR.0000000000000625.html#95">-6)</a>) </text>
<text top="496" left="116" width="377" height="20" font="1">•  Albuminuria ≥30 mcg of albumin/mg creatinine (S4.3<a href="CIR.0000000000000625.html#96">-25)</a> </text>
<text top="515" left="116" width="183" height="20" font="1">•  eGFR &lt;60 mL/min/1.73 m</text>
<text top="515" left="300" width="5" height="12" font="21">2</text>
<text top="515" left="305" width="62" height="19" font="1"> (S4.3<a href="CIR.0000000000000625.html#96">-25)</a> </text>
<text top="534" left="116" width="163" height="20" font="1">•  Retinopathy (S4.3<a href="CIR.0000000000000625.html#96">-19)</a> </text>
<text top="553" left="116" width="161" height="20" font="1">•  Neuropathy (S4.3<a href="CIR.0000000000000625.html#95">-16)</a> </text>
<text top="572" left="116" width="192" height="20" font="1">•  ABI &lt;0.9 (S4.3<a href="CIR.0000000000000625.html#96">-22,</a> S4.3<a href="CIR.0000000000000625.html#96">-24)</a> </text>
<text top="592" left="108" width="501" height="19" font="1">ABI indicates ankle-brachial index; and eGFR, estimated glomerular filtration rate. </text>
<text top="610" left="108" width="4" height="21" font="5"> </text>
<text top="630" left="108" width="4" height="21" font="5"> </text>
<text top="650" left="108" width="226" height="29" font="2"><b>4.4. Primary Prevention </b></text>
<text top="691" left="108" width="705" height="21" font="5">Primary prevention of ASCVD over the life span requires attention to prevention or management of ASCVD </text>
<text top="711" left="108" width="707" height="21" font="5">risk factors beginning early in life (Figure 2). One major ASCVD risk factor is elevated serum cholesterol, </text>
<text top="731" left="108" width="707" height="21" font="5">usually identified clinically as measured LDL-C. Screening can be performed with fasting or nonfasting </text>
<text top="751" left="108" width="706" height="21" font="5">measurement of lipids. In children, adolescents (10 to 19 years of age), and young adults (20 to 39 years </text>
<text top="771" left="108" width="707" height="21" font="5">of age), priority should be given to estimation of lifetime risk and promotion of lifestyle risk reduction. </text>
<text top="791" left="108" width="706" height="21" font="5">Drug therapy is needed only in selected patients with moderately high LDL-C levels<b> </b>(≥160 mg/dL [≥4.1 </text>
<text top="811" left="108" width="706" height="21" font="5">mmol/L]) or patients with very high LDL-C  levels<b>  </b>(190 mg/dL  [4.9 mmol/L]). Three major higher-risk </text>
<text top="832" left="108" width="706" height="21" font="5">categories are patients with severe hypercholesterolemia (LDL-C levels<b> </b>≥190 mg/dL [≥4.9 mmol/L]), adults </text>
<text top="852" left="108" width="706" height="21" font="5">with diabetes mellitus, and adults 40 to 75 years of age. Patients with severe hypercholesterolemia and </text>
<text top="872" left="108" width="706" height="21" font="5">adults 40 to 75 years of age with diabetes mellitus are candidates for immediate statin therapy without </text>
<text top="892" left="108" width="706" height="21" font="5">further risk assessment. Adults with diabetes mellitus should start with a moderate-intensity statin, and </text>
<text top="912" left="108" width="706" height="21" font="5">as they accrue multiple risk factors, a high-intensity statin may be indicated. In other adults 40 to 75 years </text>
<text top="932" left="108" width="705" height="21" font="5">of age, 10-year ASCVD risk should guide therapeutic considerations. The higher the estimated ASCVD risk, </text>
<text top="953" left="108" width="706" height="21" font="5">the more likely the patient is to benefit from evidence-based statin treatment. The risk discussion should </text>
<text top="973" left="108" width="708" height="21" font="5">also consider several “risk enhancers” that can be used to favor initiation or intensification of statin </text>
<text top="993" left="108" width="707" height="21" font="5">therapy. When risk is uncertain or if statin therapy is problematic, it can be helpful to measure CAC to </text>
<text top="1013" left="108" width="705" height="21" font="5">refine risk assessment. A CAC score predicts ASCVD events in a graded fashion and is independent of other </text>
<text top="1033" left="108" width="707" height="21" font="5">risk factors, such as age, sex, and ethnicity (S4.4<a href="CIR.0000000000000625.html#96">-1)</a>. A CAC score equal to zero is useful for reclassifying </text>
<text top="1053" left="108" width="707" height="21" font="5">patients to a lower-risk group, often allowing statin therapy to be withheld or postponed unless higher </text>
<text top="1073" left="108" width="705" height="21" font="5">risk conditions are present. For patients &gt;75 years of age, RCT evidence for statin therapy is not strong, so </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="31" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-31_1.jpg"/>
<image top="244" left="108" width="702" height="522" src="blood-cholesterol-management/CIR.0000000000000625-31_2.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 31</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="707" height="21" font="5">clinical assessment of risk status in a clinician–patient risk discussion is needed for deciding whether to </text>
<text top="144" left="108" width="368" height="21" font="5">continue or initiate statin treatment (S4.4<a href="CIR.0000000000000625.html#96">-2–S4.4-21)</a>.  </text>
<text top="164" left="108" width="4" height="21" font="5"> </text>
<text top="184" left="108" width="4" height="21" font="5"> </text>
<text top="204" left="108" width="196" height="21" font="4"><b>Figure 2. Primary Prevention</b></text>
<text top="203" left="304" width="8" height="23" font="14">  </text>
<text top="749" left="810" width="4" height="23" font="14"> </text>
<text top="786" left="108" width="359" height="19" font="1">Colors correspond to Class of Recommendation in Table 2. </text>
<text top="804" left="108" width="708" height="19" font="1">apoB indicates apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; CAC,  coronary artery calcium; </text>
<text top="823" left="108" width="712" height="19" font="1">human immunodeficiency virus; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein </text>
<text top="841" left="108" width="234" height="19" font="1">cholesterol; and Lp(a), lipoprotein (a). </text>
<text top="859" left="108" width="3" height="19" font="1"> </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="32" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="23" size="17" family="Times" color="#000000"/>
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-32_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 32</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="336" height="27" font="16"><i><b>4.4.1. Evaluation and Risk Assessment </b></i></text>
<text top="162" left="108" width="362" height="25" font="23"><i><b>4.4.1.1. Essential Process of Risk Assessment </b></i></text>
<text top="199" left="108" width="706" height="21" font="5">Children and adolescents should be tested for lipid disorders as described in Section 4.4.4.3.  Risk </text>
<text top="219" left="108" width="706" height="21" font="5">assessment in young adults 20 to 39 years of age is discussed in Section 4.4.4.2. In the young adult age </text>
<text top="239" left="108" width="705" height="21" font="5">group, measurement of risk factors allows for estimation of lifetime risk of ASCVD. (See the risk calculators </text>
<text top="259" left="108" width="714" height="21" font="5">provided on the ACC and AHA websites  (S4.4.1.1<a href="CIR.0000000000000625.html#98">-1,</a>  S4.4.1<a href="CIR.0000000000000625.html#98">-2)</a>.)  Young adults with moderate </text>
<text top="279" left="108" width="702" height="21" font="5">hypercholesterolemia (LDL-C levels<b> </b>160–189 mg/dL [4.1–4.8 mmol/L]) may be candidates for cholesterol-</text>
<text top="299" left="108" width="702" height="21" font="5">lowering drugs. After age 20 years, traditional risk factors should be assessed every 4 to 6 years (S4.4.1.1-</text>
<text top="320" left="108" width="96" height="21" font="5"><a href="CIR.0000000000000625.html#98">3,</a> S4.4.1.1<a href="CIR.0000000000000625.html#98">-4)</a>. </text>
<text top="340" left="162" width="652" height="21" font="5">In adults who are free from ASCVD, traditional ASCVD risk factors should be assessed every 4 to 6 </text>
<text top="360" left="108" width="707" height="21" font="5">years (S4.4.1.1<a href="CIR.0000000000000625.html#98">-3,</a> S4.4.1.1<a href="CIR.0000000000000625.html#98">-4)</a>. Adults 40 to 75 years of age are potential candidates for statin therapy. </text>
<text top="380" left="108" width="705" height="21" font="5">Selection of patients for statin therapy is a multistep process. The first step to determine individual risk of </text>
<text top="400" left="108" width="707" height="21" font="5">clinical ASCVD is to categorize patients into 4 categories of risk, from high to low. The categories with </text>
<text top="420" left="108" width="706" height="21" font="5">highest overall risk (secondary prevention and primary LDL-C levels<b> </b>≥190 mg/dL [≥4.9 mmol/L]) require </text>
<text top="440" left="108" width="706" height="21" font="5">prompt treatment to lower ASCVD risk without using risk calculation by the PCE, which were introduced </text>
<text top="460" left="108" width="706" height="21" font="5">in 2013. Adults 40 to 75 years of age with diabetes mellitus merit initiation of a moderate-intensity statin </text>
<text top="481" left="108" width="708" height="21" font="5">without using risk calculation by the PCE; however, it is reasonable to use PCE to further stratify risk </text>
<text top="501" left="108" width="702" height="21" font="5">(Section 4.3. on diabetes mellitus). The fourth category includes adults 40 to 75 years of age whose 10-</text>
<text top="521" left="108" width="706" height="21" font="5">year ASCVD risk is estimated by the PCE. This leads to the clinician–patient risk discussion to consider the </text>
<text top="541" left="108" width="702" height="21" font="5">pros and cons of statin therapy; factors to consider are PCE scoring, presence or absence of other risk-</text>
<text top="561" left="108" width="708" height="21" font="5">enhancing factors, potential benefit of intensified lifestyle therapy, likelihood of statin-associated side </text>
<text top="581" left="108" width="710" height="21" font="5">effects or drug–drug interactions, and patient choice. If  risk status remains uncertain after these </text>
<text top="602" left="108" width="706" height="21" font="5">considerations, measurement of CAC can provide additional information to help make a decision with </text>
<text top="622" left="108" width="168" height="21" font="5">regard to statin therapy. </text>
<text top="651" left="108" width="268" height="25" font="23"><i><b>4.4.1.2. Pooled Cohort Equations </b></i></text>
<text top="687" left="108" width="708" height="21" font="5">Several algorithms have been proposed for estimation of 10-year risk (S4.4.1.2<a href="CIR.0000000000000625.html#98">-1–S4.4.1.2-6</a>). A useful </text>
<text top="707" left="108" width="706" height="21" font="5">one,  and the most representative algorithm for the United States, is one derived from 5  prospective </text>
<text top="727" left="108" width="706" height="21" font="5">community-based studies representing a broad spectrum of the U.S.  population (PCE) (S.4.4.1.2<a href="CIR.0000000000000625.html#98">-4,</a> </text>
<text top="748" left="108" width="706" height="21" font="5">S.4.4.1.2-5) and validated in a similar natural history study (S4.4.1.2<a href="CIR.0000000000000625.html#98">-7)</a>. The PCE estimate risk of hard </text>
<text top="768" left="108" width="707" height="21" font="5">ASCVD events (MI and stroke, both fatal and nonfatal). Estimates are readily applied in clinical practice. </text>
<text top="788" left="108" width="709" height="21" font="5">Their risk factors include age, cigarette smoking, blood pressure, serum TC, HDL-C, and presence or </text>
<text top="808" left="108" width="706" height="21" font="5">absence of diabetes mellitus. The race and sex-specific PCE are best validated in non-Hispanic blacks and </text>
<text top="828" left="108" width="710" height="21" font="5">non-Hispanic whites 40  to  75 years  of age  (S4.4.1.2<a href="CIR.0000000000000625.html#98">-1–S4.4.1,2-3,</a>  S4.4.1.2<a href="CIR.0000000000000625.html#98">-7–S4.4.1.2-19)</a>. In other </text>
<text top="848" left="108" width="707" height="21" font="5">racial/ethnic groups, equations are less extensively studied. Because the PCE are population equations, </text>
<text top="869" left="108" width="706" height="21" font="5">they may overestimate or underestimate risk for individuals or population subgroups. Consequently, PCE </text>
<text top="889" left="108" width="709" height="21" font="5">estimates must be considered  in the context of a particular patient’s circumstances when deciding </text>
<text top="909" left="108" width="702" height="21" font="5">whether to use statin therapy. Using the PCE, the 2013 ACC/AHA guidelines (S4.4.1.2<a href="CIR.0000000000000625.html#98">-5)</a> identified a 10-</text>
<text top="929" left="108" width="707" height="21" font="5">year risk of ASCVD ≥7.5% as an RCT-supported threshold for benefit of statin therapy. In this guideline, </text>
<text top="949" left="108" width="707" height="21" font="5">10-year risk for ASCVD is categorized as low-risk (&lt;5%), borderline risk (5% to &lt;7.5%), intermediate risk </text>
<text top="969" left="108" width="706" height="21" font="5">(7.5% to &lt;20%), and high risk (≥20%).  In adults 20 to 39 years of age, assessment of 30-year or lifetime </text>
<text top="989" left="108" width="706" height="21" font="5">risk of a first ASCVD event can be used to inform intensity of primary-prevention efforts (S4.4.1.2<a href="CIR.0000000000000625.html#98">-20,</a> </text>
<text top="1009" left="108" width="706" height="21" font="5">S4.4.1.2<a href="CIR.0000000000000625.html#99">-21)</a>. In this guideline, 10-year risk for ASCVD is categorized as low-risk (&lt;5%), borderline risk (5% </text>
<text top="1030" left="108" width="443" height="21" font="5">to &lt;7.5%), intermediate risk (7.5% to &lt;20%), and high risk (≥20%). </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="33" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-33_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 33</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="260" height="25" font="23"><i><b>4.4.1.3. Risk-Enhancing Factors  </b></i></text>
<text top="160" left="108" width="706" height="21" font="5">Moderate intensity generic statins allow for efficacious and cost-effective primary prevention in patients </text>
<text top="180" left="108" width="706" height="21" font="5">with a 10-year risk of ASCVD &gt;7.5% (S4.4.1.3-1). Since 2013 ACC/AHA guidelines (S4.4.1.3<a href="CIR.0000000000000625.html#98">-2)</a>, the HOPE-3 </text>
<text top="201" left="108" width="705" height="21" font="5">RCT (S4.4.1.3-3) provided additional support for this finding. The pooled cohort equation (PCE) is the single </text>
<text top="221" left="108" width="708" height="21" font="5">most robust tool for estimating 10-year risk in U.S.  adults 40  to 75 years  of age. Its  strength can be </text>
<text top="241" left="108" width="708" height="21" font="5">explained by inclusion of major, independent risk factors. One limitation on the PCE when applied to </text>
<text top="261" left="108" width="708" height="21" font="5">individuals is that age counts as a risk factor and dominates risk scoring with advancing age. Age is a </text>
<text top="281" left="108" width="706" height="21" font="5">powerful population risk factor but does not necessarily reflect individual risk. Another factor influencing </text>
<text top="301" left="108" width="706" height="21" font="5">risk are baseline characteristics of populations (baseline risk). These characteristics include both genetic </text>
<text top="321" left="108" width="706" height="21" font="5">and acquired risk factors other than established major risk factors. Variation in baseline risk accounts for </text>
<text top="341" left="108" width="707" height="21" font="5">difference in risk in different ethnic groups. Absolute risk predictions depend on the baseline risk of a </text>
<text top="362" left="108" width="705" height="21" font="5">population (e.g., the U.S. population). These considerations in patients at intermediate risk leave room in </text>
<text top="382" left="108" width="707" height="21" font="5">the clinician-patient risk discussion to withhold or delay initiation of statin therapy, depending on age, </text>
<text top="402" left="108" width="397" height="21" font="5">pattern of risk factors, and patient preferences and values. </text>
<text top="422" left="162" width="652" height="21" font="5">In sum, the PCE is a powerful tool to predict population risk, but it has limitations when applied </text>
<text top="442" left="108" width="706" height="21" font="5">to individuals. One purpose of the clinician patient risk discussion is to individualize risk status based on </text>
<text top="462" left="108" width="702" height="21" font="5">PCE as well as other factors that may inform risk prediction. Among these other factors are the risk-</text>
<text top="482" left="108" width="708" height="21" font="5">enhancing factors<i>  </i>discussed in this guideline. These risk-enhancing factors are listed in Table 6, and </text>
<text top="503" left="108" width="462" height="21" font="5">evidence base and strength of association with ASCVD are shown in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625"> </a></text>
<text top="503" left="570" width="57" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Table S6</a></text>
<text top="503" left="627" width="188" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">.</a> In the general population, </text>
<text top="523" left="108" width="707" height="21" font="5">they may or may not predict risk independently of PCE. But in the clinician–patient risk discussion they </text>
<text top="543" left="108" width="706" height="21" font="5">can be useful for identifying specific factors that influence risk. Their presence helps to confirm a higher </text>
<text top="563" left="108" width="708" height="21" font="5">risk state and thereby supports a decision to initiate or intensify statin therapy.  They are useful for </text>
<text top="583" left="108" width="702" height="21" font="5">clarifying which atherogenic factors are present in a particular patient. And in some patients, certain risk-</text>
<text top="603" left="108" width="706" height="21" font="5">enhancing factors carry greater lifetime risk than denoted by 10-year risk prediction in the PCE. Finally, </text>
<text top="624" left="108" width="589" height="21" font="5">several risk-enhancing factors may be specific targets therapy beyond those of the PCE. </text>
<text top="644" left="162" width="653" height="21" font="5">A few comments may illustrate the potential usefulness of risk-enhancing factors in the patient </text>
<text top="664" left="108" width="706" height="21" font="5">discussion.  LDL-C  ≥160 mg/dL  (≥4.1 mmol/L),  apoB  ≥130  mg/dL (particularly when accompanied by </text>
<text top="684" left="108" width="708" height="21" font="5">persistently elevated triglycerides), and elevated Lp(a) denote high lifetime risk for ASCVD and favor </text>
<text top="704" left="108" width="705" height="21" font="5">initiation of statin therapy. The presence of family history of ASCVD, premature menopause, and patients </text>
<text top="724" left="108" width="706" height="21" font="5">of South Asian race appear to convey a higher baseline risk and are stronger candidates for statin therapy. </text>
<text top="744" left="108" width="705" height="21" font="5">Conditions associated with systemic inflammation (chronic inflammatory disorders, metabolic syndrome, </text>
<text top="764" left="108" width="708" height="21" font="5">chronic renal disease, and elevated hsCRP) appear to predispose to atherothrombotic events, which </text>
<text top="785" left="108" width="429" height="21" font="5">reasonably justifies statin therapy in intermediate-risk patients. </text>
<text top="817" left="108" width="4" height="21" font="4"><b> </b></text>
<text top="817" left="324" width="4" height="21" font="4"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="34" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-34_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 34</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="468" height="21" font="4"><b>Table 6. Risk-Enhancing Factors for Clinician–Patient Risk Discussion</b> </text>
<text top="144" left="108" width="4" height="21" font="5"> </text>
<text top="171" left="114" width="160" height="21" font="4"><b>Risk-Enhancing Factors </b></text>
<text top="216" left="114" width="484" height="20" font="1">•  <b>Family history of premature ASCVD</b> (males, age &lt;55 y; females, age &lt;65 y) </text>
<text top="238" left="114" width="679" height="20" font="1">•  <b>Primary hypercholesterolemia</b> (LDL-C, 160–189 mg/dL [4.1–4.8 mmol/L); non–HDL-C 190–219 mg/dL [4.9–</text>
<text top="260" left="141" width="90" height="19" font="1">5.6 mmol/L])* </text>
<text top="281" left="114" width="674" height="20" font="1">•  <b>Metabolic syndrome</b> (increased waist circumference, elevated triglycerides [&gt;175 mg/dL], elevated blood </text>
<text top="303" left="141" width="650" height="19" font="1">pressure, elevated glucose, and low HDL-C [&lt;40 mg/dL in men; &lt;50 in women mg/dL] are factors; tally of 3 </text>
<text top="324" left="141" width="131" height="19" font="1">makes the diagnosis) </text>
<text top="345" left="114" width="349" height="20" font="1">•  <b>Chronic kidney disease</b> (eGFR 15–59 mL/min/1.73 m</text>
<text top="345" left="463" width="5" height="12" font="21">2</text>
<text top="346" left="468" width="333" height="19" font="1"> with or without albuminuria; not treated with dialysis </text>
<text top="367" left="141" width="162" height="19" font="1">or kidney transplantation) </text>
<text top="388" left="114" width="442" height="20" font="1">•  <b>Chronic inflammatory conditions</b> such as psoriasis, RA, or HIV/AIDS </text>
<text top="410" left="114" width="673" height="20" font="1">•  <b>History of premature menopause (before age 40 y) and history of pregnancy-associated conditions that </b></text>
<text top="431" left="141" width="294" height="19" font="0"><b>increase later ASCVD risk such as preeclampsia </b></text>
<text top="453" left="114" width="356" height="20" font="1">•  <b>High-risk race/ethnicities</b> (e.g., South Asian ancestry) </text>
<text top="475" left="114" width="373" height="20" font="1">•  <b>Lipid/biomarkers</b>: Associated with increased ASCVD risk </text>
<text top="501" left="142" width="9" height="12" font="1">o</text>
<text top="500" left="150" width="4" height="14" font="1"> </text>
<text top="496" left="168" width="412" height="19" font="1">Persistently* elevated, primary hypertriglyceridemia (≥175 mg/dL); </text>
<text top="522" left="142" width="9" height="12" font="1">o</text>
<text top="521" left="150" width="4" height="14" font="1"> </text>
<text top="517" left="168" width="80" height="19" font="1">If measured: </text>
<text top="539" left="168" width="11" height="17" font="1"> </text>
<text top="538" left="195" width="344" height="19" font="0"><b>Elevated high-sensitivity C-reactive protein</b> (≥2.0 mg/L)<b> </b></text>
<text top="560" left="169" width="11" height="17" font="1"> </text>
<text top="559" left="196" width="601" height="19" font="0"><b>Elevated Lp(a):</b> A relative indication for its measurement is family history of premature ASCVD. An </text>
<text top="581" left="196" width="587" height="19" font="1">Lp(a) ≥50 mg/dL or ≥125 nmol/L constitutes a risk-enhancing factor especially at higher levels of </text>
<text top="602" left="196" width="41" height="19" font="1">Lp(a). <b> </b></text>
<text top="624" left="169" width="11" height="17" font="1"> </text>
<text top="623" left="196" width="591" height="19" font="0"><b>Elevated apoB</b> ≥130 mg/dL: A relative indication for its measurement would be triglyceride ≥200 </text>
<text top="644" left="196" width="594" height="19" font="1">mg/dL. A level ≥130 mg/dL corresponds to an LDL-C &gt;160 mg/dL and constitutes a risk-enhancing </text>
<text top="665" left="196" width="40" height="19" font="1">factor </text>
<text top="687" left="169" width="11" height="17" font="1"> </text>
<text top="686" left="196" width="55" height="19" font="0"><b>ABI</b> &lt;0.9 </text>
<text top="723" left="108" width="186" height="19" font="1">*Optimally, 3 determinations. </text>
<text top="741" left="108" width="707" height="19" font="1">AIDS indicates acquired immunodeficiency syndrome; ABI, ankle-brachial index; apoB, apolipoprotein B; ASCVD, </text>
<text top="759" left="108" width="706" height="19" font="1">atherosclerotic cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein </text>
<text top="777" left="108" width="705" height="19" font="1">cholesterol; HIV, human immunodeficiency virus; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a); </text>
<text top="796" left="108" width="181" height="19" font="1">and RA, rheumatoid arthritis. </text>
<text top="814" left="108" width="4" height="23" font="14"> </text>
<text top="836" left="108" width="4" height="23" font="14"> </text>
<text top="858" left="108" width="272" height="25" font="23"><i><b>4.4.1.4. Coronary Artery Calcium  </b></i></text>
<text top="894" left="108" width="708" height="21" font="5">Substantial advances in estimation of risk with CAC scoring have been made in the past 5 years. One </text>
<text top="914" left="108" width="705" height="21" font="5">purpose of CAC scoring is to reclassify risk identification of patients who will potentially benefit from statin </text>
<text top="934" left="108" width="707" height="21" font="5">therapy. This is especially useful when the clinician and patient are uncertain whether to start a statin. </text>
<text top="955" left="108" width="706" height="21" font="5">Indeed, the most important recent observation has been the finding that a CAC score of zero indicates a </text>
<text top="975" left="108" width="705" height="21" font="5">low ASCVD risk for the subsequent 10 years (S4.4.1.4<a href="CIR.0000000000000625.html#99">-1–S4.4.1.4-8</a>). Thus, measurement of CAC potentially </text>
<text top="995" left="108" width="708" height="21" font="5">allows a clinician  to withhold statin therapy in patients showing zero CAC. There are exceptions. For </text>
<text top="1015" left="108" width="706" height="21" font="5">example, CAC scores of zero in persistent cigarette smokers, patients with diabetes mellitus, those with a </text>
<text top="1035" left="108" width="707" height="21" font="5">strong family history of ASCVD, and possibly chronic inflammatory conditions such as HIV, may still be </text>
<text top="1055" left="108" width="710" height="21" font="5">associated with substantial 10-year risk (S4.4.1.4<a href="CIR.0000000000000625.html#100">-9–S4.4.1.4-12)</a>.  Nevertheless,  a sizable portion of </text>
<text top="1075" left="108" width="707" height="21" font="5">middle-aged and older patients have zero CAC, which may allow withholding of statin therapy in those </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="35" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-35_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 35</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="706" height="21" font="5">intermediate risk patients who would otherwise have a high enough risk according to the PCE to receive </text>
<text top="144" left="108" width="706" height="21" font="5">statin therapy (Figure 2). Most patients with CAC scores ≥100 Agatston units have a 10-year risk of ASCVD </text>
<text top="164" left="108" width="702" height="21" font="5">≥7.5%, a widely accepted threshold for initiation of statin therapy (S4.4.1.4<a href="CIR.0000000000000625.html#100">-13)</a>. With increasing age, 10-</text>
<text top="184" left="108" width="705" height="21" font="5">year risk accompanying CAC scores of 1 to 99 rises, usually crossing the 7.5% threshold in later middle age </text>
<text top="204" left="108" width="706" height="21" font="5">(S4.4.1.4<a href="CIR.0000000000000625.html#100">-13)</a>. When the CAC score is zero, some investigators favor remeasurement of CAC after 5 to 10 </text>
<text top="224" left="108" width="706" height="21" font="5">years (S4.4.1.4<a href="CIR.0000000000000625.html#100">-14–S4.4.1.4-16)</a>. CAC measurement has no utility in patients already treated with statins. </text>
<text top="245" left="108" width="706" height="21" font="5">Statins are associated with slower progression of overall coronary atherosclerosis volume and reduction </text>
<text top="265" left="108" width="707" height="21" font="5">of high-risk plaque features, yet statins increase the CAC score (S4.4.1.4<a href="CIR.0000000000000625.html#101">-17)</a>. A prospective randomized </text>
<text top="285" left="108" width="709" height="21" font="5">study of CAC scoring showed improved risk factor modification without an increase in downstream </text>
<text top="305" left="108" width="709" height="21" font="5">medical testing or cost (S4.4.1.4<a href="CIR.0000000000000625.html#101">-18)</a>.  In  MESA (Multi-Ethnic Study of Atherosclerosis),  CAC scanning </text>
<text top="325" left="108" width="702" height="21" font="5">delivered 0.74 to l.27 mSv of radiation, which is similar to the dose of a clinical mammogram (S4.4.1.4-</text>
<text top="345" left="108" width="707" height="21" font="5"><a href="CIR.0000000000000625.html#101">19)</a>. CAC scans should be ordered by a clinician who is fully versed in the pros and cons of diagnostic </text>
<text top="366" left="108" width="71" height="21" font="5">radiology. </text>
<text top="395" left="108" width="683" height="27" font="16"><i><b>4.4.2. Primary Prevention Adults 40 to 75 Years of Age With LDL-C Levels 70 to </b></i></text>
<text top="424" left="108" width="271" height="27" font="16"><i><b>189 mg/dL (1.7 to 4.8 mmol/L) </b></i></text>
<text top="469" left="127" width="668" height="21" font="4"><b>Primary Prevention Recommendations for Adults 40 to 75 Years of Age With LDL Levels 70 to 189 </b></text>
<text top="490" left="369" width="44" height="21" font="4"><b>mg/dL</b></text>
<text top="488" left="413" width="4" height="23" font="14"> </text>
<text top="490" left="417" width="136" height="21" font="4"><b>(1.7 to 4.8 mmol/L) </b></text>
<text top="510" left="128" width="474" height="21" font="5">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625"> </a></text>
<text top="510" left="602" width="185" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Online Data Supplement 16</a></text>
<text top="510" left="786" width="8" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">.</a> </text>
<text top="542" left="124" width="33" height="21" font="4"><b>COR </b></text>
<text top="542" left="186" width="30" height="21" font="4"><b>LOE </b></text>
<text top="542" left="455" width="132" height="21" font="4"><b>Recommendations </b></text>
<text top="606" left="136" width="4" height="21" font="4"><b>I</b></text>
<text top="605" left="141" width="4" height="23" font="3"><b> </b></text>
<text top="606" left="194" width="10" height="21" font="4"><b>A</b></text>
<text top="605" left="204" width="4" height="23" font="3"><b> </b></text>
<text top="589" left="236" width="573" height="21" font="4"><b>1.  In adults at intermediate-risk, statin therapy reduces risk of ASCVD, and in the </b></text>
<text top="609" left="255" width="549" height="21" font="4"><b>context of a risk discussion, if a decision is made for statin therapy, a moderate-</b></text>
<text top="629" left="255" width="418" height="21" font="4"><b>intensity statin should be recommended (S4.4.2<a href="CIR.0000000000000625.html#101">-1–S4.4.2-8)</a></b><b>. </b></text>
<text top="683" left="136" width="4" height="21" font="4"><b>I</b></text>
<text top="682" left="141" width="4" height="23" font="3"><b> </b></text>
<text top="683" left="194" width="10" height="21" font="4"><b>A</b></text>
<text top="682" left="204" width="4" height="23" font="3"><b> </b></text>
<text top="670" left="236" width="572" height="21" font="4"><b>2.  In intermediate-risk patients, LDL-C levels should be reduced by 30% or more, </b></text>
<text top="690" left="255" width="552" height="21" font="4"><b>and for optimal ASCVD  risk reduction, especially in high-risk patients, levels </b></text>
<text top="710" left="255" width="446" height="21" font="4"><b>should be reduced by 50% or more (S4.4.2<a href="CIR.0000000000000625.html#101">-1, </a></b><b>S4.4.2<a href="CIR.0000000000000625.html#101">-4–S4.4.2-9)</a></b><b>.  </b></text>
<text top="797" left="136" width="8" height="21" font="4"><b>I </b></text>
<text top="797" left="182" width="38" height="21" font="4"><b>B-NR </b></text>
<text top="743" left="236" width="574" height="21" font="4"><b>3.  For the primary prevention of clinical ASCVD* in adults 40 to 75 years of age </b></text>
<text top="763" left="255" width="474" height="21" font="4"><b>without diabetes mellitus and with an LDL-C level of 70 to 189 mg/dL</b></text>
<text top="762" left="730" width="4" height="23" font="14"> </text>
<text top="763" left="734" width="74" height="21" font="4"><b>(1.7 to 4.8 </b></text>
<text top="783" left="255" width="551" height="21" font="4"><b>mmol/L), the 10-year ASCVD risk of a first “hard” ASCVD event (fatal and nonfatal </b></text>
<text top="803" left="255" width="552" height="21" font="4"><b>MI or stroke) should be estimated by using the race- and sex-specific PCE, and </b></text>
<text top="823" left="255" width="552" height="21" font="4"><b>adults should be categorized as being at low risk (&lt;5%), borderline risk (5% to </b></text>
<text top="844" left="255" width="552" height="21" font="4"><b>&lt;7.5%), intermediate-risk  (≥7.5%  to &lt;20%), and high-risk  (≥20%)  (S4.4.2<a href="CIR.0000000000000625.html#101">-10, </a></b></text>
<text top="864" left="255" width="77" height="21" font="4"><b>S4.4.2<a href="CIR.0000000000000625.html#101">-11)</a></b><b>. </b></text>
<text top="930" left="136" width="8" height="21" font="4"><b>I </b></text>
<text top="930" left="182" width="38" height="21" font="4"><b>B-NR </b></text>
<text top="897" left="236" width="575" height="21" font="4"><b>4.  Clinicians and patients should engage in a risk discussion that considers risk </b></text>
<text top="917" left="255" width="552" height="21" font="4"><b>factors, adherence to healthy lifestyle, the potential for ASCVD risk-reduction </b></text>
<text top="937" left="255" width="554" height="21" font="4"><b>benefits,  and the potential for adverse effects and drug–drug interactions, as </b></text>
<text top="957" left="255" width="549" height="21" font="4"><b>well as patient preferences, for an individualized treatment decision (S4.4.2<a href="CIR.0000000000000625.html#101">-12-</a></b></text>
<text top="977" left="255" width="77" height="21" font="4"><a href="CIR.0000000000000625.html#101"><b>S4.4.2-14)</b></a><b>. </b></text>
<text top="1019" left="130" width="21" height="21" font="4"><b>IIa </b></text>
<text top="1019" left="187" width="632" height="21" font="4"><b>B-R  5.  In  intermediate-risk  adults, risk-enhancing factors favor initiation or </b></text>
<text top="1030" left="255" width="437" height="21" font="4"><b>intensification of statin therapy (S4.4.2<a href="CIR.0000000000000625.html#101">-6, </a></b><b>S4.4.2<a href="CIR.0000000000000625.html#102">-15–S4.4.2-22)</a></b><b>. </b></text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="36" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-36_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 36</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="144" left="130" width="21" height="21" font="4"><b>IIa </b></text>
<text top="144" left="182" width="38" height="21" font="4"><b>B-NR </b></text>
<text top="130" left="236" width="571" height="21" font="4"><b>6.  In intermediate-risk or selected borderline-risk adults, if the decision about statin </b></text>
<text top="151" left="255" width="555" height="21" font="4"><b>use remains uncertain, it is reasonable to use a CAC score in the decision to </b></text>
<text top="171" left="255" width="538" height="21" font="4"><b>withhold, postpone or initiate statin therapy (S4.4.2<a href="CIR.0000000000000625.html#102">-15, </a></b><b>S4.4.2<a href="CIR.0000000000000625.html#102">-17, </a></b><b>S4.4.2<a href="CIR.0000000000000625.html#102">-23)</a></b><b>.  </b></text>
<text top="289" left="130" width="21" height="21" font="4"><b>IIa </b></text>
<text top="289" left="182" width="38" height="21" font="4"><b>B-NR </b></text>
<text top="204" left="236" width="575" height="21" font="4"><b>7.  In intermediate-risk adults or selected borderline-risk adults in whom a CAC </b></text>
<text top="224" left="255" width="494" height="21" font="4"><b>score is measured for the purpose of making a treatment decision, AND </b></text>
<text top="245" left="255" width="556" height="22" font="5">•  <b>If  the coronary calcium score is zero,  it is reasonable to withhold statin </b></text>
<text top="265" left="282" width="527" height="21" font="4"><b>therapy and reassess in 5 to 10 years, as long as higher risk conditions are </b></text>
<text top="285" left="282" width="532" height="21" font="4"><b>absent  (diabetes  mellitus, family history of premature CHD, cigarette </b></text>
<text top="306" left="282" width="71" height="21" font="4"><b>smoking); </b></text>
<text top="326" left="255" width="553" height="22" font="5">•  <b>If CAC score is 1 to 99, it is reasonable to initiate statin therapy for patients </b></text>
<text top="347" left="282" width="123" height="21" font="4"><b>≥55 years of age;  </b></text>
<text top="367" left="255" width="557" height="22" font="5">•  <b>If CAC score is 100 or higher or  in the 75th percentile or higher, it is </b></text>
<text top="388" left="282" width="404" height="21" font="4"><b>reasonable to initiate statin therapy (S4.4.2<a href="CIR.0000000000000625.html#102">-17, </a></b><b>S4.4.2<a href="CIR.0000000000000625.html#102">-23)</a></b><b>.</b> </text>
<text top="447" left="130" width="21" height="21" font="4"><b>IIb </b></text>
<text top="447" left="187" width="27" height="21" font="4"><b>B-R </b></text>
<text top="421" left="236" width="572" height="21" font="4"><b>8.  In intermediate-risk adults who would benefit from more aggressive LDL-C </b></text>
<text top="441" left="255" width="553" height="21" font="4"><b>lowering and in whom high-intensity statins are advisable but not acceptable or </b></text>
<text top="461" left="255" width="553" height="21" font="4"><b>tolerated, it may be reasonable to add a nonstatin drug (ezetimibe or bile acid </b></text>
<text top="481" left="255" width="373" height="21" font="4"><b>sequestrant) to a moderate-intensity statin (S4.4.2<a href="CIR.0000000000000625.html#101">-9)</a></b><b>. </b></text>
<text top="533" left="130" width="21" height="21" font="4"><b>IIb </b></text>
<text top="533" left="187" width="27" height="21" font="4"><b>B-R </b></text>
<text top="520" left="236" width="572" height="21" font="4"><b>9.  In patients at borderline risk, in risk discussion, the presence of risk-enhancing </b></text>
<text top="540" left="255" width="552" height="21" font="4"><b>factors may justify initiation of moderate-intensity statin therapy (S4.4.2<a href="CIR.0000000000000625.html#102">-17, </a></b></text>
<text top="560" left="255" width="77" height="21" font="4"><b>S4.4.2<a href="CIR.0000000000000625.html#102">-24)</a></b><b>. </b></text>
<text top="588" left="108" width="706" height="19" font="1">*Definition of clinical ASCVD includes acute coronary syndrome (ACS), those with history of myocardial infarction </text>
<text top="606" left="108" width="705" height="19" font="1">(MI), stable or unstable angina or coronary or other arterial revascularization, stroke, transient ischemic attack (TIA), </text>
<text top="624" left="108" width="545" height="19" font="1">or peripheral artery disease (PAD) including aortic aneurysm, all of atherosclerotic origin. </text>
<text top="642" left="108" width="3" height="19" font="1"> </text>
<text top="661" left="108" width="3" height="19" font="1"> </text>
<text top="679" left="108" width="63" height="21" font="4"><b>Synopsis </b></text>
<text top="718" left="108" width="706" height="21" font="5">Adults 40 to 75 years of age in primary prevention can be classified as borderline risk (10-year risk of </text>
<text top="738" left="108" width="706" height="21" font="5">ASCVD 5%  to &lt;7.5%), intermediate-risk  (7.5%  to  &lt;20%),  and high-risk  (20%). For -intermediate-risk </text>
<text top="758" left="108" width="710" height="21" font="5">patients, moderate-  to high-intensity statin therapy  should be considered during risk discussion of </text>
<text top="778" left="108" width="706" height="21" font="5">treatment options. Additional considerations favoring use of statins in intermediate-risk patients include </text>
<text top="799" left="108" width="708" height="21" font="5">other independent risk conditions and, in selected individuals, risk-enhancing factors associated with </text>
<text top="819" left="108" width="706" height="21" font="5">greater ASCVD risk (Table 6). Although the variability of percent LDL-C lowering with high-intensity statin </text>
<text top="839" left="108" width="706" height="21" font="5">use is wide, its efficacy is proportional to the magnitude of the LDL-C reduction obtained (S4.4.2<a href="CIR.0000000000000625.html#102">-18)</a>. </text>
<text top="859" left="108" width="707" height="21" font="5">Systematic reviews indicate that those with higher baseline ASCVD risk derive greater absolute benefit </text>
<text top="879" left="108" width="707" height="21" font="5">from higher percent LDL-C reduction with evidence-based therapy (S4.4.2<a href="CIR.0000000000000625.html#101">-1,</a> S4.4.2<a href="CIR.0000000000000625.html#101">-7)</a>. Accordingly, if a </text>
<text top="899" left="108" width="705" height="21" font="5">statin is given, LDL-C levels<b> </b>should be reduced by ≥30% and optimally by ≥50%. When there is uncertainty, </text>
<text top="919" left="108" width="706" height="21" font="5">consideration of  risk-enhancing  factors  (including family history of premature ASCVD and CAC score), </text>
<text top="940" left="108" width="706" height="21" font="5">categorical risk factors, and selected biomarkers may inform the decision. CAC scoring is especially useful </text>
<text top="960" left="108" width="707" height="21" font="5">in older adults to improve specificity (S4.4.2<a href="CIR.0000000000000625.html#102">-15)</a>. A CAC score of zero revises ASCVD risk downward and </text>
<text top="980" left="108" width="478" height="21" font="5">selects adults who show little benefit from starting a statin (S4.4.2<a href="CIR.0000000000000625.html#102">-20)</a>. </text>
<text top="1009" left="108" width="295" height="21" font="4"><b>Recommendation-Specific Supportive Text </b></text>
<text top="1048" left="108" width="706" height="21" font="5">1.  Prior guidelines recommended moderate-  or high-intensity statins as first-line LDL-C–lowering </text>
<text top="1068" left="135" width="679" height="21" font="5">therapy in primary prevention of ASCVD after a risk discussion of treatment options. This was based </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="37" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-37_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 37</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="135" width="679" height="21" font="5">on 3 large-scale exclusively primary-prevention RCTs that demonstrated that  moderate-intensity </text>
<text top="144" left="135" width="679" height="21" font="5">statin therapy (S4.4.2<a href="CIR.0000000000000625.html#101">-5,</a> S4.4.2<a href="CIR.0000000000000625.html#102">-25)</a> and high-intensity statin therapy (S4.4.2<a href="CIR.0000000000000625.html#101">-6)</a> were associated with </text>
<text top="164" left="135" width="679" height="21" font="5">ASCVD risk reduction that outweighed the observable risks. Since those ACC/AHA 2013 guidelines, a </text>
<text top="184" left="135" width="675" height="21" font="5">large-scale RCT in a racially/ethnically diverse population confirmed statin benefit from a moderate-</text>
<text top="204" left="135" width="679" height="21" font="5">intensity dose of a statin as compared with placebo in intermediate-risk patients. That RCT enrolled </text>
<text top="225" left="135" width="680" height="21" font="5">men ≥55 years of age and women ≥65 years of age with at least 1 cardiovascular risk factor. In the </text>
<text top="245" left="135" width="681" height="21" font="5">placebo group, the 10-year risk of “hard”  ASCVD was 8.7%,  and  the  risk of  the expanded ASCVD </text>
<text top="265" left="135" width="678" height="21" font="5">endpoint that included coronary revascularization was 10% (S4.4.2<a href="CIR.0000000000000625.html#101">-8)</a>. After 5.6 years, those assigned </text>
<text top="285" left="135" width="684" height="21" font="5">to rosuvastatin 10 mg/d demonstrated significant ARR  in both co-primary endpoints with an </text>
<text top="305" left="135" width="675" height="21" font="5">acceptable safety record. By comparison, after a median follow-up of 1.9 years, those assigned a high-</text>
<text top="325" left="135" width="679" height="21" font="5">intensity dose of rosuvastatin in the JUPITER RCT achieved greater LDL-C-lowering and greater </text>
<text top="345" left="135" width="678" height="21" font="5">reductions in ASCVD outcomes. This corroborates meta-analyses demonstrating increased net benefit </text>
<text top="366" left="135" width="679" height="21" font="5">of evidence-based LDL-C–lowering therapy in those at risk if greater reductions in LDL-C are attained </text>
<text top="386" left="135" width="135" height="21" font="5">(S4.4.2<a href="CIR.0000000000000625.html#101">-1,</a> S4.4.2<a href="CIR.0000000000000625.html#101">-9)</a>. </text>
<text top="406" left="108" width="705" height="21" font="5">2.  If in the context of a risk discussion, maximal ASCVD risk reduction is desired, it is reasonable to use a </text>
<text top="426" left="135" width="679" height="21" font="5">high-intensity statin to lower LDL-C by ≥50%. This provides increased benefit, especially when 10-year </text>
<text top="446" left="135" width="675" height="21" font="5">ASCVD risk is ≥20%. JUPITER enrolled men ≥50 years of age and women 60 years of age with high-</text>
<text top="466" left="135" width="684" height="21" font="5">sensitivity C-reactive protein  values 2.0 mg/L. Participants randomly assigned to  20 mg/d of </text>
<text top="486" left="135" width="679" height="21" font="5">rosuvastatin achieved median reductions in LDL-C of 50% and highly significant ASCVD risk reduction </text>
<text top="507" left="135" width="679" height="21" font="5">at 1.9 years (S4.4.2<a href="CIR.0000000000000625.html#101">-6)</a>. The trial was stopped prematurely because of a highly significant reduction in </text>
<text top="527" left="135" width="681" height="21" font="5">cardiovascular death. However, wide individual variability in percent  LDL-C reduction was noted. </text>
<text top="547" left="135" width="679" height="21" font="5">Importantly, the magnitude of the percent LDL-C reduction determined benefit (S4.4.2<a href="CIR.0000000000000625.html#102">-18)</a>. The U.S. </text>
<text top="567" left="135" width="680" height="21" font="5">Preventive Services Task Force systematic review of statin therapy in primary prevention showed a </text>
<text top="587" left="135" width="681" height="21" font="5">reduced risk of all-cause and cardiovascular  death  and ASCVD events and noted greater absolute </text>
<text top="607" left="135" width="681" height="21" font="5">benefits in those at greater baseline risk (S4.4.2<a href="CIR.0000000000000625.html#101">-4)</a>,  consistent with other high-quality systematic </text>
<text top="627" left="135" width="680" height="21" font="5">reviews and meta-analyses (S4.4.2<a href="CIR.0000000000000625.html#101">-1,</a> S4.4.2<a href="CIR.0000000000000625.html#101">-7,</a> S4.4.2<a href="CIR.0000000000000625.html#102">-24)</a>. This underscores the need for aggressive </text>
<text top="648" left="135" width="682" height="21" font="5">and safe risk reduction in the  highest-risk groups and the need for follow-up LDL-C testing to </text>
<text top="668" left="135" width="551" height="21" font="5">determine adherence and adequacy of effect of the prescribed statin (S4.4.2<a href="CIR.0000000000000625.html#102">-26)</a>.  </text>
<text top="688" left="108" width="706" height="21" font="5">3.  In individuals 40 to 75 years of age, 10-year ASCVD risk assessment begins the clinician–patient risk </text>
<text top="708" left="135" width="679" height="21" font="5">discussion (S4.4.2<a href="CIR.0000000000000625.html#101">-13, </a>S4.4.2<a href="CIR.0000000000000625.html#102">-26)</a>. Required information includes age, sex, and race/ethnicity; presence </text>
<text top="728" left="135" width="679" height="21" font="5">of diabetes mellitus or cigarette smoking and treated hypertension; and a current blood pressure level </text>
<text top="748" left="135" width="679" height="21" font="5">and fasting or nonfasting TC and HDL-C levels. The PCE include a stroke endpoint and race-specific </text>
<text top="768" left="135" width="678" height="21" font="5">coefficients. This identifies, for example, a black woman who with similar risk factors is at much higher </text>
<text top="789" left="135" width="680" height="21" font="5">risk than her white counterpart. The PCE were externally validated in a high-quality natural history </text>
<text top="809" left="135" width="679" height="21" font="5">study published shortly after the 2013 ACC/AHA cholesterol guidelines were presented (S4.4.2<a href="CIR.0000000000000625.html#101">-11)</a>. </text>
<text top="829" left="135" width="679" height="21" font="5">These equations may underestimate risk in individuals of South Asian ancestry and other high-risk </text>
<text top="849" left="135" width="683" height="21" font="5">groups and may overestimate risk in selected lower-risk groups (S4.4.2<a href="CIR.0000000000000625.html#101">-10)</a>.  Unlike other risk </text>
<text top="869" left="135" width="680" height="21" font="5">estimators, the PCE use only fatal and nonfatal stroke and CHD as endpoints. Other risk estimators </text>
<text top="889" left="135" width="679" height="21" font="5">that include revascularization and additional cardiovascular endpoints provide risk estimates  that </text>
<text top="909" left="135" width="678" height="21" font="5">cannot be compared directly with those given by the PCE. Finally, the potential for errors in estimating </text>
<text top="930" left="135" width="681" height="21" font="5">ASCVD risk at both ends of the risk curve (low risk and high-risk) as noted for individuals can be </text>
<text top="950" left="135" width="393" height="21" font="5">reviewed in the clinician–patient risk discussion (Table 6).  </text>
<text top="970" left="108" width="707" height="21" font="5">4.  The present guidelines continue to emphasize the importance of a clinician–patient risk discussion </text>
<text top="990" left="135" width="679" height="21" font="5">(S4.4.2<a href="CIR.0000000000000625.html#101">-12–S4.4.2-14,</a>  S4.4.2<a href="CIR.0000000000000625.html#102">-27,</a>  S4.4.2<a href="CIR.0000000000000625.html#102">-28)</a>.  In those with a 10-year ASCVD risk of ≥7.5%,  it is </text>
<text top="1010" left="135" width="679" height="21" font="5">recommended that the discussion occur before a statin prescription is written (S4.4.2<a href="CIR.0000000000000625.html#102">-26)</a>. This frank </text>
<text top="1030" left="135" width="678" height="21" font="5">discussion, as recommended in the 2013 ACC/AHA cholesterol guidelines (S4.4.2<a href="CIR.0000000000000625.html#102">-26)</a>, should consider </text>
<text top="1050" left="135" width="681" height="21" font="5">whether ASCVD risk factors have been addressed, evaluate whether an optimal lifestyle has been </text>
<text top="1071" left="135" width="679" height="21" font="5">implemented, and review the potential for statin benefit versus the potential for adverse effects and </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="38" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-38_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 38</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="135" width="679" height="21" font="5">drug-drug interactions. Then, on  the basis of  individual characteristics and including an informed </text>
<text top="144" left="135" width="679" height="21" font="5">patient preference in shared decision-making, a risk decision about statin therapy can be made<b> </b>(Table </text>
<text top="164" left="135" width="675" height="21" font="5">7). Clinicians should indicate that as ASCVD risk increases, so does benefit of evidence-based LDL-C–</text>
<text top="184" left="135" width="679" height="21" font="5">lowering therapy. They may wish to review the drug and safety sections of the present guideline and </text>
<text top="204" left="135" width="679" height="21" font="5">stay informed on safety information that is essential for a balanced discussion. Importantly, for those </text>
<text top="225" left="135" width="679" height="21" font="5">at intermediate-risk, especially those &gt;55 years of age, risk-enhancing factors or CAC can be used to </text>
<text top="245" left="135" width="678" height="21" font="5">clarify risk if the risk decision is uncertain (S4.4.2<a href="CIR.0000000000000625.html#102">-16)</a>. Risk-enhancing factors, such as family history of </text>
<text top="265" left="135" width="679" height="21" font="5">premature ASCVD or an LDL-C of 160  to  189 mg/dL  (4.1–4.8 mmol/L),  identify individuals  whose </text>
<text top="285" left="135" width="681" height="21" font="5">ASCVD risk may indicate risk of genetic hypercholesterolemia and hence who may benefit from a </text>
<text top="305" left="135" width="373" height="21" font="5">moderate- to high-intensity statin (S4.4.2<a href="CIR.0000000000000625.html#102">-21)</a> (Table 6). </text>
<text top="325" left="108" width="702" height="21" font="5">5.  In those with intermediate ASCVD risk, defined as an ASCVD risk of 7.5% to ≤20%, knowledge of risk-</text>
<text top="345" left="135" width="681" height="21" font="5">enhancing factors is useful in understanding patient characteristics that increase ASCVD risk both </text>
<text top="366" left="135" width="679" height="21" font="5">short and long-term (Table 6). As in the 2013 ACC/AHA guideline, an ASCVD score does not assign a </text>
<text top="386" left="135" width="681" height="21" font="5">statin; it begins the decision process, which  includes  consideration of  risk-enhancing  factors. For </text>
<text top="406" left="135" width="678" height="21" font="5">example, in an RCT (S4.4.2<a href="CIR.0000000000000625.html#101">-9)</a>, a family history of premature ASCVD identified women ≥60 years of age </text>
<text top="426" left="135" width="675" height="21" font="5">with elevated high-sensitivity C-reactive protein  but  without ASCVD who benefitted from high-</text>
<text top="446" left="135" width="679" height="21" font="5">intensity statin therapy.  Those with primary elevations of LDL-C  ≥160 mg/dL  (4.1  mmol/L)  have </text>
<text top="466" left="135" width="675" height="21" font="5">elevated lifetime ASCVD risk and benefit from statin therapy (S4.4.2<a href="CIR.0000000000000625.html#102">-21,</a> S4.4.2<a href="CIR.0000000000000625.html#102">-22,</a> S4.4.2<a href="CIR.0000000000000625.html#102">-25,</a> S4.4.2-</text>
<text top="486" left="135" width="679" height="21" font="5"><a href="CIR.0000000000000625.html#102">29,</a>  S4.4.2<a href="CIR.0000000000000625.html#102">-30)</a>. Increased ASCVD risk (S4.4.2<a href="CIR.0000000000000625.html#101">-2)</a>  is seen with metabolic syndrome (S4.4.2<a href="CIR.0000000000000625.html#102">-20)</a>; </text>
<text top="507" left="135" width="679" height="21" font="5">inflammatory diseases, including psoriasis (S4.4.2<a href="CIR.0000000000000625.html#103">-31)</a> and RA; and HIV when treated with protease </text>
<text top="527" left="135" width="679" height="21" font="5">inhibitors (S4.4.2<a href="CIR.0000000000000625.html#103">-32)</a>. In women, a history of pregnancy complicated by preeclampsia and premature </text>
<text top="547" left="135" width="679" height="21" font="5">menopause (age &lt;40 years) also enhances ASCVD risk (see Section 4.4.5.3.). If measured, ABI &lt;0.9 has </text>
<text top="567" left="135" width="679" height="21" font="5">been shown to reclassify risk by the 2013 Risk Assessment Guidelines (S4.4.2<a href="CIR.0000000000000625.html#103">-33)</a>. The presence of </text>
<text top="587" left="135" width="679" height="21" font="5">risk-enhancing factors may affect the threshold for statin initiation or intensification (see sections </text>
<text top="607" left="135" width="679" height="21" font="5">4.4.2, 4.4.4, and 4.5 sections). Finally, in selected individuals, biomarkers, if measured, may identify </text>
<text top="627" left="135" width="679" height="21" font="5">individuals with increased risk of ASCVD events. Lp(a) levels, especially in those with a family history </text>
<text top="648" left="135" width="678" height="21" font="5">of premature ASCVD, can increase risk (S4.4.2<a href="CIR.0000000000000625.html#102">-16)</a>. However, no available RCT evidence supports Lp(a) </text>
<text top="668" left="135" width="675" height="21" font="5">levels as a target of therapy. Moderate primary elevations of triglycerides, non–HDL-C (TC minus HDL-</text>
<text top="688" left="135" width="679" height="21" font="5">C), and, if measured, apolipoprotein B (apoB) can improve selection of those at increased ASCVD risk </text>
<text top="708" left="135" width="84" height="21" font="5">(S4.4.2<a href="CIR.0000000000000625.html#102">-22)</a>.  </text>
<text top="728" left="108" width="706" height="21" font="5">6.  Evidence shows that a CAC score of zero can “down-risk” individuals who otherwise would qualify for </text>
<text top="748" left="135" width="679" height="21" font="5">a statin on the basis of their ASCVD 10-year risk. The ability to select those who would benefit greatly </text>
<text top="768" left="135" width="679" height="21" font="5">from statin therapy, as shown by RCTs in primary-prevention populations (S4.4.2<a href="CIR.0000000000000625.html#101">-6,</a> S4.4.2<a href="CIR.0000000000000625.html#101">-8)</a> and yet </text>
<text top="789" left="135" width="679" height="21" font="5">to withhold statin therapy in those least likely to benefit would improve specificity (S4.4.2<a href="CIR.0000000000000625.html#103">-34)</a>. For </text>
<text top="809" left="135" width="682" height="21" font="5">example, a CAC score  of  zero  in an analysis of pooled U.S.  population-based studies accurately </text>
<text top="829" left="135" width="679" height="21" font="5">discriminated between lower and higher CHD risk in older adults (S4.4.2<a href="CIR.0000000000000625.html#102">-19,</a> S4.4.2<a href="CIR.0000000000000625.html#102">-27)</a>.The BioImage </text>
<text top="849" left="135" width="679" height="21" font="5">Study in older adults (S4.4.2<a href="CIR.0000000000000625.html#102">-15)</a> and MESA (S4.4.2<a href="CIR.0000000000000625.html#102">-17)</a> showed improved detection of individuals not </text>
<text top="869" left="135" width="679" height="21" font="5">likely to benefit from statins when the CAC score was zero. Selected examples of candidates for CAC </text>
<text top="889" left="135" width="679" height="21" font="5">scoring who might benefit from knowing their CAC score is zero are listed in Table 8. Clinicians should </text>
<text top="909" left="135" width="679" height="21" font="5">not down-risk patients who are persistent cigarette smokers, have diabetes mellitus, or have a strong </text>
<text top="930" left="135" width="679" height="21" font="5">family history of ASCVD, as well as possibly those with chronic inflammatory conditions whose CAC of </text>
<text top="950" left="135" width="431" height="21" font="5">zero does not rule out risk from noncalcified plaque (S4.4.2<a href="CIR.0000000000000625.html#103">-35)</a>. </text>
<text top="970" left="108" width="706" height="21" font="5">7.  In adults at intermediate-risk (predicted 10-year risk of 7.5% to &lt;20%), substantial data indicate how </text>
<text top="990" left="135" width="683" height="21" font="5">CAC measurement can be effective in meaningfully  reclassifying risk in a large proportion of </text>
<text top="1010" left="135" width="679" height="21" font="5">individuals (S4.4.2<a href="CIR.0000000000000625.html#102">-15,</a> S4.4.2<a href="CIR.0000000000000625.html#102">-17,</a> S4.4.2<a href="CIR.0000000000000625.html#103">-36–S4.4.2-49)</a>. In such intermediate-risk adults, those with a </text>
<text top="1030" left="135" width="679" height="21" font="5">CAC score ≥100 Agatston units or CAC ≥75th percentile appear to have ASCVD event rates suggesting </text>
<text top="1050" left="135" width="678" height="21" font="5">that statin therapy would be beneficial (S4.4.2-17, S4.4.2-23). Those with a CAC of zero appear to have </text>
<text top="1071" left="135" width="680" height="21" font="5">10-year event rates in a lower range that suggests statin therapy may be of limited value for these </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="39" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-39_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 39</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="135" width="678" height="21" font="5">patients, with few exceptions including patients with diabetes mellitus, persistent smoking, and family </text>
<text top="144" left="135" width="679" height="21" font="5">history or premature ASCVD. Cigarette smoking remains a strong risk factor even in the presence of </text>
<text top="164" left="135" width="679" height="21" font="5">CAC score of zero (S4.4.2<a href="CIR.0000000000000625.html#104">-50,</a> S4.4.2<a href="CIR.0000000000000625.html#104">-51)</a>. In asymptomatic diabetes mellitus, a CAC score of zero is </text>
<text top="184" left="135" width="683" height="21" font="5">associated with a favorable 5-year prognosis; but after 5 years, the risk of mortality increases </text>
<text top="204" left="135" width="679" height="21" font="5">significantly for diabetic individuals even in the presence of a baseline CAC score of zero (S4.4.2<a href="CIR.0000000000000625.html#104">-52)</a>. </text>
<text top="225" left="135" width="679" height="21" font="5">In patients with a family history of ASCVD, CAC score of zero and may impart less short-term benefit </text>
<text top="245" left="135" width="681" height="21" font="5">from statin therapy; but considering a high lifetime risk, long-term benefit cannot be discounted </text>
<text top="265" left="135" width="679" height="21" font="5">(S4.4.2<a href="CIR.0000000000000625.html#104">-53)</a>. The same holds for CAC score of zero and a high 10 year risk (e.g., ≥20%) (S4.4.2<a href="CIR.0000000000000625.html#103">-34)</a>. For </text>
<text top="285" left="135" width="679" height="21" font="5">those with CAC scores of 1 to 99 Agatston units, 10-year ASCVD event rates are 3.8%, 6.5%, and 8.3% </text>
<text top="305" left="135" width="680" height="21" font="5">for age groups 45 to 54, 55 to 64, and 65 to 74 years (S4.4.2-23), suggesting that CAC scores in this </text>
<text top="325" left="135" width="680" height="21" font="5">range favor statin initiation only in adults &gt;55 years of age and indicating that risk reclassification is </text>
<text top="345" left="135" width="679" height="21" font="5">modest for individuals with CAC scores of 1 to 99. Therefore, for patients with CAC scores of 1 to 99, </text>
<text top="366" left="135" width="683" height="21" font="5">it is reasonable to repeat the risk discussion. If  these patients  remain  untreated, repeat CAC </text>
<text top="386" left="135" width="679" height="21" font="5">measurement in 5 to 10 years may have some value in reassessing for CAC progression, but data are </text>
<text top="406" left="135" width="679" height="21" font="5">limited (S4.4.2<a href="CIR.0000000000000625.html#101">-12,</a> S4.4.2<a href="CIR.0000000000000625.html#101">-13)</a>. A systematic review and meta-analysis suggests that knowledge that a </text>
<text top="426" left="135" width="679" height="21" font="5">patient’s CAC score is greater than zero is beneficial (S4.4.2<a href="CIR.0000000000000625.html#103">-38)</a>. Selected examples of candidates for </text>
<text top="446" left="135" width="679" height="21" font="5">CAC scoring who might benefit from knowing that their CAC score is zero are listed in Table 8. There </text>
<text top="466" left="135" width="680" height="21" font="5">is an increased likelihood that lifestyle therapies and drug therapy will be started or continued with </text>
<text top="486" left="135" width="534" height="21" font="5">significant, albeit modest, changes in risk factor levels and predicted risk levels. </text>
<text top="507" left="108" width="707" height="21" font="5">8.  Clinicians may need to address reducing ASCVD risk in higher-risk primary-prevention patients who </text>
<text top="527" left="135" width="679" height="21" font="5">either do not wish to take a statin or cannot tolerate the recommended intensity of statin therapy. In </text>
<text top="547" left="135" width="681" height="21" font="5">such patients, it may be reasonable to use LDL-C–lowering drugs that have been proven safe and </text>
<text top="567" left="135" width="680" height="21" font="5">effective in RCTs, either as monotherapy or combined with a statin (S4.4.2<a href="CIR.0000000000000625.html#101">-9)</a>. One alternative is a </text>
<text top="587" left="135" width="680" height="21" font="5">cholesterol absorption inhibitor. An RCT in adults ≥40 years of age with advanced CKD and without </text>
<text top="607" left="135" width="679" height="21" font="5">known CHD at baseline found that the addition of ezetimibe to a moderate-intensity statin lowered </text>
<text top="627" left="135" width="683" height="21" font="5">LDL-C 43 mg/dL  (1.1  mmol/L)  at  1  year.  (S4.4.2<a href="CIR.0000000000000625.html#104">-54)</a>.  After a median 4.9 years, ezetimibe and </text>
<text top="648" left="135" width="680" height="21" font="5">simvastatin 40 mg per day resulted in a 17% proportional reduction in major atherosclerotic events </text>
<text top="668" left="135" width="679" height="21" font="5">compared with placebo (S4.4.2<a href="CIR.0000000000000625.html#101">-2)</a>. Another alternative is a nonsystemic bile acid sequestrant. Bile </text>
<text top="688" left="135" width="680" height="21" font="5">acid sequestrants used as monotherapy reduced CHD endpoints in a large primary-prevention trial </text>
<text top="708" left="135" width="679" height="21" font="5">(S4.4.2<a href="CIR.0000000000000625.html#104">-55)</a>. Bile acid sequestrants can bind other drugs, so other medications must be avoided for 1 </text>
<text top="728" left="135" width="679" height="21" font="5">hour before and at least 3 to 4 hours after administration. Adding psyllium can minimize constipation </text>
<text top="748" left="135" width="679" height="21" font="5">and can reduce the bile acid sequestrant dose (S4.4.2<a href="CIR.0000000000000625.html#104">-56)</a>. These therapies should be considered in </text>
<text top="768" left="135" width="680" height="21" font="5">the context of a risk discussion that reviews potential for benefit along with tolerability and safety </text>
<text top="789" left="135" width="48" height="21" font="5">issues. </text>
<text top="809" left="108" width="706" height="21" font="5">9.  Benefit from statin therapy is seen in lower-risk individuals (S4.4.2<a href="CIR.0000000000000625.html#102">-24)</a>.. Consideration of enhancing </text>
<text top="829" left="135" width="681" height="21" font="5">factors in selected younger individuals in this lower risk range, will improve the ability to detect </text>
<text top="849" left="135" width="682" height="21" font="5">younger patients who develop MI before age 50 years (S4.4.2<a href="CIR.0000000000000625.html#104">-58,</a>  S4.4.2<a href="CIR.0000000000000625.html#104">-59)</a>.  Nonetheless, the </text>
<text top="869" left="135" width="679" height="21" font="5">challenge among those in a lower ASCVD risk category is to include those who would benefit yet avoid </text>
<text top="889" left="135" width="682" height="21" font="5">casting too wide a net,  to minimize treating those who would  derive little benefit from statin </text>
<text top="909" left="135" width="681" height="21" font="5">assignment. This risk group benefits greatly from a clinician–patient risk discussion. To arrive at a </text>
<text top="930" left="135" width="679" height="21" font="5">shared risk decision, clinicians should assess the patient’s priorities for health care, perceived ASCVD </text>
<text top="950" left="135" width="679" height="21" font="5">risk, and prior risk-reduction experiences and should use best practices to communicate numerical </text>
<text top="970" left="135" width="679" height="21" font="5">risk (S4.4.2<a href="CIR.0000000000000625.html#102">-27)</a>. The presence of risk-enhancing factors provides useful information about short term </text>
<text top="990" left="135" width="680" height="21" font="5">ASCVD risk favoring initiation of statin therapy (Table 6) (S4.4.2<a href="CIR.0000000000000625.html#104">-58)</a>. Although a CAC score can be </text>
<text top="1010" left="135" width="679" height="21" font="5">useful in selected individuals, it will be positive less often in this lower-risk group than in those with </text>
<text top="1030" left="135" width="503" height="21" font="5">higher levels of ASCVD risk and is not recommended routinely (S4.4.2<a href="CIR.0000000000000625.html#102">-17)</a>.  </text>
<text top="1050" left="108" width="4" height="21" font="5"> </text>
<text top="1050" left="324" width="4" height="21" font="5"> </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="40" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-40_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 40</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="584" height="21" font="4"><b>Table 7. Checklist for Clinician–Patient Shared Decision-Making for Initiating Therapy </b></text>
<text top="144" left="108" width="4" height="21" font="5"> </text>
<text top="171" left="116" width="91" height="19" font="0"><b>Checklist Item </b></text>
<text top="171" left="274" width="114" height="19" font="0"><b>Recommendation </b></text>
<text top="200" left="116" width="588" height="20" font="1">ASCVD risk assessment  •  Assign to statin treatment group; use ASCVD Risk Estimator Plus.* </text>
<text top="227" left="301" width="9" height="12" font="1">o</text>
<text top="225" left="310" width="4" height="14" font="1"> </text>
<text top="222" left="328" width="469" height="19" font="1">In lower-risk primary-prevention adults 40-75 y of age with LDL-C ≥70 mg/dL </text>
<text top="243" left="328" width="97" height="19" font="1">(≥1.8 mmol/L).  </text>
<text top="270" left="301" width="9" height="12" font="1">o</text>
<text top="269" left="310" width="4" height="14" font="1"> </text>
<text top="265" left="328" width="351" height="19" font="1">Not needed in secondary prevention, in those with LDL-C </text>
<text top="263" left="678" width="8" height="21" font="5">≥</text>
<text top="265" left="687" width="103" height="19" font="1">190 mg/dL (≥4.9 </text>
<text top="287" left="328" width="362" height="19" font="1">mmol/L), or in those 40-75 y of age with diabetes mellitus.  </text>
<text top="308" left="274" width="530" height="20" font="1">•  Assess other patient characteristics that influence risk. See Risk-Enhancing Factors </text>
<text top="330" left="301" width="184" height="19" font="1">(Section 4.4.1.3. and Table 6)  </text>
<text top="351" left="274" width="460" height="20" font="1">•  Assess CAC (Section 4.4.1.4.) if risk decision is uncertain and additional </text>
<text top="373" left="301" width="268" height="19" font="1">information is needed to clarify ASCVD risk. </text>
<text top="399" left="301" width="9" height="12" font="1">o</text>
<text top="397" left="310" width="4" height="14" font="1"> </text>
<text top="394" left="328" width="448" height="19" font="1">Use decision tools to explain risk (e.g., ASCVD Risk Estimator Plus,* Mayo </text>
<text top="415" left="328" width="206" height="19" font="1">Clinic Statin Choice Decision Aid).<b> </b></text>
<text top="436" left="116" width="687" height="20" font="1">Lifestyle modifications  •  Review lifestyle habits (e.g., diet, physical activity, weight or body mass index, and </text>
<text top="458" left="301" width="85" height="19" font="1">tobacco use). </text>
<text top="480" left="274" width="506" height="20" font="1">•  Endorse a healthy lifestyle and provide relevant advice, materials, or referrals. </text>
<text top="501" left="301" width="496" height="19" font="1">(e.g., CardioSmart, AHA Life’s Simple 7, NLA Patient Tear Sheets, PCNA Clinicians’ </text>
<text top="522" left="301" width="500" height="19" font="1">Lifestyle Modification Toolbox, cardiac rehabilitation, dietitian, smoking cessation </text>
<text top="543" left="301" width="64" height="19" font="1">program).<b> </b></text>
<text top="565" left="116" width="127" height="19" font="1">Potential net clinical </text>
<text top="586" left="116" width="63" height="19" font="1">benefit of </text>
<text top="607" left="116" width="112" height="19" font="1">pharmacotherapy </text>
<text top="565" left="274" width="277" height="20" font="1">•  Recommend statins as first-line therapy. </text>
<text top="587" left="274" width="510" height="20" font="1">•  Consider the combination of statin and nonstatin therapy in selected patients.  </text>
<text top="609" left="274" width="396" height="20" font="1">•  Discuss potential risk reduction from lipid-lowering therapy. </text>
<text top="631" left="274" width="438" height="20" font="1">•  Discuss the potential for adverse effects or drug–drug interactions.<b> </b></text>
<text top="653" left="116" width="123" height="19" font="1">Cost considerations </text>
<text top="654" left="274" width="529" height="20" font="1">•  Discuss potential out-of-pocket cost of therapy to the patient (e.g., insurance plan </text>
<text top="675" left="301" width="203" height="19" font="1">coverage, tier level, copayment). </text>
<text top="697" left="116" width="101" height="19" font="1">Shared decision-</text>
<text top="718" left="116" width="48" height="19" font="1">making </text>
<text top="697" left="274" width="487" height="20" font="1">•  Encourage the patient to verbalize what was heard (e.g., patient’s personal </text>
<text top="719" left="301" width="304" height="19" font="1">ASCVD risk, available options, and risks/benefits). </text>
<text top="740" left="274" width="500" height="20" font="1">•  Invite the patient to ask questions, express values and preferences, and state </text>
<text top="762" left="301" width="332" height="19" font="1">ability to adhere to lifestyle changes and medications. </text>
<text top="783" left="274" width="502" height="20" font="1">•  Refer patients to trustworthy materials to aid in their understanding of issues </text>
<text top="805" left="301" width="150" height="19" font="1">regarding risk decisions. </text>
<text top="826" left="274" width="459" height="20" font="1">•  Collaborate with the patient to determine therapy and follow-up plan. </text>
<text top="848" left="108" width="266" height="19" font="1">*ASCVD Risk Predictor Plus is available at:<a href="http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/"> </a></text>
<text top="848" left="374" width="432" height="19" font="8"><a href="http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/">http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/</a></text>
<text top="848" left="806" width="7" height="19" font="1"><a href="http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/">. </a></text>
<text top="867" left="108" width="182" height="19" font="1">Accessed September 1, 2018. </text>
<text top="885" left="108" width="708" height="19" font="1">AHA indicates American Heart Association; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery </text>
<text top="903" left="108" width="711" height="19" font="1">calcium; CKD, chronic kidney disease; HIV, human immunodeficiency virus; LDL-C, low-density lipoprotein </text>
<text top="922" left="108" width="594" height="19" font="1">cholesterol; PCNA, Preventive Cardiology Nurses Association and NLA, National Lipid Association. </text>
<text top="940" left="108" width="4" height="21" font="5"> </text>
<text top="960" left="108" width="4" height="21" font="5"> </text>
<text top="980" left="108" width="4" height="21" font="5"> </text>
<text top="980" left="324" width="4" height="21" font="5"> </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="41" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-41_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 41</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="680" height="21" font="4"><b>Table 8. Selected Examples of Candidates for CAC Measurement Who Might Benefit From Knowing </b></text>
<text top="144" left="108" width="161" height="21" font="4"><b>Their CAC Score Is Zero </b></text>
<text top="164" left="108" width="4" height="21" font="5"> </text>
<text top="191" left="114" width="608" height="21" font="4"><b>CAC Measurement Candidates Who Might Benefit from Knowing Their CAC Score Is Zero </b></text>
<text top="227" left="114" width="687" height="20" font="1">•  Patients reluctant to initiate statin therapy who wish to understand their risk and potential for benefit more </text>
<text top="249" left="141" width="57" height="19" font="1">precisely </text>
<text top="270" left="114" width="652" height="20" font="1">•  Patients concerned about need to reinstitute statin therapy after discontinuation for statin-associated </text>
<text top="292" left="141" width="67" height="19" font="1">symptoms </text>
<text top="313" left="114" width="686" height="20" font="1">•  Older patients (men, 55-80 y of age; women, 60-80 y of age) with low burden of risk factors (S4.4.2<a href="CIR.0000000000000625.html#104">-60)</a> who </text>
<text top="335" left="141" width="352" height="19" font="1">question whether they would benefit from statin therapy </text>
<text top="356" left="114" width="689" height="20" font="1">•  Middle-aged adults (40-55 y of age) with PCE-calculated 10-year risk of ASCVD 5% to &lt;7.5% with factors that </text>
<text top="378" left="141" width="428" height="19" font="1">increase their ASCVD risk, although they are in a borderline risk group </text>
<text top="406" left="108" width="705" height="19" font="1">Caveats: If patient is intermediate risk and if a risk decision is uncertain and a CAC score is performed, it is reasonable </text>
<text top="424" left="108" width="707" height="19" font="1">to withhold statin therapy unless higher risk conditions such as cigarette smoking, family history of premature </text>
<text top="442" left="108" width="709" height="19" font="1">ASCVD, or diabetes mellitus  are present, and to reassess CAC score in 5  to  10 years. Moreover, if CAC is </text>
<text top="461" left="108" width="706" height="19" font="1">recommended, it should be performed in facilities that have current technology that delivers the lowest radiation </text>
<text top="479" left="108" width="60" height="19" font="1">possible.  </text>
<text top="497" left="108" width="705" height="19" font="1">ASCVD indicates atherosclerotic cardiovascular disease; CAC, coronary artery calcium; LDL-C, low-density lipoprotein </text>
<text top="516" left="108" width="289" height="19" font="1">cholesterol; and PCE, pooled cohort equations. </text>
<text top="534" left="108" width="3" height="19" font="1"> </text>
<text top="555" left="108" width="3" height="19" font="1"> </text>
<text top="585" left="108" width="508" height="27" font="16"><i><b>4.4.3. Monitoring in Response to LDL-C–Lowering Therapy </b></i></text>
<text top="624" left="346" width="230" height="21" font="4"><b>Recommendation for Monitoring </b></text>
<text top="644" left="118" width="494" height="21" font="5">Referenced studies that support the recommendation are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625"> </a></text>
<text top="644" left="612" width="184" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Online Data Supplement 17</a></text>
<text top="644" left="796" width="8" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">.</a> </text>
<text top="665" left="128" width="33" height="21" font="4"><b>COR </b></text>
<text top="665" left="196" width="30" height="21" font="4"><b>LOE </b></text>
<text top="665" left="465" width="126" height="21" font="4"><b>Recommendation </b></text>
<text top="726" left="141" width="8" height="21" font="4"><b>I </b></text>
<text top="726" left="204" width="14" height="21" font="4"><b>A </b></text>
<text top="686" left="250" width="557" height="21" font="4"><b>1.  Adherence to changes in lifestyle and effects of LDL-C–lowering medication </b></text>
<text top="706" left="277" width="529" height="21" font="4"><b>should be assessed by measurement of fasting lipids and appropriate safety </b></text>
<text top="726" left="277" width="529" height="21" font="4"><b>indicators 4 to 12 weeks after statin initiation or dose adjustment and every </b></text>
<text top="746" left="277" width="529" height="21" font="4"><b>3  to  12 months thereafter  based on need to assess adherence or safety </b></text>
<text top="766" left="277" width="137" height="21" font="4"><b>(S4.4.3<a href="CIR.0000000000000625.html#104">-1–S4.4.3-3)</a></b><b>. </b></text>
<text top="787" left="108" width="4" height="21" font="5"> </text>
<text top="816" left="108" width="295" height="21" font="4"><b>Recommendation-Specific Supportive Text </b></text>
<text top="856" left="108" width="706" height="21" font="5">1.  Goals for LDL-C lowering in response to lifestyle therapies or a prescribed intensity of statin therapy </text>
<text top="876" left="135" width="680" height="21" font="5">are defined by percentage responses. Clinical efficacy is monitored by measurement of percentage </text>
<text top="896" left="135" width="681" height="21" font="5">reductions in LDL-C relative to baseline levels. Baseline LDL-C can be estimated by pretreatment </text>
<text top="916" left="135" width="681" height="21" font="5">measurements, chart reviews, or measurement  after a short interruption of  drug therapy. Some </text>
<text top="936" left="135" width="678" height="21" font="5">clinicians are reluctant to interrupt therapy, although risk is low. Unless a baseline level is established, </text>
<text top="956" left="135" width="679" height="21" font="5">it will be difficult to evaluate response to therapy. Good adherence to various LDL-lowering diets will </text>
<text top="977" left="135" width="679" height="21" font="5">reduce LDL-C levels by 10% to &gt;15% (S4.4.3<a href="CIR.0000000000000625.html#105">-3)</a>. Moderate-intensity statins can be expected to reduce </text>
<text top="997" left="135" width="680" height="21" font="5">LDL-C levels by another 30% to 49%, and high-intensity statins by ≥50% (Table 3, Section 3.2.). The </text>
<text top="1017" left="135" width="679" height="21" font="5">addition of ezetimibe or bile acid sequestrants to statin therapy typically provides an additional 15% </text>
<text top="1037" left="135" width="680" height="21" font="5">to 25% reduction in LDL-C. Much greater additive reductions occur by adding a PCSK9 inhibitor to </text>
<text top="1057" left="135" width="683" height="21" font="5">statin plus ezetimibe. In clinical practice, lifestyle and statin therapy are commonly introduced </text>
<text top="1077" left="135" width="681" height="21" font="5">together. The maximum percentage change will occur by 4 to 12 weeks after starting a statin or </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="42" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-42_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 42</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="135" width="682" height="21" font="5">combined therapy. At this time, drug efficacy or initial adherence to therapy can be evaluated. </text>
<text top="144" left="135" width="679" height="21" font="5">Periodic remeasurements will  make it possible to confirm adherence to therapy. Because </text>
<text top="164" left="135" width="679" height="21" font="5">recommended intensities of drug therapies will vary in adolescents, young adults, adults 40 to 75 </text>
<text top="184" left="135" width="679" height="21" font="5">years of age, those with  severe hypercholesterolemia, and those receiving therapy for secondary </text>
<text top="205" left="135" width="464" height="21" font="5">prevention, the recommended LDL-C levels to achieve will also vary.  </text>
<text top="234" left="108" width="4" height="21" font="5"> </text>
<text top="263" left="108" width="408" height="27" font="16"><i><b>4.4.4. Primary Prevention in Other Age Groups </b></i></text>
<text top="301" left="108" width="170" height="25" font="23"><i><b>4.4.4.1. Older Adults </b></i></text>
<text top="338" left="108" width="707" height="21" font="5">Additional recommendations for adults &gt;75 years of age are included in Section 4.1. (Secondary ASCVD </text>
<text top="358" left="108" width="394" height="21" font="5">Prevention) and Section 4.3. (Diabetes Mellitus in Adults).  </text>
<text top="387" left="338" width="246" height="21" font="4"><b>Recommendations for Older Adults </b></text>
<text top="408" left="126" width="474" height="21" font="5">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625"> </a></text>
<text top="408" left="600" width="195" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Online Data Supplements 18 </a></text>
<text top="431" left="434" width="46" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">and 19</a></text>
<text top="431" left="480" width="8" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">.</a><b> </b></text>
<text top="464" left="124" width="33" height="21" font="4"><b>COR </b></text>
<text top="464" left="189" width="30" height="21" font="4"><b>LOE </b></text>
<text top="464" left="458" width="132" height="21" font="4"><b>Recommendations </b></text>
<text top="511" left="130" width="21" height="21" font="4"><b>IIb </b></text>
<text top="511" left="190" width="27" height="21" font="4"><b>B-R </b></text>
<text top="497" left="244" width="561" height="21" font="4"><b>1.  In adults 75 years of age or older with an LDL-C level of 70 to 189 mg/dL</b> <b>(1.7 </b></text>
<text top="517" left="271" width="538" height="21" font="4"><b>to 4.8 mmol/L),  initiating a moderate-intensity statin may be reasonable </b></text>
<text top="537" left="271" width="158" height="21" font="4"><b>(S4.4.4.1<a href="CIR.0000000000000625.html#105">-1–S4.4.4.1-8)</a></b><b> </b></text>
<text top="582" left="130" width="21" height="21" font="4"><b>IIb </b></text>
<text top="582" left="190" width="27" height="21" font="4"><b>B-R </b></text>
<text top="558" left="244" width="562" height="21" font="4"><b>2.  In adults 75 years of age or older, it may be reasonable to stop statin therapy </b></text>
<text top="578" left="271" width="534" height="21" font="4"><b>when functional decline (physical or cognitive), multimorbidity, frailty,  or </b></text>
<text top="598" left="271" width="534" height="21" font="4"><b>reduced life-expectancy  limits  the  potential benefits of statin therapy </b></text>
<text top="618" left="271" width="90" height="21" font="4"><b>(S4.4.4.1<a href="CIR.0000000000000625.html#105">-9)</a></b><b>.  </b></text>
<text top="653" left="130" width="21" height="21" font="4"><b>IIb </b></text>
<text top="653" left="190" width="27" height="21" font="4"><b>B-R </b></text>
<text top="639" left="244" width="508" height="21" font="4"><b>3.  In adults 76 to 80 years of age with an LDL-C level of 70 to 189 mg/dL</b></text>
<text top="638" left="752" width="4" height="23" font="14"> </text>
<text top="639" left="756" width="49" height="21" font="4"><b>(1.7 to </b></text>
<text top="659" left="271" width="534" height="21" font="4"><b>4.8 mmol/L), it may be reasonable to measure CAC to reclassify those with a </b></text>
<text top="679" left="271" width="465" height="21" font="4"><b>CAC score of zero to avoid statin therapy (S4.4.4.1<a href="CIR.0000000000000625.html#105">-10, </a></b><b>S4.4.4.1<a href="CIR.0000000000000625.html#105">-11)</a></b><b>.  </b></text>
<text top="700" left="108" width="4" height="21" font="5"> </text>
<text top="729" left="108" width="63" height="21" font="4"><b>Synopsis </b></text>
<text top="769" left="108" width="708" height="21" font="5">Mounting risk factors and subclinical disease are endemic in the rapidly growing population of older </text>
<text top="789" left="108" width="707" height="21" font="5">adults. Data from RCT (S4.4.4.1<a href="CIR.0000000000000625.html#105">-1–S4.4.4.1-4)</a> and a related meta-analysis (S4.4.4.1<a href="CIR.0000000000000625.html#105">-5)</a> support primary </text>
<text top="809" left="108" width="706" height="21" font="5">prevention with statin therapy in older adults up to age 79 years, but some studies do not (S4.4.4.1<a href="CIR.0000000000000625.html#105">-12)</a>. </text>
<text top="829" left="108" width="705" height="21" font="5">Nonetheless, data in older subsets (≥80 years of age) remain sparse (S4.4.4.1<a href="CIR.0000000000000625.html#105">-6–S4.4.4.1-8)</a>. Furthermore, </text>
<text top="849" left="108" width="706" height="21" font="5">as adults grow older they are more susceptible to statin-related risks (S4.4.4.1<a href="CIR.0000000000000625.html#105">-13–S4.4.4.1-15)</a>, including </text>
<text top="869" left="108" width="708" height="21" font="5">those that arise from altered pharmacokinetics and pharmacodynamics, as well as the impact of side </text>
<text top="890" left="108" width="708" height="21" font="5">effects on  health issues such as multimorbidity, polypharmacy, frailty,  and  cognitive decline. In some </text>
<text top="910" left="108" width="706" height="21" font="5">patients, the aggregate risks associated with statins may exceed their likely benefits. Limited life spans </text>
<text top="930" left="108" width="706" height="21" font="5">may also undercut the minimum time for likely statin benefits, especially the 4 to 5 years associated with </text>
<text top="950" left="108" width="708" height="21" font="5">statins’ stroke-reducing benefits (S4.4.4.1<a href="CIR.0000000000000625.html#105">-15)</a>. Decisions to not initiate statins, or even to deprescribe </text>
<text top="970" left="108" width="708" height="21" font="5">them, are reasonable in older adults when aggregate risks outweigh potential for meaningful benefit </text>
<text top="990" left="108" width="707" height="21" font="5">(S4.4.4.1<a href="CIR.0000000000000625.html#105">-9,</a> S4.4.4.1<a href="CIR.0000000000000625.html#106">-16–S4.4.4.1-18)</a>. A shared decision-making process between clinicians and patients </text>
<text top="1010" left="108" width="713" height="21" font="5">that targets individualized decisions is warranted, with regular reassessments over time. CAC </text>
<text top="1031" left="108" width="708" height="21" font="5">determination  (S4.4.4.1<a href="CIR.0000000000000625.html#105">-10,</a>  S4.4.4.1<a href="CIR.0000000000000625.html#105">-11)</a>  focuses statin therapy on those who benefit most. For older </text>
<text top="1051" left="108" width="706" height="21" font="5">adults with CAC scores of zero, the likelihood of benefits from statin therapy does not outweigh the risks. </text>
<text top="1080" left="108" width="4" height="21" font="5"> </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="43" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-43_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 43</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="295" height="21" font="4"><b>Recommendation-Specific Supportive Text </b></text>
<text top="163" left="108" width="706" height="21" font="5">1.  An RCT enrolling 5,084 men and women 70 to 82 years of age showed no benefit from pravastatin 40 </text>
<text top="183" left="135" width="678" height="21" font="5">mg/d versus placebo in the primary-prevention subgroup (S4.4.4.1<a href="CIR.0000000000000625.html#105">-12)</a>. Another RCT using pravastatin </text>
<text top="203" left="135" width="679" height="21" font="5">40 mg per day versus usual care in older adults showed no statin benefit (S4.4.4.1<a href="CIR.0000000000000625.html#106">-19)</a> but there were </text>
<text top="223" left="135" width="678" height="21" font="5">important concerns about both adherence in those assigned to pravastatin and drop-in statin therapy </text>
<text top="244" left="135" width="679" height="21" font="5">in those assigned to usual care (S4.4.4.1<a href="CIR.0000000000000625.html#105">-1,</a> S4.4.4.1<a href="CIR.0000000000000625.html#105">-2,</a> S4.4.4.1<a href="CIR.0000000000000625.html#105">-4)</a>. A recent meta-analysis (S4.4.4.1<a href="CIR.0000000000000625.html#105">-3)</a> </text>
<text top="264" left="135" width="679" height="21" font="5">combining data from JUPITER and HOPE-3 in those ≥70 years of age showed a statistically significant </text>
<text top="284" left="135" width="682" height="21" font="5">26%  RRR  for nonfatal MI, nonfatal stroke, or cardiovascular  death. A prospective  cohort study </text>
<text top="304" left="135" width="680" height="21" font="5">(S4.4.4.1<a href="CIR.0000000000000625.html#105">-5)</a> comparing healthy older patients (age ≥70 years) who used statins with those who did </text>
<text top="324" left="135" width="679" height="21" font="5">not showed significantly lower risk of death but nonsignificant cardiovascular event reduction in the </text>
<text top="344" left="135" width="682" height="21" font="5">statin group. Other recent meta-analyses  (S4.4.4.1<a href="CIR.0000000000000625.html#105">-6–S4.4.4.1-8)</a>  support primary prevention for </text>
<text top="365" left="135" width="682" height="21" font="5">adults in their 70s. Thus, clinician–patient  discussion of risk versus benefit remains particularly </text>
<text top="385" left="135" width="679" height="21" font="5">important with inconsistent support and few data for adults &gt;80 years of age. Even a small increase </text>
<text top="405" left="135" width="679" height="21" font="5">in geriatric-specific adverse effects with statins could offset any cardiovascular benefit (S4.4.4.1<a href="CIR.0000000000000625.html#106">-20)</a>. </text>
<text top="425" left="135" width="679" height="21" font="5">Statins may be indicated if, after a clinician–patient discussion, the potential for benefit is thought to </text>
<text top="445" left="135" width="480" height="21" font="5">outweigh the risks of adverse effects, drug–drug interactions, and cost. </text>
<text top="465" left="108" width="706" height="21" font="5">2.  A counterpoint to the rationale for statin therapy in primary prevention for adults of older ages is the </text>
<text top="485" left="135" width="681" height="21" font="5">compelling rationale to discontinue therapy in  older adults with severe age-related management </text>
<text top="505" left="135" width="682" height="21" font="5">complexities. Customary risks associated with statins may be intensified by age (e.g., myalgias) </text>
<text top="526" left="135" width="684" height="21" font="5">(S4.4.4.1<a href="CIR.0000000000000625.html#105">-9)</a>  and distinctive risks may also develop because of  the broader age context (e.g., </text>
<text top="546" left="135" width="679" height="21" font="5">multimorbidity, polypharmacy, sarcopenia, falls, frailty, and cognitive decline) (S4.4.4.1<a href="CIR.0000000000000625.html#105">-15)</a>, </text>
<text top="566" left="135" width="679" height="21" font="5">potentially confounding effective statin therapy. Aggregate risks increase with age and may become </text>
<text top="586" left="135" width="680" height="21" font="5">disproportionate to the extent that risks outweigh potential for meaningful benefit. Deprescribing </text>
<text top="606" left="135" width="681" height="21" font="5">statins becomes an important option to be considered (S4.4.4.1<a href="CIR.0000000000000625.html#106">-18)</a>. Related studies are evolving, </text>
<text top="626" left="135" width="687" height="21" font="5">particularly in the palliative care domain. One randomized trial (S4.4.4.1<a href="CIR.0000000000000625.html#105">-9)</a>  and several </text>
<text top="646" left="135" width="679" height="21" font="5">nonrandomized studies (albeit of relatively lower quality) show feasibility and utility of deprescribing </text>
<text top="667" left="135" width="678" height="21" font="5">in older adults with significant management complexity (S4.4.4.1<a href="CIR.0000000000000625.html#106">-16,</a> S4.4.4.1<a href="CIR.0000000000000625.html#106">-17)</a>. Nonetheless, these </text>
<text top="687" left="135" width="679" height="21" font="5">studies also show that decisions about statins are not intuitive because many frailer or more complex </text>
<text top="707" left="135" width="682" height="21" font="5">patients may prefer to stay on statins precisely because they are at greatest cardiovascular risk </text>
<text top="727" left="135" width="681" height="21" font="5">(S4.4.4.1<a href="CIR.0000000000000625.html#106">-16)</a>. Therefore, it is warranted that decisions about  statin therapy be individualized and </text>
<text top="747" left="135" width="681" height="21" font="5">derived from clinician–patient  discussions. Moreover, given the predictable fluctuations of health </text>
<text top="767" left="135" width="452" height="21" font="5">dynamics, such shared decisions should be reconsidered regularly.  </text>
<text top="788" left="108" width="706" height="21" font="5">3.  Multiple studies indicate the utility of CAC measurement in identifying the absence of atherosclerotic </text>
<text top="808" left="135" width="675" height="21" font="5">pathophysiology in older adults (S4.4.4.1<a href="CIR.0000000000000625.html#105">-10,</a> S4.4.4.1<a href="CIR.0000000000000625.html#105">-11)</a> Moreover, with reduced costs, the long-</text>
<text top="828" left="135" width="683" height="21" font="5">term consequences of using low-dose computed tomography for CAC screening are much less </text>
<text top="848" left="135" width="678" height="21" font="5">concerning for older patients. If CAC score is zero, the patient may be reclassified to a lower-risk status </text>
<text top="868" left="135" width="681" height="21" font="5">to avoid statin therapy  (S4.4.4.1<a href="CIR.0000000000000625.html#105">-11)</a>.The BioImage study also indicated that scanning  for carotid </text>
<text top="888" left="135" width="682" height="21" font="5">plaque did not down-classify as many individuals as did a CAC  score of zero  but still improved </text>
<text top="908" left="135" width="679" height="21" font="5">specificity of statin assignment (S4.4.4.1<a href="CIR.0000000000000625.html#105">-11)</a>. Limiting statin therapy to those with CAC scores greater </text>
<text top="928" left="135" width="683" height="21" font="5">than zero, combined with clinical judgment and patient preference,  could provide a valuable </text>
<text top="949" left="135" width="389" height="21" font="5">awareness with which to inform shared decision-making.  </text>
<text top="978" left="108" width="4" height="21" font="5"> </text>
<text top="998" left="108" width="4" height="21" font="5"> </text>
<text top="1018" left="108" width="364" height="25" font="23"><i><b>4.4.4.2. Young Adults (20 to 39 Years of Age) </b></i></text>
<text top="1054" left="108" width="705" height="21" font="5">Much of atherosclerosis begins in young adulthood (S4.4.4.2<a href="CIR.0000000000000625.html#106">-1)</a>. Progression of atherosclerosis thereafter </text>
<text top="1074" left="108" width="708" height="21" font="5">becomes clinically manifest as ASCVD in middle age or later years. Thus, prevention of clinical ASCVD </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="44" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="24" size="17" family="Times" color="#000000"/>
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-44_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 44</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="705" height="21" font="5">optimally begins early in life. In children or adolescents, atherosclerosis may begin to appear in those with </text>
<text top="144" left="108" width="711" height="21" font="5">hypercholesterolemia; in this age range, more aggressive cholesterol-lowering may be indicated. </text>
<text top="164" left="108" width="706" height="21" font="5">Development of atherosclerosis in young adults most commonly is multifactorial and occurs most rapidly </text>
<text top="184" left="108" width="709" height="21" font="5">in individuals with multiple risk factors (e.g.,  hypercholesterolemia, hypertension, cigarette smoking, </text>
<text top="204" left="108" width="297" height="21" font="5">diabetes mellitus, and obesity) (S4.4.4.2<a href="CIR.0000000000000625.html#106">-2)</a>.  </text>
<text top="224" left="162" width="654" height="21" font="5">As discussed in these guidelines (Section 4.2.) FH  often goes undiagnosed. Young adults with </text>
<text top="245" left="108" width="706" height="21" font="5">primary elevations of LDL-C ≥190 mg/dl have a long-term ASCVD burden (S4.4.4.2<a href="CIR.0000000000000625.html#106">-3)</a>, and statin therapy </text>
<text top="265" left="108" width="706" height="21" font="5">is recommended. In adults with hypercholesterolemia, cascade screening often identifies other family </text>
<text top="285" left="108" width="304" height="21" font="5">members with elevated LDL-C (Section 4.2.).<b>  </b></text>
<text top="305" left="162" width="654" height="21" font="5">However even moderate hypercholesterolemia can accelerate development of atherosclerosis </text>
<text top="325" left="108" width="708" height="21" font="5">(S4.4.4.2<a href="CIR.0000000000000625.html#106">-4)</a>. Secondary causes of elevated cholesterol (hypothyroidism (TSH), obstructive liver disease </text>
<text top="345" left="108" width="705" height="21" font="5">(liver panel), renal disease and nephrosis (creatinine and urine analysis) as well as dietary and medication </text>
<text top="366" left="108" width="708" height="21" font="5">history  should be addressed appropriately  (S4.4.4.2<a href="CIR.0000000000000625.html#106">-5)</a>.  Elevations of LDL-C persisting after excluding </text>
<text top="386" left="108" width="711" height="21" font="5">secondary causes suggests genetic forms of hypercholesterolemia. Young adults who experience </text>
<text top="406" left="108" width="707" height="21" font="5">prolonged exposure to hyperlipidemia prior to age 55 are shown to have significantly increased risk of </text>
<text top="426" left="108" width="712" height="21" font="5">coronary heart disease (S4.4.4.2<a href="CIR.0000000000000625.html#106">-6)</a>.  Intensive lifestyle change has the potential to reduce the </text>
<text top="446" left="108" width="384" height="21" font="5">hyperlipidemia and associated ASCVD risk factor burden. </text>
<text top="466" left="162" width="658" height="21" font="5">A smaller group, but even at higher risk, are young adults with persistent, moderate </text>
<text top="486" left="108" width="708" height="21" font="5">hypercholesterolemia (LDL-C 160-189 mg/dL), especially when risk-enhancing factors, such as a family </text>
<text top="506" left="108" width="706" height="21" font="5">history of premature ASCVD, are present. Since there is increased probability of genetic FH in this LDL-C </text>
<text top="527" left="108" width="705" height="21" font="5">range, clinical judgment would suggest that these high risk young adults will benefit from long-term statin </text>
<text top="547" left="108" width="707" height="21" font="5">therapy (S4.4.4.2<a href="CIR.0000000000000625.html#106">-7)</a> (Section 4.2.). Indeed, it has been shown that those with higher LDL-C can gain as </text>
<text top="567" left="108" width="705" height="21" font="5">much or more benefit from cholesterol reduction as do those with lower pretreatment LDL-C but at higher </text>
<text top="587" left="108" width="191" height="21" font="5">risk (S4.4.4.2<a href="CIR.0000000000000625.html#106">-8,</a> S4.4.4.2<a href="CIR.0000000000000625.html#106">-9)</a>.  </text>
<text top="607" left="162" width="655" height="21" font="5">In young adults without phenotypically severe hypercholesterolemia, risk assessment should </text>
<text top="627" left="108" width="708" height="21" font="5">begin by estimation of lifetime risk (S4.4.4.2<a href="CIR.0000000000000625.html#106">-10)</a>.  The pooled cohort  equations (PCE) can be used to </text>
<text top="647" left="108" width="706" height="21" font="5">estimate lifetime risk starting at age 21 years (see Section 4.4.2.). This information can inform a focused </text>
<text top="668" left="108" width="706" height="21" font="5">risk discussion designed to<b> </b>improve high-risk lifestyle behaviors including tobacco use, sedentary lifestyle </text>
<text top="688" left="108" width="705" height="21" font="5">and/or poor diet (S4.4.4.2<a href="CIR.0000000000000625.html#106">-11,</a> S4.4.4.2<a href="CIR.0000000000000625.html#106">-12)</a>. When young adults with hypercholesterolemia or multiple risk </text>
<text top="708" left="108" width="702" height="21" font="5">factors are identified, lifestyle intervention is indicated. To date, no long-term RCTs with cholesterol-</text>
<text top="728" left="108" width="706" height="21" font="5">lowering drugs have been carried out in those 20 to 39 years age. However, a primary prevention RCT in </text>
<text top="748" left="108" width="706" height="21" font="5">those younger individuals at low to moderate short-term risk, but at high lifetime risk has been proposed </text>
<text top="768" left="108" width="93" height="21" font="5">(S4.4.4.2<a href="CIR.0000000000000625.html#106">-13)</a>.<b> </b></text>
<text top="788" left="162" width="653" height="21" font="5">One approach to identifying young adults who could benefit from statins or drug combination </text>
<text top="808" left="108" width="706" height="21" font="5">would be to detect significant coronary atherosclerosis with coronary artery calcium (CAC) scores. Its use </text>
<text top="829" left="108" width="707" height="21" font="5">for this purpose has been suggested (S4.4.4.2<a href="CIR.0000000000000625.html#107">-14)</a>. But again, absence of RCT data precludes guideline </text>
<text top="849" left="108" width="214" height="21" font="5">recommendations at this time.  </text>
<text top="869" left="108" width="4" height="21" font="5"> </text>
<text top="889" left="108" width="4" height="25" font="24"> </text>
<text top="889" left="324" width="4" height="25" font="23"><i><b> </b></i></text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="45" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-45_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 45</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="273" height="25" font="23"><i><b>4.4.4.3. Children and Adolescents </b></i></text>
<text top="167" left="294" width="334" height="21" font="4"><b>Recommendations for Children and Adolescents </b></text>
<text top="187" left="124" width="474" height="21" font="5">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625"> </a></text>
<text top="187" left="598" width="199" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Online Data Supplements 18, </a></text>
<text top="207" left="409" width="95" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">19, 20, and 21</a></text>
<text top="207" left="504" width="8" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">.</a> </text>
<text top="244" left="132" width="33" height="21" font="4"><b>COR</b> </text>
<text top="244" left="212" width="30" height="21" font="4"><b>LOE</b> </text>
<text top="244" left="489" width="132" height="21" font="4"><b>Recommendations</b> </text>
<text top="298" left="145" width="8" height="21" font="4"><b>I </b></text>
<text top="298" left="220" width="14" height="21" font="4"><b>A </b></text>
<text top="277" left="271" width="511" height="21" font="4"><b>1.  In children and adolescents with lipid disorders related to obesity, it is </b></text>
<text top="297" left="297" width="491" height="21" font="4"><b>recommended to intensify lifestyle therapy, including moderate caloric </b></text>
<text top="318" left="297" width="487" height="21" font="4"><b>restriction and regular aerobic physical activity (S4.4.4.3<a href="CIR.0000000000000625.html#107">-1–S4.4.4.3-4)</a></b><b>. </b></text>
<text top="364" left="145" width="8" height="21" font="4"><b>I </b></text>
<text top="364" left="208" width="38" height="21" font="4"><b>B-NR </b></text>
<text top="364" left="271" width="537" height="21" font="4"><b>2.  In children and adolescents with lipid abnormalities, lifestyle counseling is </b></text>
<text top="384" left="297" width="507" height="21" font="4"><b>beneficial for lowering LDL-C (S4.4.4.3<a href="CIR.0000000000000625.html#107">-1–S.4.4.4.3-3, </a></b><b>S4.4.4.3<a href="CIR.0000000000000625.html#107">-5–S4.4.4.3-</a></b></text>
<text top="404" left="297" width="34" height="21" font="4"><a href="CIR.0000000000000625.html#107"><b>12)</b></a><b>.  </b></text>
<text top="481" left="138" width="21" height="21" font="4"><b>IIa </b></text>
<text top="481" left="213" width="27" height="21" font="4"><b>B-R </b></text>
<text top="437" left="271" width="537" height="21" font="4"><b>3.  In children and adolescents 10 years of age or older with an LDL-C level </b></text>
<text top="457" left="297" width="510" height="21" font="4"><b>persistently 190 mg/dL (≥4.9 mmol/L) or higher or 160 mg/dL (4.1 mmol/L) </b></text>
<text top="477" left="297" width="510" height="21" font="4"><b>or higher with a clinical presentation consistent with FH (see Section 4.2.) </b></text>
<text top="497" left="297" width="515" height="21" font="4"><b>and  who do not respond adequately with 3 to 6 months of lifestyle </b></text>
<text top="517" left="297" width="507" height="21" font="4"><b>therapy, it is reasonable to initiate statin therapy (S4.4.4.3<a href="CIR.0000000000000625.html#107">-13–S4.4.4.3-</a></b></text>
<text top="538" left="297" width="30" height="21" font="4"><a href="CIR.0000000000000625.html#107"><b>16)</b></a><b>. </b></text>
<text top="596" left="138" width="21" height="21" font="4"><b>IIa </b></text>
<text top="596" left="208" width="38" height="21" font="4"><b>B-NR</b> </text>
<text top="570" left="271" width="537" height="21" font="4"><b>4.  In children and adolescents with a family history of either early CVD* or </b></text>
<text top="591" left="297" width="511" height="21" font="4"><b>significant hypercholesterolemia,† it is reasonable to measure a fasting or </b></text>
<text top="611" left="297" width="510" height="21" font="4"><b>nonfasting lipoprotein profile as early as age 2 years to detect FH or rare </b></text>
<text top="631" left="297" width="395" height="21" font="4"><b>forms of hypercholesterolemia (S4.4.4.3<a href="CIR.0000000000000625.html#107">-17–S4.4.4.3-21)</a></b><b>. </b></text>
<text top="701" left="138" width="21" height="21" font="4"><b>IIa </b></text>
<text top="701" left="208" width="38" height="21" font="4"><b>B-NR </b></text>
<text top="667" left="271" width="546" height="21" font="4"><b>5.  In  children and adolescents  found to have moderate or severe </b></text>
<text top="687" left="297" width="511" height="21" font="4"><b>hypercholesterolemia, it is reasonable to carry out reverse-cascade </b></text>
<text top="707" left="297" width="511" height="21" font="4"><b>screening of family members, which includes cholesterol testing for first-, </b></text>
<text top="727" left="297" width="510" height="21" font="4"><b>second-, and when possible, third-degree biological relatives, for detection </b></text>
<text top="747" left="297" width="467" height="21" font="4"><b>of familial forms of hypercholesterolemia (S4.4.4.3<a href="CIR.0000000000000625.html#108">-22–S4.4.4.3-24)</a></b><b>. </b></text>
<text top="794" left="138" width="21" height="21" font="4"><b>IIa</b> </text>
<text top="794" left="209" width="35" height="21" font="4"><b>C-LD </b></text>
<text top="780" left="271" width="537" height="21" font="4"><b>6.  In children and adolescents with obesity or other metabolic risk factors, it </b></text>
<text top="800" left="297" width="511" height="21" font="4"><b>is reasonable to measure a fasting lipid profile to detect lipid disorders as </b></text>
<text top="821" left="297" width="457" height="21" font="4"><b>components of the metabolic syndrome (S4.4.4.3<a href="CIR.0000000000000625.html#108">-25–S4.4.4.3-27)</a></b><b>. </b></text>
<text top="888" left="138" width="21" height="21" font="4"><b>IIb </b></text>
<text top="888" left="208" width="38" height="21" font="4"><b>B-NR </b></text>
<text top="854" left="271" width="539" height="21" font="4"><b>7.  In children and adolescents without cardiovascular risk factors or family </b></text>
<text top="874" left="297" width="510" height="21" font="4"><b>history of early CVD, it may be reasonable to measure a fasting lipid profile </b></text>
<text top="894" left="297" width="512" height="21" font="4"><b>or nonfasting non HDL-C once between the ages of 9 and 11 years, and </b></text>
<text top="914" left="297" width="511" height="21" font="4"><b>again between the ages of 17 and 21 years, to detect moderate to severe </b></text>
<text top="934" left="297" width="480" height="21" font="4"><b>lipid abnormalities (S4.4.4.3<a href="CIR.0000000000000625.html#108">-19, </a></b><b>S4.4.4.3<a href="CIR.0000000000000625.html#108">-21, </a></b><b>S4.4.4.3<a href="CIR.0000000000000625.html#108">-27–S4.4.4.3-29)</a></b><b>. </b></text>
<text top="961" left="108" width="705" height="19" font="1">*Family history of early CVD is defined here as MI, documented angina, or atherosclerosis by angiography in parents, </text>
<text top="980" left="108" width="589" height="19" font="1">siblings, grandparents, aunts, or uncles (&lt;55 years of age for men, &lt;65 years of age for women).  </text>
<text top="998" left="108" width="133" height="19" font="1">†TC ≥240 mg/dL (≥6.2</text>
<text top="996" left="241" width="4" height="21" font="5"> </text>
<text top="998" left="244" width="169" height="19" font="1">mmol/L), LDL-C ≥190 mg/dL</text>
<text top="995" left="414" width="4" height="23" font="14"> </text>
<text top="998" left="418" width="238" height="19" font="1">(≥4.9 mmol/L), non–HDL-C ≥220 mg/dL</text>
<text top="996" left="655" width="4" height="21" font="5"> </text>
<text top="998" left="659" width="154" height="19" font="1">(≥5.7 mmol/L), or known </text>
<text top="1016" left="108" width="192" height="19" font="1">primary hypercholesterolemia. </text>
<text top="1034" left="108" width="4" height="21" font="5"> </text>
<text top="1063" left="108" width="4" height="21" font="5"> </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="46" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-46_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 46</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="63" height="21" font="4"><b>Synopsis </b></text>
<text top="163" left="108" width="707" height="21" font="5">Abnormal lipid levels are relatively common in children and adolescents, affecting approximately 1 in 5 </text>
<text top="183" left="108" width="706" height="21" font="5">adolescents (S4.4.4.3<a href="CIR.0000000000000625.html#108">-25)</a>. Confirmed lipid disorders are less common but occur frequently in the presence </text>
<text top="203" left="108" width="710" height="21" font="5">of obesity, often accompanied by cardiovascular risk factors,  and contribute to increased rates of </text>
<text top="223" left="108" width="706" height="21" font="5">cardiovascular and metabolic morbidity and mortality. Severe hypercholesterolemia (LDL ≥190 mg/dL </text>
<text top="244" left="108" width="707" height="21" font="5">(≥4.9 mmol/L)) affects ~1 in 250 children and adolescents. Testing for lipid disorders can identify both </text>
<text top="264" left="108" width="707" height="21" font="5">severe hypercholesterolemia and multifactorial lifestyle-related dyslipidemia. Nonfasting lipid testing is </text>
<text top="284" left="108" width="709" height="21" font="5">effective for initial screening purposes, and  non–HDL-C  is  a reasonable screening test. No available </text>
<text top="304" left="108" width="706" height="21" font="5">evidence evaluates benefits of childhood lipid screening for modifying CVD events or associated long-term </text>
<text top="324" left="108" width="709" height="21" font="5">harm. However, significantly abnormal lipid levels track from childhood to adulthood. Furthermore, </text>
<text top="344" left="108" width="707" height="21" font="5">subclinical atherosclerosis, as measured by carotid intima-media thickness, is abnormal in children with </text>
<text top="365" left="108" width="706" height="21" font="5">FH. Strong evidence shows that lifestyle modification improves lipid levels in childhood without adverse </text>
<text top="385" left="108" width="706" height="21" font="5">effects on growth and maturation; however, effect sizes are small, and adherence may wane over time. </text>
<text top="405" left="108" width="706" height="21" font="5">Statins and nonstatins lower TC and LDL-C with minimal adverse effects in children and adolescents with </text>
<text top="425" left="108" width="710" height="21" font="5">severe hypercholesterolemia. There are scant data on pharmacological  treatment of multifactorial </text>
<text top="445" left="108" width="201" height="21" font="5">lifestyle-related dyslipidemia. </text>
<text top="474" left="108" width="295" height="21" font="4"><b>Recommendation-Specific Supportive Text </b></text>
<text top="513" left="108" width="705" height="21" font="5">1.  In children and adolescents with lipid abnormalities and obesity, lifestyle-modification therapy should </text>
<text top="534" left="135" width="678" height="21" font="5">be intensified over and above usual therapy for childhood obesity and should include moderate caloric </text>
<text top="554" left="135" width="680" height="21" font="5">restriction and sufficient physical activity (e.g., 30-60 minutes of moderate to vigorous activity on </text>
<text top="574" left="135" width="618" height="21" font="5">most days). Utilization of resources for nutritional education and counseling is encouraged.  </text>
<text top="594" left="108" width="705" height="21" font="5">2.  Lifestyle-modification interventions in childhood and adolescence show short- and long-term benefits </text>
<text top="614" left="135" width="679" height="21" font="5">to lipid levels and subclinical atherosclerosis measures in RCTs  (S4.4.4.3<a href="CIR.0000000000000625.html#107">-5–S4.4.4.3-8)</a>  and </text>
<text top="634" left="135" width="679" height="21" font="5">observational studies of children and adolescents with lipid disorders (S4.4.4.3<a href="CIR.0000000000000625.html#107">-3,</a>  S4.4.4.3<a href="CIR.0000000000000625.html#107">-9)</a>.  No </text>
<text top="654" left="135" width="679" height="21" font="5">adverse effects on growth or maturation have been demonstrated (S4.4.4.3<a href="CIR.0000000000000625.html#107">-6)</a>. The impact of these </text>
<text top="675" left="135" width="678" height="21" font="5">interventions on lipid levels and subclinical atherosclerosis is small; no studies report CVD event rates. </text>
<text top="695" left="135" width="679" height="21" font="5">There are likely other unmeasured health benefits of lifestyle-modification interventions for chronic </text>
<text top="715" left="135" width="685" height="21" font="5">disease outcomes (e.g.,  obesity, diabetes mellitus, and cancer). These benefits support the </text>
<text top="735" left="135" width="679" height="21" font="5">recommendation to treat children and adolescents with lipid disorders with lifestyle-modification </text>
<text top="755" left="135" width="679" height="21" font="5">interventions, generally by using a family-based approach and promoting a heart-healthy diet, plenty </text>
<text top="775" left="135" width="679" height="21" font="5">of physical activity, avoidance of cigarette smoking, maintenance of a healthy weight, maintenance </text>
<text top="795" left="135" width="434" height="21" font="5">of normal blood pressure, and maintenance of normal glycemia. </text>
<text top="816" left="108" width="705" height="21" font="5">3.  Statins and nonstatins lower TC and LDL-C in children and adolescents with FH (S4.4.4.3<a href="CIR.0000000000000625.html#108">-30)</a>, and other </text>
<text top="836" left="135" width="681" height="21" font="5">health conditions that put them at increased risk of CVD (S4.4.4.3<a href="CIR.0000000000000625.html#108">-31,</a> S4.4.4.3<a href="CIR.0000000000000625.html#108">-32)</a>. Evidence from </text>
<text top="856" left="135" width="681" height="21" font="5">these RCTs demonstrates low short- and medium-term adverse event rates (abnormalities in liver </text>
<text top="876" left="135" width="681" height="21" font="5">function test, creatine kinase  [CK]  levels, and reported myopathy) with statin use in children and </text>
<text top="896" left="135" width="687" height="21" font="5">adolescents with FH (S4.4.4.3<a href="CIR.0000000000000625.html#108">-30)</a>. Limited data show benefit from statins to subclinical </text>
<text top="916" left="135" width="683" height="21" font="5">atherosclerosis in FH.  These data,  coupled with the increased risk  of  CVD  in untreated severe </text>
<text top="936" left="135" width="679" height="21" font="5">hypercholesterolemia, support the use of statins in children and adolescents at ages ≥10 years who </text>
<text top="957" left="135" width="681" height="21" font="5">have  FH  (S4.4.4.3<a href="CIR.0000000000000625.html#108">-33,</a>  S4.4.4.3<a href="CIR.0000000000000625.html#108">-34)</a>  and  have not responded to 3  to 6 months of lifestyle therapy. </text>
<text top="977" left="135" width="681" height="21" font="5">Statins may be considered at age 8 years in the presence of concerning family history, extremely </text>
<text top="997" left="135" width="682" height="21" font="5">elevated LDL-C  level, or elevated Lp(a),  in the context of informed shared decision-making and </text>
<text top="1017" left="135" width="679" height="21" font="5">counseling with the patient and family. The intensity of treatment should be based on the severity of </text>
<text top="1037" left="135" width="678" height="21" font="5">the hypercholesterolemia and should incorporate patient/family preference. Scant data on the use of </text>
<text top="1057" left="135" width="681" height="21" font="5">ezetimibe in children with severe hypercholesterolemia show reasonable LDL-C lowering with no </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="47" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-47_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 47</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="135" width="679" height="21" font="5">significant adverse effects (S4.4.4.3<a href="CIR.0000000000000625.html#107">-13)</a>. Nonsystemic bile acid sequestrants can be useful for LDL-C </text>
<text top="144" left="135" width="422" height="21" font="5">lowering, but tolerability is an issue (S4.4.4.3<a href="CIR.0000000000000625.html#107">-13–S4.4.4.3-16)</a>.  </text>
<text top="164" left="108" width="706" height="21" font="5">4.  Lipid testing during childhood can identify the severe hypercholesterolemia phenotype (S4.4.4.3<a href="CIR.0000000000000625.html#108">-35)</a>. </text>
<text top="184" left="135" width="680" height="21" font="5">Severe hypercholesterolemia, which includes FH, can be identified in children and adolescents with </text>
<text top="204" left="135" width="679" height="21" font="5">an LDL-C level ≥190 mg/dL (≥4.9 mmol/L). Moreover, children and adolescents with LDL-C ≥160 mg/dL </text>
<text top="225" left="135" width="679" height="21" font="5">(≥4.1 mmol/L) and a family history of early atherosclerosis or similarly elevated cholesterol in 1 parent </text>
<text top="245" left="135" width="675" height="21" font="5">likely are those with FH and related genetic disorders associated with accelerated ASCVD (S4.4.4.3-</text>
<text top="265" left="135" width="678" height="21" font="5"><a href="CIR.0000000000000625.html#107">17–S4.4.4.3-21)</a>. Subclinical atherosclerosis data suggest divergence between affected and unaffected </text>
<text top="285" left="135" width="680" height="21" font="5">children and adolescents beginning at age 10 years (S4.4.4.3<a href="CIR.0000000000000625.html#108">-28)</a>, which supports screening by this </text>
<text top="305" left="135" width="679" height="21" font="5">age, although this topic is still considered controversial (S4.4.4.3<a href="CIR.0000000000000625.html#108">-36)</a>. Screening is advised beginning </text>
<text top="325" left="135" width="685" height="21" font="5">at age 2 years if a family history is suggestive of either early CVD or significant primary </text>
<text top="345" left="135" width="682" height="21" font="5">hypercholesterolemia.  Identification of  a child with severe hypercholesterolemia should prompt </text>
<text top="366" left="135" width="678" height="21" font="5">screening of extended family members (e.g., reverse-cascade screening), according to studies outside </text>
<text top="386" left="135" width="684" height="21" font="5">the  United States  demonstrating efficacy of this approach  (S4.4.4.3<a href="CIR.0000000000000625.html#108">-37)</a>. Screening for severe </text>
<text top="406" left="135" width="680" height="21" font="5">hypercholesterolemia on the basis of family history includes an expanded group of family members </text>
<text top="426" left="135" width="679" height="21" font="5">(e.g., grandparents, aunts, and uncles) in addition to parents and siblings because siblings of children </text>
<text top="446" left="135" width="678" height="21" font="5">are unlikely to have had cardiovascular events or been identified with significant cholesterol disorders </text>
<text top="466" left="135" width="97" height="21" font="5">(S4.4.4.3<a href="CIR.0000000000000625.html#109">-38)</a>.  </text>
<text top="486" left="108" width="706" height="21" font="5">5.  One advantage of measuring lipids in children and adolescents is to identify genetic abnormalities in </text>
<text top="507" left="135" width="682" height="21" font="5">lipid metabolism that may be present in other family members. Regardless of the age at which </text>
<text top="527" left="135" width="685" height="21" font="5">abnormalities are detected, reverse-cascade screening in families is highly effective for the </text>
<text top="547" left="135" width="514" height="21" font="5">identification of family members at risk of ASCVD (S4.4.4.3<a href="CIR.0000000000000625.html#108">-22–S4.4.4.3-24)</a>.  </text>
<text top="567" left="108" width="706" height="21" font="5">6.  Observational studies of children and adolescents show  that  obesity and other lifestyle-related </text>
<text top="587" left="135" width="679" height="21" font="5">behaviors and metabolic syndrome risk factors including lipid abnormalities (S4.4.4.3<a href="CIR.0000000000000625.html#108">-25,</a> S4.4.4.3<a href="CIR.0000000000000625.html#108">-26)</a>, </text>
<text top="607" left="135" width="680" height="21" font="5">and with subclinical atherosclerosis into young adulthood (S4.4.4.3<a href="CIR.0000000000000625.html#109">-38,</a> S4.4.4.3<a href="CIR.0000000000000625.html#109">-39)</a>, occur at higher </text>
<text top="627" left="135" width="680" height="21" font="5">rates than in lean and otherwise healthy children and adolescents. Longitudinal cohort data show </text>
<text top="648" left="135" width="679" height="21" font="5">moderate tracking of cardiovascular risk factors from childhood to adulthood in the general pediatric </text>
<text top="668" left="135" width="684" height="21" font="5">population  (S4.4.4.3<a href="CIR.0000000000000625.html#109">-40)</a>, suggesting some persistence  of the underlying pathophysiology and </text>
<text top="688" left="135" width="402" height="21" font="5">potential benefit of identifying lipid disorders in childhood.  </text>
<text top="708" left="108" width="702" height="21" font="5">7.  Selective screening for lipid disorders on the basis of family history (Recommendation 1) or lifestyle-</text>
<text top="728" left="135" width="683" height="21" font="5">related factors (Recommendation  2) identifies only a portion of childhood lipid abnormalities </text>
<text top="748" left="135" width="679" height="21" font="5">(S4.4.4.3<a href="CIR.0000000000000625.html#108">-19,</a> S4.4.4.3<a href="CIR.0000000000000625.html#108">-21,</a> S4.4.4.3<a href="CIR.0000000000000625.html#108">-26)</a> (Table 9). Therefore, concordant with the 2011 National Heart, </text>
<text top="768" left="135" width="680" height="21" font="5">Lung, and Blood Institute Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk </text>
<text top="789" left="135" width="682" height="21" font="5">Reduction in Children and Adolescents  (S4.4.4.3<a href="CIR.0000000000000625.html#109">-41)</a>,  universal pediatric lipid screening has been </text>
<text top="809" left="135" width="679" height="21" font="5">advised in recent pediatric guidelines (S4.4.4.3<a href="CIR.0000000000000625.html#109">-42)</a>, specifically focusing on ages 9 to 11 years and </text>
<text top="829" left="135" width="679" height="21" font="5">then ages 17 to 21 years because TC and LDL-C levels decrease 10% to 20% during puberty. However, </text>
<text top="849" left="135" width="679" height="21" font="5">the long-term benefits and harms of universal screening have not been tested in RCTs. Observational </text>
<text top="869" left="135" width="679" height="21" font="5">studies demonstrate that  universal screening can identify severe lipid abnormalities (S4.4.4.3<a href="CIR.0000000000000625.html#108">-18,</a> </text>
<text top="889" left="135" width="682" height="21" font="5">S4.4.4.3<a href="CIR.0000000000000625.html#108">-19)</a>, and in scant data universal screening is associated with changes in family lifestyle </text>
<text top="909" left="135" width="679" height="21" font="5">behaviors. Nonfasting lipid parameters are similar to fasting ones, and screening with a nonfasting </text>
<text top="930" left="135" width="679" height="21" font="5">non–HDL-C is a reasonable approach to population screening in childhood. Although research on this </text>
<text top="950" left="135" width="679" height="21" font="5">topic continues, universal screening may be reasonable given the substantial benefits of identifying </text>
<text top="970" left="135" width="681" height="21" font="5">severe hypercholesterolemia (see Section 4.2., “Severe Hypercholesterolemia”),  including  FH, and </text>
<text top="990" left="135" width="675" height="21" font="5">possible  benefits of lifestyle counseling for multifactorial dyslipidemias  (S4.4.4.3<a href="CIR.0000000000000625.html#107">-3,</a>  S4.4.4.3<a href="CIR.0000000000000625.html#107">-5–</a></text>
<text top="1010" left="135" width="413" height="21" font="5"><a href="CIR.0000000000000625.html#107">S4.4.4.3-9,</a> S4.4.4.3<a href="CIR.0000000000000625.html#108">-25,</a> S4.4.4.3<a href="CIR.0000000000000625.html#108">-26,</a> S4.4.4.3<a href="CIR.0000000000000625.html#109">-38–S4.4.4.3-40)</a>. </text>
<text top="1030" left="108" width="4" height="21" font="5"> </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="48" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-48_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 48</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="395" height="21" font="4"><b>Table 9. Normal and Abnormal Lipid Values in Childhood*</b></text>
<text top="125" left="503" width="7" height="19" font="1">†</text>
<text top="124" left="510" width="4" height="21" font="5"> </text>
<text top="144" left="108" width="4" height="21" font="5"> </text>
<text top="180" left="114" width="3" height="19" font="0"><b> </b></text>
<text top="171" left="317" width="80" height="19" font="0"><b>Acceptable,  </b></text>
<text top="189" left="334" width="44" height="19" font="0"><b>mg/dL </b></text>
<text top="171" left="505" width="76" height="19" font="0"><b>Borderline,  </b></text>
<text top="189" left="519" width="44" height="19" font="0"><b>mg/dL </b></text>
<text top="171" left="692" width="72" height="19" font="0"><b>Abnormal,  </b></text>
<text top="189" left="705" width="44" height="19" font="0"><b>mg/dL </b></text>
<text top="228" left="114" width="15" height="19" font="0"><b>TC</b></text>
<text top="227" left="130" width="4" height="21" font="5"> </text>
<text top="228" left="300" width="108" height="19" font="1">&lt;170 (&lt;4.3 mmol)</text>
<text top="227" left="408" width="4" height="21" font="5"> </text>
<text top="228" left="467" width="50" height="19" font="1">170-199</text>
<text top="225" left="517" width="4" height="23" font="14"> </text>
<text top="228" left="521" width="90" height="19" font="1">(4.3-5.1 mmol)</text>
<text top="227" left="612" width="4" height="21" font="5"> </text>
<text top="228" left="671" width="30" height="19" font="1">≥200</text>
<text top="225" left="701" width="4" height="23" font="14"> </text>
<text top="228" left="705" width="74" height="19" font="1">(≥5.1 mmol)</text>
<text top="227" left="780" width="4" height="21" font="5"> </text>
<text top="275" left="114" width="122" height="19" font="0"><b>Triglycerides (0-9 y)</b></text>
<text top="274" left="236" width="4" height="21" font="5"> </text>
<text top="275" left="303" width="23" height="19" font="1">&lt;75</text>
<text top="272" left="326" width="4" height="23" font="14"> </text>
<text top="275" left="330" width="74" height="19" font="1">(&lt;0.8 mmol)</text>
<text top="274" left="404" width="4" height="21" font="5"> </text>
<text top="275" left="474" width="35" height="19" font="1">75-99</text>
<text top="272" left="509" width="4" height="23" font="14"> </text>
<text top="275" left="513" width="90" height="19" font="1">(0.8-1.1 mmol)</text>
<text top="274" left="604" width="4" height="21" font="5"> </text>
<text top="275" left="671" width="30" height="19" font="1">≥100</text>
<text top="272" left="701" width="4" height="23" font="14"> </text>
<text top="275" left="705" width="74" height="19" font="1">(≥1.1 mmol)</text>
<text top="274" left="780" width="4" height="21" font="5"> </text>
<text top="322" left="114" width="137" height="19" font="0"><b>Triglycerides (10-19 y)</b></text>
<text top="321" left="251" width="4" height="21" font="5"> </text>
<text top="322" left="303" width="23" height="19" font="1">&lt;90</text>
<text top="319" left="326" width="4" height="23" font="14"> </text>
<text top="322" left="330" width="74" height="19" font="1">(&lt;1.0 mmol)</text>
<text top="321" left="404" width="4" height="21" font="5"> </text>
<text top="322" left="471" width="42" height="19" font="1">90-129</text>
<text top="319" left="513" width="4" height="23" font="14"> </text>
<text top="322" left="517" width="90" height="19" font="1">(1.0-1.5 mmol)</text>
<text top="321" left="608" width="4" height="21" font="5"> </text>
<text top="322" left="671" width="30" height="19" font="1">≥130</text>
<text top="319" left="701" width="4" height="23" font="14"> </text>
<text top="322" left="705" width="74" height="19" font="1">(≥1.4 mmol)</text>
<text top="321" left="780" width="4" height="21" font="5"> </text>
<text top="361" left="114" width="38" height="19" font="0"><b>HDL-C</b></text>
<text top="360" left="152" width="4" height="21" font="5"> </text>
<text top="361" left="303" width="23" height="19" font="1">&gt;45</text>
<text top="358" left="326" width="4" height="23" font="14"> </text>
<text top="361" left="330" width="74" height="19" font="1">(&gt;1.2 mmol)</text>
<text top="360" left="404" width="4" height="21" font="5"> </text>
<text top="361" left="474" width="35" height="19" font="1">40-45</text>
<text top="358" left="509" width="4" height="23" font="14"> </text>
<text top="361" left="513" width="90" height="19" font="1">(1.0-1.2 mmol)</text>
<text top="360" left="604" width="4" height="21" font="5"> </text>
<text top="361" left="675" width="23" height="19" font="1">&lt;40</text>
<text top="358" left="697" width="4" height="23" font="14"> </text>
<text top="361" left="701" width="74" height="19" font="1">(&lt;1.0 mmol)</text>
<text top="360" left="776" width="4" height="21" font="5"> </text>
<text top="400" left="114" width="35" height="19" font="0"><b>LDL-C</b></text>
<text top="399" left="149" width="4" height="21" font="5"> </text>
<text top="400" left="299" width="30" height="19" font="1">&lt;110</text>
<text top="397" left="329" width="4" height="23" font="14"> </text>
<text top="400" left="334" width="74" height="19" font="1">(&lt;2.8 mmol)</text>
<text top="399" left="408" width="4" height="21" font="5"> </text>
<text top="400" left="467" width="50" height="19" font="1">110-129</text>
<text top="397" left="517" width="4" height="23" font="14"> </text>
<text top="400" left="521" width="90" height="19" font="1">(2.8-3.3 mmol)</text>
<text top="399" left="612" width="4" height="21" font="5"> </text>
<text top="400" left="671" width="30" height="19" font="1">≥130</text>
<text top="397" left="701" width="4" height="23" font="14"> </text>
<text top="400" left="705" width="74" height="19" font="1">(≥3.4 mmol)</text>
<text top="399" left="780" width="4" height="21" font="5"> </text>
<text top="447" left="114" width="71" height="19" font="0"><b>Non–HDL-C</b></text>
<text top="445" left="186" width="4" height="21" font="5"> </text>
<text top="447" left="299" width="30" height="19" font="1">&lt;120</text>
<text top="444" left="329" width="4" height="23" font="14"> </text>
<text top="447" left="334" width="74" height="19" font="1">(&lt;3.1 mmol)</text>
<text top="445" left="408" width="4" height="21" font="5"> </text>
<text top="447" left="467" width="50" height="19" font="1">120-144</text>
<text top="444" left="517" width="4" height="23" font="14"> </text>
<text top="447" left="521" width="90" height="19" font="1">(3.1-3.7 mmol)</text>
<text top="445" left="612" width="4" height="21" font="5"> </text>
<text top="447" left="671" width="30" height="19" font="1">≥145</text>
<text top="444" left="701" width="4" height="23" font="14"> </text>
<text top="447" left="705" width="74" height="19" font="1">(≥3.7 mmol)</text>
<text top="445" left="780" width="4" height="21" font="5"> </text>
<text top="480" left="108" width="706" height="19" font="1">*Values for plasma lipid and lipoprotein levels are from the NCEP Expert Panel on Cholesterol Levels in Children. </text>
<text top="498" left="108" width="691" height="19" font="1">Non–HDL-C values from the Bogalusa Heart Study are equivalent to the NCEP Pediatric Panel cutpoints for LDL-C. </text>
<text top="517" left="108" width="706" height="19" font="1">†The cutpoints for high and borderline high represent approximately the 95th and 75th percentiles, respectively. </text>
<text top="535" left="108" width="429" height="19" font="1">Low cutpoints for HDL-C represent approximately the 10th percentile. </text>
<text top="553" left="108" width="705" height="19" font="1">Values given are in mg/dL. To convert to SI units, divide the results for TC, LDL-C, HDL-C, and non–HDL-C by 38.6; for </text>
<text top="571" left="108" width="174" height="19" font="1">triglycerides, divide by 88.6. </text>
<text top="590" left="108" width="708" height="19" font="1">HDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NCEP, National </text>
<text top="608" left="108" width="707" height="19" font="1">Cholesterol Education Program; SI, <i>Système international d'unités</i>  (International System of Units); and TC, total </text>
<text top="626" left="108" width="75" height="19" font="1">cholesterol. </text>
<text top="644" left="108" width="4" height="21" font="5"> </text>
<text top="665" left="108" width="4" height="21" font="5"> </text>
<text top="697" left="108" width="283" height="29" font="2"><b>4.5. Other Populations at Risk </b></text>
<text top="737" left="108" width="134" height="27" font="16"><i><b>4.5.1. Ethnicity </b></i></text>
<text top="783" left="297" width="328" height="21" font="4"><b>Recommendation for Other Populations at Risk </b></text>
<text top="806" left="114" width="494" height="21" font="5">Referenced studies that support the recommendation are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625"> </a></text>
<text top="806" left="608" width="199" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Online Data Supplements 24, </a></text>
<text top="829" left="372" width="169" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">25, 26, 27, 28, 29, and 30</a></text>
<text top="829" left="541" width="8" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">.</a><b> </b></text>
<text top="865" left="123" width="33" height="21" font="4"><b>COR </b></text>
<text top="865" left="189" width="30" height="21" font="4"><b>LOE </b></text>
<text top="865" left="464" width="126" height="21" font="4"><b>Recommendation </b></text>
<text top="938" left="130" width="21" height="21" font="4"><b>IIa </b></text>
<text top="938" left="185" width="38" height="21" font="4"><b>B-NR </b></text>
<text top="911" left="242" width="571" height="21" font="4"><b>1.  For  clinical decision-making in adults of different race/ethnicities, it is </b></text>
<text top="933" left="269" width="541" height="21" font="4"><b>reasonable for clinicians to review race/ethnic  features that can influence </b></text>
<text top="954" left="269" width="538" height="21" font="4"><b>ASCVD risk (S4.5.1<a href="CIR.0000000000000625.html#109">-1)</a></b><b> so as to adjust choice of statin or intensity of treatment </b></text>
<text top="976" left="269" width="137" height="21" font="4"><b>(S4.5.1<a href="CIR.0000000000000625.html#109">-1–S4.5.1-4)</a></b><b>. </b></text>
<text top="1006" left="108" width="4" height="21" font="5"> </text>
<text top="1035" left="108" width="4" height="21" font="4"><b> </b></text>
<text top="1035" left="324" width="4" height="21" font="4"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="49" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-49_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 49</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="63" height="21" font="4"><b>Synopsis </b></text>
<text top="163" left="108" width="707" height="21" font="5">Race/ethnicity factors can influence estimations of ASCVD risk (S4.5.1–S4.5.1<a href="CIR.0000000000000625.html#109">-4)</a>, intensity of treatment </text>
<text top="183" left="108" width="705" height="21" font="5">(S4.5.1<a href="CIR.0000000000000625.html#109">-1–S4.5.1-4)</a> or even lipid drug use (S4.5.1<a href="CIR.0000000000000625.html#109">-5,</a> S4.5.1<a href="CIR.0000000000000625.html#109">-6)</a>. Important examples include the heightened </text>
<text top="203" left="108" width="708" height="21" font="5">risk of ASCVD in those who identify as South Asians, the increased sensitivity to statins in those who </text>
<text top="223" left="108" width="706" height="21" font="5">identify as East Asians, and the increased prevalence of hypertension in blacks. An important issue in </text>
<text top="244" left="108" width="706" height="21" font="5">management of ASCVD risk in those who identify as Hispanics/Latinos in the United States is the lack of </text>
<text top="264" left="108" width="705" height="21" font="5">specificity of the term Hispanic/Latino. Race/ethnicity and country of origin, together with socioeconomic </text>
<text top="284" left="108" width="708" height="21" font="5">status and acculturation level,  should be discussed and may explain ASCVD risk factor burden more </text>
<text top="304" left="108" width="707" height="21" font="5">precisely than the generic term Hispanic/Latino (S4.5.1<a href="CIR.0000000000000625.html#109">-6–S4.5.1-11)</a>. In addition, those who identify as </text>
<text top="324" left="108" width="706" height="21" font="5">Native American/Alaskan natives have high rates of risk factors for ASCVD compared to non-Hispanic </text>
<text top="344" left="108" width="706" height="21" font="5">whites. In many ways, the increase in metabolic risk factors and propensity for diabetes mellitus </text>
<text top="365" left="108" width="705" height="21" font="5">resembles the risk profiles of those who identify as Mexican-Americans (S4.5.1<a href="CIR.0000000000000625.html#110">-12)</a>. Table 10 reviews these </text>
<text top="385" left="108" width="493" height="21" font="5">and other racial/ethnic issues that may be useful in clinical management. </text>
<text top="414" left="108" width="4" height="21" font="5"> </text>
<text top="443" left="108" width="612" height="21" font="4"><b>Table 10.</b> <b>Racial/Ethnic Issues in Evaluation, Risk Decisions, and Treatment of ASCVD Risk </b></text>
<text top="463" left="108" width="4" height="21" font="5"> </text>
<text top="484" left="116" width="3" height="19" font="0"><b> </b></text>
<text top="484" left="445" width="153" height="19" font="0"><b>Racial/Ethnic Groupings </b></text>
<text top="503" left="116" width="3" height="19" font="0"><b> </b></text>
<text top="503" left="237" width="107" height="19" font="0"><b>Asian Americans </b></text>
<text top="522" left="237" width="104" height="19" font="0"><b>(S4.5.1<a href="CIR.0000000000000625.html#109">-4, </a></b><b>S4.5.1-</b></text>
<text top="540" left="237" width="31" height="19" font="0"><a href="CIR.0000000000000625.html#110"><b>13)</b></a><b>* </b></text>
<text top="503" left="371" width="101" height="19" font="0"><b>Hispanic/Latino </b></text>
<text top="522" left="371" width="69" height="19" font="0"><b>Americans </b></text>
<text top="540" left="371" width="135" height="19" font="0"><b>(S4.5.1<a href="CIR.0000000000000625.html#109">-7–S4.5.1-11)</a></b>†<b> </b></text>
<text top="503" left="528" width="42" height="19" font="0"><b>Blacks </b></text>
<text top="522" left="528" width="71" height="19" font="0"><b>(S4.5.1<a href="CIR.0000000000000625.html#110">-14)</a></b><b> </b></text>
<text top="503" left="659" width="71" height="19" font="0"><b>Comments </b></text>
<text top="559" left="116" width="69" height="19" font="0"><b>Evaluation </b></text>
<text top="559" left="237" width="3" height="19" font="0"><b> </b></text>
<text top="559" left="371" width="3" height="19" font="0"><b> </b></text>
<text top="559" left="528" width="3" height="19" font="0"><b> </b></text>
<text top="559" left="659" width="3" height="19" font="0"><b> </b></text>
<text top="578" left="116" width="86" height="19" font="0"><b>ASCVD issues </b></text>
<text top="597" left="116" width="80" height="19" font="0"><b>informed by </b></text>
<text top="615" left="116" width="91" height="19" font="0"><b>race/ethnicity</b> </text>
<text top="579" left="237" width="84" height="19" font="1">ASCVD risk in </text>
<text top="597" left="237" width="100" height="19" font="1">people of South </text>
<text top="615" left="237" width="92" height="19" font="1">Asian and East </text>
<text top="633" left="237" width="114" height="19" font="1">Asian origin varies </text>
<text top="652" left="237" width="85" height="19" font="1">by country of </text>
<text top="670" left="237" width="111" height="19" font="1">origin; individuals </text>
<text top="689" left="237" width="100" height="19" font="1">from South Asia </text>
<text top="707" left="237" width="107" height="19" font="1">(see below) have </text>
<text top="725" left="237" width="107" height="19" font="1">increased ASCVD </text>
<text top="743" left="237" width="29" height="19" font="1">risk. </text>
<text top="579" left="371" width="118" height="19" font="1">Race/ethnicity and </text>
<text top="597" left="371" width="108" height="19" font="1">country of origin, </text>
<text top="615" left="371" width="87" height="19" font="1">together with </text>
<text top="633" left="371" width="134" height="19" font="1">socioeconomic status </text>
<text top="652" left="371" width="111" height="19" font="1">and acculturation </text>
<text top="670" left="371" width="137" height="19" font="1">level, may explain risk </text>
<text top="689" left="371" width="123" height="19" font="1">factor burden more </text>
<text top="707" left="371" width="136" height="19" font="1">precisely (e.g., ASCVD </text>
<text top="725" left="371" width="125" height="19" font="1">risk is higher among </text>
<text top="743" left="371" width="102" height="19" font="1">individuals from </text>
<text top="762" left="371" width="143" height="19" font="1">Puerto Rico than those </text>
<text top="780" left="371" width="89" height="19" font="1">from Mexico). </text>
<text top="579" left="528" width="69" height="19" font="1">ASCVD risk </text>
<text top="597" left="528" width="89" height="19" font="1">assessment in </text>
<text top="615" left="528" width="84" height="19" font="1">black women </text>
<text top="633" left="528" width="104" height="19" font="1">shows increased </text>
<text top="652" left="528" width="69" height="19" font="1">ASCVD risk </text>
<text top="670" left="528" width="96" height="19" font="1">compared with </text>
<text top="689" left="528" width="97" height="19" font="1">their otherwise </text>
<text top="707" left="528" width="82" height="19" font="1">similar white </text>
<text top="725" left="528" width="86" height="19" font="1">counterparts. </text>
<text top="579" left="659" width="141" height="19" font="1">There is heterogeneity </text>
<text top="597" left="659" width="118" height="19" font="1">in risk according to </text>
<text top="615" left="659" width="119" height="19" font="1">racial/ethnic group </text>
<text top="633" left="659" width="68" height="19" font="1">and within </text>
<text top="652" left="659" width="129" height="19" font="1">racial/ethnic groups. </text>
<text top="670" left="659" width="43" height="19" font="1">Native </text>
<text top="689" left="659" width="114" height="19" font="1">American/Alaskan </text>
<text top="707" left="659" width="138" height="19" font="1">populations have high </text>
<text top="725" left="659" width="141" height="19" font="1">rates of risk factors for </text>
<text top="743" left="659" width="126" height="19" font="1">ASCVD compared to </text>
<text top="762" left="659" width="131" height="19" font="1">non-Hispanic whites. </text>
<text top="780" left="659" width="70" height="19" font="1">(S4.5.1<a href="CIR.0000000000000625.html#110">-12)</a> </text>
<text top="808" left="116" width="74" height="19" font="0"><b>Lipid issues </b></text>
<text top="826" left="116" width="80" height="19" font="0"><b>informed by </b></text>
<text top="845" left="116" width="91" height="19" font="0"><b>race/ethnicity </b></text>
<text top="863" left="116" width="70" height="19" font="0"><b>(S4.5.1<a href="CIR.0000000000000625.html#110">-15, </a></b></text>
<text top="881" left="116" width="69" height="19" font="0"><b>S4.5.1<a href="CIR.0000000000000625.html#110">-16)</a></b><b>  </b></text>
<text top="808" left="237" width="104" height="19" font="1">Asian Americans </text>
<text top="826" left="237" width="109" height="19" font="1">have lower levels </text>
<text top="845" left="237" width="88" height="19" font="1">of HDL-C than </text>
<text top="863" left="237" width="51" height="19" font="1">whites.  </text>
<text top="881" left="237" width="94" height="19" font="1">There is higher </text>
<text top="900" left="237" width="86" height="19" font="1">prevalence of </text>
<text top="918" left="237" width="120" height="19" font="1">LDL-C among Asian </text>
<text top="936" left="237" width="108" height="19" font="1">Indians, Filipinos, </text>
<text top="955" left="237" width="89" height="19" font="1">Japanese, and </text>
<text top="973" left="237" width="107" height="19" font="1">Vietnamese than </text>
<text top="991" left="237" width="113" height="19" font="1">among whites. An </text>
<text top="1009" left="237" width="62" height="19" font="1">increased </text>
<text top="1028" left="237" width="116" height="19" font="1">prevalence of high </text>
<text top="1046" left="237" width="111" height="19" font="1">TG was seen in all </text>
<text top="1064" left="237" width="98" height="19" font="1">Asian American </text>
<text top="1083" left="237" width="74" height="19" font="1">subgroups.  </text>
<text top="808" left="371" width="98" height="19" font="1">Hispanic/Latino </text>
<text top="826" left="371" width="124" height="19" font="1">women have higher </text>
<text top="845" left="371" width="112" height="19" font="1">prevalence of low </text>
<text top="863" left="371" width="136" height="19" font="1">HDL-C compared with </text>
<text top="881" left="371" width="133" height="19" font="1">Hispanic/Latino men. </text>
<text top="808" left="528" width="116" height="19" font="1">Blacks have higher </text>
<text top="826" left="528" width="94" height="19" font="1">levels of HDL-C </text>
<text top="845" left="528" width="118" height="19" font="1">and lower levels of </text>
<text top="863" left="528" width="109" height="19" font="1">triglycerides than </text>
<text top="881" left="528" width="83" height="19" font="1">non-Hispanic </text>
<text top="900" left="528" width="115" height="19" font="1">whites or Mexican </text>
<text top="918" left="528" width="71" height="19" font="1">Americans. </text>
<text top="808" left="659" width="106" height="19" font="1">All ethnic groups </text>
<text top="826" left="659" width="145" height="19" font="1">appear to be at greater </text>
<text top="845" left="659" width="130" height="19" font="1">risk for dyslipidemia, </text>
<text top="863" left="659" width="106" height="19" font="1">but important to </text>
<text top="881" left="659" width="118" height="19" font="1">identify those with </text>
<text top="900" left="659" width="100" height="19" font="1">more sedentary </text>
<text top="918" left="659" width="109" height="19" font="1">behavior and less </text>
<text top="936" left="659" width="95" height="19" font="1">favorable diet.  </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="50" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-50_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 50</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="125" left="116" width="107" height="19" font="0"><b>Metabolic issues </b></text>
<text top="143" left="116" width="80" height="19" font="0"><b>informed by </b></text>
<text top="161" left="116" width="91" height="19" font="0"><b>race/ethnicity </b></text>
<text top="180" left="116" width="104" height="19" font="0"><b>(S4.5.1<a href="CIR.0000000000000625.html#109">-3, </a></b><b>S4.5.1-</b></text>
<text top="198" left="116" width="88" height="19" font="0"><a href="CIR.0000000000000625.html#110"><b>17, </b></a><b>S4.5.1<a href="CIR.0000000000000625.html#110">-18)</a></b><b> </b></text>
<text top="125" left="237" width="111" height="19" font="1">Increased MetS is </text>
<text top="143" left="237" width="101" height="19" font="1">seen with lower </text>
<text top="161" left="237" width="35" height="19" font="1">waist </text>
<text top="180" left="237" width="91" height="19" font="1">circumference </text>
<text top="198" left="237" width="94" height="19" font="1">than in whites. </text>
<text top="217" left="237" width="110" height="19" font="1">DM develops at a </text>
<text top="235" left="237" width="101" height="19" font="1">lower lean body </text>
<text top="253" left="237" width="119" height="19" font="1">mass and at earlier </text>
<text top="271" left="237" width="100" height="19" font="1">ages (S4.5.1<a href="CIR.0000000000000625.html#110">-19–</a></text>
<text top="290" left="237" width="69" height="19" font="1"><a href="CIR.0000000000000625.html#110">S4.5.1-21)</a>. </text>
<text top="308" left="237" width="111" height="19" font="1">Majority of risk in </text>
<text top="326" left="237" width="94" height="19" font="1">South Asians is </text>
<text top="345" left="237" width="81" height="19" font="1">explained by </text>
<text top="363" left="237" width="118" height="19" font="1">known risk factors, </text>
<text top="381" left="237" width="100" height="19" font="1">especially those </text>
<text top="400" left="237" width="107" height="19" font="1">related to insulin </text>
<text top="418" left="237" width="111" height="19" font="1">resistance (S4.5.1-</text>
<text top="436" left="237" width="27" height="19" font="1"><a href="CIR.0000000000000625.html#110">13)</a>. </text>
<text top="125" left="371" width="38" height="19" font="1">DM is </text>
<text top="143" left="371" width="117" height="19" font="1">disproportionately </text>
<text top="161" left="371" width="115" height="19" font="1">present compared </text>
<text top="180" left="371" width="101" height="19" font="1">with whites and </text>
<text top="198" left="371" width="96" height="19" font="1">blacks. There is </text>
<text top="217" left="371" width="133" height="19" font="1">increased prevalence </text>
<text top="235" left="371" width="118" height="19" font="1">of MetS and DM in </text>
<text top="253" left="371" width="122" height="19" font="1">Mexican Americans </text>
<text top="271" left="371" width="139" height="19" font="1">compared with whites </text>
<text top="290" left="371" width="120" height="19" font="1">and Puerto Ricans.  </text>
<text top="125" left="528" width="113" height="19" font="1">There is increased </text>
<text top="143" left="528" width="52" height="19" font="1">DM and </text>
<text top="161" left="528" width="88" height="19" font="1">hypertension. </text>
<text top="125" left="659" width="113" height="19" font="1">There is increased </text>
<text top="143" left="659" width="116" height="19" font="1">prevalence of DM. </text>
<text top="161" left="659" width="137" height="19" font="1">Features of MetS vary </text>
<text top="180" left="659" width="111" height="19" font="1">by race/ethnicity. </text>
<text top="198" left="659" width="133" height="19" font="1">Waist circumference, </text>
<text top="217" left="659" width="136" height="19" font="1">not weight, should be </text>
<text top="235" left="659" width="116" height="19" font="1">used to determine </text>
<text top="253" left="659" width="127" height="19" font="1">abdominal adiposity </text>
<text top="271" left="659" width="98" height="19" font="1">when possible.  </text>
<text top="455" left="116" width="91" height="19" font="0"><b>Risk Decisions </b></text>
<text top="455" left="237" width="3" height="19" font="0"><b> </b></text>
<text top="455" left="371" width="3" height="19" font="0"><b> </b></text>
<text top="455" left="528" width="7" height="19" font="0"><b>  </b></text>
<text top="455" left="659" width="3" height="19" font="0"><b> </b></text>
<text top="477" left="116" width="97" height="19" font="0"><b>PCE (S4.5.1<a href="CIR.0000000000000625.html#110">-22- </a></b></text>
<text top="496" left="116" width="69" height="19" font="0"><a href="CIR.0000000000000625.html#110"><b>S4.5.1-25)</b></a><b>  </b></text>
<text top="478" left="237" width="117" height="19" font="1">No separate PCE is </text>
<text top="496" left="237" width="112" height="19" font="1">available; use PCE </text>
<text top="514" left="237" width="95" height="19" font="1">for whites. PCE </text>
<text top="532" left="237" width="29" height="19" font="1">may </text>
<text top="551" left="237" width="93" height="19" font="1">underestimate </text>
<text top="569" left="237" width="84" height="19" font="1">ASCVD risk in </text>
<text top="587" left="237" width="111" height="19" font="1">South Asians. PCE </text>
<text top="606" left="237" width="113" height="19" font="1">may overestimate </text>
<text top="624" left="237" width="110" height="19" font="1">risk in East Asians </text>
<text top="642" left="237" width="77" height="19" font="1">(S4.5.1<a href="CIR.0000000000000625.html#110">-26)</a>.  </text>
<text top="478" left="371" width="117" height="19" font="1">No separate PCE is </text>
<text top="496" left="371" width="133" height="19" font="1">available; use PCE for </text>
<text top="514" left="371" width="142" height="19" font="1">non-Hispanic whites. If </text>
<text top="532" left="371" width="109" height="19" font="1">African-American </text>
<text top="551" left="371" width="96" height="19" font="1">ancestry is also </text>
<text top="569" left="371" width="137" height="19" font="1">present, then use PCE </text>
<text top="587" left="371" width="66" height="19" font="1">for blacks. </text>
<text top="478" left="528" width="115" height="19" font="1">Use PCE for blacks </text>
<text top="496" left="528" width="73" height="19" font="1">(S4.5.1-10). </text>
<text top="478" left="659" width="102" height="19" font="1">Country-specific </text>
<text top="496" left="659" width="129" height="19" font="1">race/ethnicity, along </text>
<text top="514" left="659" width="124" height="19" font="1">with socioeconomic </text>
<text top="532" left="659" width="112" height="19" font="1">status, may affect </text>
<text top="551" left="659" width="127" height="19" font="1">estimation of risk by </text>
<text top="569" left="659" width="34" height="19" font="1">PCE.  </text>
<text top="661" left="116" width="65" height="19" font="0"><b>CAC score </b></text>
<text top="680" left="116" width="70" height="19" font="0"><b>(S4.5.1<a href="CIR.0000000000000625.html#111">-27–</a></b></text>
<text top="698" left="116" width="69" height="19" font="0"><a href="CIR.0000000000000625.html#111"><b>S4.5.1-30)</b></a><b>  </b></text>
<text top="661" left="237" width="98" height="19" font="1">In terms of CAC </text>
<text top="680" left="237" width="90" height="19" font="1">burden, South </text>
<text top="698" left="237" width="101" height="19" font="1">Asian men were </text>
<text top="716" left="237" width="89" height="19" font="1">similar to non-</text>
<text top="735" left="237" width="93" height="19" font="1">Hispanic white </text>
<text top="753" left="237" width="101" height="19" font="1">men, but higher </text>
<text top="771" left="237" width="97" height="19" font="1">CAC when than </text>
<text top="789" left="237" width="95" height="19" font="1">blacks, Latinos, </text>
<text top="808" left="237" width="77" height="19" font="1">and Chinese </text>
<text top="826" left="237" width="110" height="19" font="1">Americans. South </text>
<text top="845" left="237" width="112" height="19" font="1">Asian women had </text>
<text top="863" left="237" width="114" height="19" font="1">similar CAC scores </text>
<text top="881" left="237" width="86" height="19" font="1">to whites and </text>
<text top="899" left="237" width="117" height="19" font="1">other racial/ethnic </text>
<text top="918" left="237" width="111" height="19" font="1">women, although </text>
<text top="936" left="237" width="118" height="19" font="1">CAC burden higher </text>
<text top="954" left="237" width="75" height="19" font="1">in older age </text>
<text top="973" left="237" width="73" height="19" font="1">(S4.5.1<a href="CIR.0000000000000625.html#111">-31)</a>. </text>
<text top="661" left="371" width="135" height="19" font="1">CAC predicts similarly </text>
<text top="680" left="371" width="137" height="19" font="1">in whites and in those </text>
<text top="698" left="371" width="96" height="19" font="1">who identify as </text>
<text top="716" left="371" width="105" height="19" font="1">Hispanic/Latino.  </text>
<text top="661" left="528" width="86" height="19" font="1">In MESA, CAC </text>
<text top="680" left="528" width="111" height="19" font="1">score was highest </text>
<text top="698" left="528" width="79" height="19" font="1">in white and </text>
<text top="716" left="528" width="89" height="19" font="1">Hispanic men, </text>
<text top="735" left="528" width="115" height="19" font="1">with blacks having </text>
<text top="753" left="528" width="114" height="19" font="1">significantly lower </text>
<text top="771" left="528" width="97" height="19" font="1">prevalence and </text>
<text top="789" left="528" width="99" height="19" font="1">severity of CAC. </text>
<text top="661" left="659" width="139" height="19" font="1">Risk factor differences </text>
<text top="680" left="659" width="111" height="19" font="1">in MESA between </text>
<text top="698" left="659" width="143" height="19" font="1">ethnicities did not fully </text>
<text top="716" left="659" width="125" height="19" font="1">explain variability in </text>
<text top="735" left="659" width="122" height="19" font="1">CAC. However, CAC </text>
<text top="753" left="659" width="107" height="19" font="1">predicted ASCVD </text>
<text top="771" left="659" width="141" height="19" font="1">events over and above </text>
<text top="789" left="659" width="137" height="19" font="1">traditional risk factors </text>
<text top="808" left="659" width="99" height="19" font="1">in all ethnicities </text>
<text top="826" left="659" width="73" height="19" font="1">(S4.5.1<a href="CIR.0000000000000625.html#111">-32)</a>. </text>
<text top="1001" left="116" width="69" height="19" font="0"><b>Treatment </b></text>
<text top="1001" left="237" width="3" height="19" font="1"> </text>
<text top="1001" left="371" width="3" height="19" font="1"> </text>
<text top="1001" left="528" width="3" height="19" font="1"> </text>
<text top="1001" left="659" width="3" height="19" font="1"> </text>
<text top="1024" left="116" width="55" height="19" font="0"><b>Lifestyle </b></text>
<text top="1042" left="116" width="100" height="19" font="0"><b>counseling (use </b></text>
<text top="1060" left="116" width="80" height="19" font="0"><b>principles of </b></text>
<text top="1024" left="237" width="77" height="19" font="1">Use lifestyle </text>
<text top="1042" left="237" width="85" height="19" font="1">counseling to </text>
<text top="1060" left="237" width="88" height="19" font="1">recommend a </text>
<text top="1079" left="237" width="114" height="19" font="1">heart-healthy diet </text>
<text top="1024" left="371" width="77" height="19" font="1">Use lifestyle </text>
<text top="1042" left="371" width="85" height="19" font="1">counseling to </text>
<text top="1060" left="371" width="125" height="19" font="1">recommend a heart-</text>
<text top="1079" left="371" width="142" height="19" font="1">healthy diet consistent </text>
<text top="1024" left="528" width="77" height="19" font="1">Use lifestyle </text>
<text top="1042" left="528" width="85" height="19" font="1">counseling to </text>
<text top="1060" left="528" width="88" height="19" font="1">recommend a </text>
<text top="1079" left="528" width="114" height="19" font="1">heart-healthy diet </text>
<text top="1024" left="659" width="63" height="19" font="1">Asian and </text>
<text top="1042" left="659" width="143" height="19" font="1">Hispanic/Latino groups </text>
<text top="1060" left="659" width="69" height="19" font="1">need to be </text>
<text top="1079" left="659" width="143" height="19" font="1">disaggregated because </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="51" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-51_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 51</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="125" left="116" width="98" height="19" font="0"><b>Mediterranean </b></text>
<text top="143" left="116" width="104" height="19" font="0"><b>and DASH diets) </b></text>
<text top="125" left="237" width="97" height="19" font="1">consistent with </text>
<text top="143" left="237" width="80" height="19" font="1">racial/ethnic </text>
<text top="161" left="237" width="93" height="19" font="1">preferences to </text>
<text top="180" left="237" width="110" height="19" font="1">avoid weight gain </text>
<text top="198" left="237" width="96" height="19" font="1">and address BP </text>
<text top="217" left="237" width="65" height="19" font="1">and lipids. </text>
<text top="125" left="371" width="110" height="19" font="1">with racial/ethnic </text>
<text top="143" left="371" width="129" height="19" font="1">preferences to avoid </text>
<text top="161" left="371" width="100" height="19" font="1">weight gain and </text>
<text top="180" left="371" width="135" height="19" font="1">address BP and lipids. </text>
<text top="125" left="528" width="96" height="19" font="1">consistent with </text>
<text top="143" left="528" width="80" height="19" font="1">racial/ethnic </text>
<text top="161" left="528" width="93" height="19" font="1">preferences to </text>
<text top="180" left="528" width="110" height="19" font="1">avoid weight gain </text>
<text top="198" left="528" width="96" height="19" font="1">and address BP </text>
<text top="217" left="528" width="65" height="19" font="1">and lipids. </text>
<text top="125" left="659" width="140" height="19" font="1">of regional differences </text>
<text top="143" left="659" width="146" height="19" font="1">in lifestyle preferences. </text>
<text top="161" left="659" width="129" height="19" font="1">Challenge is to avoid </text>
<text top="180" left="659" width="114" height="19" font="1">increased sodium, </text>
<text top="198" left="659" width="133" height="19" font="1">sugar, and calories as </text>
<text top="217" left="659" width="121" height="19" font="1">groups acculturate. </text>
<text top="235" left="116" width="74" height="19" font="0"><b>Intensity of </b></text>
<text top="254" left="116" width="91" height="19" font="0"><b>statin therapy </b></text>
<text top="272" left="116" width="104" height="19" font="0"><b>and response to </b></text>
<text top="290" left="116" width="96" height="19" font="0"><b>LDL-C lowering </b></text>
<text top="235" left="237" width="112" height="19" font="1">Japanese patients </text>
<text top="254" left="237" width="105" height="19" font="1">may be sensitive </text>
<text top="272" left="237" width="116" height="19" font="1">to statin dosing. In </text>
<text top="291" left="237" width="91" height="19" font="1">an open-label, </text>
<text top="309" left="237" width="76" height="19" font="1">randomized </text>
<text top="327" left="237" width="52" height="19" font="1">primary-</text>
<text top="345" left="237" width="102" height="19" font="1">prevention trial, </text>
<text top="364" left="237" width="59" height="19" font="1">Japanese </text>
<text top="382" left="237" width="113" height="19" font="1">participants had a </text>
<text top="400" left="237" width="106" height="19" font="1">reduction in CVD </text>
<text top="419" left="237" width="101" height="19" font="1">events with low-</text>
<text top="437" left="237" width="110" height="19" font="1">intensity doses of </text>
<text top="455" left="237" width="88" height="19" font="1">pravastatin as </text>
<text top="474" left="237" width="96" height="19" font="1">compared with </text>
<text top="492" left="237" width="98" height="19" font="1">placebo (S4.5.1-</text>
<text top="510" left="237" width="53" height="19" font="1"><a href="CIR.0000000000000625.html#111">33)</a>. In a </text>
<text top="528" left="237" width="67" height="19" font="1">secondary-</text>
<text top="547" left="237" width="102" height="19" font="1">prevention trial, </text>
<text top="565" left="237" width="59" height="19" font="1">Japanese </text>
<text top="583" left="237" width="106" height="19" font="1">participants with </text>
<text top="602" left="237" width="97" height="19" font="1">CAD benefitted </text>
<text top="620" left="237" width="108" height="19" font="1">from a moderate-</text>
<text top="638" left="237" width="104" height="19" font="1">intensity dose of </text>
<text top="657" left="237" width="75" height="19" font="1">pitavastatin </text>
<text top="675" left="237" width="77" height="19" font="1">(S4.5.1<a href="CIR.0000000000000625.html#111">-34)</a>.  </text>
<text top="235" left="371" width="139" height="19" font="1">No sensitivity to statin </text>
<text top="254" left="371" width="112" height="19" font="1">dosage is seen, as </text>
<text top="272" left="371" width="124" height="19" font="1">compared with non-</text>
<text top="291" left="371" width="109" height="19" font="1">Hispanic white or </text>
<text top="309" left="371" width="107" height="19" font="1">black individuals. </text>
<text top="235" left="528" width="102" height="19" font="1">No sensitivity to </text>
<text top="254" left="528" width="97" height="19" font="1">statin dosage is </text>
<text top="272" left="528" width="117" height="19" font="1">seen, as compared </text>
<text top="291" left="528" width="113" height="19" font="1">with non-Hispanic </text>
<text top="309" left="528" width="110" height="19" font="1">white individuals. </text>
<text top="235" left="659" width="124" height="19" font="1">Using a lower statin </text>
<text top="254" left="659" width="130" height="19" font="1">intensity in Japanese </text>
<text top="272" left="659" width="111" height="19" font="1">patients may give </text>
<text top="291" left="659" width="142" height="19" font="1">results similar to those </text>
<text top="309" left="659" width="105" height="19" font="1">seen with higher </text>
<text top="327" left="659" width="109" height="19" font="1">intensities in non-</text>
<text top="345" left="659" width="119" height="19" font="1">Japanese patients.  </text>
<text top="694" left="116" width="42" height="19" font="0"><b>Safety </b></text>
<text top="694" left="237" width="44" height="19" font="1">Higher </text>
<text top="712" left="237" width="79" height="19" font="1">rosuvastatin </text>
<text top="731" left="237" width="108" height="19" font="1">plasma levels are </text>
<text top="749" left="237" width="109" height="19" font="1">seen in Japanese, </text>
<text top="767" left="237" width="100" height="19" font="1">Chinese, Malay, </text>
<text top="786" left="237" width="110" height="19" font="1">and Asian Indians </text>
<text top="804" left="237" width="112" height="19" font="1">as compared with </text>
<text top="822" left="237" width="113" height="19" font="1">whites (S4.5.1<a href="CIR.0000000000000625.html#111">-35–</a></text>
<text top="841" left="237" width="97" height="19" font="1"><a href="CIR.0000000000000625.html#111">S4.5.1-37)</a>. FDA </text>
<text top="859" left="237" width="94" height="19" font="1">recommends a </text>
<text top="877" left="237" width="121" height="19" font="1">lower starting dose </text>
<text top="896" left="237" width="54" height="19" font="1">(5 mg of </text>
<text top="914" left="237" width="94" height="19" font="1">rosuvastatin in </text>
<text top="932" left="237" width="103" height="19" font="1">Asians versus 10 </text>
<text top="950" left="237" width="89" height="19" font="1">mg in whites). </text>
<text top="969" left="237" width="119" height="19" font="1">Caution is urged as </text>
<text top="987" left="237" width="118" height="19" font="1">dose is uptitrated.  </text>
<text top="694" left="371" width="130" height="19" font="1">There are no specific </text>
<text top="712" left="371" width="111" height="19" font="1">safety issues with </text>
<text top="731" left="371" width="107" height="19" font="1">statins related to </text>
<text top="749" left="371" width="98" height="19" font="1">Hispanic/Latino </text>
<text top="767" left="371" width="130" height="19" font="1">ethnicity (S4.5.1<a href="CIR.0000000000000625.html#111">-38)</a>. </text>
<text top="694" left="528" width="115" height="19" font="1">Baseline serum CK </text>
<text top="712" left="528" width="107" height="19" font="1">values are higher </text>
<text top="731" left="528" width="102" height="19" font="1">in blacks than in </text>
<text top="749" left="528" width="117" height="19" font="1">whites (S4.5.1<a href="CIR.0000000000000625.html#111">-39)</a>. </text>
<text top="767" left="528" width="57" height="19" font="1">The 95th </text>
<text top="786" left="528" width="65" height="19" font="1">percentile </text>
<text top="804" left="528" width="93" height="19" font="1">race/ethnicity- </text>
<text top="822" left="528" width="99" height="19" font="1">specific and sex-</text>
<text top="841" left="528" width="110" height="19" font="1">specific serum CK </text>
<text top="859" left="528" width="108" height="19" font="1">normal levels are </text>
<text top="877" left="528" width="78" height="19" font="1">available for </text>
<text top="896" left="528" width="113" height="19" font="1">assessing changes </text>
<text top="914" left="528" width="80" height="19" font="1">in serum CK. </text>
<text top="694" left="659" width="134" height="19" font="1">Clinicians should take </text>
<text top="712" left="659" width="146" height="19" font="1">Asian race into account </text>
<text top="731" left="659" width="141" height="19" font="1">when prescribing dose </text>
<text top="749" left="659" width="124" height="19" font="1">of rosuvastatin (See </text>
<text top="767" left="659" width="115" height="19" font="1">package insert). In </text>
<text top="786" left="659" width="122" height="19" font="1">adults of East Asian </text>
<text top="804" left="659" width="135" height="19" font="1">descent, other statins </text>
<text top="822" left="659" width="95" height="19" font="1">should be used </text>
<text top="841" left="659" width="117" height="19" font="1">preferentially over </text>
<text top="859" left="659" width="139" height="19" font="1">simvastatin (S4.5.1<a href="CIR.0000000000000625.html#109">-5)</a>. </text>
<text top="1006" left="108" width="8" height="21" font="5">*</text>
<text top="1007" left="116" width="696" height="19" font="1">The term Asian characterizes a diverse portion of the world’s population. Individuals from Bangladesh, India, Nepal, </text>
<text top="1026" left="108" width="705" height="19" font="1">Pakistan, and Sri Lanka make up most of the South Asian group (S.4.5.1<a href="CIR.0000000000000625.html#110">-26)</a>. Individuals from Japan, Korea, and China </text>
<text top="1045" left="108" width="238" height="19" font="1">make up most of the East Asian group. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="52" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="25" size="11" family="Times" color="#000000"/>
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-52_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 52</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="8" height="21" font="5">†</text>
<text top="125" left="116" width="699" height="19" font="1">The term Hispanics/Latinos in the United States characterizes a diverse population group. This includes white, </text>
<text top="144" left="108" width="706" height="19" font="1">black, and Native American races. Their ancestry goes from Europe to America, including among these, individuals </text>
<text top="163" left="108" width="371" height="19" font="1">from the Caribbean, Mexico, and Central and South America.</text>
<text top="161" left="479" width="4" height="21" font="5"> </text>
<text top="181" left="108" width="708" height="19" font="1">ASCVD indicates atherosclerotic cardiovascular disease; BP, blood pressure; CAC, coronary artery calcium; CAD, </text>
<text top="199" left="108" width="709" height="19" font="1">coronary artery disease; CK, creatine kinase; CVD, cardiovascular disease; DASH, Dietary Approaches to Stop </text>
<text top="218" left="108" width="705" height="19" font="1">Hypertension; DM, type 2 diabetes mellitus; FDA, U.S. Food and Drug Administration; HDL-C, high-density lipoprotein </text>
<text top="236" left="108" width="712" height="19" font="1">cholesterol; LDL-C, low-density lipoprotein cholesterol; MESA, Multi-Ethnic Study of Atherosclerosis; MetS, </text>
<text top="254" left="108" width="346" height="19" font="1">metabolic syndrome; and PCE, pooled cohort equations. </text>
<text top="272" left="108" width="4" height="21" font="5"> </text>
<text top="292" left="108" width="4" height="21" font="5"> </text>
<text top="313" left="108" width="247" height="27" font="16"><i><b>4.5.2. Hypertriglyceridemia  </b></i></text>
<text top="355" left="307" width="5" height="16" font="14"> </text>
<text top="352" left="311" width="304" height="21" font="4"><b>Recommendations for Hypertriglyceridemia </b></text>
<text top="372" left="126" width="474" height="21" font="5">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625"> </a></text>
<text top="372" left="600" width="195" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Online Data Supplements 31 </a></text>
<text top="392" left="434" width="46" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">and 32</a></text>
<text top="392" left="480" width="8" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">.</a><b> </b></text>
<text top="413" left="131" width="33" height="21" font="4"><b>COR </b></text>
<text top="413" left="206" width="30" height="21" font="4"><b>LOE </b></text>
<text top="413" left="468" width="132" height="21" font="4"><b>Recommendations </b></text>
<text top="486" left="143" width="8" height="21" font="4"><b>I </b></text>
<text top="486" left="202" width="38" height="21" font="4"><b>B-NR </b></text>
<text top="437" left="264" width="545" height="21" font="4"><b>1.  In adults  20 years  of age or older  with moderate hypertriglyceridemia </b></text>
<text top="457" left="291" width="515" height="21" font="4"><b>(fasting or nonfasting triglycerides 175 to 499 mg/dL [1.9 to 5.6 mmol/L]), </b></text>
<text top="477" left="291" width="515" height="21" font="4"><b>clinicians should address and treat lifestyle factors (obesity and metabolic </b></text>
<text top="497" left="291" width="517" height="21" font="4"><b>syndrome), secondary factors (diabetes mellitus, chronic liver or kidney </b></text>
<text top="517" left="291" width="519" height="21" font="4"><b>disease and/or nephrotic syndrome, hypothyroidism), and medications </b></text>
<text top="537" left="291" width="251" height="21" font="4"><b>that increase triglycerides (S4.5.2<a href="CIR.0000000000000625.html#111">-1)</a></b><b>.</b></text>
<text top="540" left="541" width="3" height="17" font="25"><b> </b></text>
<text top="616" left="137" width="21" height="21" font="4"><b>IIa </b></text>
<text top="616" left="207" width="27" height="21" font="4"><b>B-R </b></text>
<text top="567" left="264" width="553" height="21" font="4"><b>2.   In adults 40 to 75 years of age with moderate or severe </b></text>
<text top="587" left="291" width="515" height="21" font="4"><b>hypertriglyceridemia and ASCVD risk of 7.5% or higher, it is reasonable to </b></text>
<text top="608" left="291" width="516" height="21" font="4"><b>reevaluate ASCVD risk after lifestyle and secondary factors are addressed </b></text>
<text top="628" left="291" width="515" height="21" font="4"><b>and to consider a persistently elevated triglyceride level as a factor favoring </b></text>
<text top="648" left="291" width="511" height="21" font="4"><b>initiation or intensification of statin therapy (see Section 4.4.2.) (S4.5.2<a href="CIR.0000000000000625.html#111">-2–</a></b></text>
<text top="668" left="291" width="72" height="21" font="4"><a href="CIR.0000000000000625.html#111"><b>S4.5.2-6)</b></a><b>.  </b></text>
<text top="727" left="137" width="21" height="21" font="4"><b>IIa </b></text>
<text top="727" left="207" width="27" height="21" font="4"><b>B-R </b></text>
<text top="698" left="264" width="544" height="21" font="4"><b>3.  In adults 40 to 75 years of age with severe hypertriglyceridemia (fasting </b></text>
<text top="718" left="291" width="515" height="21" font="4"><b>triglycerides ≥500 mg/dL [≥5.6 mmol/L]) and ASCVD risk of 7.5% or higher, </b></text>
<text top="738" left="291" width="515" height="21" font="4"><b>it is reasonable to address reversible causes of high triglyceride and  to </b></text>
<text top="758" left="291" width="420" height="21" font="4"><b>initiate statin therapy (S4.5.2<a href="CIR.0000000000000625.html#112">-3–S4.5.2-5, </a></b><b>S4.5.2<a href="CIR.0000000000000625.html#112">-7, </a></b><b>S4.5.2<a href="CIR.0000000000000625.html#112">-8)</a></b><b>.  </b></text>
<text top="857" left="137" width="21" height="21" font="4"><b>IIa </b></text>
<text top="857" left="202" width="38" height="21" font="4"><b>B-NR </b></text>
<text top="788" left="264" width="542" height="21" font="4"><b>4.  In adults with severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL </b></text>
<text top="808" left="291" width="515" height="21" font="4"><b>[≥5.7  mmol/L]),  and  especially  fasting  triglycerides  ≥1000 mg/dL  (11.3 </b></text>
<text top="828" left="291" width="521" height="21" font="4"><b>mmol/L)), it is reasonable to identify and address other causes of </b></text>
<text top="849" left="291" width="520" height="21" font="4"><b>hypertriglyceridemia),  and if triglycerides are persistently elevated or </b></text>
<text top="869" left="291" width="511" height="21" font="4"><b>increasing, to further reduce triglycerides by implementation of a very low-</b></text>
<text top="889" left="291" width="516" height="21" font="4"><b>fat diet, avoidance of refined carbohydrates and alcohol, consumption of </b></text>
<text top="909" left="291" width="515" height="21" font="4"><b>omega-3 fatty acids, and, if necessary to prevent acute pancreatitis, fibrate </b></text>
<text top="929" left="291" width="194" height="21" font="4"><b>therapy (S4.5.2<a href="CIR.0000000000000625.html#112">-7, </a></b><b>S4.5.2<a href="CIR.0000000000000625.html#112">-9)</a></b><b>. </b></text>
<text top="959" left="108" width="4" height="21" font="5"> </text>
<text top="988" left="108" width="63" height="21" font="4"><b>Synopsis </b></text>
<text top="1028" left="108" width="706" height="21" font="5">Two categories of elevated triglycerides consist of moderate hypertriglyceridemia (fasting or nonfasting </text>
<text top="1048" left="108" width="706" height="21" font="5">triglycerides 150-499 mg/dL [1.6-5.6 mmol/L]) and severe hypertriglyceridemia (fasting triglycerides ≥500 </text>
<text top="1068" left="108" width="706" height="21" font="5">mg/dL [≥5.6 mmol/L]). In the former, excess triglycerides are carried in VLDL. In the latter, most patients </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="53" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-53_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 53</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="707" height="21" font="5">have elevated VLDL plus chylomicrons. VLDL are believed to be atherogenic, similar to LDL. There are </text>
<text top="144" left="108" width="707" height="21" font="5">many causes of elevated VLDL, and it is reasonable to reduce their levels to reduce risk of ASCVD. With </text>
<text top="164" left="108" width="706" height="21" font="5">severe hypertriglyceridemia, elevations of VLDL raise risk of ASCVD, but increases in chylomicrons impart </text>
<text top="184" left="108" width="549" height="21" font="5">risk of acute pancreatitis. Therapies should address excesses in both lipoproteins. </text>
<text top="213" left="108" width="295" height="21" font="4"><b>Recommendation-Specific Supportive Text </b></text>
<text top="253" left="108" width="705" height="21" font="5">1.  In patients with moderate hypertriglyceridemia, it is reasonable to reduce both atherogenic VLDL and </text>
<text top="273" left="135" width="680" height="21" font="5">associated risk factors by nonpharmacological means where possible. This can best be achieved by </text>
<text top="293" left="135" width="679" height="21" font="5">identification and treatment of the multiple underlying causes of elevated triglycerides (e.g., lifestyle </text>
<text top="313" left="135" width="683" height="21" font="5">causes, secondary disorders, and triglyceride-raising drugs) (S4.5.2<a href="CIR.0000000000000625.html#111">-1)</a>.  Triglyceride-raising drugs </text>
<text top="333" left="135" width="679" height="21" font="5">include oral estrogens, tamoxifen, raloxifene, retinoids, immunosuppressive drugs (cyclosporine, </text>
<text top="353" left="135" width="681" height="21" font="5">sirolimus, tacrolimus), beta blockers, interferon, atypical antipsychotic drugs, protease inhibitors, </text>
<text top="374" left="135" width="687" height="21" font="5">thiazide diuretics, glucocorticoids, rosiglitazone, bile acid sequestrants, L-asparaginase, and </text>
<text top="394" left="135" width="133" height="21" font="5">cyclophosphamide. </text>
<text top="414" left="108" width="705" height="21" font="5">2.  Most patients with severe hypertriglyceridemia have multiple ASCVD risk factors and are at enhanced </text>
<text top="434" left="135" width="683" height="21" font="5">risk of  developing atherosclerotic disease (S4.5.2<a href="CIR.0000000000000625.html#112">-3–S4.5.2-5,</a>  S4.5.2<a href="CIR.0000000000000625.html#112">-9)</a>. This risk is conveyed by </text>
<text top="454" left="135" width="682" height="21" font="5">atherogenic VLDL plus other factors,  such as obesity, metabolic syndrome, and hyperglycemia. </text>
<text top="474" left="135" width="680" height="21" font="5">Although chylomicronemia per se may not be atherogenic, in most patients it associates with other </text>
<text top="494" left="135" width="680" height="21" font="5">atherogenic factors (S4.5.2<a href="CIR.0000000000000625.html#112">-10–S4.5.2-13)</a>. For this reason, initiation of statin therapy is reasonable. </text>
<text top="514" left="135" width="679" height="21" font="5">We stress that statins alone cannot prevent increasing levels of triglycerides in the face of secondary </text>
<text top="535" left="135" width="680" height="21" font="5">causes (see Recommendation 1) from triggering acute hypertriglyceridemic pancreatitis. Indeed, in </text>
<text top="555" left="135" width="678" height="21" font="5">the pregnant woman with severe hypertriglyceridemia, statins are not part of the treatment regimen </text>
<text top="575" left="135" width="679" height="21" font="5">because they are not recommended at the present time in pregnancy. (See Section 5., “Statin Safety </text>
<text top="595" left="135" width="239" height="21" font="5">and Statin-Associated Side Effects.) </text>
<text top="615" left="108" width="709" height="21" font="5">3.  Epidemiological  studies show that patients with moderate hypertriglyceridemia generally are at </text>
<text top="635" left="135" width="683" height="21" font="5">increased  risk  of  ASCVD  (S4.5.2<a href="CIR.0000000000000625.html#111">-2–S4.5.2-4)</a>. Few studies that primarily recruited patients with </text>
<text top="655" left="135" width="680" height="21" font="5">hypertriglyceridemia have been carried out with triglyceride-lowering drugs. Statin therapy reduces </text>
<text top="676" left="135" width="680" height="21" font="5">VLDL similarly to fibrates (S4.5.2<a href="CIR.0000000000000625.html#112">-5)</a>, and statin trials include hypertriglyceridemic patients. Indeed, </text>
<text top="696" left="135" width="678" height="21" font="5">there is evidence to show that VLDL excess increases the patient’s ASCVD risk and hence benefit from </text>
<text top="716" left="135" width="679" height="21" font="5">statin therapy (S4.5.2<a href="CIR.0000000000000625.html#112">-6)</a>. Therefore, if an adult patient with moderate hypertriglyceridemia has poorly </text>
<text top="736" left="135" width="679" height="21" font="5">controlled major risk factors for ASCVD and a 10-year risk of ASCVD ≥7.5% by the PCE, it is reasonable </text>
<text top="756" left="135" width="679" height="21" font="5">to either initiate or intensify statin therapy. (See Section 4.4.2., “Primary Prevention in Adults 40 to </text>
<text top="776" left="135" width="123" height="21" font="5">75 Years of Age.”) </text>
<text top="797" left="108" width="710" height="21" font="5">4.  Most  patients with triglycerides ≥500 mg/dL (≥5.6  mmol/L)  have elevations of both VLDL and </text>
<text top="817" left="135" width="679" height="21" font="5">chylomicrons. Elevations of chylomicrons typically are present when triglycerides are ≥500 mg/dL </text>
<text top="837" left="135" width="679" height="21" font="5">(≥5.6 mmol/L), and chylomicronemia may cause acute pancreatitis. The higher the triglyceride level, </text>
<text top="857" left="135" width="675" height="21" font="5">the greater is the risk (S4.5.2<a href="CIR.0000000000000625.html#112">-7)</a>. Patients with triglycerides in the 500- to 999-mg/dL (5.6- to 11.2-</text>
<text top="877" left="135" width="680" height="21" font="5">mmol/L) range are at risk of developing unrecognized marked increases in triglycerides, leading to </text>
<text top="897" left="135" width="681" height="21" font="5">pancreatitis. Most cases of severe hypertriglyceridemia have a genetic component, but secondary </text>
<text top="917" left="135" width="679" height="21" font="5">factors may contribute (S4.5.2<a href="CIR.0000000000000625.html#112">-9,</a> S4.5.2<a href="CIR.0000000000000625.html#112">-14)</a>. To prevent acute pancreatitis, it is reasonable to reduce </text>
<text top="937" left="135" width="681" height="21" font="5">triglycerides  whenever levels exceed 500 mg/dL  (5.6 mmol/L). This reduction can be achieved by </text>
<text top="958" left="135" width="679" height="21" font="5">addressing and eliminating the underlying factors as described in Recommendation 1, implementing </text>
<text top="978" left="135" width="679" height="21" font="5">a very low-fat diet (S4.5.2<a href="CIR.0000000000000625.html#112">-9)</a>, and adding fibrates or omega-3 fatty acids for patients with persistently </text>
<text top="998" left="135" width="679" height="21" font="5">elevated severe hypertriglyceridemia  (S4.5.2<a href="CIR.0000000000000625.html#112">-15)</a>. These are the most reliable pharmacological </text>
<text top="1018" left="135" width="680" height="21" font="5">therapies to reduce triglycerides to a safer level. If a fibrate is necessary in a patient being treated </text>
<text top="1038" left="135" width="679" height="21" font="5">with a statin, it is safer to use fenofibrate than gemfibrozil because of lower risk of severe myopathy </text>
<text top="1058" left="135" width="682" height="21" font="5">(S4.5.2<a href="CIR.0000000000000625.html#112">-16)</a>. Severe or life-threatening hypertriglyceridemia during pregnancy is best managed in </text>
<text top="1078" left="135" width="311" height="21" font="5">consultation with a lipid specialist (S4.5.2<a href="CIR.0000000000000625.html#112">-17)</a>. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="54" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-54_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 54</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="4" height="21" font="5"> </text>
<text top="153" left="108" width="276" height="27" font="16"><i><b>4.5.3. Issues Specific to Women </b></i></text>
<text top="192" left="294" width="333" height="21" font="4"><b>Recommendations for Issues Specific to Women </b></text>
<text top="212" left="124" width="474" height="21" font="5">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625"> </a></text>
<text top="212" left="598" width="199" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Online Data Supplements 33, </a></text>
<text top="233" left="422" width="70" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">34, and 35</a></text>
<text top="233" left="492" width="8" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">.</a><b> </b></text>
<text top="253" left="131" width="33" height="21" font="4"><b>COR </b></text>
<text top="253" left="210" width="30" height="21" font="4"><b>LOE </b></text>
<text top="253" left="472" width="132" height="21" font="4"><b>Recommendations </b></text>
<text top="337" left="143" width="8" height="21" font="4"><b>I </b></text>
<text top="337" left="205" width="38" height="21" font="4"><b>B-NR</b> </text>
<text top="286" left="271" width="542" height="21" font="4"><b>1.  Clinicians should consider conditions specific to women,  such as </b></text>
<text top="306" left="298" width="503" height="21" font="4"><b>premature  menopause  (age &lt;40 years)  and  history of  pregnancy-</b></text>
<text top="326" left="298" width="507" height="21" font="4"><b>associated disorders (hypertension, preeclampsia, gestational diabetes </b></text>
<text top="347" left="298" width="513" height="21" font="4"><b>mellitus, small-for-gestational-age infants, preterm deliveries), when </b></text>
<text top="367" left="298" width="510" height="21" font="4"><b>discussing  lifestyle intervention  and the potential for benefit of statin </b></text>
<text top="387" left="298" width="194" height="21" font="4"><b>therapy (S4.5.3<a href="CIR.0000000000000625.html#112">-1–S4.5.3-6)</a></b><b>. </b></text>
<text top="437" left="143" width="8" height="21" font="4"><b>I </b></text>
<text top="437" left="207" width="35" height="21" font="4"><b>C-LD </b></text>
<text top="417" left="271" width="535" height="21" font="4"><b>2.  Women of childbearing age who are treated with statin therapy and are </b></text>
<text top="437" left="298" width="507" height="21" font="4"><b>sexually active should be counseled to use a reliable form of contraception </b></text>
<text top="457" left="298" width="145" height="21" font="4"><b>(S4.5.3<a href="CIR.0000000000000625.html#113">-7–S4.5.3-12)</a></b><b>. </b></text>
<text top="527" left="143" width="8" height="21" font="4"><b>I </b></text>
<text top="527" left="207" width="35" height="21" font="4"><b>C-LD </b></text>
<text top="487" left="271" width="539" height="21" font="4"><b>3.  Women of childbearing age with hypercholesterolemia who plan to </b></text>
<text top="507" left="298" width="508" height="21" font="4"><b>become pregnant should stop the statin 1 to 2 months before pregnancy </b></text>
<text top="527" left="298" width="508" height="21" font="4"><b>is attempted, or if they become pregnant while on a statin, should have </b></text>
<text top="547" left="298" width="503" height="21" font="4"><b>the statin stopped as soon as the pregnancy is discovered (S4.5.3<a href="CIR.0000000000000625.html#113">-7–</a></b></text>
<text top="568" left="298" width="77" height="21" font="4"><a href="CIR.0000000000000625.html#113"><b>S4.5.3-12)</b></a><b>. </b></text>
<text top="598" left="108" width="4" height="21" font="5"> </text>
<text top="618" left="108" width="63" height="21" font="4"><b>Synopsis </b></text>
<text top="657" left="108" width="706" height="21" font="5">Although atherosclerosis typically occurs later in women than in men, CVD remains the leading cause of </text>
<text top="677" left="108" width="706" height="21" font="5">death in women. Statins clearly reduce ASCVD events in women as well as in men with ASCVD. The 2015 </text>
<text top="697" left="108" width="706" height="21" font="5">meta-analysis by the CTT Collaboration showed no heterogeneity by gender for the risk of major vascular </text>
<text top="717" left="108" width="705" height="21" font="5">events with statin therapy in participants with a history of vascular disease (S4.5.3<a href="CIR.0000000000000625.html#113">-13)</a>.<b> </b>A history of certain </text>
<text top="737" left="108" width="709" height="21" font="5">pregnancy-related conditions and premature  menopause  (age &lt;40 years)  have been associated with </text>
<text top="758" left="108" width="706" height="21" font="5">increased ASCVD risk.<b> </b>However,<b> </b>current best practice emphasizes that statins should not be taken during </text>
<text top="778" left="108" width="705" height="21" font="5">pregnancy. Thus, women of childbearing age who are on statin therapy and are sexually active should use </text>
<text top="798" left="108" width="706" height="21" font="5">a reliable form of contraception to avoid pregnancy. When pregnancy is planned, stopping statin therapy </text>
<text top="818" left="108" width="706" height="21" font="5">1 to 2 months before pregnancy is attempted is suggested as reasonable guidance. When an unplanned </text>
<text top="838" left="108" width="706" height="21" font="5">pregnancy  occurs, statins should be stopped immediately when the pregnancy is discovered.  Both </text>
<text top="858" left="108" width="706" height="21" font="5">cholesterol and triglycerides rise with pregnancy, and those with genetic lipid disorders should consider </text>
<text top="878" left="108" width="485" height="21" font="5">consulting a clinician with lipid expertise before starting the pregnancy.  </text>
<text top="908" left="108" width="295" height="21" font="4"><b>Recommendation-Specific Supportive Text </b></text>
<text top="947" left="108" width="707" height="21" font="5">1.  Several conditions specific to women (e.g., hypertensive disorders during pregnancy, preeclampsia, </text>
<text top="967" left="135" width="679" height="21" font="5">gestational diabetes mellitus, delivering a preterm or low-birth-weight infant (S4.5.3<a href="CIR.0000000000000625.html#113">-2–S4.5.3-4)</a>, and </text>
<text top="987" left="135" width="680" height="21" font="5">premature menopause [age &lt;40 years] (S4.5.3<a href="CIR.0000000000000625.html#113">-5,</a> S4.5.3<a href="CIR.0000000000000625.html#113">-6,</a> S4.5.3<a href="CIR.0000000000000625.html#113">-14)</a>) have been shown to increase </text>
<text top="1007" left="135" width="679" height="21" font="5">ASCVD risk. The present guideline includes preeclampsia and premature menopause (age &lt;40 years) </text>
<text top="1027" left="135" width="679" height="21" font="5">as risk-enhancing factors for statin therapy because they appear to increase ASCVD risk in the same </text>
<text top="1047" left="135" width="679" height="21" font="5">range as other risk-enhancing factors. On the other hand, the mechanism or cause of preterm birth is </text>
<text top="1068" left="135" width="679" height="21" font="5">often unknown; therefore, it is difficult to routinely include this condition as a risk-enhancing factor </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="55" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-55_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 55</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="135" width="680" height="21" font="5">for statin therapy. Furthermore, if gestational diabetes mellitus predisposes a woman to metabolic </text>
<text top="144" left="135" width="680" height="21" font="5">syndrome or diabetes mellitus, these are already identified as risk-enhancing or major ASCVD risk </text>
<text top="164" left="135" width="682" height="21" font="5">factors.  After  pregnancy and throughout the life course of every woman, a thorough pregnancy </text>
<text top="184" left="135" width="679" height="21" font="5">history should be obtained, and risk factors and risk-enhancing factors should be identified. </text>
<text top="204" left="135" width="685" height="21" font="5">Interventions should include aggressive lifestyle counseling to reduce ASCVD risk and when </text>
<text top="225" left="135" width="679" height="21" font="5">appropriate, statin therapy, if ASCVD risk estimation indicates that the potential for benefit  from </text>
<text top="245" left="135" width="680" height="21" font="5">statin therapy outweighs the potential for adverse effects. Decisions should be made in the context </text>
<text top="265" left="135" width="585" height="21" font="5">of a risk discussion and should take into consideration an informed patient preference. </text>
<text top="285" left="108" width="706" height="21" font="5">2.  All statins are currently contraindicated in pregnant women, primarily as a result of a 2004 series of </text>
<text top="305" left="135" width="679" height="21" font="5">cases of first-trimester statin exposure reported to the FDA, which showed 20 cases of malformation, </text>
<text top="325" left="135" width="679" height="21" font="5">including 5 severe defects of the central nervous system and 5 unilateral limb deficiencies (S4.5.3<a href="CIR.0000000000000625.html#113">-7)</a>. </text>
<text top="345" left="135" width="679" height="21" font="5">In all cases of adverse birth outcomes, the statin used was lipophilic. No malformation was identified </text>
<text top="366" left="135" width="680" height="21" font="5">in the 14 infants exposed to pravastatin (hydrophilic). Since this case series, cohort studies of statin </text>
<text top="386" left="135" width="679" height="21" font="5">exposure in pregnancy did not show an increase in teratogenic risk (S4.5.3<a href="CIR.0000000000000625.html#113">-8–S4.5.3-10)</a>, and in fact, </text>
<text top="406" left="135" width="681" height="21" font="5">the safety of pravastatin is under study for the prevention of preeclampsia in high-risk pregnant </text>
<text top="426" left="135" width="682" height="21" font="5">women  (S4.5.3<a href="CIR.0000000000000625.html#113">-15)</a>.  In a meta-analysis of 6  studies of pregnant women exposed to statins, no </text>
<text top="446" left="135" width="679" height="21" font="5">increased risk of birth defects was observed compared with control subjects. However, there was an </text>
<text top="466" left="135" width="679" height="21" font="5">increased risk of miscarriage in the statin-exposed women versus controls (S4.5.3<a href="CIR.0000000000000625.html#113">-11)</a>. Furthermore, </text>
<text top="486" left="135" width="680" height="21" font="5">in a recent retrospective cohort study that used time-to-event analysis as a covariate, the adjusted </text>
<text top="507" left="135" width="679" height="21" font="5">hazard ratio of spontaneous pregnancy loss in the statin-exposed group was increased (S4.5.3<a href="CIR.0000000000000625.html#113">-12)</a>. </text>
<text top="527" left="135" width="679" height="21" font="5">The increase in miscarriages may be related to confounders, such as older age, CVD risk factors, and </text>
<text top="547" left="135" width="134" height="21" font="5">other medications.  </text>
<text top="567" left="108" width="709" height="21" font="5">3.  A reasonable approach is to stop statins 1  to  2 months before pregnancy is attempted. When </text>
<text top="587" left="135" width="681" height="21" font="5">pregnancy is unplanned, statin therapy should be stopped promptly and not restarted until after </text>
<text top="607" left="135" width="682" height="21" font="5">pregnancy and breastfeeding are  completed.  Cholesterol levels rise in pregnancy,  with a similar </text>
<text top="627" left="135" width="679" height="21" font="5">percentage rise in normal women and those with heterozygous FH. Women with FH do not appear to </text>
<text top="648" left="135" width="682" height="21" font="5">have a higher risk of preterm delivery or of having infants with low birth weight or congenital </text>
<text top="668" left="135" width="679" height="21" font="5">malformations than unaffected women,  but undetected bias cannot  be ruled  out  (S4.5.3<a href="CIR.0000000000000625.html#113">-16)</a>.  An </text>
<text top="688" left="135" width="682" height="21" font="5">experienced lipid specialist should be consulted for women with homozygous FH whose care is </text>
<text top="708" left="135" width="682" height="21" font="5">beyond the scope of the present guideline.  Also,  triglyceride levels rise progressively with each </text>
<text top="728" left="135" width="680" height="21" font="5">trimester, and women with triglyceride levels ≥500 mg/dL (5.6 mmol/L) at the onset of pregnancy </text>
<text top="748" left="135" width="679" height="21" font="5">may develop severe hypertriglyceridemia during the third trimester of pregnancy, which can lead to </text>
<text top="768" left="135" width="679" height="21" font="5">pancreatitis  (S4.5.3<a href="CIR.0000000000000625.html#113">-17)</a>.  Advising patients on lifestyle (including both diet and physical activity), </text>
<text top="789" left="135" width="679" height="21" font="5">optimally managing diseases like diabetes mellitus and hypothyroidism, and choosing medications </text>
<text top="809" left="135" width="680" height="21" font="5">that are less likely to raise triglycerides can reduce levels of triglycerides before pregnancy begins. </text>
<text top="829" left="135" width="679" height="21" font="5">Treatment of severe hypertriglyceridemic pregnancy is also beyond the scope of the present guideline </text>
<text top="849" left="135" width="421" height="21" font="5">and requires consultation with an experienced lipid specialist.  </text>
<text top="869" left="108" width="4" height="21" font="5"> </text>
<text top="898" left="108" width="196" height="27" font="16"><i><b>4.5.4 Adults With CKD </b></i></text>
<text top="941" left="322" width="5" height="16" font="3"><b> </b></text>
<text top="937" left="327" width="273" height="21" font="4"><b>Recommendations for Adults With CKD </b></text>
<text top="958" left="124" width="474" height="21" font="5">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625"> </a></text>
<text top="958" left="598" width="199" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Online Data Supplements 36, </a></text>
<text top="978" left="422" width="70" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">37, and 38</a></text>
<text top="978" left="492" width="4" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">.</a></text>
<text top="976" left="496" width="4" height="23" font="3"><b> </b></text>
<text top="999" left="131" width="33" height="21" font="4"><b>COR </b></text>
<text top="999" left="206" width="30" height="21" font="4"><b>LOE </b></text>
<text top="999" left="469" width="132" height="21" font="4"><b>Recommendations </b></text>
<text top="1044" left="137" width="21" height="21" font="4"><b>IIa </b></text>
<text top="1044" left="207" width="27" height="21" font="4"><b>B-R </b></text>
<text top="1028" left="265" width="499" height="21" font="4"><b>1.  In adults 40 to 75 years of age with LDL-C 70 to 189 mg/dL (1.7 to 4.8 </b></text>
<text top="1049" left="290" width="513" height="21" font="4"><b>mmol/L) who are at 10-year ASCVD risk of 7.5% or higher, CKD not treated </b></text>
<text top="1069" left="290" width="471" height="21" font="4"><b>with dialysis or kidney transplantation is a risk-enhancing factor and </b></text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="56" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-56_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 56</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="125" left="290" width="479" height="21" font="4"><b>initiation of a moderate-intensity statin or moderate-intensity statins </b></text>
<text top="145" left="290" width="409" height="21" font="4"><b>combined with ezetimibe can be useful (S4.5.4<a href="CIR.0000000000000625.html#113">-1, </a></b><b>S4.5.4<a href="CIR.0000000000000625.html#114">-2)</a></b><b>. </b></text>
<text top="195" left="136" width="21" height="21" font="4"><b>IIb </b></text>
<text top="195" left="204" width="35" height="21" font="4"><b>C-LD </b></text>
<text top="175" left="265" width="517" height="21" font="4"><b>2.  In adults with advanced kidney disease that requires dialysis treatment </b></text>
<text top="195" left="290" width="459" height="21" font="4"><b>who are currently on LDL-lowering therapy with a statin, it may be </b></text>
<text top="215" left="290" width="305" height="21" font="4"><b>reasonable to continue the statin (S4.5.4<a href="CIR.0000000000000625.html#114">-2)</a></b><b>. </b></text>
<text top="264" left="125" width="45" height="21" font="4"><b>III: No </b></text>
<text top="284" left="120" width="53" height="21" font="4"><b>Benefit </b></text>
<text top="274" left="207" width="27" height="21" font="4"><b>B-R </b></text>
<text top="245" left="265" width="516" height="21" font="4"><b>3.  In adults with advanced kidney disease who require dialysis treatment, </b></text>
<text top="265" left="290" width="421" height="21" font="4"><b>initiation of a statin is not recommended (S4.5.4<a href="CIR.0000000000000625.html#114">-3, </a></b><b>S4.5.4<a href="CIR.0000000000000625.html#114">-4)</a></b><b>. </b></text>
<text top="333" left="108" width="4" height="21" font="5"> </text>
<text top="362" left="108" width="63" height="21" font="4"><b>Synopsis</b> </text>
<text top="401" left="108" width="706" height="21" font="5">CKD is a risk-enhancing factor for ASCVD. In risk discussion with intermediate-risk patients, the presence </text>
<text top="421" left="108" width="709" height="21" font="5">of CKD favors initiation of statin therapy. In adults with advanced kidney disease requiring dialysis </text>
<text top="441" left="108" width="705" height="21" font="5">treatment who are currently on pharmacological LDL-lowering therapy with a statin, it may be reasonable </text>
<text top="461" left="108" width="706" height="21" font="5">to continue the statin (S4.5.4<a href="CIR.0000000000000625.html#114">-2)</a>. In adults with CKD that requires dialysis treatment, initiation of a statin </text>
<text top="482" left="108" width="503" height="21" font="5">is not recommended on the basis of 2 large-scale RCTs (S4.5.4<a href="CIR.0000000000000625.html#114">-3,</a> S4.5.4<a href="CIR.0000000000000625.html#114">-4)</a>. </text>
<text top="511" left="108" width="295" height="21" font="4"><b>Recommendation-Specific Supportive Text </b></text>
<text top="541" left="108" width="281" height="21" font="5">1.  Reduced eGFR (&lt;60 mL/min/1.73 m</text>
<text top="541" left="389" width="8" height="13" font="22">2 </text>
<text top="541" left="400" width="410" height="21" font="5">not on dialysis) and presence  of albuminuria (albumin-to-</text>
<text top="561" left="135" width="680" height="21" font="5">creatinine ratio ≥30 mcg/mg) are independently associated with elevated risk of ASCVD. Hence, in </text>
<text top="581" left="135" width="675" height="21" font="5">intermediate-risk patients, CKD counts as a risk-enhancing factor. According to some studies (S4.5.4-</text>
<text top="601" left="135" width="680" height="21" font="5"><a href="CIR.0000000000000625.html#114">5)</a>, the cardiovascular risk for persons with reduced eGFR may be as high as that observed among </text>
<text top="621" left="135" width="680" height="21" font="5">patients with diabetes mellitus and no CKD. Presence of albuminuria with reduced eGFR multiplies </text>
<text top="642" left="135" width="681" height="21" font="5">this CVD risk. The risk is graded and increases with severity of eGFR impairment, with observed </text>
<text top="662" left="135" width="360" height="21" font="5">threshold of risk beginning around 75 mL/min/1.73 m</text>
<text top="662" left="495" width="5" height="13" font="22">2</text>
<text top="662" left="500" width="314" height="21" font="5">, whereas the risk associated with albuminuria </text>
<text top="682" left="135" width="679" height="21" font="5">is linear (S4.5.4<a href="CIR.0000000000000625.html#114">-6)</a>. Trials show absolute benefit from statin use, and this benefit is consistent across </text>
<text top="702" left="135" width="683" height="21" font="5">eGFR  stages. However, the RRR  per LDL-C–lowering  may be lower with more advanced CKD. </text>
<text top="722" left="135" width="681" height="21" font="5">Albuminuria is independently associated with CVD risk. However, the one trial done for primary </text>
<text top="742" left="135" width="681" height="21" font="5">prevention in persons with albuminuria and preserved eGFR had too few events to be conclusive </text>
<text top="762" left="135" width="72" height="21" font="5">(S4.5.4<a href="CIR.0000000000000625.html#114">-7)</a>. </text>
<text top="783" left="108" width="706" height="21" font="5">2.  According to this recommendation, in patients with CKD who are currently taking a statin, it may be </text>
<text top="803" left="135" width="680" height="21" font="5">reasonable to continue the statin. In support of this, in the SHARP trial (Study of Heart and Renal </text>
<text top="823" left="135" width="679" height="21" font="5">Protection)  (simvastatin  plus  ezetimibe  versus  placebo), &gt;30% of persons transitioned to dialysis </text>
<text top="843" left="135" width="679" height="21" font="5">(S4.5.4<a href="CIR.0000000000000625.html#114">-2)</a>. After weighting for subgroup-specific reductions in LDL-C was performed, the proportional </text>
<text top="863" left="135" width="679" height="21" font="5">effects on major atherosclerotic events were similar in patients on dialysis and those who were not </text>
<text top="883" left="135" width="77" height="21" font="5">on dialysis. </text>
<text top="903" left="108" width="707" height="21" font="5">3.  Although persons on dialysis have the highest absolute risk of events (and thus potential for higher </text>
<text top="924" left="135" width="675" height="21" font="5">ARR), the proportion of deaths thought to be due to atherosclerotic events is lower (S4.5.4<a href="CIR.0000000000000625.html#114">-3,</a> S4.5.4-</text>
<text top="944" left="135" width="679" height="21" font="5"><a href="CIR.0000000000000625.html#114">4)</a>. The lack of benefit in RCTs with statin initiation among persons on dialysis raises the question of </text>
<text top="964" left="135" width="681" height="21" font="5">competing risks. Unfortunately, there are not enough data to distinguish the potential for benefit </text>
<text top="984" left="135" width="571" height="21" font="5">from statin therapy between those on peritoneal dialysis and those on hemodialysis. </text>
<text top="1025" left="108" width="4" height="21" font="5"> </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="57" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-57_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 57</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="517" height="27" font="16"><i><b>4.5.5. Adults With Chronic Inflammatory Disorders and HIV </b></i></text>
<text top="163" left="200" width="522" height="21" font="4"><b>Recommendations for Adults With Chronic Inflammatory Disorders and HIV </b></text>
<text top="183" left="128" width="474" height="21" font="5">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625"> </a></text>
<text top="183" left="602" width="185" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Online Data Supplement 39</a></text>
<text top="183" left="786" width="8" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">.</a><b> </b></text>
<text top="208" left="128" width="33" height="21" font="4"><b>COR </b></text>
<text top="208" left="196" width="30" height="21" font="4"><b>LOE </b></text>
<text top="208" left="461" width="132" height="21" font="4"><b>Recommendations </b></text>
<text top="259" left="134" width="21" height="21" font="4"><b>IIa </b></text>
<text top="259" left="192" width="38" height="21" font="4"><b>B-NR </b></text>
<text top="233" left="250" width="500" height="21" font="4"><b>1.  In adults 40 to 75 years of age with LDL-C 70 to 189 mg/dL (1.7 to 4.8 </b></text>
<text top="253" left="277" width="458" height="21" font="4"><b>mmol/L) who have a 10-year ASCVD risk of 7.5% or higher, chronic </b></text>
<text top="273" left="277" width="478" height="21" font="4"><b>inflammatory disorders and HIV are risk-enhancing factors and in risk </b></text>
<text top="294" left="277" width="510" height="21" font="4"><b>discussion favor moderate-intensity statin therapy or high-intensity statin </b></text>
<text top="314" left="277" width="203" height="21" font="4"><b>therapy (S4.5.5<a href="CIR.0000000000000625.html#114">-1–S4.5.5-12)</a></b><b>. </b></text>
<text top="360" left="134" width="21" height="21" font="4"><b>IIa </b></text>
<text top="360" left="192" width="38" height="21" font="4"><b>B-NR </b></text>
<text top="335" left="250" width="553" height="21" font="4"><b>2.  In patients with chronic inflammatory disorders or HIV, a fasting lipid profile </b></text>
<text top="355" left="277" width="515" height="21" font="4"><b>and assessment of ASCVD risk factors can be useful as a) a guide to benefit </b></text>
<text top="375" left="277" width="488" height="21" font="4"><b>of statin therapy and b) for monitoring or adjusting lipid-lowering drug </b></text>
<text top="395" left="277" width="484" height="21" font="4"><b>therapy before and 4 to 12 weeks after starting inflammatory disease–</b></text>
<text top="415" left="277" width="454" height="21" font="4"><b>modifying therapy or antiretroviral therapy (S4.5.5<a href="CIR.0000000000000625.html#115">-12–S4.5.5-20)</a></b><b>. </b></text>
<text top="452" left="134" width="21" height="21" font="4"><b>IIa </b></text>
<text top="452" left="192" width="38" height="21" font="4"><b>B-NR </b></text>
<text top="436" left="250" width="538" height="21" font="4"><b>3.  In adults with RA who undergo ASCVD risk assessment with measurement </b></text>
<text top="456" left="277" width="496" height="21" font="4"><b>of a lipid profile, it can be useful to recheck lipid values and other major </b></text>
<text top="476" left="277" width="508" height="21" font="4"><b>ASCVD risk factors 2 to 4 months after the patient’s inflammatory disease </b></text>
<text top="496" left="277" width="293" height="21" font="4"><b>has been controlled (S4.5.5<a href="CIR.0000000000000625.html#115">-21–S4.5.5-23)</a></b><b>. </b></text>
<text top="526" left="108" width="4" height="21" font="5"> </text>
<text top="555" left="108" width="63" height="21" font="4"><b>Synopsis </b></text>
<text top="595" left="108" width="705" height="21" font="5">Chronic inflammatory disorders and HIV infection are conditions that often enhance risk. Clinicians should </text>
<text top="615" left="108" width="706" height="21" font="5">first focus on helping patients with these diagnoses to optimize their lifestyle habits. After a 3- to 6-month </text>
<text top="635" left="108" width="706" height="21" font="5">trial of lifestyle improvements, including cessation of cigarette smoking, the patient’s 10-year ASCVD risk </text>
<text top="655" left="108" width="706" height="21" font="5">estimate should be reassessed. If the patient’s ASCVD risk estimate is ≥5% over 10 years, it is reasonable </text>
<text top="675" left="108" width="707" height="21" font="5">to begin moderate-intensity statin therapy. If the patient or clinician remains uncertain about the need </text>
<text top="695" left="108" width="706" height="21" font="5">for statin therapy or if the patient has had side effects with a statin in the past, a CAC scan can be used to </text>
<text top="716" left="108" width="707" height="21" font="5">improve risk assessment. The absence of CAC in a nonsmoking man ≥40 years of age or a nonsmoking </text>
<text top="736" left="108" width="706" height="21" font="5">woman ≥45 years of age would indicate that the patient is likely at very low risk of an ASCVD event over </text>
<text top="756" left="108" width="708" height="21" font="5">the subsequent decade. Such patients can then focus on lifestyle habits and delay the decision about </text>
<text top="776" left="108" width="706" height="21" font="5">statin therapy for about 5 years. Similarly, a CAC score ≥75th percentile for a patient’s age and sex or an </text>
<text top="796" left="108" width="705" height="21" font="5">absolute score ≥100 Agatston units would support the decision to use statin therapy and intensify lifestyle </text>
<text top="816" left="108" width="99" height="21" font="5">modifications. </text>
<text top="845" left="108" width="295" height="21" font="4"><b>Recommendation-Specific Supportive Text </b></text>
<text top="885" left="108" width="711" height="21" font="5">1.  Inflammation promotes atherosclerosis and is a key feature of many chronic rheumatologic </text>
<text top="905" left="135" width="679" height="21" font="5">inflammatory joint disorders,  such systemic lupus erythematosus, RA, and psoriasis (S4.5.5<a href="CIR.0000000000000625.html#114">-1)</a>. </text>
<text top="925" left="135" width="679" height="21" font="5">Inflammation mediates the progression of atherosclerosis, as well as instability, erosion, and rupture </text>
<text top="945" left="135" width="678" height="21" font="5">of vulnerable atherosclerotic plaques (S4.5.5<a href="CIR.0000000000000625.html#114">-2)</a>. Among individuals with RA, the risk of an MI has been </text>
<text top="965" left="135" width="679" height="21" font="5">estimated to be similar to that of an adult with diabetes mellitus or one who is about 10 years older </text>
<text top="985" left="135" width="679" height="21" font="5">without RA (S4.5.5<a href="CIR.0000000000000625.html#114">-3)</a>. A large meta-analysis found that persons with RA had an approximately 50% </text>
<text top="1006" left="135" width="679" height="21" font="5">increased risk of CVD death (S4.5.5<a href="CIR.0000000000000625.html#114">-4)</a>. Individuals with systemic lupus erythematosus and advanced </text>
<text top="1026" left="135" width="679" height="21" font="5">psoriasis have a similarly increased risk of CVD (S4.5.5<a href="CIR.0000000000000625.html#114">-5–S4.5.5-7)</a>. HIV infection is associated with an </text>
<text top="1046" left="135" width="675" height="21" font="5">increased risk of an ASCVD event even if viremia has been controlled by antiretroviral therapy (S4.5.5-</text>
<text top="1066" left="135" width="679" height="21" font="5"><a href="CIR.0000000000000625.html#114">8)</a>. There is an increased risk of MI in association with long-term use of antiretroviral therapy, and MI </text>
<text top="1086" left="135" width="679" height="21" font="5">rates are increased in individuals with HIV (S4.5.5<a href="CIR.0000000000000625.html#114">-9)</a>. Traditional ASCVD risk factors, long-term use of </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="58" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-58_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 58</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="135" width="688" height="21" font="5">antiretroviral therapy, prolonged  immune activation, and inflammation are mediators of </text>
<text top="144" left="135" width="679" height="21" font="5">atherosclerosis progression and development (S4.5.5<a href="CIR.0000000000000625.html#114">-9,</a> S4.5.5<a href="CIR.0000000000000625.html#114">-10)</a>. Coinfection with hepatitis C virus </text>
<text top="164" left="135" width="675" height="21" font="5">is frequently present in HIV-infected individuals and further increases ASCVD risk (S4.5.5<a href="CIR.0000000000000625.html#114">-11,</a> S4.5.5-</text>
<text top="184" left="135" width="33" height="21" font="5"><a href="CIR.0000000000000625.html#115">12)</a>.  </text>
<text top="204" left="108" width="710" height="21" font="5">2.  The accuracy of the ASCVD risk estimator has not been well validated for adults with chronic </text>
<text top="225" left="135" width="680" height="21" font="5">inflammatory disorders or HIV infection. Assessment of traditional risk factors often has resulted in </text>
<text top="245" left="135" width="679" height="21" font="5">underestimation of actual risk and the potential for undertreatment with pharmacological therapy </text>
<text top="265" left="135" width="678" height="21" font="5">(S4.5.5<a href="CIR.0000000000000625.html#115">-13,</a> S4.5.5<a href="CIR.0000000000000625.html#115">-14)</a>. Traditional risk factors should be assessed early in the disease process and then </text>
<text top="285" left="135" width="678" height="21" font="5">modified. Rates of smoking in HIV-infected adults have generally been 2 to 3 times that of the general </text>
<text top="305" left="135" width="678" height="21" font="5">population (S4.5.5<a href="CIR.0000000000000625.html#115">-15,</a> S4.5.5<a href="CIR.0000000000000625.html#115">-16)</a>. Multiple studies have demonstrated underestimation of ASCVD risk </text>
<text top="325" left="135" width="679" height="21" font="5">in patients with chronic inflammatory conditions or HIV (S4.5.5<a href="CIR.0000000000000625.html#115">-15,</a> S4.5.5<a href="CIR.0000000000000625.html#115">-16)</a>. Antiretroviral therapy </text>
<text top="345" left="135" width="679" height="21" font="5">may adversely affect lipid levels, glycemic control, and endothelial function (S4.5.5<a href="CIR.0000000000000625.html#115">-17–S4.5.5-19)</a> and </text>
<text top="366" left="135" width="681" height="21" font="5">has been associated with adverse changes in body composition (lipodystrophy). However, use of </text>
<text top="386" left="135" width="679" height="21" font="5">newer agents may lessen the metabolic derangements of antiretroviral therapy. Similarly, the use of </text>
<text top="406" left="135" width="675" height="21" font="5">prednisone in chronic inflammatory diseases may worsen glycemic control and dyslipidemia (S4.5.5-</text>
<text top="426" left="135" width="681" height="21" font="5"><a href="CIR.0000000000000625.html#115">20)</a>. The most common lipid abnormality phenotype in persons with HIV infection is an elevated </text>
<text top="446" left="135" width="682" height="21" font="5">triglyceride level with a low HDL-C. In HIV-infected adults, triglycerides should preferentially be </text>
<text top="466" left="135" width="207" height="21" font="5">measured in the fasting state.  </text>
<text top="486" left="108" width="705" height="21" font="5">3.  Patients with RA who are untreated or who have high disease activity generally have decreased levels </text>
<text top="507" left="135" width="678" height="21" font="5">of TC, triglycerides, HDL-C, and LDL-C (S4.5.5<a href="CIR.0000000000000625.html#115">-21)</a>. These lower lipid levels are likely attributable in part </text>
<text top="527" left="135" width="681" height="21" font="5">to increased inflammation and may lead to functional proatherogenic changes, such as decreased </text>
<text top="547" left="135" width="679" height="21" font="5">cholesterol efflux capacity of HDL-C (S4.5.5<a href="CIR.0000000000000625.html#115">-22)</a>. Treatment with anti-inflammatory medications, such </text>
<text top="567" left="135" width="679" height="21" font="5">as  tumor necrosis factor alpha  inhibitors or methotrexate,  is associated with an increase in  and </text>
<text top="587" left="135" width="679" height="21" font="5">normalization of lipid levels and a reduction in the ratio of TC to HDL-C (S4.5.5<a href="CIR.0000000000000625.html#115">-23)</a>. Thus, to produce </text>
<text top="607" left="135" width="681" height="21" font="5">a more accurate risk estimate, ASCVD risk estimation should be repeated when the patient has a </text>
<text top="627" left="135" width="680" height="21" font="5">stable and low disease activity with normalization of their lipid levels; lower lipid levels measured </text>
<text top="648" left="135" width="679" height="21" font="5">during high disease activity may lead to a significant underestimation of ASCVD risk for patients with </text>
<text top="668" left="135" width="26" height="21" font="5">RA. </text>
<text top="688" left="108" width="4" height="21" font="5"> </text>
<text top="717" left="108" width="4" height="21" font="5"> </text>
<text top="746" left="108" width="498" height="31" font="11"><b>5. Statin Safety and Statin-Associated Side Effects </b></text>
<text top="789" left="220" width="482" height="21" font="4"><b>Recommendations for Statin Safety and Statin-Associated Side Effects </b></text>
<text top="810" left="126" width="474" height="21" font="5">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625"> </a></text>
<text top="810" left="600" width="195" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Online Data Supplements 40 </a></text>
<text top="830" left="434" width="46" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">and 41</a></text>
<text top="830" left="480" width="8" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">.</a> </text>
<text top="851" left="134" width="33" height="21" font="4"><b>COR </b></text>
<text top="851" left="216" width="30" height="21" font="4"><b>LOE </b></text>
<text top="851" left="476" width="132" height="21" font="4"><b>Recommendations </b></text>
<text top="918" left="147" width="8" height="21" font="4"><b>I </b></text>
<text top="918" left="224" width="14" height="21" font="4"><b>A</b> </text>
<text top="884" left="278" width="512" height="21" font="4"><b>1.  A clinician–patient risk discussion is recommended before initiation of </b></text>
<text top="904" left="305" width="486" height="21" font="4"><b>statin therapy to review net clinical benefit, weighing the potential for </b></text>
<text top="924" left="305" width="470" height="21" font="4"><b>ASCVD risk reduction against the potential for statin-associated side </b></text>
<text top="944" left="305" width="500" height="21" font="4"><b>effects, statin–drug interactions, and safety, while emphasizing that side </b></text>
<text top="964" left="305" width="343" height="21" font="4"><b>effects can be addressed successfully (S5<a href="CIR.0000000000000625.html#115">-1–S5-7)</a></b><b>. </b></text>
<text top="999" left="147" width="8" height="21" font="4"><b>I</b> </text>
<text top="999" left="224" width="14" height="21" font="4"><b>A</b> </text>
<text top="985" left="278" width="524" height="21" font="4"><b>2.  In patients with statin-associated muscle symptoms (SAMS), a thorough </b></text>
<text top="1005" left="305" width="491" height="21" font="4"><b>assessment of symptoms is recommended, in addition to an evaluation </b></text>
<text top="1025" left="305" width="400" height="21" font="4"><b>for nonstatin causes and predisposing factors (S5<a href="CIR.0000000000000625.html#115">-3–S5-7)</a></b><b>. </b></text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="59" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-59_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 59</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="149" left="147" width="8" height="21" font="4"><b>I </b></text>
<text top="149" left="218" width="27" height="21" font="4"><b>B-R </b></text>
<text top="125" left="278" width="519" height="21" font="4"><b>3.  In patients with indication for statin therapy, identification of potential </b></text>
<text top="145" left="305" width="473" height="21" font="4"><b>predisposing factors for statin-associated side effects, including new-</b></text>
<text top="165" left="305" width="492" height="21" font="4"><b>onset diabetes mellitus and SAMS, is recommended before initiation of </b></text>
<text top="185" left="305" width="160" height="21" font="4"><b>treatment (S5<a href="CIR.0000000000000625.html#115">-3–S5-7)</a></b><b>. </b></text>
<text top="230" left="147" width="8" height="21" font="4"><b>I </b></text>
<text top="230" left="218" width="27" height="21" font="4"><b>B-R </b></text>
<text top="206" left="278" width="507" height="21" font="4"><b>4.  In patients with statin-associated side effects that are not severe, it is </b></text>
<text top="226" left="305" width="492" height="21" font="4"><b>recommended to reassess and to rechallenge to achieve a maximal LDL-</b></text>
<text top="246" left="305" width="441" height="21" font="4"><b>C lowering by modified dosing regimen, an alternate statin or in </b></text>
<text top="266" left="305" width="337" height="21" font="4"><b>combination with nonstatin therapy (S5<a href="CIR.0000000000000625.html#115">-3–S5-8)</a></b><b>. </b></text>
<text top="321" left="147" width="8" height="21" font="4"><b>I </b></text>
<text top="321" left="218" width="27" height="21" font="4"><b>B-R </b></text>
<text top="287" left="278" width="516" height="21" font="4"><b>5.  In patients with increased diabetes mellitus risk or new-onset diabetes </b></text>
<text top="307" left="305" width="463" height="21" font="4"><b>mellitus, it is recommended to continue statin therapy, with added </b></text>
<text top="327" left="305" width="483" height="21" font="4"><b>emphasis on adherence, net clinical benefit, and the core principles of </b></text>
<text top="348" left="305" width="459" height="21" font="4"><b>regular moderate-intensity physical activity, maintaining a healthy </b></text>
<text top="368" left="305" width="445" height="21" font="4"><b>dietary pattern, and sustaining modest weight loss (S5<a href="CIR.0000000000000625.html#116">-8–S5-12)</a></b><b>. </b></text>
<text top="438" left="147" width="8" height="21" font="4"><b>I </b></text>
<text top="438" left="214" width="35" height="21" font="4"><b>C-LD </b></text>
<text top="389" left="278" width="520" height="21" font="4"><b>6.  In patients treated with statins, it is recommended to measure creatine </b></text>
<text top="409" left="305" width="441" height="21" font="4"><b>kinase levels in individuals with severe statin-associated muscle </b></text>
<text top="429" left="305" width="418" height="21" font="4"><b>symptoms, objective muscle weakness, and to measure liver </b></text>
<text top="449" left="305" width="490" height="21" font="4"><b>transaminases (aspartate aminotransferase, alanine aminotransferase) </b></text>
<text top="469" left="305" width="465" height="21" font="4"><b>as well as total bilirubin and alkaline phosphatase (hepatic panel) if </b></text>
<text top="489" left="305" width="424" height="21" font="4"><b>there are symptoms suggesting hepatotoxicity (S5<a href="CIR.0000000000000625.html#116">-13–S5-15)</a></b><b>. </b></text>
<text top="553" left="147" width="8" height="21" font="4"><b>I </b></text>
<text top="553" left="218" width="27" height="21" font="4"><b>B-R </b></text>
<text top="519" left="278" width="497" height="21" font="4"><b>7.  In patients at increased ASCVD risk with chronic, stable liver disease </b></text>
<text top="539" left="305" width="436" height="21" font="4"><b>(including non-alcoholic fatty liver disease) when appropriately </b></text>
<text top="560" left="305" width="442" height="21" font="4"><b>indicated, it is reasonable to use statins after obtaining baseline </b></text>
<text top="580" left="305" width="473" height="21" font="4"><b>measurements and determining a schedule of monitoring and safety </b></text>
<text top="600" left="305" width="152" height="21" font="4"><b>checks (S5<a href="CIR.0000000000000625.html#116">-16–S5-18)</a></b><b>.</b> </text>
<text top="655" left="140" width="21" height="21" font="4"><b>IIa </b></text>
<text top="655" left="218" width="27" height="21" font="4"><b>B-R </b></text>
<text top="621" left="278" width="525" height="21" font="4"><b>8.  In patients at increased ASCVD risk with severe statin-associated muscle </b></text>
<text top="641" left="305" width="463" height="21" font="4"><b>symptoms or recurrent statin-associated muscle symptoms despite </b></text>
<text top="661" left="305" width="451" height="21" font="4"><b>appropriate statin rechallenge, it is reasonable to use RCT proven </b></text>
<text top="681" left="305" width="499" height="21" font="4"><b>nonstatin therapy that is likely to provide net clinical benefit (S5<a href="CIR.0000000000000625.html#116">-5, </a></b><b>S5<a href="CIR.0000000000000625.html#116">-6, </a></b></text>
<text top="701" left="305" width="51" height="21" font="4"><b>S5<a href="CIR.0000000000000625.html#116">-19)</a></b><b>. </b></text>
<text top="722" left="128" width="45" height="21" font="4"><b>III: No </b></text>
<text top="745" left="124" width="53" height="21" font="4"><b>Benefit </b></text>
<text top="734" left="218" width="27" height="21" font="4"><b>B-R </b></text>
<text top="722" left="278" width="515" height="21" font="4"><b>9.  Coenzyme Q10 is not recommended for routine use in patients treated </b></text>
<text top="742" left="305" width="391" height="21" font="4"><b>with statins or for the treatment of SAMS (S5<a href="CIR.0000000000000625.html#116">-20, </a></b><b>S5<a href="CIR.0000000000000625.html#116">-21)</a></b><b>. </b></text>
<text top="778" left="128" width="45" height="21" font="4"><b>III: No </b></text>
<text top="801" left="124" width="53" height="21" font="4"><b>Benefit </b></text>
<text top="790" left="214" width="35" height="21" font="4"><b>C-LD </b></text>
<text top="778" left="278" width="485" height="21" font="4"><b>10. In patients treated with statins, routine measurements of creatine </b></text>
<text top="798" left="305" width="418" height="21" font="4"><b>kinase and transaminase levels are not useful (S5<a href="CIR.0000000000000625.html#116">-13–S5-15)</a></b><b>. </b></text>
<text top="843" left="108" width="4" height="21" font="5"> </text>
<text top="872" left="108" width="63" height="21" font="4"><b>Synopsis </b></text>
<text top="912" left="108" width="708" height="21" font="5">Statin therapy is usually well tolerated and safe (S5<a href="CIR.0000000000000625.html#115">-1,</a>  S5<a href="CIR.0000000000000625.html#116">-14,</a>  S5<a href="CIR.0000000000000625.html#117">-22–S5-24)</a>. As with other classes of </text>
<text top="932" left="108" width="706" height="21" font="5">medications, associated side effects are seen. Instead of the label <i>statin intolerance</i>, the present guideline </text>
<text top="952" left="108" width="708" height="21" font="5">prefers <i>statin-associated side effects</i> because the large majority of patients are able to tolerate statin </text>
<text top="972" left="108" width="705" height="21" font="5">rechallenge with an alternative statin or alternative regimen, such as reduced dose or in combination with </text>
<text top="992" left="108" width="706" height="21" font="5">nonstatins. Although infrequent or rare in clinical trials, statin-associated side effects can be challenging </text>
<text top="1012" left="108" width="706" height="21" font="5">to assess and manage (S5<a href="CIR.0000000000000625.html#117">-25,</a> S5<a href="CIR.0000000000000625.html#117">-26)</a>. The most frequent are SAMS. SAMS usually are subjective myalgia, </text>
<text top="1033" left="108" width="706" height="21" font="5">reported observationally in 5% to 20% of patients (S5<a href="CIR.0000000000000625.html#116">-11–S5-14)</a>. SAMS often result in nonadherence and </text>
<text top="1053" left="108" width="706" height="21" font="5">can adversely impact ASCVD outcomes (S5<a href="CIR.0000000000000625.html#117">-27–S5-29)</a>. Statins modestly increase risk of incident diabetes </text>
<text top="1073" left="108" width="707" height="21" font="5">mellitus in susceptible individuals (S5<a href="CIR.0000000000000625.html#116">-8–S5-11)</a>, but this should not be cause for discontinuation (Table </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="60" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-60_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 60</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="707" height="21" font="5">11). The present guideline recommends a comprehensive approach to statin-associated symptoms. The </text>
<text top="144" left="108" width="706" height="21" font="5">clinician should reassess, rediscuss, and encourage rechallenge as the initial approach unless side effects </text>
<text top="164" left="108" width="706" height="21" font="5">are severe. Ongoing communication is integral to patient care,  as  is  regular monitoring to check for </text>
<text top="184" left="108" width="657" height="21" font="5">adherence, adequacy of response, new associated symptoms, and reaffirmation of benefit (S5<a href="CIR.0000000000000625.html#115">-2)</a>. </text>
<text top="213" left="108" width="295" height="21" font="4"><b>Recommendation-Specific Supportive Text </b></text>
<text top="253" left="108" width="708" height="21" font="5">1.  A  clinician–patient  risk discussion focused on indications, benefits, risks of statin-associated side </text>
<text top="273" left="135" width="679" height="21" font="5">effects, and patient concerns and preferences should precede initiation of statin treatment (S5<a href="CIR.0000000000000625.html#115">-2)</a>. </text>
<text top="293" left="135" width="675" height="21" font="5">This dialogue is the foundation of a longitudinal care partnership that is based on informed decision-</text>
<text top="313" left="135" width="679" height="21" font="5">making. Future encounters should address statin response, emphasize adherence, and  reaffirm </text>
<text top="333" left="135" width="679" height="21" font="5">benefit. Statin-associated symptoms should be comprehensively assessed, and because most can be </text>
<text top="353" left="135" width="679" height="21" font="5">well managed (S5<a href="CIR.0000000000000625.html#115">-3–S5-7)</a>,  the goal should be to optimize patient-centered strategies for ASCVD </text>
<text top="374" left="135" width="85" height="21" font="5">prevention.  </text>
<text top="394" left="108" width="702" height="21" font="5">2.  The majority of SAMS are subjective myalgia (pain, aches) in the absence of other findings (S5<a href="CIR.0000000000000625.html#116">-13,</a> S5-</text>
<text top="414" left="135" width="680" height="21" font="5"><a href="CIR.0000000000000625.html#117">25,</a> S5<a href="CIR.0000000000000625.html#117">-30)</a>. Myalgia is more likely to be statin associated if it is bilateral, involves proximal muscles, </text>
<text top="434" left="135" width="679" height="21" font="5">has its onset within weeks to months after initiation of statins, and resolves after discontinuation of </text>
<text top="454" left="135" width="678" height="21" font="5">statins (S5<a href="CIR.0000000000000625.html#116">-13,</a> S5<a href="CIR.0000000000000625.html#116">-14)</a>. A thorough assessment of symptoms is recommended, in addition to evaluation </text>
<text top="474" left="135" width="680" height="21" font="5">for nonstatin etiologies, assessment of predisposing factors, and a physical exam. Objective muscle </text>
<text top="494" left="135" width="679" height="21" font="5">weakness (myopathy) and associated significant increase in CK (myositis) are rare (S5<a href="CIR.0000000000000625.html#115">-1,</a> S5<a href="CIR.0000000000000625.html#117">-22,</a> S5<a href="CIR.0000000000000625.html#117">-30)</a> </text>
<text top="514" left="135" width="679" height="21" font="5">but require prompt statin cessation and evaluation for reversible causes. Rhabdomyolysis (CK &gt;10 </text>
<text top="535" left="135" width="678" height="21" font="5">times upper limit of normal, with evidence of renal injury) is exceedingly rare and usually encountered </text>
<text top="555" left="135" width="679" height="21" font="5">in  the setting of a patient with several predisposing comorbidities and concomitant high-risk </text>
<text top="575" left="135" width="503" height="21" font="5">medications (S5<a href="CIR.0000000000000625.html#115">-1,</a> S5<a href="CIR.0000000000000625.html#117">-22,</a> S5<a href="CIR.0000000000000625.html#117">-30)</a>. It requires immediate medical attention.  </text>
<text top="595" left="108" width="705" height="21" font="5">3.  Before lipid-lowering therapy with a statin is initiated, a comprehensive evaluation of musculoskeletal </text>
<text top="615" left="135" width="679" height="21" font="5">symptoms (with documentation) is recommended because such symptoms are common at baseline </text>
<text top="635" left="135" width="684" height="21" font="5">in the general adult population (S5<a href="CIR.0000000000000625.html#115">-3–S5-6)</a>.  Before  therapy,  it is also important to identify </text>
<text top="655" left="135" width="679" height="21" font="5">predisposing factors for SAMS, including demographics, comorbid conditions, and use of medications </text>
<text top="676" left="135" width="679" height="21" font="5">that can adversely affect statin metabolism (S5<a href="CIR.0000000000000625.html#115">-3,</a> S5<a href="CIR.0000000000000625.html#116">-13,</a> S5<a href="CIR.0000000000000625.html#116">-14)</a> (Table 11). Proactive and preemptive </text>
<text top="696" left="135" width="678" height="21" font="5">identification of patients at potential increased risk of statin-associated side effects should help guide </text>
<text top="716" left="135" width="632" height="21" font="5">informed clinical decision-making and is supportive of the goals of safe and effective therapy.  </text>
<text top="736" left="108" width="706" height="21" font="5">4.  Several creatively designed randomized crossover trials in patients with SAMS (S5<a href="CIR.0000000000000625.html#115">-3–S5-7)</a> support a </text>
<text top="756" left="135" width="678" height="21" font="5">management strategy of statin discontinuation until symptoms improve, followed by rechallenge with </text>
<text top="776" left="135" width="682" height="21" font="5">a reduced dose, alternative  agent, or alternative  dosing regimen while monitoring for recurrent </text>
<text top="797" left="135" width="679" height="21" font="5">symptoms.  If  the approach of reassess, rediscuss (net clinical benefit), and rechallenge  is used,  a </text>
<text top="817" left="135" width="679" height="21" font="5">majority of patients will be able to be successfully treated with at least one or several statins (S5<a href="CIR.0000000000000625.html#117">-29,</a> </text>
<text top="837" left="135" width="675" height="21" font="5">S5<a href="CIR.0000000000000625.html#117">-31)</a>. In patients at increased ASCVD risk,  the goal should be to treat with the guideline-</text>
<text top="857" left="135" width="679" height="21" font="5">recommended maximally tolerated statin dose. Patients who experience rhabdomyolysis with statin </text>
<text top="877" left="135" width="679" height="21" font="5">therapy may need to discontinue statin use indefinitely, although reversible causes should be sought </text>
<text top="897" left="135" width="682" height="21" font="5">(S5<a href="CIR.0000000000000625.html#117">-32)</a>. Clinicians should be aware of a rare disorder, statin-associated autoimmune myopathy </text>
<text top="917" left="135" width="679" height="21" font="5">(muscle weakness, marked and persistent CK elevation, presence of HMG CoA reductase [HMGCR] </text>
<text top="937" left="135" width="679" height="21" font="5">antibodies, necrotizing myopathy, and lack of or incomplete resolution on statin discontinuation), that </text>
<text top="958" left="135" width="679" height="21" font="5">requires statin cessation and additional therapy directed at the autoimmune process (S5<a href="CIR.0000000000000625.html#117">-32)</a>. Patients </text>
<text top="978" left="135" width="680" height="21" font="5">with statin-associated autoimmune myopathy may benefit from seeing a neurologist specializing in </text>
<text top="998" left="135" width="179" height="21" font="5">neuromuscular disorders.  </text>
<text top="1018" left="108" width="706" height="21" font="5">5.  Evidence indicates that statins modestly increase the risk of incident or statin-associated new-onset </text>
<text top="1038" left="135" width="678" height="21" font="5">diabetes mellitus in individuals with predisposing risk factors for diabetes mellitus, components of the </text>
<text top="1058" left="135" width="679" height="21" font="5">metabolic syndrome, and higher-intensity statin use (S5<a href="CIR.0000000000000625.html#116">-8–S5-11)</a>. The specific mechanisms leading </text>
<text top="1078" left="135" width="678" height="21" font="5">to statin-associated diabetes mellitus remain unclear, although it is unlikely that statins directly cause </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="61" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-61_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 61</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="135" width="680" height="21" font="5">diabetes mellitus. Rather, it appears that a small number of individuals with diabetic susceptibility </text>
<text top="144" left="135" width="680" height="21" font="5">cross the threshold to incident diabetes mellitus after statin therapy. is initiated It is important that </text>
<text top="164" left="135" width="680" height="21" font="5">patients are informed of the potential risk of new-onset diabetes mellitus before initiation of statin </text>
<text top="184" left="135" width="679" height="21" font="5">therapy. Because the benefits of statin therapy are shown to outweigh the risks of new-onset diabetes </text>
<text top="204" left="135" width="678" height="21" font="5">mellitus, the possibility of incident diabetes mellitus should not be a contraindication to statin therapy </text>
<text top="225" left="135" width="679" height="21" font="5">or indication for statin discontinuation (S5<a href="CIR.0000000000000625.html#116">-8,</a> S5<a href="CIR.0000000000000625.html#116">-14,</a> S5<a href="CIR.0000000000000625.html#117">-33)</a>. In individuals at increased risk of both </text>
<text top="245" left="135" width="679" height="21" font="5">ASCVD and incident diabetes mellitus,  it is recommended that counseling based on the ADA </text>
<text top="265" left="135" width="682" height="21" font="5">prevention approach be provided.  This approach encourages  regular moderate physical activity, </text>
<text top="285" left="135" width="681" height="21" font="5">maintaining a healthy dietary pattern, and sustaining modest weight loss (according to  the core </text>
<text top="305" left="135" width="378" height="21" font="5">principles of the Diabetes Prevention Program) (S5<a href="CIR.0000000000000625.html#116">-12)</a>.  </text>
<text top="325" left="108" width="706" height="21" font="5">6.  In patients with statin-associated side effects, it is recommended that CK be measured in the case of </text>
<text top="345" left="135" width="680" height="21" font="5">severe SAMS and in the presence of objective muscle weakness. After baseline liver transaminases, </text>
<text top="366" left="135" width="675" height="21" font="5">the FDA recommends measuring transaminases (aspartate aminotransferase  [serum  glutamic-</text>
<text top="386" left="135" width="679" height="21" font="5">oxaloacetic transaminase] and alanine aminotransferase [serum glutamic-pyruvic transaminase]) if </text>
<text top="406" left="135" width="471" height="21" font="5">there are signs or symptoms suggesting hepatotoxicity (S5<a href="CIR.0000000000000625.html#116">-13–S5-15)</a>. </text>
<text top="426" left="108" width="702" height="21" font="5">7.  An asymptomatic increase in transaminases (&gt;3 times upper limit of normal) is an infrequent statin-</text>
<text top="446" left="135" width="679" height="21" font="5">associated side effect that often resolves with dose reduction or rechallenge with alternative statins </text>
<text top="466" left="135" width="680" height="21" font="5">(S5<a href="CIR.0000000000000625.html#115">-1,</a> S5<a href="CIR.0000000000000625.html#117">-22)</a>. Severe statin-associated hepatotoxicity is rare, and the incidence is not impacted by </text>
<text top="486" left="135" width="679" height="21" font="5">routine monitoring of transaminases (S5<a href="CIR.0000000000000625.html#117">-34)</a>. A thorough evaluation for nonstatin etiologies is </text>
<text top="507" left="135" width="688" height="21" font="5">warranted when significant transaminase elevation persists. Importantly, statins are not </text>
<text top="527" left="135" width="679" height="21" font="5">contraindicated in patients with increased ASCVD risk with chronic, stable liver disease (e.g., </text>
<text top="547" left="135" width="552" height="21" font="5">nonalcoholic fatty liver), and limited data suggest potential benefit (S5<a href="CIR.0000000000000625.html#116">-16–S5-18)</a>. </text>
<text top="567" left="108" width="707" height="21" font="5">8.  Severe statin-associated side effects are rare, and recurrent SAMS are infrequent when a thorough </text>
<text top="587" left="135" width="679" height="21" font="5">reassessment and management strategy of reassess, rediscuss, and rechallenge is used. In patients at </text>
<text top="607" left="135" width="679" height="21" font="5">increased ASCVD risk with severe statin-associated side effects or recurrent SAMS, nonstatin therapy </text>
<text top="627" left="135" width="500" height="21" font="5">should be considered when there is net clinical benefit (S5<a href="CIR.0000000000000625.html#116">-5,</a> S5<a href="CIR.0000000000000625.html#116">-6,</a> S5<a href="CIR.0000000000000625.html#116">-19)</a>. </text>
<text top="648" left="108" width="706" height="21" font="5">9.  The clinical diagnosis of SAMS remains challenging, given that the majority of symptoms are subjective </text>
<text top="668" left="135" width="682" height="21" font="5">and  definitive diagnostic criteria do not exist (S5<a href="CIR.0000000000000625.html#116">-13)</a>. Multiple potential mechanisms have been </text>
<text top="688" left="135" width="681" height="21" font="5">suggested to contribute to SAMS,  including depletion of ubiquinone or coenzyme Q10. Available </text>
<text top="708" left="135" width="680" height="21" font="5">evidence, however, does not support the use of coenzyme Q10 supplementation for routine use in </text>
<text top="728" left="135" width="495" height="21" font="5">patients treated with statins or for the treatment of SAMS (S5<a href="CIR.0000000000000625.html#116">-20,</a> S5<a href="CIR.0000000000000625.html#116">-21)</a>. </text>
<text top="748" left="108" width="702" height="21" font="5">10.  The majority of SAMS are subjective myalgia in the absence of other findings (S5<a href="CIR.0000000000000625.html#115">-3,</a> S5<a href="CIR.0000000000000625.html#116">-13,</a> S5<a href="CIR.0000000000000625.html#116">-14,</a> S5-</text>
<text top="768" left="135" width="681" height="21" font="5"><a href="CIR.0000000000000625.html#117">23,</a> S5<a href="CIR.0000000000000625.html#117">-30)</a>, and an asymptomatic increase in transaminases (&gt;3 times upper limit of normal) is an </text>
<text top="789" left="135" width="680" height="21" font="5">infrequent statin-associated side effect (S5<a href="CIR.0000000000000625.html#115">-1,</a> S5<a href="CIR.0000000000000625.html#117">-22,</a> S5<a href="CIR.0000000000000625.html#117">-24)</a>. Therefore, CK and transaminase levels </text>
<text top="809" left="135" width="681" height="21" font="5">should not be routinely measured given the unlikely impact on clinical outcomes, and the lack of </text>
<text top="829" left="135" width="259" height="21" font="5">established cost effectiveness (S5<a href="CIR.0000000000000625.html#116">-15)</a>. </text>
<text top="849" left="108" width="4" height="21" font="5"> </text>
<text top="869" left="108" width="4" height="21" font="5"> </text>
<text top="889" left="108" width="4" height="21" font="4"><b> </b></text>
<text top="889" left="324" width="4" height="21" font="4"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="62" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-62_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 62</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="319" height="21" font="4"><b>Table 11. Statin-Associated Side Effects (SASE)</b> </text>
<text top="144" left="108" width="4" height="21" font="5"> </text>
<text top="165" left="116" width="156" height="21" font="4"><b>Statin-Associated Side </b></text>
<text top="185" left="116" width="50" height="21" font="4"><b>Effects </b></text>
<text top="185" left="337" width="75" height="21" font="4"><b>Frequency </b></text>
<text top="185" left="474" width="145" height="21" font="4"><b>Predisposing Factors </b></text>
<text top="185" left="652" width="136" height="21" font="4"><b>Quality of Evidence </b></text>
<text top="206" left="116" width="302" height="21" font="4"><b>Statin-associated muscle symptoms (SAMS) </b></text>
<text top="232" left="114" width="148" height="21" font="5">Myalgias (CK Normal) </text>
<text top="232" left="291" width="151" height="21" font="5">Infrequent (1% to 5%) </text>
<text top="252" left="291" width="166" height="21" font="5">in RCTs; frequent (5% to </text>
<text top="273" left="291" width="149" height="21" font="5">10%) in observational </text>
<text top="293" left="291" width="130" height="21" font="5">studies and clinical </text>
<text top="313" left="291" width="50" height="21" font="5">setting </text>
<text top="232" left="470" width="141" height="21" font="5">Age, female sex, low </text>
<text top="252" left="470" width="119" height="21" font="5">body mass index, </text>
<text top="273" left="470" width="147" height="21" font="5">high-risk medications </text>
<text top="293" left="470" width="132" height="21" font="5">(CYP3A4 inhibitors, </text>
<text top="313" left="470" width="143" height="21" font="5">OATP1B1 inhibitors), </text>
<text top="333" left="470" width="133" height="21" font="5">comorbidities (HIV, </text>
<text top="353" left="470" width="136" height="21" font="5">renal, liver, thyroid, </text>
<text top="373" left="470" width="78" height="21" font="5">preexisting </text>
<text top="393" left="470" width="121" height="21" font="5">myopathy), Asian </text>
<text top="413" left="470" width="112" height="21" font="5">ancestry, excess </text>
<text top="434" left="470" width="148" height="21" font="5">alcohol, high levels of </text>
<text top="454" left="470" width="143" height="21" font="5">physical activity, and </text>
<text top="474" left="470" width="53" height="21" font="5">trauma </text>
<text top="232" left="635" width="36" height="21" font="5">RCTs </text>
<text top="252" left="635" width="152" height="21" font="5">cohorts/observational </text>
<text top="495" left="116" width="134" height="21" font="5">Myositis/myopathy </text>
<text top="515" left="116" width="109" height="21" font="5">(CK &gt; ULN) with </text>
<text top="535" left="116" width="151" height="21" font="5">concerning symptoms </text>
<text top="555" left="116" width="149" height="21" font="5">or objective weakness</text>
<text top="561" left="265" width="4" height="13" font="1"> </text>
<text top="495" left="291" width="35" height="21" font="5">Rare </text>
<text top="499" left="470" width="4" height="13" font="1"> </text>
<text top="495" left="635" width="36" height="21" font="5">RCTs </text>
<text top="515" left="635" width="152" height="21" font="5">cohorts/observational </text>
<text top="576" left="116" width="113" height="21" font="5">Rhabdomyolysis </text>
<text top="596" left="116" width="145" height="21" font="5">(CK &gt;10× ULN + renal </text>
<text top="616" left="116" width="43" height="21" font="5">injury)</text>
<text top="622" left="160" width="4" height="13" font="0"><b> </b></text>
<text top="576" left="291" width="31" height="21" font="5">Rare</text>
<text top="582" left="322" width="4" height="13" font="1"> </text>
<text top="580" left="470" width="4" height="13" font="1"> </text>
<text top="576" left="635" width="36" height="21" font="5">RCTs </text>
<text top="596" left="635" width="149" height="21" font="5">cohorts/observational</text>
<text top="602" left="784" width="4" height="13" font="1"> </text>
<text top="637" left="116" width="119" height="21" font="5">Statin-associated </text>
<text top="657" left="116" width="162" height="21" font="5">autoimmune myopathy </text>
<text top="678" left="116" width="140" height="21" font="5">(HMGCR antibodies, </text>
<text top="698" left="116" width="156" height="21" font="5">incomplete resolution)<b> </b></text>
<text top="637" left="291" width="35" height="21" font="5">Rare </text>
<text top="637" left="470" width="4" height="21" font="5"> </text>
<text top="637" left="635" width="88" height="21" font="5">Case reports </text>
<text top="719" left="116" width="141" height="21" font="4"><b>New-onset diabetes </b></text>
<text top="739" left="116" width="63" height="21" font="4"><b>mellitus  </b></text>
<text top="719" left="291" width="165" height="21" font="5">Depends on population; </text>
<text top="739" left="291" width="115" height="21" font="5">more frequent if </text>
<text top="759" left="291" width="146" height="21" font="5">diabetes mellitus risk </text>
<text top="779" left="291" width="135" height="21" font="5">factors are present, </text>
<text top="799" left="291" width="128" height="21" font="5">such as body mass </text>
<text top="819" left="291" width="164" height="21" font="5">index ≥30, fasting blood </text>
<text top="840" left="291" width="128" height="21" font="5">sugar ≥100 mg/dL; </text>
<text top="860" left="291" width="164" height="21" font="5">metabolic syndrome, or </text>
<text top="880" left="291" width="87" height="21" font="5">A1c ≥6% <a href="CIR.0000000000000625.html#116">(8)</a>. </text>
<text top="719" left="470" width="147" height="21" font="5">Diabetes mellitus risk </text>
<text top="739" left="470" width="123" height="21" font="5">factors/metabolic </text>
<text top="759" left="470" width="71" height="21" font="5">syndrome </text>
<text top="779" left="470" width="139" height="21" font="5">High-intensity statin </text>
<text top="799" left="470" width="56" height="21" font="5">therapy </text>
<text top="719" left="635" width="139" height="21" font="5">RCTs/meta-analyses </text>
<text top="901" left="116" width="37" height="21" font="4"><b>Liver </b></text>
<text top="922" left="116" width="97" height="21" font="5">Transaminase </text>
<text top="942" left="116" width="118" height="21" font="5">elevation 3× ULN </text>
<text top="922" left="291" width="4" height="21" font="5"> </text>
<text top="942" left="291" width="75" height="21" font="5">Infrequent </text>
<text top="922" left="470" width="4" height="21" font="5"> </text>
<text top="922" left="635" width="4" height="21" font="5"> </text>
<text top="942" left="635" width="43" height="21" font="5">RCTs/ </text>
<text top="963" left="635" width="152" height="21" font="5">cohorts/observational </text>
<text top="983" left="635" width="88" height="21" font="5">Case reports </text>
<text top="1004" left="116" width="98" height="21" font="5">Hepatic failure</text>
<text top="1009" left="215" width="4" height="13" font="0"><b> </b></text>
<text top="1004" left="291" width="31" height="21" font="5">Rare</text>
<text top="1009" left="322" width="4" height="13" font="1"> </text>
<text top="1008" left="470" width="4" height="13" font="1"> </text>
<text top="1008" left="635" width="4" height="13" font="1"> </text>
<text top="1024" left="108" width="4" height="21" font="5"> </text>
<text top="1024" left="324" width="4" height="21" font="5"> </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="63" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-63_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 63</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="125" left="116" width="164" height="21" font="4"><b>Central nervous system </b></text>
<text top="152" left="116" width="127" height="21" font="5">Memory/cognition</text>
<text top="157" left="243" width="4" height="13" font="0"><b> </b></text>
<text top="152" left="291" width="87" height="21" font="5">Rare/unclear</text>
<text top="157" left="378" width="4" height="13" font="1"> </text>
<text top="156" left="470" width="4" height="13" font="1"> </text>
<text top="152" left="635" width="114" height="21" font="5">Case reports; no </text>
<text top="172" left="635" width="76" height="21" font="5">increase in </text>
<text top="192" left="635" width="129" height="21" font="5">memory/cognition </text>
<text top="212" left="635" width="134" height="21" font="5">problems in 3 large-</text>
<text top="232" left="635" width="69" height="21" font="5">scale RCTs</text>
<text top="238" left="704" width="4" height="13" font="1"> </text>
<text top="253" left="116" width="51" height="21" font="4"><b>Cancer </b></text>
<text top="253" left="291" width="157" height="21" font="5">No definite association </text>
<text top="253" left="470" width="4" height="21" font="5"> </text>
<text top="253" left="635" width="139" height="21" font="5">RCTs/meta-analyses </text>
<text top="274" left="116" width="40" height="21" font="4"><b>Other</b></text>
<text top="280" left="156" width="4" height="13" font="1"> </text>
<text top="295" left="116" width="102" height="21" font="5">Renal function </text>
<text top="295" left="291" width="132" height="21" font="5">Unclear/unfounded</text>
<text top="301" left="423" width="4" height="13" font="1"> </text>
<text top="299" left="470" width="4" height="13" font="1"> </text>
<text top="299" left="635" width="4" height="13" font="1"> </text>
<text top="316" left="116" width="67" height="21" font="5">Cataracts </text>
<text top="316" left="291" width="52" height="21" font="5">Unclear</text>
<text top="322" left="343" width="4" height="13" font="1"> </text>
<text top="320" left="470" width="4" height="13" font="1"> </text>
<text top="320" left="635" width="4" height="13" font="1"> </text>
<text top="337" left="116" width="110" height="21" font="5">Tendon rupture </text>
<text top="337" left="291" width="132" height="21" font="5">Unclear/unfounded</text>
<text top="342" left="423" width="4" height="13" font="1"> </text>
<text top="341" left="470" width="4" height="13" font="1"> </text>
<text top="341" left="635" width="4" height="13" font="1"> </text>
<text top="358" left="116" width="137" height="21" font="5">Hemorrhagic stroke </text>
<text top="358" left="291" width="52" height="21" font="5">Unclear</text>
<text top="363" left="343" width="4" height="13" font="1"> </text>
<text top="362" left="470" width="4" height="13" font="1"> </text>
<text top="362" left="635" width="4" height="13" font="1"> </text>
<text top="378" left="116" width="307" height="21" font="5">Interstitial lung disease  Unclear/unfounded</text>
<text top="384" left="423" width="4" height="13" font="1"> </text>
<text top="383" left="470" width="4" height="13" font="1"> </text>
<text top="383" left="635" width="4" height="13" font="1"> </text>
<text top="399" left="116" width="121" height="21" font="5">Low testosterone </text>
<text top="399" left="291" width="132" height="21" font="5">Unclear/unfounded</text>
<text top="405" left="423" width="4" height="13" font="1"> </text>
<text top="403" left="470" width="4" height="13" font="1"> </text>
<text top="403" left="635" width="4" height="13" font="1"> </text>
<text top="420" left="108" width="705" height="19" font="1">CK indicates creatine kinase; HIV, human immunodeficiency virus; HMGCR, 3-hydroxy-3-methyl-glutaryl-coenzyme </text>
<text top="439" left="108" width="707" height="19" font="1">A reductase; SAMS, statin-associated muscle symptoms; SAAM, statin-associated autoimmune myopathy; SASE, </text>
<text top="457" left="108" width="378" height="19" font="1">statin associated side effects; and ULN, upper limit of normal. </text>
<text top="475" left="108" width="4" height="21" font="5"> </text>
<text top="524" left="108" width="191" height="31" font="11"><b>6. Implementation </b></text>
<text top="568" left="326" width="271" height="21" font="4"><b>Recommendations for Implementation </b></text>
<text top="588" left="124" width="474" height="21" font="5">Referenced studies that support recommendations are summarized in<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625"> </a></text>
<text top="588" left="598" width="199" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Online Data Supplements 42, </a></text>
<text top="608" left="397" width="119" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">43, 44, 45, and 46</a></text>
<text top="608" left="517" width="8" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">.</a> </text>
<text top="629" left="127" width="33" height="21" font="4"><b>COR </b></text>
<text top="629" left="196" width="30" height="21" font="4"><b>LOE </b></text>
<text top="629" left="462" width="132" height="21" font="4"><b>Recommendations </b></text>
<text top="705" left="140" width="8" height="21" font="4"><b>I </b></text>
<text top="705" left="204" width="14" height="21" font="4"><b>A </b></text>
<text top="660" left="251" width="558" height="21" font="4"><b>1.  Interventions focused on improving adherence to prescribed therapy are </b></text>
<text top="680" left="278" width="530" height="21" font="4"><b>recommended for management of adults with elevated cholesterol levels, </b></text>
<text top="701" left="278" width="546" height="21" font="4"><b>including telephone reminders, calendar reminders, integrated </b></text>
<text top="721" left="278" width="528" height="21" font="4"><b>multidisciplinary educational activities, and pharmacist-led interventions, </b></text>
<text top="741" left="278" width="517" height="21" font="4"><b>such as simplification of the drug regimen to once-daily dosing</b> <b>(S6<a href="CIR.0000000000000625.html#117">-1–S6-4)</a></b><b>. </b></text>
<text top="810" left="140" width="8" height="21" font="4"><b>I </b></text>
<text top="810" left="192" width="38" height="21" font="4"><b>B-NR </b></text>
<text top="771" left="251" width="555" height="21" font="4"><b>2.  Clinicians, health systems, and health plans should identify patients who are </b></text>
<text top="791" left="278" width="530" height="21" font="4"><b>not receiving guideline-directed medical therapy and should  facilitate the </b></text>
<text top="811" left="278" width="528" height="21" font="4"><b>initiation of appropriate guideline-directed medical therapy,  using </b></text>
<text top="831" left="278" width="508" height="21" font="4"><b>multifaceted strategies to improve guideline implementation (S6<a href="CIR.0000000000000625.html#117">-5, </a></b><b>S6<a href="CIR.0000000000000625.html#118">-6)</a></b><b>. </b></text>
<text top="906" left="140" width="8" height="21" font="4"><b>I </b></text>
<text top="906" left="192" width="38" height="21" font="4"><b>B-NR </b></text>
<text top="861" left="251" width="555" height="21" font="4"><b>3.  Before therapy is prescribed, a patient-clinician discussion should take place </b></text>
<text top="881" left="278" width="531" height="21" font="4"><b>to promote shared decision-making  and  should  include the potential for </b></text>
<text top="901" left="278" width="530" height="21" font="4"><b>ASCVD  risk-reduction benefit, adverse effects, drug-drug interactions, and </b></text>
<text top="921" left="278" width="220" height="21" font="4"><b>patient preferences (S6<a href="CIR.0000000000000625.html#118">-7, </a></b><b>S6<a href="CIR.0000000000000625.html#118">-8)</a></b><b>.</b></text>
<text top="920" left="498" width="4" height="23" font="14"> </text>
<text top="963" left="108" width="4" height="21" font="5"> </text>
<text top="1001" left="108" width="63" height="21" font="4"><b>Synopsis</b> </text>
<text top="1041" left="108" width="706" height="21" font="5">Guideline publication does not guarantee guideline implementation. Healthcare delivery is complex, and </text>
<text top="1061" left="108" width="707" height="21" font="5">barriers to guideline implementation can occur at the patient, clinician, health system, and health plan </text>
<text top="1081" left="108" width="705" height="21" font="5">levels, leading to gaps in care. A more concerted effort, with multifaceted strategies aimed at the patient, </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="64" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-64_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 64</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="706" height="21" font="5">clinician, health system, and health plan, is needed to overcome the barriers and achieve wider guideline </text>
<text top="144" left="108" width="118" height="21" font="5">implementation<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625"> (</a></text>
<text top="144" left="226" width="58" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Table S7</a></text>
<text top="144" left="284" width="532" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">)</a>. The patient is a key player in successful guideline implementation, and the </text>
<text top="164" left="108" width="706" height="21" font="5">clinician–patient discussion is crucial to the successful initiation and continuation of guideline-directed </text>
<text top="184" left="108" width="708" height="21" font="5">management and therapy (Table 7). As part of the clinician–patient discussion, the patient should be </text>
<text top="204" left="108" width="706" height="21" font="5">encouraged to state what was heard, ask questions, express values and preferences, and state ability and </text>
<text top="225" left="108" width="706" height="21" font="5">willingness to adhere to lifestyle changes and medications. This is where a discussion of out-of-pocket </text>
<text top="245" left="108" width="705" height="21" font="5">costs can occur. Clinicians should use multiple interventions to promote adherence, including asking more </text>
<text top="265" left="108" width="713" height="21" font="5">specific questions about adherence, aiming for  once-daily dosing, using automated reminders, </text>
<text top="285" left="108" width="639" height="21" font="5">participating in multidisciplinary educational activities, and using pharmacist-led interventions. </text>
<text top="314" left="108" width="295" height="21" font="4"><b>Recommendation-Specific Supportive Text </b></text>
<text top="353" left="108" width="712" height="21" font="5">1.  Interventions focused on improving adherence to prescribed therapy are recommended for </text>
<text top="374" left="135" width="679" height="21" font="5">management of adults with elevated cholesterol levels. A Cochrane systematic review demonstrated </text>
<text top="394" left="135" width="680" height="21" font="5">that intensification of patient care interventions improves both short- and long-term adherence to </text>
<text top="414" left="135" width="684" height="21" font="5">medication,  as well as meaningful reduction in LDL-C levels. Interventions include telephone </text>
<text top="434" left="135" width="681" height="21" font="5">reminders, calendar reminders, integrated multidisciplinary educational activities, simplification of </text>
<text top="454" left="135" width="679" height="21" font="5">the drug regimen to once-daily dosing, and pharmacist-led interventions (S6<a href="CIR.0000000000000625.html#117">-1–S6-4)</a>.<b> </b>Clinicians may </text>
<text top="474" left="135" width="101" height="21" font="5">wish to revi<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">ew </a></text>
<text top="474" left="236" width="217" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Table S7 in the Web Supplement</a></text>
<text top="474" left="453" width="361" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">,</a> “Strategies to Improve Guideline Implementation by </text>
<text top="494" left="135" width="548" height="21" font="5">Setting and Target Audience Measures to Improve Lipid Medication Adherence.” <b> </b></text>
<text top="514" left="108" width="705" height="21" font="5">2.  Clinicians do not follow guidelines for many reasons (S6<a href="CIR.0000000000000625.html#118">-9)</a>, and cholesterol guideline implementation </text>
<text top="535" left="135" width="682" height="21" font="5">has not been  optimal  (S6<a href="CIR.0000000000000625.html#118">-10–S6-13)</a>. Interventions aimed at the clinician may improve guideline </text>
<text top="555" left="135" width="685" height="21" font="5">implementation. Educational outreach or academic detailing visits are generally effective for </text>
<text top="575" left="135" width="679" height="21" font="5">improving process-of-care, clinical, cost-reduction, and cost-effectiveness outcomes (S6<a href="CIR.0000000000000625.html#117">-5)</a>. Audits of </text>
<text top="595" left="135" width="679" height="21" font="5">individual clinical performance and feedback are generally effective in improving process-of-care and </text>
<text top="615" left="135" width="681" height="21" font="5">clinical outcomes (S6<a href="CIR.0000000000000625.html#117">-5)</a>. Reminders and individual pay-for-performance are generally effective for </text>
<text top="635" left="135" width="151" height="21" font="5">cost reduction (S6<a href="CIR.0000000000000625.html#117">-5)</a>. <b> </b></text>
<text top="655" left="108" width="4" height="21" font="5"> </text>
<text top="655" left="135" width="4" height="21" font="5"> </text>
<text top="655" left="162" width="651" height="21" font="5">Even if guideline-directed management and therapy are prescribed, patients may be nonadherent </text>
<text top="676" left="135" width="682" height="21" font="5">or not get the prescribed medication for a variety of reasons (S6<a href="CIR.0000000000000625.html#118">-14)</a>. Patients who are initially </text>
<text top="696" left="135" width="679" height="21" font="5">adherent to statin therapy may not demonstrate long-term adherence (S6<a href="CIR.0000000000000625.html#118">-15,</a>  S6<a href="CIR.0000000000000625.html#118">-16)</a>.  Adherent </text>
<text top="716" left="135" width="675" height="21" font="5">patients, with and without clinical ASCVD, have improved outcomes and reduced costs (S6<a href="CIR.0000000000000625.html#118">-15,</a> S6<a href="CIR.0000000000000625.html#118">-17–</a></text>
<text top="736" left="135" width="680" height="21" font="5"><a href="CIR.0000000000000625.html#118">S6-20)</a>. Formulary restrictions and prior authorization requirements have been associated with care </text>
<text top="756" left="135" width="680" height="21" font="5">delays and nonadherence (S6<a href="CIR.0000000000000625.html#118">-21)</a>. Interventions aimed at the patient may improve adherence and </text>
<text top="776" left="135" width="124" height="21" font="5">clinical outcomes. </text>
<text top="797" left="108" width="4" height="21" font="5"> </text>
<text top="797" left="135" width="4" height="21" font="5"> </text>
<text top="797" left="162" width="653" height="21" font="5">Guideline implementation strategies that are aimed at the patient, clinician, health system, and </text>
<text top="817" left="135" width="681" height="21" font="5">health plan are needed. Barriers to guideline implementation should be analyzed in advance, and </text>
<text top="837" left="135" width="679" height="21" font="5">implementation strategies should be tailored to the setting and target audience. Multiple strategies </text>
<text top="857" left="135" width="433" height="21" font="5">may be needed to effectively implement guidelines (S6<a href="CIR.0000000000000625.html#117">-5, </a>S6<a href="CIR.0000000000000625.html#118">-6)</a> <a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">(</a></text>
<text top="857" left="568" width="219" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Table S7 in the Web Supplement</a></text>
<text top="857" left="787" width="13" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">).</a> </text>
<text top="877" left="108" width="706" height="21" font="5">3.  Patients who participate in shared decision-making may have better health outcomes, better </text>
<text top="897" left="135" width="679" height="21" font="5">healthcare experiences, and lower costs (S6<a href="CIR.0000000000000625.html#118">-7,</a> S6<a href="CIR.0000000000000625.html#118">-8)</a>. During the clinician–patient risk discussion with </text>
<text top="917" left="135" width="679" height="21" font="5">shared decision-making, the patient participates with the clinician in deciding lifestyle modifications, </text>
<text top="937" left="135" width="679" height="21" font="5">medication treatment, and goals of therapy. The clinician should explain the patient’s risk of clinical </text>
<text top="958" left="135" width="680" height="21" font="5">ASCVD and how the treatment recommendations reduce ASCVD risk. The patient should verbalize </text>
<text top="978" left="135" width="682" height="21" font="5">values, attitudes, abilities,  concerns, and personal goals for making lifestyle changes and taking </text>
<text top="998" left="135" width="681" height="21" font="5">medications,  including concerns about  cost  (S6<a href="CIR.0000000000000625.html#118">-22)</a>. The clinician may use a checklist to facilitate </text>
<text top="1018" left="135" width="279" height="21" font="5">shared decision-making with the patien<a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">t (</a></text>
<text top="1018" left="414" width="219" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Table S8 in the Web Supplement</a></text>
<text top="1018" left="633" width="13" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">).</a> </text>
<text top="1038" left="108" width="4" height="21" font="5"> </text>
<text top="1038" left="135" width="4" height="21" font="5"> </text>
<text top="1038" left="162" width="648" height="21" font="5">The clinician should use tools and techniques to support shared decision-making (S6<a href="CIR.0000000000000625.html#118">-7,</a> S6<a href="CIR.0000000000000625.html#118">-22–S6-</a></text>
<text top="1058" left="135" width="679" height="21" font="5"><a href="CIR.0000000000000625.html#118">26)</a>. Decision aids may allow the patient to be more knowledgeable, have better risk perception, and </text>
<text top="1078" left="135" width="682" height="21" font="5">have a clearer understanding of  their values (S6<a href="CIR.0000000000000625.html#118">-8,</a>  S6<a href="CIR.0000000000000625.html#119">-27)</a>. Question prompt lists may increase </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="65" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-65_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 65</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="135" width="679" height="21" font="5">knowledge by including questions about the purpose or goal of treatment, the risk with and without </text>
<text top="144" left="135" width="681" height="21" font="5">treatment, how the medication should be taken, potential side effects and how to manage them, </text>
<text top="164" left="135" width="679" height="21" font="5">when to notify the office, and monitoring and follow-up. Motivational interviewing (S6<a href="CIR.0000000000000625.html#119">-28)</a>  and </text>
<text top="184" left="135" width="494" height="21" font="5">decision coaching may also promote patient knowledge and satisfaction.  </text>
<text top="205" left="108" width="4" height="21" font="5"> </text>
<text top="233" left="108" width="338" height="31" font="11"><b>7. Cost and Value Considerations  </b></text>
<text top="276" left="108" width="503" height="29" font="2"><b>7.1. Economic Value Considerations: PCSK9 Inhibitors </b></text>
<text top="317" left="108" width="708" height="21" font="5">ACC/AHA clinical guidelines now recognize the importance of considering economic value in making </text>
<text top="337" left="108" width="709" height="21" font="5">recommendations,  in accordance with  the principles established by an expert group (S7.1<a href="CIR.0000000000000625.html#119">-1)</a>. PCSK9 </text>
<text top="357" left="108" width="706" height="21" font="5">inhibitors further reduce LDL-C  when combined with other LDL-lowering drugs,  and  they  reduced </text>
<text top="377" left="108" width="706" height="21" font="5">composite cardiovascular events in 2 RCTs of high-risk, secondary-prevention patients with clinical ASCVD </text>
<text top="397" left="108" width="706" height="21" font="5">(S7.1<a href="CIR.0000000000000625.html#119">-2)</a>.  The  cost-effectiveness and economic value of PCSK9 inhibitors have been assessed  by  using </text>
<text top="418" left="108" width="135" height="21" font="5">simulation models <a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">(</a></text>
<text top="418" left="243" width="247" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Online Data Supplements 47 and 48</a></text>
<text top="418" left="490" width="325" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">)</a>; the published models are based on different </text>
<text top="438" left="108" width="706" height="21" font="5">sets of assumptions. Compared with statin therapy for secondary prevention, PCSK9 inhibitors have </text>
<text top="458" left="108" width="706" height="21" font="5">incremental cost-effectiveness ratios (S7.1<a href="CIR.0000000000000625.html#119">-3)</a> from $141,700 to $450,000 per quality-adjusted life-year </text>
<text top="478" left="108" width="707" height="21" font="5">(QALY) added, at mid-2018 list prices. None of the published models report “good value” (&lt;$50,000 per </text>
<text top="498" left="108" width="708" height="21" font="5">QALY added; Table 12), and virtually all indicate “low value” (≥$150,000 per QALY added). All models </text>
<text top="518" left="108" width="708" height="21" font="5">projected mortality benefit by assuming that  mortality  rate  reductions either parallel LDL-C lowering </text>
<text top="538" left="108" width="349" height="21" font="5">(S7.1<a href="CIR.0000000000000625.html#119">-4)</a> or parallel RRRs for nonfatal ASCVD events. </text>
<text top="559" left="162" width="652" height="21" font="5">All models project higher lifetime cost from use of PCSK9 inhibitors because the cost will exceed </text>
<text top="579" left="108" width="705" height="21" font="5">any savings from prevention of cardiovascular events. To be cost-effective by conventional standards, the </text>
<text top="599" left="108" width="706" height="21" font="5">cost of PCSK9 inhibitors will have to be reduced on the order of 70% to 85% in the United States (S7.1<a href="CIR.0000000000000625.html#119">-3)</a>. </text>
<text top="619" left="108" width="707" height="21" font="5">At any given price, the economic value of PCSK9 inhibitors will be improved by restricting their use to </text>
<text top="639" left="108" width="709" height="21" font="5">patients at very high-risk  of  ASCVD events, as recommended in the present  guidelines. The inverse </text>
<text top="659" left="108" width="706" height="21" font="5">relationship between improved survival and the incremental cost-effectiveness ratio (Figure 3) indicates </text>
<text top="679" left="108" width="709" height="21" font="5">that  the  economic value of PCSK9 inhibitors will be improved by selecting higher-risk patients. One </text>
<text top="699" left="108" width="706" height="21" font="5">simulation model suggested that restricting the use of PCSK9 inhibitor therapy to patients with baseline </text>
<text top="720" left="108" width="702" height="21" font="5">LDL-C levels ≥119 mg/dL (≥3 mmol/L), instead of ≥70 mg/dL (≥1.8 mmol/L), would improve their cost-</text>
<text top="740" left="108" width="705" height="21" font="5">effectiveness to $150,000 per QALY added, instead of $268,000 (S7.1<a href="CIR.0000000000000625.html#119">-5)</a>. Another study projected a similar </text>
<text top="760" left="108" width="706" height="21" font="5">improvement in economic value (S7.1<a href="CIR.0000000000000625.html#119">-6)</a>. Thus, raising the threshold for LDL-C on maximal statin therapy </text>
<text top="780" left="108" width="511" height="21" font="5">to initiate a PCSK9 inhibitor should improve its cost-effectiveness (Figure 3). </text>
<text top="800" left="108" width="4" height="21" font="5"> </text>
<text top="800" left="162" width="653" height="21" font="5">Only 2 economic models have specifically examined the value provided by PCSK9 inhibitors for </text>
<text top="820" left="108" width="369" height="21" font="5">primary prevention in patients with heterozygous FH <a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">(</a></text>
<text top="820" left="477" width="188" height="21" font="13"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">Online Data Supplement 45</a></text>
<text top="820" left="665" width="149" height="21" font="5"><a href="https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000625">)</a>. One model (S7.1<a href="CIR.0000000000000625.html#119">-7)</a> </text>
<text top="840" left="108" width="705" height="21" font="5">found low value when PCSK9 inhibitors were used for FH ($503,000 per QALY added), whereas the second </text>
<text top="861" left="108" width="708" height="21" font="5">model (S7.1<a href="CIR.0000000000000625.html#119">-8)</a> reported intermediate value (incremental cost-effectiveness ratio of $75,900 per QALY </text>
<text top="881" left="108" width="524" height="21" font="5">added). Consequently, the value of PCSK9 inhibitor therapy in FH is uncertain. </text>
<text top="901" left="108" width="4" height="21" font="5"> </text>
<text top="901" left="162" width="4" height="21" font="5"> </text>
<text top="921" left="108" width="4" height="21" font="4"><b> </b></text>
<text top="921" left="324" width="4" height="21" font="4"><b> </b></text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="66" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-66_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 66</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="627" height="21" font="4"><b>Table 12. Proposed Integration of Level of Value Into Clinical Guideline Recommendations*</b> </text>
<text top="144" left="108" width="4" height="21" font="5"> </text>
<text top="165" left="116" width="100" height="21" font="4"><b>Level of Value </b></text>
<text top="198" left="116" width="100" height="21" font="4"><b>Level of Value </b></text>
<text top="231" left="116" width="520" height="21" font="4"><b>High value:</b> Better outcomes at lower cost or ICER &lt;$50,000 per QALY gained </text>
<text top="263" left="116" width="404" height="21" font="4"><b>Intermediate value:</b> $50,000 to &lt;$150,000 per QALY gained </text>
<text top="295" left="116" width="267" height="21" font="4"><b>Low value:</b> ≥$150,000 per QALY gained </text>
<text top="327" left="116" width="674" height="21" font="4"><b>Uncertain value: </b>Value examined, but data are insufficient to draw a conclusion because of absence </text>
<text top="350" left="116" width="627" height="21" font="5">of studies, low-quality studies, conflicting studies, or prior studies that are no longer relevant </text>
<text top="382" left="116" width="402" height="21" font="4"><b>Not assessed:</b> Value not assessed by the writing committee </text>
<text top="415" left="116" width="386" height="21" font="5">Proposed abbreviations for each value recommendation: </text>
<text top="448" left="116" width="688" height="21" font="5">Level of value: H to indicate high value; I, intermediate value; L, low value; U, uncertain value; and NA, </text>
<text top="471" left="116" width="133" height="21" font="5">value not assessed. </text>
<text top="504" left="108" width="705" height="19" font="1">*Dollar amounts used in this table are based on U.S. GDP data from 2012 and were obtained from WHO-CHOICE </text>
<text top="522" left="108" width="239" height="19" font="1">Cost-Effectiveness Thresholds (S7.1<a href="CIR.0000000000000625.html#119">-9)</a>. </text>
<text top="541" left="108" width="261" height="19" font="1">Reproduced from Anderson et al. (S7.1<a href="CIR.0000000000000625.html#119">-1)</a>. </text>
<text top="559" left="108" width="705" height="19" font="1">GDP indicates gross domestic product; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-years; </text>
<text top="577" left="108" width="571" height="19" font="1">and WHO-CHOICE, World Health Organization Choosing Interventions that are Cost-Effective. </text>
<text top="595" left="108" width="4" height="21" font="4"><b> </b></text>
<text top="595" left="324" width="4" height="21" font="5"> </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="67" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-67_1.jpg"/>
<image top="156" left="108" width="648" height="505" src="blood-cholesterol-management/CIR.0000000000000625-67_2.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 67</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="395" height="21" font="4"><b>Figure 3. Cost-Effectiveness Analysis for PCSK9 Inhibitors  </b></text>
<text top="647" left="756" width="4" height="21" font="4"><b> </b></text>
<text top="675" left="108" width="707" height="19" font="1">Conceptual relationship between the clinical effectiveness of PCSK9 inhibitor therapy, measured in QALYs added </text>
<text top="693" left="108" width="706" height="19" font="1">compared with statin therapy, on the horizontal axis, and their clinical value, measured in dollars per QALY added, </text>
<text top="711" left="108" width="709" height="19" font="1">on the vertical axis. The top curve indicates the relationship at full U.S  list price of PCSK9 inhibitor therapy </text>
<text top="730" left="108" width="705" height="19" font="1">($14,000/y), the middle curve indicates the relationship if the price were reduced by 50% (i.e., to $7,000/y), and the </text>
<text top="748" left="108" width="551" height="19" font="1">bottom curve indicates the relationship if the price were reduced by 75% (i.e., to $3,500/y).</text>
<text top="746" left="659" width="4" height="21" font="5"> </text>
<text top="748" left="662" width="151" height="19" font="1">Reproduced from Hlatky </text>
<text top="766" left="108" width="84" height="19" font="1">et al (S7.1<a href="CIR.0000000000000625.html#119">-3)</a>. </text>
<text top="784" left="108" width="405" height="19" font="1">CV indicates cardiovascular; and QALY, quality-adjusted life-years. </text>
<text top="802" left="108" width="4" height="21" font="5"> </text>
<text top="832" left="108" width="4" height="21" font="5"> </text>
<text top="864" left="108" width="4" height="21" font="5"> </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="68" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-68_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 68</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="361" height="31" font="11"><b>8. Limitations and Knowledge Gaps  </b></text>
<text top="166" left="108" width="320" height="29" font="2"><b>8.1. Randomized Controlled Trials </b></text>
<text top="207" left="108" width="706" height="21" font="5">ACC/AHA guidelines are based largely on the outcomes of RCTs. Cholesterol guidelines have fortunately </text>
<text top="227" left="108" width="708" height="21" font="5">benefited from a large number of RCTs of cholesterol-lowering therapies.  They have established that </text>
<text top="247" left="108" width="706" height="21" font="5">greater reductions of LDL-C are accompanied by greater reductions in risk of ASCVD. Robust RCTs exist for </text>
<text top="268" left="108" width="708" height="21" font="5">both primary and secondary prevention. Most of the data from RCTs have been obtained with statin </text>
<text top="288" left="108" width="709" height="21" font="5">therapy.  Important limited data have also been obtained with nonstatins as add-on drugs to statin </text>
<text top="308" left="108" width="706" height="21" font="5">therapy. Nevertheless, more data are needed to determine the full scope of the benefit of nonstatin drugs. </text>
<text top="328" left="108" width="473" height="21" font="5">Several important questions need to be addressed by additional RCTs. </text>
<text top="348" left="145" width="672" height="21" font="5">1.  In secondary prevention, does  a lower limit for LDL-C attainment exist,  beyond which the </text>
<text top="368" left="172" width="607" height="21" font="5">incremental benefit attained is worth neither the risks nor the cost of additional therapy?  </text>
<text top="388" left="145" width="669" height="21" font="5">2.  In secondary prevention, what are the indications for adding PCSK9 inhibitors to maximal statin </text>
<text top="409" left="172" width="64" height="21" font="5">therapy? </text>
<text top="429" left="145" width="669" height="21" font="5">3.  In patients with ASCVD who have statin-associated side effects, are PCSK9 inhibitors an effective </text>
<text top="449" left="172" width="306" height="21" font="5">and safe substitute for high-intensity statins? </text>
<text top="469" left="145" width="669" height="21" font="5">4.  In primary prevention for adults 45 to 75 years of age (LDL-C &lt;90 mg/dL [&lt;2.3 mmol/L]) with or </text>
<text top="489" left="172" width="642" height="21" font="5">without  diabetes mellitus, what is the incremental risk reduction imparted by high-intensity </text>
<text top="509" left="172" width="360" height="21" font="5">statins as compared with moderate-intensity statins? </text>
<text top="529" left="145" width="669" height="21" font="5">5.  In primary prevention for adults 45 to 75 years of age (LDL-C &lt;190 mg/dL [&lt;4.9 mmol/L]) with or </text>
<text top="550" left="172" width="638" height="21" font="5">without  diabetes mellitus, what is the incremental risk reduction imparted by moderate-</text>
<text top="570" left="172" width="568" height="21" font="5">intensity statins plus ezetimibe as compared with moderate-intensity statins alone?  </text>
<text top="590" left="145" width="670" height="21" font="5">6.  Is statin therapy efficacious and safe in older patients (&gt;75 years of age)? If so, what is a net </text>
<text top="610" left="172" width="290" height="21" font="5">benefit of statin therapy in this age group? </text>
<text top="630" left="145" width="670" height="21" font="5">7.  In patients with severe hypercholesterolemia, what are the efficacy and net benefit of PCSK9 </text>
<text top="650" left="172" width="393" height="21" font="5">inhibitors as add-on treatment to maximal statin therapy? </text>
<text top="670" left="145" width="665" height="21" font="5">8.  What is the efficacy of moderate-intensity and high-intensity statin therapy in patients with risk-</text>
<text top="690" left="172" width="555" height="21" font="5">enhancing factors (e.g., chronic inflammatory disease, CKD, metabolic syndrome)? </text>
<text top="711" left="108" width="4" height="21" font="5"> </text>
<text top="731" left="108" width="198" height="29" font="2"><b>8.2. Risk Assessment </b></text>
<text top="771" left="108" width="705" height="21" font="5">In primary prevention, the appropriate selection of patients for cholesterol-lowering drug therapy is highly </text>
<text top="792" left="108" width="706" height="21" font="5">dependent on risk assessment.  Previous guidelines made use of risk-assessment algorithms (e.g., </text>
<text top="812" left="108" width="710" height="21" font="5">Framingham risk scoring or PCE) to estimate risk. Although these equations are useful, they may </text>
<text top="832" left="108" width="706" height="21" font="5">overestimate or underestimate risk for individual patients. For this reason, the 2013 ACC/AHA guidelines </text>
<text top="852" left="108" width="707" height="21" font="5">(S8.2<a href="CIR.0000000000000625.html#120">-1)</a> introduced the clinician–patient risk discussion to facilitate clinical decisions about appropriate </text>
<text top="872" left="108" width="706" height="21" font="5">therapy. In the present guidelines, the clinician–patient risk discussion has been amplified and made an </text>
<text top="892" left="108" width="706" height="21" font="5">integral part of the clinical decision. In addition, in cases in which uncertainty exists, the measurement of </text>
<text top="912" left="108" width="708" height="21" font="5">CAC has been proposed as a third step in making a treatment decision. Each of these steps could be </text>
<text top="933" left="108" width="213" height="21" font="5">improved for future guidelines. </text>
<text top="962" left="108" width="323" height="27" font="16"><i><b>8.2.1. Continuing Refinement of PCE  </b></i></text>
<text top="1000" left="108" width="710" height="21" font="5">Because  the population baseline risk may be continually declining in the U.S.  population, ongoing </text>
<text top="1020" left="108" width="706" height="21" font="5">epidemiological study is needed to assess and update population risk. An example is the development of </text>
<text top="1040" left="108" width="474" height="21" font="5">QRISK in the U.K. population, which is continually expanding its scope. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="69" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-69_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 69</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="398" height="27" font="16"><i><b>8.2.2. Improvement in Lifetime Risk Estimate  </b></i></text>
<text top="162" left="108" width="707" height="21" font="5">The present guidelines include a lifetime ASCVD risk algorithm for those 20 to 59 years of age, but it is </text>
<text top="183" left="108" width="705" height="21" font="5">based on an insufficient database. Along with a risk algorithm for short-term risk of ASCVD (e.g., 10 years), </text>
<text top="203" left="108" width="707" height="21" font="5">a more robust lifetime risk algorithm would facilitate the clinician–patient risk discussion for treatment </text>
<text top="223" left="108" width="70" height="21" font="5">decisions. </text>
<text top="252" left="108" width="469" height="27" font="16"><i><b>8.2.3. Refinement of Clinician–Patient Risk Discussion </b></i></text>
<text top="290" left="108" width="705" height="21" font="5">An ongoing study of how a clinician can best interact with a patient to arrive at an informed decision must </text>
<text top="311" left="108" width="702" height="21" font="5">be done, taking multiple factors into consideration. This is particularly important because cholesterol-</text>
<text top="331" left="108" width="345" height="21" font="5">lowering therapy is meant to be a lifetime therapy. </text>
<text top="360" left="108" width="420" height="27" font="16"><i><b>8.2.4. Monitoring and Adjustment of Treatment </b></i></text>
<text top="398" left="108" width="707" height="21" font="5">The clinician–patient risk discussion will likely prove inadequate unless an ongoing interaction between </text>
<text top="418" left="108" width="706" height="21" font="5">the patient and clinician occurs. This involves monitoring the effectiveness of therapy and adherence to </text>
<text top="439" left="108" width="705" height="21" font="5">therapy. Thus, the clinician–patient risk discussion should include more than the initial treatment decision. </text>
<text top="459" left="108" width="702" height="21" font="5">Ongoing research on how to improve the entire process of initial decision-making and long-term follow-</text>
<text top="479" left="108" width="109" height="21" font="5">up is necessary. </text>
<text top="508" left="108" width="321" height="27" font="16"><i><b>8.2.5. Prognostic Significance of CAC </b></i></text>
<text top="547" left="108" width="706" height="21" font="5">The present guideline makes use of the available data to predict the risk associated with CAC. These data </text>
<text top="567" left="108" width="707" height="21" font="5">need to be amplified by new and ongoing studies to guide treatment decisions. Particular uncertainty </text>
<text top="587" left="108" width="706" height="21" font="5">exists about the predictive value of intermediate CAC scores. In addition, the predictive significance of a </text>
<text top="607" left="108" width="706" height="21" font="5">CAC score of zero must be further verified in follow-up studies. For patients with a CAC score of zero, it is </text>
<text top="627" left="108" width="679" height="21" font="5">currently uncertain when and if follow-up CAC measurements should be done to reassess risk status. </text>
<text top="656" left="108" width="4" height="21" font="5"> </text>
<text top="676" left="108" width="4" height="21" font="5"> </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="70" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-70_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="435" width="48" height="19" font="1">Page 70</text>
<text top="1130" left="483" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="154" height="23" font="3"><b>Presidents and Staff</b> </text>
<text top="146" left="108" width="4" height="21" font="5"> </text>
<text top="166" left="108" width="218" height="21" font="19"><i><b>American College of Cardiology</b></i> </text>
<text top="186" left="108" width="288" height="21" font="5">C. Michael Valentine, MD, FACC, President </text>
<text top="206" left="108" width="396" height="21" font="5">Timothy W. Attebery, MBA, FACHE, Chief Executive Officer </text>
<text top="226" left="108" width="702" height="21" font="5">William J. Oetgen, MD, MBA, FACC, Executive Vice President, Science, Education, Quality, and Publishing </text>
<text top="246" left="108" width="555" height="21" font="5">MaryAnne Elma, MPH, Senior Director, Science, Education, Quality, and Publishing </text>
<text top="267" left="108" width="585" height="21" font="5">Amelia Scholtz, PhD, Publications Manager, Science, Education, Quality, and Publishing </text>
<text top="287" left="108" width="8" height="21" font="5">  </text>
<text top="307" left="108" width="416" height="21" font="19"><i><b>American College of Cardiology/American Heart Association</b></i> </text>
<text top="327" left="108" width="485" height="21" font="5">Katherine A. Sheehan, PhD, Director, Guideline Strategy and Operations </text>
<text top="347" left="108" width="396" height="21" font="5">Abdul R. Abdullah, MD, Senior Manager, Guideline Science </text>
<text top="367" left="108" width="8" height="22" font="6"><i> </i> </text>
<text top="388" left="108" width="194" height="21" font="19"><i><b>American Heart Association</b></i> </text>
<text top="408" left="108" width="245" height="21" font="5">Ivor Benjamin, MD, FAHA, President </text>
<text top="428" left="108" width="253" height="21" font="5">Nancy Brown, Chief Executive Officer </text>
<text top="448" left="108" width="471" height="21" font="5">Rose Marie Robertson, MD, FAHA, Chief Science and Medicine Officer </text>
<text top="468" left="108" width="625" height="21" font="5">Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice President, Office of Science Operations </text>
<text top="488" left="108" width="580" height="21" font="5">Prashant Nedungadi, PhD, Science and Medicine Advisor, Office of Science Operations </text>
<text top="508" left="108" width="698" height="21" font="5">Jody Hundley, Production and Operations Manager, Scientific Publications, Office of Science Operations </text>
<text top="529" left="108" width="4" height="21" font="5"> </text>
<text top="549" left="108" width="260" height="21" font="4"><b>Key Words</b>: AHA Scientific Statements </text>
<text top="548" left="368" width="402" height="22" font="5">■ Guidelines ■ biomarkers, coronary artery calcium score ■ </text>
<text top="569" left="108" width="114" height="21" font="5">pharmacological </text>
<text top="568" left="222" width="552" height="22" font="5">■ cardiovascular disease ■ cholesterol, LDL-cholesterol ■ diabetes mellitus ■ drug </text>
<text top="589" left="108" width="56" height="21" font="5">therapy </text>
<text top="588" left="164" width="620" height="22" font="5">■ hydroxymethylglutaryl-CoA reductase inhibitors/statins ■ hypercholesterolemia ■ lipids ■ </text>
<text top="609" left="108" width="133" height="21" font="5">patient compliance </text>
<text top="608" left="241" width="565" height="22" font="5">■ primary prevention ■ risk assessment ■ risk reduction discussion ■ risk treatment </text>
<text top="629" left="108" width="227" height="21" font="5">discussion, secondary prevention </text>
<text top="629" left="334" width="463" height="22" font="5">■ ezetimibe ■ proprotein convertase subtilisin/kexin type 9 inhibitor </text>
<text top="649" left="108" width="123" height="21" font="5">(PCSK9) inhibitors </text>
<text top="669" left="108" width="4" height="21" font="5"> </text>
<text top="699" left="108" width="4" height="23" font="14"> </text>
<text top="699" left="324" width="4" height="23" font="14"> </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="71" position="absolute" top="0" left="0" height="918" width="1188">
<image top="341" left="149" width="891" height="236" src="blood-cholesterol-management/CIR.0000000000000625-71_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="862" left="570" width="48" height="19" font="1">Page 71</text>
<text top="860" left="618" width="4" height="21" font="5"> </text>
<text top="151" left="108" width="636" height="23" font="3"><b>Appendix 1. Author Relationships With Industry and Other Entities (Relevant)—2018 </b></text>
<text top="173" left="108" width="947" height="23" font="3"><b>AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol* </b></text>
<text top="195" left="108" width="108" height="23" font="3"><b>(August 2018) </b></text>
<text top="282" left="143" width="73" height="19" font="0"><b>Committee </b></text>
<text top="300" left="151" width="57" height="19" font="0"><b>Member </b></text>
<text top="300" left="337" width="83" height="19" font="0"><b>Employment </b></text>
<text top="300" left="513" width="71" height="19" font="0"><b>Consultant </b></text>
<text top="282" left="601" width="59" height="19" font="0"><b>Speakers </b></text>
<text top="300" left="607" width="48" height="19" font="0"><b>Bureau </b></text>
<text top="263" left="681" width="78" height="19" font="0"><b>Ownership/ </b></text>
<text top="282" left="679" width="82" height="19" font="0"><b>Partnership/ </b></text>
<text top="300" left="691" width="58" height="19" font="0"><b>Principal </b></text>
<text top="282" left="778" width="57" height="19" font="0"><b>Personal </b></text>
<text top="300" left="777" width="60" height="19" font="0"><b>Research </b></text>
<text top="227" left="860" width="83" height="19" font="0"><b>Institutional, </b></text>
<text top="245" left="852" width="98" height="19" font="0"><b>Organizational, </b></text>
<text top="263" left="873" width="57" height="19" font="0"><b>or Other </b></text>
<text top="282" left="872" width="58" height="19" font="0"><b>Financial </b></text>
<text top="300" left="877" width="49" height="19" font="0"><b>Benefit </b></text>
<text top="300" left="971" width="97" height="19" font="0"><b>Expert Witness </b></text>
<text top="319" left="116" width="103" height="19" font="1">Scott M. Grundy </text>
<text top="337" left="116" width="44" height="19" font="1">(<i>Chair</i>) </text>
<text top="319" left="257" width="207" height="19" font="1">University of Texas Southwestern </text>
<text top="337" left="257" width="239" height="19" font="1">Medical Center at Dallas—Professor of </text>
<text top="356" left="257" width="111" height="19" font="1">Internal Medicine </text>
<text top="319" left="513" width="36" height="19" font="1">None </text>
<text top="319" left="597" width="36" height="19" font="1">None </text>
<text top="319" left="679" width="36" height="19" font="1">None </text>
<text top="319" left="774" width="36" height="19" font="1">None </text>
<text top="319" left="852" width="36" height="19" font="1">None </text>
<text top="319" left="963" width="36" height="19" font="1">None </text>
<text top="375" left="116" width="111" height="19" font="1">Neil J. Stone (<i>Vice </i></text>
<text top="392" left="116" width="40" height="20" font="9"><i>Chair</i>) </text>
<text top="375" left="257" width="240" height="19" font="1">Northwestern Medicine/Northwestern </text>
<text top="393" left="257" width="198" height="19" font="1">University—Bonow Professor of </text>
<text top="411" left="257" width="132" height="19" font="1">Medicine, Cardiology </text>
<text top="375" left="513" width="36" height="19" font="1">None </text>
<text top="375" left="597" width="36" height="19" font="1">None </text>
<text top="375" left="679" width="36" height="19" font="1">None </text>
<text top="375" left="774" width="36" height="19" font="1">None </text>
<text top="375" left="852" width="36" height="19" font="1">None </text>
<text top="375" left="963" width="36" height="19" font="1">None </text>
<text top="431" left="116" width="94" height="19" font="1">Alison L. Bailey </text>
<text top="431" left="257" width="232" height="19" font="1">Erlanger Health System/ University of </text>
<text top="449" left="257" width="202" height="19" font="1">Tennessee College of Medicine—</text>
<text top="467" left="257" width="206" height="19" font="1">Program Director, Cardiovascular </text>
<text top="485" left="257" width="185" height="19" font="1">Diseases Fellowship; Director, </text>
<text top="504" left="257" width="210" height="19" font="1">Preventive cardiology and Cardiac </text>
<text top="522" left="257" width="89" height="19" font="1">Rehabilitation </text>
<text top="431" left="513" width="36" height="19" font="1">None </text>
<text top="431" left="597" width="36" height="19" font="1">None </text>
<text top="431" left="679" width="36" height="19" font="1">None </text>
<text top="431" left="774" width="36" height="19" font="1">None </text>
<text top="431" left="852" width="36" height="19" font="1">None </text>
<text top="431" left="963" width="36" height="19" font="1">None </text>
<text top="541" left="116" width="72" height="19" font="1">Craig Beam </text>
<text top="541" left="257" width="221" height="19" font="1">CBRE—Managing Director; National </text>
<text top="559" left="257" width="211" height="19" font="1">Cultivation/ Strategic Investments </text>
<text top="578" left="257" width="45" height="19" font="1">Leader </text>
<text top="541" left="513" width="36" height="19" font="1">None </text>
<text top="541" left="597" width="36" height="19" font="1">None </text>
<text top="541" left="679" width="36" height="19" font="1">None </text>
<text top="541" left="774" width="36" height="19" font="1">None </text>
<text top="541" left="852" width="36" height="19" font="1">None </text>
<text top="541" left="963" width="36" height="19" font="1">None </text>
<text top="597" left="116" width="94" height="19" font="1">Kim K. Birtcher </text>
<text top="597" left="257" width="200" height="19" font="1">University of Houston College of </text>
<text top="615" left="257" width="182" height="19" font="1">Pharmacy—Clinical Professor </text>
<text top="597" left="513" width="36" height="19" font="1">None </text>
<text top="597" left="597" width="36" height="19" font="1">None </text>
<text top="597" left="679" width="36" height="19" font="1">None </text>
<text top="597" left="774" width="36" height="19" font="1">None </text>
<text top="597" left="852" width="36" height="19" font="1">None </text>
<text top="597" left="963" width="36" height="19" font="1">None </text>
<text top="634" left="116" width="362" height="19" font="1">Roger S. Blumenthal  Johns Hopkins University, Ciccarone </text>
<text top="652" left="257" width="213" height="19" font="1">Center for the Prevention of Heart </text>
<text top="671" left="257" width="201" height="19" font="1">Disease—Professor of Medicine  </text>
<text top="634" left="513" width="36" height="19" font="1">None </text>
<text top="634" left="597" width="36" height="19" font="1">None </text>
<text top="634" left="679" width="36" height="19" font="1">None </text>
<text top="634" left="774" width="36" height="19" font="1">None </text>
<text top="634" left="852" width="36" height="19" font="1">None </text>
<text top="634" left="963" width="36" height="19" font="1">None </text>
<text top="690" left="116" width="94" height="19" font="1">Lynne T. Braun </text>
<text top="690" left="257" width="205" height="19" font="1">Rush University Medical Center—</text>
<text top="708" left="257" width="214" height="19" font="1">Professor of Nursing and Medicine </text>
<text top="690" left="513" width="36" height="19" font="1">None </text>
<text top="690" left="597" width="36" height="19" font="1">None </text>
<text top="690" left="679" width="36" height="19" font="1">None </text>
<text top="690" left="774" width="36" height="19" font="1">None </text>
<text top="690" left="852" width="36" height="19" font="1">None </text>
<text top="690" left="963" width="36" height="19" font="1">None </text>
<text top="727" left="116" width="110" height="19" font="1">Sarah De Ferranti </text>
<text top="727" left="257" width="232" height="19" font="1">Boston Children’s Hospital—Assistant </text>
<text top="746" left="257" width="140" height="19" font="1">Professor of Pediatrics </text>
<text top="727" left="513" width="36" height="19" font="1">None </text>
<text top="727" left="597" width="36" height="19" font="1">None </text>
<text top="727" left="679" width="36" height="19" font="1">None </text>
<text top="727" left="774" width="36" height="19" font="1">None </text>
<text top="727" left="852" width="36" height="19" font="1">None </text>
<text top="727" left="963" width="36" height="19" font="1">None </text>
<text top="765" left="116" width="89" height="19" font="1">Joseph Faiella-</text>
<text top="783" left="116" width="75" height="19" font="1">Tommasino </text>
<text top="765" left="257" width="195" height="19" font="1">Touro College, School of Health </text>
<text top="783" left="257" width="212" height="19" font="1">Sciences—Chairman and Assistant </text>
<text top="801" left="257" width="231" height="19" font="1">Dean of Physician Assistant Programs </text>
<text top="765" left="513" width="36" height="19" font="1">None </text>
<text top="765" left="597" width="36" height="19" font="1">None </text>
<text top="765" left="679" width="36" height="19" font="1">None </text>
<text top="765" left="774" width="36" height="19" font="1">None </text>
<text top="765" left="852" width="36" height="19" font="1">None </text>
<text top="765" left="963" width="36" height="19" font="1">None </text>
<text top="457" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="72" position="absolute" top="0" left="0" height="918" width="1188">
<image top="341" left="149" width="891" height="236" src="blood-cholesterol-management/CIR.0000000000000625-72_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="862" left="570" width="48" height="19" font="1">Page 72</text>
<text top="860" left="618" width="4" height="21" font="5"> </text>
<text top="125" left="116" width="107" height="19" font="1">Daniel E. Forman </text>
<text top="125" left="257" width="196" height="19" font="1">University of Pittsburgh—Chair, </text>
<text top="143" left="257" width="125" height="19" font="1">Geriatric Cardiology </text>
<text top="125" left="513" width="36" height="19" font="1">None </text>
<text top="125" left="597" width="36" height="19" font="1">None </text>
<text top="125" left="679" width="36" height="19" font="1">None </text>
<text top="125" left="774" width="36" height="19" font="1">None </text>
<text top="125" left="852" width="36" height="19" font="1">None </text>
<text top="125" left="963" width="36" height="19" font="1">None </text>
<text top="162" left="116" width="106" height="19" font="1">Ronald Goldberg </text>
<text top="162" left="257" width="243" height="19" font="1">University of Miami, Diabetes Research </text>
<text top="181" left="257" width="206" height="19" font="1">Institute—Professor of Medicine, </text>
<text top="199" left="257" width="238" height="19" font="1">Division of Endocrinology, Metabolism </text>
<text top="217" left="257" width="83" height="19" font="1">and Diabetes </text>
<text top="162" left="513" width="36" height="19" font="1">None </text>
<text top="162" left="597" width="36" height="19" font="1">None </text>
<text top="162" left="679" width="36" height="19" font="1">None </text>
<text top="162" left="774" width="36" height="19" font="1">None </text>
<text top="162" left="852" width="36" height="19" font="1">None </text>
<text top="162" left="963" width="36" height="19" font="1">None </text>
<text top="236" left="116" width="358" height="19" font="1">Paul A. Heidenreich  Stanford University, Department of </text>
<text top="255" left="257" width="221" height="19" font="1">Medicine—Professor, Vice Chair for </text>
<text top="273" left="257" width="47" height="19" font="1">Quality </text>
<text top="236" left="513" width="36" height="19" font="1">None </text>
<text top="236" left="597" width="36" height="19" font="1">None </text>
<text top="236" left="679" width="36" height="19" font="1">None </text>
<text top="236" left="774" width="36" height="19" font="1">None </text>
<text top="236" left="852" width="36" height="19" font="1">None </text>
<text top="236" left="963" width="36" height="19" font="1">None </text>
<text top="292" left="116" width="93" height="19" font="1">Mark A. Hlatky </text>
<text top="292" left="257" width="184" height="19" font="1">Stanford University, School of </text>
<text top="310" left="257" width="191" height="19" font="1">Medicine—Professor of Health </text>
<text top="328" left="257" width="179" height="19" font="1">Research Policy, Professor of </text>
<text top="347" left="257" width="153" height="19" font="1">Cardiovascular Medicine </text>
<text top="292" left="513" width="36" height="19" font="1">None </text>
<text top="292" left="597" width="36" height="19" font="1">None </text>
<text top="292" left="679" width="36" height="19" font="1">None </text>
<text top="292" left="774" width="36" height="19" font="1">None </text>
<text top="292" left="852" width="36" height="19" font="1">None </text>
<text top="292" left="963" width="36" height="19" font="1">None </text>
<text top="366" left="116" width="100" height="19" font="1">Daniel W. Jones </text>
<text top="366" left="257" width="202" height="19" font="1">University of Mississippi Medical </text>
<text top="384" left="257" width="218" height="19" font="1">Center—Professor of Medicine and </text>
<text top="402" left="257" width="202" height="19" font="1">Physiology; Director, Clinical and </text>
<text top="421" left="257" width="119" height="19" font="1">Population Science </text>
<text top="366" left="513" width="36" height="19" font="1">None </text>
<text top="366" left="597" width="36" height="19" font="1">None </text>
<text top="366" left="679" width="36" height="19" font="1">None </text>
<text top="366" left="774" width="36" height="19" font="1">None </text>
<text top="366" left="852" width="36" height="19" font="1">None </text>
<text top="366" left="963" width="36" height="19" font="1">None </text>
<text top="440" left="116" width="364" height="19" font="1">Donald Lloyd-Jones  Northwestern University—Eileen M. </text>
<text top="458" left="257" width="230" height="19" font="1">Foell Professor; Chair, Department of </text>
<text top="477" left="257" width="129" height="19" font="1">Preventive Medicine </text>
<text top="440" left="513" width="36" height="19" font="1">None </text>
<text top="440" left="597" width="36" height="19" font="1">None </text>
<text top="440" left="679" width="36" height="19" font="1">None </text>
<text top="440" left="774" width="36" height="19" font="1">None </text>
<text top="440" left="852" width="36" height="19" font="1">None </text>
<text top="440" left="963" width="36" height="19" font="1">None </text>
<text top="496" left="116" width="324" height="19" font="1">Nuria Lopez-Pajares  Temple University—Physician </text>
<text top="496" left="513" width="36" height="19" font="1">None </text>
<text top="496" left="597" width="36" height="19" font="1">None </text>
<text top="496" left="679" width="36" height="19" font="1">None </text>
<text top="496" left="774" width="36" height="19" font="1">None </text>
<text top="496" left="852" width="36" height="19" font="1">None </text>
<text top="496" left="963" width="36" height="19" font="1">None </text>
<text top="530" left="116" width="100" height="19" font="1">Chiadi Ndumele </text>
<text top="530" left="257" width="215" height="19" font="1">Johns Hopkins University School of </text>
<text top="548" left="257" width="198" height="19" font="1">Medicine—Robert E. Meyerhoff </text>
<text top="566" left="257" width="195" height="19" font="1">Assistant Professor of Medicine </text>
<text top="530" left="513" width="36" height="19" font="1">None </text>
<text top="530" left="597" width="36" height="19" font="1">None </text>
<text top="530" left="679" width="36" height="19" font="1">None </text>
<text top="530" left="774" width="36" height="19" font="1">None </text>
<text top="530" left="852" width="36" height="19" font="1">None </text>
<text top="530" left="963" width="36" height="19" font="1">None </text>
<text top="585" left="116" width="97" height="19" font="1">Carl E. Orringer </text>
<text top="585" left="257" width="214" height="19" font="1">University of Miami, Soffer Clinical </text>
<text top="604" left="257" width="236" height="19" font="1">Research Center—Associate Professor </text>
<text top="585" left="513" width="36" height="19" font="1">None </text>
<text top="585" left="597" width="36" height="19" font="1">None </text>
<text top="585" left="679" width="36" height="19" font="1">None </text>
<text top="585" left="774" width="36" height="19" font="1">None </text>
<text top="585" left="852" width="36" height="19" font="1">None </text>
<text top="585" left="963" width="36" height="19" font="1">None </text>
<text top="623" left="116" width="98" height="19" font="1">Carmen Peralta </text>
<text top="623" left="257" width="171" height="19" font="1">University of California, San </text>
<text top="641" left="257" width="209" height="19" font="1">Francisco—Associate Professor of </text>
<text top="659" left="257" width="212" height="19" font="1">Medicine; Kidney Health Research </text>
<text top="678" left="257" width="209" height="19" font="1">Collaborative—Executive Director </text>
<text top="623" left="513" width="36" height="19" font="1">None </text>
<text top="623" left="597" width="36" height="19" font="1">None </text>
<text top="623" left="679" width="36" height="19" font="1">None </text>
<text top="623" left="774" width="36" height="19" font="1">None </text>
<text top="623" left="852" width="36" height="19" font="1">None </text>
<text top="623" left="963" width="36" height="19" font="1">None </text>
<text top="697" left="116" width="91" height="19" font="1">Joseph Saseen </text>
<text top="697" left="257" width="202" height="19" font="1">University of Colorado, Anschutz </text>
<text top="715" left="257" width="231" height="19" font="1">Medical Campus—Professor and Vice </text>
<text top="733" left="257" width="179" height="19" font="1">Chair, Department of Clinical </text>
<text top="752" left="257" width="226" height="19" font="1">Pharmacy; Professor, Department of </text>
<text top="770" left="257" width="103" height="19" font="1">Family Medicine </text>
<text top="697" left="513" width="36" height="19" font="1">None </text>
<text top="697" left="597" width="36" height="19" font="1">None </text>
<text top="697" left="679" width="36" height="19" font="1">None </text>
<text top="697" left="774" width="36" height="19" font="1">None </text>
<text top="697" left="852" width="36" height="19" font="1">None </text>
<text top="697" left="963" width="36" height="19" font="1">None </text>
<text top="789" left="116" width="115" height="19" font="1">Sidney C. Smith, Jr </text>
<text top="789" left="257" width="222" height="19" font="1">University of North Carolina, Chapel </text>
<text top="807" left="257" width="170" height="19" font="1">Hill—Professor of Medicine </text>
<text top="789" left="513" width="36" height="19" font="1">None </text>
<text top="789" left="597" width="36" height="19" font="1">None </text>
<text top="789" left="679" width="36" height="19" font="1">None </text>
<text top="789" left="774" width="36" height="19" font="1">None </text>
<text top="789" left="852" width="36" height="19" font="1">None </text>
<text top="789" left="963" width="36" height="19" font="1">None </text>
<text top="457" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="73" position="absolute" top="0" left="0" height="918" width="1188">
<image top="341" left="149" width="891" height="236" src="blood-cholesterol-management/CIR.0000000000000625-73_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="862" left="570" width="48" height="19" font="1">Page 73</text>
<text top="860" left="618" width="4" height="21" font="5"> </text>
<text top="125" left="116" width="354" height="19" font="1">Laurence S. Sperling  Emory University, Rollins School of </text>
<text top="143" left="257" width="235" height="19" font="1">Public Health—Professor of Medicine, </text>
<text top="161" left="257" width="236" height="19" font="1">Cardiology; Professor of Global Health </text>
<text top="125" left="513" width="36" height="19" font="1">None </text>
<text top="125" left="597" width="36" height="19" font="1">None </text>
<text top="125" left="679" width="36" height="19" font="1">None </text>
<text top="125" left="774" width="36" height="19" font="1">None </text>
<text top="125" left="852" width="36" height="19" font="1">None </text>
<text top="125" left="963" width="36" height="19" font="1">None </text>
<text top="181" left="116" width="89" height="19" font="1">Salim S. Virani </text>
<text top="181" left="257" width="208" height="19" font="1">Baylor College of Medicine, Texas </text>
<text top="199" left="257" width="233" height="19" font="1">Medical Center—Associate Professor, </text>
<text top="217" left="257" width="220" height="19" font="1">Section of Cardiovascular Research; </text>
<text top="235" left="257" width="195" height="19" font="1">Associate Director for Research </text>
<text top="181" left="513" width="36" height="19" font="1">None </text>
<text top="181" left="597" width="36" height="19" font="1">None </text>
<text top="181" left="679" width="36" height="19" font="1">None </text>
<text top="181" left="774" width="36" height="19" font="1">None </text>
<text top="181" left="852" width="36" height="19" font="1">None </text>
<text top="181" left="963" width="36" height="19" font="1">None </text>
<text top="255" left="116" width="94" height="19" font="1">Joseph Yeboah </text>
<text top="255" left="257" width="238" height="19" font="1">Wake Forest Baptist Health—Assistant </text>
<text top="273" left="257" width="180" height="19" font="1">Professor, Internal Medicine, </text>
<text top="291" left="257" width="93" height="19" font="1">Cardiovascular </text>
<text top="255" left="513" width="36" height="19" font="1">None </text>
<text top="255" left="597" width="36" height="19" font="1">None </text>
<text top="255" left="679" width="36" height="19" font="1">None </text>
<text top="255" left="774" width="36" height="19" font="1">None </text>
<text top="255" left="852" width="36" height="19" font="1">None </text>
<text top="255" left="963" width="36" height="19" font="1">None </text>
<text top="336" left="108" width="975" height="19" font="1">This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These </text>
<text top="354" left="108" width="975" height="19" font="1">relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development </text>
<text top="372" left="108" width="975" height="19" font="1">process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business </text>
<text top="390" left="108" width="975" height="19" font="1">if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business </text>
<text top="409" left="108" width="975" height="19" font="1">entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no </text>
<text top="427" left="108" width="795" height="19" font="1">financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.  </text>
<text top="446" left="162" width="921" height="19" font="1">According to the ACC/AHA, a person has a <i>relevant</i> relationship IF: a) the <i>relationship or interest</i> relates to the same or similar subject matter, intellectual </text>
<text top="464" left="108" width="976" height="19" font="1">property or asset, topic, or issue addressed in the <i>document;</i> or b) the <i>company/entity</i> (with whom the relationship exists) makes a drug, drug class, or device </text>
<text top="482" left="108" width="976" height="19" font="1">addressed in the <i>document</i> or makes a competing drug or device addressed in the <i>document</i>; or c) the <i>person or a member of the person’s household</i>, has a </text>
<text top="500" left="108" width="840" height="19" font="1">reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the <i>document</i>. </text>
<text top="519" left="108" width="3" height="19" font="1"> </text>
<text top="537" left="108" width="976" height="19" font="1">*The Cholesterol Guideline began in September 2016. Over the initial years of the CMS Open Payment System, understandably, there have been many issues </text>
<text top="555" left="108" width="978" height="19" font="1">related to the accurate reporting of food and beverage payments. For this reason, the ACC and AHA have not considered these minor charges relevant </text>
<text top="574" left="108" width="170" height="19" font="1">relationships with industry. </text>
<text top="592" left="108" width="3" height="19" font="1"> </text>
<text top="610" left="108" width="976" height="19" font="1">AACVPR indicates American Association of Cardiovascular and Pulmonary Rehabilitation; AAPA, American Academy of Physician Assistants; ABC, Association of </text>
<text top="629" left="108" width="975" height="19" font="1">Black Cardiologists; ACC, American College of Cardiology; ACPM, American College of Preventive Medicine; ADA, American Diabetes Association; AGS, American </text>
<text top="647" left="108" width="978" height="19" font="1">Geriatrics Society; AHA, American Heart Association; APhA, American Pharmacists Association; ASPC, American Society for Preventive Cardiology; PCNA, </text>
<text top="665" left="108" width="284" height="19" font="1">Preventive Cardiovascular Nurses Association. </text>
<text top="683" left="108" width="4" height="21" font="5"> </text>
<text top="703" left="108" width="4" height="23" font="3"><b> </b></text>
<text top="703" left="324" width="4" height="23" font="3"><b> </b></text>
<text top="457" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="74" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="26" size="11" family="Times" color="#000000"/>
<image top="341" left="149" width="891" height="236" src="blood-cholesterol-management/CIR.0000000000000625-74_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="862" left="570" width="48" height="19" font="1">Page 74</text>
<text top="860" left="618" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="704" height="23" font="3"><b>Appendix 2. Reviewer Relationships With Industry and Other Entities (Comprehensive)—2018 </b></text>
<text top="146" left="108" width="938" height="23" font="3"><b>AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol </b></text>
<text top="168" left="108" width="108" height="23" font="3"><b>(August 2018) </b></text>
<text top="249" left="116" width="29" height="17" font="25"><b>Peer </b></text>
<text top="266" left="116" width="56" height="17" font="25"><b>Reviewer </b></text>
<text top="266" left="201" width="90" height="17" font="25"><b>Representation </b></text>
<text top="266" left="312" width="75" height="17" font="25"><b>Employment </b></text>
<text top="266" left="418" width="64" height="17" font="25"><b>Consultant </b></text>
<text top="249" left="510" width="54" height="17" font="25"><b>Speakers </b></text>
<text top="266" left="515" width="43" height="17" font="25"><b>Bureau </b></text>
<text top="233" left="597" width="70" height="17" font="25"><b>Ownership/ </b></text>
<text top="249" left="595" width="74" height="17" font="25"><b>Partnership/ </b></text>
<text top="266" left="606" width="52" height="17" font="25"><b>Principal </b></text>
<text top="249" left="716" width="52" height="17" font="25"><b>Personal </b></text>
<text top="266" left="714" width="54" height="17" font="25"><b>Research </b></text>
<text top="200" left="807" width="75" height="17" font="25"><b>Institutional, </b></text>
<text top="216" left="801" width="88" height="17" font="25"><b>Organizational, </b></text>
<text top="233" left="820" width="51" height="17" font="25"><b>or Other </b></text>
<text top="249" left="819" width="53" height="17" font="25"><b>Financial </b></text>
<text top="266" left="823" width="44" height="17" font="25"><b>Benefit </b></text>
<text top="249" left="926" width="39" height="17" font="25"><b>Expert </b></text>
<text top="266" left="922" width="48" height="17" font="25"><b>Witness </b></text>
<text top="266" left="1019" width="37" height="17" font="25"><b>Salary </b></text>
<text top="283" left="116" width="48" height="17" font="26">Philip A. </text>
<text top="299" left="116" width="30" height="17" font="26">Ades </text>
<text top="283" left="199" width="42" height="17" font="26">Official </text>
<text top="299" left="199" width="66" height="17" font="26">Reviewer— </text>
<text top="316" left="199" width="48" height="17" font="26">AACVPR </text>
<text top="283" left="305" width="73" height="17" font="26">University of </text>
<text top="299" left="305" width="52" height="17" font="26">Vermont </text>
<text top="316" left="305" width="47" height="17" font="26">Medical </text>
<text top="332" left="305" width="49" height="17" font="26">Center—</text>
<text top="349" left="305" width="70" height="17" font="26">Professor of </text>
<text top="365" left="305" width="54" height="17" font="26">Medicine </text>
<text top="283" left="406" width="33" height="17" font="26">None </text>
<text top="283" left="508" width="33" height="17" font="26">None </text>
<text top="283" left="580" width="33" height="17" font="26">None </text>
<text top="283" left="698" width="33" height="17" font="26">None </text>
<text top="283" left="798" width="33" height="17" font="26">None </text>
<text top="283" left="905" width="33" height="17" font="26">None </text>
<text top="283" left="1000" width="33" height="17" font="26">None </text>
<text top="382" left="116" width="48" height="17" font="26">Karen P. </text>
<text top="399" left="116" width="59" height="17" font="26">Alexander </text>
<text top="382" left="199" width="42" height="17" font="26">Official </text>
<text top="399" left="199" width="88" height="17" font="26">Reviewer—ACC </text>
<text top="415" left="199" width="68" height="17" font="26">Science and </text>
<text top="432" left="199" width="42" height="17" font="26">Quality </text>
<text top="449" left="199" width="64" height="17" font="26">Committee </text>
<text top="382" left="305" width="31" height="17" font="26">Duke </text>
<text top="399" left="305" width="58" height="17" font="26">University </text>
<text top="415" left="305" width="47" height="17" font="26">Medical </text>
<text top="432" left="305" width="49" height="17" font="26">Center—</text>
<text top="449" left="305" width="70" height="17" font="26">Professor of </text>
<text top="465" left="305" width="85" height="17" font="26">Medicine/Cardi</text>
<text top="481" left="305" width="33" height="17" font="26">ology </text>
<text top="383" left="406" width="33" height="17" font="26">None </text>
<text top="383" left="508" width="33" height="17" font="26">None </text>
<text top="383" left="580" width="33" height="17" font="26">None </text>
<text top="383" left="698" width="36" height="18" font="26">• GSK </text>
<text top="400" left="698" width="34" height="18" font="26">• NIH </text>
<text top="382" left="798" width="33" height="17" font="26">None </text>
<text top="383" left="905" width="33" height="17" font="26">None </text>
<text top="383" left="1000" width="33" height="17" font="26">None </text>
<text top="499" left="116" width="65" height="17" font="26">Theresa M. </text>
<text top="515" left="116" width="39" height="17" font="26">Beckie </text>
<text top="499" left="199" width="42" height="17" font="26">Official </text>
<text top="515" left="199" width="63" height="17" font="26">Reviewer—</text>
<text top="531" left="199" width="48" height="17" font="26">AACVPR </text>
<text top="499" left="305" width="73" height="17" font="26">University of </text>
<text top="515" left="305" width="35" height="17" font="26">South </text>
<text top="531" left="305" width="53" height="17" font="26">Florida— </text>
<text top="548" left="305" width="79" height="17" font="26">Professor and </text>
<text top="565" left="305" width="87" height="17" font="26">Associate Dean </text>
<text top="581" left="305" width="61" height="17" font="26">of the PhD </text>
<text top="598" left="305" width="50" height="17" font="26">Program </text>
<text top="499" left="406" width="33" height="17" font="26">None </text>
<text top="499" left="508" width="33" height="17" font="26">None </text>
<text top="499" left="580" width="33" height="17" font="26">None </text>
<text top="499" left="698" width="33" height="17" font="26">None </text>
<text top="499" left="798" width="33" height="17" font="26">None </text>
<text top="499" left="905" width="33" height="17" font="26">None </text>
<text top="499" left="1000" width="33" height="17" font="26">None </text>
<text top="615" left="116" width="124" height="17" font="26">Kathy Berra  Official </text>
<text top="631" left="199" width="63" height="17" font="26">Reviewer—</text>
<text top="648" left="199" width="34" height="17" font="26">PCNA </text>
<text top="615" left="305" width="50" height="17" font="26">Stanford </text>
<text top="631" left="305" width="58" height="17" font="26">University </text>
<text top="615" left="406" width="82" height="17" font="26">Omada Health </text>
<text top="615" left="508" width="33" height="17" font="26">None </text>
<text top="615" left="580" width="33" height="17" font="26">None </text>
<text top="615" left="698" width="33" height="17" font="26">None </text>
<text top="615" left="798" width="72" height="18" font="26">• Council on </text>
<text top="632" left="809" width="60" height="17" font="26">Aspirin for </text>
<text top="648" left="809" width="63" height="17" font="26">Health and </text>
<text top="665" left="809" width="80" height="17" font="26">Prevention - a </text>
<text top="681" left="809" width="77" height="17" font="26">committee of </text>
<text top="698" left="809" width="69" height="17" font="26">the Altarum </text>
<text top="714" left="809" width="52" height="17" font="26">Institute  </text>
<text top="731" left="798" width="72" height="18" font="26">• Preventive </text>
<text top="748" left="809" width="83" height="17" font="26">Cardiovascular </text>
<text top="764" left="809" width="41" height="17" font="26">Nurses </text>
<text top="781" left="809" width="66" height="17" font="26">Association </text>
<text top="615" left="905" width="33" height="17" font="26">None </text>
<text top="615" left="1000" width="33" height="17" font="26">None </text>
<text top="457" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="75" position="absolute" top="0" left="0" height="918" width="1188">
<image top="341" left="149" width="891" height="236" src="blood-cholesterol-management/CIR.0000000000000625-75_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="862" left="570" width="48" height="19" font="1">Page 75</text>
<text top="860" left="618" width="4" height="21" font="5"> </text>
<text top="125" left="116" width="58" height="17" font="26">William T. </text>
<text top="141" left="116" width="38" height="17" font="26">Cefalu </text>
<text top="125" left="199" width="42" height="17" font="26">Official </text>
<text top="141" left="199" width="90" height="17" font="26">Reviewer—ADA </text>
<text top="125" left="305" width="55" height="17" font="26">American </text>
<text top="141" left="305" width="51" height="17" font="26">Diabetes </text>
<text top="158" left="305" width="75" height="17" font="26">Association—</text>
<text top="174" left="305" width="87" height="17" font="26">Chief Scientific, </text>
<text top="191" left="305" width="70" height="17" font="26">Medical and </text>
<text top="207" left="305" width="86" height="17" font="26">Mission Officer </text>
<text top="125" left="406" width="33" height="17" font="26">None </text>
<text top="125" left="508" width="33" height="17" font="26">None </text>
<text top="125" left="580" width="33" height="17" font="26">None </text>
<text top="125" left="698" width="33" height="17" font="26">None </text>
<text top="125" left="798" width="33" height="17" font="26">None </text>
<text top="125" left="905" width="33" height="17" font="26">None </text>
<text top="125" left="1000" width="33" height="17" font="26">None </text>
<text top="224" left="116" width="57" height="17" font="26">Mary Ann </text>
<text top="241" left="116" width="68" height="17" font="26">Champagne </text>
<text top="224" left="199" width="70" height="17" font="26">Official Peer </text>
<text top="241" left="199" width="63" height="17" font="26">Reviewer—</text>
<text top="257" left="199" width="34" height="17" font="26">PCNA </text>
<text top="224" left="305" width="50" height="17" font="26">Stanford </text>
<text top="241" left="305" width="72" height="17" font="26">Hospital and </text>
<text top="257" left="305" width="47" height="17" font="26">Clinics—</text>
<text top="274" left="305" width="77" height="17" font="26">Clinical Nurse </text>
<text top="290" left="305" width="78" height="17" font="26">Specialist and </text>
<text top="307" left="305" width="69" height="17" font="26">Coordinator </text>
<text top="224" left="406" width="33" height="17" font="26">None </text>
<text top="225" left="508" width="33" height="17" font="26">None </text>
<text top="225" left="580" width="33" height="17" font="26">None </text>
<text top="224" left="698" width="33" height="17" font="26">None </text>
<text top="224" left="798" width="33" height="17" font="26">None </text>
<text top="225" left="905" width="33" height="17" font="26">None </text>
<text top="225" left="1000" width="33" height="17" font="26">None </text>
<text top="324" left="116" width="45" height="17" font="26">Joaquin </text>
<text top="341" left="116" width="49" height="17" font="26">Cigarroa </text>
<text top="324" left="199" width="42" height="17" font="26">Official </text>
<text top="341" left="199" width="63" height="17" font="26">Reviewer—</text>
<text top="357" left="199" width="82" height="17" font="26">ACC/AHA Task </text>
<text top="373" left="199" width="93" height="17" font="26">Force on Clinical </text>
<text top="390" left="199" width="47" height="17" font="26">Practice </text>
<text top="406" left="199" width="61" height="17" font="26">Guidelines </text>
<text top="324" left="305" width="83" height="17" font="26">Oregon Health </text>
<text top="341" left="305" width="68" height="17" font="26">and Science </text>
<text top="357" left="305" width="71" height="17" font="26">University— </text>
<text top="373" left="305" width="42" height="17" font="26">Clinical </text>
<text top="390" left="305" width="70" height="17" font="26">Professor of </text>
<text top="406" left="305" width="54" height="17" font="26">Medicine </text>
<text top="324" left="406" width="33" height="17" font="26">None </text>
<text top="324" left="508" width="33" height="17" font="26">None </text>
<text top="324" left="580" width="33" height="17" font="26">None </text>
<text top="324" left="698" width="33" height="17" font="26">None </text>
<text top="324" left="798" width="33" height="17" font="26">None </text>
<text top="324" left="905" width="33" height="17" font="26">None </text>
<text top="324" left="1000" width="33" height="17" font="26">None </text>
<text top="424" left="116" width="62" height="17" font="26">Stephen R. </text>
<text top="440" left="116" width="43" height="17" font="26">Daniels<b> </b></text>
<text top="424" left="199" width="42" height="17" font="26">Official </text>
<text top="440" left="199" width="89" height="17" font="26">Reviewer—AAP </text>
<text top="424" left="305" width="73" height="17" font="26">University of </text>
<text top="440" left="305" width="53" height="17" font="26">Colorado </text>
<text top="457" left="305" width="54" height="17" font="26">School of </text>
<text top="473" left="305" width="66" height="17" font="26">Medicine— </text>
<text top="490" left="305" width="79" height="17" font="26">Professor and </text>
<text top="506" left="305" width="35" height="17" font="26">Chair, </text>
<text top="522" left="305" width="84" height="17" font="26">Department of </text>
<text top="539" left="305" width="60" height="17" font="26">Pediatrics; </text>
<text top="556" left="305" width="58" height="17" font="26">Children’s </text>
<text top="572" left="305" width="48" height="17" font="26">Hospital </text>
<text top="589" left="305" width="62" height="17" font="26">Colorado—</text>
<text top="605" left="305" width="83" height="17" font="26">Pediatrician-in-</text>
<text top="621" left="305" width="67" height="17" font="26">Chief and L. </text>
<text top="638" left="305" width="41" height="17" font="26">Joseph </text>
<text top="654" left="305" width="62" height="17" font="26">Butterfield </text>
<text top="671" left="305" width="45" height="17" font="26">Chair in </text>
<text top="687" left="305" width="57" height="17" font="26">Pediatrics </text>
<text top="424" left="408" width="52" height="18" font="26">•  Sanofi-</text>
<text top="441" left="422" width="44" height="17" font="26">Aventis </text>
<text top="424" left="508" width="33" height="17" font="26">None </text>
<text top="424" left="580" width="33" height="17" font="26">None </text>
<text top="424" left="698" width="33" height="17" font="26">None </text>
<text top="424" left="796" width="91" height="18" font="26">•  Novo Nordisk </text>
<text top="441" left="810" width="23" height="17" font="26">Inc. </text>
<text top="424" left="905" width="33" height="17" font="26">None </text>
<text top="424" left="1000" width="33" height="17" font="26">None </text>
<text top="457" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="76" position="absolute" top="0" left="0" height="918" width="1188">
<image top="341" left="149" width="891" height="236" src="blood-cholesterol-management/CIR.0000000000000625-76_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="862" left="570" width="48" height="19" font="1">Page 76</text>
<text top="860" left="618" width="4" height="21" font="5"> </text>
<text top="125" left="116" width="124" height="17" font="26">Dave Dixon   Official </text>
<text top="141" left="199" width="89" height="17" font="26">Reviewer—NLA </text>
<text top="125" left="305" width="44" height="17" font="26">Virginia </text>
<text top="141" left="305" width="81" height="17" font="26">Commonwealt</text>
<text top="158" left="305" width="68" height="17" font="26">h University </text>
<text top="174" left="305" width="54" height="17" font="26">School of </text>
<text top="191" left="305" width="70" height="17" font="26">Pharmacy— </text>
<text top="207" left="305" width="55" height="17" font="26">Associate </text>
<text top="224" left="305" width="79" height="17" font="26">Professor and </text>
<text top="240" left="305" width="78" height="17" font="26">Vice-Chair for </text>
<text top="257" left="305" width="42" height="17" font="26">Clinical </text>
<text top="273" left="305" width="48" height="17" font="26">Services </text>
<text top="125" left="406" width="33" height="17" font="26">None </text>
<text top="125" left="508" width="33" height="17" font="26">None </text>
<text top="125" left="580" width="33" height="17" font="26">None </text>
<text top="125" left="698" width="33" height="17" font="26">None </text>
<text top="125" left="798" width="33" height="17" font="26">None </text>
<text top="125" left="905" width="33" height="17" font="26">None </text>
<text top="125" left="1000" width="33" height="17" font="26">None </text>
<text top="290" left="116" width="42" height="17" font="26">Earl W. </text>
<text top="307" left="116" width="54" height="17" font="26">Ferguson </text>
<text top="290" left="199" width="42" height="17" font="26">Official </text>
<text top="307" left="199" width="63" height="17" font="26">Reviewer—</text>
<text top="323" left="199" width="37" height="17" font="26">ACPM </text>
<text top="290" left="305" width="61" height="17" font="26">Ridgecrest </text>
<text top="307" left="305" width="50" height="17" font="26">Regional </text>
<text top="323" left="305" width="57" height="17" font="26">Hospital—</text>
<text top="340" left="305" width="73" height="17" font="26">Independent </text>
<text top="356" left="305" width="66" height="17" font="26">Consultant  </text>
<text top="290" left="406" width="33" height="17" font="26">None </text>
<text top="290" left="508" width="33" height="17" font="26">None </text>
<text top="290" left="580" width="75" height="18" font="26">• Bakersfield </text>
<text top="308" left="591" width="89" height="17" font="26">Heart Hospital† </text>
<text top="290" left="698" width="33" height="17" font="26">None </text>
<text top="290" left="798" width="55" height="18" font="26">• Growth </text>
<text top="308" left="809" width="50" height="17" font="26">Creators </text>
<text top="324" left="809" width="80" height="17" font="26">Inc./Radekal/P</text>
<text top="341" left="809" width="38" height="17" font="26">ertexa </text>
<text top="357" left="798" width="66" height="18" font="26">• California </text>
<text top="374" left="809" width="39" height="17" font="26">Health </text>
<text top="391" left="809" width="69" height="17" font="26">Information </text>
<text top="407" left="809" width="67" height="17" font="26">Partnership </text>
<text top="424" left="809" width="71" height="17" font="26">and Services </text>
<text top="440" left="809" width="80" height="17" font="26">Organization† </text>
<text top="290" left="905" width="33" height="17" font="26">None </text>
<text top="290" left="1000" width="33" height="17" font="26">None </text>
<text top="478" left="116" width="59" height="17" font="26">Edward A. </text>
<text top="495" left="116" width="36" height="17" font="26">Gill, Jr </text>
<text top="478" left="199" width="42" height="17" font="26">Official </text>
<text top="495" left="199" width="89" height="17" font="26">Reviewer—NLA </text>
<text top="478" left="305" width="73" height="17" font="26">University of </text>
<text top="495" left="305" width="53" height="17" font="26">Colorado </text>
<text top="511" left="305" width="61" height="17" font="26">Cardiology </text>
<text top="528" left="305" width="58" height="17" font="26">Division —</text>
<text top="544" left="305" width="70" height="17" font="26">Professor of </text>
<text top="561" left="305" width="83" height="17" font="26">Clinic Practice, </text>
<text top="577" left="305" width="55" height="17" font="26">Medicine-</text>
<text top="594" left="305" width="61" height="17" font="26">Cardiology </text>
<text top="478" left="406" width="33" height="17" font="26">None </text>
<text top="478" left="508" width="33" height="17" font="26">None </text>
<text top="478" left="580" width="33" height="17" font="26">None </text>
<text top="478" left="698" width="33" height="17" font="26">None </text>
<text top="478" left="798" width="33" height="17" font="26">None </text>
<text top="478" left="905" width="33" height="17" font="26">None </text>
<text top="479" left="999" width="48" height="18" font="26">•  Acute </text>
<text top="495" left="1013" width="54" height="17" font="26">Coronary </text>
<text top="512" left="1013" width="59" height="17" font="26">Syndrome </text>
<text top="529" left="1013" width="44" height="17" font="26">- 2007† </text>
<text top="611" left="116" width="41" height="17" font="26">Tyler J. </text>
<text top="627" left="116" width="58" height="17" font="26">Gluckman </text>
<text top="611" left="199" width="42" height="17" font="26">Official </text>
<text top="627" left="199" width="88" height="17" font="26">Reviewer—ACC </text>
<text top="644" left="199" width="50" height="17" font="26">Board of </text>
<text top="660" left="199" width="60" height="17" font="26">Governors </text>
<text top="611" left="305" width="81" height="17" font="26">Providence St. </text>
<text top="627" left="305" width="79" height="17" font="26">Vincent Heart </text>
<text top="644" left="305" width="41" height="17" font="26">Clinic—</text>
<text top="660" left="305" width="47" height="17" font="26">Medical </text>
<text top="677" left="305" width="48" height="17" font="26">Director </text>
<text top="611" left="406" width="75" height="18" font="26">• Boehringer </text>
<text top="628" left="417" width="57" height="17" font="26">Ingelheim </text>
<text top="645" left="417" width="70" height="17" font="26">Pharmaceuti</text>
<text top="661" left="417" width="24" height="17" font="26">cals </text>
<text top="611" left="508" width="33" height="17" font="26">None </text>
<text top="611" left="580" width="33" height="17" font="26">None </text>
<text top="611" left="698" width="33" height="17" font="26">None </text>
<text top="611" left="798" width="33" height="17" font="26">None </text>
<text top="611" left="905" width="33" height="17" font="26">None </text>
<text top="611" left="1000" width="33" height="17" font="26">None </text>
<text top="697" left="116" width="124" height="17" font="26">Rita Kalyani  Official </text>
<text top="713" left="199" width="90" height="17" font="26">Reviewer—ADA </text>
<text top="697" left="305" width="81" height="17" font="26">Johns Hopkins </text>
<text top="713" left="305" width="54" height="17" font="26">School of </text>
<text top="730" left="305" width="63" height="17" font="26">Medicine—</text>
<text top="746" left="305" width="55" height="17" font="26">Associate </text>
<text top="763" left="305" width="70" height="17" font="26">Professor of </text>
<text top="779" left="305" width="54" height="17" font="26">Medicine </text>
<text top="697" left="406" width="33" height="17" font="26">None </text>
<text top="697" left="508" width="33" height="17" font="26">None </text>
<text top="697" left="580" width="33" height="17" font="26">None </text>
<text top="697" left="698" width="33" height="17" font="26">None </text>
<text top="697" left="798" width="33" height="17" font="26">None </text>
<text top="697" left="905" width="33" height="17" font="26">None </text>
<text top="697" left="1000" width="33" height="17" font="26">None </text>
<text top="457" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="77" position="absolute" top="0" left="0" height="918" width="1188">
<image top="341" left="149" width="891" height="236" src="blood-cholesterol-management/CIR.0000000000000625-77_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="862" left="570" width="48" height="19" font="1">Page 77</text>
<text top="860" left="618" width="4" height="21" font="5"> </text>
<text top="125" left="116" width="59" height="17" font="26">Norma M. </text>
<text top="141" left="116" width="34" height="17" font="26">Keller </text>
<text top="125" left="199" width="42" height="17" font="26">Official </text>
<text top="141" left="199" width="88" height="17" font="26">Reviewer—ACC </text>
<text top="158" left="199" width="50" height="17" font="26">Board of </text>
<text top="174" left="199" width="60" height="17" font="26">Governors </text>
<text top="125" left="305" width="56" height="17" font="26">New York </text>
<text top="141" left="305" width="58" height="17" font="26">University </text>
<text top="158" left="305" width="47" height="17" font="26">Medical </text>
<text top="174" left="305" width="80" height="17" font="26">Center—Chief </text>
<text top="191" left="305" width="76" height="17" font="26">of Cardiology </text>
<text top="125" left="406" width="33" height="17" font="26">None </text>
<text top="125" left="508" width="33" height="17" font="26">None </text>
<text top="125" left="580" width="33" height="17" font="26">None </text>
<text top="125" left="698" width="33" height="17" font="26">None </text>
<text top="125" left="798" width="33" height="17" font="26">None </text>
<text top="125" left="905" width="33" height="17" font="26">None </text>
<text top="125" left="1000" width="33" height="17" font="26">None </text>
<text top="208" left="116" width="64" height="17" font="26">Amit Khera </text>
<text top="208" left="199" width="42" height="17" font="26">Official </text>
<text top="224" left="199" width="63" height="17" font="26">Reviewer—</text>
<text top="241" left="199" width="31" height="17" font="26">ASPC </text>
<text top="208" left="305" width="73" height="17" font="26">University of </text>
<text top="224" left="305" width="34" height="17" font="26">Texas </text>
<text top="241" left="305" width="80" height="17" font="26">Southwestern </text>
<text top="257" left="305" width="47" height="17" font="26">Medical </text>
<text top="274" left="305" width="49" height="17" font="26">Center—</text>
<text top="290" left="305" width="52" height="17" font="26">Assistant </text>
<text top="307" left="305" width="70" height="17" font="26">Professor of </text>
<text top="323" left="305" width="54" height="17" font="26">Medicine </text>
<text top="208" left="406" width="33" height="17" font="26">None </text>
<text top="208" left="508" width="33" height="17" font="26">None </text>
<text top="208" left="580" width="33" height="17" font="26">None </text>
<text top="208" left="698" width="33" height="17" font="26">None </text>
<text top="208" left="798" width="33" height="17" font="26">None </text>
<text top="208" left="905" width="33" height="17" font="26">None </text>
<text top="208" left="1000" width="33" height="17" font="26">None </text>
<text top="341" left="116" width="32" height="17" font="26">Carol </text>
<text top="357" left="116" width="62" height="17" font="26">Kirkpatrick </text>
<text top="341" left="199" width="42" height="17" font="26">Official </text>
<text top="357" left="199" width="89" height="17" font="26">Reviewer—NLA </text>
<text top="341" left="305" width="66" height="17" font="26">Idaho State </text>
<text top="357" left="305" width="67" height="17" font="26">University—</text>
<text top="373" left="305" width="52" height="17" font="26">Wellness </text>
<text top="390" left="305" width="40" height="17" font="26">Center </text>
<text top="406" left="305" width="79" height="17" font="26">Director/Clinic</text>
<text top="423" left="305" width="68" height="17" font="26">al Associate </text>
<text top="440" left="305" width="55" height="17" font="26">Professor </text>
<text top="456" left="305" width="43" height="17" font="26">Kasiska </text>
<text top="472" left="305" width="61" height="17" font="26">Division of </text>
<text top="489" left="305" width="39" height="17" font="26">Health </text>
<text top="505" left="305" width="49" height="17" font="26">Sciences </text>
<text top="341" left="408" width="63" height="18" font="26">•  National </text>
<text top="358" left="422" width="29" height="17" font="26">Lipid </text>
<text top="374" left="422" width="66" height="17" font="26">Association </text>
<text top="341" left="508" width="33" height="17" font="26">None </text>
<text top="341" left="580" width="33" height="17" font="26">None </text>
<text top="341" left="698" width="33" height="17" font="26">None </text>
<text top="341" left="798" width="33" height="17" font="26">None </text>
<text top="341" left="905" width="33" height="17" font="26">None </text>
<text top="341" left="1000" width="33" height="17" font="26">None </text>
<text top="522" left="116" width="57" height="17" font="26">G. B. John </text>
<text top="539" left="116" width="47" height="17" font="26">Mancini </text>
<text top="522" left="199" width="42" height="17" font="26">Official </text>
<text top="539" left="199" width="88" height="17" font="26">Reviewer—ACC </text>
<text top="556" left="199" width="50" height="17" font="26">Board of </text>
<text top="572" left="199" width="60" height="17" font="26">Governors </text>
<text top="522" left="305" width="62" height="17" font="26">Vancouver </text>
<text top="539" left="305" width="48" height="17" font="26">Hospital </text>
<text top="556" left="305" width="53" height="17" font="26">Research </text>
<text top="572" left="305" width="58" height="17" font="26">Pavilion— </text>
<text top="589" left="305" width="69" height="17" font="26">Professor of </text>
<text top="605" left="305" width="54" height="17" font="26">Medicine </text>
<text top="523" left="406" width="56" height="18" font="26">• Amgen  </text>
<text top="540" left="406" width="48" height="18" font="26">• Bayer  </text>
<text top="557" left="406" width="75" height="18" font="26">• Boehringer </text>
<text top="574" left="417" width="57" height="17" font="26">Ingelheim </text>
<text top="591" left="417" width="70" height="17" font="26">Pharmaceuti</text>
<text top="607" left="417" width="49" height="17" font="26">cals, Inc  </text>
<text top="624" left="406" width="74" height="18" font="26">• Eli Lilly and </text>
<text top="641" left="417" width="58" height="17" font="26">Company  </text>
<text top="657" left="406" width="65" height="18" font="26">• Esperion  </text>
<text top="675" left="406" width="52" height="18" font="26">• Merck  </text>
<text top="692" left="406" width="48" height="18" font="26">• Pfizer  </text>
<text top="709" left="406" width="77" height="18" font="26">• Regeneron  </text>
<text top="726" left="406" width="49" height="18" font="26">• Sanofi-</text>
<text top="743" left="417" width="47" height="17" font="26">aventis/ </text>
<text top="760" left="417" width="66" height="17" font="26">Regeneron  </text>
<text top="776" left="406" width="52" height="18" font="26">• Servier </text>
<text top="523" left="508" width="33" height="17" font="26">None </text>
<text top="523" left="580" width="33" height="17" font="26">None </text>
<text top="523" left="698" width="33" height="17" font="26">None </text>
<text top="522" left="798" width="33" height="17" font="26">None </text>
<text top="523" left="905" width="33" height="17" font="26">None </text>
<text top="523" left="1000" width="33" height="17" font="26">None </text>
<text top="457" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="78" position="absolute" top="0" left="0" height="918" width="1188">
<image top="341" left="149" width="891" height="236" src="blood-cholesterol-management/CIR.0000000000000625-78_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="862" left="570" width="48" height="19" font="1">Page 78</text>
<text top="860" left="618" width="4" height="21" font="5"> </text>
<text top="125" left="116" width="48" height="17" font="26">Laxmi S. </text>
<text top="141" left="116" width="39" height="17" font="26">Mehta </text>
<text top="125" left="199" width="42" height="17" font="26">Official </text>
<text top="141" left="199" width="88" height="17" font="26">Reviewer—ACC </text>
<text top="158" left="199" width="68" height="17" font="26">Science and </text>
<text top="174" left="199" width="42" height="17" font="26">Quality </text>
<text top="191" left="199" width="64" height="17" font="26">Committee </text>
<text top="125" left="305" width="61" height="17" font="26">Ohio State </text>
<text top="141" left="305" width="67" height="17" font="26">University—</text>
<text top="158" left="305" width="70" height="17" font="26">Professor of </text>
<text top="174" left="305" width="58" height="17" font="26">Medicine; </text>
<text top="191" left="305" width="43" height="17" font="26">Section </text>
<text top="207" left="305" width="62" height="17" font="26">Director of </text>
<text top="224" left="305" width="73" height="17" font="26">Preventative </text>
<text top="240" left="305" width="85" height="17" font="26">Cardiology and </text>
<text top="257" left="305" width="55" height="17" font="26">Women’s </text>
<text top="273" left="305" width="83" height="17" font="26">Cardiovascular </text>
<text top="290" left="305" width="39" height="17" font="26">Health </text>
<text top="125" left="406" width="33" height="17" font="26">None </text>
<text top="125" left="508" width="33" height="17" font="26">None </text>
<text top="125" left="580" width="33" height="17" font="26">None </text>
<text top="125" left="698" width="33" height="17" font="26">None </text>
<text top="125" left="796" width="47" height="18" font="26">•  AHA† </text>
<text top="125" left="905" width="33" height="17" font="26">None </text>
<text top="125" left="1000" width="33" height="17" font="26">None </text>
<text top="307" left="116" width="34" height="17" font="26">David </text>
<text top="323" left="116" width="66" height="17" font="26">Montgomer</text>
<text top="340" left="116" width="9" height="17" font="26">y </text>
<text top="307" left="199" width="42" height="17" font="26">Official </text>
<text top="323" left="199" width="89" height="17" font="26">Reviewer—ABC </text>
<text top="307" left="305" width="56" height="17" font="26">Piedmont </text>
<text top="323" left="305" width="84" height="17" font="26">Heart Institute-</text>
<text top="340" left="305" width="80" height="17" font="26">—Cardiologist </text>
<text top="307" left="406" width="33" height="17" font="26">None </text>
<text top="307" left="508" width="33" height="17" font="26">None </text>
<text top="307" left="580" width="33" height="17" font="26">None </text>
<text top="307" left="698" width="33" height="17" font="26">None </text>
<text top="307" left="798" width="33" height="17" font="26">None </text>
<text top="307" left="905" width="33" height="17" font="26">None </text>
<text top="307" left="1000" width="33" height="17" font="26">None </text>
<text top="393" left="116" width="50" height="17" font="26">Michelle </text>
<text top="409" left="116" width="40" height="17" font="26">Odden </text>
<text top="393" left="199" width="42" height="17" font="26">Official </text>
<text top="409" left="199" width="89" height="17" font="26">Reviewer—AGS </text>
<text top="393" left="305" width="75" height="17" font="26">Oregon State </text>
<text top="409" left="305" width="67" height="17" font="26">University—</text>
<text top="426" left="305" width="55" height="17" font="26">Associate </text>
<text top="442" left="305" width="55" height="17" font="26">Professor </text>
<text top="393" left="406" width="33" height="17" font="26">None </text>
<text top="393" left="508" width="33" height="17" font="26">None </text>
<text top="393" left="580" width="33" height="17" font="26">None </text>
<text top="393" left="698" width="33" height="17" font="26">None </text>
<text top="393" left="798" width="33" height="17" font="26">None </text>
<text top="393" left="905" width="33" height="17" font="26">None </text>
<text top="393" left="1000" width="33" height="17" font="26">None </text>
<text top="459" left="116" width="48" height="17" font="26">Daniel J. </text>
<text top="476" left="116" width="35" height="17" font="26">Rader </text>
<text top="459" left="199" width="42" height="17" font="26">Official </text>
<text top="476" left="199" width="90" height="17" font="26">Reviewer—AHA </text>
<text top="459" left="305" width="44" height="17" font="26">Cooper-</text>
<text top="476" left="305" width="58" height="17" font="26">McClure—</text>
<text top="492" left="305" width="70" height="17" font="26">Professor of </text>
<text top="509" left="305" width="58" height="17" font="26">Medicine; </text>
<text top="525" left="305" width="73" height="17" font="26">University of </text>
<text top="542" left="305" width="75" height="17" font="26">Pennsylvania </text>
<text top="558" left="305" width="54" height="17" font="26">School of </text>
<text top="575" left="305" width="63" height="17" font="26">Medicine—</text>
<text top="591" left="305" width="51" height="17" font="26">Director, </text>
<text top="608" left="305" width="62" height="17" font="26">Preventive </text>
<text top="624" left="305" width="83" height="17" font="26">Cardiovascular </text>
<text top="641" left="305" width="54" height="17" font="26">Medicine </text>
<text top="459" left="406" width="65" height="18" font="26">• Alnylam* </text>
<text top="477" left="406" width="70" height="18" font="26">• Novartis*  </text>
<text top="494" left="406" width="55" height="18" font="26">• Pfizer*  </text>
<text top="511" left="406" width="51" height="18" font="26">• DalCor </text>
<text top="528" left="406" width="82" height="18" font="26">• MedImmune</text>
<text top="545" left="417" width="26" height="17" font="26">, Inc </text>
<text top="459" left="508" width="33" height="17" font="26">None </text>
<text top="459" left="580" width="77" height="18" font="26">• Staten Bio* </text>
<text top="477" left="580" width="100" height="18" font="26">• VascularStrategi</text>
<text top="494" left="591" width="22" height="17" font="26">es* </text>
<text top="459" left="698" width="33" height="17" font="26">None </text>
<text top="459" left="798" width="33" height="17" font="26">None </text>
<text top="459" left="905" width="33" height="17" font="26">None </text>
<text top="459" left="1000" width="33" height="17" font="26">None </text>
<text top="658" left="116" width="65" height="17" font="26">Michael W. </text>
<text top="674" left="116" width="26" height="17" font="26">Rich </text>
<text top="658" left="199" width="42" height="17" font="26">Official </text>
<text top="674" left="199" width="89" height="17" font="26">Reviewer—AGS </text>
<text top="658" left="305" width="69" height="17" font="26">Washington </text>
<text top="674" left="305" width="58" height="17" font="26">University </text>
<text top="691" left="305" width="54" height="17" font="26">School of </text>
<text top="707" left="305" width="66" height="17" font="26">Medicine— </text>
<text top="724" left="305" width="70" height="17" font="26">Professor of </text>
<text top="740" left="305" width="57" height="17" font="26">Medicine  </text>
<text top="658" left="406" width="33" height="17" font="26">None </text>
<text top="658" left="508" width="33" height="17" font="26">None </text>
<text top="658" left="580" width="33" height="17" font="26">None </text>
<text top="658" left="698" width="33" height="17" font="26">None </text>
<text top="658" left="798" width="33" height="17" font="26">None </text>
<text top="658" left="905" width="33" height="17" font="26">None </text>
<text top="658" left="1000" width="33" height="17" font="26">None </text>
<text top="457" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="79" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="27" size="11" family="Times" color="#2d2d2d"/>
	<fontspec id="28" size="11" family="Times" color="#222222"/>
<image top="341" left="149" width="891" height="236" src="blood-cholesterol-management/CIR.0000000000000625-79_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="862" left="570" width="48" height="19" font="1">Page 79</text>
<text top="860" left="618" width="4" height="21" font="5"> </text>
<text top="125" left="116" width="54" height="17" font="26">Mirvat A. </text>
<text top="141" left="116" width="46" height="17" font="26">Alasnag </text>
<text top="125" left="199" width="47" height="17" font="26">Content </text>
<text top="141" left="199" width="88" height="17" font="26">Reviewer—ACC </text>
<text top="158" left="199" width="70" height="17" font="26">Early Career </text>
<text top="174" left="199" width="50" height="17" font="26">Member </text>
<text top="191" left="199" width="44" height="17" font="26">Section </text>
<text top="125" left="305" width="56" height="17" font="27">King Fahd </text>
<text top="141" left="305" width="79" height="17" font="27">Armed Forces </text>
<text top="158" left="305" width="52" height="17" font="27">Hospital, </text>
<text top="174" left="305" width="79" height="17" font="27">Jeddah-KSA —</text>
<text top="191" left="305" width="81" height="17" font="27">Interventional </text>
<text top="207" left="305" width="65" height="17" font="27">Cardiologist</text>
<text top="207" left="370" width="3" height="17" font="26"> </text>
<text top="125" left="406" width="33" height="17" font="26">None </text>
<text top="125" left="508" width="33" height="17" font="26">None </text>
<text top="125" left="580" width="33" height="17" font="26">None </text>
<text top="125" left="698" width="33" height="17" font="26">None </text>
<text top="125" left="798" width="33" height="17" font="26">None </text>
<text top="125" left="905" width="33" height="17" font="26">None </text>
<text top="125" left="1000" width="33" height="17" font="26">None </text>
<text top="224" left="116" width="37" height="17" font="26">Kim K. </text>
<text top="241" left="116" width="47" height="17" font="26">Birtcher </text>
<text top="224" left="199" width="47" height="17" font="26">Content </text>
<text top="241" left="199" width="63" height="17" font="26">Reviewer—</text>
<text top="257" left="199" width="82" height="17" font="26">ACC/AHA Task </text>
<text top="274" left="199" width="93" height="17" font="26">Force on Clinical </text>
<text top="290" left="199" width="47" height="17" font="26">Practice </text>
<text top="307" left="199" width="61" height="17" font="26">Guidelines </text>
<text top="224" left="305" width="73" height="17" font="26">University of </text>
<text top="241" left="305" width="50" height="17" font="26">Houston </text>
<text top="257" left="305" width="58" height="17" font="26">College of </text>
<text top="274" left="305" width="67" height="17" font="26">Pharmacy—</text>
<text top="290" left="305" width="42" height="17" font="26">Clinical </text>
<text top="307" left="305" width="55" height="17" font="26">Professor </text>
<text top="225" left="406" width="55" height="18" font="26">• Jones &amp; </text>
<text top="242" left="415" width="45" height="17" font="26">Bartlett </text>
<text top="258" left="415" width="50" height="17" font="26">Learning </text>
<text top="224" left="508" width="33" height="17" font="26">None </text>
<text top="224" left="580" width="33" height="17" font="26">None </text>
<text top="224" left="698" width="33" height="17" font="26">None </text>
<text top="225" left="798" width="86" height="18" font="26">• Accreditation </text>
<text top="242" left="807" width="63" height="17" font="26">Council for </text>
<text top="258" left="807" width="42" height="17" font="26">Clinical </text>
<text top="275" left="807" width="66" height="17" font="26">Lipidology† </text>
<text top="224" left="905" width="33" height="17" font="26">None </text>
<text top="225" left="1000" width="3" height="17" font="26"> </text>
<text top="324" left="116" width="57" height="17" font="26">Conrad B. </text>
<text top="341" left="116" width="31" height="17" font="26">Blum </text>
<text top="324" left="199" width="47" height="17" font="26">Content </text>
<text top="341" left="199" width="66" height="17" font="26">Reviewer— </text>
<text top="357" left="199" width="55" height="17" font="26">ACC/AHA </text>
<text top="324" left="305" width="68" height="17" font="26">Medicine at </text>
<text top="341" left="305" width="55" height="17" font="26">Columbia </text>
<text top="357" left="305" width="58" height="17" font="26">University </text>
<text top="373" left="305" width="47" height="17" font="26">Medical </text>
<text top="390" left="305" width="49" height="17" font="26">Center—</text>
<text top="406" left="305" width="55" height="17" font="26">Professor </text>
<text top="324" left="406" width="33" height="17" font="26">None </text>
<text top="324" left="508" width="33" height="17" font="26">None </text>
<text top="324" left="580" width="33" height="17" font="26">None </text>
<text top="324" left="698" width="33" height="17" font="26">None </text>
<text top="324" left="796" width="74" height="18" font="26">•  ACC-AHA† </text>
<text top="324" left="905" width="33" height="17" font="26">None </text>
<text top="324" left="1000" width="33" height="17" font="26">None </text>
<text top="424" left="116" width="47" height="17" font="26">Bernard </text>
<text top="440" left="116" width="41" height="17" font="26">Dennis </text>
<text top="424" left="199" width="47" height="17" font="26">Content </text>
<text top="440" left="199" width="63" height="17" font="26">Reviewer—</text>
<text top="457" left="199" width="76" height="17" font="26">ACC/AHA Lay </text>
<text top="473" left="199" width="54" height="17" font="26">Reviewer </text>
<text top="424" left="305" width="41" height="17" font="28">Dennis </text>
<text top="440" left="305" width="82" height="17" font="28">Associates, LLC</text>
<text top="440" left="388" width="3" height="17" font="26"> </text>
<text top="424" left="406" width="33" height="17" font="26">None </text>
<text top="424" left="508" width="33" height="17" font="26">None </text>
<text top="424" left="580" width="33" height="17" font="26">None </text>
<text top="424" left="698" width="33" height="17" font="26">None </text>
<text top="424" left="798" width="33" height="17" font="26">None </text>
<text top="424" left="905" width="33" height="17" font="26">None </text>
<text top="424" left="1000" width="33" height="17" font="26">None </text>
<text top="490" left="116" width="36" height="17" font="26">Henry </text>
<text top="507" left="116" width="52" height="17" font="26">Ginsberg </text>
<text top="490" left="199" width="47" height="17" font="26">Content </text>
<text top="507" left="199" width="90" height="17" font="26">Reviewer—AHA </text>
<text top="490" left="305" width="55" height="17" font="26">Columbia </text>
<text top="507" left="305" width="62" height="17" font="26">University, </text>
<text top="523" left="305" width="43" height="17" font="26">Irving—</text>
<text top="540" left="305" width="70" height="17" font="26">Professor of </text>
<text top="556" left="305" width="54" height="17" font="26">Medicine </text>
<text top="491" left="406" width="49" height="18" font="26">• Merck </text>
<text top="508" left="406" width="76" height="18" font="26">• Resverlogix </text>
<text top="525" left="406" width="49" height="18" font="26">• Sanofi-</text>
<text top="542" left="417" width="63" height="17" font="26">Regeneron </text>
<text top="559" left="406" width="53" height="18" font="26">• Amgen </text>
<text top="576" left="406" width="47" height="18" font="26">• Akcea </text>
<text top="593" left="406" width="47" height="18" font="26">•  Kowa </text>
<text top="610" left="406" width="59" height="18" font="26">•  Janssen </text>
<text top="627" left="406" width="62" height="18" font="26">• Esperion </text>
<text top="490" left="508" width="33" height="17" font="26">None </text>
<text top="490" left="580" width="33" height="17" font="26">None </text>
<text top="490" left="698" width="33" height="17" font="26">None </text>
<text top="490" left="798" width="33" height="17" font="26">None </text>
<text top="490" left="905" width="33" height="17" font="26">None </text>
<text top="490" left="1000" width="33" height="17" font="26">None </text>
<text top="666" left="116" width="18" height="17" font="26">Ira </text>
<text top="683" left="116" width="54" height="17" font="26">Goldberg </text>
<text top="666" left="199" width="47" height="17" font="26">Content </text>
<text top="683" left="199" width="90" height="17" font="26">Reviewer—AHA </text>
<text top="666" left="305" width="88" height="17" font="26">NYU Division of </text>
<text top="683" left="305" width="85" height="17" font="26">Endocrinology, </text>
<text top="699" left="305" width="78" height="17" font="26">Diabetes, and </text>
<text top="716" left="305" width="78" height="17" font="26">Metabolism—</text>
<text top="732" left="305" width="48" height="17" font="26">Director </text>
<text top="666" left="406" width="57" height="18" font="26">• Akcea*  </text>
<text top="684" left="406" width="53" height="18" font="26">• Amgen </text>
<text top="701" left="406" width="78" height="18" font="26">• Arrowhead  </text>
<text top="718" left="406" width="58" height="18" font="26">• Intarcia  </text>
<text top="735" left="406" width="52" height="18" font="26">• Merck  </text>
<text top="752" left="406" width="74" height="18" font="26">• Regeneron </text>
<text top="666" left="508" width="33" height="17" font="26">None </text>
<text top="666" left="580" width="33" height="17" font="26">None </text>
<text top="666" left="698" width="33" height="17" font="26">None </text>
<text top="666" left="798" width="33" height="17" font="26">None </text>
<text top="666" left="905" width="33" height="17" font="26">None </text>
<text top="666" left="1000" width="33" height="17" font="26">None </text>
<text top="457" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="80" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="29" size="11" family="Times" color="#1b1b1b"/>
	<fontspec id="30" size="11" family="Times" color="#1b1b1b"/>
<image top="341" left="149" width="891" height="236" src="blood-cholesterol-management/CIR.0000000000000625-80_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="862" left="570" width="48" height="19" font="1">Page 80</text>
<text top="860" left="618" width="4" height="21" font="5"> </text>
<text top="125" left="116" width="41" height="17" font="26">José A. </text>
<text top="141" left="116" width="35" height="17" font="26">Joglar </text>
<text top="125" left="199" width="47" height="17" font="26">Content </text>
<text top="141" left="199" width="66" height="17" font="26">Reviewer— </text>
<text top="158" left="199" width="82" height="17" font="26">ACC/AHA Task </text>
<text top="174" left="199" width="93" height="17" font="26">Force on Clinical </text>
<text top="191" left="199" width="47" height="17" font="26">Practice </text>
<text top="207" left="199" width="61" height="17" font="26">Guidelines </text>
<text top="125" left="305" width="18" height="17" font="26">UT </text>
<text top="141" left="305" width="80" height="17" font="26">Southwestern </text>
<text top="158" left="305" width="87" height="17" font="26">Medical Center </text>
<text top="174" left="305" width="67" height="17" font="26">University—</text>
<text top="191" left="305" width="70" height="17" font="26">Professor of </text>
<text top="207" left="305" width="54" height="17" font="26">Medicine </text>
<text top="125" left="406" width="33" height="17" font="26">None </text>
<text top="125" left="508" width="33" height="17" font="26">None </text>
<text top="125" left="580" width="33" height="17" font="26">None </text>
<text top="125" left="698" width="33" height="17" font="26">None </text>
<text top="125" left="798" width="33" height="17" font="26">None </text>
<text top="125" left="905" width="33" height="17" font="26">None </text>
<text top="125" left="1000" width="33" height="17" font="26">None </text>
<text top="224" left="116" width="51" height="17" font="26">Glenn N. </text>
<text top="241" left="116" width="39" height="17" font="26">Levine </text>
<text top="224" left="199" width="47" height="17" font="26">Content </text>
<text top="241" left="199" width="63" height="17" font="26">Reviewer—</text>
<text top="257" left="199" width="82" height="17" font="26">ACC/AHA Task </text>
<text top="274" left="199" width="93" height="17" font="26">Force on Clinical </text>
<text top="290" left="199" width="47" height="17" font="26">Practice </text>
<text top="307" left="199" width="61" height="17" font="26">Guidelines </text>
<text top="224" left="305" width="81" height="17" font="26">Baylor College </text>
<text top="241" left="305" width="80" height="17" font="26">of Medicine— </text>
<text top="257" left="305" width="70" height="17" font="26">Professor of </text>
<text top="274" left="305" width="58" height="17" font="26">Medicine; </text>
<text top="290" left="305" width="60" height="17" font="26">Michael E. </text>
<text top="307" left="305" width="51" height="17" font="26">DeBakey </text>
<text top="323" left="305" width="47" height="17" font="26">Medical </text>
<text top="340" left="305" width="49" height="17" font="26">Center—</text>
<text top="356" left="305" width="51" height="17" font="26">Director, </text>
<text top="373" left="305" width="72" height="17" font="26">Cardiac Care </text>
<text top="389" left="305" width="26" height="17" font="26">Unit </text>
<text top="224" left="406" width="33" height="17" font="26">None </text>
<text top="224" left="508" width="33" height="17" font="26">None </text>
<text top="224" left="580" width="33" height="17" font="26">None </text>
<text top="224" left="698" width="33" height="17" font="26">None </text>
<text top="224" left="798" width="33" height="17" font="26">None </text>
<text top="225" left="904" width="78" height="18" font="26">•  Defendant, </text>
<text top="242" left="917" width="40" height="17" font="26">Out-of-</text>
<text top="258" left="917" width="47" height="17" font="26">hospital </text>
<text top="275" left="917" width="62" height="17" font="26">cardiopulm</text>
<text top="291" left="917" width="35" height="17" font="26">onary </text>
<text top="308" left="917" width="39" height="17" font="26">arrest, </text>
<text top="324" left="917" width="37" height="17" font="26">2017* </text>
<text top="225" left="1000" width="33" height="17" font="26">None </text>
<text top="406" left="116" width="130" height="17" font="26">Daniel Levy  Content </text>
<text top="423" left="199" width="63" height="17" font="26">Reviewer—</text>
<text top="440" left="199" width="58" height="17" font="26">ACC/AHA  </text>
<text top="406" left="305" width="59" height="17" font="26">Center for </text>
<text top="423" left="305" width="63" height="17" font="26">Population </text>
<text top="440" left="305" width="52" height="17" font="26">Studies—</text>
<text top="456" left="305" width="48" height="17" font="26">Director;</text>
<text top="456" left="354" width="3" height="17" font="29"> </text>
<text top="472" left="305" width="78" height="17" font="30"><i>Journal of the </i></text>
<text top="488" left="305" width="55" height="17" font="30"><i>American </i></text>
<text top="505" left="305" width="56" height="17" font="30"><i>Society of </i></text>
<text top="521" left="305" width="85" height="18" font="30"><i>Hypertension</i>—</text>
<text top="538" left="305" width="80" height="17" font="29">Editor-in-Chief</text>
<text top="538" left="385" width="3" height="17" font="26"> </text>
<text top="407" left="406" width="33" height="17" font="26">None </text>
<text top="407" left="508" width="33" height="17" font="26">None </text>
<text top="407" left="580" width="33" height="17" font="26">None </text>
<text top="407" left="698" width="33" height="17" font="26">None </text>
<text top="406" left="798" width="33" height="17" font="26">None </text>
<text top="407" left="905" width="33" height="17" font="26">None </text>
<text top="407" left="1000" width="33" height="17" font="26">None </text>
<text top="556" left="116" width="56" height="17" font="26">Theodore </text>
<text top="572" left="116" width="53" height="17" font="26">Mazzone </text>
<text top="556" left="199" width="47" height="17" font="26">Content </text>
<text top="572" left="199" width="66" height="17" font="26">Reviewer— </text>
<text top="589" left="199" width="55" height="17" font="26">ACC/AHA </text>
<text top="556" left="305" width="67" height="17" font="26">NorthShore </text>
<text top="572" left="305" width="58" height="17" font="26">University </text>
<text top="589" left="305" width="83" height="17" font="26">Health System-</text>
<text top="605" left="305" width="71" height="17" font="26">—Chairman, </text>
<text top="621" left="305" width="84" height="17" font="26">Department of </text>
<text top="638" left="305" width="54" height="17" font="26">Medicine </text>
<text top="556" left="406" width="33" height="17" font="26">None </text>
<text top="556" left="508" width="33" height="17" font="26">None </text>
<text top="556" left="580" width="33" height="17" font="26">None </text>
<text top="556" left="698" width="33" height="17" font="26">None </text>
<text top="556" left="798" width="33" height="17" font="26">None </text>
<text top="556" left="905" width="33" height="17" font="26">None </text>
<text top="556" left="1000" width="33" height="17" font="26">None </text>
<text top="457" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="81" position="absolute" top="0" left="0" height="918" width="1188">
<image top="341" left="149" width="891" height="236" src="blood-cholesterol-management/CIR.0000000000000625-81_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="862" left="570" width="48" height="19" font="1">Page 81</text>
<text top="860" left="618" width="4" height="21" font="5"> </text>
<text top="125" left="116" width="54" height="17" font="26">Patrick E. </text>
<text top="141" left="116" width="49" height="17" font="26">McBride </text>
<text top="125" left="199" width="47" height="17" font="26">Content </text>
<text top="141" left="199" width="63" height="17" font="26">Reviewer—</text>
<text top="158" left="199" width="55" height="17" font="26">ACC/AHA </text>
<text top="125" left="305" width="73" height="17" font="26">University of </text>
<text top="141" left="305" width="59" height="17" font="26">Wisconsin </text>
<text top="158" left="305" width="54" height="17" font="26">School of </text>
<text top="174" left="305" width="78" height="17" font="26">Medicine and </text>
<text top="191" left="305" width="84" height="17" font="26">Public Health—</text>
<text top="207" left="305" width="55" height="17" font="26">Professor </text>
<text top="224" left="305" width="55" height="17" font="26">Emeritus, </text>
<text top="240" left="305" width="75" height="17" font="26">Departments </text>
<text top="257" left="305" width="68" height="17" font="26">of Medicine </text>
<text top="273" left="305" width="88" height="17" font="26">(Cardiovascular </text>
<text top="290" left="305" width="82" height="17" font="26">Medicine) and </text>
<text top="306" left="305" width="39" height="17" font="26">Family </text>
<text top="323" left="305" width="54" height="17" font="26">Medicine </text>
<text top="125" left="406" width="33" height="17" font="26">None </text>
<text top="125" left="508" width="33" height="17" font="26">None </text>
<text top="125" left="580" width="53" height="18" font="26">•  Health </text>
<text top="142" left="594" width="84" height="17" font="26">Decisions, Inc† </text>
<text top="125" left="698" width="33" height="17" font="26">None </text>
<text top="125" left="798" width="33" height="17" font="26">None </text>
<text top="125" left="905" width="33" height="17" font="26">None </text>
<text top="125" left="1000" width="33" height="17" font="26">None </text>
<text top="340" left="116" width="46" height="17" font="26">Karen J. </text>
<text top="356" left="116" width="62" height="17" font="26">McConnell </text>
<text top="340" left="199" width="47" height="17" font="26">Content </text>
<text top="356" left="199" width="63" height="17" font="26">Reviewer—</text>
<text top="373" left="199" width="33" height="17" font="26">APhA </text>
<text top="340" left="305" width="87" height="17" font="26">Catholic Health </text>
<text top="356" left="305" width="66" height="17" font="26">Initiatives—</text>
<text top="373" left="305" width="43" height="17" font="26">System </text>
<text top="389" left="305" width="62" height="17" font="26">Director of </text>
<text top="406" left="305" width="42" height="17" font="26">Clinical </text>
<text top="422" left="305" width="57" height="17" font="26">Pharmacy </text>
<text top="439" left="305" width="48" height="17" font="26">Services </text>
<text top="340" left="406" width="33" height="17" font="26">None </text>
<text top="340" left="508" width="33" height="17" font="26">None </text>
<text top="340" left="580" width="33" height="17" font="26">None </text>
<text top="340" left="698" width="33" height="17" font="26">None </text>
<text top="340" left="798" width="33" height="17" font="26">None </text>
<text top="340" left="905" width="33" height="17" font="26">None </text>
<text top="340" left="1000" width="33" height="17" font="26">None </text>
<text top="456" left="116" width="57" height="17" font="26">Pamela B. </text>
<text top="472" left="116" width="40" height="17" font="26">Morris </text>
<text top="456" left="199" width="47" height="17" font="26">Content </text>
<text top="472" left="199" width="88" height="17" font="26">Reviewer—ACC </text>
<text top="489" left="199" width="77" height="17" font="26">Prevention of </text>
<text top="505" left="199" width="83" height="17" font="26">Cardiovascular </text>
<text top="522" left="199" width="45" height="17" font="26">Disease </text>
<text top="538" left="199" width="50" height="17" font="26">Member </text>
<text top="555" left="199" width="44" height="17" font="26">Section </text>
<text top="456" left="305" width="70" height="17" font="26">The Medical </text>
<text top="472" left="305" width="73" height="17" font="26">University of </text>
<text top="489" left="305" width="35" height="17" font="26">South </text>
<text top="505" left="305" width="57" height="17" font="26">Carolina—</text>
<text top="522" left="305" width="70" height="17" font="26">Professor of </text>
<text top="538" left="305" width="57" height="17" font="26">Medicine, </text>
<text top="555" left="305" width="62" height="17" font="26">Director of </text>
<text top="571" left="305" width="73" height="17" font="26">Preventative </text>
<text top="588" left="305" width="61" height="17" font="26">Cardiology </text>
<text top="456" left="406" width="53" height="18" font="26">• Amgen </text>
<text top="473" left="406" width="65" height="18" font="26">• Esperion  </text>
<text top="490" left="406" width="48" height="18" font="26">• Sanofi </text>
<text top="507" left="417" width="66" height="17" font="26">Regeneron  </text>
<text top="456" left="508" width="33" height="17" font="26">None </text>
<text top="456" left="580" width="33" height="17" font="26">None </text>
<text top="456" left="698" width="33" height="17" font="26">None </text>
<text top="456" left="798" width="33" height="17" font="26">None </text>
<text top="456" left="905" width="33" height="17" font="26">None </text>
<text top="456" left="1000" width="33" height="17" font="26">None </text>
<text top="605" left="116" width="49" height="17" font="26">Nathalie </text>
<text top="621" left="116" width="35" height="17" font="26">Pamir </text>
<text top="605" left="199" width="47" height="17" font="26">Content </text>
<text top="621" left="199" width="90" height="17" font="26">Reviewer—AHA </text>
<text top="638" left="199" width="52" height="17" font="26">Scientific </text>
<text top="654" left="199" width="44" height="17" font="26">Council </text>
<text top="605" left="305" width="83" height="17" font="26">Oregon Health </text>
<text top="621" left="305" width="68" height="17" font="26">and Science </text>
<text top="638" left="305" width="67" height="17" font="26">University—</text>
<text top="654" left="305" width="52" height="17" font="26">Assistant </text>
<text top="671" left="305" width="55" height="17" font="26">Professor </text>
<text top="605" left="406" width="33" height="17" font="26">None </text>
<text top="605" left="508" width="33" height="17" font="26">None </text>
<text top="605" left="580" width="33" height="17" font="26">None </text>
<text top="605" left="698" width="33" height="17" font="26">None </text>
<text top="605" left="798" width="33" height="17" font="26">None </text>
<text top="605" left="905" width="33" height="17" font="26">None </text>
<text top="605" left="1000" width="33" height="17" font="26">None </text>
<text top="457" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="82" position="absolute" top="0" left="0" height="918" width="1188">
<image top="341" left="149" width="891" height="236" src="blood-cholesterol-management/CIR.0000000000000625-82_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="862" left="570" width="48" height="19" font="1">Page 82</text>
<text top="860" left="618" width="4" height="21" font="5"> </text>
<text top="125" left="116" width="53" height="17" font="26">Janelle F. </text>
<text top="141" left="116" width="54" height="17" font="26">Ruisinger </text>
<text top="125" left="199" width="47" height="17" font="26">Content </text>
<text top="141" left="199" width="63" height="17" font="26">Reviewer—</text>
<text top="158" left="199" width="33" height="17" font="26">APhA </text>
<text top="125" left="305" width="82" height="17" font="26">The University </text>
<text top="141" left="305" width="55" height="17" font="26">of Kansas </text>
<text top="158" left="305" width="54" height="17" font="26">School of </text>
<text top="174" left="305" width="61" height="17" font="26">Pharmacy, </text>
<text top="191" left="305" width="84" height="17" font="26">Department of </text>
<text top="207" left="305" width="57" height="17" font="26">Pharmacy </text>
<text top="224" left="305" width="56" height="17" font="26">Practice—</text>
<text top="240" left="305" width="42" height="17" font="26">Clinical </text>
<text top="257" left="305" width="59" height="17" font="26">Professor; </text>
<text top="273" left="305" width="37" height="17" font="26">KUMC </text>
<text top="290" left="305" width="87" height="17" font="26">Atherosclerosis </text>
<text top="306" left="305" width="54" height="17" font="26">and Lipid-</text>
<text top="323" left="305" width="57" height="17" font="26">Apheresis </text>
<text top="339" left="305" width="49" height="17" font="26">Center—</text>
<text top="355" left="305" width="42" height="17" font="26">Clinical </text>
<text top="372" left="305" width="64" height="17" font="26">Pharmacist </text>
<text top="125" left="406" width="33" height="17" font="26">None </text>
<text top="125" left="508" width="33" height="17" font="26">None </text>
<text top="125" left="580" width="33" height="17" font="26">None </text>
<text top="125" left="698" width="62" height="18" font="26">• Amgen†  </text>
<text top="142" left="698" width="84" height="18" font="26">• Regeneron†  </text>
<text top="159" left="698" width="49" height="18" font="26">• Sanofi-</text>
<text top="176" left="709" width="50" height="17" font="26">Aventis† </text>
<text top="125" left="796" width="69" height="18" font="26">•  American </text>
<text top="142" left="810" width="57" height="17" font="26">Society of </text>
<text top="159" left="810" width="82" height="17" font="26">Health System </text>
<text top="175" left="810" width="69" height="17" font="26">Pharmacists </text>
<text top="125" left="905" width="33" height="17" font="26">None </text>
<text top="125" left="1000" width="33" height="17" font="26">None </text>
<text top="389" left="116" width="40" height="17" font="26">Joshua </text>
<text top="406" left="116" width="57" height="17" font="26">Schulman-</text>
<text top="422" left="116" width="44" height="17" font="26">Marcus </text>
<text top="389" left="199" width="47" height="17" font="26">Content </text>
<text top="406" left="199" width="88" height="17" font="26">Reviewer—ACC </text>
<text top="422" left="199" width="70" height="17" font="26">Early Career </text>
<text top="439" left="199" width="50" height="17" font="26">Member </text>
<text top="455" left="199" width="44" height="17" font="26">Section </text>
<text top="389" left="305" width="87" height="17" font="26">Albany Medical </text>
<text top="406" left="305" width="49" height="17" font="26">Center—</text>
<text top="422" left="305" width="52" height="17" font="26">Assistant </text>
<text top="439" left="305" width="70" height="17" font="26">Professor of </text>
<text top="455" left="305" width="54" height="17" font="26">Medicine </text>
<text top="389" left="406" width="33" height="17" font="26">None </text>
<text top="389" left="508" width="33" height="17" font="26">None </text>
<text top="389" left="580" width="33" height="17" font="26">None </text>
<text top="389" left="698" width="33" height="17" font="26">None </text>
<text top="389" left="798" width="33" height="17" font="26">None </text>
<text top="389" left="905" width="33" height="17" font="26">None </text>
<text top="389" left="1000" width="33" height="17" font="26">None </text>
<text top="475" left="116" width="61" height="17" font="26">Michael D. </text>
<text top="492" left="116" width="45" height="17" font="26">Shapiro </text>
<text top="475" left="199" width="47" height="17" font="26">Content </text>
<text top="492" left="199" width="88" height="17" font="26">Reviewer—ACC </text>
<text top="508" left="199" width="77" height="17" font="26">Prevention of </text>
<text top="524" left="199" width="83" height="17" font="26">Cardiovascular </text>
<text top="541" left="199" width="45" height="17" font="26">Disease </text>
<text top="557" left="199" width="50" height="17" font="26">Member </text>
<text top="574" left="199" width="44" height="17" font="26">Section </text>
<text top="475" left="305" width="83" height="17" font="26">Oregon Health </text>
<text top="492" left="305" width="56" height="17" font="26">&amp; Science </text>
<text top="508" left="305" width="67" height="17" font="26">University—</text>
<text top="524" left="305" width="55" height="17" font="26">Associate </text>
<text top="541" left="305" width="70" height="17" font="26">Professor of </text>
<text top="557" left="305" width="78" height="17" font="26">Medicine and </text>
<text top="574" left="305" width="57" height="17" font="26">Radiology </text>
<text top="475" left="406" width="50" height="18" font="26">• Akcea  </text>
<text top="492" left="406" width="56" height="18" font="26">• Amgen  </text>
<text top="510" left="406" width="57" height="18" font="26">• Kastle*  </text>
<text top="527" left="406" width="60" height="18" font="26">• Novartis </text>
<text top="544" left="417" width="72" height="17" font="26">Corporation  </text>
<text top="560" left="406" width="74" height="18" font="26">• Regeneron </text>
<text top="475" left="508" width="33" height="17" font="26">None </text>
<text top="475" left="580" width="33" height="17" font="26">None </text>
<text top="475" left="698" width="57" height="18" font="26">• Akcea†  </text>
<text top="492" left="698" width="60" height="18" font="26">• Amarin† </text>
<text top="510" left="698" width="59" height="18" font="26">• Amgen† </text>
<text top="475" left="798" width="33" height="17" font="26">None </text>
<text top="475" left="905" width="33" height="17" font="26">None </text>
<text top="475" left="1000" width="33" height="17" font="26">None </text>
<text top="599" left="116" width="35" height="17" font="26">Susan </text>
<text top="616" left="116" width="35" height="17" font="26">Shero </text>
<text top="599" left="199" width="47" height="17" font="26">Content </text>
<text top="616" left="199" width="66" height="17" font="26">Reviewer— </text>
<text top="632" left="199" width="55" height="17" font="26">ACC/AHA </text>
<text top="599" left="305" width="69" height="17" font="26">NIH NHLBI—</text>
<text top="616" left="305" width="75" height="17" font="26">Public Health </text>
<text top="632" left="305" width="44" height="17" font="26">Advisor </text>
<text top="599" left="406" width="33" height="17" font="26">None </text>
<text top="599" left="508" width="33" height="17" font="26">None </text>
<text top="599" left="580" width="33" height="17" font="26">None </text>
<text top="599" left="698" width="33" height="17" font="26">None </text>
<text top="599" left="798" width="33" height="17" font="26">None </text>
<text top="599" left="905" width="33" height="17" font="26">None </text>
<text top="599" left="1000" width="33" height="17" font="26">None </text>
<text top="685" left="116" width="49" height="17" font="26">James L. </text>
<text top="702" left="116" width="47" height="17" font="26">Young II </text>
<text top="685" left="199" width="47" height="17" font="26">Content </text>
<text top="702" left="199" width="90" height="17" font="26">Reviewer—AHA </text>
<text top="685" left="305" width="60" height="17" font="26">Beaumont </text>
<text top="702" left="305" width="48" height="17" font="26">Health—</text>
<text top="718" left="305" width="83" height="17" font="26">Patient/Family </text>
<text top="735" left="305" width="41" height="17" font="26">Liaison </text>
<text top="685" left="406" width="33" height="17" font="26">None </text>
<text top="685" left="508" width="33" height="17" font="26">None </text>
<text top="685" left="580" width="33" height="17" font="26">None </text>
<text top="685" left="698" width="33" height="17" font="26">None </text>
<text top="685" left="798" width="33" height="17" font="26">None </text>
<text top="685" left="905" width="33" height="17" font="26">None </text>
<text top="685" left="1000" width="33" height="17" font="26">None </text>
<text top="771" left="108" width="955" height="17" font="26">This table represents all relationships of reviewers with industry and other entities that were reported at the time of peer review, including those not deemed to be relevant </text>
<text top="787" left="108" width="955" height="17" font="26">to this document, at the time this document was under review. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed </text>
<text top="804" left="108" width="955" height="17" font="26">to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair </text>
<text top="820" left="108" width="955" height="17" font="26">market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships </text>
<text top="457" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="83" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="31" size="11" family="Times" color="#0000ff"/>
<image top="341" left="149" width="891" height="236" src="blood-cholesterol-management/CIR.0000000000000625-83_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="862" left="570" width="48" height="19" font="1">Page 83</text>
<text top="860" left="618" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="957" height="17" font="26">that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to </text>
<text top="141" left="108" width="589" height="17" font="31"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy</a></text>
<text top="141" left="697" width="367" height="17" font="26"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy"> </a>for definitions of disclosure categories or additional information </text>
<text top="157" left="108" width="342" height="17" font="26">about the ACC/AHA Disclosure Policy for Writing Committees. </text>
<text top="173" left="108" width="3" height="17" font="26"> </text>
<text top="190" left="108" width="138" height="17" font="26">*Significant relationship. </text>
<text top="206" left="108" width="121" height="17" font="26">†No financial benefit. </text>
<text top="223" left="108" width="3" height="17" font="26"> </text>
<text top="239" left="108" width="958" height="17" font="26">AACVPR indicates American Association of Cardiovascular and Pulmonary Rehabilitation; AAPA, American Academy of Physician Assistants; ABC, Association of Black </text>
<text top="256" left="108" width="955" height="17" font="26">Cardiologists; ACC, American College of Cardiology; ACPM, American College of Preventive Medicine; ADA, American Diabetes Association; AGS, American Geriatrics Society; </text>
<text top="272" left="108" width="955" height="17" font="26">AHA, American Heart Association; APhA, American Pharmacists Association; ASPC, American Society for Preventive Cardiology; GSK, GlaskoSmithKline; KSA, Kingdom of Saudi </text>
<text top="289" left="108" width="956" height="17" font="26">Arabia; KUMC, University of Kansas Medical Center; LDL, low-density lipoprotein; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institutes of Health; NLA, </text>
<text top="305" left="108" width="744" height="17" font="26">National Lipid Association; NYU, New York University; PCNA, Preventive Cardiovascular Nurses Association; and UT, University of Texas. </text>
<text top="326" left="108" width="5" height="16" font="14"> </text>
<text top="347" left="108" width="5" height="16" font="14"> </text>
<text top="347" left="324" width="5" height="16" font="14"> </text>
<text top="457" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="84" position="absolute" top="0" left="0" height="918" width="1188">
<image top="341" left="149" width="891" height="236" src="blood-cholesterol-management/CIR.0000000000000625-84_1.jpg"/>
<text top="54" left="108" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="108" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="862" left="570" width="48" height="19" font="1">Page 84</text>
<text top="860" left="618" width="4" height="21" font="5"> </text>
<text top="124" left="108" width="4" height="21" font="5"> </text>
<text top="124" left="324" width="4" height="21" font="5"> </text>
<text top="457" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="85" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="32" size="19" family="Times" color="#000000"/>
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-85_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="456" width="48" height="19" font="1">Page 85</text>
<text top="1130" left="505" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="116" height="31" font="11"><b>References </b></text>
<text top="141" left="124" width="154" height="31" font="11"><b>1. Introduction </b></text>
<text top="175" left="124" width="373" height="29" font="2"><b>1.1. Methodology and Evidence Review </b></text>
<text top="207" left="124" width="50" height="21" font="5">S1.1-1. </text>
<text top="207" left="219" width="525" height="21" font="5">Wilson PWF, Polonsky TS, Miedema MD, et al. Systematic review for the 2018 </text>
<text top="227" left="219" width="595" height="21" font="5">AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the </text>
<text top="247" left="219" width="621" height="21" font="5">management of blood cholesterol: a report of the American College of Cardiology/American </text>
<text top="267" left="219" width="583" height="21" font="5">Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;In press. </text>
<text top="296" left="124" width="4" height="21" font="5"> </text>
<text top="328" left="124" width="256" height="29" font="2"><b>1.4. Scope of the Guideline </b></text>
<text top="360" left="124" width="50" height="21" font="5">S1.4-1. </text>
<text top="360" left="219" width="604" height="21" font="5">Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of </text>
<text top="380" left="219" width="609" height="21" font="5">LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. </text>
<text top="400" left="219" width="183" height="21" font="5">Lancet. 2010;376:1670-81. </text>
<text top="429" left="124" width="50" height="21" font="5">S1.4-2. </text>
<text top="429" left="219" width="594" height="21" font="5">Chou R, Dana T, Blazina I, et al. Statin use for the prevention of cardiovascular disease in </text>
<text top="449" left="219" width="607" height="21" font="5">adults: a systematic review for the U.S. Preventive Services Task Force. Rockville, MD: U.S. </text>
<text top="470" left="219" width="531" height="21" font="5">Agency for Healthcare Research and Quality; 2016. Report No.: 14-05206-EF-2. </text>
<text top="499" left="124" width="50" height="21" font="5">S1.4-3. </text>
<text top="499" left="219" width="526" height="21" font="5">Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of </text>
<text top="519" left="219" width="470" height="21" font="5">cardiovascular disease. Cochrane Database Syst Rev. 2013;CD004816. </text>
<text top="548" left="124" width="50" height="21" font="5">S1.4-4. </text>
<text top="548" left="219" width="612" height="21" font="5">Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of </text>
<text top="568" left="219" width="588" height="21" font="5">blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the </text>
<text top="588" left="219" width="558" height="21" font="5">American College of Cardiology/American Heart Association Task Force on Practice </text>
<text top="608" left="219" width="272" height="21" font="5">Guidelines. Circulation. 2014;129:S1-45. </text>
<text top="638" left="124" width="4" height="21" font="5"> </text>
<text top="670" left="124" width="494" height="29" font="2"><b>1.5. Class of Recommendation and Level of Evidence </b></text>
<text top="701" left="124" width="50" height="21" font="5">S1.5-1. </text>
<text top="701" left="219" width="569" height="21" font="5">Halperin JL, Levine GN, Al-Khatib SM, et al. Further evolution of the ACC/AHA clinical </text>
<text top="721" left="219" width="610" height="21" font="5">practice guideline recommendation classification system: a report of the American College </text>
<text top="742" left="219" width="568" height="21" font="5">of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. </text>
<text top="762" left="219" width="202" height="21" font="5">Circulation. 2015;133:1426-8. </text>
<text top="791" left="124" width="4" height="21" font="5"> </text>
<text top="823" left="124" width="374" height="31" font="11"><b>2. High Blood Cholesterol and ASCVD </b></text>
<text top="857" left="124" width="460" height="29" font="2"><b>2.1. Serum Cholesterol, Lipoproteins, and ASCVD </b></text>
<text top="888" left="124" width="322" height="27" font="16"><i><b>2.1.2. Cholesterol, LDL-C, and ASCVD</b></i><b> </b></text>
<text top="918" left="124" width="62" height="21" font="5">S2.1.2-1. </text>
<text top="918" left="219" width="604" height="21" font="5">Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of </text>
<text top="938" left="219" width="611" height="21" font="5">premature death from coronary heart disease continuous and graded? Findings in 356,222 </text>
<text top="958" left="219" width="535" height="21" font="5">primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. </text>
<text top="978" left="219" width="122" height="21" font="5">1986;256:2823-8. </text>
<text top="998" left="124" width="62" height="21" font="5">S2.1.2-2. </text>
<text top="998" left="219" width="590" height="21" font="5">Kannel WB, Castelli WP, Gordon T, et al. Serum cholesterol, lipoproteins, and the risk of </text>
<text top="1019" left="219" width="534" height="21" font="5">coronary heart disease. The Framingham study. Ann Intern Med. 1971;74:1-12. </text>
<text top="1039" left="124" width="62" height="21" font="5">S2.1.2-3. </text>
<text top="1039" left="219" width="612" height="21" font="5">Lawes CMMVH, S; Law MR,; Rogers, A. High Cholesterol. In: Ezzati M, Lopez AD, Rodgers A, </text>
<text top="1059" left="219" width="572" height="21" font="5">et al, eds. Comparative Quantification of Health Risks: Global and Regional Burden of </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="86" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="33" size="14" family="Times" color="#222222"/>
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-86_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="456" width="48" height="19" font="1">Page 86</text>
<text top="1130" left="505" width="4" height="21" font="5"> </text>
<text top="108" left="219" width="589" height="21" font="5">Disease Attributable to Selected Major Risk Factors. Geneva, Switzerland: World Health </text>
<text top="128" left="219" width="282" height="21" font="5">Organization; 2004:391-496. Available at:<a href="http://apps.who.int/iris/handle/10665/42770"> </a></text>
<text top="128" left="500" width="308" height="21" font="13"><a href="http://apps.who.int/iris/handle/10665/42770">http://apps.who.int/iris/handle/10665/42770</a></text>
<text top="128" left="808" width="8" height="21" font="5"><a href="http://apps.who.int/iris/handle/10665/42770">. </a></text>
<text top="148" left="219" width="200" height="21" font="5">Accessed September 7, 2018. </text>
<text top="168" left="124" width="62" height="21" font="5">S2.1.2-4. </text>
<text top="168" left="219" width="599" height="21" font="5">Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and </text>
<text top="188" left="219" width="557" height="21" font="5">the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. </text>
<text top="208" left="219" width="114" height="21" font="5">2014;64:485-94. </text>
<text top="228" left="124" width="62" height="21" font="5">S2.1.2-5. </text>
<text top="228" left="219" width="601" height="21" font="5">Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute </text>
<text top="249" left="219" width="370" height="21" font="5">coronary syndromes. N Engl J Med. 2015;372:2387-97. </text>
<text top="269" left="124" width="62" height="21" font="5">S2.1.2-6. </text>
<text top="269" left="219" width="601" height="21" font="5">Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients </text>
<text top="289" left="219" width="416" height="21" font="5">with cardiovascular disease. N Engl J Med. 2017;376:1713-22. </text>
<text top="309" left="124" width="62" height="21" font="5">S2.1.2-7. </text>
<text top="309" left="219" width="537" height="21" font="5">Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and </text>
<text top="329" left="219" width="575" height="21" font="5">cardiovascular risk reduction among different therapeutic interventions: a systematic </text>
<text top="349" left="219" width="355" height="21" font="5">review and meta-analysis. JAMA. 2016;316:1289-97. </text>
<text top="370" left="124" width="4" height="21" font="5"> </text>
<text top="390" left="124" width="308" height="27" font="16"><i><b>2.1.3. LDL-C and Other Risk Factors</b></i><b> </b></text>
<text top="419" left="124" width="62" height="21" font="5">S2.1.3-1. </text>
<text top="419" left="219" width="586" height="21" font="5">Wilson PW, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk </text>
<text top="439" left="219" width="323" height="21" font="5">factor categories. Circulation. 1998;97:1837-47. </text>
<text top="459" left="124" width="62" height="21" font="5">S2.1.3-2. </text>
<text top="459" left="219" width="612" height="21" font="5">Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of </text>
<text top="480" left="219" width="588" height="21" font="5">blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the </text>
<text top="500" left="219" width="558" height="21" font="5">American College of Cardiology/American Heart Association Task Force on Practice </text>
<text top="520" left="219" width="272" height="21" font="5">Guidelines. Circulation. 2014;129:S1-45. </text>
<text top="540" left="124" width="62" height="21" font="5">S2.1.3-3. </text>
<text top="540" left="219" width="527" height="21" font="5">Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic </text>
<text top="560" left="219" width="531" height="21" font="5">cardiovascular disease pooled cohort risk equations. JAMA. 2014;311:1406-15. </text>
<text top="580" left="124" width="62" height="21" font="5">S2.1.3-4. </text>
<text top="580" left="219" width="579" height="21" font="5">Mora S, Wenger NK, Cook NR, et al. Evaluation of the pooled cohort risk equations for </text>
<text top="603" left="219" width="602" height="21" font="5">cardiovascular risk prediction in a multiethnic cohort from the Women’s Health Initiative. </text>
<text top="627" left="219" width="253" height="21" font="33">JAMA Intern Med. 2018;178:1231-40.</text>
<text top="627" left="471" width="4" height="21" font="5"> </text>
<text top="659" left="124" width="4" height="21" font="5"> </text>
<text top="691" left="124" width="415" height="29" font="2"><b>2.2. Measurements of LDL-C and Non-HDL-C </b></text>
<text top="723" left="124" width="50" height="21" font="5">S2.2-1. </text>
<text top="723" left="219" width="599" height="21" font="5">Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of </text>
<text top="743" left="219" width="555" height="21" font="5">normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk </text>
<text top="763" left="219" width="287" height="21" font="5">prediction. Circulation. 2008;118:2047-56. </text>
<text top="783" left="124" width="50" height="21" font="5">S2.2-2. </text>
<text top="783" left="219" width="568" height="21" font="5">Langsted A, Nordestgaard BG. Nonfasting lipids, lipoproteins, and apolipoproteins in </text>
<text top="803" left="219" width="592" height="21" font="5">individuals with and without diabetes: 58 434 individuals from the Copenhagen General </text>
<text top="823" left="219" width="303" height="21" font="5">Population Study. Clin Chem. 2011;57:482-9. </text>
<text top="843" left="124" width="50" height="21" font="5">S2.2-3. </text>
<text top="843" left="219" width="545" height="21" font="5">Mora S, Rifai N, Buring JE, et al. Comparison of LDL cholesterol concentrations by </text>
<text top="863" left="219" width="579" height="21" font="5">Friedewald calculation and direct measurement in relation to cardiovascular events in </text>
<text top="884" left="219" width="297" height="21" font="5">27,331 women. Clin Chem. 2009;55:888-94. </text>
<text top="904" left="124" width="50" height="21" font="5">S2.2-4. </text>
<text top="904" left="219" width="606" height="21" font="5">Sidhu D, Naugler C. Fasting time and lipid levels in a community-based population: a cross-</text>
<text top="924" left="219" width="357" height="21" font="5">sectional study. Arch Intern Med. 2012;172:1707-10. </text>
<text top="944" left="124" width="50" height="21" font="5">S2.2-5. </text>
<text top="944" left="219" width="564" height="21" font="5">Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of </text>
<text top="964" left="219" width="310" height="21" font="5">vascular disease. JAMA. 2009;302:1993-2000. </text>
<text top="984" left="124" width="50" height="21" font="5">S2.2-6. </text>
<text top="984" left="219" width="565" height="21" font="5">Doran B, Guo Y, Xu J, et al. Prognostic value of fasting versus nonfasting low-density </text>
<text top="1004" left="219" width="608" height="21" font="5">lipoprotein cholesterol levels on long-term mortality: insight from the National Health and </text>
<text top="1025" left="219" width="512" height="21" font="5">Nutrition Examination Survey III (NHANES-III). Circulation. 2014;130:546-53. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="87" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-87_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="456" width="48" height="19" font="1">Page 87</text>
<text top="1130" left="505" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="50" height="21" font="5">S2.2-7. </text>
<text top="108" left="219" width="617" height="21" font="5">Martin SS, Blaha MJ, Elshazly MB, et al. Friedewald-estimated versus directly measured low-</text>
<text top="128" left="219" width="608" height="21" font="5">density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol. 2013;62:732-</text>
<text top="148" left="219" width="16" height="21" font="5">9. </text>
<text top="168" left="124" width="50" height="21" font="5">S2.2-8. </text>
<text top="168" left="219" width="598" height="21" font="5">Martin SS, Blaha MJ, Elshazly MB, et al. Comparison of a novel method vs the Friedewald </text>
<text top="188" left="219" width="600" height="21" font="5">equation for estimating low-density lipoprotein cholesterol levels from the standard lipid </text>
<text top="208" left="219" width="220" height="21" font="5">profile. JAMA. 2013;310:2061-8. </text>
<text top="228" left="124" width="50" height="21" font="5">S2.2-9. </text>
<text top="228" left="219" width="553" height="21" font="5">Sathiyakumar V, Park J, Golozar A, et al. Fasting versus nonfasting and low-density </text>
<text top="249" left="219" width="409" height="21" font="5">lipoprotein cholesterol accuracy. Circulation. 2018;137:10-9. </text>
<text top="269" left="124" width="58" height="21" font="5">S2.2-10. </text>
<text top="269" left="219" width="538" height="21" font="5">Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for </text>
<text top="289" left="219" width="589" height="21" font="5">determination of a lipid profile: clinical and laboratory implications including flagging at </text>
<text top="309" left="219" width="569" height="21" font="5">desirable concentration cut-points—a joint consensus statement from the European </text>
<text top="329" left="219" width="579" height="21" font="5">Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory </text>
<text top="349" left="219" width="273" height="21" font="5">Medicine. Eur Heart J. 2016;37:1944-58. </text>
<text top="370" left="124" width="58" height="21" font="5">S2.2-11. </text>
<text top="370" left="219" width="513" height="21" font="5">Mora S, Rifai N, Buring JE, et al. Fasting compared with nonfasting lipids and </text>
<text top="390" left="219" width="593" height="21" font="5">apolipoproteins for predicting incident cardiovascular events. Circulation. 2008;118:993-</text>
<text top="410" left="219" width="41" height="21" font="5">1001. </text>
<text top="430" left="124" width="58" height="21" font="5">S2.2-12. </text>
<text top="430" left="219" width="619" height="21" font="5">Brunzell JD, Albers JJ, Chait A, et al. Plasma lipoproteins in familial combined hyperlipidemia </text>
<text top="450" left="219" width="497" height="21" font="5">and monogenic familial hypertriglyceridemia. J Lipid Res. 1983;24:147-55. </text>
<text top="470" left="124" width="58" height="21" font="5">S2.2-13. </text>
<text top="470" left="219" width="615" height="21" font="5">Sniderman AD, Tremblay A, De Graaf J, et al. Phenotypes of hypertriglyceridemia caused by </text>
<text top="490" left="219" width="441" height="21" font="5">excess very-low-density lipoprotein. J Clin Lipidol. 2012;6:427-33. </text>
<text top="519" left="124" width="4" height="21" font="5"> </text>
<text top="549" left="124" width="559" height="29" font="2"><b>2.3. Measurements of Apolipoprotein B and Lipoprotein (a) </b></text>
<text top="580" left="124" width="50" height="21" font="5">S2.3-1. </text>
<text top="580" left="219" width="583" height="21" font="5">Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein </text>
<text top="600" left="219" width="600" height="21" font="5">cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of </text>
<text top="621" left="219" width="454" height="21" font="5">cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4:337-45. </text>
<text top="641" left="124" width="50" height="21" font="5">S2.3-2. </text>
<text top="641" left="219" width="566" height="21" font="5">Grundy SM, Vega GL, Tomassini JE, et al. Correlation of non-high-density lipoprotein </text>
<text top="661" left="219" width="543" height="21" font="5">cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during </text>
<text top="681" left="219" width="607" height="21" font="5">simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis </text>
<text top="701" left="219" width="347" height="21" font="5">of the SAFARI trial). Am J Cardiol. 2009;104:548-53. </text>
<text top="721" left="124" width="50" height="21" font="5">S2.3-3. </text>
<text top="721" left="219" width="615" height="21" font="5">Sniderman AD, Tremblay A, De Graaf J, et al. Phenotypes of hypertriglyceridemia caused by </text>
<text top="741" left="219" width="441" height="21" font="5">excess very-low-density lipoprotein. J Clin Lipidol. 2012;6:427-33. </text>
<text top="761" left="124" width="50" height="21" font="5">S2.3-4. </text>
<text top="761" left="219" width="611" height="21" font="5">Grundy SM, Vega GL, Tomassini JE, et al. Comparisons of apolipoprotein B levels estimated </text>
<text top="782" left="219" width="603" height="21" font="5">by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density </text>
<text top="802" left="219" width="597" height="21" font="5">lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial). Am J Cardiol. </text>
<text top="822" left="219" width="105" height="21" font="5">2011;108:40-6. </text>
<text top="842" left="124" width="50" height="21" font="5">S2.3-5. </text>
<text top="842" left="219" width="577" height="21" font="5">Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision </text>
<text top="862" left="219" width="531" height="21" font="5">pathway on the role of non-statin therapies for LDL-cholesterol lowering in the </text>
<text top="882" left="218" width="570" height="21" font="5">management of atherosclerotic cardiovascular disease risk: a report of the American </text>
<text top="902" left="218" width="618" height="21" font="5">College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. </text>
<text top="922" left="218" width="114" height="21" font="5">2016;68:92-125. </text>
<text top="943" left="124" width="50" height="21" font="5">S2.3-6. </text>
<text top="943" left="218" width="572" height="21" font="5">Tsimikas S. A Test in Context: Lipoprotein(a): diagnosis, prognosis, controversies, and </text>
<text top="963" left="218" width="380" height="21" font="5">emerging therapies. J Am Coll Cardiol. 2017;69:692-711. </text>
<text top="983" left="124" width="50" height="21" font="5">S2.3-7. </text>
<text top="983" left="218" width="576" height="21" font="5">Cook NR, Mora S, Ridker PM. Lipoprotein(a) and cardiovascular risk prediction among </text>
<text top="1003" left="218" width="292" height="21" font="5">women. J Am Coll Cardiol. 2018;72:287-96. </text>
<text top="1023" left="124" width="4" height="21" font="5"> </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="88" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-88_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="456" width="48" height="19" font="1">Page 88</text>
<text top="1130" left="505" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="493" height="29" font="2"><b>2.4. Monitoring Response of LDL-C to Statin Therapy </b></text>
<text top="139" left="124" width="50" height="21" font="5">S2.4-1. </text>
<text top="139" left="219" width="596" height="21" font="5">Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy </text>
<text top="159" left="219" width="580" height="21" font="5">and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from </text>
<text top="180" left="219" width="486" height="21" font="5">170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81. </text>
<text top="200" left="124" width="50" height="21" font="5">S2.4-2. </text>
<text top="200" left="219" width="600" height="21" font="5">Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and </text>
<text top="220" left="219" width="557" height="21" font="5">the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. </text>
<text top="240" left="219" width="114" height="21" font="5">2014;64:485-94. </text>
<text top="269" left="124" width="4" height="21" font="5"> </text>
<text top="301" left="124" width="266" height="31" font="11"><b>3. Therapeutic Modalities  </b></text>
<text top="335" left="124" width="225" height="29" font="2"><b>3.1. Lifestyle Therapies  </b></text>
<text top="367" left="124" width="540" height="27" font="16"><i><b>3.1.1. Diet Composition, Weight Control, and Physical Activity</b></i><b> </b></text>
<text top="396" left="124" width="62" height="21" font="5">S3.1.1-1. </text>
<text top="396" left="219" width="584" height="21" font="5">Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to </text>
<text top="416" left="219" width="609" height="21" font="5">reduce cardiovascular risk: a report of the American College of Cardiology/American Heart </text>
<text top="436" left="219" width="513" height="21" font="5">Association Task Force on Practice Guidelines. Circulation. 2014;129:S76-99. </text>
<text top="457" left="124" width="62" height="21" font="5">S3.1.1-2. </text>
<text top="457" left="219" width="617" height="21" font="5">Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management </text>
<text top="477" left="219" width="484" height="21" font="5">of overweight and obesity in adults: a report of the American College of </text>
<text top="497" left="219" width="607" height="21" font="5">Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity </text>
<text top="517" left="219" width="266" height="21" font="5">Society. Circulation. 2014;129:S102-38. </text>
<text top="537" left="124" width="62" height="21" font="5">S3.1.1-3. </text>
<text top="537" left="219" width="609" height="21" font="5">Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a </text>
<text top="557" left="219" width="364" height="21" font="5">Mediterranean diet. N Engl J Med. 2013;368:1279-90. </text>
<text top="577" left="124" width="62" height="21" font="5">S3.1.1-4. </text>
<text top="577" left="219" width="618" height="21" font="5">Lichtenstein AH, Appel LJ, Brands M, et al. Summary of American Heart Association diet and </text>
<text top="597" left="219" width="609" height="21" font="5">lifestyle recommendations revision 2006. Arterioscler Thromb Vasc Biol. 2006;26:2186-91. </text>
<text top="618" left="124" width="62" height="21" font="5">S3.1.1-5. </text>
<text top="618" left="219" width="567" height="21" font="5">Warburton DE, Charlesworth S, Ivey A, et al. A systematic review of the evidence for </text>
<text top="638" left="219" width="568" height="21" font="5">Canada's physical activity guidelines for adults. Int J Behav Nutr Phys Act. 2010;7:39. </text>
<text top="658" left="124" width="4" height="21" font="5"> </text>
<text top="678" left="124" width="443" height="27" font="16"><i><b>3.1.2. Lifestyle Therapies and Metabolic Syndrome</b></i><b> </b></text>
<text top="707" left="124" width="62" height="21" font="5">S3.1.2-1. </text>
<text top="707" left="219" width="614" height="21" font="5">Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular </text>
<text top="728" left="219" width="606" height="21" font="5">events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll </text>
<text top="748" left="219" width="169" height="21" font="5">Cardiol. 2007;49:403-14. </text>
<text top="768" left="124" width="62" height="21" font="5">S3.1.2-2. </text>
<text top="768" left="219" width="592" height="21" font="5">Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with </text>
<text top="788" left="219" width="598" height="21" font="5">alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. </text>
<text top="808" left="219" width="220" height="21" font="5">Eur Heart J. 2015;36:2996-3003. </text>
<text top="828" left="124" width="62" height="21" font="5">S3.1.2-3. </text>
<text top="828" left="219" width="621" height="21" font="5">Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim </text>
<text top="849" left="219" width="566" height="21" font="5">statement of the International Diabetes Federation Task Force on Epidemiology and </text>
<text top="869" left="219" width="603" height="21" font="5">Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World </text>
<text top="889" left="219" width="600" height="21" font="5">Heart Federation; International Atherosclerosis Society; and International Association for </text>
<text top="909" left="219" width="347" height="21" font="5">the Study of Obesity. Circulation. 2009;120:1640-5. </text>
<text top="929" left="124" width="62" height="21" font="5">S3.1.2-4. </text>
<text top="929" left="219" width="597" height="21" font="5">Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol </text>
<text top="949" left="219" width="174" height="21" font="5">Metab. 2007;92:399-404. </text>
<text top="969" left="124" width="62" height="21" font="5">S3.1.2-5. </text>
<text top="969" left="219" width="593" height="21" font="5">Aguilar M, Bhuket T, Torres S, et al. Prevalence of the metabolic syndrome in the United </text>
<text top="989" left="219" width="297" height="21" font="5">States, 2003-2012. JAMA. 2015;313:1973-4. </text>
<text top="1010" left="124" width="4" height="21" font="5"> </text>
<text top="1030" left="124" width="241" height="29" font="2"><b>3.2. Lipid-Lowering Drugs </b></text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="89" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-89_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="456" width="48" height="19" font="1">Page 89</text>
<text top="1130" left="505" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="50" height="21" font="5">S3.2-1. </text>
<text top="108" left="219" width="610" height="21" font="5">Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific </text>
<text top="128" left="219" width="548" height="21" font="5">statement from the American Heart Association. Circulation. 2011;123:2292-333. </text>
<text top="148" left="124" width="4" height="21" font="5"> </text>
<text top="168" left="124" width="186" height="27" font="16"><i><b>3.2.1. Statin Therapy</b></i><b> </b></text>
<text top="198" left="124" width="62" height="21" font="5">S3.2.1-1. </text>
<text top="198" left="219" width="612" height="21" font="5">Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of </text>
<text top="218" left="219" width="588" height="21" font="5">blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the </text>
<text top="238" left="219" width="558" height="21" font="5">American College of Cardiology/American Heart Association Task Force on Practice </text>
<text top="258" left="219" width="272" height="21" font="5">Guidelines. Circulation. 2014;129:S1-45. </text>
<text top="278" left="124" width="62" height="21" font="5">S3.2.1-2. </text>
<text top="278" left="219" width="609" height="21" font="5">Karlson BW, Wiklund O, Palmer MK, et al. Variability of low-density lipoprotein cholesterol </text>
<text top="298" left="219" width="599" height="21" font="5">response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from </text>
<text top="318" left="219" width="427" height="21" font="5">VOYAGER. Eur Heart J Cardiovasc Pharmacother. 2016;2:212-7. </text>
<text top="339" left="124" width="62" height="21" font="5">S3.2.1-3. </text>
<text top="339" left="219" width="560" height="21" font="5">Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose </text>
<text top="359" left="219" width="566" height="21" font="5">simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a </text>
<text top="379" left="219" width="368" height="21" font="5">randomized controlled trial. JAMA. 2005;294:2437-45. </text>
<text top="399" left="124" width="62" height="21" font="5">S3.2.1-4. </text>
<text top="399" left="219" width="620" height="21" font="5">U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Available at: </text>
<text top="419" left="219" width="339" height="21" font="13"><a href="https://www.accessdata.fda.gov/scripts/cder/daf/">https://www.accessdata.fda.gov/scripts/cder/daf/</a></text>
<text top="419" left="557" width="186" height="21" font="5"><a href="https://www.accessdata.fda.gov/scripts/cder/daf/">.</a> Accessed January 8, 2018. </text>
<text top="439" left="124" width="62" height="21" font="5">S3.2.1-5. </text>
<text top="439" left="219" width="604" height="21" font="5">Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men </text>
<text top="459" left="219" width="540" height="21" font="5">and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207. </text>
<text top="480" left="124" width="62" height="21" font="5">S3.2.1-6. </text>
<text top="480" left="219" width="608" height="21" font="5">Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the </text>
<text top="500" left="219" width="479" height="21" font="5">Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9. </text>
<text top="520" left="124" width="62" height="21" font="5">S3.2.1-7. </text>
<text top="520" left="219" width="588" height="21" font="5">Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with </text>
<text top="540" left="219" width="608" height="21" font="5">lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. </text>
<text top="560" left="219" width="580" height="21" font="5">Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-22. </text>
<text top="580" left="124" width="62" height="21" font="5">S3.2.1-8. </text>
<text top="580" left="219" width="592" height="21" font="5">Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after </text>
<text top="600" left="219" width="616" height="21" font="5">myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent </text>
<text top="620" left="219" width="391" height="21" font="5">Events Trial investigators. N Engl J Med. 1996;335:1001-9. </text>
<text top="641" left="124" width="62" height="21" font="5">S3.2.1-9. </text>
<text top="641" left="219" width="622" height="21" font="5">Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in </text>
<text top="661" left="219" width="620" height="21" font="5">men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl </text>
<text top="681" left="219" width="170" height="21" font="5">J Med. 1995;333:1301-7. </text>
<text top="701" left="124" width="71" height="21" font="5">S3.2.1-10. </text>
<text top="701" left="219" width="600" height="21" font="5">Prevention of cardiovascular events and death with pravastatin in patients with coronary </text>
<text top="721" left="219" width="602" height="21" font="5">heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-</text>
<text top="741" left="219" width="25" height="21" font="5">57. </text>
<text top="762" left="124" width="71" height="21" font="5">S3.2.1-11. </text>
<text top="762" left="219" width="596" height="21" font="5">MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-</text>
<text top="782" left="219" width="533" height="21" font="5">risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:23-33. </text>
<text top="802" left="124" width="71" height="21" font="5">S3.2.1-12. </text>
<text top="802" left="219" width="601" height="21" font="5">Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or </text>
<text top="822" left="219" width="392" height="21" font="5">transient ischemic attack. N Engl J Med. 2006;355:549-59. </text>
<text top="842" left="124" width="71" height="21" font="5">S3.2.1-13. </text>
<text top="842" left="219" width="604" height="21" font="5">Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with </text>
<text top="862" left="219" width="503" height="21" font="5">statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-504. </text>
<text top="882" left="124" width="71" height="21" font="5">S3.2.1-14. </text>
<text top="882" left="219" width="567" height="21" font="5">LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in </text>
<text top="902" left="219" width="482" height="21" font="5">patients with stable coronary disease. N Engl J Med. 2005;352:1425-35. </text>
<text top="923" left="124" width="71" height="21" font="5">S3.2.1-15. </text>
<text top="923" left="219" width="615" height="21" font="5">Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with </text>
<text top="943" left="219" width="576" height="21" font="5">pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. </text>
<text top="963" left="219" width="130" height="21" font="5">2006;368:1155-63. </text>
<text top="983" left="124" width="71" height="21" font="5">S3.2.1-16. </text>
<text top="983" left="219" width="568" height="21" font="5">Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons </text>
<text top="1003" left="219" width="439" height="21" font="5">without cardiovascular disease. N Engl J Med. 2016;374:2021-31. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="90" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-90_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="456" width="48" height="19" font="1">Page 90</text>
<text top="1130" left="505" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="71" height="21" font="5">S3.2.1-17. </text>
<text top="108" left="219" width="604" height="21" font="5">Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of </text>
<text top="128" left="219" width="609" height="21" font="5">LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. </text>
<text top="148" left="219" width="183" height="21" font="5">Lancet. 2010;376:1670-81. </text>
<text top="168" left="124" width="71" height="21" font="5">S3.2.1-18. </text>
<text top="168" left="219" width="620" height="21" font="5">Naito R, Miyauchi K, Daida H. Racial differences in the cholesterol-lowering effect of statin. J </text>
<text top="188" left="219" width="248" height="21" font="5">Atheroscler Thromb. 2017;24:19-25. </text>
<text top="208" left="124" width="71" height="21" font="5">S3.2.1-19. </text>
<text top="208" left="219" width="582" height="21" font="5">Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and </text>
<text top="228" left="219" width="346" height="21" font="5">safety of statin therapy. Lancet. 2016;388:2532-61. </text>
<text top="249" left="124" width="71" height="21" font="5">S3.2.1-20. </text>
<text top="249" left="219" width="605" height="21" font="5">American College of Cardiology. American College of Cardiology LDL-C Manager. Available </text>
<text top="269" left="219" width="22" height="21" font="5">at:<a href="http://tools.acc.org/ldl"> </a></text>
<text top="269" left="240" width="154" height="21" font="13"><a href="http://tools.acc.org/ldl">http://tools.acc.org/ldl</a></text>
<text top="269" left="394" width="186" height="21" font="5"><a href="http://tools.acc.org/ldl">.</a> Accessed January 8, 2018. </text>
<text top="289" left="124" width="4" height="21" font="5"> </text>
<text top="309" left="124" width="234" height="27" font="16"><i><b>3.2.2. Nonstatin Therapies</b></i><b> </b></text>
<text top="339" left="124" width="62" height="21" font="5">S3.2.2-1. </text>
<text top="339" left="219" width="601" height="21" font="5">Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute </text>
<text top="359" left="219" width="370" height="21" font="5">coronary syndromes. N Engl J Med. 2015;372:2387-97. </text>
<text top="379" left="124" width="62" height="21" font="5">S3.2.2-2. </text>
<text top="379" left="219" width="577" height="21" font="5">Kashani A, Sallam T, Bheemreddy S, et al. Review of side-effect profile of combination </text>
<text top="399" left="219" width="608" height="21" font="5">ezetimibe and statin therapy in randomized clinical trials. Am J Cardiol. 2008;101:1606-13. </text>
<text top="419" left="124" width="62" height="21" font="5">S3.2.2-3. </text>
<text top="419" left="219" width="596" height="21" font="5">Khan AR, Bavishi C, Riaz H, et al. Increased risk of adverse neurocognitive outcomes with </text>
<text top="439" left="219" width="592" height="21" font="5">proprotein convertase subtilisin-kexin type 9 inhibitors. Circ Cardiovasc Qual Outcomes. </text>
<text top="459" left="219" width="125" height="21" font="5">2017;10:e003153. </text>
<text top="480" left="124" width="62" height="21" font="5">S3.2.2-4. </text>
<text top="480" left="219" width="577" height="21" font="5">Robinson JG, Rosenson RS, Farnier M, et al. Safety of very low low-density lipoprotein </text>
<text top="500" left="219" width="602" height="21" font="5">cholesterol levels with alirocumab: pooled data from randomized trials. J Am Coll Cardiol. </text>
<text top="520" left="219" width="114" height="21" font="5">2017;69:471-82. </text>
<text top="540" left="124" width="62" height="21" font="5">S3.2.2-5. </text>
<text top="540" left="219" width="601" height="21" font="5">Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients </text>
<text top="560" left="219" width="416" height="21" font="5">with cardiovascular disease. N Engl J Med. 2017;376:1713-22. </text>
<text top="580" left="124" width="62" height="21" font="5">S3.2.2-6. </text>
<text top="580" left="219" width="621" height="21" font="5">Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a randomized trial of evolocumab. </text>
<text top="600" left="219" width="217" height="21" font="5">N Engl J Med. 2017;377:633-43. </text>
<text top="620" left="124" width="4" height="21" font="5"> </text>
<text top="641" left="124" width="424" height="27" font="16"><i><b>3.2.3. Nonstatin Add-on Drugs to Statin Therapy</b></i><b> </b></text>
<text top="670" left="124" width="62" height="21" font="5">S3.2.3-1. </text>
<text top="670" left="219" width="608" height="21" font="5">Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute </text>
<text top="690" left="219" width="373" height="21" font="5">Coronary Syndromes. N Engl J Med. 2015;372:2387-97. </text>
<text top="711" left="124" width="62" height="21" font="5">S3.2.3-2. </text>
<text top="711" left="219" width="617" height="21" font="5">Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-</text>
<text top="731" left="219" width="588" height="21" font="5">centered management of dyslipidemia: part 1--full report. J Clin Lipidol. 2015;9:129-69. </text>
<text top="751" left="124" width="62" height="21" font="5">S3.2.3-3. </text>
<text top="751" left="219" width="612" height="21" font="5">Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular </text>
<text top="771" left="219" width="600" height="21" font="5">risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated </text>
<text top="791" left="219" width="544" height="21" font="5">doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. </text>
<text top="811" left="219" width="122" height="21" font="5">2015;36:1186-94. </text>
<text top="831" left="124" width="62" height="21" font="5">S3.2.3-4. </text>
<text top="831" left="219" width="610" height="21" font="5">Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing </text>
<text top="851" left="219" width="437" height="21" font="5">lipids and cardiovascular events. N Engl J Med. 2015;372:1500-9. </text>
<text top="881" left="124" width="4" height="21" font="5"> </text>
<text top="913" left="124" width="318" height="31" font="11"><b>4. Patient Management Groups </b></text>
<text top="946" left="124" width="324" height="29" font="2"><b>4.1. Secondary ASCVD Prevention  </b></text>
<text top="978" left="124" width="50" height="21" font="5">S4.1-1. </text>
<text top="978" left="219" width="601" height="21" font="5">Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or </text>
<text top="998" left="219" width="392" height="21" font="5">transient ischemic attack. N Engl J Med. 2006;355:549-59. </text>
<text top="1018" left="124" width="50" height="21" font="5">S4.1-2. </text>
<text top="1018" left="219" width="579" height="21" font="5">Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the </text>
<text top="1038" left="219" width="595" height="21" font="5">National Cholesterol Educational Program goal versus 'usual' care in secondary coronary </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="91" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-91_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="456" width="48" height="19" font="1">Page 91</text>
<text top="1130" left="505" width="4" height="21" font="5"> </text>
<text top="108" left="219" width="601" height="21" font="5">heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation </text>
<text top="128" left="219" width="352" height="21" font="5">(GREACE) study. Curr Med Res Opin. 2002;18:220-8. </text>
<text top="148" left="124" width="50" height="21" font="5">S4.1-3. </text>
<text top="148" left="219" width="604" height="21" font="5">Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of </text>
<text top="168" left="219" width="609" height="21" font="5">LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. </text>
<text top="188" left="219" width="183" height="21" font="5">Lancet. 2010;376:1670-81. </text>
<text top="208" left="124" width="50" height="21" font="5">S4.1-4. </text>
<text top="208" left="219" width="582" height="21" font="5">Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and </text>
<text top="228" left="219" width="346" height="21" font="5">safety of statin therapy. Lancet. 2016;388:2532-61. </text>
<text top="249" left="124" width="50" height="21" font="5">S4.1-5. </text>
<text top="249" left="219" width="594" height="21" font="5">Group HPSC. Randomized trial of the effects of cholesterol-lowering with simvastatin on </text>
<text top="269" left="219" width="596" height="21" font="5">peripheral vascular and other major vascular outcomes in 20,536 people with peripheral </text>
<text top="289" left="219" width="620" height="21" font="5">arterial disease and other high-risk conditions. J Vasc Surg. 2007;45:645-54; discussion 53-4. </text>
<text top="309" left="124" width="50" height="21" font="5">S4.1-6. </text>
<text top="309" left="219" width="608" height="21" font="5">Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the </text>
<text top="329" left="219" width="479" height="21" font="5">Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9. </text>
<text top="349" left="124" width="50" height="21" font="5">S4.1-7. </text>
<text top="349" left="219" width="592" height="21" font="5">Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after </text>
<text top="370" left="219" width="616" height="21" font="5">myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent </text>
<text top="390" left="219" width="391" height="21" font="5">Events Trial investigators. N Engl J Med. 1996;335:1001-9. </text>
<text top="410" left="124" width="50" height="21" font="5">S4.1-8. </text>
<text top="410" left="219" width="600" height="21" font="5">Prevention of cardiovascular events and death with pravastatin in patients with coronary </text>
<text top="430" left="219" width="602" height="21" font="5">heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-</text>
<text top="450" left="219" width="25" height="21" font="5">57. </text>
<text top="470" left="124" width="50" height="21" font="5">S4.1-9. </text>
<text top="470" left="219" width="602" height="21" font="5">Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of </text>
<text top="490" left="219" width="583" height="21" font="5">low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive </text>
<text top="510" left="219" width="605" height="21" font="5">changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153-62. </text>
<text top="531" left="124" width="58" height="21" font="5">S4.1-10. </text>
<text top="531" left="218" width="544" height="21" font="5">Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of </text>
<text top="551" left="218" width="613" height="21" font="5">antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-</text>
<text top="571" left="218" width="273" height="21" font="5">controlled trial. Lancet. 2002;360:23-33. </text>
<text top="591" left="124" width="58" height="21" font="5">S4.1-11. </text>
<text top="591" left="218" width="619" height="21" font="5">Knopp RH, d'Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention </text>
<text top="611" left="218" width="590" height="21" font="5">of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for </text>
<text top="631" left="218" width="619" height="21" font="5">Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus </text>
<text top="651" left="218" width="286" height="21" font="5">(ASPEN). Diabetes Care. 2006;29:1478-85. </text>
<text top="671" left="124" width="58" height="21" font="5">S4.1-12. </text>
<text top="671" left="218" width="584" height="21" font="5">Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary </text>
<text top="692" left="218" width="620" height="21" font="5">heart disease treated aggressively in lipid-lowering disease management clinics: the alliance </text>
<text top="712" left="218" width="278" height="21" font="5">study. J Am Coll Cardiol. 2004;44:1772-9. </text>
<text top="732" left="124" width="58" height="21" font="5">S4.1-13. </text>
<text top="732" left="218" width="573" height="21" font="5">Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events </text>
<text top="752" left="218" width="621" height="21" font="5">following successful first percutaneous coronary intervention: a randomized controlled trial. </text>
<text top="772" left="218" width="177" height="21" font="5">JAMA. 2002;287:3215-22. </text>
<text top="792" left="124" width="58" height="21" font="5">S4.1-14. </text>
<text top="792" left="218" width="562" height="21" font="5">Bohula EA, Morrow DA, Giugliano RP, et al. Atherothrombotic risk stratification and </text>
<text top="812" left="218" width="480" height="21" font="5">ezetimibe for secondary prevention. J Am Coll Cardiol. 2017;69:911-21. </text>
<text top="833" left="124" width="58" height="21" font="5">S4.1-15. </text>
<text top="833" left="218" width="601" height="21" font="5">Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute </text>
<text top="853" left="218" width="370" height="21" font="5">coronary syndromes. N Engl J Med. 2015;372:2387-97. </text>
<text top="873" left="124" width="58" height="21" font="5">S4.1-16. </text>
<text top="873" left="218" width="621" height="21" font="5">Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a randomized trial of evolocumab. </text>
<text top="893" left="218" width="217" height="21" font="5">N Engl J Med. 2017;377:633-43. </text>
<text top="913" left="124" width="58" height="21" font="5">S4.1-17. </text>
<text top="913" left="218" width="601" height="21" font="5">Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients </text>
<text top="933" left="218" width="416" height="21" font="5">with cardiovascular disease. N Engl J Med. 2017;376:1713-22. </text>
<text top="953" left="124" width="58" height="21" font="5">S4.1-18. </text>
<text top="953" left="218" width="617" height="21" font="5">Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute </text>
<text top="974" left="218" width="331" height="21" font="5">coronary syndrome. N Engl J Med. 2018;In press. </text>
<text top="994" left="124" width="58" height="21" font="5">S4.1-19. </text>
<text top="994" left="218" width="525" height="21" font="5">Wilson PWF, Polonsky TS, Miedema MD, et al. Systematic review for the 2018 </text>
<text top="1014" left="218" width="595" height="21" font="5">AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the </text>
<text top="1034" left="218" width="621" height="21" font="5">management of blood cholesterol: a report of the American College of Cardiology/American </text>
<text top="1054" left="218" width="583" height="21" font="5">Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;In press. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="92" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-92_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="456" width="48" height="19" font="1">Page 92</text>
<text top="1130" left="505" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="58" height="21" font="5">S4.1-20. </text>
<text top="108" left="219" width="523" height="21" font="5">Hlatky MA, Kazi DS. PCSK9 inhibitors: economics and policy. J Am Coll Cardiol. </text>
<text top="128" left="219" width="122" height="21" font="5">2017;70:2677-87. </text>
<text top="157" left="124" width="58" height="21" font="5">S4.1-21. </text>
<text top="157" left="219" width="570" height="21" font="5">Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 inhibitor therapy in </text>
<text top="177" left="219" width="613" height="21" font="5">patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular </text>
<text top="197" left="219" width="226" height="21" font="5">disease. JAMA. 2016;316:743-53. </text>
<text top="226" left="124" width="58" height="21" font="5">S4.1-22. </text>
<text top="226" left="219" width="536" height="21" font="5">Gandra SR, Villa G, Fonarow GC, et al. Cost-effectiveness of LDL-C lowering with </text>
<text top="246" left="219" width="579" height="21" font="5">evolocumab in patients with high cardiovascular risk in the United States. Clin Cardiol. </text>
<text top="267" left="219" width="114" height="21" font="5">2016;39:313-20. </text>
<text top="287" left="124" width="58" height="21" font="5">S4.1-23. </text>
<text top="287" left="219" width="590" height="21" font="5">Bellosta S, Corsini A. Statin drug interactions and related adverse reactions. Expert Opin </text>
<text top="307" left="219" width="178" height="21" font="5">Drug Saf. 2012;11:933-46. </text>
<text top="327" left="124" width="58" height="21" font="5">S4.1-24. </text>
<text top="327" left="219" width="602" height="21" font="5">Gnjidic D, Le Couteur DG, Blyth FM, et al. Statin use and clinical outcomes in older men: a </text>
<text top="347" left="219" width="442" height="21" font="5">prospective population-based study. BMJ Open. 2013;3:e002333. </text>
<text top="367" left="124" width="58" height="21" font="5">S4.1-25. </text>
<text top="367" left="219" width="592" height="21" font="5">Gray SL, Boudreau RM, Newman AB, et al. Angiotensin-converting enzyme inhibitor and </text>
<text top="388" left="219" width="607" height="21" font="5">statin use and incident mobility limitation in community-dwelling older adults: the Health, </text>
<text top="408" left="219" width="481" height="21" font="5">Aging and Body Composition study. J Am Geriatr Soc. 2011;59:2226-32. </text>
<text top="428" left="124" width="58" height="21" font="5">S4.1-26. </text>
<text top="428" left="219" width="596" height="21" font="5">Ho CK, Walker SW. Statins and their interactions with other lipid-modifying medications: </text>
<text top="448" left="219" width="409" height="21" font="5">safety issues in the elderly. Ther Adv Drug Saf. 2012;3:35-46. </text>
<text top="468" left="124" width="58" height="21" font="5">S4.1-27. </text>
<text top="468" left="219" width="611" height="21" font="5">LaCroix AZ, Gray SL, Aragaki A, et al. Statin use and incident frailty in women aged 65 years </text>
<text top="488" left="219" width="593" height="21" font="5">or older: prospective findings from the Women's Health Initiative Observational Study. J </text>
<text top="508" left="219" width="303" height="21" font="5">Gerontol A Biol Sci Med Sci. 2008;63:369-75. </text>
<text top="528" left="124" width="58" height="21" font="5">S4.1-28. </text>
<text top="528" left="219" width="603" height="21" font="5">Pilotto A, Panza F, Copetti M, et al. Statin treatment and mortality in community-dwelling </text>
<text top="549" left="219" width="597" height="21" font="5">S4.1-frail older patients with diabetes mellitus: a retrospective observational study. PLoS </text>
<text top="569" left="219" width="169" height="21" font="5">One. 2015;10:e0130946. </text>
<text top="589" left="124" width="58" height="21" font="5">S4.1-29. </text>
<text top="589" left="219" width="613" height="21" font="5">Qi K, Reeve E, Hilmer SN, et al. Older peoples' attitudes regarding polypharmacy, statin use </text>
<text top="609" left="219" width="609" height="21" font="5">and willingness to have statins deprescribed in Australia. Int J Clin Pharm. 2015;37:949-57. </text>
<text top="629" left="124" width="58" height="21" font="5">S4.1-30. </text>
<text top="629" left="219" width="602" height="21" font="5">Scott D, Blizzard L, Fell J, et al. Statin therapy, muscle function and falls risk in community-</text>
<text top="649" left="219" width="308" height="21" font="5">dwelling older adults. QJM. 2009;102:625-33. </text>
<text top="669" left="124" width="58" height="21" font="5">S4.1-31. </text>
<text top="669" left="219" width="604" height="21" font="5">Thai M, Reeve E, Hilmer SN, et al. Prevalence of statin-drug interactions in older people: a </text>
<text top="690" left="219" width="385" height="21" font="5">systematic review. Eur J Clin Pharmacol. 2016;72:513-21. </text>
<text top="710" left="124" width="58" height="21" font="5">S4.1-32. </text>
<text top="710" left="219" width="592" height="21" font="5">Feldman HH, Doody RS, Kivipelto M, et al. Randomized controlled trial of atorvastatin in </text>
<text top="730" left="219" width="492" height="21" font="5">mild to moderate Alzheimer disease: LEADe. Neurology. 2010;74:956-64. </text>
<text top="750" left="124" width="58" height="21" font="5">S4.1-33. </text>
<text top="750" left="219" width="603" height="21" font="5">Houx PJ, Shepherd J, Blauw GJ, et al. Testing cognitive function in elderly populations: the </text>
<text top="770" left="219" width="612" height="21" font="5">PROSPER study. PROspective Study of Pravastatin in the Elderly at Risk. J Neurol Neurosurg </text>
<text top="790" left="219" width="182" height="21" font="5">Psychiatry. 2002;73:385-9. </text>
<text top="810" left="124" width="58" height="21" font="5">S4.1-34. </text>
<text top="810" left="219" width="603" height="21" font="5">Rodriguez F, Maron DJ, Knowles JW, et al. Association between intensity of statin therapy </text>
<text top="830" left="219" width="563" height="21" font="5">and mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. </text>
<text top="851" left="219" width="97" height="21" font="5">2017;2:47-54. </text>
<text top="871" left="124" width="58" height="21" font="5">S4.1-35. </text>
<text top="871" left="218" width="595" height="21" font="5">Sano M, Bell KL, Galasko D, et al. A randomized, double-blind, placebo-controlled trial of </text>
<text top="891" left="218" width="455" height="21" font="5">simvastatin to treat Alzheimer disease. Neurology. 2011;77:556-63. </text>
<text top="911" left="124" width="58" height="21" font="5">S4.1-36. </text>
<text top="911" left="218" width="608" height="21" font="5">Trompet S, van Vliet P, de Craen AJ, et al. Pravastatin and cognitive function in the elderly. </text>
<text top="931" left="218" width="382" height="21" font="5">Results of the PROSPER study. J Neurol. 2010;257:85-90. </text>
<text top="951" left="124" width="58" height="21" font="5">S4.1-37. </text>
<text top="951" left="218" width="593" height="21" font="5">Feinstein MJ, Jhund P, Kang J, et al. Do statins reduce the risk of myocardial infarction in </text>
<text top="972" left="218" width="600" height="21" font="5">patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. </text>
<text top="992" left="218" width="221" height="21" font="5">Eur J Heart Fail. 2015;17:434-41. </text>
<text top="1012" left="124" width="58" height="21" font="5">S4.1-38. </text>
<text top="1012" left="218" width="580" height="21" font="5">Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart </text>
<text top="1032" left="218" width="276" height="21" font="5">failure. N Engl J Med. 2007;357:2248-61. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="93" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-93_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="456" width="48" height="19" font="1">Page 93</text>
<text top="1130" left="505" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="58" height="21" font="5">S4.1-39. </text>
<text top="108" left="219" width="552" height="21" font="5">Taguchi N, Rubin ET, Hosokawa A, et al. Prenatal exposure to HMG-CoA reductase </text>
<text top="128" left="219" width="556" height="21" font="5">inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol. 2008;26:175-7. </text>
<text top="148" left="124" width="58" height="21" font="5">S4.1-40. </text>
<text top="148" left="219" width="575" height="21" font="5">Group L-TIwPiIDLS. Prevention of cardiovascular events and death with pravastatin in </text>
<text top="168" left="219" width="613" height="21" font="5">patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J </text>
<text top="188" left="219" width="169" height="21" font="5">Med. 1998;339:1349-57. </text>
<text top="208" left="124" width="58" height="21" font="5">S4.1-41. </text>
<text top="208" left="219" width="618" height="21" font="5">Cannon CP, Khan I, Klimchak AC, et al. Simulation of lipid-lowering therapy intensification in </text>
<text top="228" left="219" width="588" height="21" font="5">a oopulation with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2:959-66. </text>
<text top="249" left="124" width="54" height="21" font="5">S4.1-42 </text>
<text top="249" left="219" width="589" height="21" font="5">Virani SS, Akeroyd JM, Nambi V, et al. Estimation of eligibility for proprotein convertase </text>
<text top="269" left="219" width="605" height="21" font="5">subtilisin/kexin type 9 inhibitors and associated costs based on the FOURIER Trial (Further </text>
<text top="289" left="219" width="603" height="21" font="5">Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): </text>
<text top="309" left="219" width="538" height="21" font="5">Insights from the Department of Veterans Affairs. Circulation. 2017;135:2572-4. </text>
<text top="329" left="124" width="58" height="21" font="5">S4.1-43. </text>
<text top="329" left="219" width="593" height="21" font="5">Bohula EA, Bonaca MP, Braunwald E, et al. Atherothrombotic risk sStratification and the </text>
<text top="349" left="219" width="615" height="21" font="5">efficacy and safety of vorapaxar in patients with stable ischemic heart disease and previous </text>
<text top="370" left="219" width="353" height="21" font="5">myocardial infarction. Circulation. 2016;134:304-13. </text>
<text top="390" left="124" width="58" height="21" font="5">S4.1-44. </text>
<text top="390" left="219" width="614" height="21" font="5">Tikkanen MJ, Holme I, Cater NB, et al. Comparison of efficacy and safety of atorvastatin (80 </text>
<text top="410" left="219" width="596" height="21" font="5">mg) to simvastatin (20 to 40 mg) in patients aged &lt;65 versus &gt;or=65 years with coronary </text>
<text top="430" left="219" width="597" height="21" font="5">heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] </text>
<text top="450" left="219" width="263" height="21" font="5">study). Am J Cardiol. 2009;103:577-82. </text>
<text top="470" left="124" width="58" height="21" font="5">S4.1-45. </text>
<text top="470" left="219" width="588" height="21" font="5">Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic </text>
<text top="490" left="219" width="576" height="21" font="5">heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. </text>
<text top="510" left="219" width="174" height="21" font="5">Lancet. 2008;372:1231-9. </text>
<text top="531" left="124" width="58" height="21" font="5">S4.1-46. </text>
<text top="531" left="219" width="545" height="21" font="5">Rogers JK, Jhund PS, Perez AC, et al. Effect of rosuvastatin on repeat heart failure </text>
<text top="551" left="219" width="590" height="21" font="5">hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart </text>
<text top="571" left="219" width="272" height="21" font="5">Failure). JACC Heart Fail. 2014;2:289-97. </text>
<text top="591" left="124" width="58" height="21" font="5">S4.1-47. </text>
<text top="591" left="219" width="585" height="21" font="5">Cleland JG, McMurray JJ, Kjekshus J, et al. Plasma concentration of amino-terminal pro-</text>
<text top="611" left="219" width="596" height="21" font="5">brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and </text>
<text top="631" left="219" width="622" height="21" font="5">interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin </text>
<text top="651" left="219" width="477" height="21" font="5">Multinational Trial in Heart Failure). J Am Coll Cardiol. 2009;54:1850-9. </text>
<text top="681" left="124" width="4" height="21" font="5"> </text>
<text top="714" left="124" width="646" height="29" font="2"><b>4.2. Severe Hypercholesterolemia (LDL-C </b>≥<b>190 mg/dL [≥4.9 mmol/L]) </b></text>
<text top="746" left="124" width="50" height="21" font="5">S4.2-1. </text>
<text top="746" left="219" width="551" height="21" font="5">Besseling J, Hovingh GK, Huijgen R, et al. Statins in Familial Hypercholesterolemia: </text>
<text top="766" left="219" width="575" height="21" font="5">Consequences for Coronary Artery Disease and All-Cause Mortality. J Am Coll Cardiol. </text>
<text top="786" left="219" width="114" height="21" font="5">2016;68:252-60. </text>
<text top="806" left="124" width="50" height="21" font="5">S4.2-2. </text>
<text top="806" left="219" width="579" height="21" font="5">Khera AV, Won HH, Peloso GM, et al. Diagnostic yield and clinical utility of sequencing </text>
<text top="826" left="219" width="621" height="21" font="5">familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll </text>
<text top="846" left="219" width="177" height="21" font="5">Cardiol. 2016;67:2578-89. </text>
<text top="866" left="124" width="50" height="21" font="5">S4.2-3. </text>
<text top="866" left="219" width="485" height="21" font="5">Nanchen D, Gencer B, Muller O, et al. Prognosis of patients with familial </text>
<text top="887" left="219" width="584" height="21" font="5">hypercholesterolemia after acute coronary syndromes. Circulation. 2016;134:698-709. </text>
<text top="907" left="124" width="50" height="21" font="5">S4.2-4. </text>
<text top="907" left="219" width="589" height="21" font="5">Perak AM, Ning H, de Ferranti SD, et al. Long-term risk of atherosclerotic cardiovascular </text>
<text top="927" left="219" width="560" height="21" font="5">disease in US adults with the familial hypercholesterolemia phenotype. Circulation. </text>
<text top="947" left="219" width="105" height="21" font="5">2016;134:9-19. </text>
<text top="967" left="124" width="50" height="21" font="5">S4.2-5. </text>
<text top="967" left="219" width="622" height="21" font="5">Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in </text>
<text top="987" left="219" width="620" height="21" font="5">men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl </text>
<text top="1007" left="219" width="170" height="21" font="5">J Med. 1995;333:1301-7. </text>
<text top="1027" left="124" width="50" height="21" font="5">S4.2-6. </text>
<text top="1027" left="219" width="547" height="21" font="5">Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial </text>
<text top="1048" left="219" width="489" height="21" font="5">hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="94" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-94_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="456" width="48" height="19" font="1">Page 94</text>
<text top="1130" left="505" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="50" height="21" font="5">S4.2-7. </text>
<text top="108" left="219" width="604" height="21" font="5">Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of </text>
<text top="128" left="219" width="609" height="21" font="5">LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. </text>
<text top="148" left="219" width="183" height="21" font="5">Lancet. 2010;376:1670-81. </text>
<text top="168" left="124" width="50" height="21" font="5">S4.2-8. </text>
<text top="168" left="219" width="601" height="21" font="5">Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute </text>
<text top="188" left="219" width="370" height="21" font="5">coronary syndromes. N Engl J Med. 2015;372:2387-97. </text>
<text top="208" left="124" width="50" height="21" font="5">S4.2-9. </text>
<text top="208" left="219" width="537" height="21" font="5">Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and </text>
<text top="228" left="219" width="575" height="21" font="5">cardiovascular risk reduction among different therapeutic interventions: a systematic </text>
<text top="249" left="219" width="355" height="21" font="5">review and meta-analysis. JAMA. 2016;316:1289-97. </text>
<text top="269" left="124" width="58" height="21" font="5">S4.2-10. </text>
<text top="269" left="219" width="580" height="21" font="5">Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial </text>
<text top="289" left="219" width="379" height="21" font="5">hypercholesterolemia. N Engl J Med. 2008;358:1431-43. </text>
<text top="309" left="124" width="58" height="21" font="5">S4.2-11. </text>
<text top="309" left="219" width="600" height="21" font="5">Huijgen R, Abbink EJ, Bruckert E, et al. Colesevelam added to combination therapy with a </text>
<text top="329" left="219" width="619" height="21" font="5">statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, </text>
<text top="349" left="219" width="469" height="21" font="5">randomized, double-blind, controlled trial. Clin Ther. 2010;32:615-25. </text>
<text top="370" left="124" width="58" height="21" font="5">S4.2-12. </text>
<text top="370" left="219" width="536" height="21" font="5">Ross S, D'Mello M, Anand SS, et al. Effect of bile acid sequestrants on the risk of </text>
<text top="390" left="219" width="557" height="21" font="5">cardiovascular events: a Mendelian randomization analysis. Circ Cardiovasc Genet. </text>
<text top="410" left="219" width="105" height="21" font="5">2015;8:618-27. </text>
<text top="430" left="124" width="58" height="21" font="5">S4.2-13. </text>
<text top="430" left="219" width="592" height="21" font="5">Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with </text>
<text top="450" left="219" width="598" height="21" font="5">alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. </text>
<text top="470" left="219" width="220" height="21" font="5">Eur Heart J. 2015;36:2996-3003. </text>
<text top="490" left="124" width="58" height="21" font="5">S4.2-14. </text>
<text top="490" left="219" width="553" height="21" font="5">Perez de Isla L, Alonso R, Mata N, et al. Predicting cardiovascular events in familial </text>
<text top="510" left="219" width="588" height="21" font="5">hypercholesterolemia: the SAFEHEART Registry (Spanish Familial Hypercholesterolemia </text>
<text top="531" left="219" width="311" height="21" font="5">Cohort Study). Circulation. 2017;135:2133-44. </text>
<text top="551" left="124" width="58" height="21" font="5">S4.2-15. </text>
<text top="551" left="219" width="546" height="21" font="5">Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in </text>
<text top="571" left="219" width="581" height="21" font="5">heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-</text>
<text top="591" left="219" width="381" height="21" font="5">blind, placebo-controlled trial. Lancet. 2015;385:331-40. </text>
<text top="611" left="124" width="58" height="21" font="5">S4.2-16. </text>
<text top="611" left="219" width="616" height="21" font="5">Nicholls SJ, Brandrup-Wognsen G, Palmer M, et al. Meta-analysis of comparative efficacy of </text>
<text top="631" left="219" width="613" height="21" font="5">increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of </text>
<text top="651" left="219" width="447" height="21" font="5">atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105:69-76. </text>
<text top="671" left="124" width="58" height="21" font="5">S4.2-17. </text>
<text top="671" left="219" width="496" height="21" font="5">Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate </text>
<text top="692" left="219" width="601" height="21" font="5">hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. 2016;176:1834-42. </text>
<text top="712" left="124" width="58" height="21" font="5">S4.2-18. </text>
<text top="712" left="219" width="558" height="21" font="5">Robinson JG, Huijgen R, Ray K, et al. Determining when to add nonstatin therapy: a </text>
<text top="732" left="219" width="398" height="21" font="5">quantitative approach. J Am Coll Cardiol. 2016;68:2412-21. </text>
<text top="752" left="124" width="58" height="21" font="5">S4.2-19. </text>
<text top="752" left="219" width="567" height="21" font="5">Vallejo-Vaz AJ, Robertson M, Catapano AL, et al. Low-density lipoprotein cholesterol </text>
<text top="772" left="218" width="590" height="21" font="5">lowering for the primary prevention of cardiovascular disease among men with primary </text>
<text top="792" left="218" width="591" height="21" font="5">elevations of low-density lipoprotein cholesterol levels of 190 mg/dL or above: analyses </text>
<text top="812" left="218" width="608" height="21" font="5">from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial </text>
<text top="833" left="218" width="462" height="21" font="5">and 20-year observational follow-up. Circulation. 2017;136:1878-91. </text>
<text top="853" left="124" width="58" height="21" font="5">S4.2-20. </text>
<text top="853" left="218" width="562" height="21" font="5">Bohula EA, Morrow DA, Giugliano RP, et al. Atherothrombotic risk stratification and </text>
<text top="873" left="218" width="480" height="21" font="5">ezetimibe for secondary prevention. J Am Coll Cardiol. 2017;69:911-21. </text>
<text top="902" left="124" width="4" height="21" font="5"> </text>
<text top="934" left="124" width="297" height="29" font="2"><b>4.3. Diabetes Mellitus in Adults </b></text>
<text top="966" left="124" width="50" height="21" font="5">S4.3-1. </text>
<text top="966" left="219" width="582" height="21" font="5">Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular </text>
<text top="986" left="219" width="621" height="21" font="5">disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study </text>
<text top="1006" left="219" width="568" height="21" font="5">(CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-96. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="95" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-95_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="456" width="48" height="19" font="1">Page 95</text>
<text top="1130" left="505" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="50" height="21" font="5">S4.3-2. </text>
<text top="108" left="219" width="564" height="21" font="5">Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-</text>
<text top="128" left="219" width="605" height="21" font="5">lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled </text>
<text top="148" left="219" width="217" height="21" font="5">trial. Lancet. 2003;361:2005-16. </text>
<text top="168" left="124" width="50" height="21" font="5">S4.3-3. </text>
<text top="168" left="219" width="592" height="21" font="5">de Vries FM, Denig P, Pouwels KB, et al. Primary prevention of major cardiovascular and </text>
<text top="188" left="219" width="536" height="21" font="5">cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs. </text>
<text top="208" left="219" width="122" height="21" font="5">2012;72:2365-73. </text>
<text top="228" left="124" width="50" height="21" font="5">S4.3-4. </text>
<text top="228" left="219" width="619" height="21" font="5">Knopp RH, d'Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention </text>
<text top="249" left="219" width="590" height="21" font="5">of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for </text>
<text top="269" left="219" width="619" height="21" font="5">Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus </text>
<text top="289" left="219" width="284" height="21" font="5">(ASPEN). Diabetes care. 2006;29:1478-85. </text>
<text top="309" left="124" width="50" height="21" font="5">S4.3-5. </text>
<text top="309" left="219" width="609" height="21" font="5">Mulnier HE, Seaman HE, Raleigh VS, et al. Risk of myocardial infarction in men and women </text>
<text top="329" left="219" width="554" height="21" font="5">with type 2 diabetes in the UK: a cohort study using the General Practice Research </text>
<text top="349" left="219" width="286" height="21" font="5">Database. Diabetologia. 2008;51:1639-45. </text>
<text top="370" left="124" width="50" height="21" font="5">S4.3-6. </text>
<text top="370" left="219" width="555" height="21" font="5">Rana JS, Liu JY, Moffet HH, et al. Diabetes and prior coronary heart disease are not </text>
<text top="390" left="219" width="581" height="21" font="5">necessarily risk equivalent for future coronary heart disease events. J Gen Intern Med. </text>
<text top="410" left="219" width="114" height="21" font="5">2016;31:387-93. </text>
<text top="430" left="124" width="50" height="21" font="5">S4.3-7. </text>
<text top="430" left="219" width="618" height="21" font="5">Sever PS, Poulter NR, Dahlof B, et al. Reduction in cardiovascular events with atorvastatin in </text>
<text top="450" left="219" width="579" height="21" font="5">2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-</text>
<text top="470" left="219" width="406" height="21" font="5">lowering arm (ASCOT-LLA). Diabetes Ccare. 2005;28:1151-7. </text>
<text top="490" left="124" width="50" height="21" font="5">S4.3-8. </text>
<text top="490" left="219" width="582" height="21" font="5">Soedamah-Muthu SS, Fuller JH, Mulnier HE, et al. High risk of cardiovascular disease in </text>
<text top="510" left="219" width="616" height="21" font="5">patients with type 1 diabetes in the U.K.: a cohort study using the general practice research </text>
<text top="531" left="219" width="292" height="21" font="5">database. Diabetes Care. 2006;29:798-804. </text>
<text top="551" left="124" width="50" height="21" font="5">S4.3-9. </text>
<text top="551" left="219" width="615" height="21" font="5">Wong ND, Glovaci D, Wong K, et al. Global cardiovascular disease risk assessment in United </text>
<text top="571" left="219" width="418" height="21" font="5">States adults with diabetes. Diab Vasc Dis Res. 2012;9:146-52. </text>
<text top="591" left="124" width="58" height="21" font="5">S4.3-10. </text>
<text top="591" left="219" width="619" height="21" font="5">Karmali KN, Goff DC Jr, Ning H, et al. A systematic examination of the 2013 ACC/AHA pooled </text>
<text top="611" left="219" width="593" height="21" font="5">cohort risk assessment tool for atherosclerotic cardiovascular disease. J Am Coll Cardiol. </text>
<text top="631" left="219" width="114" height="21" font="5">2014;64:959-68. </text>
<text top="651" left="124" width="58" height="21" font="5">S4.3-11. </text>
<text top="651" left="219" width="527" height="21" font="5">Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic </text>
<text top="671" left="219" width="533" height="21" font="5">cardiovascular disease Pooled Cohort risk equations. JAMA. 2014;311:1406-15. </text>
<text top="692" left="124" width="58" height="21" font="5">S4.3-12. </text>
<text top="692" left="219" width="604" height="21" font="5">Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of </text>
<text top="712" left="219" width="609" height="21" font="5">LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. </text>
<text top="732" left="219" width="183" height="21" font="5">Lancet. 2010;376:1670-81. </text>
<text top="752" left="124" width="58" height="21" font="5">S4.3-13. </text>
<text top="752" left="218" width="604" height="21" font="5">Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men </text>
<text top="772" left="218" width="540" height="21" font="5">and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207. </text>
<text top="792" left="124" width="58" height="21" font="5">S4.3-14. </text>
<text top="792" left="218" width="601" height="21" font="5">Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute </text>
<text top="812" left="218" width="370" height="21" font="5">coronary syndromes. N Engl J Med. 2015;372:2387-97. </text>
<text top="833" left="124" width="58" height="21" font="5">S4.3-15. </text>
<text top="833" left="218" width="545" height="21" font="5">Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with </text>
<text top="853" left="218" width="620" height="21" font="5">simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal </text>
<text top="873" left="218" width="527" height="21" font="5">Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181-92. </text>
<text top="893" left="124" width="58" height="21" font="5">S4.3-16. </text>
<text top="893" left="218" width="577" height="21" font="5">Brownrigg JR, de Lusignan S, McGovern A, et al. Peripheral neuropathy and the risk of </text>
<text top="913" left="218" width="509" height="21" font="5">cardiovascular events in type 2 diabetes mellitus. Heart. 2014;100:1837-43. </text>
<text top="933" left="124" width="58" height="21" font="5">S4.3-17. </text>
<text top="933" left="218" width="565" height="21" font="5">Constantino MI, Molyneaux L, Limacher-Gisler F, et al. Long-term complications and </text>
<text top="953" left="218" width="619" height="21" font="5">mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 </text>
<text top="974" left="218" width="280" height="21" font="5">diabetes. Diabetes Care. 2013;36:3863-9. </text>
<text top="994" left="124" width="58" height="21" font="5">S4.3-18. </text>
<text top="994" left="218" width="576" height="21" font="5">Dabelea D, Stafford JM, Mayer-Davis EJ, et al. Association of type 1 diabetes vs type 2 </text>
<text top="1014" left="218" width="602" height="21" font="5">diabetes diagnosed during childhood and adolescence with complications during teenage </text>
<text top="1034" left="218" width="359" height="21" font="5">years and young adulthood. JAMA. 2017;317:825-35. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="96" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-96_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="456" width="48" height="19" font="1">Page 96</text>
<text top="1130" left="505" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="58" height="21" font="5">S4.3-19. </text>
<text top="108" left="219" width="576" height="21" font="5">Guo VY, Cao B, Wu X, et al. Prospective association between diabetic retinopathy and </text>
<text top="128" left="219" width="603" height="21" font="5">cardiovascular disease—a systematic review and meta-analysis of cohort studies. J Stroke </text>
<text top="148" left="219" width="237" height="21" font="5">Cerebrovasc Dis. 2016;25:1688-95. </text>
<text top="168" left="124" width="58" height="21" font="5">S4.3-20. </text>
<text top="168" left="219" width="593" height="21" font="5">Huo X, Gao L, Guo L, et al. Risk of non-fatal cardiovascular diseases in early-onset versus </text>
<text top="188" left="219" width="591" height="21" font="5">late-onset type 2 diabetes in China: a cross-sectional study. Lancet Diabetes Endocrinol. </text>
<text top="208" left="219" width="105" height="21" font="5">2016;4:115-24. </text>
<text top="228" left="124" width="58" height="21" font="5">S4.3-21. </text>
<text top="228" left="219" width="575" height="21" font="5">Nezarat N, Budoff MJ, Luo Y, et al. Presence, characteristics, and volumes of coronary </text>
<text top="249" left="219" width="566" height="21" font="5">plaque determined by computed tomography angiography in young type 2 diabetes </text>
<text top="269" left="219" width="283" height="21" font="5">mellitus. Am J Cardiol. 2017;119:1566-71. </text>
<text top="289" left="124" width="58" height="21" font="5">S4.3-22. </text>
<text top="289" left="219" width="547" height="21" font="5">Ogren M, Hedblad B, Engstrom G, et al. Prevalence and prognostic significance of </text>
<text top="309" left="219" width="596" height="21" font="5">asymptomatic peripheral arterial disease in 68-year-old men with diabetes. Results from </text>
<text top="329" left="219" width="601" height="21" font="5">the population study 'Men born in 1914' from Malmo, Sweden. Eur J Vasc Endovasc Surg. </text>
<text top="349" left="219" width="105" height="21" font="5">2005;29:182-9. </text>
<text top="370" left="124" width="58" height="21" font="5">S4.3-23. </text>
<text top="370" left="219" width="572" height="21" font="5">Pambianco G, Costacou T, Ellis D, et al. The 30-year natural history of type 1 diabetes </text>
<text top="390" left="219" width="597" height="21" font="5">complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. </text>
<text top="410" left="219" width="181" height="21" font="5">Diabetes. 2006;55:1463-9. </text>
<text top="430" left="124" width="58" height="21" font="5">S4.3-24. </text>
<text top="430" left="219" width="610" height="21" font="5">Pang XH, Han J, Ye WL, et al. Lower extremity peripheral arterial disease is an independent </text>
<text top="450" left="219" width="621" height="21" font="5">predictor of coronary heart disease and stroke risks in patients with type 2 diabetes mellitus </text>
<text top="470" left="219" width="315" height="21" font="5">in China. Int J Endocrinol. 2017;2017:9620513. </text>
<text top="490" left="124" width="58" height="21" font="5">S4.3-25. </text>
<text top="490" left="219" width="620" height="21" font="5">Svensson MK, Cederholm J, Eliasson B, et al. Albuminuria and renal function as predictors of </text>
<text top="510" left="219" width="557" height="21" font="5">cardiovascular events and mortality in a general population of patients with type 2 </text>
<text top="531" left="219" width="600" height="21" font="5">diabetes: a nationwide observational study from the Swedish National Diabetes Register. </text>
<text top="551" left="219" width="230" height="21" font="5">Diab Vasc Dis Res. 2013;10:520-9. </text>
<text top="571" left="124" width="58" height="21" font="5">S4.3-26. </text>
<text top="571" left="219" width="611" height="21" font="5">Ridker PM, Lonn E, Paynter NP, et al. Primary prevention with statin therapy in the elderly: </text>
<text top="591" left="219" width="561" height="21" font="5">new meta-analyses from the contemporary JUPITER and HOPE-3 randomized trials. </text>
<text top="611" left="219" width="211" height="21" font="5">Circulation. 2017;135:1979-81. </text>
<text top="631" left="124" width="58" height="21" font="5">S4.3-27. </text>
<text top="631" left="219" width="537" height="21" font="5">Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and </text>
<text top="651" left="219" width="575" height="21" font="5">cardiovascular risk reduction among different therapeutic interventions: a systematic </text>
<text top="671" left="218" width="355" height="21" font="5">review and meta-analysis. JAMA. 2016;316:1289-97. </text>
<text top="692" left="124" width="58" height="21" font="5">S4.3-28. </text>
<text top="692" left="218" width="601" height="21" font="5">Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute </text>
<text top="712" left="218" width="370" height="21" font="5">coronary syndromes. N Engl J Med. 2015;372:2387-97. </text>
<text top="741" left="124" width="4" height="21" font="5"> </text>
<text top="773" left="124" width="226" height="29" font="2"><b>4.4. Primary Prevention </b></text>
<text top="805" left="124" width="50" height="21" font="5">S4.4-1. </text>
<text top="805" left="219" width="593" height="21" font="5">Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with </text>
<text top="825" left="219" width="542" height="21" font="5">atherosclerotic cardiovascular disease (ASCVD) events: the Multi-Ethnic Study of </text>
<text top="845" left="219" width="359" height="21" font="5">Atherosclerosis (MESA). Eur Heart J. 2018;39:2401-8. </text>
<text top="865" left="124" width="50" height="21" font="5">S4.4-2. </text>
<text top="865" left="219" width="619" height="21" font="5">Avorn J. The psychology of clinical decision making—implications for medication use. N Engl </text>
<text top="885" left="219" width="170" height="21" font="5">J Med. 2018;378:689-91. </text>
<text top="905" left="124" width="50" height="21" font="5">S4.4-3. </text>
<text top="905" left="219" width="577" height="21" font="5">Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision </text>
<text top="926" left="219" width="531" height="21" font="5">pathway on the role of non-statin therapies for LDL-cholesterol lowering in the </text>
<text top="946" left="219" width="570" height="21" font="5">management of atherosclerotic cardiovascular disease risk: a report of the American </text>
<text top="966" left="219" width="618" height="21" font="5">College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. </text>
<text top="986" left="219" width="114" height="21" font="5">2016;68:92-125. </text>
<text top="1006" left="124" width="50" height="21" font="5">S4.4-4. </text>
<text top="1006" left="219" width="587" height="21" font="5">Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 focused update of the 2016 ACC </text>
<text top="1026" left="219" width="606" height="21" font="5">expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol </text>
<text top="1047" left="219" width="607" height="21" font="5">lowering in the management of atherosclerotic cardiovascular disease risk: a report of the </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="97" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-97_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="456" width="48" height="19" font="1">Page 97</text>
<text top="1130" left="505" width="4" height="21" font="5"> </text>
<text top="108" left="219" width="599" height="21" font="5">American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am </text>
<text top="128" left="219" width="215" height="21" font="5">Coll Cardiol. 2017;70:1785-822. </text>
<text top="148" left="124" width="50" height="21" font="5">S4.4-5. </text>
<text top="148" left="219" width="527" height="21" font="5">Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic </text>
<text top="168" left="219" width="531" height="21" font="5">cardiovascular disease pooled cohort risk equations. JAMA. 2014;311:1406-15. </text>
<text top="188" left="124" width="50" height="21" font="5">S4.4-6. </text>
<text top="188" left="219" width="584" height="21" font="5">Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to </text>
<text top="208" left="219" width="609" height="21" font="5">reduce cardiovascular risk: a report of the American College of Cardiology/American Heart </text>
<text top="228" left="219" width="513" height="21" font="5">Association Task Force on Practice Guidelines. Circulation. 2014;129:S76-99. </text>
<text top="249" left="124" width="50" height="21" font="5">S4.4-7. </text>
<text top="249" left="219" width="617" height="21" font="5">Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management </text>
<text top="269" left="219" width="484" height="21" font="5">of overweight and obesity in adults: a report of the American College of </text>
<text top="289" left="219" width="607" height="21" font="5">Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity </text>
<text top="309" left="219" width="266" height="21" font="5">Society. Circulation. 2014;129:S102-38. </text>
<text top="329" left="124" width="50" height="21" font="5">S4.4-8. </text>
<text top="329" left="219" width="571" height="21" font="5">U.S. Department of Health and Human Services. 2008 Physical Activity Guidelines for </text>
<text top="349" left="219" width="617" height="21" font="5">Americans. Available at: https://health.gov/paguidelines/pdf/paguide.pdf. Accessed August </text>
<text top="370" left="219" width="66" height="21" font="5">24, 2018. </text>
<text top="390" left="124" width="50" height="21" font="5">S4.4-9. </text>
<text top="390" left="219" width="609" height="21" font="5">Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a </text>
<text top="410" left="219" width="364" height="21" font="5">Mediterranean diet. N Engl J Med. 2013;368:1279-90. </text>
<text top="430" left="124" width="58" height="21" font="5">S4.4-10. </text>
<text top="430" left="219" width="607" height="21" font="5">U.S. Department of Health and Human Services and U.S. Department of Agriculture. 2015–</text>
<text top="450" left="219" width="518" height="21" font="5">2020 Dietary Guidelines for Americans. 8th ed. December 2015. Available at: </text>
<text top="470" left="219" width="548" height="21" font="5">http://health.gov/dietaryguidelines/2015/guidelines/. Accessed August 24, 2018. </text>
<text top="490" left="124" width="58" height="21" font="5">S4.4-11. </text>
<text top="490" left="219" width="618" height="21" font="5">Lichtenstein AH, Appel LJ, Brands M, et al. Summary of American Heart Association diet and </text>
<text top="510" left="219" width="609" height="21" font="5">lifestyle recommendations revision 2006. Arterioscler Thromb Vasc Biol. 2006;26:2186-91. </text>
<text top="531" left="124" width="58" height="21" font="5">S4.4-12. </text>
<text top="531" left="219" width="588" height="21" font="5">Ginsberg HN, Kris-Etherton P, Dennis B, et al. Effects of reducing dietary saturated fatty </text>
<text top="551" left="219" width="591" height="21" font="5">acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1. </text>
<text top="571" left="219" width="312" height="21" font="5">Arterioscler Thromb Vasc Biol. 1998;18:441-9. </text>
<text top="591" left="124" width="58" height="21" font="5">S4.4-13. </text>
<text top="591" left="219" width="584" height="21" font="5">Dehghan M, Mente A, Zhang X, et al. Associations of fats and carbohydrate intake with </text>
<text top="611" left="219" width="557" height="21" font="5">cardiovascular disease and mortality in 18 countries from five continents (PURE): a </text>
<text top="631" left="219" width="357" height="21" font="5">prospective cohort study. Lancet. 2017;390:2050-62. </text>
<text top="651" left="124" width="58" height="21" font="5">S4.4-14. </text>
<text top="651" left="219" width="586" height="21" font="5">Chen M, Li Y, Sun Q, et al. Dairy fat and risk of cardiovascular disease in 3 cohorts of US </text>
<text top="671" left="219" width="282" height="21" font="5">adults. Am J Clin Nutr. 2016;104:1209-17. </text>
<text top="692" left="124" width="58" height="21" font="5">S4.4-15. </text>
<text top="692" left="219" width="616" height="21" font="5">Loria CM, Liu K, Lewis CE, et al. Early adult risk factor levels and subsequent coronary artery </text>
<text top="712" left="219" width="456" height="21" font="5">calcification: the CARDIA Study. J Am Coll Cardiol. 2007;49:2013-20. </text>
<text top="732" left="124" width="58" height="21" font="5">S4.4-16. </text>
<text top="732" left="219" width="618" height="21" font="5">Carr JJ, Jacobs DR Jr, Terry JG, et al. Association of coronary artery calcium in adults aged 32 </text>
<text top="752" left="219" width="597" height="21" font="5">to 46 years with incident coronary heart disease and death. JAMA Cardiol. 2017;2:391-9. </text>
<text top="772" left="124" width="58" height="21" font="5">S4.4-17. </text>
<text top="772" left="219" width="544" height="21" font="5">Choosing interventions that are cost effective (WHO-CHOICE): cost-effectiveness </text>
<text top="792" left="219" width="453" height="21" font="5">thresholds. Geneva, Switzerland: World Health Organization; 2009. </text>
<text top="812" left="124" width="58" height="21" font="5">S4.4-18. </text>
<text top="812" left="219" width="597" height="21" font="5">Physical Activity Guidelines Advisory Committee report, 2008. To the Secretary of Health </text>
<text top="833" left="219" width="512" height="21" font="5">and Human Services. Part A: executive summary. Nutr Rev. 2009;67:114-20. </text>
<text top="853" left="124" width="58" height="21" font="5">S4.4-19. </text>
<text top="853" left="218" width="567" height="21" font="5">Warburton DE, Charlesworth S, Ivey A, et al. A systematic review of the evidence for </text>
<text top="873" left="218" width="573" height="21" font="5">Canada's Physical Activity Guidelines for Adults. Int J Behav Nutr Phys Act. 2010;7:39. </text>
<text top="893" left="124" width="58" height="21" font="5">S4.4-20. </text>
<text top="893" left="218" width="567" height="21" font="5">Shiroma EJ, Lee IM. Physical activity and cardiovascular health: lessons learned from </text>
<text top="913" left="218" width="603" height="21" font="5">epidemiological studies across age, gender, and race/ethnicity. Circulation. 2010;122:743-</text>
<text top="933" left="218" width="25" height="21" font="5">52. </text>
<text top="953" left="124" width="58" height="21" font="5">S4.4-21. </text>
<text top="953" left="218" width="603" height="21" font="5">Sattelmair J, Pertman J, Ding EL, et al. Dose response between physical activity and risk of </text>
<text top="974" left="218" width="476" height="21" font="5">coronary heart disease: a meta-analysis. Circulation. 2011;124:789-95. </text>
<text top="1003" left="124" width="4" height="21" font="5"> </text>
<text top="1035" left="124" width="336" height="27" font="16"><i><b>4.4.1. Evaluation and Risk Assessment</b></i><b> </b></text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="98" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-98_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="456" width="48" height="19" font="1">Page 98</text>
<text top="1130" left="505" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="362" height="25" font="23"><i><b>4.4.1.1. Essential Process of Risk Assessment </b></i></text>
<text top="144" left="124" width="579" height="21" font="5">S4.4.1.1-1.  American College of Cardiology. ASCVD Risk Predictor Plus. Available at: </text>
<text top="164" left="219" width="548" height="21" font="5">http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/. Accessed </text>
<text top="184" left="219" width="135" height="21" font="5">September 1, 2018. </text>
<text top="205" left="124" width="533" height="21" font="5">S4.4.1.1-2.  American Heart Association. ASCVD-Risk-Calculator. Available at: </text>
<text top="225" left="219" width="615" height="21" font="5">https://professional.heart.org/professional/GuidelinesStatements/ASCVDRiskCalculator/UC</text>
<text top="245" left="219" width="462" height="21" font="5">M_457698_ASCVD-Risk-Calculator.jsp. Accessed September 1, 2018. </text>
<text top="265" left="124" width="699" height="21" font="5">S4.4.1.1-3.  Karp I, Abrahamowicz M, Bartlett G, et al. Updated risk factor values and the ability of the </text>
<text top="285" left="219" width="622" height="21" font="5">multivariable risk score to predict coronary heart disease. Am J Epidemiol. 2004;160:707-16. </text>
<text top="305" left="124" width="713" height="21" font="5">S4.4.1.1-4.  Pencina MJ, D'Agostino RB Sr, Larson MG, et al. Predicting the 30-year risk of cardiovascular </text>
<text top="325" left="219" width="470" height="21" font="5">disease: the Framingham Heart Study. Circulation. 2009;119:3078-84. </text>
<text top="345" left="124" width="4" height="21" font="5"> </text>
<text top="366" left="124" width="4" height="21" font="5"> </text>
<text top="386" left="124" width="268" height="25" font="23"><i><b>4.4.1.2. Pooled Cohort Equations </b></i></text>
<text top="422" left="124" width="676" height="21" font="5">S4.4.1.2-1.  DeFilippis AP, Young R, Carrubba CJ, et al. An analysis of calibration and discrimination </text>
<text top="442" left="219" width="615" height="21" font="5">among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. </text>
<text top="462" left="219" width="122" height="21" font="5">2015;162:266-75. </text>
<text top="483" left="124" width="663" height="21" font="5">S4.4.1.2-2.  Kavousi M, Leening MJ, Nanchen D, et al. Comparison of application of the ACC/AHA </text>
<text top="503" left="219" width="565" height="21" font="5">guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology </text>
<text top="523" left="219" width="521" height="21" font="5">guidelines for cardiovascular disease prevention in a European cohort. JAMA. </text>
<text top="543" left="219" width="130" height="21" font="5">2014;311:1416-23. </text>
<text top="563" left="124" width="670" height="21" font="5">S4.4.1.2-3.  Wolfson J, Vock DM, Bandyopadhyay S, et al. Use and customization of risk scores for </text>
<text top="583" left="219" width="585" height="21" font="5">predicting cardiovascular events using electronic health record data. J Am Heart Assoc. </text>
<text top="603" left="219" width="117" height="21" font="5">2017;6:e003670. </text>
<text top="624" left="124" width="711" height="21" font="5">S4.4.1.2-4.  Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of </text>
<text top="644" left="219" width="559" height="21" font="5">cardiovascular risk: a report of the American College of Cardiology/American Heart </text>
<text top="664" left="219" width="513" height="21" font="5">Association Task Force on Practice Guidelines. Circulation. 2014;129:S49-73. </text>
<text top="684" left="124" width="707" height="21" font="5">S4.4.1.2-5.  Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of </text>
<text top="704" left="219" width="588" height="21" font="5">blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the </text>
<text top="724" left="219" width="558" height="21" font="5">American College of Cardiology/American Heart Association Task Force on Practice </text>
<text top="744" left="219" width="272" height="21" font="5">Guidelines. Circulation. 2014;129:S1-45. </text>
<text top="764" left="124" width="670" height="21" font="5">S4.4.1.2-6.  JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of </text>
<text top="785" left="219" width="419" height="21" font="5">cardiovascular disease (JBS3). Heart. 2014;100(suppl 2):ii1-67. </text>
<text top="805" left="124" width="621" height="21" font="5">S4.4.1.2-7.  Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic </text>
<text top="825" left="219" width="533" height="21" font="5">cardiovascular disease Pooled Cohort risk equations. JAMA. 2014;311:1406-15. </text>
<text top="845" left="124" width="699" height="21" font="5">S4.4.1.2-8.  Andersson C, Enserro D, Larson MG, et al. Implications of the US cholesterol guidelines on </text>
<text top="865" left="219" width="608" height="21" font="5">eligibility for statin therapy in the community: comparison of observed and predicted risks </text>
<text top="885" left="219" width="573" height="21" font="5">in the Framingham Heart Study Offspring Cohort. J Am Heart Assoc. 2015;4:e001888. </text>
<text top="905" left="124" width="631" height="21" font="5">S4.4.1.2-9.  Colantonio LD, Richman JS, Carson AP, et al. Performance of the atherosclerotic </text>
<text top="926" left="219" width="618" height="21" font="5">cardiovascular disease pooled cohort risk equations by social deprivation status. J Am Heart </text>
<text top="946" left="219" width="163" height="21" font="5">Assoc. 2017;6:e005676. </text>
<text top="966" left="124" width="678" height="21" font="5">S4.4.1.2-10.  Cook NR, Ridker PM. Further insight into the cardiovascular risk calculator: the roles of </text>
<text top="986" left="219" width="596" height="21" font="5">statins, revascularizations, and underascertainment in the Women's Health Study. JAMA </text>
<text top="1006" left="219" width="214" height="21" font="5">Intern Med. 2014;174:1964-71. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="99" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-99_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="456" width="48" height="19" font="1">Page 99</text>
<text top="1130" left="505" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="703" height="21" font="5">S4.4.1.2-11.  Dalton JE, Perzynski AT, Zidar DA, et al. Accuracy of cardiovascular risk prediction varies by </text>
<text top="128" left="219" width="576" height="21" font="5">neighborhood socioeconomic position: a retrospective cohort study. Ann Intern Med. </text>
<text top="148" left="219" width="122" height="21" font="5">2017;167:456-64. </text>
<text top="168" left="124" width="697" height="21" font="5">S4.4.1.2-12.  Feinstein MJ, Nance RM, Drozd DR, et al. Assessing and refining myocardial infarction risk </text>
<text top="188" left="219" width="613" height="21" font="5">estimation among patients with human immunodeficiency virus: a study by the Centers for </text>
<text top="208" left="219" width="570" height="21" font="5">AIDS Research Network of Integrated Clinical Systems. JAMA Cardiol. 2017;2:155-62. </text>
<text top="228" left="124" width="687" height="21" font="5">S4.4.1.2-13.  Flueckiger P, Qureshi W, Michos ED, et al. Guideline-based statin/lipid-lowering therapy </text>
<text top="249" left="219" width="571" height="21" font="5">eligibility for primary prevention and accuracy of coronary artery calcium and clinical </text>
<text top="269" left="219" width="573" height="21" font="5">cardiovascular events: the Multi-Ethnic Study of Atherosclerosis (MESA). Clin Cardiol. </text>
<text top="289" left="219" width="105" height="21" font="5">2017;40:163-9. </text>
<text top="309" left="124" width="695" height="21" font="5">S4.4.1.2-14.  Loprinzi PD, Addoh O. Predictive validity of the American College of Cardiology/American </text>
<text top="329" left="219" width="570" height="21" font="5">Heart Association pooled cohort equations in predicting all-cause and cardiovascular </text>
<text top="349" left="219" width="585" height="21" font="5">disease-specific mortality in a national prospective cohort study of adults in the United </text>
<text top="370" left="219" width="263" height="21" font="5">States. Mayo Clin Proc. 2016;91:763-9. </text>
<text top="390" left="124" width="702" height="21" font="5">S4.4.1.2-15.  Mortensen MB, Afzal S, Nordestgaard BG, et al. Primary prevention with statins: ACC/AHA </text>
<text top="410" left="219" width="568" height="21" font="5">risk-based approach versus trial-based approaches to guide statin therapy. J Am Coll </text>
<text top="430" left="219" width="186" height="21" font="5">Cardiol. 2015;66:2699-709. </text>
<text top="450" left="124" width="691" height="21" font="5">S4.4.1.2-16.  Mortensen MB, Nordestgaard BG, Afzal S, et al. ACC/AHA guidelines superior to ESC/EAS </text>
<text top="470" left="219" width="608" height="21" font="5">guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen </text>
<text top="490" left="219" width="374" height="21" font="5">General Population Study. Eur Heart J. 2017;38:586-94. </text>
<text top="510" left="124" width="680" height="21" font="5">S4.4.1.2-17.  Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of coronary artery calcium testing </text>
<text top="531" left="219" width="580" height="21" font="5">among statin candidates according to American College of Cardiology/American Heart </text>
<text top="551" left="219" width="521" height="21" font="5">Association cholesterol management guidelines: MESA (Multi-Ethnic Study of </text>
<text top="571" left="219" width="358" height="21" font="5">Atherosclerosis). J Am Coll Cardiol. 2015;66:1657-68. </text>
<text top="591" left="124" width="706" height="21" font="5">S4.4.1.2-18.  Rana JS, Tabada GH, Solomon MD, et al. Accuracy of the atherosclerotic cardiovascular risk </text>
<text top="611" left="219" width="611" height="21" font="5">equation in a large contemporary, multiethnic population. J Am Coll Cardiol. 2016;67:2118-</text>
<text top="631" left="219" width="25" height="21" font="5">30. </text>
<text top="651" left="124" width="677" height="21" font="5">S4.4.1.2-19.  Ungprasert P, Matteson EL, Crowson CS. Reliability of cardiovascular risk calculators to </text>
<text top="671" left="219" width="586" height="21" font="5">estimate accurately the risk of cardiovascular disease in patients with sarcoidosis. Am J </text>
<text top="692" left="219" width="177" height="21" font="5">Cardiol. 2017;120:868-73. </text>
<text top="712" left="124" width="713" height="21" font="5">S4.4.1.2-20.  Pencina MJ, D'Agostino RB Sr, Larson MG, et al. Predicting the 30-year risk of cardiovascular </text>
<text top="732" left="219" width="470" height="21" font="5">disease: the Framingham Heart Study. Circulation. 2009;119:3078-84. </text>
<text top="752" left="124" width="678" height="21" font="5">S4.4.1.2-21.  Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular </text>
<text top="772" left="219" width="517" height="21" font="5">disease by risk factor burden at 50 years of age. Circulation. 2006;113:791-8. </text>
<text top="792" left="124" width="4" height="21" font="5"> </text>
<text top="813" left="124" width="260" height="25" font="23"><i><b>4.4.1.3. Risk-Enhancing Factors  </b></i></text>
<text top="849" left="124" width="63" height="21" font="5">4.4.1.3-1 </text>
<text top="849" left="219" width="485" height="21" font="5">American College of Cardiology. ASCVD Risk Predictor Plus. Available at: </text>
<text top="869" left="219" width="548" height="21" font="5">http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/. Accessed </text>
<text top="889" left="219" width="135" height="21" font="5">September 1, 2018. </text>
<text top="909" left="124" width="63" height="21" font="5">4.4.1.3-2 </text>
<text top="909" left="219" width="612" height="21" font="5">Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of </text>
<text top="930" left="219" width="588" height="21" font="5">blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the </text>
<text top="950" left="219" width="558" height="21" font="5">American College of Cardiology/American Heart Association Task Force on Practice </text>
<text top="970" left="219" width="272" height="21" font="5">Guidelines. Circulation. 2014;129:S1-45. </text>
<text top="990" left="124" width="662" height="21" font="5">S4.4.1.3-3.  Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons </text>
<text top="1010" left="219" width="439" height="21" font="5">without cardiovascular disease. N Engl J Med. 2016;374:2021-31. </text>
<text top="1030" left="124" width="4" height="21" font="5"> </text>
<text top="1050" left="124" width="272" height="25" font="23"><i><b>4.4.1.4. Coronary Artery Calcium  </b></i></text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="100" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-100_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="453" width="55" height="19" font="1">Page 100</text>
<text top="1130" left="508" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="680" height="21" font="5">S4.4.1.4-1.  Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of coronary artery calcium testing </text>
<text top="128" left="219" width="580" height="21" font="5">among statin candidates according to American College of Cardiology/American Heart </text>
<text top="148" left="219" width="521" height="21" font="5">Association cholesterol management guidelines: MESA (Multi-Ethnic Study of </text>
<text top="168" left="219" width="358" height="21" font="5">Atherosclerosis). J Am Coll Cardiol. 2015;66:1657-68. </text>
<text top="188" left="124" width="713" height="21" font="5">S4.4.1.4-2.  Carr JJ, Jacobs DR Jr, Terry JG, et al. Association of coronary artery calcium in adults aged 32 </text>
<text top="208" left="219" width="597" height="21" font="5">to 46 years with incident coronary heart disease and death. JAMA Cardiol. 2017;2:391-9. </text>
<text top="228" left="124" width="704" height="21" font="5">S4.4.1.4-3.  Han D, O'Hartaigh B, Lee JH, et al. Assessment of coronary artery calcium scoring for statin </text>
<text top="249" left="219" width="619" height="21" font="5">treatment strategy according to ACC/AHA guidelines in asymptomatic Korean adults. Yonsei </text>
<text top="269" left="219" width="145" height="21" font="5">Med J. 2017;58:82-9. </text>
<text top="289" left="124" width="702" height="21" font="5">S4.4.1.4-4.  Hong JC, Blankstein R, Blaha M, et al. Cost-effectiveness of coronary artery calcium testing </text>
<text top="309" left="219" width="591" height="21" font="5">among statin candidates according to the American College of Cardiology and American </text>
<text top="329" left="219" width="563" height="21" font="5">Heart Association cholesterol guidelines. J Am Coll Cardiol. 2017;69(11 suppl):1828. </text>
<text top="349" left="124" width="701" height="21" font="5">S4.4.1.4-5.  Mahabadi AA, Mohlenkamp S, Lehmann N, et al. CAC score improves coronary and CV risk </text>
<text top="370" left="219" width="591" height="21" font="5">assessment above statin indication by ESC and AHA/ACC primary prevention guidelines. </text>
<text top="390" left="219" width="287" height="21" font="5">JACC Cardiovasc Imaging. 2017;10:143-53. </text>
<text top="410" left="124" width="658" height="21" font="5">S4.4.1.4-6.  Mortensen MB, Fuster V, Muntendam P, et al. A simple disease-guided approach to </text>
<text top="430" left="219" width="620" height="21" font="5">personalize ACC/AHA-recommended statin allocation in elderly people: the BioImage Study. </text>
<text top="450" left="219" width="233" height="21" font="5">J Am Coll Cardiol. 2016;68:881-91. </text>
<text top="470" left="124" width="705" height="21" font="5">S4.4.1.4-7.  Pursnani A, Massaro JM, D'Agostino RB Sr, et al. Guideline-based statin eligibility, coronary </text>
<text top="490" left="219" width="482" height="21" font="5">artery calcification, and cardiovascular events. JAMA. 2015;314:134-41. </text>
<text top="510" left="124" width="687" height="21" font="5">S4.4.1.4-8.  Yeboah J, Polonsky TS, Young R, et al. Utility of nontraditional risk markers in individuals </text>
<text top="531" left="219" width="619" height="21" font="5">ineligible for statin therapy according to the 2013 American College of Cardiology/American </text>
<text top="551" left="218" width="478" height="21" font="5">Heart Association cholesterol guidelines. Circulation. 2015;132:916-22. </text>
<text top="571" left="124" width="674" height="21" font="5">S4.4.1.4-9.  Budoff MJ, McClelland RL, Nasir K, et al. Cardiovascular events with absent or minimal </text>
<text top="591" left="218" width="568" height="21" font="5">coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J. </text>
<text top="611" left="218" width="122" height="21" font="5">2009;158:554-61. </text>
<text top="631" left="124" width="686" height="21" font="5">S4.4.1.4-10.  McEvoy JW, Blaha MJ, Rivera JJ, et al. Mortality rates in smokers and nonsmokers in the </text>
<text top="651" left="218" width="618" height="21" font="5">presence or absence of coronary artery calcification. JACC Cardiovasc Imaging. 2012;5:1037-</text>
<text top="671" left="218" width="25" height="21" font="5">45. </text>
<text top="692" left="124" width="655" height="21" font="5">S4.4.1.4-11.  Cohen R, Budoff M, McClelland RL, et al. Significance of a positive family history for </text>
<text top="712" left="218" width="580" height="21" font="5">coronary heart disease in patients with a zero coronary artery calcium score (from the </text>
<text top="732" left="218" width="474" height="21" font="5">Multi-Ethnic Study of Atherosclerosis). Am J Cardiol. 2014;114:1210-4. </text>
<text top="752" left="124" width="645" height="21" font="5">S4.4.1.4-12.  Metkus TS, Brown T, Budoff M, et al. HIV infection is associated with an increased </text>
<text top="772" left="218" width="580" height="21" font="5">prevalence of coronary noncalcified plaque among participants with a coronary artery </text>
<text top="792" left="218" width="589" height="21" font="5">calcium score of zero: Multicenter AIDS Cohort Study (MACS). HIV Med. 2015;16:635-9. </text>
<text top="812" left="124" width="687" height="21" font="5">S4.4.1.4-13.  Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with </text>
<text top="833" left="218" width="540" height="21" font="5">atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of </text>
<text top="853" left="218" width="357" height="21" font="5">atherosclerosis (MESA). Eur Heart J. 2018;39:2401-8. </text>
<text top="873" left="124" width="667" height="21" font="5">S4.4.1.4-14.  Valenti V, B OH, Heo R, et al. A 15-year warranty period for asymptomatic individuals </text>
<text top="893" left="218" width="562" height="21" font="5">without coronary artery calcium: a prospective follow-Up of 9,715 individuals. JACC </text>
<text top="913" left="218" width="234" height="21" font="5">Cardiovasc Imaging. 2015;8:900-9. </text>
<text top="933" left="124" width="637" height="21" font="5">S4.4.1.4-15.  Lehmann N, Erbel R, Mahabadi AA, et al. Value of progression of coronary artery </text>
<text top="953" left="218" width="589" height="21" font="5">calcification for risk prediction of coronary and cardiovascular events: result of the HNR </text>
<text top="974" left="218" width="396" height="21" font="5">Study (Heinz Nixdorf Recall). Circulation. 2018;137:665-79. </text>
<text top="994" left="124" width="703" height="21" font="5">S4.4.1.4-16.  Alluri K, McEvoy JW, Dardari ZA, et al. Distribution and burden of newly detected coronary </text>
<text top="1014" left="219" width="614" height="21" font="5">artery calcium: results from the Multi-Ethnic Study of Atherosclerosis. J Cardiovasc Comput </text>
<text top="1034" left="219" width="186" height="21" font="5">Tomogr. 2015;9:337-44 e1. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="101" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-101_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="453" width="55" height="19" font="1">Page 101</text>
<text top="1130" left="508" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="716" height="21" font="5">S4.4.1.4-17.  Lee S-E, Chang H-J, Sung JM, et al. Effects of statins on coronary atherosclerotic plaques: the </text>
<text top="128" left="219" width="419" height="21" font="5">PARADIGM study. JACC Cardiovasc Imaging. 2018;11:1475-84. </text>
<text top="148" left="124" width="660" height="21" font="5">S4.4.1.4-18.  Rozanski A, Gransar H, Shaw LJ, et al. Impact of coronary artery calcium scanning on </text>
<text top="168" left="219" width="612" height="21" font="5">coronary risk factors and downstream testing the EISNER (Early Identification of Subclinical </text>
<text top="188" left="219" width="604" height="21" font="5">Atherosclerosis by Noninvasive Imaging Research) prospective randomized trial. J Am Coll </text>
<text top="208" left="219" width="177" height="21" font="5">Cardiol. 2011;57:1622-32. </text>
<text top="228" left="124" width="664" height="21" font="5">S4.4.1.4-19.  Chevalier M, Moran P, Ten JI, et al. Patient dose in digital mammography. Med Phys. </text>
<text top="249" left="219" width="114" height="21" font="5">2004;31:2471-9. </text>
<text top="278" left="124" width="4" height="21" font="5"> </text>
<text top="310" left="124" width="683" height="27" font="16"><i><b>4.4.2. Primary Prevention Adults 40 to 75 Years of Age With LDL-C Levels 70 to </b></i></text>
<text top="340" left="124" width="253" height="27" font="16"><i><b>189 mg/dL (1.7–4.8 mmol/L) </b></i></text>
<text top="369" left="124" width="62" height="21" font="5">S4.4.2-1. </text>
<text top="369" left="219" width="604" height="21" font="5">Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of </text>
<text top="389" left="219" width="609" height="21" font="5">LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. </text>
<text top="409" left="219" width="183" height="21" font="5">Lancet. 2010;376:1670-81. </text>
<text top="429" left="124" width="62" height="21" font="5">S4.4.2-2. </text>
<text top="429" left="219" width="545" height="21" font="5">Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with </text>
<text top="449" left="219" width="620" height="21" font="5">simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal </text>
<text top="470" left="219" width="527" height="21" font="5">Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181-92. </text>
<text top="490" left="124" width="62" height="21" font="5">S4.4.2-3. </text>
<text top="490" left="219" width="573" height="21" font="5">Cholesterol Treatment Trialists’ (CTT) Collaboration, Herrington W, Emberson J, et al. </text>
<text top="510" left="219" width="568" height="21" font="5">Impact of renal function on the effects of LDL cholesterol lowering with statin-based </text>
<text top="530" left="219" width="605" height="21" font="5">regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet </text>
<text top="550" left="219" width="248" height="21" font="5">Diabetes Endocrinol. 2016;4:829-39. </text>
<text top="570" left="124" width="62" height="21" font="5">S4.4.2-4. </text>
<text top="570" left="219" width="594" height="21" font="5">Chou R, Dana T, Blazina I, et al. Statin use for the prevention of cardiovascular disease in </text>
<text top="590" left="219" width="607" height="21" font="5">adults: a systematic review for the U.S. Preventive Services Task Force. Rockville, MD: U.S. </text>
<text top="611" left="219" width="531" height="21" font="5">Agency for Healthcare Research and Quality; 2016. Report No.: 14-05206-EF-2. </text>
<text top="631" left="124" width="62" height="21" font="5">S4.4.2-5. </text>
<text top="631" left="219" width="588" height="21" font="5">Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with </text>
<text top="651" left="219" width="608" height="21" font="5">lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. </text>
<text top="671" left="219" width="580" height="21" font="5">Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-22. </text>
<text top="691" left="124" width="62" height="21" font="5">S4.4.2-6. </text>
<text top="691" left="219" width="604" height="21" font="5">Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men </text>
<text top="711" left="219" width="540" height="21" font="5">and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207. </text>
<text top="731" left="124" width="62" height="21" font="5">S4.4.2-7. </text>
<text top="731" left="219" width="526" height="21" font="5">Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of </text>
<text top="751" left="219" width="470" height="21" font="5">cardiovascular disease. Cochrane Database Syst Rev. 2013;CD004816. </text>
<text top="772" left="124" width="62" height="21" font="5">S4.4.2-8. </text>
<text top="772" left="219" width="568" height="21" font="5">Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons </text>
<text top="792" left="219" width="439" height="21" font="5">without cardiovascular disease. N Engl J Med. 2016;374:2021-31. </text>
<text top="812" left="124" width="62" height="21" font="5">S4.4.2-9. </text>
<text top="812" left="219" width="537" height="21" font="5">Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and </text>
<text top="832" left="219" width="575" height="21" font="5">cardiovascular risk reduction among different therapeutic interventions: a systematic </text>
<text top="852" left="219" width="355" height="21" font="5">review and meta-analysis. JAMA. 2016;316:1289-97. </text>
<text top="872" left="124" width="71" height="21" font="5">S4.4.2-10. </text>
<text top="872" left="219" width="619" height="21" font="5">Karmali KN, Goff DC Jr, Ning H, et al. A systematic examination of the 2013 ACC/AHA pooled </text>
<text top="893" left="219" width="592" height="21" font="5">cohort risk assessment tool for atherosclerotic cardiovascular disease. J Am Coll Cardiol. </text>
<text top="913" left="219" width="114" height="21" font="5">2014;64:959-68. </text>
<text top="933" left="124" width="71" height="21" font="5">S4.4.2-11. </text>
<text top="933" left="218" width="527" height="21" font="5">Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic </text>
<text top="953" left="218" width="531" height="21" font="5">cardiovascular disease pooled cohort risk equations. JAMA. 2014;311:1406-15. </text>
<text top="973" left="124" width="71" height="21" font="5">S4.4.2-12. </text>
<text top="973" left="218" width="488" height="21" font="5">Krumholz HM. Treatment of cholesterol in 2017. JAMA. 2017;318:417-8. </text>
<text top="993" left="124" width="71" height="21" font="5">S4.4.2-13. </text>
<text top="993" left="218" width="599" height="21" font="5">Martin SS, Sperling LS, Blaha MJ, et al. Clinician-patient risk discussion for atherosclerotic </text>
<text top="1013" left="218" width="594" height="21" font="5">cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA </text>
<text top="1033" left="218" width="312" height="21" font="5">Guidelines. J Am Coll Cardiol. 2015;65:1361-8. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="102" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-102_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="453" width="55" height="19" font="1">Page 102</text>
<text top="1130" left="508" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="71" height="21" font="5">S4.4.2-14. </text>
<text top="108" left="219" width="569" height="21" font="5">Stacey D, Legare F, Lewis K, et al. Decision aids for people facing health treatment or </text>
<text top="128" left="219" width="463" height="21" font="5">screening decisions. Cochrane Database Syst Rev. 2017;4:CD001431. </text>
<text top="148" left="124" width="71" height="21" font="5">S4.4.2-15. </text>
<text top="148" left="219" width="563" height="21" font="5">Mortensen MB, Fuster V, Muntendam P, et al. A simple disease-guided approach to </text>
<text top="168" left="219" width="619" height="21" font="5">personalize ACC/AHA-recommended statin allocation in elderly people: the BioImage study. </text>
<text top="188" left="219" width="233" height="21" font="5">J Am Coll Cardiol. 2016;68:881-91. </text>
<text top="208" left="124" width="71" height="21" font="5">S4.4.2-16. </text>
<text top="208" left="219" width="535" height="21" font="5">Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of </text>
<text top="228" left="219" width="614" height="21" font="5">cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck study. </text>
<text top="249" left="219" width="233" height="21" font="5">J Am Coll Cardiol. 2014;64:851-60. </text>
<text top="269" left="124" width="71" height="21" font="5">S4.4.2-17. </text>
<text top="269" left="219" width="585" height="21" font="5">Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of coronary artery calcium testing </text>
<text top="289" left="219" width="580" height="21" font="5">among statin candidates according to American College of Cardiology/American Heart </text>
<text top="309" left="219" width="521" height="21" font="5">Association cholesterol management guidelines: MESA (Multi-Ethnic Study of </text>
<text top="329" left="219" width="358" height="21" font="5">Atherosclerosis). J Am Coll Cardiol. 2015;66:1657-68. </text>
<text top="349" left="124" width="71" height="21" font="5">S4.4.2-18. </text>
<text top="349" left="219" width="592" height="21" font="5">Ridker PM, Mora S, Rose L. Percent reduction in LDL cholesterol following high-intensity </text>
<text top="370" left="219" width="594" height="21" font="5">statin therapy: potential implications for guidelines and for the prescription of emerging </text>
<text top="390" left="219" width="343" height="21" font="5">lipid-lowering agents. Eur Heart J. 2016;37:1373-9. </text>
<text top="410" left="124" width="71" height="21" font="5">S4.4.2-19. </text>
<text top="410" left="219" width="619" height="21" font="5">Yano Y, O'Donnell CJ, Kuller L, et al. Association of coronary artery calcium score vs age with </text>
<text top="430" left="219" width="596" height="21" font="5">cardiovascular risk in older adults: an analysis of pooled population-based studies. JAMA </text>
<text top="450" left="219" width="161" height="21" font="5">Cardiol. 2017;2:986-94. </text>
<text top="470" left="124" width="71" height="21" font="5">S4.4.2-20. </text>
<text top="470" left="219" width="542" height="21" font="5">Malik S, Zhao Y, Budoff M, et al. Coronary artery calcium score for long-term risk </text>
<text top="490" left="219" width="595" height="21" font="5">classification in individuals with type 2 diabetes and metabolic syndrome from the Multi-</text>
<text top="510" left="219" width="427" height="21" font="5">Ethnic Study of Atherosclerosis. JAMA Cardiol. 2017;2:1332-40. </text>
<text top="531" left="124" width="71" height="21" font="5">S4.4.2-21. </text>
<text top="531" left="219" width="591" height="21" font="5">Sniderman AD, Tsimikas S, Fazio S. The severe hypercholesterolemia phenotype: clinical </text>
<text top="551" left="219" width="576" height="21" font="5">diagnosis, management, and emerging therapies. J Am Coll Cardiol. 2014;63:1935-47. </text>
<text top="571" left="124" width="71" height="21" font="5">S4.4.2-22. </text>
<text top="571" left="219" width="583" height="21" font="5">Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein </text>
<text top="591" left="219" width="600" height="21" font="5">cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of </text>
<text top="611" left="219" width="454" height="21" font="5">cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4:337-45. </text>
<text top="631" left="124" width="71" height="21" font="5">S4.4.2-23. </text>
<text top="631" left="218" width="593" height="21" font="5">Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with </text>
<text top="651" left="218" width="542" height="21" font="5">atherosclerotic cardiovascular disease (ASCVD) events: the Multi-Ethnic Study of </text>
<text top="671" left="218" width="359" height="21" font="5">Atherosclerosis (MESA). Eur Heart J. 2018;39:2401-8. </text>
<text top="692" left="124" width="71" height="21" font="5">S4.4.2-24. </text>
<text top="692" left="218" width="590" height="21" font="5">Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with </text>
<text top="712" left="218" width="586" height="21" font="5">statin therapy in people at low risk of vascular disease: meta-analysis of individual data </text>
<text top="732" left="218" width="356" height="21" font="5">from 27 randomised trials. Lancet. 2012;380:581-90. </text>
<text top="752" left="124" width="71" height="21" font="5">S4.4.2-25. </text>
<text top="752" left="218" width="615" height="21" font="5">Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with </text>
<text top="772" left="218" width="577" height="21" font="5">pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. </text>
<text top="792" left="218" width="130" height="21" font="5">2006;368:1155-63. </text>
<text top="812" left="124" width="71" height="21" font="5">S4.4.2-26. </text>
<text top="812" left="218" width="612" height="21" font="5">Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of </text>
<text top="833" left="218" width="588" height="21" font="5">blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the </text>
<text top="853" left="218" width="558" height="21" font="5">American College of Cardiology/American Heart Association Task Force on Practice </text>
<text top="873" left="218" width="272" height="21" font="5">Guidelines. Circulation. 2014;129:S1-45. </text>
<text top="893" left="124" width="71" height="21" font="5">S4.4.2-27. </text>
<text top="893" left="218" width="615" height="21" font="5">Navar AM, Stone NJ, Martin SS. What to say and how to say it: effective communication for </text>
<text top="913" left="218" width="473" height="21" font="5">cardiovascular disease prevention. Curr Opin Cardiol. 2016;31:537-44. </text>
<text top="933" left="124" width="71" height="21" font="5">S4.4.2-28. </text>
<text top="933" left="218" width="574" height="21" font="5">Laing ST. High-intensity statins: guideline expectations and clinical application. JAMA. </text>
<text top="953" left="218" width="122" height="21" font="5">2017;317:2543-4. </text>
<text top="974" left="124" width="71" height="21" font="5">S4.4.2-29. </text>
<text top="974" left="218" width="540" height="21" font="5">Thanassoulis G, Pencina MJ, Sniderman AD. The benefit model for prevention of </text>
<text top="994" left="218" width="618" height="21" font="5">cardiovascular disease: an opportunity to harmonize guidelines. JAMA Cardiol. 2017;2:1175-</text>
<text top="1014" left="218" width="16" height="21" font="5">6. </text>
<text top="1034" left="124" width="71" height="21" font="5">S4.4.2-30. </text>
<text top="1034" left="218" width="610" height="21" font="5">Soran H, Schofield JD, Durrington PN. Cholesterol, not just cardiovascular risk, is important </text>
<text top="1054" left="218" width="531" height="21" font="5">in deciding who should receive statin treatment. Eur Heart J. 2015;36:2975-83. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="103" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-103_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="453" width="55" height="19" font="1">Page 103</text>
<text top="1130" left="508" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="71" height="21" font="5">S4.4.2-31. </text>
<text top="108" left="219" width="574" height="21" font="5">Samarasekera EJ, Neilson JM, Warren RB, et al. Incidence of cardiovascular disease in </text>
<text top="128" left="219" width="564" height="21" font="5">individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol. </text>
<text top="148" left="219" width="122" height="21" font="5">2013;133:2340-6. </text>
<text top="168" left="124" width="71" height="21" font="5">S4.4.2-32. </text>
<text top="168" left="219" width="602" height="21" font="5">Feinstein MJ, Nance RM, Drozd DR, et al. Assessing and refining myocardial infarction risk </text>
<text top="188" left="219" width="613" height="21" font="5">estimation among patients with human immunodeficiency virus: a study by the Centers for </text>
<text top="208" left="219" width="570" height="21" font="5">AIDS Research Network of Integrated Clinical Systems. JAMA Cardiol. 2017;2:155-62. </text>
<text top="228" left="124" width="71" height="21" font="5">S4.4.2-33. </text>
<text top="228" left="219" width="616" height="21" font="5">Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of </text>
<text top="249" left="219" width="559" height="21" font="5">cardiovascular risk: a report of the American College of Cardiology/American Heart </text>
<text top="269" left="219" width="572" height="21" font="5">Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S49-73. </text>
<text top="289" left="124" width="71" height="21" font="5">S4.4.2-34. </text>
<text top="289" left="219" width="602" height="21" font="5">Blaha MJ, Cainzos-Achirica M, Greenland P, et al. Role of coronary artery calcium score of </text>
<text top="309" left="219" width="603" height="21" font="5">zero and other negative risk markers for cardiovascular disease: the Multi-Ethnic Study of </text>
<text top="329" left="219" width="366" height="21" font="5">Atherosclerosis (MESA). Circulation. 2016;133:849-58. </text>
<text top="349" left="124" width="71" height="21" font="5">S4.4.2-35. </text>
<text top="349" left="219" width="560" height="21" font="5">Cohen R, Budoff M, McClelland RL, et al. Significance of a positive family history for </text>
<text top="370" left="219" width="580" height="21" font="5">coronary heart disease in patients with a zero coronary artery calcium score (from the </text>
<text top="390" left="219" width="474" height="21" font="5">Multi-Ethnic Study of Atherosclerosis). Am J Cardiol. 2014;114:1210-4. </text>
<text top="410" left="124" width="71" height="21" font="5">S4.4.2-36. </text>
<text top="410" left="219" width="618" height="21" font="5">Carr JJ, Jacobs DR Jr, Terry JG, et al. Association of coronary artery calcium in adults aged 32 </text>
<text top="430" left="219" width="597" height="21" font="5">to 46 years with incident coronary heart disease and death. JAMA Cardiol. 2017;2:391-9. </text>
<text top="450" left="124" width="71" height="21" font="5">S4.4.2-37. </text>
<text top="450" left="219" width="613" height="21" font="5">Fudim M, Zalawadiya S, Patel DK, et al. Data on coronary artery calcium score performance </text>
<text top="470" left="219" width="539" height="21" font="5">and cardiovascular risk reclassification across gender and ethnicities. Data Brief. </text>
<text top="490" left="219" width="105" height="21" font="5">2016;6:578-81. </text>
<text top="510" left="124" width="71" height="21" font="5">S4.4.2-38. </text>
<text top="510" left="219" width="551" height="21" font="5">Gupta A, Lau E, Varshney R, et al. The identification of calcified coronary plaque is </text>
<text top="531" left="219" width="583" height="21" font="5">associated with initiation and continuation of pharmacological and lifestyle preventive </text>
<text top="551" left="219" width="599" height="21" font="5">therapies: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2017;10:833-</text>
<text top="571" left="218" width="25" height="21" font="5">42. </text>
<text top="591" left="124" width="71" height="21" font="5">S4.4.2-39. </text>
<text top="591" left="218" width="609" height="21" font="5">Han D, O'Hartaigh B, Lee JH, et al. Assessment of coronary artery calcium scoring for statin </text>
<text top="611" left="218" width="619" height="21" font="5">treatment strategy according to ACC/AHA guidelines in asymptomatic Korean adults. Yonsei </text>
<text top="631" left="218" width="145" height="21" font="5">Med J. 2017;58:82-9. </text>
<text top="651" left="124" width="71" height="21" font="5">S4.4.2-40. </text>
<text top="651" left="218" width="608" height="21" font="5">Hong JC, Blankstein R, Blaha M, et al. Cost-effectiveness of coronary artery calcium testing </text>
<text top="671" left="218" width="591" height="21" font="5">among statin candidates according to the American College of Cardiology and American </text>
<text top="692" left="218" width="563" height="21" font="5">Heart Association cholesterol guidelines. J Am Coll Cardiol. 2017;69(11 suppl):1828. </text>
<text top="712" left="124" width="71" height="21" font="5">S4.4.2-41. </text>
<text top="712" left="218" width="584" height="21" font="5">Kavousi M, Desai CS, Ayers C, et al. Prevalence and prognostic implications of coronary </text>
<text top="732" left="218" width="548" height="21" font="5">artery calcification in low-risk women: a meta-analysis. JAMA. 2016;316:2126-34. </text>
<text top="752" left="124" width="71" height="21" font="5">S4.4.2-42. </text>
<text top="752" left="218" width="607" height="21" font="5">Mahabadi AA, Mohlenkamp S, Lehmann N, et al. CAC score improves coronary and CV risk </text>
<text top="772" left="218" width="591" height="21" font="5">assessment above statin indication by ESC and AHA/ACC primary prevention guidelines. </text>
<text top="792" left="218" width="287" height="21" font="5">JACC Cardiovasc Imaging. 2017;10:143-53. </text>
<text top="812" left="124" width="71" height="21" font="5">S4.4.2-43. </text>
<text top="812" left="218" width="554" height="21" font="5">McClelland RL, Jorgensen NW, Budoff M, et al. 10-Year coronary heart disease risk </text>
<text top="833" left="218" width="617" height="21" font="5">prediction using coronary artery calcium and traditional risk factors: derivation in the MESA </text>
<text top="853" left="218" width="590" height="21" font="5">(Multi-Ethnic Study of Atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) </text>
<text top="873" left="218" width="511" height="21" font="5">Study and the DHS (Dallas Heart Study). J Am Coll Cardiol. 2015;66:1643-53. </text>
<text top="893" left="124" width="71" height="21" font="5">S4.4.2-44. </text>
<text top="893" left="219" width="611" height="21" font="5">Pursnani A, Massaro JM, D'Agostino RB Sr, et al. Guideline-based statin eligibility, coronary </text>
<text top="913" left="219" width="482" height="21" font="5">artery calcification, and cardiovascular events. JAMA. 2015;314:134-41. </text>
<text top="934" left="124" width="71" height="21" font="5">S4.4.2-45. </text>
<text top="934" left="219" width="607" height="21" font="5">Qureshi WT, Rana JS, Yeboah J, et al. Risk stratification for primary prevention of coronary </text>
<text top="954" left="219" width="595" height="21" font="5">artery disease: roles of C-reactive protein and coronary artery calcium. Curr Cardiol Rep. </text>
<text top="974" left="219" width="92" height="21" font="5">2015;17:110. </text>
<text top="994" left="124" width="71" height="21" font="5">S4.4.2-46. </text>
<text top="994" left="219" width="610" height="21" font="5">Shah RV, Spahillari A, Mwasongwe S, et al. Subclinical atherosclerosis, statin eligibility, and </text>
<text top="1014" left="219" width="550" height="21" font="5">outcomes in African American individuals: the Jackson Heart study. JAMA Cardiol. </text>
<text top="1034" left="219" width="105" height="21" font="5">2017;2:644-52. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="104" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-104_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="453" width="55" height="19" font="1">Page 104</text>
<text top="1130" left="508" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="71" height="21" font="5">S4.4.2-47. </text>
<text top="108" left="219" width="591" height="21" font="5">Waheed S, Pollack S, Roth M, et al. Collective impact of conventional cardiovascular risk </text>
<text top="128" left="219" width="615" height="21" font="5">factors and coronary calcium score on clinical outcomes with or without statin therapy: the </text>
<text top="148" left="219" width="380" height="21" font="5">St Francis Heart Study. Atherosclerosis. 2016;255:193-9. </text>
<text top="168" left="124" width="71" height="21" font="5">S4.4.2-48. </text>
<text top="168" left="219" width="592" height="21" font="5">Yeboah J, Polonsky TS, Young R, et al. Utility of nontraditional risk markers in individuals </text>
<text top="188" left="219" width="619" height="21" font="5">ineligible for statin therapy according to the 2013 American College of Cardiology/American </text>
<text top="208" left="219" width="478" height="21" font="5">Heart Association cholesterol guidelines. Circulation. 2015;132:916-22. </text>
<text top="228" left="124" width="71" height="21" font="5">S4.4.2-49. </text>
<text top="228" left="219" width="532" height="21" font="5">Yeboah J, Young R, McClelland RL, et al. Utility of nontraditional risk markers in </text>
<text top="249" left="219" width="605" height="21" font="5">atherosclerotic cardiovascular disease risk assessment. J Am Coll Cardiol. 2016;67:139-47. </text>
<text top="269" left="124" width="71" height="21" font="5">S4.4.2-50. </text>
<text top="269" left="219" width="579" height="21" font="5">Budoff MJ, McClelland RL, Nasir K, et al. Cardiovascular events with absent or minimal </text>
<text top="289" left="219" width="568" height="21" font="5">coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J. </text>
<text top="309" left="219" width="122" height="21" font="5">2009;158:554-61. </text>
<text top="329" left="124" width="71" height="21" font="5">S4.4.2-51. </text>
<text top="329" left="219" width="574" height="21" font="5">Schulman-Marcus J, Valenti V, Hartaigh BO, et al. Prognostic utility of coronary artery </text>
<text top="349" left="219" width="610" height="21" font="5">calcium scoring in active smokers: a 15-year follow-up study. Int J Cardiol. 2014;177:581-3. </text>
<text top="370" left="124" width="71" height="21" font="5">S4.4.2-52. </text>
<text top="370" left="219" width="543" height="21" font="5">Valenti V, Hartaigh BO, Cho I, et al. Absence of coronary artery calcium identifies </text>
<text top="390" left="219" width="599" height="21" font="5">asymptomatic diabetic individuals at low near-term but not long-term risk of mortality: a </text>
<text top="410" left="219" width="564" height="21" font="5">15-year follow-up study of 9715 patients. Circ Cardiovasc Imaging. 2016;9:e003528. </text>
<text top="430" left="124" width="71" height="21" font="5">S4.4.2-53. </text>
<text top="430" left="219" width="584" height="21" font="5">Patel J, Al Rifai M, Blaha MJ, et al. Coronary artery calcium improves risk assessment in </text>
<text top="450" left="219" width="611" height="21" font="5">adults with a family history of premature coronary heart disease: results from Multi-Ethnic </text>
<text top="470" left="218" width="453" height="21" font="5">Study of Atherosclerosis. Circ Cardiovasc Imaging. 2015;8:e003186. </text>
<text top="490" left="124" width="71" height="21" font="5">S4.4.2-54. </text>
<text top="490" left="218" width="605" height="21" font="5">Sharp Collaborative Group null. Study of Heart and Renal Protection (SHARP): randomized </text>
<text top="510" left="218" width="579" height="21" font="5">trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 </text>
<text top="531" left="218" width="492" height="21" font="5">patients with chronic kidney disease. Am Heart J. 2010;160:785-794.e10. </text>
<text top="551" left="124" width="71" height="21" font="5">S4.4.2-55. </text>
<text top="551" left="218" width="560" height="21" font="5">The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in </text>
<text top="571" left="218" width="415" height="21" font="5">incidence of coronary heart disease. JAMA. 1984;251:351-64. </text>
<text top="591" left="124" width="71" height="21" font="5">S4.4.2-56. </text>
<text top="591" left="218" width="620" height="21" font="5">Spence JD, Huff MW, Heidenheim P, et al. Combination therapy with colestipol and psyllium </text>
<text top="611" left="218" width="510" height="21" font="5">mucilloid in patients with hyperlipidemia. Ann Intern Med. 1995;123:493-9. </text>
<text top="631" left="124" width="71" height="21" font="5">S4.4.2-57. </text>
<text top="631" left="218" width="592" height="21" font="5">Pandya A, Sy S, Cho S, et al. Cost-effectiveness of 10-year risk thresholds for initiation of </text>
<text top="651" left="218" width="598" height="21" font="5">statin therapy for primary prevention of cardiovascular disease. JAMA. 2015;314:142-50. </text>
<text top="671" left="124" width="71" height="21" font="5">S4.4.2-58. </text>
<text top="671" left="218" width="600" height="21" font="5">Singh A, Collins BL, Gupta A, et al. Cardiovascular risk and statin eligibility of young adults </text>
<text top="692" left="218" width="524" height="21" font="5">after an MI: Partners YOUNG-MI Registry. J Am Coll Cardiol. 2018;71:292-302. </text>
<text top="712" left="124" width="71" height="21" font="5">S4.4.2-59. </text>
<text top="712" left="218" width="587" height="21" font="5">Navar-Boggan AM, Peterson ED, D'Agostino RB Sr, et al. Using age- and sex-specific risk </text>
<text top="732" left="218" width="611" height="21" font="5">thresholds to guide statin therapy: one size may not fit all. J Am Coll Cardiol. 2015;65:1633-</text>
<text top="752" left="218" width="16" height="21" font="5">9. </text>
<text top="772" left="124" width="71" height="21" font="5">S4.4.2-60. </text>
<text top="772" left="218" width="606" height="21" font="5">The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of </text>
<text top="792" left="218" width="536" height="21" font="5">reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. </text>
<text top="812" left="218" width="122" height="21" font="5">1984;251:365-74. </text>
<text top="842" left="124" width="4" height="21" font="5"> </text>
<text top="874" left="124" width="508" height="27" font="16"><i><b>4.4.3. Monitoring in Response to LDL-C–Lowering Therapy </b></i></text>
<text top="903" left="124" width="62" height="21" font="5">S4.4.3-1. </text>
<text top="903" left="219" width="612" height="21" font="5">Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of </text>
<text top="924" left="219" width="588" height="21" font="5">blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the </text>
<text top="944" left="219" width="558" height="21" font="5">American College of Cardiology/American Heart Association Task Force on Practice </text>
<text top="964" left="219" width="272" height="21" font="5">Guidelines. Circulation. 2014;129:S1-45. </text>
<text top="984" left="124" width="62" height="21" font="5">S4.4.3-2. </text>
<text top="984" left="219" width="579" height="21" font="5">Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are </text>
<text top="1004" left="219" width="618" height="21" font="5">associated with improved adherence to statin therapy. Pharmacoeconomics. 2004;22(suppl </text>
<text top="1024" left="219" width="64" height="21" font="5">3):13-23. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="105" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-105_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="453" width="55" height="19" font="1">Page 105</text>
<text top="1130" left="508" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="62" height="21" font="5">S4.4.3-3. </text>
<text top="108" left="219" width="613" height="21" font="5">Chiavaroli L, Nishi SK, Khan TA, et al. Portfolio dietary pattern and cardiovascular disease: a </text>
<text top="128" left="219" width="600" height="21" font="5">systematic review and meta-analysis of controlled trials. Prog Cardiovasc Dis. 2018;61:43-</text>
<text top="148" left="219" width="25" height="21" font="5">53. </text>
<text top="177" left="124" width="4" height="21" font="5"> </text>
<text top="209" left="124" width="409" height="27" font="16"><i><b>4.4.4. Primary Prevention in Other Age Groups </b></i></text>
<text top="239" left="124" width="170" height="25" font="23"><i><b>4.4.4.1. Older Adults </b></i></text>
<text top="275" left="124" width="693" height="21" font="5">S4.4.4.1-1.  Glynn RJ, Koenig W, Nordestgaard BG, et al. Rosuvastatin for primary prevention in older </text>
<text top="295" left="219" width="568" height="21" font="5">persons with elevated C-reactive protein and low to average low-density lipoprotein </text>
<text top="315" left="219" width="524" height="21" font="5">cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med. </text>
<text top="336" left="219" width="167" height="21" font="5">2010;152:488-96, w174. </text>
<text top="356" left="124" width="699" height="21" font="5">S4.4.4.1-2.  Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men </text>
<text top="376" left="219" width="540" height="21" font="5">and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207. </text>
<text top="396" left="124" width="705" height="21" font="5">S4.4.4.1-3.  Ridker PM, Lonn E, Paynter NP, et al. Primary prevention with statin therapy in the elderly: </text>
<text top="416" left="219" width="561" height="21" font="5">new meta-analyses from the contemporary JUPITER and HOPE-3 randomized trials. </text>
<text top="436" left="219" width="211" height="21" font="5">Circulation. 2017;135:1979-81. </text>
<text top="456" left="124" width="662" height="21" font="5">S4.4.4.1-4.  Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons </text>
<text top="476" left="219" width="439" height="21" font="5">without cardiovascular disease. N Engl J Med. 2016;374:2021-31. </text>
<text top="497" left="124" width="690" height="21" font="5">S4.4.4.1-5.  Orkaby AR, Gaziano JM, Djousse L, et al. Statins for primary prevention of cardiovascular </text>
<text top="517" left="219" width="467" height="21" font="5">events and mortality in older men. J Am Geriatr Soc. 2017;65:2362-8. </text>
<text top="537" left="124" width="685" height="21" font="5">S4.4.4.1-6.  Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with </text>
<text top="557" left="219" width="586" height="21" font="5">statin therapy in people at low risk of vascular disease: meta-analysis of individual data </text>
<text top="577" left="219" width="356" height="21" font="5">from 27 randomised trials. Lancet. 2012;380:581-90. </text>
<text top="597" left="124" width="675" height="21" font="5">S4.4.4.1-7.  Savarese G, Gotto AM Jr, Paolillo S, et al. Benefits of statins in elderly subjects without </text>
<text top="617" left="219" width="584" height="21" font="5">established cardiovascular disease: a meta-analysis. J Am Coll Cardiol. 2013;62:2090-9. </text>
<text top="638" left="124" width="680" height="21" font="5">S4.4.4.1-8.  Teng M, Lin L, Zhao YJ, et al. Statins for primary prevention of cardiovascular disease in </text>
<text top="658" left="219" width="567" height="21" font="5">elderly patients: systematic review and meta-analysis. Drugs Aging. 2015;32:649-61. </text>
<text top="678" left="124" width="664" height="21" font="5">S4.4.4.1-9.  Kutner JS, Blatchford PJ, Taylor DH Jr, et al. Safety and benefit of discontinuing statin </text>
<text top="698" left="219" width="589" height="21" font="5">therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA </text>
<text top="718" left="219" width="214" height="21" font="5">Intern Med. 2015;175:691-700. </text>
<text top="738" left="124" width="701" height="21" font="5">S4.4.4.1-10.  Mahabadi AA, Mohlenkamp S, Lehmann N, et al. CAC score improves coronary and CV risk </text>
<text top="758" left="219" width="591" height="21" font="5">assessment above statin indication by ESC and AHA/ACC primary prevention guidelines. </text>
<text top="779" left="219" width="287" height="21" font="5">JACC Cardiovasc Imaging. 2017;10:143-53. </text>
<text top="799" left="124" width="658" height="21" font="5">S4.4.4.1-11.  Mortensen MB, Fuster V, Muntendam P, et al. A simple disease-guided approach to </text>
<text top="819" left="218" width="619" height="21" font="5">personalize ACC/AHA-recommended statin allocation in elderly people: the BioImage study. </text>
<text top="839" left="218" width="233" height="21" font="5">J Am Coll Cardiol. 2016;68:881-91. </text>
<text top="859" left="124" width="710" height="21" font="5">S4.4.4.1-12.  Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular </text>
<text top="879" left="218" width="518" height="21" font="5">disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-30. </text>
<text top="899" left="124" width="681" height="21" font="5">S4.4.4.1-13.  Mortensen MB, Falk E. Primary prevention with statins in the elderly. J Am Coll Cardiol. </text>
<text top="920" left="218" width="105" height="21" font="5">2018;71:85-94. </text>
<text top="940" left="124" width="660" height="21" font="5">S4.4.4.1-14.  Bell SP, Orr NM, Dodson JA, et al. What to expect from the evolving field of geriatric </text>
<text top="960" left="218" width="319" height="21" font="5">cardiology. J Am Coll Cardiol. 2015;66:1286-99. </text>
<text top="980" left="124" width="695" height="21" font="5">S4.4.4.1-15.  Fleg JL, Forman DE, Berra K, et al. Secondary prevention of atherosclerotic cardiovascular </text>
<text top="1000" left="218" width="561" height="21" font="5">disease in older adults: a scientific statement from the American Heart Association. </text>
<text top="1020" left="218" width="211" height="21" font="5">Circulation. 2013;128:2422-46. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="106" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-106_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="453" width="55" height="19" font="1">Page 106</text>
<text top="1130" left="508" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="673" height="21" font="5">S4.4.4.1-16.  Garfinkel D, Ilhan B, Bahat G. Routine deprescribing of chronic medications to combat </text>
<text top="128" left="219" width="337" height="21" font="5">polypharmacy. Ther Adv Drug Saf. 2015;6:212-33. </text>
<text top="148" left="124" width="707" height="21" font="5">S4.4.4.1-17.  Qi K, Reeve E, Hilmer SN, et al. Older peoples' attitudes regarding polypharmacy, statin use </text>
<text top="168" left="219" width="609" height="21" font="5">and willingness to have statins deprescribed in Australia. Int J Clin Pharm. 2015;37:949-57. </text>
<text top="188" left="124" width="673" height="21" font="5">S4.4.4.1-18.  Rossello X, Pocock SJ, Julian DG. Long-term use of cardiovascular drugs: challenges for </text>
<text top="208" left="219" width="444" height="21" font="5">research and for patient care. J Am Coll Cardiol. 2015;66:1273-85. </text>
<text top="228" left="124" width="688" height="21" font="5">S4.4.4.1-19.  Han BH, Sutin D, Williamson JD, et al. Effect of statin treatment vs usual care on primary </text>
<text top="249" left="219" width="592" height="21" font="5">cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial. </text>
<text top="269" left="219" width="248" height="21" font="5">JAMA Intern Med. 2017;177:955-65. </text>
<text top="289" left="124" width="676" height="21" font="5">S4.4.4.1-20.  Odden MC, Pletcher MJ, Coxson PG, et al. Cost-effectiveness and population impact of </text>
<text top="309" left="219" width="590" height="21" font="5">statins for primary prevention in adults aged 75 years or older in the United States. Ann </text>
<text top="329" left="219" width="206" height="21" font="5">Intern Med. 2015;162:533-41. </text>
<text top="358" left="124" width="4" height="21" font="5"> </text>
<text top="391" left="124" width="364" height="25" font="23"><i><b>4.4.4.2. Young Adults (20 to 39 Years of Age) </b></i></text>
<text top="427" left="124" width="713" height="21" font="5">S4.4.4.2-1.  Strong JP, Malcom GT, Oalmann MC, et al. The PDAY Study: natural history, risk factors, and </text>
<text top="447" left="219" width="607" height="21" font="5">pathobiology. Pathobiological Determinants of Atherosclerosis in Youth. Ann N Y Acad Sci. </text>
<text top="467" left="219" width="233" height="21" font="5">1997;811:226-35; discussion 35-7. </text>
<text top="487" left="124" width="712" height="21" font="5">S4.4.4.2-2.  McGill HC Jr, McMahan CA, Herderick EE, et al. Effects of coronary heart disease risk factors </text>
<text top="507" left="219" width="621" height="21" font="5">on atherosclerosis of selected regions of the aorta and right coronary artery. PDAY Research </text>
<text top="528" left="219" width="614" height="21" font="5">Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc </text>
<text top="548" left="219" width="147" height="21" font="5">Biol. 2000;20:836-45. </text>
<text top="568" left="124" width="663" height="21" font="5">S4.4.4.2-3.  Williams RR, Hopkins PN, Hunt SC, et al. Population-based frequency of dyslipidemia </text>
<text top="588" left="219" width="547" height="21" font="5">syndromes in coronary-prone families in Utah. Arch Intern Med. 1990;150:582-8. </text>
<text top="608" left="124" width="710" height="21" font="5">S4.4.4.2-4.  McGill HC Jr, McMahan CA, Malcom GT, et al. Effects of serum lipoproteins and smoking on </text>
<text top="628" left="219" width="578" height="21" font="5">atherosclerosis in young men and women. The PDAY Research Group. Pathobiological </text>
<text top="648" left="219" width="604" height="21" font="5">Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol. 1997;17:95-106. </text>
<text top="669" left="124" width="656" height="21" font="5">S4.4.4.2-5.  Vodnala D, Rubenfire M, Brook RD. Secondary causes of dyslipidemia. Am J Cardiol. </text>
<text top="689" left="219" width="114" height="21" font="5">2012;110:823-5. </text>
<text top="709" left="124" width="687" height="21" font="5">S4.4.4.2-6.  Lloyd-Jones DM, Wilson PW, Larson MG, et al. Lifetime risk of coronary heart disease by </text>
<text top="729" left="219" width="484" height="21" font="5">cholesterol levels at selected ages. Arch Intern Med. 2003;163:1966-72. </text>
<text top="749" left="124" width="687" height="21" font="5">S4.4.4.2-7.  Domanski M, Lloyd-Jones D, Fuster V, et al. Can we dramatically reduce the incidence of </text>
<text top="769" left="219" width="373" height="21" font="5">coronary heart disease? Nat Rev Cardiol. 2011;8:721-5. </text>
<text top="789" left="124" width="706" height="21" font="5">S4.4.4.2-8.  Durrington PN, Soran H. Cholesterol levels should play a more important role in identifying </text>
<text top="809" left="219" width="310" height="21" font="5">statin recipients. Circulation. 2017;135:627-9. </text>
<text top="830" left="124" width="634" height="21" font="5">S4.4.4.2-9.  Thanassoulis G, Pencina MJ, Sniderman AD. The benefit model for prevention of </text>
<text top="850" left="219" width="618" height="21" font="5">cardiovascular disease: an opportunity to harmonize guidelines. JAMA Cardiol. 2017;2:1175-</text>
<text top="870" left="219" width="16" height="21" font="5">6. </text>
<text top="890" left="124" width="650" height="21" font="5">S4.4.4.2-10.  Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med. </text>
<text top="910" left="219" width="114" height="21" font="5">2012;366:321-9. </text>
<text top="930" left="124" width="710" height="21" font="5">S4.4.4.2-11.  Lehr AL, Driver SL, Stone NJ. The ABCDs of lifestyle counseling. JAMA Cardiol. 2016;1:505-6. </text>
<text top="950" left="124" width="677" height="21" font="5">S4.4.4.2-12.  Omura JD, Watson KB, Loustalot F, et al. Primary care providers' awareness of physical </text>
<text top="971" left="218" width="554" height="21" font="5">activity-related intensive behavioral counseling services for cardiovascular disease </text>
<text top="991" left="218" width="395" height="21" font="5">prevention. Am J Health Promot. 2018:890117118784226. </text>
<text top="1011" left="124" width="703" height="21" font="5">S4.4.4.2-13.  Domanski MJ, Fuster V, Diaz-Mitoma F, et al. Next steps in primary prevention of coronary </text>
<text top="1031" left="219" width="621" height="21" font="5">heart disease: rationale for and design of the ECAD trial. J Am Coll Cardiol. 2015;66:1828-36. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="107" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-107_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="453" width="55" height="19" font="1">Page 107</text>
<text top="1130" left="508" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="713" height="21" font="5">S4.4.4.2-14.  Carr JJ, Jacobs DR Jr, Terry JG, et al. Association of coronary artery calcium in adults aged 32 </text>
<text top="128" left="219" width="597" height="21" font="5">to 46 years with incident coronary heart disease and death. JAMA Cardiol. 2017;2:391-9. </text>
<text top="157" left="124" width="4" height="21" font="5"> </text>
<text top="189" left="124" width="277" height="25" font="23"><i><b>4.4.4.3. Children and Adolescents  </b></i></text>
<text top="225" left="124" width="709" height="21" font="5">S4.4.4.3-1.  Iannuzzi A, Licenziati MR, Vacca M, et al. Comparison of two diets of varying glycemic index </text>
<text top="246" left="219" width="585" height="21" font="5">on carotid subclinical atherosclerosis in obese children. Heart Vessels. 2009;24:419-24. </text>
<text top="266" left="124" width="697" height="21" font="5">S4.4.4.3-2.  Murphy EC, Carson L, Neal W, et al. Effects of an exercise intervention using Dance Dance </text>
<text top="286" left="219" width="573" height="21" font="5">Revolution on endothelial function and other risk factors in overweight children. Int J </text>
<text top="306" left="219" width="200" height="21" font="5">Pediatr Obes. 2009;4:205-14. </text>
<text top="326" left="124" width="667" height="21" font="5">S4.4.4.3-3.  Pratt RE, Kavey RE, Quinzi D. Combined dyslipidemia in obese children: response to a </text>
<text top="346" left="219" width="371" height="21" font="5">focused lifestyle approach. J Clin Lipidol. 2014;8:181-6. </text>
<text top="366" left="124" width="705" height="21" font="5">S4.4.4.3-4.  de Ferranti SD, Milliren CE, Denhoff ER, et al. Providing food to treat adolescents at risk for </text>
<text top="387" left="219" width="435" height="21" font="5">cardiovascular disease. Obesity (Silver Spring). 2015;23:2109-17. </text>
<text top="407" left="124" width="695" height="21" font="5">S4.4.4.3-5.  Niinikoski H, Lagstrom H, Jokinen E, et al. Impact of repeated dietary counseling between </text>
<text top="427" left="219" width="609" height="21" font="5">infancy and 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP </text>
<text top="447" left="219" width="255" height="21" font="5">study. Circulation. 2007;116:1032-40. </text>
<text top="467" left="124" width="676" height="21" font="5">S4.4.4.3-6.  Obarzanek E, Kimm SY, Barton BA, et al. Long-term safety and efficacy of a cholesterol-</text>
<text top="487" left="219" width="582" height="21" font="5">lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year </text>
<text top="507" left="219" width="594" height="21" font="5">results of the Dietary Intervention Study in Children (DISC). Pediatrics. 2001;107:256-64. </text>
<text top="528" left="124" width="658" height="21" font="5">S4.4.4.3-7.  Dorgan JF, Liu L, Barton BA, et al. Adolescent diet and metabolic syndrome in young </text>
<text top="548" left="219" width="603" height="21" font="5">women: results of the Dietary Intervention Study in Children (DISC) follow-up study. J Clin </text>
<text top="568" left="219" width="275" height="21" font="5">Endocrinol Metab. 2011;96:E1999-2008. </text>
<text top="588" left="124" width="662" height="21" font="5">S4.4.4.3-8.  Wong H, Chahal N, Manlhiot C, et al. Flaxseed in pediatric hyperlipidemia: a placebo-</text>
<text top="608" left="219" width="568" height="21" font="5">controlled, blinded, randomized clinical trial of dietary flaxseed supplementation for </text>
<text top="628" left="219" width="579" height="21" font="5">children and adolescents with hypercholesterolemia. JAMA Pediatr. 2013;167:708-13. </text>
<text top="648" left="124" width="675" height="21" font="5">S4.4.4.3-9.  Zachariah JP, Chan J, Mendelson MM, et al. Adolescent dyslipidemia and standardized </text>
<text top="668" left="219" width="617" height="21" font="5">lifestyle modification: benchmarking real-world practice. J Am Coll Cardiol. 2016;68:2122-3. </text>
<text top="689" left="124" width="685" height="21" font="5">S4.4.4.3-10.  Torvik K, Narverud I, Ottestad I, et al. Dietary counseling is associated with an improved </text>
<text top="709" left="219" width="612" height="21" font="5">lipid profile in children with familial hypercholesterolemia. Atherosclerosis. 2016;252:21-7. </text>
<text top="729" left="124" width="650" height="21" font="5">S4.4.4.3-11.  Koletzko B, Kupke I, Wendel U. Treatment of hypercholesterolemia in children and </text>
<text top="749" left="219" width="291" height="21" font="5">adolescents. Acta Paediatr. 1992;81:682-5. </text>
<text top="769" left="124" width="661" height="21" font="5">S4.4.4.3-12.  Tershakovec AM, Shannon BM, Achterberg CL, et al. One-year follow-up of nutrition </text>
<text top="789" left="219" width="552" height="21" font="5">education for hypercholesterolemic children. Am J Public Health. 1998;88:258-61. </text>
<text top="809" left="124" width="673" height="21" font="5">S4.4.4.3-13.  Kusters DM, Caceres M, Coll M, et al. Efficacy and safety of ezetimibe monotherapy in </text>
<text top="830" left="219" width="556" height="21" font="5">children with heterozygous familial or nonfamilial hypercholesterolemia. J Pediatr. </text>
<text top="850" left="219" width="164" height="21" font="5">2015;166:1377-84 e1-3. </text>
<text top="870" left="124" width="665" height="21" font="5">S4.4.4.3-14.  Yeste D, Chacon P, Clemente M, et al. Ezetimibe as monotherapy in the treatment of </text>
<text top="890" left="218" width="530" height="21" font="5">hypercholesterolemia in children and adolescents. J Pediatr Endocrinol Metab. </text>
<text top="910" left="218" width="114" height="21" font="5">2009;22:487-92. </text>
<text top="930" left="124" width="636" height="21" font="5">S4.4.4.3-15.  Clauss S, Wai KM, Kavey RE, et al. Ezetimibe treatment of pediatric patients with </text>
<text top="950" left="218" width="342" height="21" font="5">hypercholesterolemia. J Pediatr. 2009;154:869-72. </text>
<text top="971" left="124" width="716" height="21" font="5">S4.4.4.3-16.  Sonnett T, Robinson J, Milani P, et al. Role of colesevelam in managing heterozygous familial </text>
<text top="991" left="218" width="616" height="21" font="5">hypercholesterolemia in adolescents and children. Adolesc Health Med Ther. 2010;1:53-60. </text>
<text top="1011" left="124" width="596" height="21" font="5">S4.4.4.3-17.  Wald DS, Kasturiratne A, Godoy A, et al. Child-parent screening for familial </text>
<text top="1031" left="218" width="333" height="21" font="5">hypercholesterolemia. J Pediatr. 2011;159:865-7. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="108" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-108_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="453" width="55" height="19" font="1">Page 108</text>
<text top="1130" left="508" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="709" height="21" font="5">S4.4.4.3-18.  Wald DS, Bestwick JP, Morris JK, et al. Child-parent familial hypercholesterolemia screening </text>
<text top="128" left="219" width="334" height="21" font="5">in primary care. N Engl J Med. 2016;375:1628-37. </text>
<text top="148" left="124" width="690" height="21" font="5">S4.4.4.3-19.  Ritchie SK, Murphy EC, Ice C, et al. Universal versus targeted blood cholesterol screening </text>
<text top="168" left="219" width="430" height="21" font="5">among youth: the CARDIAC project. Pediatrics. 2010;126:260-5. </text>
<text top="188" left="124" width="642" height="21" font="5">S4.4.4.3-20.  Skovby F, Micic S, Jepsen B, et al. Screening for familial hypercholesterolaemia by </text>
<text top="208" left="219" width="553" height="21" font="5">measurement of apolipoproteins in capillary blood. Arch Dis Child. 1991;66:844-7. </text>
<text top="228" left="124" width="630" height="21" font="5">S4.4.4.3-21.  Garcia RE, Moodie DS. Routine cholesterol surveillance in childhood. Pediatrics. </text>
<text top="249" left="219" width="105" height="21" font="5">1989;84:751-5. </text>
<text top="269" left="124" width="705" height="21" font="5">S4.4.4.3-22.  Ned RM, Sijbrands EJ. Cascade screening for familial hypercholesterolemia (FH). PLoS Curr. </text>
<text top="289" left="219" width="121" height="21" font="5">2011;3:RRN1238. </text>
<text top="309" left="124" width="716" height="21" font="5">S4.4.4.3-23.  Bender R, Bell DA, Hooper AJ, et al. Screening for familial hypercholesterolaemia. Pathology. </text>
<text top="329" left="219" width="105" height="21" font="5">2012;44:122-8. </text>
<text top="349" left="124" width="562" height="21" font="5">S4.4.4.3-24.  National Institute for Health and Care Excellence (NICE) (UK). Familial </text>
<text top="370" left="219" width="468" height="21" font="5">hypercholesterolaemia: identification and management. Available at: </text>
<text top="390" left="219" width="458" height="21" font="5">http://www.nice.org.uk/guidance/CG71. Accessed August 24, 2018. </text>
<text top="410" left="124" width="674" height="21" font="5">S4.4.4.3-25.  Kit BK, Kuklina E, Carroll MD, et al. Prevalence of and trends in dyslipidemia and blood </text>
<text top="430" left="219" width="600" height="21" font="5">pressure among US children and adolescents, 1999-2012. JAMA Pediatr. 2015;169:272-9. </text>
<text top="450" left="124" width="697" height="21" font="5">S4.4.4.3-26.  May AL, Kuklina EV, Yoon PW. Prevalence of cardiovascular disease risk factors among US </text>
<text top="470" left="219" width="371" height="21" font="5">adolescents, 1999-2008. Pediatrics. 2012;129:1035-41. </text>
<text top="490" left="124" width="695" height="21" font="5">S4.4.4.3-27.  Lozano P, Henrikson NB, Morrison CC, et al. Lipid screening in childhood and adolescence </text>
<text top="510" left="219" width="608" height="21" font="5">for detection of multifactorial dyslipidemia: evidence report and systematic review for the </text>
<text top="531" left="219" width="403" height="21" font="5">US Preventive Services Task Force. JAMA. 2016;316:634-44. </text>
<text top="551" left="124" width="586" height="21" font="5">S4.4.4.3-28.  Gidding SS, Champagne MA, de Ferranti SD, et al. The agenda for familial </text>
<text top="571" left="219" width="558" height="21" font="5">hypercholesterolemia: a scientific statement from the American Heart Association. </text>
<text top="591" left="219" width="211" height="21" font="5">Circulation. 2015;132:2167-92. </text>
<text top="611" left="124" width="681" height="21" font="5">S4.4.4.3-29.  Lozano P, Henrikson NB, Dunn J, et al. Lipid screening in childhood and adolescence for </text>
<text top="631" left="218" width="606" height="21" font="5">detection of familial hypercholesterolemia: evidence report and systematic review for the </text>
<text top="651" left="218" width="403" height="21" font="5">US Preventive Services Task Force. JAMA. 2016;316:645-55. </text>
<text top="671" left="124" width="581" height="21" font="5">S4.4.4.3-30.  Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial </text>
<text top="692" left="218" width="479" height="21" font="5">hypercholesterolemia. Cochrane Database Syst Rev. 2017;7:CD006401. </text>
<text top="712" left="124" width="651" height="21" font="5">S4.4.4.3-31.  Schanberg LE, Sandborg C, Barnhart HX, et al. Use of atorvastatin in systemic lupus </text>
<text top="732" left="218" width="523" height="21" font="5">erythematosus in children and adolescents. Arthritis Rheum. 2012;64:285-96. </text>
<text top="752" left="124" width="684" height="21" font="5">S4.4.4.3-32.  Ardoin SP, Schanberg LE, Sandborg CI, et al. Secondary analysis of APPLE study suggests </text>
<text top="772" left="218" width="611" height="21" font="5">atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher </text>
<text top="792" left="218" width="352" height="21" font="5">C reactive protein. Ann Rheum Dis. 2014;73:557-66. </text>
<text top="812" left="124" width="684" height="21" font="5">S4.4.4.3-33.  Perak AM, Ning H, de Ferranti SD, et al. Long-term risk of atherosclerotic cardiovascular </text>
<text top="833" left="218" width="560" height="21" font="5">disease in US adults with the familial hypercholesterolemia phenotype. Circulation. </text>
<text top="853" left="218" width="105" height="21" font="5">2016;134:9-19. </text>
<text top="873" left="124" width="701" height="21" font="5">S4.4.4.3-34.  Neil HA, Hawkins MM, Durrington PN, et al. Non-coronary heart disease mortality and risk </text>
<text top="893" left="218" width="583" height="21" font="5">of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a </text>
<text top="913" left="218" width="406" height="21" font="5">prospective registry study. Atherosclerosis. 2005;179:293-7. </text>
<text top="933" left="124" width="686" height="21" font="5">S4.4.4.3-35.  Sniderman AD, Tsimikas S, Fazio S. The severe hypercholesterolemia phenotype: clinical </text>
<text top="953" left="218" width="576" height="21" font="5">diagnosis, management, and emerging therapies. J Am Coll Cardiol. 2014;63:1935-47. </text>
<text top="974" left="124" width="676" height="21" font="5">S4.4.4.3-36.  Smith AJ, Turner EL, Kinra S. Universal cholesterol screening in childhood: a systematic </text>
<text top="994" left="218" width="260" height="21" font="5">review. Acad Pediatr. 2016;16:716-25. </text>
<text top="1014" left="124" width="690" height="21" font="5">S4.4.4.3-37.  Kerr M, Pears R, Miedzybrodzka Z, et al. Cost effectiveness of cascade testing for familial </text>
<text top="1034" left="218" width="608" height="21" font="5">hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the </text>
<text top="1054" left="218" width="222" height="21" font="5">UK. Eur Heart J. 2017;38:1832-9. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="109" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-109_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="453" width="55" height="19" font="1">Page 109</text>
<text top="1130" left="508" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="635" height="21" font="5">S4.4.4.3-38.  Berenson GS. Childhood risk factors predict adult risk associated with subclinical </text>
<text top="128" left="219" width="531" height="21" font="5">cardiovascular disease. The Bogalusa Heart Study. Am J Cardiol. 2002;90:3L-7L. </text>
<text top="148" left="124" width="652" height="21" font="5">S4.4.4.3-39.  Juonala M, Magnussen CG, Venn A, et al. Influence of age on associations between </text>
<text top="168" left="219" width="609" height="21" font="5">childhood risk factors and carotid intima-media thickness in adulthood: the Cardiovascular </text>
<text top="188" left="219" width="612" height="21" font="5">Risk in Young Finns Study, the Childhood Determinants of Adult Health Study, the Bogalusa </text>
<text top="208" left="219" width="573" height="21" font="5">Heart Study, and the Muscatine Study for the International Childhood Cardiovascular </text>
<text top="228" left="219" width="382" height="21" font="5">Cohort (i3C) Consortium. Circulation. 2010;122:2514-20. </text>
<text top="249" left="124" width="705" height="21" font="5">S4.4.4.3-40.  Juhola J, Magnussen CG, Viikari JS, et al. Tracking of serum lipid levels, blood pressure, and </text>
<text top="269" left="219" width="577" height="21" font="5">body mass index from childhood to adulthood: the Cardiovascular Risk in Young Finns </text>
<text top="289" left="219" width="233" height="21" font="5">Study. J Pediatr. 2011;159:584-90. </text>
<text top="309" left="124" width="673" height="21" font="5">S4.4.4.3-41.  Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in </text>
<text top="329" left="219" width="569" height="21" font="5">Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on </text>
<text top="349" left="219" width="544" height="21" font="5">integrated guidelines for cardiovascular health and risk reduction in children and </text>
<text top="370" left="219" width="466" height="21" font="5">adolescents: summary report. Pediatrics. 2011;128(suppl 5):S213-56. </text>
<text top="390" left="124" width="706" height="21" font="5">S4.4.4.3-42.  Gidding SS, Daniels SR, Kavey RE, et al. Developing the 2011 integrated pediatric guidelines </text>
<text top="410" left="219" width="427" height="21" font="5">for cardiovascular risk reduction. Pediatrics. 2012;129:e1311-9. </text>
<text top="439" left="124" width="4" height="21" font="5"> </text>
<text top="471" left="124" width="283" height="29" font="2"><b>4.5. Other Populations at Risk </b></text>
<text top="503" left="124" width="134" height="27" font="16"><i><b>4.5.1. Ethnicity </b></i></text>
<text top="532" left="124" width="62" height="21" font="5">S4.5.1-1. </text>
<text top="532" left="219" width="621" height="21" font="5">Carnethon MR, Pu J, Howard G, et al. Cardiovascular health in African Americans: a scientific </text>
<text top="552" left="219" width="548" height="21" font="5">statement from the American Heart Association. Circulation. 2017;136:e393-423. </text>
<text top="572" left="124" width="62" height="21" font="5">S4.5.1-2. </text>
<text top="572" left="219" width="603" height="21" font="5">Gujral UP, Vittinghoff E, Mongraw-Chaffin M, et al. Cardiometabolic abnormalities among </text>
<text top="593" left="219" width="617" height="21" font="5">normal-weight persons from five racial/ethnic groups in the United States: a cross-sectional </text>
<text top="613" left="219" width="443" height="21" font="5">analysis of two cohort studies. Ann Intern Med. 2017;166:628-36. </text>
<text top="633" left="124" width="62" height="21" font="5">S4.5.1-3. </text>
<text top="633" left="219" width="613" height="21" font="5">Rao G, Powell-Wiley TM, Ancheta I, et al. Identification of obesity and cardiovascular risk in </text>
<text top="653" left="219" width="608" height="21" font="5">ethnically and racially diverse populations: a scientific statement from the American Heart </text>
<text top="673" left="219" width="287" height="21" font="5">Association. Circulation. 2015;132:457-72. </text>
<text top="693" left="124" width="62" height="21" font="5">S4.5.1-4. </text>
<text top="693" left="219" width="569" height="21" font="5">Hata J, Kiyohara Y. Epidemiology of stroke and coronary artery disease in Asia. Circ J. </text>
<text top="713" left="219" width="122" height="21" font="5">2013;77:1923-32. </text>
<text top="734" left="124" width="62" height="21" font="5">S4.5.1-5. </text>
<text top="734" left="219" width="608" height="21" font="5">Group H-TC. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients </text>
<text top="754" left="219" width="613" height="21" font="5">of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons </text>
<text top="774" left="219" width="405" height="21" font="5">for stopping study treatment. Eur Heart J. 2013;34:1279-91. </text>
<text top="794" left="124" width="62" height="21" font="5">S4.5.1-6. </text>
<text top="794" left="219" width="602" height="21" font="5">Feinstein MJ, Nance RM, Drozd DR, et al. Assessing and refining myocardial infarction risk </text>
<text top="814" left="219" width="613" height="21" font="5">estimation among patients with human immunodeficiency virus: a study by the Centers for </text>
<text top="834" left="218" width="570" height="21" font="5">AIDS Research Network of Integrated Clinical Systems. JAMA Cardiol. 2017;2:155-62. </text>
<text top="854" left="124" width="62" height="21" font="5">S4.5.1-7. </text>
<text top="854" left="218" width="523" height="21" font="5">Daviglus ML, Pirzada A, Talavera GA. Cardiovascular disease risk factors in the </text>
<text top="874" left="218" width="598" height="21" font="5">Hispanic/Latino population: lessons from the Hispanic Community Health Study/Study of </text>
<text top="895" left="218" width="383" height="21" font="5">Latinos (HCHS/SOL). Prog Cardiovasc Dis. 2014;57:230-6. </text>
<text top="915" left="124" width="62" height="21" font="5">S4.5.1-8. </text>
<text top="915" left="219" width="609" height="21" font="5">Daviglus ML, Pirzada A, Durazo-Arvizu R, et al. Prevalence of low cardiovascular risk profile </text>
<text top="935" left="219" width="555" height="21" font="5">among diverse Hispanic/Latino adults in the United States by age, sex, and level of </text>
<text top="955" left="219" width="601" height="21" font="5">tacculturation: the Hispanic Community Health Study/Study of Latinos. J Am Heart Assoc. </text>
<text top="975" left="219" width="117" height="21" font="5">2016;5:e003929. </text>
<text top="995" left="124" width="62" height="21" font="5">S4.5.1-9. </text>
<text top="995" left="219" width="544" height="21" font="5">Gonzalez HM, Tarraf W, Rodriguez CJ, et al. Cardiovascular health among diverse </text>
<text top="1016" left="219" width="606" height="21" font="5">Hispanics/Latinos: Hispanic Community Health Study/Study of Latinos (HCHS/SOL) results. </text>
<text top="1036" left="219" width="203" height="21" font="5">Am Heart J. 2016;176:134-44. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="110" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-110_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="453" width="55" height="19" font="1">Page 110</text>
<text top="1130" left="508" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="71" height="21" font="5">S4.5.1-10. </text>
<text top="108" left="219" width="583" height="21" font="5">Qureshi WT, Kaplan RC, Swett K, et al. American College of Cardiology/American Heart </text>
<text top="128" left="219" width="559" height="21" font="5">Association (ACC/AHA) Class I guidelines for the treatment of cholesterol to reduce </text>
<text top="148" left="219" width="609" height="21" font="5">atherosclerotic cardiovascular risk: implications for US Hispanics/Latinos based on findings </text>
<text top="168" left="219" width="617" height="21" font="5">from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). J Am Heart Assoc. </text>
<text top="188" left="219" width="117" height="21" font="5">2017;6:e005045. </text>
<text top="208" left="124" width="71" height="21" font="5">S4.5.1-11. </text>
<text top="208" left="219" width="618" height="21" font="5">Schneiderman N, Chirinos DA, Aviles-Santa ML, et al. Challenges in preventing heart disease </text>
<text top="228" left="219" width="586" height="21" font="5">in hispanics: early lessons learned from the Hispanic Community Health Study/Study of </text>
<text top="249" left="219" width="391" height="21" font="5">Latinos (HCHS/SOL). Prog Cardiovasc Dis. 2014;57:253-61. </text>
<text top="269" left="124" width="71" height="21" font="5">S4.5.1-12. </text>
<text top="269" left="219" width="601" height="21" font="5">Hutchinson RN, Shin S. Systematic review of health disparities for cardiovascular diseases </text>
<text top="289" left="219" width="599" height="21" font="5">and associated factors among American Indian and Alaska Native populations. PLoS One. </text>
<text top="309" left="219" width="109" height="21" font="5">2014;9:e80973. </text>
<text top="329" left="124" width="71" height="21" font="5">S4.5.1-13. </text>
<text top="329" left="219" width="603" height="21" font="5">Volgman AS, Palaniappan LS, Aggarwal NT, et al. Atherosclerotic cardiovascular disease in </text>
<text top="349" left="219" width="597" height="21" font="5">South Asians in the United States: epidemiology, risk factors, and treatments: a scientific </text>
<text top="370" left="219" width="523" height="21" font="5">statement from the American Heart Association. Circulation. 2018;138:e1-34. </text>
<text top="390" left="124" width="71" height="21" font="5">S4.5.1-14. </text>
<text top="390" left="219" width="584" height="21" font="5">Conomos MP, Laurie CA, Stilp AM, et al. Genetic diversity and association studies in US </text>
<text top="410" left="219" width="616" height="21" font="5">Hispanic/Latino populations: applications in the Hispanic Community Health Study/Study of </text>
<text top="430" left="219" width="290" height="21" font="5">Latinos. Am J Hum Genet. 2016;98:165-84. </text>
<text top="450" left="124" width="71" height="21" font="5">S4.5.1-15. </text>
<text top="450" left="219" width="556" height="21" font="5">Frank AT, Zhao B, Jose PO, et al. Racial/ethnic differences in dyslipidemia patterns. </text>
<text top="470" left="219" width="194" height="21" font="5">Circulation. 2014;129:570-9. </text>
<text top="490" left="124" width="71" height="21" font="5">S4.5.1-16. </text>
<text top="490" left="219" width="584" height="21" font="5">Pu J, Romanelli R, Zhao B, et al. Dyslipidemia in special ethnic populations. Cardiol Clin. </text>
<text top="510" left="219" width="114" height="21" font="5">2015;33:325-33. </text>
<text top="531" left="124" width="71" height="21" font="5">S4.5.1-17. </text>
<text top="531" left="219" width="563" height="21" font="5">Basu S, Hong A, Siddiqi A. Using decomposition analysis to identify modifiable racial </text>
<text top="551" left="219" width="569" height="21" font="5">disparities in the distribution of blood pressure in the United States. Am J Epidemiol. </text>
<text top="571" left="219" width="122" height="21" font="5">2015;182:345-53. </text>
<text top="591" left="124" width="71" height="21" font="5">S4.5.1-18. </text>
<text top="591" left="219" width="557" height="21" font="5">Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a </text>
<text top="611" left="219" width="497" height="21" font="5">harmonious definition among adults in the US. J Diabetes. 2010;2:180-93. </text>
<text top="631" left="124" width="71" height="21" font="5">S4.5.1-19. </text>
<text top="631" left="219" width="597" height="21" font="5">Gujral UP, Pradeepa R, Weber MB, et al. Type 2 diabetes in South Asians: similarities and </text>
<text top="651" left="219" width="599" height="21" font="5">differences with white Caucasian and other populations. Ann N Y Acad Sci. 2013;1281:51-</text>
<text top="672" left="219" width="25" height="21" font="5">63. </text>
<text top="692" left="124" width="71" height="21" font="5">S4.5.1-20. </text>
<text top="692" left="219" width="620" height="21" font="5">Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and differences with populations </text>
<text top="712" left="219" width="463" height="21" font="5">in Europe and the United States. Ann N Y Acad Sci. 2013;1281:64-91. </text>
<text top="732" left="124" width="71" height="21" font="5">S4.5.1-21. </text>
<text top="732" left="218" width="615" height="21" font="5">Menke A, Casagrande S, Geiss L, et al. Prevalence of and trends in diabetes among adults in </text>
<text top="752" left="218" width="373" height="21" font="5">the United States, 1988-2012. JAMA. 2015;314:1021-9. </text>
<text top="772" left="124" width="71" height="21" font="5">S4.5.1-22. </text>
<text top="772" left="218" width="621" height="21" font="5">DeFilippis AP, Young R, McEvoy JW, et al. Risk score overestimation: the impact of individual </text>
<text top="792" left="218" width="599" height="21" font="5">cardiovascular risk factors and preventive therapies on the performance of the American </text>
<text top="812" left="218" width="601" height="21" font="5">Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease </text>
<text top="833" left="218" width="492" height="21" font="5">risk score in a modern multi-ethnic cohort. Eur Heart J. 2017;38:598-608. </text>
<text top="853" left="124" width="71" height="21" font="5">S4.5.1-23. </text>
<text top="853" left="218" width="616" height="21" font="5">Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of </text>
<text top="873" left="218" width="559" height="21" font="5">cardiovascular risk: a report of the American College of Cardiology/American Heart </text>
<text top="893" left="218" width="514" height="21" font="5">Association Task Force on Practice Guidelines. Circulation. 2014;129:S49-73. </text>
<text top="913" left="124" width="71" height="21" font="5">S4.5.1-24. </text>
<text top="913" left="218" width="527" height="21" font="5">Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic </text>
<text top="933" left="218" width="533" height="21" font="5">cardiovascular disease Pooled Cohort risk equations. JAMA. 2014;311:1406-15. </text>
<text top="953" left="124" width="71" height="21" font="5">S4.5.1-25. </text>
<text top="953" left="218" width="612" height="21" font="5">Rana JS, Tabada GH, Solomon MD, et al. Accuracy of the atherosclerotic cardiovascular risk </text>
<text top="974" left="218" width="611" height="21" font="5">equation in a large contemporary, multiethnic population. J Am Coll Cardiol. 2016;67:2118-</text>
<text top="994" left="218" width="25" height="21" font="5">30. </text>
<text top="1014" left="124" width="71" height="21" font="5">S4.5.1-26. </text>
<text top="1014" left="218" width="551" height="21" font="5">Kandula NR, Kanaya AM, Liu K, et al. Association of 10-year and lifetime predicted </text>
<text top="1034" left="218" width="622" height="21" font="5">cardiovascular disease risk with subclinical atherosclerosis in South Asians: findings from the </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="111" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-111_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="453" width="55" height="19" font="1">Page 111</text>
<text top="1130" left="508" width="4" height="21" font="5"> </text>
<text top="108" left="219" width="613" height="21" font="5">Mediators of Atherosclerosis in South Asians Living in America (MASALA) study. J Am Heart </text>
<text top="128" left="219" width="163" height="21" font="5">Assoc. 2014;3:e001117. </text>
<text top="148" left="124" width="71" height="21" font="5">S4.5.1-27. </text>
<text top="148" left="219" width="609" height="21" font="5">Alluri K, McEvoy JW, Dardari ZA, et al. Distribution and burden of newly detected coronary </text>
<text top="168" left="219" width="614" height="21" font="5">artery calcium: results from the Multi-Ethnic Study of Atherosclerosis. J Cardiovasc Comput </text>
<text top="188" left="219" width="186" height="21" font="5">Tomogr. 2015;9:337-44.e1. </text>
<text top="208" left="124" width="71" height="21" font="5">S4.5.1-28. </text>
<text top="208" left="219" width="620" height="21" font="5">Cho YK, Jung CH, Kang YM, et al. 2013 ACC/AHA cholesterol guideline versus 2004 NCEP ATP </text>
<text top="228" left="219" width="567" height="21" font="5">III guideline in the prediction of coronary artery calcification progression in a Korean </text>
<text top="249" left="219" width="321" height="21" font="5">Population. J Am Heart Assoc. 2016;5:e003410. </text>
<text top="269" left="124" width="71" height="21" font="5">S4.5.1-29. </text>
<text top="269" left="219" width="576" height="21" font="5">Manolio TA, Arnold AM, Post W, et al. Ethnic differences in the relationship of carotid </text>
<text top="289" left="219" width="557" height="21" font="5">atherosclerosis to coronary calcification: the Multi-Ethnic Study of Atherosclerosis. </text>
<text top="309" left="219" width="225" height="21" font="5">Atherosclerosis. 2008;197:132-8. </text>
<text top="329" left="124" width="71" height="21" font="5">S4.5.1-30. </text>
<text top="329" left="219" width="614" height="21" font="5">Osawa K, Nakanishi R, Budoff M. Coronary artery calcification. Glob Heart. 2016;11:287-93. </text>
<text top="349" left="124" width="71" height="21" font="5">S4.5.1-31. </text>
<text top="349" left="219" width="594" height="21" font="5">Kanaya AM, Kandula NR, Ewing SK, et al. Comparing coronary artery calcium among U.S. </text>
<text top="370" left="219" width="512" height="21" font="5">South Asians with four racial/ethnic groups: the MASALA and MESA studies. </text>
<text top="390" left="219" width="225" height="21" font="5">Atherosclerosis. 2014;234:102-7. </text>
<text top="410" left="124" width="71" height="21" font="5">S4.5.1-32. </text>
<text top="410" left="219" width="602" height="21" font="5">Greenland P, Blaha MJ, Budoff MJ, et al. Coronary calcium score and cardiovascular risk. J </text>
<text top="430" left="219" width="224" height="21" font="5">Am Coll Cardiol. 2018;72:434-47. </text>
<text top="450" left="124" width="71" height="21" font="5">S4.5.1-33. </text>
<text top="450" left="219" width="615" height="21" font="5">Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with </text>
<text top="470" left="219" width="576" height="21" font="5">pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. </text>
<text top="490" left="219" width="130" height="21" font="5">2006;368:1155-63. </text>
<text top="510" left="124" width="71" height="21" font="5">S4.5.1-34. </text>
<text top="510" left="219" width="613" height="21" font="5">Kimura T, Inoue T, Taguchi I, et al. Does high-intensity pitavastatin therapy further improve </text>
<text top="531" left="219" width="577" height="21" font="5">clinical outcomes? The REAL-CAD study in 13,054 patients with stable coronary artery </text>
<text top="551" left="219" width="247" height="21" font="5">disease. Circulation. 2017;136:e450. </text>
<text top="571" left="124" width="71" height="21" font="5">S4.5.1-35. </text>
<text top="571" left="219" width="509" height="21" font="5">Birmingham BK, Bujac SR, Elsby R, et al. Rosuvastatin pharmacokinetics and </text>
<text top="591" left="219" width="603" height="21" font="5">pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur J Clin </text>
<text top="611" left="219" width="193" height="21" font="5">Pharmacol. 2015;71:329-40. </text>
<text top="631" left="124" width="71" height="21" font="5">S4.5.1-36. </text>
<text top="631" left="219" width="619" height="21" font="5">Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in </text>
<text top="651" left="219" width="545" height="21" font="5">white and Asian subjects residing in the same environment. Clin Pharmacol Ther. </text>
<text top="672" left="219" width="114" height="21" font="5">2005;78:330-41. </text>
<text top="692" left="124" width="71" height="21" font="5">S4.5.1-37. </text>
<text top="692" left="219" width="511" height="21" font="5">Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol. 2007;99:410-4. </text>
<text top="712" left="124" width="71" height="21" font="5">S4.5.1-38. </text>
<text top="712" left="219" width="600" height="21" font="5">Lloret R, Ycas J, Stein M, et al. Comparison of rosuvastatin versus atorvastatin in Hispanic-</text>
<text top="732" left="219" width="614" height="21" font="5">Americans with hypercholesterolemia (from the STARSHIP trial). Am J Cardiol. 2006;98:768-</text>
<text top="752" left="219" width="25" height="21" font="5">73. </text>
<text top="772" left="124" width="71" height="21" font="5">S4.5.1-39. </text>
<text top="772" left="219" width="550" height="21" font="5">George MD, McGill NK, Baker JF. Creatine kinase in the U.S. population: Impact of </text>
<text top="792" left="219" width="567" height="21" font="5">demographics, comorbidities, and body composition on the normal range. Medicine </text>
<text top="812" left="219" width="192" height="21" font="5">(Baltimore). 2016;95:e4344. </text>
<text top="842" left="124" width="4" height="21" font="5"> </text>
<text top="874" left="124" width="247" height="27" font="16"><i><b>4.5.2. Hypertriglyceridemia  </b></i></text>
<text top="903" left="124" width="62" height="21" font="5">S4.5.2-1. </text>
<text top="903" left="219" width="612" height="21" font="5">Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of </text>
<text top="924" left="219" width="588" height="21" font="5">blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the </text>
<text top="944" left="219" width="558" height="21" font="5">American College of Cardiology/American Heart Association Task Force on Practice </text>
<text top="964" left="219" width="272" height="21" font="5">Guidelines. Circulation. 2014;129:S1-45. </text>
<text top="984" left="124" width="62" height="21" font="5">S4.5.2-2. </text>
<text top="984" left="219" width="609" height="21" font="5">Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease </text>
<text top="1004" left="219" width="593" height="21" font="5">independent of high-density lipoprotein cholesterol level: a meta-analysis of population-</text>
<text top="1024" left="219" width="398" height="21" font="5">based prospective studies. J Cardiovasc Risk. 1996;3:213-9. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="112" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-112_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="453" width="55" height="19" font="1">Page 112</text>
<text top="1130" left="508" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="62" height="21" font="5">S4.5.2-3. </text>
<text top="108" left="219" width="610" height="21" font="5">Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial </text>
<text top="128" left="219" width="618" height="21" font="5">infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299-308. </text>
<text top="148" left="124" width="62" height="21" font="5">S4.5.2-4. </text>
<text top="148" left="219" width="617" height="21" font="5">Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, et al. Nonfasting triglycerides and risk of ischemic </text>
<text top="168" left="219" width="400" height="21" font="5">stroke in the general population. JAMA. 2008;300:2142-52. </text>
<text top="188" left="124" width="62" height="21" font="5">S4.5.2-5. </text>
<text top="188" left="219" width="612" height="21" font="5">Karlson BW, Palmer MK, Nicholls SJ, et al. A VOYAGER meta-analysis of the impact of statin </text>
<text top="208" left="219" width="574" height="21" font="5">therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with </text>
<text top="228" left="219" width="360" height="21" font="5">hypertriglyceridemia. Am J Cardiol. 2016;117:1444-8. </text>
<text top="249" left="124" width="62" height="21" font="5">S4.5.2-6. </text>
<text top="249" left="219" width="596" height="21" font="5">Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, et al. The effects of lowering </text>
<text top="269" left="219" width="606" height="21" font="5">LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis </text>
<text top="289" left="219" width="476" height="21" font="5">of individual data from 27 randomised trials. Lancet. 2012;380:581-90. </text>
<text top="309" left="124" width="62" height="21" font="5">S4.5.2-7. </text>
<text top="309" left="219" width="617" height="21" font="5">Christian JB, Arondekar B, Buysman EK, et al. Clinical and economic benefits observed when </text>
<text top="329" left="219" width="510" height="21" font="5">follow-up triglyceride levels are less than 500 mg/dL in patients with severe </text>
<text top="349" left="219" width="343" height="21" font="5">hypertriglyceridemia. J Clin Lipidol. 2012;6:450-61. </text>
<text top="370" left="124" width="62" height="21" font="5">S4.5.2-8. </text>
<text top="370" left="219" width="587" height="21" font="5">Duane WC, Hunninghake DB, Freeman ML, et al. Simvastatin, a competitive inhibitor of </text>
<text top="390" left="219" width="598" height="21" font="5">HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology. </text>
<text top="410" left="219" width="114" height="21" font="5">1988;8:1147-50. </text>
<text top="430" left="124" width="62" height="21" font="5">S4.5.2-9. </text>
<text top="430" left="219" width="605" height="21" font="5">Rhodes KS, Weintraub M, Marchlewicz EH, et al. Medical nutrition therapy is the essential </text>
<text top="450" left="219" width="608" height="21" font="5">cornerstone for effective treatment of &#34;refractory&#34; severe hypertriglyceridemia regardless </text>
<text top="470" left="219" width="595" height="21" font="5">of pharmaceutical treatment: evidence from a lipid management program. J Clin Lipidol. </text>
<text top="490" left="219" width="105" height="21" font="5">2015;9:559-67. </text>
<text top="510" left="124" width="71" height="21" font="5">S4.5.2-10. </text>
<text top="510" left="219" width="621" height="21" font="5">Greenberg BH, Blackwelder WC, Levy RI. Primary type V hyperlipoproteinemia. A descriptive </text>
<text top="531" left="219" width="365" height="21" font="5">study in 32 families. Ann Intern Med. 1977;87:526-34. </text>
<text top="551" left="124" width="71" height="21" font="5">S4.5.2-11. </text>
<text top="551" left="219" width="558" height="21" font="5">Steiner G, Adelman AG, Silver MD. Early coronary atherosclerosis in primary type V </text>
<text top="571" left="219" width="395" height="21" font="5">hyperlipoproteinemia. Can Med Assoc J. 1971;105:1172-4. </text>
<text top="591" left="124" width="71" height="21" font="5">S4.5.2-12. </text>
<text top="591" left="218" width="587" height="21" font="5">Neil HA, Cooper J, Betteridge DJ, et al. All-cause and cardiovascular mortality in treated </text>
<text top="611" left="218" width="559" height="21" font="5">patients with severe hypertriglyceridaemia: a long-term prospective registry study. </text>
<text top="631" left="218" width="233" height="21" font="5">Atherosclerosis. 2010;211:618-23. </text>
<text top="651" left="124" width="71" height="21" font="5">S4.5.2-13. </text>
<text top="651" left="218" width="600" height="21" font="5">Christian JB, Arondekar B, Buysman EK, et al. Determining triglyceride reductions needed </text>
<text top="671" left="218" width="542" height="21" font="5">for clinical impact in severe hypertriglyceridemia. Am J Med. 2014;127:36-44 e1. </text>
<text top="692" left="124" width="71" height="21" font="5">S4.5.2-14. </text>
<text top="692" left="218" width="596" height="21" font="5">Chait A, Brunzell JD. Severe hypertriglyceridemia: role of familial and acquired disorders. </text>
<text top="712" left="218" width="202" height="21" font="5">Metabolism. 1983;32:209-14. </text>
<text top="732" left="124" width="71" height="21" font="5">S4.5.2-15. </text>
<text top="732" left="218" width="585" height="21" font="5">Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) </text>
<text top="752" left="218" width="570" height="21" font="5">therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-</text>
<text top="772" left="218" width="563" height="21" font="5">controlled, Randomized, double-blINd, 12-week study with an open-label Extension </text>
<text top="792" left="218" width="322" height="21" font="5">[MARINE] trial). Am J Cardiol. 2011;108:682-90. </text>
<text top="812" left="124" width="71" height="21" font="5">S4.5.2-16. </text>
<text top="812" left="218" width="600" height="21" font="5">Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for management of clinically </text>
<text top="833" left="218" width="572" height="21" font="5">significant drug-drug interactions with statins and select agents used in patients with </text>
<text top="853" left="218" width="562" height="21" font="5">cardiovascular disease: a scientific statement from the American Heart Association. </text>
<text top="873" left="218" width="211" height="21" font="5">Circulation. 2016;134:e468-95. </text>
<text top="893" left="124" width="71" height="21" font="5">S4.5.2-17. </text>
<text top="893" left="218" width="615" height="21" font="5">Basar R, Uzum AK, Canbaz B, et al. Therapeutic apheresis for severe hypertriglyceridemia in </text>
<text top="913" left="218" width="346" height="21" font="5">pregnancy. Arch Gynecol Obstet. 2013;287:839-43. </text>
<text top="942" left="124" width="4" height="21" font="5"> </text>
<text top="975" left="124" width="276" height="27" font="16"><i><b>4.5.3. Issues Specific to Women </b></i></text>
<text top="1013" left="124" width="62" height="21" font="5">S4.5.3-1. </text>
<text top="1013" left="219" width="582" height="21" font="5">Ouyang P, Wenger NK, Taylor D, et al. Strategies and methods to study female-specific </text>
<text top="1033" left="219" width="605" height="21" font="5">cardiovascular health and disease: a guide for clinical scientists. Biol Sex Differ. 2016;7:19. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="113" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-113_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="453" width="55" height="19" font="1">Page 113</text>
<text top="1130" left="508" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="62" height="21" font="5">S4.5.3-2. </text>
<text top="108" left="219" width="605" height="21" font="5">Grandi SM, Vallee-Pouliot K, Reynier P, et al. Hypertensive disorders in pregnancy and the </text>
<text top="128" left="219" width="585" height="21" font="5">risk of subsequent cardiovascular disease. Paediatr Perinat Epidemiol. 2017;31:412-21. </text>
<text top="148" left="124" width="62" height="21" font="5">S4.5.3-3. </text>
<text top="148" left="219" width="611" height="21" font="5">Shostrom DCV, Sun Y, Oleson JJ, et al. History of gestational diabetes mellitus in relation to </text>
<text top="168" left="219" width="573" height="21" font="5">cardiovascular disease and cardiovascular risk factors in US women. Front Endocrinol </text>
<text top="188" left="219" width="165" height="21" font="5">(Lausanne). 2017;8:144. </text>
<text top="208" left="124" width="62" height="21" font="5">S4.5.3-4. </text>
<text top="208" left="219" width="525" height="21" font="5">Catov JM, Newman AB, Roberts JM, et al. Preterm delivery and later maternal </text>
<text top="228" left="219" width="389" height="21" font="5">cardiovascular disease risk. Epidemiology. 2007;18:733-9. </text>
<text top="249" left="124" width="62" height="21" font="5">S4.5.3-5. </text>
<text top="249" left="219" width="611" height="21" font="5">Muka T, Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause and </text>
<text top="269" left="219" width="614" height="21" font="5">time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, </text>
<text top="289" left="219" width="605" height="21" font="5">and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol. 2016;1:767-</text>
<text top="309" left="219" width="25" height="21" font="5">76. </text>
<text top="329" left="124" width="62" height="21" font="5">S4.5.3-6. </text>
<text top="329" left="219" width="611" height="21" font="5">Roeters van Lennep JE, Heida KY, Bots ML, et al. Cardiovascular disease risk in women with </text>
<text top="349" left="219" width="612" height="21" font="5">premature ovarian insufficiency: A systematic review and meta-analysis. Eur J Prev Cardiol. </text>
<text top="370" left="219" width="114" height="21" font="5">2016;23:178-86. </text>
<text top="390" left="124" width="62" height="21" font="5">S4.5.3-7. </text>
<text top="390" left="219" width="598" height="21" font="5">Edison RJ, Muenke M. Central nervous system and limb anomalies in case reports of first-</text>
<text top="410" left="219" width="402" height="21" font="5">trimester statin exposure. N Engl J Med. 2004;350:1579-82. </text>
<text top="430" left="124" width="62" height="21" font="5">S4.5.3-8. </text>
<text top="430" left="219" width="612" height="21" font="5">Ofori B, Rey E, Berard A. Risk of congenital anomalies in pregnant users of statin drugs. Br J </text>
<text top="450" left="219" width="230" height="21" font="5">Clin Pharmacol. 2007;64:496-509. </text>
<text top="470" left="124" width="62" height="21" font="5">S4.5.3-9. </text>
<text top="470" left="219" width="552" height="21" font="5">Taguchi N, Rubin ET, Hosokawa A, et al. Prenatal exposure to HMG-CoA reductase </text>
<text top="490" left="219" width="556" height="21" font="5">inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol. 2008;26:175-7. </text>
<text top="510" left="124" width="71" height="21" font="5">S4.5.3-10. </text>
<text top="510" left="218" width="557" height="21" font="5">Winterfeld U, Allignol A, Panchaud A, et al. Pregnancy outcome following maternal </text>
<text top="531" left="218" width="522" height="21" font="5">exposure to statins: a multicentre prospective study. BJOG. 2013;120:463-71. </text>
<text top="551" left="124" width="71" height="21" font="5">S4.5.3-11. </text>
<text top="551" left="218" width="616" height="21" font="5">Zarek J, Koren G. The fetal safety of statins: a systematic review and meta-analysis. J Obstet </text>
<text top="571" left="218" width="205" height="21" font="5">Gynaecol Can. 2014;36:506-9. </text>
<text top="591" left="124" width="71" height="21" font="5">S4.5.3-12. </text>
<text top="591" left="218" width="597" height="21" font="5">McGrogan A, Snowball J, Charlton RA. Statins during pregnancy: a cohort study using the </text>
<text top="611" left="218" width="622" height="21" font="5">General Practice Research Database to investigate pregnancy loss. Pharmacoepidemiol Drug </text>
<text top="631" left="218" width="142" height="21" font="5">Saf. 2017;26:843-52. </text>
<text top="651" left="124" width="71" height="21" font="5">S4.5.3-13. </text>
<text top="651" left="218" width="606" height="21" font="5">Fulcher J, O'Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among </text>
<text top="671" left="218" width="552" height="21" font="5">men and women: meta-analysis of individual data from 174,000 participants in 27 </text>
<text top="692" left="218" width="316" height="21" font="5">randomised trials. Lancet. 2015;385:1397-405. </text>
<text top="712" left="124" width="71" height="21" font="5">S4.5.3-14. </text>
<text top="712" left="219" width="622" height="21" font="5">Ley SH, Li Y, Tobias DK, et al. Duration of reproductive life span, age at menarche, and age at </text>
<text top="732" left="219" width="612" height="21" font="5">menopause are associated with risk of cardiovascular disease in women. J Am Heart Assoc. </text>
<text top="752" left="219" width="117" height="21" font="5">2017;6:e006713. </text>
<text top="772" left="124" width="71" height="21" font="5">S4.5.3-15. </text>
<text top="772" left="219" width="620" height="21" font="5">Costantine MM, Cleary K, Hebert MF, et al. Safety and pharmacokinetics of pravastatin used </text>
<text top="792" left="219" width="568" height="21" font="5">for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized </text>
<text top="813" left="219" width="397" height="21" font="5">controlled trial. Am J Obstet Gynecol. 2016;214:720.e1-17. </text>
<text top="833" left="124" width="71" height="21" font="5">S4.5.3-16. </text>
<text top="833" left="219" width="480" height="21" font="5">Toleikyte I, Retterstol K, Leren TP, et al. Pregnancy outcomes in familial </text>
<text top="853" left="219" width="521" height="21" font="5">hypercholesterolemia: a registry-based study. Circulation. 2011;124:1606-14. </text>
<text top="873" left="124" width="71" height="21" font="5">S4.5.3-17. </text>
<text top="873" left="219" width="535" height="21" font="5">Sanderson SL, Iverius PH, Wilson DE. Successful hyperlipemic pregnancy. JAMA. </text>
<text top="893" left="219" width="130" height="21" font="5">1991;265:1858-60. </text>
<text top="922" left="124" width="4" height="21" font="5"> </text>
<text top="955" left="124" width="196" height="27" font="16"><i><b>4.5.4 Adults With CKD </b></i></text>
<text top="993" left="124" width="62" height="21" font="5">S4.5.4-1. </text>
<text top="993" left="219" width="573" height="21" font="5">Cholesterol Treatment Trialists’ (CTT) Collaboration, Herrington W, Emberson J, et al. </text>
<text top="1013" left="219" width="568" height="21" font="5">Impact of renal function on the effects of LDL cholesterol lowering with statin-based </text>
<text top="1033" left="219" width="605" height="21" font="5">regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet </text>
<text top="1053" left="219" width="248" height="21" font="5">Diabetes Endocrinol. 2016;4:829-39. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="114" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-114_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="453" width="55" height="19" font="1">Page 114</text>
<text top="1130" left="508" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="62" height="21" font="5">S4.5.4-2. </text>
<text top="108" left="219" width="545" height="21" font="5">Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with </text>
<text top="128" left="219" width="620" height="21" font="5">simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal </text>
<text top="148" left="219" width="527" height="21" font="5">Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181-92. </text>
<text top="168" left="124" width="62" height="21" font="5">S4.5.4-3. </text>
<text top="168" left="219" width="592" height="21" font="5">Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in </text>
<text top="188" left="219" width="467" height="21" font="5">patients undergoing hemodialysis. N Engl J Med. 2009;360:1395-407. </text>
<text top="208" left="124" width="62" height="21" font="5">S4.5.4-4. </text>
<text top="208" left="219" width="591" height="21" font="5">Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus </text>
<text top="228" left="219" width="392" height="21" font="5">undergoing hemodialysis. N Engl J Med. 2005;353:238-48. </text>
<text top="249" left="124" width="62" height="21" font="5">S4.5.4-5. </text>
<text top="249" left="219" width="605" height="21" font="5">Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney </text>
<text top="269" left="219" width="569" height="21" font="5">disease compared with those with diabetes: a population-level cohort study. Lancet. </text>
<text top="289" left="219" width="122" height="21" font="5">2012;380:807-14. </text>
<text top="309" left="124" width="62" height="21" font="5">S4.5.4-6. </text>
<text top="309" left="219" width="562" height="21" font="5">Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular </text>
<text top="329" left="219" width="568" height="21" font="5">filtration rate and albuminuria with all-cause and cardiovascular mortality in general </text>
<text top="349" left="219" width="521" height="21" font="5">population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073-81. </text>
<text top="370" left="124" width="62" height="21" font="5">S4.5.4-7. </text>
<text top="370" left="219" width="558" height="21" font="5">Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on </text>
<text top="390" left="219" width="595" height="21" font="5">cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110:2809-16. </text>
<text top="419" left="124" width="4" height="21" font="5"> </text>
<text top="451" left="124" width="517" height="27" font="16"><i><b>4.5.5. Adults With Chronic Inflammatory Disorders and HIV </b></i></text>
<text top="489" left="124" width="62" height="21" font="5">S4.5.5-1. </text>
<text top="489" left="219" width="594" height="21" font="5">Mantel A, Holmqvist M, Jernberg T, et al. Rheumatoid arthritis is associated with a more </text>
<text top="510" left="219" width="617" height="21" font="5">severe presentation of acute coronary syndrome and worse short-term outcome. Eur Heart </text>
<text top="530" left="219" width="135" height="21" font="5">J. 2015;36:3413-22. </text>
<text top="550" left="124" width="62" height="21" font="5">S4.5.5-2. </text>
<text top="550" left="219" width="589" height="21" font="5">Douglas KM, Pace AV, Treharne GJ, et al. Excess recurrent cardiac events in rheumatoid </text>
<text top="570" left="219" width="553" height="21" font="5">arthritis patients with acute coronary syndrome. Ann Rheum Dis. 2006;65:348-53. </text>
<text top="590" left="124" width="62" height="21" font="5">S4.5.5-3. </text>
<text top="590" left="219" width="541" height="21" font="5">Lindhardsen J, Ahlehoff O, Gislason GH, et al. The risk of myocardial infarction in </text>
<text top="610" left="219" width="607" height="21" font="5">rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum </text>
<text top="630" left="219" width="142" height="21" font="5">Dis. 2011;70:929-34. </text>
<text top="651" left="124" width="62" height="21" font="5">S4.5.5-4. </text>
<text top="651" left="219" width="607" height="21" font="5">Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients </text>
<text top="671" left="219" width="568" height="21" font="5">with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. </text>
<text top="691" left="219" width="114" height="21" font="5">2008;59:1690-7. </text>
<text top="711" left="124" width="62" height="21" font="5">S4.5.5-5. </text>
<text top="711" left="219" width="596" height="21" font="5">Wajed J, Ahmad Y, Durrington PN, et al. Prevention of cardiovascular disease in systemic </text>
<text top="731" left="219" width="583" height="21" font="5">lupus erythematosus--proposed guidelines for risk factor management. Rheumatology </text>
<text top="751" left="219" width="161" height="21" font="5">(Oxford). 2004;43:7-12. </text>
<text top="771" left="124" width="62" height="21" font="5">S4.5.5-6. </text>
<text top="771" left="219" width="595" height="21" font="5">Westerweel PE, Luyten RK, Koomans HA, et al. Premature atherosclerotic cardiovascular </text>
<text top="791" left="219" width="516" height="21" font="5">disease in systemic lupus erythematosus. Arthritis Rheum. 2007;56:1384-96. </text>
<text top="812" left="124" width="62" height="21" font="5">S4.5.5-7. </text>
<text top="812" left="219" width="594" height="21" font="5">Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of </text>
<text top="832" left="219" width="600" height="21" font="5">cardiovascular mortality: cohort study using the General Practice Research Database. Eur </text>
<text top="852" left="219" width="168" height="21" font="5">Heart J. 2010;31:1000-6. </text>
<text top="872" left="124" width="62" height="21" font="5">S4.5.5-8. </text>
<text top="872" left="219" width="577" height="21" font="5">Hanna DB, Ramaswamy C, Kaplan RC, et al. Trends in cardiovascular disease Mortality </text>
<text top="892" left="219" width="578" height="21" font="5">among persons with HIV in New York City, 2001-2012. Clin Infect Dis. 2016;63:1122-9. </text>
<text top="912" left="124" width="62" height="21" font="5">S4.5.5-9. </text>
<text top="912" left="219" width="551" height="21" font="5">Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and </text>
<text top="933" left="219" width="601" height="21" font="5">cardiovascular risk factors among patients with human immunodeficiency virus disease. J </text>
<text top="953" left="219" width="279" height="21" font="5">Clin Endocrinol Metab. 2007;92:2506-12. </text>
<text top="973" left="124" width="71" height="21" font="5">S4.5.5-10. </text>
<text top="973" left="219" width="569" height="21" font="5">Kearns A, Gordon J, Burdo TH, et al. HIV-1-associated atherosclerosis: unraveling the </text>
<text top="993" left="219" width="327" height="21" font="5">missing link. J Am Coll Cardiol. 2017;69:3084-98. </text>
<text top="1013" left="124" width="71" height="21" font="5">S4.5.5-11. </text>
<text top="1013" left="219" width="602" height="21" font="5">Dregan A, Chowienczyk P, Molokhia M. Cardiovascular and type 2 diabetes morbidity and </text>
<text top="1033" left="219" width="600" height="21" font="5">all-cause mortality among diverse chronic inflammatory disorders. Heart. 2017;103:1867-</text>
<text top="1053" left="219" width="25" height="21" font="5">73. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="115" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-115_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="453" width="55" height="19" font="1">Page 115</text>
<text top="1130" left="508" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="71" height="21" font="5">S4.5.5-12. </text>
<text top="108" left="219" width="568" height="21" font="5">Fernandez-Montero JV, Barreiro P, de Mendoza C, et al. Hepatitis C virus coinfection </text>
<text top="128" left="219" width="599" height="21" font="5">independently increases the risk of cardiovascular disease in HIV-positive patients. J Viral </text>
<text top="148" left="219" width="154" height="21" font="5">Hepat. 2016;23:47-52. </text>
<text top="168" left="124" width="71" height="21" font="5">S4.5.5-13. </text>
<text top="168" left="219" width="570" height="21" font="5">Bartels CM, Kind AJ, Everett C, et al. Low frequency of primary lipid screening among </text>
<text top="188" left="219" width="539" height="21" font="5">medicare patients with rheumatoid arthritis. Arthritis Rheum. 2011;63:1221-30. </text>
<text top="208" left="124" width="71" height="21" font="5">S4.5.5-14. </text>
<text top="208" left="219" width="594" height="21" font="5">Toms TE, Panoulas VF, Douglas KM, et al. Statin use in rheumatoid arthritis in relation to </text>
<text top="228" left="219" width="579" height="21" font="5">actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated </text>
<text top="249" left="219" width="351" height="21" font="5">cardiovascular risk? Ann Rheum Dis. 2010;69:683-8. </text>
<text top="269" left="124" width="71" height="21" font="5">S4.5.5-15. </text>
<text top="269" left="219" width="607" height="21" font="5">Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of </text>
<text top="289" left="219" width="392" height="21" font="5">myocardial infarction. N Engl J Med. 2003;349:1993-2003. </text>
<text top="309" left="124" width="71" height="21" font="5">S4.5.5-16. </text>
<text top="309" left="219" width="602" height="21" font="5">Feinstein MJ, Nance RM, Drozd DR, et al. Assessing and refining myocardial infarction risk </text>
<text top="329" left="219" width="613" height="21" font="5">estimation among patients with human immunodeficiency virus: a study by the Centers for </text>
<text top="349" left="219" width="570" height="21" font="5">AIDS Research Network of Integrated Clinical Systems. JAMA Cardiol. 2017;2:155-62. </text>
<text top="370" left="124" width="71" height="21" font="5">S4.5.5-17. </text>
<text top="370" left="219" width="574" height="21" font="5">Arts EE, Popa C, Den Broeder AA, et al. Performance of four current risk algorithms in </text>
<text top="390" left="219" width="619" height="21" font="5">predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis. </text>
<text top="410" left="219" width="114" height="21" font="5">2015;74:668-74. </text>
<text top="430" left="124" width="71" height="21" font="5">S4.5.5-18. </text>
<text top="430" left="219" width="608" height="21" font="5">Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by </text>
<text top="450" left="219" width="572" height="21" font="5">protease inhibitors independent of changes in body composition in patients with HIV </text>
<text top="470" left="219" width="373" height="21" font="5">infection. J Acquir Immune Defic Syndr. 2000;23:35-43. </text>
<text top="490" left="124" width="71" height="21" font="5">S4.5.5-19. </text>
<text top="490" left="219" width="611" height="21" font="5">Ledergerber B, Furrer H, Rickenbach M, et al. Factors associated with the incidence of type </text>
<text top="510" left="219" width="594" height="21" font="5">2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect </text>
<text top="531" left="218" width="134" height="21" font="5">Dis. 2007;45:111-9. </text>
<text top="551" left="124" width="71" height="21" font="5">S4.5.5-20. </text>
<text top="551" left="218" width="589" height="21" font="5">Davis JM 3rd, Maradit Kremers H, Crowson CS, et al. Glucocorticoids and cardiovascular </text>
<text top="571" left="218" width="549" height="21" font="5">events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. </text>
<text top="591" left="218" width="114" height="21" font="5">2007;56:820-30. </text>
<text top="611" left="124" width="71" height="21" font="5">S4.5.5-21. </text>
<text top="611" left="218" width="602" height="21" font="5">Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the </text>
<text top="631" left="218" width="591" height="21" font="5">impact of serum lipid measures and systemic inflammation on the risk of cardiovascular </text>
<text top="651" left="218" width="273" height="21" font="5">disease. Ann Rheum Dis. 2011;70:482-7. </text>
<text top="671" left="124" width="71" height="21" font="5">S4.5.5-22. </text>
<text top="671" left="218" width="548" height="21" font="5">Ronda N, Favari E, Borghi MO, et al. Impaired serum cholesterol efflux capacity in </text>
<text top="692" left="218" width="603" height="21" font="5">rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis. 2014;73:609-15. </text>
<text top="712" left="124" width="71" height="21" font="5">S4.5.5-23. </text>
<text top="712" left="218" width="619" height="21" font="5">Navarro-Millan I, Charles-Schoeman C, Yang S, et al. Changes in lipoproteins associated with </text>
<text top="732" left="218" width="567" height="21" font="5">methotrexate or combination therapy in early rheumatoid arthritis: results from the </text>
<text top="752" left="218" width="529" height="21" font="5">treatment of early rheumatoid arthritis trial. Arthritis Rheum. 2013;65:1430-8. </text>
<text top="781" left="124" width="4" height="21" font="5"> </text>
<text top="813" left="124" width="498" height="31" font="11"><b>5. Statin Safety and Statin-Associated Side Effects </b></text>
<text top="847" left="124" width="37" height="21" font="5">S5-1. </text>
<text top="847" left="219" width="526" height="21" font="5">Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of </text>
<text top="867" left="219" width="470" height="21" font="5">cardiovascular disease. Cochrane Database Syst Rev. 2013;CD004816. </text>
<text top="887" left="124" width="37" height="21" font="5">S5-2. </text>
<text top="887" left="219" width="599" height="21" font="5">Martin SS, Sperling LS, Blaha MJ, et al. Clinician-patient risk discussion for atherosclerotic </text>
<text top="908" left="219" width="594" height="21" font="5">cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA </text>
<text top="928" left="219" width="312" height="21" font="5">Guidelines. J Am Coll Cardiol. 2015;65:1361-8. </text>
<text top="948" left="124" width="37" height="21" font="5">S5-3. </text>
<text top="948" left="219" width="568" height="21" font="5">Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. </text>
<text top="968" left="219" width="202" height="21" font="5">Circulation. 2013;127:96-103. </text>
<text top="988" left="124" width="37" height="21" font="5">S5-4. </text>
<text top="988" left="219" width="611" height="21" font="5">Gupta A, Thompson D, Whitehouse A, et al. Adverse events associated with unblinded, but </text>
<text top="1008" left="219" width="591" height="21" font="5">not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-</text>
<text top="1028" left="219" width="614" height="21" font="5">Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-</text>
<text top="1049" left="219" width="452" height="21" font="5">randomised non-blind extension phase. Lancet. 2017;389:2473-81. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="116" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-116_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="453" width="55" height="19" font="1">Page 116</text>
<text top="1130" left="508" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="37" height="21" font="5">S5-5. </text>
<text top="108" left="219" width="563" height="21" font="5">Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs </text>
<text top="128" left="219" width="581" height="21" font="5">ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized </text>
<text top="148" left="219" width="261" height="21" font="5">clinical trial. JAMA. 2016;315:1580-90. </text>
<text top="168" left="124" width="37" height="21" font="5">S5-6. </text>
<text top="168" left="219" width="554" height="21" font="5">Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs </text>
<text top="188" left="219" width="558" height="21" font="5">ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY </text>
<text top="208" left="219" width="409" height="21" font="5">ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9:758-69. </text>
<text top="228" left="124" width="37" height="21" font="5">S5-7. </text>
<text top="228" left="219" width="613" height="21" font="5">Joy TR, Monjed A, Zou GY, et al. N-of-1 (single-patient) trials for statin-related myalgia. Ann </text>
<text top="249" left="219" width="206" height="21" font="5">Intern Med. 2014;160:301-10. </text>
<text top="269" left="124" width="37" height="21" font="5">S5-8. </text>
<text top="269" left="219" width="598" height="21" font="5">Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of </text>
<text top="289" left="219" width="535" height="21" font="5">statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. </text>
<text top="309" left="219" width="122" height="21" font="5">2012;380:565-71. </text>
<text top="329" left="124" width="37" height="21" font="5">S5-9. </text>
<text top="329" left="219" width="619" height="21" font="5">Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared </text>
<text top="349" left="219" width="531" height="21" font="5">with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556-64. </text>
<text top="370" left="124" width="46" height="21" font="5">S5-10. </text>
<text top="370" left="219" width="595" height="21" font="5">Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative </text>
<text top="390" left="219" width="454" height="21" font="5">meta-analysis of randomised statin trials. Lancet. 2010;375:735-42. </text>
<text top="410" left="124" width="46" height="21" font="5">S5-11. </text>
<text top="410" left="219" width="591" height="21" font="5">Navarese EP, Buffon A, Andreotti F, et al. Meta-analysis of impact of different types and </text>
<text top="430" left="219" width="548" height="21" font="5">doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013;111:1123-30. </text>
<text top="450" left="124" width="46" height="21" font="5">S5-12. </text>
<text top="450" left="219" width="568" height="21" font="5">Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 </text>
<text top="470" left="219" width="560" height="21" font="5">diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403. </text>
<text top="490" left="124" width="46" height="21" font="5">S5-13. </text>
<text top="490" left="219" width="593" height="21" font="5">Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on </text>
<text top="510" left="219" width="544" height="21" font="5">statin therapy—European Atherosclerosis Society consensus panel statement on </text>
<text top="531" left="219" width="480" height="21" font="5">assessment, aetiology and management. Eur Heart J. 2015;36:1012-22. </text>
<text top="551" left="124" width="46" height="21" font="5">S5-14. </text>
<text top="551" left="219" width="589" height="21" font="5">Thompson PD, Panza G, Zaleski A, et al. Statin-associated side effects. J Am Coll Cardiol. </text>
<text top="571" left="219" width="130" height="21" font="5">2016;67:2395-410. </text>
<text top="591" left="124" width="46" height="21" font="5">S5-15. </text>
<text top="591" left="218" width="612" height="21" font="5">Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of </text>
<text top="611" left="218" width="588" height="21" font="5">blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the </text>
<text top="631" left="218" width="558" height="21" font="5">American College of Cardiology/American Heart Association Task Force on Practice </text>
<text top="651" left="218" width="272" height="21" font="5">Guidelines. Circulation. 2014;129:S1-45. </text>
<text top="671" left="124" width="46" height="21" font="5">S5-16. </text>
<text top="671" left="218" width="620" height="21" font="5">Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment </text>
<text top="692" left="218" width="619" height="21" font="5">for cardiovascular events in patients with coronary heart disease and abnormal liver tests in </text>
<text top="712" left="218" width="609" height="21" font="5">the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc </text>
<text top="732" left="218" width="243" height="21" font="5">analysis. Lancet. 2010;376:1916-22. </text>
<text top="752" left="124" width="46" height="21" font="5">S5-17. </text>
<text top="752" left="218" width="567" height="21" font="5">Foster T, Budoff MJ, Saab S, et al. Atorvastatin and antioxidants for the treatment of </text>
<text top="772" left="218" width="595" height="21" font="5">nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J </text>
<text top="792" left="218" width="207" height="21" font="5">Gastroenterol. 2011;106:71-7. </text>
<text top="812" left="124" width="46" height="21" font="5">S5-18. </text>
<text top="812" left="218" width="546" height="21" font="5">Tikkanen MJ, Fayyad R, Faergeman O, et al. Effect of intensive lipid lowering with </text>
<text top="833" left="218" width="595" height="21" font="5">atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-</text>
<text top="853" left="218" width="525" height="21" font="5">moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol. </text>
<text top="873" left="218" width="130" height="21" font="5">2013;168:3846-52. </text>
<text top="893" left="124" width="46" height="21" font="5">S5-19. </text>
<text top="893" left="218" width="577" height="21" font="5">Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision </text>
<text top="913" left="218" width="531" height="21" font="5">pathway on the role of non-statin therapies for LDL-cholesterol lowering in the </text>
<text top="933" left="218" width="570" height="21" font="5">management of atherosclerotic cardiovascular disease risk: a report of the American </text>
<text top="953" left="218" width="618" height="21" font="5">College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. </text>
<text top="974" left="218" width="114" height="21" font="5">2016;68:92-125. </text>
<text top="994" left="124" width="46" height="21" font="5">S5-20. </text>
<text top="994" left="218" width="605" height="21" font="5">Taylor BA, Lorson L, White CM, et al. A randomized trial of coenzyme Q10 in patients with </text>
<text top="1014" left="218" width="423" height="21" font="5">confirmed statin myopathy. Atherosclerosis. 2015;238:329-35. </text>
<text top="1034" left="124" width="46" height="21" font="5">S5-21. </text>
<text top="1034" left="218" width="554" height="21" font="5">Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-induced </text>
<text top="1054" left="218" width="612" height="21" font="5">myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90:24-34. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="117" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-117_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="453" width="55" height="19" font="1">Page 117</text>
<text top="1130" left="508" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="46" height="21" font="5">S5-22. </text>
<text top="108" left="219" width="604" height="21" font="5">Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of </text>
<text top="128" left="219" width="609" height="21" font="5">LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. </text>
<text top="148" left="219" width="183" height="21" font="5">Lancet. 2010;376:1670-81. </text>
<text top="168" left="124" width="46" height="21" font="5">S5-23. </text>
<text top="168" left="219" width="582" height="21" font="5">Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and </text>
<text top="188" left="219" width="346" height="21" font="5">safety of statin therapy. Lancet. 2016;388:2532-61. </text>
<text top="208" left="124" width="46" height="21" font="5">S5-24. </text>
<text top="208" left="219" width="568" height="21" font="5">Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons </text>
<text top="228" left="219" width="439" height="21" font="5">without cardiovascular disease. N Engl J Med. 2016;374:2021-31. </text>
<text top="249" left="124" width="46" height="21" font="5">S5-25. </text>
<text top="249" left="219" width="582" height="21" font="5">Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-</text>
<text top="269" left="219" width="612" height="21" font="5">dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther. </text>
<text top="289" left="219" width="114" height="21" font="5">2005;19:403-14. </text>
<text top="309" left="124" width="46" height="21" font="5">S5-26. </text>
<text top="309" left="219" width="570" height="21" font="5">Cohen JD, Brinton EA, Ito MK, et al. Understanding statin Use in America and Gaps in </text>
<text top="329" left="219" width="600" height="21" font="5">Patient Education (USAGE): an Internet-based survey of 10,138 current and former statin </text>
<text top="349" left="219" width="239" height="21" font="5">users. J Clin Lipidol. 2012;6:208-15. </text>
<text top="370" left="124" width="46" height="21" font="5">S5-27. </text>
<text top="370" left="219" width="561" height="21" font="5">Serban MC, Colantonio LD, Manthripragada AD, et al. Statin Intolerance and Risk of </text>
<text top="390" left="219" width="594" height="21" font="5">Coronary Heart Events and All-cause mortality following myocardial infarction. J Am Coll </text>
<text top="410" left="219" width="177" height="21" font="5">Cardiol. 2017;69:1386-95. </text>
<text top="430" left="124" width="46" height="21" font="5">S5-28. </text>
<text top="430" left="219" width="609" height="21" font="5">Zhang H, Plutzky J, Shubina M, et al. Continued statin prescriptions after adverse reactions </text>
<text top="450" left="219" width="488" height="21" font="5">and patient outcomes: a cohort study. Ann Intern Med. 2017;167:221-7. </text>
<text top="470" left="124" width="46" height="21" font="5">S5-29. </text>
<text top="470" left="219" width="592" height="21" font="5">Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a </text>
<text top="490" left="219" width="329" height="21" font="5">cohort study. Ann Intern Med. 2013;158:526-34. </text>
<text top="510" left="124" width="46" height="21" font="5">S5-30. </text>
<text top="510" left="219" width="608" height="21" font="5">Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems </text>
<text top="531" left="219" width="293" height="21" font="5">in clinical trials. Am Heart J. 2014;168:6-15. </text>
<text top="551" left="124" width="46" height="21" font="5">S5-31. </text>
<text top="551" left="219" width="553" height="21" font="5">Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin </text>
<text top="571" left="219" width="512" height="21" font="5">intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166:597-603. </text>
<text top="591" left="124" width="46" height="21" font="5">S5-32. </text>
<text top="591" left="219" width="585" height="21" font="5">Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016;374:664-9. </text>
<text top="611" left="124" width="46" height="21" font="5">S5-33. </text>
<text top="611" left="218" width="620" height="21" font="5">Richardson K, Schoen M, French B, et al. Statins and cognitive function: a systematic review. </text>
<text top="631" left="218" width="236" height="21" font="5">Ann Intern Med. 2013;159:688-97. </text>
<text top="651" left="124" width="46" height="21" font="5">S5-34. </text>
<text top="651" left="218" width="616" height="21" font="5">Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of </text>
<text top="671" left="218" width="559" height="21" font="5">cardiovascular risk: a report of the American College of Cardiology/American Heart </text>
<text top="692" left="218" width="513" height="21" font="5">Association Task Force on Practice Guidelines. Circulation. 2014;129:S49-73. </text>
<text top="721" left="124" width="4" height="21" font="5"> </text>
<text top="753" left="124" width="191" height="31" font="11"><b>6. Implementation </b></text>
<text top="787" left="124" width="37" height="21" font="5">S6-1. </text>
<text top="787" left="219" width="574" height="21" font="5">Brown BG, Bardsley J, Poulin D, et al. Moderate dose, three-drug therapy with niacin, </text>
<text top="807" left="219" width="574" height="21" font="5">lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in </text>
<text top="827" left="219" width="587" height="21" font="5">patients with hyperlipidemia and coronary artery disease. Am J Cardiol. 1997;80:111-5. </text>
<text top="847" left="124" width="37" height="21" font="5">S6-2. </text>
<text top="847" left="219" width="595" height="21" font="5">Tamblyn R, Reidel K, Huang A, et al. Increasing the detection and response to adherence </text>
<text top="867" left="219" width="574" height="21" font="5">problems with cardiovascular medication in primary care through computerized drug </text>
<text top="887" left="219" width="603" height="21" font="5">management systems: a randomized controlled trial. Med Decis Making. 2010;30:176-88. </text>
<text top="908" left="124" width="37" height="21" font="5">S6-3. </text>
<text top="908" left="219" width="610" height="21" font="5">Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence </text>
<text top="928" left="219" width="616" height="21" font="5">and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. </text>
<text top="948" left="219" width="168" height="21" font="5">JAMA. 2013;310:918-29. </text>
<text top="968" left="124" width="37" height="21" font="5">S6-4. </text>
<text top="968" left="219" width="580" height="21" font="5">van Driel ML, Morledge MD, Ulep R, et al. Interventions to improve adherence to lipid-</text>
<text top="988" left="219" width="479" height="21" font="5">lowering medication. Cochrane Database Syst Rev. 2016;12:CD004371. </text>
<text top="1008" left="124" width="37" height="21" font="5">S6-5. </text>
<text top="1008" left="219" width="614" height="21" font="5">Chan WV, Pearson TA, Bennett GC, et al. ACC/AHA special report: clinical practice guideline </text>
<text top="1028" left="219" width="614" height="21" font="5">implementation strategies: a summary of systematic reviews by the NHLBI Implementation </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="118" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-118_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="453" width="55" height="19" font="1">Page 118</text>
<text top="1130" left="508" width="4" height="21" font="5"> </text>
<text top="108" left="219" width="572" height="21" font="5">Science Work Group: a report of the American College of Cardiology/American Heart </text>
<text top="128" left="219" width="574" height="21" font="5">Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e122-37. </text>
<text top="148" left="124" width="37" height="21" font="5">S6-6. </text>
<text top="148" left="219" width="590" height="21" font="5">Fischer F, Lange K, Klose K, et al. Barriers and strategies in guideline implementation—a </text>
<text top="168" left="219" width="292" height="21" font="5">scoping review. Healthcare (Basel). 2016;4. </text>
<text top="188" left="124" width="37" height="21" font="5">S6-7. </text>
<text top="188" left="219" width="598" height="21" font="5">Stacey D, Hill S, McCaffery K, et al. Shared decision making interventions: theoretical and </text>
<text top="208" left="219" width="568" height="21" font="5">empirical evidence with implications for health literacy. Stud Health Technol Inform. </text>
<text top="228" left="219" width="122" height="21" font="5">2017;240:263-83. </text>
<text top="249" left="124" width="37" height="21" font="5">S6-8. </text>
<text top="249" left="219" width="569" height="21" font="5">Stacey D, Legare F, Lewis K, et al. Decision aids for people facing health treatment or </text>
<text top="269" left="219" width="463" height="21" font="5">screening decisions. Cochrane Database Syst Rev. 2017;4:CD001431. </text>
<text top="289" left="124" width="37" height="21" font="5">S6-9. </text>
<text top="289" left="219" width="552" height="21" font="5">Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice </text>
<text top="309" left="219" width="470" height="21" font="5">guidelines? A framework for improvement. JAMA. 1999;282:1458-65. </text>
<text top="329" left="124" width="46" height="21" font="5">S6-10. </text>
<text top="329" left="219" width="520" height="21" font="5">Pokharel Y, Tang F, Jones PG, et al. Adoption of the 2013 American College of </text>
<text top="349" left="219" width="593" height="21" font="5">Cardiology/American Heart Association cholesterol management guideline in cardiology </text>
<text top="370" left="219" width="342" height="21" font="5">practices nationwide. JAMA Cardiol. 2017;2:361-9. </text>
<text top="390" left="124" width="46" height="21" font="5">S6-11. </text>
<text top="390" left="219" width="540" height="21" font="5">Rodriguez F, Lin S, Maron DJ, et al. Use of high-intensity statins for patients with </text>
<text top="410" left="219" width="574" height="21" font="5">atherosclerotic cardiovascular disease in the Veterans Affairs Health System: practice </text>
<text top="430" left="219" width="483" height="21" font="5">impact of the new cholesterol guidelines. Am Heart J. 2016;182:97-102. </text>
<text top="450" left="124" width="46" height="21" font="5">S6-12. </text>
<text top="450" left="219" width="593" height="21" font="5">Pokharel Y, Gosch K, Nambi V, et al. Practice-level variation in statin use among patients </text>
<text top="470" left="219" width="583" height="21" font="5">with diabetes: insights from the PINNACLE Registry. J Am Coll Cardiol. 2016;68:1368-9. </text>
<text top="490" left="124" width="46" height="21" font="5">S6-13. </text>
<text top="490" left="219" width="572" height="21" font="5">Hira RS, Cowart JB, Akeroyd JM, et al. Risk factor optimization and guideline-directed </text>
<text top="510" left="219" width="573" height="21" font="5">medical therapy in US veterans with peripheral arterial and ischemic cerebrovascular </text>
<text top="531" left="219" width="613" height="21" font="5">disease compared to veterans with coronary heart disease. Am J Cardiol. 2016;118:1144-9. </text>
<text top="551" left="124" width="46" height="21" font="5">S6-14. </text>
<text top="551" left="218" width="574" height="21" font="5">Viswanathan M, Golin CE, Jones CD, et al. Interventions to improve adherence to self-</text>
<text top="571" left="218" width="596" height="21" font="5">administered medications for chronic diseases in the United States: a systematic review. </text>
<text top="591" left="218" width="236" height="21" font="5">Ann Intern Med. 2012;157:785-95. </text>
<text top="611" left="124" width="46" height="21" font="5">S6-15. </text>
<text top="611" left="218" width="584" height="21" font="5">Slejko JF, Ho M, Anderson HD, et al. Adherence to statins in primary prevention: yearly </text>
<text top="631" left="218" width="479" height="21" font="5">adherence changes and outcomes. J Manag Care Pharm. 2014;20:51-7. </text>
<text top="651" left="124" width="46" height="21" font="5">S6-16. </text>
<text top="651" left="218" width="587" height="21" font="5">Zimolzak AJ, Spettell CM, Fernandes J, et al. Early detection of poor adherers to statins: </text>
<text top="671" left="218" width="584" height="21" font="5">applying individualized surveillance to pay for performance. PLoS One. 2013;8:e79611. </text>
<text top="692" left="124" width="46" height="21" font="5">S6-17. </text>
<text top="692" left="218" width="604" height="21" font="5">Bitton A, Choudhry NK, Matlin OS, et al. The impact of medication adherence on coronary </text>
<text top="712" left="218" width="609" height="21" font="5">artery disease costs and outcomes: a systematic review. Am J Med. 2013;126:357.e7-.e27. </text>
<text top="732" left="124" width="46" height="21" font="5">S6-18. </text>
<text top="732" left="218" width="573" height="21" font="5">Korhonen MJ, Robinson JG, Annis IE, et al. Adherence tradeoff to multiple preventive </text>
<text top="752" left="218" width="571" height="21" font="5">therapies and all-cause mortality after acute myocardial infarction. J Am Coll Cardiol. </text>
<text top="772" left="218" width="122" height="21" font="5">2017;70:1543-54. </text>
<text top="792" left="124" width="46" height="21" font="5">S6-19. </text>
<text top="792" left="218" width="619" height="21" font="5">Dragomir A, Cote R, White M, et al. Relationship between adherence level to statins, clinical </text>
<text top="812" left="218" width="565" height="21" font="5">issues and health-care costs in real-life clinical setting. Value Health. 2010;13:87-94. </text>
<text top="833" left="124" width="46" height="21" font="5">S6-20. </text>
<text top="833" left="218" width="584" height="21" font="5">Zhao Y, Zabriski S, Bertram C. Associations between statin adherence level, health care </text>
<text top="853" left="218" width="440" height="21" font="5">costs, and utilization. J Manag Care Spec Pharm. 2014;20:703-13. </text>
<text top="873" left="124" width="46" height="21" font="5">S6-21. </text>
<text top="873" left="218" width="609" height="21" font="5">Happe LE, Clark D, Holliday E, et al. A systematic literature review assessing the directional </text>
<text top="893" left="218" width="618" height="21" font="5">impact of managed care formulary restrictions on medication adherence, clinical outcomes, </text>
<text top="913" left="218" width="569" height="21" font="5">economic outcomes, and health care resource utilization. J Manag Care Spec Pharm. </text>
<text top="933" left="218" width="114" height="21" font="5">2014;20:677-84. </text>
<text top="953" left="124" width="46" height="21" font="5">S6-22. </text>
<text top="953" left="218" width="588" height="21" font="5">Drozda JP Jr, Ferguson TB Jr, Jneid H, et al. 2015 ACC/AHA focused update of secondary </text>
<text top="974" left="218" width="514" height="21" font="5">prevention lipid performance measures: a report of the American College of </text>
<text top="994" left="218" width="556" height="21" font="5">Cardiology/American Heart Association Task Force on Performance Measures. Circ </text>
<text top="1014" left="218" width="285" height="21" font="5">Cardiovasc Qual Outcomes. 2016;9:68-95. </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="119" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-119_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="453" width="55" height="19" font="1">Page 119</text>
<text top="1130" left="508" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="46" height="21" font="5">S6-23. </text>
<text top="108" left="219" width="583" height="21" font="5">Krones T, Keller H, Sonnichsen A, et al. Absolute cardiovascular disease risk and shared </text>
<text top="128" left="219" width="606" height="21" font="5">decision making in primary care: a randomized controlled trial. Ann Fam Med. 2008;6:218-</text>
<text top="148" left="219" width="25" height="21" font="5">27. </text>
<text top="168" left="124" width="46" height="21" font="5">S6-24. </text>
<text top="168" left="219" width="270" height="21" font="5">ASCVD Risk Estimator Plus. Available at:<a href="http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/"> </a></text>
<text top="168" left="489" width="289" height="21" font="13"><a href="http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/">http://tools.acc.org/ASCVD-Risk-Estimator-</a></text>
<text top="188" left="219" width="185" height="21" font="13"><a href="http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/">Plus/#!/calculate/estimate/</a></text>
<text top="188" left="404" width="208" height="21" font="5"><a href="http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/">. A</a>ccessed September 1, 2018. </text>
<text top="208" left="124" width="46" height="21" font="5">S6-25. </text>
<text top="208" left="219" width="269" height="21" font="5">Statin Choice Decision Aid. Available at:<a href="https://statindecisionaid.mayoclinic.org/"> </a></text>
<text top="208" left="487" width="273" height="21" font="13"><a href="https://statindecisionaid.mayoclinic.org/">https://statindecisionaid.mayoclinic.org/</a></text>
<text top="208" left="761" width="73" height="21" font="5"><a href="https://statindecisionaid.mayoclinic.org/">. A</a>ccessed </text>
<text top="228" left="219" width="124" height="21" font="5">October 13, 2018. </text>
<text top="249" left="124" width="46" height="21" font="5">S6-26. </text>
<text top="249" left="219" width="609" height="21" font="5">Barry MJ, Edgman-Levitan S. Shared decision making--pinnacle of patient-centered care. N </text>
<text top="269" left="219" width="194" height="21" font="5">Engl J Med. 2012;366:780-1. </text>
<text top="289" left="124" width="46" height="21" font="5">S6-27. </text>
<text top="289" left="219" width="603" height="21" font="5">Shay LA, Lafata JE. Where is the evidence? A systematic review of shared decision making </text>
<text top="309" left="219" width="401" height="21" font="5">and patient outcomes. Med Decis Making. 2015;35:114-31. </text>
<text top="329" left="124" width="46" height="21" font="5">S6-28. </text>
<text top="329" left="219" width="429" height="21" font="5">Using Motivational Interviewing to Create Change. Available at: </text>
<text top="349" left="219" width="612" height="21" font="13"><a href="http://pharmacistsletter.therapeuticresearch.com/(X(1)S(0wvsds30xqejdo551cdariq1))/ce/cecourse.aspx?pc=12-243&amp;AspxAutoDetectCookieSupport=1">http://pharmacistsletter.therapeuticresearch.com/(X(1)S(0wvsds30xqejdo551cdariq1))/ce/</a></text>
<text top="370" left="219" width="409" height="21" font="13"><a href="http://pharmacistsletter.therapeuticresearch.com/(X(1)S(0wvsds30xqejdo551cdariq1))/ce/cecourse.aspx?pc=12-243&amp;AspxAutoDetectCookieSupport=1">cecourse.aspx?pc=12-243&amp;AspxAutoDetectCookieSupport=1</a></text>
<text top="370" left="627" width="186" height="21" font="5"><a href="http://pharmacistsletter.therapeuticresearch.com/(X(1)S(0wvsds30xqejdo551cdariq1))/ce/cecourse.aspx?pc=12-243&amp;AspxAutoDetectCookieSupport=1">. A</a>ccessed March 27, 2018. </text>
<text top="399" left="124" width="4" height="21" font="5"> </text>
<text top="431" left="124" width="338" height="31" font="11"><b>7. Cost and Value Considerations  </b></text>
<text top="464" left="124" width="503" height="29" font="2"><b>7.1. Economic Value Considerations: PCSK9 Inhibitors </b></text>
<text top="496" left="124" width="50" height="21" font="5">S7.1-1. </text>
<text top="496" left="219" width="552" height="21" font="5">Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on cost/value </text>
<text top="516" left="219" width="582" height="21" font="5">methodology in clinical practice guidelines and performance measures: a report of the </text>
<text top="536" left="219" width="592" height="21" font="5">American College of Cardiology/American Heart Association Task Force on Performance </text>
<text top="556" left="219" width="541" height="21" font="5">Measures and Task Force on Practice Guidelines. Circulation. 2014;129:2329-45. </text>
<text top="577" left="124" width="50" height="21" font="5">S7.1-2. </text>
<text top="577" left="219" width="601" height="21" font="5">Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients </text>
<text top="597" left="219" width="416" height="21" font="5">with cardiovascular disease. N Engl J Med. 2017;376:1713-22. </text>
<text top="617" left="124" width="50" height="21" font="5">S7.1-3. </text>
<text top="617" left="219" width="523" height="21" font="5">Hlatky MA, Kazi DS. PCSK9 Inhibitors: economics and policy. J Am Coll Cardiol. </text>
<text top="637" left="219" width="122" height="21" font="5">2017;70:2677-87. </text>
<text top="657" left="124" width="50" height="21" font="5">S7.1-4. </text>
<text top="657" left="219" width="547" height="21" font="5">Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering </text>
<text top="677" left="219" width="596" height="21" font="5">treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised </text>
<text top="698" left="219" width="289" height="21" font="5">trials of statins. Lancet. 2005;366:1267-78. </text>
<text top="718" left="124" width="50" height="21" font="5">S7.1-5. </text>
<text top="718" left="219" width="598" height="21" font="5">Fonarow GC, Keech AC, Pedersen TR, et al. Cost-effectiveness of evolocumab therapy for </text>
<text top="738" left="219" width="582" height="21" font="5">reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. </text>
<text top="758" left="219" width="211" height="21" font="5">JAMA Cardiol. 2017;2:1069-78. </text>
<text top="778" left="124" width="50" height="21" font="5">S7.1-6. </text>
<text top="778" left="219" width="558" height="21" font="5">Robinson JG, Huijgen R, Ray K, et al. Determining when to add nonstatin therapy: a </text>
<text top="798" left="219" width="398" height="21" font="5">quantitative approach. J Am Coll Cardiol. 2016;68:2412-21. </text>
<text top="818" left="124" width="50" height="21" font="5">S7.1-7. </text>
<text top="818" left="219" width="570" height="21" font="5">Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 inhibitor therapy in </text>
<text top="838" left="219" width="613" height="21" font="5">patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular </text>
<text top="859" left="219" width="226" height="21" font="5">disease. JAMA. 2016;316:743-53. </text>
<text top="879" left="124" width="50" height="21" font="5">S7.1-8. </text>
<text top="879" left="219" width="536" height="21" font="5">Gandra SR, Villa G, Fonarow GC, et al. Cost-effectiveness of LDL-C lowering with </text>
<text top="899" left="219" width="579" height="21" font="5">evolocumab in patients with high cardiovascular risk in the United States. Clin Cardiol. </text>
<text top="919" left="219" width="114" height="21" font="5">2016;39:313-20. </text>
<text top="939" left="124" width="50" height="21" font="5">S7.1-9. </text>
<text top="939" left="219" width="544" height="21" font="5">Choosing interventions that are cost effective (WHO-CHOICE): cost-effectiveness </text>
<text top="959" left="218" width="453" height="21" font="5">thresholds. Geneva, Switzerland: World Health Organization; 2009. </text>
<text top="988" left="124" width="4" height="21" font="5"> </text>
<text top="1021" left="124" width="361" height="31" font="11"><b>8. Limitations and Knowledge Gaps  </b></text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<page number="120" position="absolute" top="0" left="0" height="1188" width="918">
<image top="503" left="115" width="688" height="183" src="blood-cholesterol-management/CIR.0000000000000625-120_1.jpg"/>
<text top="54" left="124" width="112" height="19" font="0"><b>Grundy SM, et al. </b></text>
<text top="72" left="124" width="278" height="19" font="0"><b>2018 Cholesterol Clinical Practice Guidelines </b></text>
<text top="1132" left="453" width="55" height="19" font="1">Page 120</text>
<text top="1130" left="508" width="4" height="21" font="5"> </text>
<text top="108" left="124" width="198" height="29" font="2"><b>8.2. Risk Assessment </b></text>
<text top="139" left="124" width="50" height="21" font="5">S8.2-1. </text>
<text top="139" left="219" width="612" height="21" font="5">Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of </text>
<text top="159" left="219" width="588" height="21" font="5">blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the </text>
<text top="180" left="219" width="558" height="21" font="5">American College of Cardiology/American Heart Association Task Force on Practice </text>
<text top="200" left="219" width="272" height="21" font="5">Guidelines. Circulation. 2014;129:S1-45. </text>
<text top="234" left="124" width="5" height="16" font="14"> </text>
<text top="592" left="30" width="0" height="11" font="7">Downloaded from http://ahajournals.org by on May 19, 2019</text>
</page>
<outline>
<item page="5">Top 10 Take-Home Messages to Reduce Risk of Atherosclerotic Cardiovascular Disease Through Cholesterol Management</item>
<item page="7">Preamble</item>
<item page="8">1. Introduction</item>
<outline>
<item page="8">1.1. Methodology and Evidence Review</item>
<item page="9">1.2. Organization of the Writing Committee</item>
<item page="9">1.3. Document Review and Approval</item>
<item page="9">1.4. Scope of the Guideline</item>
<item page="10">1.5. Class of Recommendation and Level of Evidence</item>
<item page="12">1.6. Abbreviations</item>
</outline>
<item page="13">2. High Blood Cholesterol and ASCVD</item>
<outline>
<item page="13">2.1. Serum Cholesterol, Lipoproteins, and ASCVD</item>
<outline>
<item page="13">2.1.1. Cholesterol, Lipoproteins, and Apolipoprotein B</item>
<item page="13">2.1.2. Cholesterol, LDL-C, and ASCVD</item>
<item page="13">2.1.3. LDL-C and Other Risk Factors</item>
</outline>
<item page="14">2.2. Measurements of LDL-C and Non–HDL-C</item>
<item page="15">2.3. Measurements of Apolipoprotein B and Lipoprotein (a)</item>
<item page="15">2.4. Monitoring Response of LDL-C to Statin Therapy</item>
</outline>
<item page="16">3. Therapeutic Modalities</item>
<outline>
<item page="16">3.1. Lifestyle Therapies</item>
<outline>
<item page="16">3.1.1. Diet Composition, Weight Control, and Physical Activity</item>
<item page="16">3.1.2. Lifestyle Therapies and Metabolic Syndrome</item>
</outline>
<item page="16">3.2. Lipid-Lowering Drugs</item>
<outline>
<item page="16">3.2.1. Statin Therapy</item>
<item page="17">3.2.2. Nonstatin Therapies</item>
<item page="18">3.2.3. Nonstatin Add-on Drugs to Statin Therapy</item>
</outline>
</outline>
<item page="18">4. Patient Management Groups</item>
<outline>
<item page="18">4.1. Secondary ASCVD Prevention</item>
<item page="25">4.2. Severe Hypercholesterolemia (LDL-C ≥190 mg/dL [≥4.9 mmol/L])</item>
<item page="27">4.3. Diabetes Mellitus in Adults</item>
<item page="30">4.4. Primary Prevention</item>
<outline>
<item page="32">4.4.1. Evaluation and Risk Assessment</item>
<outline>
<item page="32">4.4.1.1. Essential Process of Risk Assessment</item>
<item page="32">4.4.1.2. Pooled Cohort Equations</item>
<item page="33">4.4.1.3. Risk-Enhancing Factors</item>
<item page="34">4.4.1.4. Coronary Artery Calcium</item>
</outline>
<item page="35">4.4.2. Primary Prevention Adults 40 to 75 Years of Age With LDL-C Levels 70 to 189 mg/dL (1.7 to 4.8 mmol/L)</item>
<item page="41">4.4.3. Monitoring in Response to LDL-C–Lowering Therapy</item>
<item page="42">4.4.4. Primary Prevention in Other Age Groups</item>
<outline>
<item page="42">4.4.4.1. Older Adults</item>
<item page="43">4.4.4.2. Young Adults (20 to 39 Years of Age)</item>
<item page="45">4.4.4.3. Children and Adolescents</item>
</outline>
</outline>
<item page="48">4.5. Other Populations at Risk</item>
<outline>
<item page="48">4.5.1. Ethnicity</item>
<item page="52">4.5.2. Hypertriglyceridemia</item>
<outline>
<item page="54">4.5.3. Issues Specific to Women</item>
<item page="55">4.5.4 Adults With CKD</item>
<item page="57">4.5.5. Adults With Chronic Inflammatory Disorders and HIV</item>
</outline>
</outline>
</outline>
<item page="58">5. Statin Safety and Statin-Associated Side Effects</item>
<item page="63">6. Implementation</item>
<item page="65">7. Cost and Value Considerations</item>
<outline>
<item page="65">7.1. Economic Value Considerations: PCSK9 Inhibitors</item>
</outline>
<item page="68">8. Limitations and Knowledge Gaps</item>
<outline>
<item page="68">8.1. Randomized Controlled Trials</item>
<item page="68">8.2. Risk Assessment</item>
<outline>
<item page="68">8.2.1. Continuing Refinement of PCE</item>
<item page="69">8.2.2. Improvement in Lifetime Risk Estimate</item>
<item page="69">8.2.3. Refinement of Clinician–Patient Risk Discussion</item>
<item page="69">8.2.4. Monitoring and Adjustment of Treatment</item>
<item page="69">8.2.5. Prognostic Significance of CAC</item>
</outline>
</outline>
<item page="71">Appendix 1. Author Relationships With Industry and Other Entities (Relevant)—2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol* (August 2018)</item>
<item page="74">Appendix 2. Reviewer Relationships With Industry and Other Entities (Comprehensive)—2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (August 2018)</item>
<item page="85">References</item>
<item page="85">1. Introduction</item>
<outline>
<item page="85">1.1. Methodology and Evidence Review</item>
<item page="85">1.4. Scope of the Guideline</item>
<item page="85">1.5. Class of Recommendation and Level of Evidence</item>
</outline>
<item page="85">2. High Blood Cholesterol and ASCVD</item>
<outline>
<item page="85">2.1. Serum Cholesterol, Lipoproteins, and ASCVD</item>
<outline>
<item page="85">2.1.2. Cholesterol, LDL-C, and ASCVD</item>
<item page="86">2.1.3. LDL-C and Other Risk Factors</item>
</outline>
<item page="86">2.2. Measurements of LDL-C and Non-HDL-C</item>
<item page="87">2.3. Measurements of Apolipoprotein B and Lipoprotein (a)</item>
<item page="88">2.4. Monitoring Response of LDL-C to Statin Therapy</item>
</outline>
<item page="88">3. Therapeutic Modalities</item>
<outline>
<item page="88">3.1. Lifestyle Therapies</item>
<outline>
<item page="88">3.1.1. Diet Composition, Weight Control, and Physical Activity</item>
<item page="88">3.1.2. Lifestyle Therapies and Metabolic Syndrome</item>
</outline>
<item page="88">3.2. Lipid-Lowering Drugs</item>
<outline>
<item page="89">3.2.1. Statin Therapy</item>
<item page="90">3.2.2. Nonstatin Therapies</item>
<item page="90">3.2.3. Nonstatin Add-on Drugs to Statin Therapy</item>
</outline>
</outline>
<item page="90">4. Patient Management Groups</item>
<outline>
<item page="90">4.1. Secondary ASCVD Prevention</item>
<item page="93">4.2. Severe Hypercholesterolemia (LDL-C (190 mg/dL [≥4.9 mmol/L])</item>
<item page="94">4.3. Diabetes Mellitus in Adults</item>
<item page="96">4.4. Primary Prevention</item>
<outline>
<item page="97">4.4.1. Evaluation and Risk Assessment</item>
<outline>
<item page="98">4.4.1.1. Essential Process of Risk Assessment</item>
<item page="98">4.4.1.2. Pooled Cohort Equations</item>
<item page="99">4.4.1.3. Risk-Enhancing Factors</item>
<item page="99">4.4.1.4. Coronary Artery Calcium</item>
</outline>
<item page="101">4.4.2. Primary Prevention Adults 40 to 75 Years of Age With LDL-C Levels 70 to 189 mg/dL (1.7–4.8 mmol/L)</item>
<item page="104">4.4.3. Monitoring in Response to LDL-C–Lowering Therapy</item>
<item page="105">4.4.4. Primary Prevention in Other Age Groups</item>
<outline>
<item page="105">4.4.4.1. Older Adults</item>
<item page="106">4.4.4.2. Young Adults (20 to 39 Years of Age)</item>
<item page="107">4.4.4.3. Children and Adolescents</item>
</outline>
</outline>
<item page="109">4.5. Other Populations at Risk</item>
<outline>
<item page="109">4.5.1. Ethnicity</item>
<item page="111">4.5.2. Hypertriglyceridemia</item>
<outline>
<item page="112">4.5.3. Issues Specific to Women</item>
<item page="113">4.5.4 Adults With CKD</item>
<item page="114">4.5.5. Adults With Chronic Inflammatory Disorders and HIV</item>
</outline>
</outline>
</outline>
<item page="115">5. Statin Safety and Statin-Associated Side Effects</item>
<item page="117">6. Implementation</item>
<item page="119">7. Cost and Value Considerations</item>
<outline>
<item page="119">7.1. Economic Value Considerations: PCSK9 Inhibitors</item>
</outline>
<item page="119">8. Limitations and Knowledge Gaps</item>
<outline>
<item page="120">8.2. Risk Assessment</item>
</outline>
</outline>
</pdf2xml>
